Page last updated: 2024-11-04

fluoxetine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fluoxetine, also known as Prozac, is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It was first synthesized by Eli Lilly and Company in 1974 and approved by the Food and Drug Administration (FDA) in 1987. Fluoxetine works by increasing the levels of serotonin in the brain, a neurotransmitter that plays a role in mood, sleep, appetite, and other functions. It is commonly prescribed for the treatment of major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. Fluoxetine is also used off-label for other conditions, such as anxiety, social phobia, and post-traumatic stress disorder. Fluoxetine is generally well-tolerated, but common side effects include nausea, headache, drowsiness, and sexual dysfunction. More serious side effects, such as serotonin syndrome and suicidal thoughts, are possible but rare. Fluoxetine is a highly effective treatment for depression and other mental health conditions. It is widely studied to understand its mechanisms of action, therapeutic effects, and potential for new applications. Research on fluoxetine continues to contribute to the understanding of brain function and the development of new treatments for mental illness.'

(S)-fluoxetine : An N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine that has S configuration. [The antidepressant drug fluoxetine is a racemate comprising equimolar amounts of (R)- and (S)-fluoxetine]. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1548968
CHEMBL ID1169388
CHEBI ID86992
SCHEMBL ID33947
MeSH IDM0008635
PubMed CID3386
CHEMBL ID41
CHEBI ID86990
CHEBI ID5118
SCHEMBL ID8353
MeSH IDM0008635

Synonyms (209)

Synonym
BIDD:PXR0168
PDSP2_000623
PDSP1_000627
LOPAC0_000554
tocris-0927
lopac-f-1553
NCGC00024879-01
NCGC00015428-02
cas-59333-67-4
NCGC00015428-01
lopac-f-1678
lopac-f-132
NCGC00016888-01
NCGC00015428-03
NCGC00015428-04
NCGC00162186-01
sfx ,
(3s)-n-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
NCGC00016888-03
(s)-n-methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine
(s)-n-methyl-gamma-(4-trifluoromethylphenoxy)-3-phenylpropylamine
(s)-fluoxetine
(s)-prozac
(-)-fluoxetine
(s)-(-)-fluoxetine
DB08544
(s)-n-methyl-3-(4-trifluoromethylphenoxy)-3-phenylpropylamine
(s)-n-methyl-3-(4-trifluoromethylphenyloxy)-3-(phenyl)propylamine
CHEMBL1169388
chebi:86992 ,
fluoxetine-r-(-)
bdbm81875
CCG-204644
NCGC00015428-09
NCGC00016888-02
NCGC00015428-05
SCHEMBL33947
100568-02-3
(s)-n-methyl-3-phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine
fluoxetine, (s)-
benzenepropanamine, n-methyl-.gamma.-(4-(trifluoromethyl)phenoxy)-, (.gamma.s)-
fluoxetine, (-)-
6MYD4C025Q ,
benzenepropanamine, n-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (gammas)-
unii-6myd4c025q
methyl[(3s)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl]amine
mmv001561
DTXSID60904656
Q27097744
SDCCGSBI-0050537.P002
NCGC00016888-06
s-fluoxetine
benzenepropanamine,?n-methyl-.gamma.-[4-(trifluoromethyl)phenoxy]-, (.gamma.s)-
AB00053774-13
AB00053774-14
BRD-A31159102-003-05-6
BRD-A31159102-001-01-9
gtpl203
DIVK1C_006819
n-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine
n-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine
SPECTRUM_001679
n-methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
fluoxetin
(+) or (-)-n-methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
n-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
fluoxetina [inn-spanish]
fluoxetinum [inn-latin]
(+) or (-)-n-methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
fluoxetina [spanish]
benzenepropamine, n-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-
fluoxetine [usan:inn:ban]
benzenepropanamine, n-methyl-gamma-(4-(trifluoromethyl)phenoxy)-, (+-)-
BPBIO1_000509
BSPBIO_000461
BSPBIO_003375
57226-07-0
nsc-283480
nsc283480
LOPAC0_000558
BPBIO1_000354
BIOMOL-NT_000152
(+/-)-n-methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine
animex-on
benzenepropanamine, n-methyl-gamma-[4-(trifluoromethyl)phenoxy]-, (+/-)-
3-(p-trifluoromethylphenoxy)-n-methyl-3-phenylpropylamine
pulvules
(+/-)-n-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
portal
dl-3-(p-trifluoromethylphenoxy)-n-methyl-3-phenylpropylamine
fluoxetine
(+/-)-n-methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine
(+/-)-n-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]
benzenepropanamine, n-methyl-gamma-[4-(trifluoromethyl)phenoxy]-
(+/-)-n-methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine
54910-89-3
eufor
fluval
AB00053774
DB00472
(+-)-n-methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine
(+-)-n-methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine
D00326
fluoxetine (usan/inn)
fluoxetine (tn)
PRESTWICK3_000511
NCGC00024879-04
KBIO2_004727
KBIOGR_001166
KBIO3_002595
KBIO2_007295
KBIO2_002159
KBIO1_001763
KBIOSS_002159
SPBIO_002382
SPECTRUM4_000613
SPECPLUS_000723
SPECTRUM3_001648
SPBIO_001815
PRESTWICK0_000511
SPECTRUM2_001658
PRESTWICK1_000511
PRESTWICK2_000511
SPECTRUM5_001518
NCGC00024879-03
HMS2090H14
NCGC00015428-10
methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine
cid_62857
bdbm30130
L000931
chembl41 ,
nsc-758685
fluoxetin ratiopharm
chebi:86990 ,
NCGC00015428-08
AKOS003663021
STK734483
BBL012251
dtxsid7023067 ,
tox21_110144
cas-54910-89-3
dtxcid903067
CCG-204648
NCGC00015428-13
NCGC00015428-06
NCGC00015428-07
NCGC00015428-12
NCGC00015428-11
nsc 758685
fluoxetinum
fluoxetina
01k63sup8d ,
nsc 283480
unii-01k63sup8d
FT-0626489
chebi:5118
EPITOPE ID:224550
fluoxetine [who-dd]
dl-n-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
n-methyl-.gamma.-(4-(trifluoromethyl)phenoxy)benzenepropanamine
fluoxetine [usan]
fluoxetine [vandf]
fluoxetine [mi]
fluoxetine [inn]
(+/-)-n-methyl-3-phenyl-3-((.alpha.,alpha.,.alpha.-trifluoro-p-tolyl)oxy)propylamine
benzenepropanamine, n-methyl-g-(4-(trifluoromethyl)phenoxy)-, (+/-)-
fluoxetine [ema epar veterinary]
NS-140
HY-B0102
SCHEMBL8353
tox21_110144_1
NCGC00015428-15
n-methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine
n-methyl-3-phenyl-3-(p-trifluoromethylphenoxy)propylamine
n-methyl 3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
(.+/-.)-n-methyl-3-phenyl-3-[(.alpha.,.alpha.,.alpha.-trifluoro-p-tolyl)oxy]propylamine
n-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine #
benzenepropanamine, n-methyl-.gamma.-[4-(trifluoromethyl)phenoxy]-, (.+/-.)-
(.+/-.)-n-methyl-3-phenyl-3-[(.alpha.,la,.alpha.-trifluoro-p-tolyl)oxy]propylamine
AB00053774_16
AB00053774_15
mfcd00072041
AC-8478
SBI-0050541.P003
n-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine
Q422244
AS-44989
n-methyl-3-phenyl-3-(4-(trifluoromethyl)phenoxy)propan-1-amine
BCP28440
ly-110140;ly 110140;ly110140
BRD-A31159102-003-16-3
AB9783
SDCCGSBI-0050541.P004
NCGC00015428-27
AMY32526
n-methyl-3-[4-(trifluoromethyl)phenoxy]-3-(3-tritiophenyl)propan-1-amine
SR-01000002988-18
EN300-199668
benzenepropanamine, n-methyl-?-[4-(trifluoromethyl)phenoxy]-
ly-110140 free base
ps06 - fluoxetine/norfluoxetine
fluoxetine-d5
(+/-)-n-methyl-3-phenyl-3-((alpha,alpha.,alpha-trifluoro-p-tolyl)oxy)propylamine
n-methyl-gamma-(4-(trifluoromethyl)-phenoxy)-benzenepropanamine
fluoxetina (inn-spanish)
n06ab03
fluoxetine (ema epar veterinary)
fluoxetinum (inn-latin)

Research Excerpts

Overview

Fluoxetine (FLX) is a blockbuster drug with annual sales in the billions of dollars. It is a highly prescribed selective serotonin reuptake inhibitor (SSRI) in the treatment of depression and is reported to be a risk factor for fractures.

ExcerptReferenceRelevance
"Fluoxetine (FLX) is a psychoactive drug that acts as an antidepressant. "( Effects of oxidative stress induced by environmental relevant concentrations of fluoxetine on the embryonic development on Danio rerio.
Cardoso-Vera, JD; Dublán-García, O; Elizalde-Velázquez, GA; Galar-Martínez, M; Gómez-Oliván, LM; Heredia-García, G; Islas-Flores, H; Orozco-Hernández, JM; SanJuan-Reyes, N, 2022
)
2.39
"Fluoxetine (FLX) is a blockbuster drug with annual sales in the billions of dollars. "( Bacterial degradation of the anti-depressant drug fluoxetine produces trifluoroacetic acid and fluoride ion.
Khan, MF; Murphy, CD, 2021
)
2.32
"Fluoxetine is a widely used selective serotonin reuptake inhibitor in the treatment of these disorders."( Effects of social stress and fluoxetine treatment on fracture healing in a rat femur fracture model.
Adanır, O; Alagöz, E; Atçı, T; Çay, T; Özbay, H, 2022
)
1.73
"Fluoxetine is a well-studied serotonin selective reuptake inhibitor (SSRI)."( Fluoxetine attenuates apoptosis in early brain injury after subarachnoid hemorrhage through Notch1/ASK1/p38 MAPK signaling pathway.
Li, C; Liu, M; Su, W; Zhong, W, 2022
)
2.89
"Fluoxetine, which is a well-known antidepressant drug, is studied in hydrated cholesterol-free and cholesterol-containing lipid bilayers through unbiased and biased atomistic molecular dynamics simulations. "( Molecular simulations of fluoxetine in hydrated lipid bilayers, as well as in aqueous solutions containing β-cyclodextrin.
Avramopoulos, A; Megariotis, G; Mikaelian, G; Romanos, N; Theodorou, DN, 2022
)
2.47
"Fluoxetine is a highly prescribed selective serotonin reuptake inhibitor (SSRI) in the treatment of depression and is reported to be a risk factor for fractures."( Fluoxetine improves bone microarchitecture and mechanical properties in rodents undergoing chronic mild stress - an animal model of depression.
Chua, AN; Ho, CS; Ho, RC; Kumarsing, RA; Lam, RW; McIntyre, RS; Wong, HK, 2022
)
2.89
"Fluoxetine is an antidepressant drug that is heavily preferred in the cure of depression, which is from the selective serotonin reuptake inhibitor (SSRI) group. "( Immunostimulatory activity of fluoxetine in macrophages via regulation of the PI3K and P38 signaling pathways.
Ayaz, F; Önal, HT; Yetkin, D, 2023
)
2.64
"Fluoxetine is a thoroughly safety-tested drug that may target the sigma-1 receptor (σ1-R)."( Repurposing fluoxetine to treat lymphocytic leukemia: Apoptosis induction, sigma-1 receptor upregulation, inhibition of IL-2 cytokine production, and autophagy induction.
Brimson, JM; Brimson, S; Chomchoei, C, 2022
)
1.82
"Fluoxetine (Fx) is an antidepressant member in the family of selective serotonin reuptake inhibitors (SSRI) that can induce positive effects by reducing oxidative damage in brain tissues."( Effects of fluoxetine withdrawal in the brainstem and hypothalamus of overnourished rats: Chronic modulation on oxidative stress levels.
Beltrão de Lemos, MDT; de Andrade Silva, SC; de Lima, FA; de Santana, JH; Lagranha, CJ; Martins Silva, DG; Rodrigues, TO, 2023
)
2.02
"Fluoxetine (FLT) is a widely used antidepressant in clinical practice, which can be metabolized into active norfluoxetine (NFLT) in vivo. "( Stereoselective study of fluoxetine and norfluoxetine across the blood-brain barrier mediated by organic cation transporter 1/3 in rats using an enantioselective UPLC-MS/MS method.
An, H; Fang, J; Ge, Z; He, Z; Hu, B; Lin, H; Sun, Y; Wang, M; Wei, Y, 2023
)
2.66
"Fluoxetine is a selective serotonin reuptake inhibitor that is less frequently associated with severe toxicity in acute overdose compared with other psychotropic medications. "( Generalized seizures after acute fluoxetine overdose in four adolescents.
Kolbeck, MK; Nacca, N; Schult, RF, 2024
)
3.17
"Fluoxetine is a pharmacological agent that has been widely used to determine the neurotransmission of serotonin in the central nervous system. "( Hair loss in a female patient after administration of fluoxetine: a case report and review of the literature.
Ecomomou, M; Kontoangelos, K; Papageorgiou, C; Peppou, L; Yiannopoulou, KG, 2019
)
2.21
"Fluoxetine is an effective agent for the treatment of PE with significant improvement realized in IELT, ejaculatory control, and distress levels for both men and their partners. "( Compliance With Fluoxetine Use in Men With Primary Premature Ejaculation.
Gonzalez, J; Guhring, P; Jenkins, LC; Mulhall, JP; Parker, M; Tal, R, 2019
)
2.3
"Fluoxetine is a widely prescribed antidepressant that has been frequently detected in aquatic environments and is associated with a series of neurological, behavioural and neuroendocrine disruptions in nontarget organisms. "( Influence of dissolved organic matter on the accumulation, metabolite production and multi-biological effects of environmentally relevant fluoxetine in crucian carp (Carassius auratus).
Bao, X; Ji, Y; Ling, X; Liu, J; Lu, G; Yan, Z; Yang, H; Zhang, X, 2020
)
2.2
"Fluoxetine (FLX) is a common selective serotonin reuptake inhibitor, which is used in adolescents with psychiatric disorders. "( Effects of adolescent administration of fluoxetine on novel object recognition memory, anxiety-like behaviors, and hippocampal brain-derived neurotrophic factor level.
Adak, O; Dehghany, R; Saadati, H; Sadegzadeh, F; Sakhaie, N, 2020
)
2.27
"Fluoxetine is a selective serotonin reuptake inhibitor, commonly used for the treatment of a variety of psychopathological conditions. "( Dermestes maculatus (Coleoptera: Dermestidae) development under fluoxetine effect using two drug administration models.
Centeno, ND; Costantino, A; Ferrero, AA; Lazzarini, N; Zanetti, NI, 2021
)
2.3
"Fluoxetine is a first-line selective serotonin reuptake inhibitor widely applied for the treatment of depression; however, it induces abnormal hepatic lipid metabolism. "( Downregulation of glucose-6-phosphatase expression contributes to fluoxetine-induced hepatic steatosis.
Bai, M; Chen, Y; Gu, Y; Jiang, H; Li, P; Lu, S; Ma, Z; Yang, X; Zhou, H, 2021
)
2.3
"Fluoxetine (FLX) is a selective serotonin reuptake inhibitor (SSRIs) and is considered one of the first highly selective antidepressants of the monoamine neurotransmitter serotonin (5-HT)."( Development and in vitro evaluation of microparticles of fluoxetine in galactomannan against biofilms of S. aureus methicilin resistant.
Barroso, FDD; Brito, DHA; Cavalcanti, BC; de Andrade Neto, JB; de Moraes, MO; Josino, MAA; Júnior, HVN; Juvêncio da Silva, L; Ricardo, NMPS; Rocha da Silva, C, 2021
)
1.59
"Fluoxetine is a racemate consisting of both stereoisomers, while the S-form is the dominant serotonin reuptake inhibitor."( The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue.
Bodem, J; Danov, O; Geiger, N; Hilpert, H; Kirschner, L; Oberwinkler, H; Seibel, J; Sewald, K; Steinke, M; Zimniak, M, 2021
)
1.62
"Fluoxetine (Fx) is an FDA-approved anti-depressant agent and one of the selective serotonin reuptake inhibitor drugs (SSRI), used in neurological disorder treatment."( Modulation of the Nitric Oxide/BH4 Pathway Protects Against Irradiation-Induced Neuronal Damage.
Abdel-Rafei, MK; Moustafa, EM; Rashed, ER; Thabet, NM, 2021
)
1.34
"Fluoxetine is a selective serotonin reuptake inhibitor, which also has an immunomodulatory effect. "( The role of 5-HT
Boyko, A; Kudrin, V; Melnikov, M; Pashenkov, M; Rogovskii, V; Sviridova, A, 2021
)
2.06
"Fluoxetine is a selective serotonin reuptake inhibitor that is metabolized to norfluoxetine by cytochrome P450 (CYP) 2D6, CYP2C19, and CYP3A4. "( Prediction of Fluoxetine and Norfluoxetine Pharmacokinetic Profiles Using Physiologically Based Pharmacokinetic Modeling.
Chae, YJ; Jeong, HC; Kang, W; Lee, S; Shin, KH; Yun, HY, 2021
)
2.42
"Fluoxetine is an antidepressant commonly prescribed not only to adults but also to children for the treatment of depression, obsessive-compulsive disorder, and neurodevelopmental disorders. "( Long-Term Fluoxetine Administration Causes Substantial Lipidome Alteration of the Juvenile Macaque Brain.
Anikanov, N; Bobrovskiy, DM; Golub, MS; Horn, AKE; Khaitovich, P; Khrameeva, E; Ogurtsova, P; Park, DI; Petrova, D; Stekolshchikova, E; Tkachev, A; Turck, CW, 2021
)
2.47
"Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor antidepressant."( Effects of fluoxetine on changes of pain sensitivity in chronic stress model rats.
Chang, JL; Lian, YN; Lu, Q; Wang, Y; Zhang, FM; Zhang, Y, 2017
)
1.57
"Fluoxetine (Flx) is a first-line treatment for depression; however, its downstream mechanisms of action beyond serotonergic signaling remain ill-defined."( Fluoxetine reverses behavior changes in socially isolated rats: role of the hippocampal GSH-dependent defense system and proinflammatory cytokines.
Filipović, D; Gass, P; Perić, I; Stanisavljević, A, 2017
)
2.62
"Fluoxetine (FLX) is an antidepressant drug that belongs to the class of selective serotonin reuptake inhibitors. "( Fluoxetine induces apoptosis through endoplasmic reticulum stress via mitogen-activated protein kinase activation and histone hyperacetylation in SK-N-BE(2)-M17 human neuroblastoma cells.
Choe, W; Choi, JH; Ha, J; Jeong, YJ; Kang, I; Kim, SS; Yeo, EJ; Yoon, KS; Yu, AR, 2017
)
3.34
"Fluoxetine is a widely used antidepressant belonging to the selective serotonin reuptake inhibitor class; it is used in the treatment of major depression, obsessive compulsive, premenstrual dysphoric, panic and post-traumatic stress disorders. "( Analytical methodologies for the stereoselective determination of fluoxetine: An overview.
Budău, M; Cârcu-Dobrin, M; Hancu, G; Rusu, A, 2018
)
2.16
"Fluoxetine is an antidepressant which enhances serotonergic neurotransmission through selective inhibition of neuronal reuptake of serotonin."( Neuroplasticity and behavioral effects of fluoxetine after experimental stroke.
Qu, H; Sun, X; Sun, Y; Xiao, T; Zhao, C; Zhao, S, 2017
)
1.44
"Fluoxetine is a clinically successful antidepressant. "( (R)-fluoxetine enhances cognitive flexibility and hippocampal cell proliferation in mice.
Dawe, GS; Marwari, S, 2018
)
2.48
"Fluoxetine (Flx) is a selective serotonin reuptake inhibitor that alters the male reproductive system when administered at the adult stage or after maternal exposure. "( Fluoxetine treatment of prepubertal male rats uniformly diminishes sex hormone levels and, in a subpopulation of animals, negatively affects sperm quality.
Aragón-Martínez, A; Ayala, ME; Gonzáles, A; Olivarez, RM, 2018
)
3.37
"Fluoxetine is a selective serotonin reuptake inhibitor used as an antidepressant and has been frequently detected in aquatic environments. "( Effects of acute and chronic exposures of fluoxetine on the Chinese fish, topmouth gudgeon Pseudorasbora parva.
Chen, H; Dong, W; Hou, L; Mu, L; Schlenk, D; Xie, L; Yang, B; Zeng, X; Zhang, Q; Zhao, J, 2018
)
2.19
"Fluoxetine is a selective serotonin reuptake inhibitor that is commonly used in children and adolescents. "( Fluoxetine-Induced Sleep Bruxism Rapidly Treated With Once-Nightly Dosing of Buspirone in a 6-Year-Old Girl.
Akbaş, B; Bilgiç, A,
)
3.02
"Fluoxetine is an antidepressant, which exerts a powerful neurogenic effect on dentate gyrus progenitor cells, but is ineffective on stem cells."( Fluoxetine or Sox2 reactivate proliferation-defective stem and progenitor cells of the adult and aged dentate gyrus.
Caruso, C; Ceccarelli, M; Coccurello, R; Costanzi, M; D'Andrea, G; Giacovazzo, G; Micheli, L; Tirone, F, 2018
)
2.64
"Fluoxetine (FLX) is an antidepressant from the selective serotonin reuptake inhibitor class that has largely been used for the treatment of depression in pregnancy. "( Maternal exposure to fluoxetine during gestation and lactation induces long lasting changes in the DNA methylation profile of offspring's brain and affects the social interaction of rat.
Estrada, VB; Francis-Oliveira, J; Gomes, MV; Moreira, EG; Pelosi, GG; Silva, AS; Toffoli, LV; Veríssimo, LF, 2018
)
2.24
"Fluoxetine (FLX) is a pharmaceutical used to treat affective disorders in humans, but as environmental contaminant also affects inadvertently exposed fish in urban watersheds. "( Developmental fluoxetine exposure in zebrafish reduces offspring basal cortisol concentration via life stage-dependent maternal transmission.
Haddad, M; Martinez, R; Mennigen, JA; Navarro-Martin, L; Trudeau, VL; Vera-Chang, MN; Zon, J, 2019
)
2.32
"Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that reduces obsessive-compulsive symptoms. "( The SOFIA Study: Negative Multi-center Study of Low Dose Fluoxetine on Repetitive Behaviors in Children and Adolescents with Autistic Disorder.
Arnold, LE; Attalla, A; Bregman, JD; Cartwright, C; Childress, A; Chugani, H; Frazier, J; Ginsberg, L; Handen, BL; Hendren, R; Herscu, P; King, B; Kolevzon, A; Melmed, R; Minshew, N; Mintz, M; Murphy, T; Owley, T; Sikich, L; Snape, MF, 2020
)
2.25
"Fluoxetine is an open channel blocker of fetal muscle acetylcholine (ACh) receptor (AChR) and slow-channel mutant AChRs. "( Fluoxetine prevents acetylcholine-induced excitotoxicity blocking human endplate acetylcholine receptor.
Catalano, M; Deflorio, C; Fucile, S; Grassi, F; Limatola, C, 2014
)
3.29
"Fluoxetine is an open channel blocker, but it also affects AChR in the closed state. "( Fluoxetine prevents acetylcholine-induced excitotoxicity blocking human endplate acetylcholine receptor.
Catalano, M; Deflorio, C; Fucile, S; Grassi, F; Limatola, C, 2014
)
3.29
"Fluoxetine (FLX) is a selective serotonin reuptake inhibitor (SSRI). "( Neurogenesis and increase in differentiated neural cell survival via phosphorylation of Akt1 after fluoxetine treatment of stem cells.
Darbandi-Azar, A; Keyhanvar, P; Kheradmand, D; Rahmani, A; Shoae-Hassani, A, 2013
)
2.05
"Fluoxetine is an antidepressant used worldwide for the treatment of depression and other psychological disorders. "( Effects of the antidepressant fluoxetine on the immune parameters and acetylcholinesterase activity of the clam Venerupis philippinarum.
Marin, MG; Matozzo, V; Munari, M, 2014
)
2.13
"Fluoxetine is an antidepressant that has been largely used for treatment of depression in pregnancy. "( Maternal exposure to fluoxetine during gestation and lactation affects the DNA methylation programming of rat's offspring: modulation by folic acid supplementation.
Gomes, MV; Moreira, EG; Oliveira, JF; Pelosi, GG; Rodrigues, GM; Silva, AS; Toffoli, LV, 2014
)
2.16
"Fluoxetine (FLX) is a selective serotonin (5-HT) reuptake inhibitor present in the aquatic environment which is known to bioconcentrate in the brains of exposed fish. "( Effects of intracerebroventricular administered fluoxetine on cardio-ventilatory functions in rainbow trout (Oncorhynchus mykiss).
Kermorgant, M; Lancien, F; Le Mével, JC; Mimassi, N; Tyler, CR, 2014
)
2.1
"Fluoxetine is an antidepressant that has anti-inflammatory and antihyperalgesic effects in experimental models of pain and inflammation. "( Experimental study on the role of 5-HT2 serotonin receptors in the mechanism of anti-inflammatory and antihyperalgesic action of antidepressant fluoxetine.
Delev, DP; Kostadinov, ID; Kostadinova, II; Murdjeva, MA,
)
1.77
"Fluoxetine is a selective serotonin reuptake inhibitor used to treat depression in pregnant and nursing women. "( Fluoxetine induces changes in the testicle and testosterone in adult male rats exposed via placenta and lactation.
Amorim, MJ; Andrade, AJ; da Silva Junior, VA; de Morais, RN; de Torres, SM; Monteiro Filho, WO; Tenorio, BM, 2014
)
3.29
"Fluoxetine (FLX) is a chiral fluorinated pharmaceutical indicated mainly for the treatment of depression and is one of the most dispensed drugs in the world. "( Enantioselective biodegradation of fluoxetine by the bacterial strain Labrys portucalensis F11.
Afonso, CM; Castro, PM; Moreira, IS; Ribeiro, AR; Tiritan, ME, 2014
)
2.12
"Fluoxetine is a serotonin-specific reuptake inhibitor that has been used as an antidepressant. "( Effect of fluoxetine on [Ca²⁺]i and cell viability in OC2 human oral cancer cells.
Chang, HT; Chen, IL; Cheng, JS; Chou, CT; Jan, CR; Kuo, CC; Kuo, DH; Liang, WZ; Lin, KL; Shieh, P; Tseng, LL; Wu, RF, 2014
)
2.25
"Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) widely used in the treatment of major depression. "( Impact of excipients in the chronic toxicity of fluoxetine on the alga Chlorella vulgaris.
Delerue-Matos, C; Figueiredo, SA; Santos, LH; Silva, A,
)
1.83
"Fluoxetine is a commonly prescribed psychotropic medication for a variety of behavioral diagnoses in veterinary practice, and fluoxetine in Pluronic lecithin organogel has been used successfully in treating inappropriate urine spraying in felines. "( Evaluation of the stability of fluoxetine in pluronic lecithin organogel and the determination of an appropriate beyond-use date.
Peacock, GF; Sauvageot, J,
)
1.86
"Fluoxetine (FLX) is a chiral fluorinated pharmaceutical mainly indicated for treatment of depression and is one of the most distributed drugs. "( Removal of fluoxetine and its effects in the performance of an aerobic granular sludge sequential batch reactor.
Amorim, CL; Castro, PM; Mesquita, RB; Moreira, IS; Rangel, AO; Ribeiro, AR; Tiritan, ME; van Loosdrecht, MC, 2015
)
2.25
"Fluoxetine (FLX) is an anti-depressant of the selective serotonin reuptake inhibitors (SSRI) and was previously shown to be neuroprotective in vitro and in vivo."( The antidepressant fluoxetine protects the hippocampus from brain damage in experimental pneumococcal meningitis.
Grandgirard, D; Leib, SL; Liechti, FD, 2015
)
1.47
"Fluoxetine is a widely used antidepressant. "( Effect of fluoxetine on induced tooth movement in rats.
Batista Rodrigues Johann, AC; Camargoa, ES; Franzon Frigotto, GC; Guariza Filho, O; Miranda de Araujo, C; Tanaka, OM, 2015
)
2.26
"Fluoxetine (FLX) is an antidepressant worldwide prescribed throughout life stages, including pregnancy and breastfeeding. "( Does fish oil or folic acid prevent vascular changes in female progeny caused by maternal exposure to fluoxetine?
Barbosa, DS; Ceravolo, GS; Gameiro, JG; Higachi, L; Higashi, CM; Matsumoto, AK; Moreira, EG; Moura, KF; Oliveira, LC, 2016
)
2.09
"Fluoxetine is a serotonin reuptake inhibitor and may rarely cause hyponatremia."( SEVERE HYPONATREMIA, EPISTAXIS, AND FLUOXETINE.
Cinemre, H; Eraslan, Ö; Kaya, T; Tamer, A; Yücel, M,
)
1.13
"Fluoxetine is a selective serotonin reuptake inhibitor and long-lived open channel blocker of the acetylcholine receptor, often used in the treatment of slow-channel congenital myasthenic syndromes (CMS)."( Rapsyn congenital myasthenic syndrome worsened by fluoxetine.
Benarroch, EE; Laughlin, RS; Litchy, WJ; Milone, M; Visser, AC, 2017
)
2.15
"Fluoxetine is a medication used to treat Major Depressive Disorder and other psychiatric conditions. "( Chronic fluoxetine dissociates contextual from auditory fear memory.
Mayford, M; Sanders, J, 2016
)
2.31
"Fluoxetine (FLX) is a selective serotonin (5-HT) reuptake inhibitor known for its effects modifying aggressiveness, personality traits, and anxiety-like behaviors. "( Acute fluoxetine treatment increases aggressiveness in juvenile matrinxã (Brycon amazonicus).
Barbosa Júnior, A; Serra, M; Urbinati, EC; Wolkers, CPB, 2017
)
2.38
"Fluoxetine is an antidepressant that acts as a selective serotonin reuptake inhibitor (SSRI)."( Behavioral and biochemical responses of hybrid striped bass during and after fluoxetine exposure.
Gaworecki, KM; Klaine, SJ, 2008
)
1.3
"Fluoxetine is a serotonin re-uptake inhibitor, generally used as an antidepressant. "( Fluoxetine effects assessment on the life cycle of aquatic invertebrates.
Fink, G; Garric, J; Gust, M; Mons, R; Péry, AR; Ramil, M; Ternes, T; Vollat, B, 2008
)
3.23
"Fluoxetine is a selective serotonin reuptake inhibitor widely used for treating depression. "( Fluoxetine inhibition of glycine receptor activity in rat hippocampal neurons.
Cheng, XP; Lu, YG; Sun, H; Xu, TL; Ye, ZY; Zhou, JN, 2008
)
3.23
"Fluoxetine (FLX) is a widely prescribed antidepressant. "( Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells.
Brocke, K; Gratopp, A; Ikonomidou, C; Kupisz, K; Rzeski, W; Sifringer, M; Stepulak, A; Turski, L, 2008
)
3.23
"Fluoxetine is a selective serotonin reuptake inhibitor that is widely used in the treatment of major depression including after stroke. "( Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect.
Kim, C; Kim, SW; Lee, JK; Lim, CM; Park, JY; Yoon, SH, 2009
)
3.24
"Fluoxetine is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class, which is commonly prescribed to treat a wide spectrum of mood disorders including depression during pregnancy and lactation. "( Estimation of embryotoxic effect of fluoxetine using embryonic stem cell differentiation system.
Kusakawa, S; Miyamoto, Y; Sanbe, A; Tanoue, A; Yamauchi, J, 2008
)
2.06
"Fluoxetine is a moderately effective and well-tolerated treatment for hypochondriasis."( A double-masked, placebo-controlled study of fluoxetine for hypochondriasis.
Cheng, J; Fallon, BA; Liebowitz, MR; Petkova, E; Sanchez-Lacay, A; Schneier, F; Skritskaya, N; Vermes, D, 2008
)
1.33
"Fluoxetine is a widely used antidepressant, frequently found in aquatic ecosystems. "( Effects of fluoxetine on the reproduction of two prosobranch mollusks: Potamopyrgus antipodarum and Valvata piscinalis.
Buronfosse, T; Garric, J; Giamberini, L; Gust, M; Mons, R; Ramil, M, 2009
)
2.19
"Fluoxetine (FLX) is a selective serotonin reuptake inhibitor and is among the top 100 drugs prescribed yearly in the United States and the United Kingdom. "( Effects of fluoxetine exposure on serotonin-related activity in the sheepshead minnow (Cyprinodon variegatus) using LC/MS/MS detection and quantitation.
Pennington, PL; Sapozhnikova, Y; Winder, VL; Wirth, EF, 2009
)
2.19
"Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) and one of the commonly prescribed antidepressants. "( Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus.
Han, PL; Jin, Y; Kim, SW; Lee, JK; Lim, CM; Park, JY; Seo, JS; Yoon, SH, 2009
)
3.24
"Fluoxetine is a highly prescribed model SSRI used to assess impacts of antidepressants on aquatic organisms."( Cross-species comparison of fluoxetine metabolism with fish liver microsomes.
Chu, S; Metcalfe, CD; Paterson, G; Smith, EM; Wilson, JY, 2010
)
1.38
"Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor that, when given chronically, alters different neurotransmitter systems. "( Chronic treatment with fluoxetine decreases cerebral metabolic responses to the 5-HT1A agonist 8-hydroxy-2(di-N-propylamino)tetralin and increases those to the 5-HT2A/2C agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane and to the dopaminergic agonist
Ermani, M; Freo, U; Merico, A; Ori, C, 2010
)
2.11
"Fluoxetine (FLX) is a pharmaceutical acting as a selective serotonin reuptake inhibitor and is used to treat depression in humans. "( Waterborne fluoxetine disrupts the reproductive axis in sexually mature male goldfish, Carassius auratus.
Chang, JP; Duarte-Guterman, P; Lado, WE; Langlois, VS; Mennigen, JA; Metcalfe, CD; Moon, TW; Trudeau, VL; Zamora, JM, 2010
)
2.19
"Fluoxetine (FLX) is a drug commonly used as antidepressant. "( Fluoxetine induces preventive and complex effects against colon cancer development in epithelial and stromal areas in rats.
Bonato, PS; Brandão, ML; Carvalho, MC; Ferreira, FR; Garcia, SB; Jabor, VA; Kannen, V; Marini, T; Silva, WA; Turatti, A; Zanette, DL, 2011
)
3.25
"Fluoxetine (Flux) is a fluorine-containing drug that selectively inhibits serotonin reuptake. "( Impact of fluoxetine on liver damage in rats.
Inkielewicz-Stępniak, I, 2011
)
2.21
"Fluoxetine (Prozac) is a selective serotonin reuptake inhibitor currently used to treat depression and mood disorders. "( Pharmacokinetics of fluoxetine in rhesus macaques following multiple routes of administration.
Howell, LL; Sawyer, EK, 2011
)
2.14
"Fluoxetine is an inhibitor of the main metabolizing enzymes of lansoprazole and could influence the pharmacokinetics of lansoprazole. "( Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects.
Leucuta, SE; Muntean, D; Neag, M; Popa, A; Vlase, L, 2011
)
2.21
"Fluoxetine appears to be a safe and effective treatment in improving symptoms in, and the quality of life of, men with difficult CP/CPPS. "( Fluoxetine ameliorates symptoms of refractory chronic prostatitis/chronic pelvic pain syndrome.
Chen, J; Jiang, H; Wang, P; Wang, S; Xia, D, 2011
)
3.25
"Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant that is widely prescribed. "( DNA-binding studies of fluoxetine antidepressant.
Chitsazan, A; Javanmardi, S; Kashanian, S; Omidfar, K; Paknejad, M, 2012
)
2.13
"Fluoxetine is a widely used antidepressant drug which inhibits the reuptake of serotonin in the central nervous system (CNS). "( Fluoxetine upregulates phosphorylated-AKT and phosphorylated-ERK1/2 proteins in neural stem cells: evidence for a crosstalk between AKT and ERK1/2 pathways.
Cai, Z; Huang, W; Qi, Z; Wang, S; Xie, P; Yao, S; Zhao, Y; Zhu, X, 2013
)
3.28
"Fluoxetine is a widely used antidepressant with an action that is primarily attributed to the inhibition of serotonin re-uptake into the synaptic terminals of the central nervous system. "( Fluoxetine suppresses synaptically induced [Ca²⁺]i spikes and excitotoxicity in cultured rat hippocampal neurons.
Choi, SJ; Hahn, SJ; Hong, YJ; Kim, HJ; Kim, TH; Rhie, DJ; Sung, KW; Yang, JS; Yoon, SH, 2013
)
3.28
"Fluoxetine is a selective serotonin [5-hydroxytryptamine (5-HT)] reuptake inhibitor (SSRI) commonly used to treat depression. "( Effects of fluoxetine and TFMPP on spontaneous seizures in rats with pilocarpine-induced epilepsy.
Dudek, FE; Hernandez, EJ; Williams, PA, 2002
)
2.15
"Fluoxetine is a selective serotonin reuptake inhibitor of the neuronal reuptake pump increasing synaptic concentrations of serotonin, and 8-OH-DPAT is a specific serotonin (5-HT1A) receptor agonist."( Effects of acute treatment with 8-OH-DPAT and fluoxetine on aggressive behaviour in male song sparrows (Melospiza melodia morphna).
Sperry, TS; Thompson, CK; Wingfield, JC, 2003
)
1.3
"Fluoxetine is a selective serotonin reuptake inhibitor used widely in the treatment of depression. "( Fluoxetine increases GABA(A) receptor activity through a novel modulatory site.
Drafts, BC; Fisher, JL; Robinson, RT, 2003
)
3.2
"Fluoxetine is a widely prescribed antidepressant and acts physiologically as a selective serotonin reuptake inhibitor (SSRI)."( Reproductive assessment of Japanese medaka (Oryzias latipes) following a four-week fluoxetine (SSRI) exposure.
Brooks, BW; Foran, CM; Huggett, DB; Slattery, M; Weston, J, 2004
)
1.27
"Fluoxetine alone is a superior treatment to CBT alone (P =.01)."( Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
Burns, B; Curry, J; Domino, M; Fairbank, J; March, J; McNulty, S; Petrycki, S; Severe, J; Silva, S; Vitiello, B; Wells, K, 2004
)
2.49
"Fluoxetine (Prozac) is a serotonin reuptake inhibitor. "( Fluoxetine increases extracellular levels of 3-methoxy-4-hydroxyphenylglycol in cultured COLO320 DM cells.
Liu, YL; Yue, CT,
)
3.02
"Fluoxetine is a potent inhibitor of CYP2D6, and imipramine is metabolized by CYP2D6."( QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine.
Blackmon, CL; Nykamp, DL; Roberson, AG; Schmidt, PE, 2005
)
1.27
"Fluoxetine is an anorexic agent known to reduce food intake and weight gain. "( Role of neuropeptide Y and proopiomelanocortin in fluoxetine-induced anorexia.
Choi, SH; Jahng, JW; Kim, BT; Lee, SY; Myung, CS; Song, GY, 2005
)
2.02
"Fluoxetine is an antidepressant drug, only recently discovered to be a QT interval prolonging agent. "( Prolonged QT interval in an infant of a fluoxetine treated mother.
Dubnov, G; Fogelman, R; Merlob, P, 2005
)
2.04
"Fluoxetine is an effective and well-tolerated short-term treatment for pain and constipation-predominant irritable bowel syndrome."( The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study.
Ghoddoosi, A; Malekzadeh, R; Merat, S; Rashidioon, A; Vahedi, H, 2005
)
2.13
"Fluoxetine (Prozac) is a potent antidepressant compound inhibiting serotonin reuptake, but also Na+, K+ and Ca2+ channels and reported to both trigger and prevent apoptosis. "( Fluoxetine (Prozac) interaction with the mitochondrial voltage-dependent anion channel and protection against apoptotic cell death.
Abu-Hamad, S; Israelson, A; Nahon, E; Varda, SB, 2005
)
3.21
"Fluoxetine is a widely used antidepressant compound which inhibits the reuptake of serotonin in the central nervous system. "( Fluoxetine up-regulates expression of cellular FLICE-inhibitory protein and inhibits LPS-induced apoptosis in hippocampus-derived neural stem cell.
Chang, YL; Chen, SJ; Chiou, SH; Ho, LL; Hsu, WM; Ku, HH; Lee, CH; Peng, CH, 2006
)
3.22
"Fluoxetine (Prozac) is a widely prescribed drug in adults and children, and it has an active metabolite, norfluoxetine, with a prolonged elimination time. "( Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
Anderson, CL; Anson, BD; Delisle, BP; Eckhardt, LL; Gillman, BM; Holzem, KM; January, CT; Klemens, CA; Makielski, JC; Rajamani, S; Valdivia, CR, 2006
)
2
"Fluoxetine seems to be a better cost-utility SSRI option for treating depressive disorders in PC."( Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia.
Haro, JM; Peñarrubia, MT; Pinto-Meza, A; Serrano-Blanco, A; Suárez, D, 2006
)
1.78
"Fluoxetine monotherapy is an established treatment for pediatric mood disorders; however its efficacy in ADHD and comorbid mood disorder is unknown."( Fluoxetine monotherapy in attention-deficit/hyperactivity disorder and comorbid non-bipolar mood disorders in children and adolescents.
Butterbaugh, GJ; Layman, AK; Purnell, W; Quintana, H, 2007
)
2.5
"Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) broadly used in the treatment of human mood disorders and gastrointestinal diseases involving the serotoninergic system. "( Effect of long-term fluoxetine treatment on the human serotonin transporter in Caco-2 cells.
Alcalde, AI; Iceta, R; Mesonero, JE, 2007
)
2.11
"Fluoxetine is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women. "( Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.
Belik, J; Fornaro, E; Li, D; Pan, J, 2007
)
2.1
"Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that was introduced in 1986. "( The distribution of fluoxetine in human fluids and tissues.
Angier, MK; Johnson, RD; Lewis, RJ, 2007
)
2.11
"Fluoxetine is a biologically active pharmaceutical chemical that has been detected at parts-per-trillion levels in surface waters in North America and Europe. "( Acute and chronic toxicity of fluoxetine (selective serotonin reuptake inhibitor) in western mosquitofish.
Black, MC; Henry, TB, 2008
)
2.08
"Fluoxetine is an efficacious, nonsedative antidepressant, but its selective efficacy on symptoms of insomnia has not been thoroughly explored. "( The effects of fluoxetine on symptoms of insomnia in depressed patients.
Faries, D; Satterlee, WG, 1995
)
2.09
"Fluoxetine is a recently introduced, widely used antidepressant. "( Stimulation of glycogenolysis in astrocytes by fluoxetine, an antidepressant acting like 5-HT.
Chen, Y; Hertz, L; Peng, L; Zhang, X, 1993
)
1.99
"Fluoxetine is a selective serotonin reuptake inhibitor that often is associated with a modest weight loss when used for the treatment of depression, although it also has been reported to have the opposite effects of weight gain and hyperphagia in some patients. "( Hyperphagia and weight loss during fluoxetine treatment.
Braun, BG; Fichtner, CG, 1994
)
2.01
"Fluoxetine is a selective serotonin re-uptake inhibitor and thus being a specific antidepressant has its specific responder. "( Fluoxetine in patients with major depressive disorder--a responder analysis.
Heinrich, K; Klieser, E; Lehmann, E, 1995
)
3.18
"Fluoxetine is an effective pharmacotherapeutic agent for treating PTSD and its associated features, particularly in patients without chronic treatment histories."( Fluoxetine in posttraumatic stress disorder.
Berkowitz, R; Dreyfuss, D; Fisler, R; Michaels, M; Saxe, G; Shera, D; van der Kolk, BA, 1994
)
3.17
"Fluoxetine is a widely used serotonin reuptake inhibitor effective in the treatment of depression. "( A developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats.
Acuff-Smith, KD; Buelke-Sam, J; Fisher, JE; Moran, MS; Schilling, MA; Vorhees, CV, 1994
)
1.96
"Fluoxetine is an effective and well-tolerated treatment for this condition when used over time."( Long-term fluoxetine treatment of late luteal phase dysphoric disorder.
Pearlstein, TB; Stone, AB, 1994
)
1.41
"Fluoxetine is a relatively new antidepressant, reported to have minimal side-effects. "( Seizures associated with fluoxetine therapy.
Prasher, VP, 1993
)
2.03
"Fluoxetine might prove to be a useful adjunct therapy in obese Type 2 diabetic patients where short-term weight loss and fall in carbohydrate intake and an improvement in glycaemia are indicated."( Fluoxetine in the treatment of obese type 2 diabetic patients.
O'Kane, M; Wales, JK; Wiles, PG,
)
2.3
"Fluoxetine, 20 mg/day, is a well-tolerated and effective treatment option in the management of geriatric major depression."( Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression.
Holman, SL; Tollefson, GD, 1993
)
1.22
"Fluoxetine is a new antidepressant used by many young women."( Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac)
Donnenfeld, A; Feldkamp, M; Leen-Mitchell, M; McCormack, M; Pastuszak, A; Pinelli, M; Schick-Boschetto, B; Sihn, S; Woodland, C; Zuber, C, 1993
)
1.25
"Fluoxetine appears to be an effective and well-tolerated antidepressant in elderly inpatients of varying age, levels of depression, and psychiatric diagnoses."( The use and tolerability of fluoxetine in geropsychiatric inpatients.
Kunik, ME; Molinari, V; Orengo, CA; Workman, RH, 1996
)
2.03
"Fluoxetine (Prozac) is an effective and increasingly widely used antidepressant. "( Fluoxetine treatment comprises the antiemetic efficacy of ondansetron in cancer patients.
Koriech, OM, 1995
)
3.18
"Fluoxetine is a commonly prescribed antidepressant with frequent gastrointestinal side effects. "( Modulation of ionic currents in isolated canine and human jejunal circular smooth muscle cells by fluoxetine.
Farrugia, G, 1996
)
1.95
"Fluoxetine (F) is a specific serotonin-reuptake inhibitor that has been shown to promote weight loss and improve glycemic control in obese diabetic patients. "( Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity.
Astrup, A; Bak, JF; Bjerre, U; Breum, L; Jacobsen, S, 1995
)
2.05
"Fluoxetine is a specific serotonin reuptake inhibitor."( Fluoxetine in the treatment of depression in Asian (Chinese and Indian) patients in Singapore.
Kok, LP; Tan, CT; Tsoi, WF, 1995
)
2.46
"Fluoxetine is a 5-hydroxytryptamine (5-HT, serotonin)-selective reuptake inhibitor (SSRI) and is one of the main drugs used for the treatment of depression. "( Fluoxetine selectively alters 5-hydroxytryptamine1A and gamma-aminobutyric acidB receptor-mediated hyperpolarization in area CA1, but not area CA3, hippocampal pyramidal cells.
Beck, SG; Birnstiel, S; Choi, KC; Pouliot, WA, 1997
)
3.18
"Fluoxetine is an effective and well-tolerated drug and appears to have considerable promise in treating a range of symptoms in women with PMS."( Fluoxetine in the treatment of premenstrual syndrome.
Corakçi, A; Erhan, G; Mercan, R; Ozeren, S; Yücesoy, I, 1997
)
3.18
"As fluoxetine is a potent inhibitor of cytochrome P450 (CYP) 2D6, these results also provide indirect evidence for an involvement of CYP2D6 in the metabolism of haloperidol."( Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.
Avenoso, A; Campo, G; Caputi, AP; Facciolă, G; Ferlito, M; Perucca, E; Spinà, E; Zuccaro, P, 1997
)
1.13
"Fluoxetine (Prozac) is a new anti-depressant introduced on the marked in France since 1989. "( [Interstitial lung disease linked to fluoxetine].
Lamblin, C; Vandezande, LM; Wallaert, B, 1997
)
2.01
"Fluoxetine is an effective and well-tolerated treatment for the long treatment of PMDD. "( [Premenstrual dysphoric disorder: long-term treatment with fluoxetine and discontinuation].
de la Gándara Martín, JJ,
)
1.82
"Fluoxetine is a known inhibitor of the CYP2D6 isoenzyme (along with CYP3A4 and CYP2C) and has been shown to increase TCA serum concentrations."( Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction.
Michalets, EL; Smith, LK; Van Tassel, ED,
)
0.85
"Fluoxetine is a selective serotonin reuptake inhibitor used for the treatment of major depression."( A fatal drug interaction between clozapine and fluoxetine.
Ferslew, KE; Hagardorn, AN; Harlan, GC; McCormick, WF, 1998
)
1.28
"Fluoxetine is a serotonin re-uptake blocker commonly used to treat endogenous depression. "( Fluoxetine induces the transcription of genes encoding c-fos, corticotropin-releasing factor and its type 1 receptor in rat brain.
Horowitz, JM; Laflamme, N; Rivest, S; Torres, G, 1998
)
3.19
"Fluoxetine is an antidepressant drug, a potent and specific inhibitor of serotonin reuptake (SSRI). "( Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants.
Furst, S; Kecskemeti, V; Pacher, P; Ungvari, Z, 1998
)
2.02
"Fluoxetine is an atypical antidepressant drug, which selectively inhibits the neuronal reuptake of serotonin, and is widely used in the treatment of depressive disorders. "( Determination of fluoxetine and norfluoxetine in human plasma by high-pressure liquid chromatography with fluorescence detection.
Bugamelli, F; Casamenti, G; Mandrioli, R; Raggi, MA; Volterra, V, 1998
)
2.08
"Fluoxetine is a selective serotonin reuptake inhibitor. "( Effects of fluoxetine administration on mu-opoid receptor immunostaining in the rat forebrain.
Abecia, LC; Acebes, I; Casis, L; Casis, O; de Gandarias, JM; Echevarría, E, 1999
)
2.14
"Fluoxetine is an effective antidepressant in the context of HIV illness. "( Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial.
Rabkin, JG; Rabkin, R; Wagner, GJ, 1999
)
3.19
"Fluoxetine 20 mg/d is an effective and well-tolerated treatment for women with PMDD, a severe variant of PMS."( The role of fluoxetine in the treatment of premenstrual dysphoric disorder.
Dillon, J; Judge, R; Romano, S; Shuler, C; Sundell, K, 1999
)
1.4
"Fluoxetine (Prozac) is an antidepressant that is thought to act by blocking presynaptic reuptake of the neurotransmitter serotonin. "( Fluoxetine-resistant mutants in C. elegans define a novel family of transmembrane proteins.
Choy, RK; Thomas, JH, 1999
)
3.19
"Fluoxetine is a widely used antidepressant compound having selective serotonin reuptake inhibitor properties. "( Electrophysiological effects of fluoxetine in mammalian cardiac tissues.
Bányász, T; Kecskeméti, V; Korom, Z; Magyar, J; Nánási, PP; Pacher, P; Pankucsi, C; Szigligeti, P; Ungvári, Z, 2000
)
2.03
"Fluoxetine (Prozac) is a potent selective serotonin reuptake inhibitor used for the treatment of major depression. "( Chiral high-performance liquid chromatographic analysis of fluoxetine and norfluoxetine in rabbit plasma, urine, and vitreous humor using an acetylated beta-cyclodextrin column.
Skrinska, VA; Wong, SH; Yee, L, 2000
)
1.99
"Fluoxetine is a potent and selective inhibitor of neuronal serotonin (5-hydroxytryptamine) reuptake. "( Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness.
Cheer, SM; Goa, KL, 2001
)
3.2
"Fluoxetine is an antidepressant that is administered as a racemic mixture of equipotent R- and S-enantiomers."( Effect of alosetron on the pharmacokinetics of fluoxetine.
D'Souza, DL; Dimmitt, DC; Koch, KM; Nezamis, J; Robbins, DK; Simms, L, 2001
)
1.29
"Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) with demonstrated efficacy in the treatment of major depressive episodes. "( [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].
Bonnet-Perrin, E; Etain, B,
)
1.98
"Fluoxetine is a commonly prescribed antidepressant compound. "( The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels.
Gut, B; Kiehn, J; Thomas, D; Wendt-Nordahl, G, 2002
)
2.06
"Fluoxetine was found to be a competitive inhibitor of 5-HT uptake by the myenteric plexus and was a more potent inhibitor of 5-HT uptake than was chlorimipramine."( Uptake and release of 5-hydroxytryptamine by enteric 5-hydroxytryptaminergic neurones: effects of fluoxetine (Lilly 110140) and chlorimipramine.
Gershon, MD; Jonakait, GM, 1979
)
1.2
"Fluoxetine is an antidepressant drug with weight reducing properties. "( An assessment of the thermogenic effects of fluoxetine in obese subjects.
Andrews, JF; Murphy, CM; Stinson, JC; Tomkin, GH, 1992
)
1.99
"Fluoxetine is a potent and specific inhibitor of 5-HT uptake even after prolonged dosing. "( The human pharmacology of fluoxetine.
Lucas, RA, 1992
)
2.03
"Fluoxetine is an inhibitor of serotonin re-uptake which has been found to produce weight loss in humans and animals. "( A randomized double-blind clinical trial of fluoxetine in obese diabetics.
Bray, GA; Devine, W; Fujioka, K; Gray, DS, 1992
)
1.99
"Fluoxetine is an antidepressant that is thought to act through inhibition of serotonin reuptake in the central nervous system. "( Abnormal platelet aggregation associated with fluoxetine therapy.
Alderman, CP; Ben-Tovim, DI; Moritz, CK, 1992
)
1.98
"Fluoxetine appears to be a highly effective, well-tolerated treatment for the psychological and physical symptoms accompanying severe PMS."( Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study.
Chan, YF; Moossazadeh, F; Mortola, JF; Wood, SH; Yen, SS, 1992
)
1.99
"Fluoxetine is an effective serotonin reuptake inhibitor antidepressant that can fail to alleviate either insomnia or major depression in a substantial minority of depressed patients. "( Possible trazodone potentiation of fluoxetine: a case series.
Cole, JO; Glass, L; Nierenberg, AA, 1992
)
2
"Fluoxetine appears to be a safe and effective drug for migraine prophylaxis, and deserves further therapeutic trials with larger groups for longer periods of time."( Fluoxetine prophylaxis of migraine.
Adly, C; Chesson, A; Straumanis, J, 1992
)
2.45
"Fluoxetine is a potent and specific serotonin re-uptake inhibitor and an effective antidepressant drug. "( Fluoxetine shortens circadian period for wheel running activity in mice.
Lumia, AR; McEldowney, S; Possidente, B; Rapp, M, 1992
)
3.17
"Fluoxetine (FLX) is a selective serotonin (5-HT) reuptake inhibitor with therapeutic benefit in patients with obsessive-compulsive disorder (OCD). "( Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder.
Hoh, A; Lesch, KP; Müller, T; Osterheider, M; Schulte, HM, 1991
)
2.13
"Fluoxetine is a highly specific serotonin reuptake inhibitor. "( Clinical studies with fluoxetine in obesity.
Wise, SD, 1992
)
2.04
"Fluoxetine is a serotonin-specific antidepressant approved in 1987 by the Food and Drug Administration for treatment of depression. "( Pharmacokinetics of second generation antidepressants: fluoxetine.
Goodnick, PJ, 1991
)
1.97
"Fluoxetine is a novel antidepressant known to block the reuptake of serotonin with little effect on other neurotransmitter systems."( The role of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction.
Fawcett, J; Guy, C; Jeffriess, H; Schaff, M; Zajecka, J, 1991
)
1.26
"Fluoxetine (Prozac) is a new antidepressant, first marketed in the United States in January 1988. "( The effects of fluoxetine in the overdose patient.
Borys, DJ; Day, LC; Krenzelok, EP; Ling, LJ; Reisdorf, JJ; Setzer, SC, 1990
)
2.07
"Fluoxetine (PROZAC) is a recently marketed straight chain antidepressant unrelated to the cyclic anti-depressants. "( Fluoxetine ingestion: a one year retrospective study.
Morse, S; Muir, C; Spiller, HA, 1990
)
3.16
"Fluoxetine is a novel antidepressant, with 5HT uptake inhibitory properties."( Clinical and experimental studies on fluoxetine: effects on serotonin uptake.
Butler, J; Leonard, BE, 1990
)
1.27
"Fluoxetine (Prozac) is a nontricyclic serotonin (5-hydroxytryptamine) reuptake inhibitor commonly prescribed for the treatment of depression. "( Fluoxetine and the bleeding time.
Humphries, JE; VandenBerg, SR; Wheby, MS, 1990
)
3.16
"Fluoxetine is a specific and long-lasting inhibitor of serotonin reuptake. "( A behavioural profile of fluoxetine-induced anorexia.
Barnfield, AM; Clifton, PG; Philcox, L, 1989
)
2.02
"Fluoxetine is a new, chemically unique antidepressant. "( An overview of fluoxetine, a new serotonin-specific antidepressant.
Boyer, WF; Feighner, JP, 1989
)
2.07
"Fluoxetine is an antidepressant drug with a unique chemical configuration which enhances serotoninergic transmission by inhibiting serotonin uptake. "( Fluoxetine: prescribing guidelines for the newest antidepressant.
Lippmann, S; Pary, R; Tobias, C, 1989
)
3.16
"Fluoxetine is a new antidepressant which enhances serotoninergic neurotransmission through potent and selective inhibition of neuronal reuptake of serotonin. "( Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
Benfield, P; Heel, RC; Lewis, SP, 1986
)
3.16
"Fluoxetine is a potent and selective inhibitor of the neuronal serotonin-uptake carrier and is a clinically effective antidepressant. "( Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor.
Fuller, RW; Krushinski, JH; Leander, JD; Robertson, DW, 1988
)
1.94
"Fluoxetine is a specific and potent inhibitor of presynaptic serotonin reuptake and has been shown to be a clinically effective antidepressant. "( Fluoxetine disposition and elimination in cirrhosis.
Bergstrom, RF; Lemberger, L; Schenker, S; Wolen, RL, 1988
)
3.16
"Fluoxetine is a new antidepressant with pharmacologic effects apparently limited to blockade of neuronal serotonin reuptake. "( An open trial of fluoxetine in the treatment of panic attacks.
Campeas, RB; Davies, SO; Fyer, AJ; Fyer, MR; Goetz, D; Gorman, JM; Klein, DF; Liebowitz, MR, 1987
)
2.06
"Fluoxetine is a specific inhibitor of serotonin re-uptake with very minimal affinity for serotonergic or other receptors."( Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity.
Bosomworth, J; Levine, LR; Rosenblatt, S, 1987
)
1.26
"Fluoxetine is a bicyclic antidepressant that is a specific and potent inhibitor of the presynaptic reuptake of serotonin. "( Fluoxetine: a serotonin-specific, second-generation antidepressant.
Bowden, CL; Crismon, ML; Sommi, RW,
)
3.02
"Fluoxetine is a selective inhibitor of serotonin uptake in vitro. "( The pharmacologic profile of fluoxetine.
Fuller, RW; Stark, P; Wong, DT, 1985
)
2

Effects

Fluoxetine has a favorable adverse effect profile when compared with older classes of antidepressants. It has an additive effect on the effect of isoniazid, and their concomitant use in the delivery system can have significant effects.

Fluoxetine (FLX) has been widely used as first-line treatment in cases of depression and other neuropsychiatric disorders. It has been shown to improve cognition in the early stage of AD and to be associated with diminishing synapse degeneration in the hippocampus.

ExcerptReferenceRelevance
"Fluoxetine also has an additive effect on the effect of isoniazid, and their concomitant use in the delivery system can have significant effects in treating infection of all clinical strains of Mtb."( An effective nano drug delivery and combination therapy for the treatment of Tuberculosis.
Amiri, V; Delorme, V; Ebrahimzadeh, N; Kasaeian, A; Maleki, M; Masoumi, M; Pourazar, S; Sadeghinia, M; Sheikhpour, M, 2022
)
1.44
"Fluoxetine treatment has a clear antiaggressive effect in impulsive aggressive individuals with IED. "( A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder.
Coccaro, EF; Kavoussi, RJ; Lee, RJ, 2009
)
2.04
"Fluoxetine has a better analgesic effect than a placebo in treating persistent somatoform pain disorder, and is considered a safe treatment; its analgesic effect may be related to an antidepressant effect."( A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder.
Li, CB; Li, QW; Lu, Z; Luo, YL; Wu, WY; Zhang, MY, 2009
)
2.03
"Fluoxetine has a favorable adverse effect profile when compared with older classes of antidepressants."( Memory loss in a patient treated with fluoxetine.
Burton, RM; Joss, JD; Keller, CA, 2003
)
1.31
"Fluoxetine has a half-life of 2-7 days, whereas the half-life of norfluoxetine ranges between 4 and 15 days."( [Fluoxetine: an update of its use in major depressive disorder in adults].
Gourion, D; Perrin, E; Quintin, P,
)
1.76
"Fluoxetine has a t1/2 of 2-4 days and has an active metabolite with a t1/2 of 7-15 days."( Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline.
Preskorn, S, 1994
)
1.23
"Fluoxetine has a nonlinear pharmacokinetic profile."( Clinical pharmacokinetics of fluoxetine.
Altamura, AC; Moro, AR; Percudani, M, 1994
)
1.3
"Fluoxetine treatment has an antiaggressive effect on impulsive aggressive individuals with DSM-III-R personality disorder."( Fluoxetine and impulsive aggressive behavior in personality-disordered subjects.
Coccaro, EF; Kavoussi, RJ, 1997
)
3.18
"Fluoxetine (FLX) has a unique pharmacokinetic profile. "( Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial.
Bessette, D; Burke, WJ; Hendricks, SE; Jacques, D; McArthur-Miller, D; McKillup, T; Stull, T; Wilson, J, 2000
)
2.09
"Fluoxetine, which has a long half-life, was more difficult to titrate."( Apathy and indifference in patients on fluvoxamine and fluoxetine.
Hoehn-Saric, R; Lipsey, JR; McLeod, DR, 1990
)
1.25
"Fluoxetine (FLX) has been widely used as first-line treatment in cases of depression and other neuropsychiatric disorders. "( Vinpocetine attenuates fluoxetine-induced liver damage in rats; Role of Nrf2 and PPAR-γ.
Mohamed Kamel, GA, 2021
)
2.37
"Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro."( Fluoxetine-induced hepatic lipid accumulation is mediated by prostaglandin endoperoxide synthase 1 and is linked to elevated 15-deoxy-Δ
Ayyash, A; Holloway, AC, 2022
)
2.89
"Fluoxetine also has an additive effect on the effect of isoniazid, and their concomitant use in the delivery system can have significant effects in treating infection of all clinical strains of Mtb."( An effective nano drug delivery and combination therapy for the treatment of Tuberculosis.
Amiri, V; Delorme, V; Ebrahimzadeh, N; Kasaeian, A; Maleki, M; Masoumi, M; Pourazar, S; Sadeghinia, M; Sheikhpour, M, 2022
)
1.44
"Fluoxetine has been used as the first line for the therapy of depression. "( Gap junction is essential for the antidepressant effects of fluoxetine.
Chen, NH; Chu, SF; Jiang, H; Li, FF; Lou, YX; Ren, Q; Shao, QH; Wan, JF; Wang, ZZ; Xia, CY; Yan, X; Yang, PF; Zhang, NN; Zhang, XL; Zhang, Y; Zhang, YN; Zhu, HY, 2023
)
2.6
"Fluoxetine (Flx) has been widely used to treat MDD, but its mechanisms of action remain elusive."( Chronic fluoxetine treatment in socially-isolated rats modulates the prefrontal cortex synaptoproteome.
Bernardi, RE; Filipović, D; Novak, B; Turck, CW; Xiao, J; Yan, Y, 2023
)
2.07
"Fluoxetine (FLX) has been shown to improve cognition in the early stage of AD and to be associated with diminishing synapse degeneration in the hippocampus."( Fluoxetine Protects against Dendritic Spine Loss in Middle-aged APPswe/PSEN1dE9 Double Transgenic Alzheimer's Disease Mice.
Gao, Y; Huang, W; Ma, J; Tang, W; Tang, Y, 2020
)
2.72
"Fluoxetine (FLX) has been considered as an effective anti-depressant drug. "( Optimized integration of fluoxetine and 7, 8-dihydroxyflavone as an efficient therapy for reversing depressive-like behavior in mice during the perimenopausal period.
Amin, N; Botchway, BOA; Chen, Y; Fang, M; Hu, S; Hu, Z; Ma, Y; Ren, Q; Tan, X; Xie, S, 2020
)
2.3
"Fluoxetine (FLX) has become the first-line drug in the pharmacotherapy of patients with depression. "(
Marzouk, MA; Mohamed, OS; Osman, DA, 2021
)
2.06
"Fluoxetine has been shown to have the anti-inflammatory properties in many disease models."( Fluoxetine-enhanced autophagy ameliorates early brain injury via inhibition of NLRP3 inflammasome activation following subrachnoid hemorrhage in rats.
Chen, G; Chen, JS; Chen, JY; Fan, LF; Gu, C; Li, JR; Nie, S; Peng, YC; Wang, C; Wang, L; Wang, ZJ; Wu, C; Xu, HZ; Yan, F, 2017
)
2.62
"Fluoxetine has been shown to induce anti-tumour activity. "( Fluoxetine selectively induces p53-independent apoptosis in human colorectal cancer cells.
Afshinjavid, S; Fatokun, AA; Javid, FA; Marcinkute, M, 2019
)
3.4
"Fluoxetine has been reported to treat anorexia nervosa (AN) caused by chemotherapy in patients with cholangiocarcinoma effectively. "( Efficacy of fluoxetine for anorexia nervosa caused by chemotherapy in patients with cholangiocarcinoma.
Feng, Y; Guo, LQ; Qu, YK; Sun, HW; Teng, XL; Zhang, CY, 2019
)
2.34
"Fluoxetine therefore has inverse effects on mPFC activation in ASD and ADHD during reversal learning, suggesting dissociated underlying serotonin abnormalities."( Inverse Effect of Fluoxetine on Medial Prefrontal Cortex Activation During Reward Reversal in ADHD and Autism.
Barrett, N; Brammer, M; Chantiluke, K; Giampietro, V; Murphy, DG; Rubia, K; Simmons, A, 2015
)
1.47
"Fluoxetine has also demonstrated utility in the treatment of other disorders for which its prescription has now been approved."( Fluoxetine: a case history of its discovery and preclinical development.
Berrocoso, E; Bravo, L; Mico, JA; Perez-Caballero, L; Torres-Sanchez, S, 2014
)
2.57
"Fluoxetine (FLX) has been one of the most widely studied selective serotonin reuptake inhibitors in adolescents. "( Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder.
Arnaiz, JA; Blázquez, A; Gassó, P; Lafuente, A; Lázaro, L; Mas, S; Méndez, I; Plana, MT; Torra, M, 2014
)
2.3
"Fluoxetine has been shown to be effective in clinical and experimental studies of neuropathic pain. "( Serotonergic modulation in neuropathy induced by oxaliplatin: effect on the 5HT2C receptor.
Baptista-de-Souza, D; Canto-de-Souza, A; Di Cesare Mannelli, L; Ghelardini, C; Micheli, L; Nunes-de-Souza, RL; Zanardelli, M, 2014
)
1.85
"Fluoxetine has anti-inflammatory and antihyperalgesic effects in the carrageenan model of inflammation. "( Experimental study on the role of 5-HT2 serotonin receptors in the mechanism of anti-inflammatory and antihyperalgesic action of antidepressant fluoxetine.
Delev, DP; Kostadinov, ID; Kostadinova, II; Murdjeva, MA,
)
1.77
"Fluoxetine has been used among older adults as an all-purpose drug for the treatment of depressive disorders because of psychosocial adversities, lack of social support, and limited access to adequate healthcare services for the treatment of this disorder."( Treatment of depression in older adults beyond fluoxetine.
Wagner, GA, 2015
)
1.4
"Fluoxetine has emerged as a novel treatment for persistent amblyopia because in adult animals it reinstates critical period-like ocular dominance plasticity and promotes recovery of visual acuity. "( Effects of Fluoxetine and Visual Experience on Glutamatergic and GABAergic Synaptic Proteins in Adult Rat Visual Cortex.
Beshara, S; Beston, BR; Murphy, KM; Pinto, JG,
)
1.96
"Fluoxetine exposure has been found to influence boldness and exploration in a range of fish species; however, how it might alter behavior in multiple contexts or over time is rarely examined."( Dose-dependent fluoxetine effects on boldness in male Siamese fighting fish.
Campbell, BA; Dzieweczynski, TL; Kane, JL, 2016
)
1.51
"Fluoxetine has been associated with hypoglycaemia in patients with diabetes mellitus."( Fluoxetine-Induced Hypoglycaemia in a Patient with Congenital Hyperinsulinism on Lanreotide Therapy.
Didi, M; Giri, D; Price, V; Senniappan, S; Yung, Z, 2016
)
2.6
"Fluoxetine (FLX) has been widely prescribed for use during depression in pregnancy and lactation."( In utero and lactational exposure to fluoxetine delays puberty onset in female rats offspring.
Anselmo-Franci, JA; Ceravolo, GS; de Azevedo Camin, N; Dos Santos, AH; Gerardin, DC; Kiss, AC; Mesquita, Sde F; Moreira, EG; Pelosi, GG; Vieira, ML, 2016
)
1.43
"Fluoxetine has been viewed as an agent that may interfere with cell fate by triggering apoptosis."( Fluoxetine and the mitochondria: A review of the toxicological aspects.
de Oliveira, MR, 2016
)
2.6
"Fluoxetine (FLX) has paradoxical anxiogenic-like effects during the acute phase of treatment. "( Anxiogenic-like effects of fluoxetine render adult male rats vulnerable to the effects of a novel stress.
García-García, L; Gomez, F, 2017
)
2.19
"Fluoxetine has relatively high affinity for Gq/11 protein-coupled 5-HT(2) receptors. "( Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation.
Cai, L; Hertz, L; Li, B; Nu, W; Peng, L; Zhang, H; Zhang, S, 2008
)
3.23
"Fluoxetine has sustained efficacy on patients with obsessive-compulsive disorder and is generally well tolerated. "( Effectiveness of fluoxetine on various subtypes of obsessive-compulsive disorder.
Farhang, S; Farnam, A; Goreishizadeh, MA, 2008
)
2.13
"Fluoxetine has been shown to enhance several behavioral effects of cocaine, including its discriminative-stimulus effects. "( Fluoxetine does not alter the ability of dopamine D(1)- and D(2)-like agonists to substitute for cocaine in squirrel monkeys.
Katz, JL; Soto, PL, 2009
)
3.24
"Fluoxetine has been tested in a two-species water-sediment system, which allowed a two-generation study with Chironomus riparius and a partial life-cycle with the freshwater snail Physa acuta to be performed at the same time. "( Assessing the effects of fluoxetine on Physa acuta (Gastropoda, Pulmonata) and Chironomus riparius (Insecta, Diptera) using a two-species water-sediment test.
Fernández, C; Sánchez-Argüello, P; Tarazona, JV, 2009
)
2.1
"Fluoxetine treatment has a clear antiaggressive effect in impulsive aggressive individuals with IED. "( A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder.
Coccaro, EF; Kavoussi, RJ; Lee, RJ, 2009
)
2.04
"Fluoxetine has a better analgesic effect than a placebo in treating persistent somatoform pain disorder, and is considered a safe treatment; its analgesic effect may be related to an antidepressant effect."( A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder.
Li, CB; Li, QW; Lu, Z; Luo, YL; Wu, WY; Zhang, MY, 2009
)
2.03
"Fluoxetine has been observed to reduce negative consequences of stress on the immune system in experimental and clinical models, but there are no data on its effects on oral candidiasis."( Effects of psychological stress and fluoxetine on development of oral candidiasis in rats.
Balboa, J; Freire-Garabal, M; Novío, S; Núñez, MJ; Suárez, JA, 2010
)
1.36
"Fluoxetine has been reported to decrease the number of "mature" calbindin-positive cells in the dentate gyrus; we found this still occurred on the side of a CA3 lesion."( Novel control by the CA3 region of the hippocampus on neurogenesis in the dentate gyrus of the adult rat.
Herbert, J; Liu, JX; Pinnock, SB, 2011
)
1.09
"Fluoxetine also has blocking effects on various ion channels, including Ca(2+) channels."( Fluoxetine suppresses synaptically induced [Ca²⁺]i spikes and excitotoxicity in cultured rat hippocampal neurons.
Choi, SJ; Hahn, SJ; Hong, YJ; Kim, HJ; Kim, TH; Rhie, DJ; Sung, KW; Yang, JS; Yoon, SH, 2013
)
2.55
"Fluoxetine hydrochloride has been prepared using two similar synthetic routes, both of which rely upon an ether formation reaction mediated by a base. "( Utilizing capillary gas chromatography mass spectrometry to determine 4-benzotrifluoride t-butyl ether as a reaction by-product in fluoxetine synthesized using potassium t-butoxide as base.
Buccilli, LA; Dodson, PN; Mitchell, D; Robbins, DK, 2003
)
1.97
"Fluoxetine has a favorable adverse effect profile when compared with older classes of antidepressants."( Memory loss in a patient treated with fluoxetine.
Burton, RM; Joss, JD; Keller, CA, 2003
)
1.31
"Fluoxetine has a half-life of 2-7 days, whereas the half-life of norfluoxetine ranges between 4 and 15 days."( [Fluoxetine: an update of its use in major depressive disorder in adults].
Gourion, D; Perrin, E; Quintin, P,
)
1.76
"Fluoxetine has been given to stroke patients to combat depression but its effects on recovery of function are not known."( Fluoxetine and recovery of motor function after focal ischemia in rats.
Corbett, D; Windle, V, 2005
)
2.49
"Fluoxetine now has largely (albeit not completely) substituted older and less safe drugs such as tricyclic antidepressants."( Fluoxetine metabolism and pharmacological interactions: the role of cytochrome p450.
Forti, GC; Mandrioli, R; Raggi, MA, 2006
)
2.5
"Fluoxetine has been reported to be a novel allosteric modulator of GABA(A) receptors with the notable exception of receptors that contain the alpha5-subunit isoform [Robinson, R.T., Drafts, B.C., Fisher, J.L., 2003. "( A single point mutation of the GABA(A) receptor alpha5-subunit confers fluoxetine sensitivity.
Davies, M; Derry, JM; Dunn, SM; Paulsen, IM, 2007
)
2.02
"Fluoxetine (FLX) has been widely prescribed for depression during pregnancy and/or lactation. "( Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation.
Costa, LC; Lisboa, SF; Moreira, EG; Oliveira, PE; Venâncio, EJ, 2007
)
2.02
"Fluoxetine has been shown to provide protection from MDMA induced long term neurotoxicity. "( Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat.
Eddington, ND; Upreti, VV, 2008
)
3.23
"As fluoxetine has different effects on different brain regions and as learning is not a unitary phenomenon, it may be the case that fluoxetine has different effects on different types of learning and memory paradigms."( Effects of fluoxetine on hippocampal-dependent and hippocampal-independent learning tasks.
Chan, K; Valluzzi, JA, 2007
)
1.24
"Norfluoxetine has been detected for the first time in sewage water and a preliminary analysis gave average concentrations of 150 and 225 ng/L for norfluoxetine and fluoxetine, respectively."( Hollow-fibre supported liquid membrane extraction for determination of fluoxetine and norfluoxetine concentration at ultra trace level in sewage samples.
Mårtensson, L; Mathiasson, L; Zorita, S, 2007
)
1.09
"Fluoxetine has a t1/2 of 2-4 days and has an active metabolite with a t1/2 of 7-15 days."( Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline.
Preskorn, S, 1994
)
1.23
"Fluoxetine has demonstrated, in controlled studies, significantly lower rates of side-effects and treatment dropout than TCAs while showing similar efficacy."( The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs. tricyclics.
Beuzen, JN; Le Pen, C; Levy, E; Meurgey, F; Ravily, V, 1994
)
1.24
"Fluoxetine has a nonlinear pharmacokinetic profile."( Clinical pharmacokinetics of fluoxetine.
Altamura, AC; Moro, AR; Percudani, M, 1994
)
1.3
"Fluoxetine has been reported to increase carbamazepine (CBZ) plasma concentrations and cause adverse effects. "( Evaluation of the effect of fluoxetine on the formation of carbamazepine epoxide.
Anderson, GD; Gidal, BE; Miyoshi, HR; Seaton, TL; Wilenksy, AJ, 1993
)
2.02
"Fluoxetine has been reported to have interactions with antipsychotics and other antidepressants with symptoms of toxicity of these drugs. "( Possible interaction between fluoxetine and pimozide causing sinus bradycardia.
Ahmed, I; Dagincourt, PG; Miller, LG; Shader, RI, 1993
)
2.02
"Fluoxetine has been reported to produce bruising, bleeding, and other hematologic disorders. "( Bruising associated with the use of fluoxetine.
Kelly, MW; Pai, VB,
)
1.85
"Fluoxetine has no measurable electrocardiographic effects, which suggests an increased safety margin for cardiac adverse effects."( Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder.
Baker, B; Dorian, P; Irvine, MJ; Mitchell, J; Sandor, P; Schell, C; Shapiro, C, 1997
)
1.3
"Fluoxetine has been widely prescribed by physicians knowledgeable in pharmacology and in the treatment of depression because of its proven efficacy (ie, equal to that of tricyclic antidepressants [TCAs]), its ease of administration (with full therapeutic dosing usually starting from day 1), its generally benign side-effect profile, its remarkable safety in over-dose, and its proven effectiveness in the most common depressed patient population--anxious, agitated, depressed patients--as well as in patients with various subtypes and severities of depression."( Fluoxetine tenth anniversary update: the progress continues.
Holtz, A; Stokes, PE,
)
2.3
"Fluoxetine treatment has an antiaggressive effect on impulsive aggressive individuals with DSM-III-R personality disorder."( Fluoxetine and impulsive aggressive behavior in personality-disordered subjects.
Coccaro, EF; Kavoussi, RJ, 1997
)
3.18
"Fluoxetine has been reported to suppress food intake in animal models of feeding. "( 5HT1A receptor antagonists enhance the functional activity of fluoxetine in a mouse model of feeding.
Iyengar, S; Li, DL; Simmons, RM, 1998
)
1.98
"Fluoxetine, which has been shown to inhibit NPY release, inhibited spontaneous food intake and completely blocked the stimulation of food intake by HS014."( Evidence that orexigenic effects of melanocortin 4 receptor antagonist HS014 are mediated by neuropeptide Y.
Kask, A; Korrovits, P; Rägo, L; Schiöth, HB; Wikberg, JE, 1998
)
1.02
"Fluoxetine has been associated with weight loss during acute treatment, but no controlled studies of weight change during long-term treatment with fluoxetine or other selective serotonin reuptake inhibitors have been reported. "( Changes in weight during a 1-year trial of fluoxetine.
Amsterdam, JD; Beasley, CM; Kim, Y; Michelson, D; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Sundell, KL; Zajecka, J, 1999
)
2.01
"Fluoxetine has displayed an efficacious response in controlled studies of patients with PTSD who were predominantly female, suffered civilian (noncombat) traumas, and were overall experiencing less severe PTSD."( Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans.
Beckham, JC; Davidson, JR; Feldman, ME; Hertzberg, MA; Kudler, HS, 2000
)
1.35
"Fluoxetine (FLX) has a unique pharmacokinetic profile. "( Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial.
Bessette, D; Burke, WJ; Hendricks, SE; Jacques, D; McArthur-Miller, D; McKillup, T; Stull, T; Wilson, J, 2000
)
2.09
"Fluoxetine has shown superior efficacy compared with placebo in the treatment of depression in patients with HIV/AIDS, diabetes mellitus or stroke; however, it has not significantly improved depressive symptoms versus placebo in patients with cancer. "( Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness.
Cheer, SM; Goa, KL, 2001
)
3.2
"Fluoxetine 20 mg has been reported to be effective for emotional and physical premenstrual symptoms with continuous daily dosing (every day of the menstrual cycle) and with luteal phase daily dosing (from ovulation to menses)."( Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder.
Pearlstein, T; Yonkers, KA, 2002
)
1.44
"Fluoxetine has no effect on normal blood pressure although mean heart rate is slightly reduced."( The human pharmacology of fluoxetine.
Lucas, RA, 1992
)
1.31
"Fluoxetine has been reported to cause cardiac conduction abnormalities in otherwise normal individuals. "( Case report of a syncopal episode associated with fluoxetine.
Dreyling, CA; McAnally, LE; Threlkeld, KR, 1992
)
1.98
"Fluoxetine's efficacy has been principally based on convincing open-label studies and clinical practice."( Serotonergic antidepressants and their efficacy in obsessive compulsive disorder.
Dominguez, RA, 1992
)
1
"Fluoxetine has been available for use as an antidepressant since early 1988. "( A possible association between fluoxetine use and suicide.
Bost, RO; Kemp, PM,
)
1.86
"Fluoxetine has been greeted with an enthusiasm that claims some advantages over other antidepressants."( Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.
Ciraulo, DA; Shader, RI, 1990
)
2.44
"Fluoxetine has found a variety of therapeutic application."( Fluoxetine, a selective inhibitor of serotonin uptake.
Fuller, RW; Robertson, DW; Wong, DT, 1991
)
2.45
"Fluoxetine, which has a long half-life, was more difficult to titrate."( Apathy and indifference in patients on fluvoxamine and fluoxetine.
Hoehn-Saric, R; Lipsey, JR; McLeod, DR, 1990
)
1.25
"Fluoxetine has overall therapeutic efficacy comparable with imipramine, amitriptyline and doxepin in patients with unipolar depression treated for 5 to 6 weeks, although it may be less effective than tricyclic antidepressants in relieving sleep disorders in depressed patients."( Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.
Benfield, P; Heel, RC; Lewis, SP, 1986
)
2.44
"Fluoxetine has been used with success in obsessive-compulsive disorder and intention myoclonus, however, its use in these disorders remains investigational."( Fluoxetine: a serotonin-specific, second-generation antidepressant.
Bowden, CL; Crismon, ML; Sommi, RW,
)
2.3

Actions

Fluoxetine is known to cause disruptions in reproductive behavior of freshwater mussels (order Unionoida) It can enhance combined learning and memory abilities and prolong such memories in mice by promoting the function of barrel cortex cells.

ExcerptReferenceRelevance
"Both fluoxetine and AKS466 inhibit the acid ceramidase activity, cause endo-lysosomal ceramide elevation, and interfere with viral replication."( The Acid Ceramidase Is a SARS-CoV-2 Host Factor.
Bodem, J; Brenner, D; Diesendorf, V; Fähr, S; Geiger, N; Kersting, L; König, EM; Reinhard, S; Roll, V; Sauer, M; Schlegel, J; Schneider-Schaulies, S; Seibel, J; Sostmann, M; Stelz, L, 2022
)
1.18
"Fluoxetine plays an important role in the treatment of onychotillomania and other psychiatric disorders."( Fluoxetine for the treatment of onychotillomania associated with obsessive-compulsive disorder: a case report.
Aljhani, S, 2022
)
2.89
"Fluoxetine plays neuroprotective effects in relieving LPS-induced depression-like and motor behaviors. "( Fluoxetine shows neuroprotective effects against LPS-induced neuroinflammation via the Notch signaling pathway.
Jing, B; Lei, J; Li, M; Li, X; Tian, H; Xue, B; Zhang, J; Zhang, N, 2022
)
3.61
"Fluoxetine can enhance combined learning and memory abilities and prolong such memories in mice by promoting the function of the barrel cortex cells."( [Fluoxetine enhances combined learning and memory abilities of mice by promoting neural cell functions in the barrel cortex].
Huo, Q; Sun, Y; Zhang, T; Zhang, W, 2020
)
2.19
"Fluoxetine is known to cause disruptions in reproductive behavior of freshwater mussels (order Unionoida), including stimulating release of gametes, parturition of glochidia (larvae), and changes in lure display and foot protrusion."( Chronic fluoxetine exposure alters movement and burrowing in adult freshwater mussels.
Bringolf, RB; Brooks, BW; Chambliss, CK; Du, B; Fritts, AK; Haddad, SP; Hazelton, PD, 2014
)
1.56
"Fluoxetine did, however, increase the dendritic arborization of these cells, which was reduced in the mice with lesions."( The effects of chronic fluoxetine treatment following injury of medial frontal cortex in mice.
Barneto, AA; Dyck, RH; McAllister, BB; Patel, PP; Spanswick, SC, 2015
)
1.45
"Fluoxetine was found to suppress Ca(2+) signaling in response to T cell receptor activation."( Fluoxetine suppresses calcium signaling in human T lymphocytes through depletion of intracellular calcium stores.
Broeckx, BJ; De Bock, M; De Spiegelaere, W; Deforce, D; Gobin, V; Kiselinova, M; Leybaert, L; Van Steendam, K; Vandekerckhove, L, 2015
)
2.58
"Fluoxetine also did not increase forced swim struggle behavior in juvenile mice of all strains, but was effective in increasing struggle in adults."( Differential sensitivity to SSRI and tricyclic antidepressants in juvenile and adult mice of three strains.
Baker, KB; Davis, KW; Gerhardt, B; Lanthorn, TH; Malbari, MM; Mason, SS; Pogorelov, VM; Ritter, R; Savelieva, KV; Wray, SP, 2009
)
1.07
"Fluoxetine did not cause significant mortality at levels near currently reported environmental concentrations."( Effects of fluoxetine exposure on serotonin-related activity in the sheepshead minnow (Cyprinodon variegatus) using LC/MS/MS detection and quantitation.
Pennington, PL; Sapozhnikova, Y; Winder, VL; Wirth, EF, 2009
)
1.46
"Fluoxetine was found to suppress neuronal cell loss when injected at 10 mg/kg and the effect was enhanced at 50 mg/kg."( Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus.
Han, PL; Jin, Y; Kim, SW; Lee, JK; Lim, CM; Park, JY; Seo, JS; Yoon, SH, 2009
)
2.52
"Fluoxetine was chosen because it has become a first-line drug for the treatment of affective disorders."( Metabolic mapping of the effects of the antidepressant fluoxetine on the brains of congenitally helpless rats.
Barrett, DW; Colorado, RA; Gonzalez-Lima, F; Shumake, J, 2010
)
1.33
"Fluoxetine caused an increase in anxiety-like behavior in treated adult, but not adolescent, rats. "( Age-dependent effects of chronic fluoxetine treatment on the serotonergic system one week following treatment.
Booij, J; Bouet, V; Boulouard, M; Dauphin, F; Freret, T; Gsell, W; Klomp, A; Lopez-Tremoleda, J; Reneman, L; Wylezinska-Arridge, M, 2012
)
2.1
"This fluoxetine-induced increase in GDNF and BDNF protein levels was accompanied by activation of the ERK signaling pathway."( Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.
Adame, A; Inglis, C; Mante, M; Masliah, E; May, V; Patrick, C; Rockenstein, E; Spencer, B; Ubhi, K; Winkler, J, 2012
)
2.28
"fluoxetine) anxiolytics inhibit marble burying."( A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants.
Kolb, Y; Nicolas, LB; Prinssen, EP, 2006
)
1.06
"The fluoxetine group had lower depression scores at termination than the placebo group, but these differences did not achieve statistical significance."( Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder.
Corral, MR; Gorman, CP; Joffe, RT; Lam, RW; Levitt, AJ; Michalon, M; Morehouse, RL; Steiner, M; Tam, W; Watson, GD, 1995
)
1.04
"Fluoxetine did not inhibit the metabolism of terfenadine and is unlikely to affect the metabolism of terfenadine or other drugs that are CYP3A substrates."( Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine.
Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Hatcher, BL, 1997
)
1.97
"Fluoxetine appeared to increase abstinence rates among high BDI smokers compared to high BDI smokers assigned placebo."( The effects of fluoxetine combined with nicotine inhalers in smoking cessation--a randomized trial.
Bjornsdottir, US; Blondal, T; Gudmundsson, LJ; Hilmarsdottir, H; Jonsdottir, D; Kristjansson, F; Nilsson, F; Tomasson, K, 1999
)
1.38
"Fluoxetine appears to cause a low incidence of adverse cardiac effects. "( Fluoxetine-induced bradycardia and syncope in two patients.
Ellison, JM; Ely, E; Milofsky, JE, 1990
)
3.16
"Fluoxetine may increase the plasma levels of standard tricyclic antidepressants and the likelihood of tricyclic antidepressant toxicity."( Increased plasma tricyclic antidepressant concentrations in two patients concurrently treated with fluoxetine.
Akiskal, HS; Deal, N; Downs, AD; Downs, JM; Rosenthal, TL, 1989
)
1.21

Treatment

Fluoxetine treatment reversed MDMA-induced anxiety in the emergence test and depressive-like effects in the forced swim test, yet exhibited no effects on the social interaction test. Treatment of old mice further increased hippocampal S100B, suggesting that aging does not interfere with fluoxetin's action on hippocampus.

ExcerptReferenceRelevance
"The fluoxetine-treated group took 20mg fluoxetine daily for 90 days in a phase II trial and were compared to fluoxetine-untreated historical controls."( Efficacy of Fluoxetine for Post-Ischemic Stroke Depression in Tanzania.
Chiwanga, F; Ismail, S; Kapina, B; Massawe, E; Mateen, FJ; Mworia, NA; Okeng'o, K; Rice, DR; Wasserman, M, 2022
)
1.58
"Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ"( Fluoxetine-induced hepatic lipid accumulation is mediated by prostaglandin endoperoxide synthase 1 and is linked to elevated 15-deoxy-Δ
Ayyash, A; Holloway, AC, 2022
)
2.89
"Fluoxetine treatment in the luxol fast blue (LFB) staining of the corpus callosum has been led to an increase in myelination capacity in all doses and times."( Effect of fluoxetine treatment on neurotoxicity induced by lysolecithin in male rats.
Ahmadi, M; Alipour, M; Chehelcheraghi, F; Gholami, E; Gholami, MR; Khaksarian, M; Rezaian, J; Tavakoli, A, 2022
)
1.85
"Fluoxetine treatment showed protective effect against SI, AD and prevents exacerbation of CVD."( Fluoxetine ameliorates Alzheimer's disease progression and prevents the exacerbation of cardiovascular dysfunction of socially isolated depressed rats through activation of Nrf2/HO-1 and hindering TLR4/NLRP3 inflammasome signaling pathway.
Aboutaleb, AS; Abu-Elfotuh, K; Al-Najjar, AH; Badawi, GA; Mohammed, AA, 2022
)
2.89
"Fluoxetine treatment significantly reduced the BW gain, hyperglycaemia, creatinine, and BUN in diabetic rats. "( Oral fluoxetine treatment changes serotonergic sympatho-regulation in experimental type 1 diabetes.
Alarcón-Torrecillas, C; Fernández-González, JF; García-Domingo, M; García-Pedraza, JÁ; López, C; Martín, ML; Morán, A; Rodríguez-Barbero, A, 2022
)
2.68
"Fluoxetine treated (Group II) received 24 mg/kg/day of fluoxetine dissolved in 1.0 mL of tap water once a day."( Electron microscopic study on the effect of chronic fluoxetine treatment on pituitary gland and the possible therapeutic effect of adipose-derived mesenchymal stem cells in adult male albino rats.
Abd Allah, EG; Mohammed, MZ; Seliem, AO; Wahba, NS, 2022
)
1.69
"Fluoxetine-treated and placebo-treated patients had the same overall impact on FMMS scores at 1 month ( P =0.41)."( Recovery in Stroke Patients Treated With Fluoxetine Versus Placebo: A Pooled Analysis of 7,165 Patients.
Ahmed, E; Doheim, MF; Elfil, M; Elsnhory, A; Fathy, A; Hagrass, AI; Hanbal, A; Hasan, MT; Ouerdane, Y; Ragab, KM, 2023
)
1.9
"Fluoxetine is safe treatment for refractory primary monosymptomatic nocturnal enuresis in children with good initial response that declines at 12 weeks."( The Safety and Efficacy of Fluoxetine for the Treatment of Refractory Primary Monosymptomatic Nocturnal Enuresis in Children: A Randomized Placebo-Controlled Trial.
Abdelhalim, A; El-Kenawy, MR; Hashem, A; Helmy, TE; Hussiny, M; Soltan, MA, 2022
)
2.46
"Fluoxetine treatment was applied in chronic variable mild stress (CVMS)-exposed (environmental hit) CD1 mice carrying one mutated allele of pituitary adenylate cyclase-activating polypeptide gene (genetic hit) that were previously exposed to maternal deprivation (epigenetic hit) vs."( Fluoxetine treatment supports predictive validity of the three hit model of depression in male PACAP heterozygous mice and underpins the impact of early life adversity on therapeutic efficacy.
Berta, G; Csernus, V; Farkas, J; Füredi, N; Gaszner, B; Gaszner, T; Hashimoto, H; Kormos, V; Kovács, LÁ; Kun, D; Reglődi, D; Ujvári, B, 2022
)
2.89
"Fluoxetine treatment was applied to test the predictive validity of our model."( Epigenetic and Neuronal Activity Markers Suggest the Recruitment of the Prefrontal Cortex and Hippocampus in the Three-Hit Model of Depression in Male PACAP Heterozygous Mice.
Farkas, J; Füredi, N; Gaszner, B; Gaszner, T; Hashimoto, H; Kormos, V; Kovács, LÁ; Kun, D; Reglődi, D; Ujvári, B, 2022
)
1.44
"Fluoxetine treatment increases the free concentration of the neurotransmitter serotonin and this monoamine is implicated in the regulation of the neurogenic process; however, the target of the action of this neurotransmitter has not been fully elucidated."( Fluoxetine increased adult neurogenesis is mediated by 5-HT3 receptor.
Blasco-Ibañez, JM; Crespo, C; Nácher, J; Olivas-Cano, I; Rodriguez-Andreu, JM; Varea, E, 2023
)
3.07
"Fluoxetine treatment partially reversed the down-regulation of SIRT1 level and the number of SIRT1"( [Effects of SIRT1 in amygdala on chronic restraint stress-induced depression-like behaviors in rats].
Chen, NN; Huang, CY; Yang, XR; Zhang, HM; Zhou, F, 2022
)
2.16
"Fluoxetine pretreatment partially restored the deteriorated cognitive function, downregulated proinflammatory cytokine levels, restrained microglial activation, alleviated neural apoptosis, and suppressed the increase in TLR4, MyD88, and p-NF-κB p65 in microglia."( Fluoxetine alleviates postoperative cognitive dysfunction by attenuating TLR4/MyD88/NF-κB signaling pathway activation in aged mice.
Chen, Y; Lin, D; Liu, L; Wu, Y; Yao, Y; Zheng, X, 2023
)
3.07
"Fluoxetine pretreatment suppressed hippocampal neuroinflammation and mitigated POCD by inhibiting microglial TLR4/MyD88/NF-κB pathway activation in aged mice."( Fluoxetine alleviates postoperative cognitive dysfunction by attenuating TLR4/MyD88/NF-κB signaling pathway activation in aged mice.
Chen, Y; Lin, D; Liu, L; Wu, Y; Yao, Y; Zheng, X, 2023
)
3.8
"Fluoxetine-treated monkeys with MAOA low transcription polymorphism had significantly lower ["( Serotonin Transporter Binding Potentials in Brain of Juvenile Monkeys 1 Year After Discontinuation of a 2-Year Treatment With Fluoxetine.
Campos, LJ; Fox, AS; Golub, MS; Hogrefe, CE, 2019
)
2.16
"Fluoxetine treatment also increased cell survival, particularly in wild type mice, though it did not affect proliferation."( Effects of social defeat stress and fluoxetine treatment on neurogenesis and behavior in mice that lack zinc transporter 3 (ZnT3) and vesicular zinc.
Dyck, RH; Fu, S; McAllister, BB; Pochakom, A, 2020
)
1.55
"Fluoxetine-treated mice with a femur fracture were treated with propranolol initiated at the time of fracture, and a battery of analyses demonstrated a reversal of the detrimental effect of fluoxetine on fracture healing in response to propranolol treatment."( Propranolol Reverses Impaired Fracture Healing Response Observed With Selective Serotonin Reuptake Inhibitor Treatment.
Bradaschia-Correa, V; Buchalter, DB; Ihejirika, R; Josephson, AM; Leclerc, K; Lee, S; Leucht, P; Litwa, HP; Markus, D; Remark, LH; Tejwani, R; Wong, MZ; Yim, NL, 2020
)
1.28
"The fluoxetine treatments reduced only the BLA's c-Fos expression."( Basolateral Amygdala but Not Medial Prefrontal Cortex Contributes to Chronic Fluoxetine Treatments for PTSD Symptoms in Mice.
Huang, ACW; Ou, CY; Shyu, BC; Yu, YH, 2020
)
1.27
"Fluoxetine treatment increased lipid accumulation in association with increased mRNA expression of tryptophan hydroxylase 1 ("( Fluoxetine-induced hepatic lipid accumulation is linked to elevated serotonin production.
Ayyash, A; Holloway, AC, 2021
)
2.79
"Fluoxetine treatment exhibited antidepressant effects and ameliorated the molecular changes induced by LPS."( Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression.
Ali, T; He, K; Li, N; Li, S; Li, W; Liu, Z; Rahman, SU; Ren, Q; Shah, FA; Yu, ZJ; Zheng, C, 2021
)
2.79
"Fluoxetine treatment resulted in a decrease in viral protein expression."( The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue.
Bodem, J; Danov, O; Geiger, N; Hilpert, H; Kirschner, L; Oberwinkler, H; Seibel, J; Sewald, K; Steinke, M; Zimniak, M, 2021
)
1.62
"fluoxetine in the treatment of postmenopausal MDD."( Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study.
Boyce, P; Chen, R; Feng, L; Hu, Y; Shi, H; Wang, G; Wang, X; Xiao, L; Yang, R; Zhou, J; Zhu, X, 2021
)
1.69
"With fluoxetine treatment, these reductions were achieved 12 weeks after OBX and the volumes were comparable to normal control rats."( The olfactory bulbectomized rat model is not an appropriate model for studying depression based on morphological/stereological studies of the hippocampus.
Schmitz, C; Steinbusch, HWM; Strekalova, T; Turgut, M; Yurttas, C, 2017
)
0.91
"Fluoxetine and melatonin treatments decreased TBARS in both cortices."( The antidepressant effect of melatonin and fluoxetine in diabetic rats is associated with a reduction of the oxidative stress in the prefrontal and hippocampal cortices.
Boudah, A; Jasmin, L; Rebai, R, 2017
)
1.44
"Fluoxetine treatment was associated with an improvement in depressive symptomology and HRQOL. "( Factors related to the improvement in quality of life for depressed inpatients treated with fluoxetine.
Lin, CH; Lu, MJ; Wang, FC; Yang, WC, 2017
)
2.12
"Fluoxetine treatment following the JVS significantly decreased the proportion of affected animals as measured in adulthood."( Fluoxetine treatment is effective in a rat model of childhood-induced post-traumatic stress disorder.
Ariel, L; Edut, S; Inbar, S; Richter-Levin, G, 2017
)
2.62
"Fluoxetine treatment reversed learned helplessness-induced changes in many long noncoding RNAs and target genes."( Long Noncoding RNA-Associated Transcriptomic Changes in Resiliency or Susceptibility to Depression and Response to Antidepressant Treatment.
Dwivedi, Y; Roy, B; Wang, Q, 2018
)
1.2
"Fluoxetine (8.2 mg/kg) treatment for 40 days significantly reduced (P < 0.01) the levels of the P1NP while escitalopram (2.0 mg/kg) was without such effects."( Differential effects of serotonin reuptake inhibitors fluoxetine and escitalopram on bone markers and microarchitecture in Wistar rats.
Kothari, P; Kumar, M; Trivedi, R; Vohora, D; Wadhwa, R, 2018
)
1.45
"Fluoxetine treatment induced a significant decrease in S2 quantities and in the number of sharp waves in S1."( Partial homologies between sleep states in lizards, mammals, and birds suggest a complex evolution of sleep states in amniotes.
Arthaud, S; Barrillot, B; Beuf, O; Herrel, A; Libourel, PA; Luppi, PH; Massot, B; Morel, AL, 2018
)
1.2
"Fluoxetine successfully treated depression-like behavior but had no effects on the white matter or its component myelinated fibers in the CUS rat model of depression."( Changes in white matter and the effects of fluoxetine on such changes in the CUS rat model of depression.
Chao, FL; Chen, LM; Du, L; Gao, Y; Huang, CX; Liang, X; Luo, YM; Ma, J; Qi, YQ; Tang, J; Tang, Y; Wang, SR; Xiao, Q; Yao, Y; Zhang, L; Zhang, Y, 2019
)
2.22
"fluoxetine treatment induced a long-lasting increase in alcohol consumption during relapse, an effect that was not observed in the case of bupropion treatment. "( Bupropion, a possible antidepressant without negative effects on alcohol relapse.
Alen, F; Antón, M; Arco, R; Ballesta, A; de Fonseca, FR; de Heras, RG; Nogueira-Arjona, R; Orio, L; Pavón, FJ; Ramírez-López, M; Romero-Sanchiz, P; Serrano, A; Suárez, J; Vargas, A, 2019
)
1.96
"Fluoxetine treatment reduced the infarct size of rats after cerebral ischemia reperfusion injury."( Fluoxetine mitigating late-stage cognition and neurobehavior impairment induced by cerebral ischemia reperfusion injury through inhibiting ERS-mediated neurons apoptosis in the hippocampus.
Ge, MY; Li, Y; Peng, L; Wang, S; Xu, F; Yin, J; Zhang, G; Zhang, Q, 2019
)
2.68
"Fluoxetine treatment had a significant effect on maximal aerobic capacity in mice without exercise, but more significant effects on gripping strength and anxiety when combined with exercise training, e.g. "( Muscular and mitochondrial effects of long-term fluoxetine treatment in mice, combined with physical endurance exercise on treadmill.
Coudore, F; Gardier, A; Khabil, S; Nazari, QA; Tutakhail, A, 2019
)
2.21
"Fluoxetine treatment and exercise stimulation also had synergistic effects on strength and increased mitochondrial activity, cellular oxidative and antioxidant capacity in two different muscles."( Muscular and mitochondrial effects of long-term fluoxetine treatment in mice, combined with physical endurance exercise on treadmill.
Coudore, F; Gardier, A; Khabil, S; Nazari, QA; Tutakhail, A, 2019
)
2.21
"Fluoxetine treatment was shown to cause a locomotor sensitized response to a challenge dose of amphetamine (0.5 mg/kg), indicating the presence of a supersensitive dopaminergic transmission."( Increased alcohol consumption in rats after subchronic antidepressant treatment.
Alén, F; de Fonseca, FR; de Heras, RG; Gorriti, MÁ; Orio, L; Pozo, MÁ; Ramírez-López, MT, 2013
)
1.11
"Fluoxetine treatment restored the Bdnf mRNA expression levels, as well as the number of proliferating cells in the granule cell layer of the dentate gyrus, which further supports the hypothesis that links depression to impaired neurogenesis."( Long-lasting neurotoxic effects of exposure to methylmercury during development.
Bose, R; Ceccatelli, S; Edoff, K; Onishchenko, N; Spulber, S, 2013
)
1.11
"Both fluoxetine and EA treatment restored the normal concentration of GDNF in the serum of DD patients."( Effects of electroacupuncture on depression and the production of glial cell line-derived neurotrophic factor compared with fluoxetine: a randomized controlled pilot study.
Bao, F; He, W; Ma, C; Sun, H; Wang, DH; Zhang, J; Zhang, YX; Zhao, H, 2013
)
1.05
"Fluoxetine treatment (10 mg/kg) after global ischemia significantly inhibited mRNA expression of MMP-2 and -9 and reduced MMP-9 activity."( Fluoxetine inhibits transient global ischemia-induced hippocampal neuronal death and memory impairment by preventing blood-brain barrier disruption.
Choi, HY; Kang, SR; Lee, HE; Lee, JY; Ryu, JH; Yune, TY, 2014
)
2.57
"Fluoxetine treatment was associated with a larger whole hippocampal volume but surprisingly resulted in lower numbers of immature neurons."( Impact of social status and antidepressant treatment on neurogenesis in the baboon hippocampus.
Arango, V; Bedi, G; Boldrini, M; Choi, CW; Foltin, RW; Hen, R; Shamy, JL; Wall, MM; Wu, MV, 2014
)
1.12
"Fluoxetine treatment in adulthood evokes antidepressant and anxiolytic responses. "( Hippocampal HDAC4 contributes to postnatal fluoxetine-evoked depression-like behavior.
Chachra, P; Desouza, LA; Kennedy, P; Nestler, EJ; Pena, CJ; Sarkar, A; Vaidya, VA, 2014
)
2.11
"Fluoxetine treatment in stressed females upregulated whole pMAPK signalling particularly those in nucleus which was followed with BDNF expression and normalization of behaviour."( Fluoxetine signature on hippocampal MAPK signalling in sex-dependent manner.
Adzic, M; Bozovic, N; Djordjevic, J; Lukic, I; Mitic, M, 2015
)
2.58
"Fluoxetine treatment significantly reduced advertisement calling and territorial behavior in E."( Chronic fluoxetine treatment promotes submissive behavior in the territorial frog, Eleutherodactylus coqui.
Regen, EM; Ten Eyck, GR, 2014
)
1.56
"Fluoxetine treatment significantly reduced glucose stimulated insulin secretion (GSIS). "( Fluoxetine-induced pancreatic beta cell dysfunction: New insight into the benefits of folic acid in the treatment of depression.
De Long, NE; Hardy, DB; Holloway, AC; Hyslop, JR; Raha, S, 2014
)
3.29
"Fluoxetine treatment in F1 males not only reversed the impairment of fear extinction in F1 males but also the low anxiety-like behaviors in their F2 offspring."( Fluoxetine treatment reverses the intergenerational impact of maternal separation on fear and anxiety behaviors.
Cao, J; Mao, RR; Xiong, GJ; Xu, L; Yang, Y, 2015
)
2.58
"In fluoxetine-treated mice, HDAC inhibitors increased enrichment of acetylated histone H4 protein and RNA polymerase II at promotor 3 of the brain-derived neurotrophic factor (Bdnf) gene and increased Bdnf transcription from this promotor."( An HDAC-dependent epigenetic mechanism that enhances the efficacy of the antidepressant drug fluoxetine.
Schmauss, C, 2015
)
1.15
"Fluoxetine pretreatment suppressed the development of morphine-induced constipation and the associated increase in AQP3 expression in the colon."( Morphine-Induced Constipation Develops With Increased Aquaporin-3 Expression in the Colon via Increased Serotonin Secretion.
Fueki, A; Haga, Y; Hayakawa, A; Ikarashi, N; Kon, R; Kusunoki, Y; Machida, Y; Ochiai, W; Sugiyama, K; Tajima, M, 2015
)
1.14
"Fluoxetine treatment corrected the SPS increases in the NAA/Cr and Cho/Cr levels in the amygdala on day 4 and in the hippocampus on day 14, but it failed to normalise SPS-associated decreases in NAA/Cr levels in the left hippocampus on day 1."( Effects of fluoxetine on the amygdala and the hippocampus after administration of a single prolonged stress to male Wistar rates: In vivo proton magnetic resonance spectroscopy findings.
Han, F; Shi, Y; Wen, L; Xiao, B, 2015
)
1.53
"Fluoxetine treatment did not affect these behavioral alterations, but it did increase the social dominance of the injured mice, as assessed by the tube test."( The effects of chronic fluoxetine treatment following injury of medial frontal cortex in mice.
Barneto, AA; Dyck, RH; McAllister, BB; Patel, PP; Spanswick, SC, 2015
)
1.45
"Fluoxetine treatment increased superoxide anion generation (O2(-)) and the expression of cyclooxygenase (COX)-1 in the rat aorta."( Contribution of oxidative stress and prostanoids in endothelial dysfunction induced by chronic fluoxetine treatment.
D'Orléans-Juste, P; Resstel, LB; Simplicio, JA; Tirapelli, CR; Tirapelli, DP, 2015
)
1.36
"Fluoxetine treatment increased endothelium-dependent and independent vasorelaxation (analyzed by mesenteric resistance arteries reactivity) as well as constitutive NO synthase (NOS) activity, phosphorylation of eNOS at Serine1177 and NO production, determined by western blot and fluorescence."( Chronic fluoxetine treatment increases NO bioavailability and calcium-sensitive potassium channels activation in rat mesenteric resistance arteries.
Antunes-Rodrigues, J; Carneiro, FS; Evora, PR; Ferreira, NS; Mestriner, FL; Pereira, CA; Resstel, LB; Tostes, RC, 2015
)
1.57
"Fluoxetine treatment did not affect the survival or differentiation of newly generated cells in the SVZ i.e., the enhanced neurogenesis was not translated into a behavioral outcome."( Fluoxetine Enhances Neurogenesis in Aged Rats with Cortical Infarcts, but This is not Reflected in a Behavioral Recovery.
Jolkkonen, J; Liu, T; Sun, X; Xiao, T; Zhao, C; Zhao, M; Zhao, S; Zhou, Z, 2016
)
2.6
"Fluoxetine treatment blocked stress-induced up-regulation of HMGB1 and subsequent NF-κB activation, whereas TDZD-8 administration attenuated NF-κB activation downstream of HMGB1."( Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior.
Armini, RS; Beurel, E; Cheng, Y; Jope, RS; Martinez, A; Mouhsine, H; Pardo, M; Zagury, JF, 2016
)
1.16
"Fluoxetine-treated animals spent 30% more time in social interaction than vehicle controls."( Peer social interaction is facilitated in juvenile rhesus monkeys treated with fluoxetine.
Bulleri, AM; Golub, MS; Hogrefe, CE, 2016
)
1.38
"Fluoxetine treatment showed limited behavioral and neuroendocrine efficacy, however it reduced microglial (Iba-1) expression, and increased cell proliferation, neurogenesis (via cell survival), and the expression of the polysialylated neuronal cell adhesion molecule (PSA-NCAM) in the dentate gyrus, although these effects varied by region (dorsal, ventral) and ovarian status."( Ovarian hormones, but not fluoxetine, impart resilience within a chronic unpredictable stress model in middle-aged female rats.
Chaiton, JA; Galea, LAM; Lieblich, SE; Mahmoud, R; Wainwright, SR, 2016
)
1.46
"Fluoxetine treatment exerted antidepressant effect in all rat lines irrespective of its effect on AS."( Effect of chronic fluoxetine treatment on audiogenic epilepsy, symptoms of anxiety and depression in rats of four lines.
Fedotova, IB; Nikolaev, GM; Perepelkina, OV; Poletaeva, II; Sarkissova, KY; Surina, NM, 2016
)
1.49
"Fluoxetine treatment exerted an antidepressant effect in all rat strains irrespective of its effect on AS."( Genetic background contributes to the co-morbidity of anxiety and depression with audiogenic seizure propensity and responses to fluoxetine treatment.
Fedotova, IB; Kostina, ZA; Nikolaev, GM; Perepelkina, OV; Poletaeva, II; Sarkisova, KY; Surina, NM, 2017
)
1.38
"Fluoxetine is the treatment of first choice."( [A place for SSRIs in the treatment of severely depressed children and adolescents].
Buitelaar, JK; Roobol, TH, 2008
)
1.07
"Fluoxetine treatment groups received either acute (saline injections for 20 days followed by 3 fluoxetine treatments over 24 h) or chronic (once daily fluoxetine for 21 days) drug administration."( Reduced efficacy of fluoxetine following MDMA ("Ecstasy")-induced serotonin loss in rats.
Durkin, S; Harkin, A; Prendergast, A, 2008
)
1.39
"Fluoxetine-treated patients (n=13) did not differ from placebo-treated patients (n=13) on any key demographic or behavioral variables."( Placebo-controlled, randomized trial of fluoxetine in the treatment of aggression in male intimate partner abusers.
Coccaro, EF; Kavoussi, RJ; Lee, R, 2008
)
1.33
"The fluoxetine-treated brain was found to show marked repressions of microglia activation, neutrophil infiltration, and proinflammatory marker expressions."( Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect.
Kim, C; Kim, SW; Lee, JK; Lim, CM; Park, JY; Yoon, SH, 2009
)
2.28
"Fluoxetine treatment could reverse CMS-induced inhibition of PKA activity and ERK1/2 phosphorylation in both genotypes."( Requirement of AQP4 for antidepressive efficiency of fluoxetine: implication in adult hippocampal neurogenesis.
Ding, JH; Fan, Y; Hu, G; Kong, H; Sha, LL; Wu, J; Xiao, M, 2009
)
1.32
"With fluoxetine treatment, there were correlations between the concentrations of kynurenine metabolites and the psychiatric rating scores, whereas no correlations were found with BDNF or inflammatory markers."( Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling.
Bridel, MA; Christofides, J; Cowlard, R; Darlington, LG; Forrest, CM; Mackay, GM; Mitchell, S; Stone, TW, 2009
)
1.03
"Fluoxetine treatment reduced or in most cases, completely eliminated the number of neurons in the LSO stained for 5-HT."( Experimental evidence that the serotonin transporter mediates serotonin accumulation in LSO neurons of the postnatal mouse.
Thompson, AM; Thompson, GC, 2009
)
1.07
"Fluoxetine treatment resulted in a sustained reduction in OAS-M aggression, and OAS-M irritability scores, apparent as early as week 2 (p < .01 for aggression and p < .001 for irritability at endpoint). "( A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder.
Coccaro, EF; Kavoussi, RJ; Lee, RJ, 2009
)
2.04
"Fluoxetine treatment has a clear antiaggressive effect in impulsive aggressive individuals with IED. "( A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder.
Coccaro, EF; Kavoussi, RJ; Lee, RJ, 2009
)
2.04
"Fluoxetine treatments of 25 and 50 microgg(-1) were sub-lethal and were used in subsequent experiments."( Fluoxetine treatment affects nitrogen waste excretion and osmoregulation in a marine teleost fish.
McDonald, MD; Medeiros, LR; Morando, MB, 2009
)
2.52
"Fluoxetine treatment decreased the density of 5-HT(4) receptor binding in the CA1 field of hippocampus as well as in several areas of the striatum over the doses of 5-10 mg/kg."( Long-term treatment with fluoxetine induces desensitization of 5-HT4 receptor-dependent signalling and functionality in rat brain.
Castro, E; Mostany, R; Pazos, A; Valdizán, EM; Vidal, R, 2009
)
1.38
"The fluoxetine treatment reduced B(max) in all three rat strains when the saline and respective fluoxetine groups were compared (e.g., the FSL-SAL relative to FSL-FLX groups)."( Chronic fluoxetine treatment has a larger effect on the density of a serotonin transporter in the Flinders Sensitive Line (FSL) rat model of depression than in normal rats.
Diksic, M; Kovacević, T; Skelin, I, 2010
)
1.28
"Fluoxetine-treated C57BL/6J mice made fewer errors than controls during the early phase of reversal when perseverative behavior is relatively high."( Pharmacological or genetic inactivation of the serotonin transporter improves reversal learning in mice.
Brigman, JL; Bussey, TJ; Deneris, E; Fox, S; Harvey-White, J; Holmes, A; Izquierdo, A; Mathur, P; Murphy, DL; Saksida, LM, 2010
)
1.08
"Fluoxetine treatment (5mg/kg body mass, 21day, intraperitoneally) induced a decrease in B(max) and in the amount of Hsp70 co-immunoprecipitated with the glucocorticoid receptor only in males, and stimulated the association of the receptor with Hsp90 in females."( Sexually dimorphic functional alterations of rat hepatic glucocorticoid receptor in response to fluoxetine.
Adzic, M; Djordjevic, A; Djordjevic, J; Elaković, I; Matić, G; Radojcić, M; Vasiljević, D, 2010
)
1.3
"Fluoxetine treatment during adolescence also impaired sexual copulatory behaviors in adulthood."( Short- and long-term functional consequences of fluoxetine exposure during adolescence in male rats.
Bolaños-Guzmán, CA; Iñiguez, SD; Warren, BL, 2010
)
1.34
"Fluoxetine treatments of 25 and 50 microgg(-1) were sublethal and were used in subsequent experiments."( Fluoxetine treatment affects nitrogen waste excretion and osmoregulation in a marine teleost fish.
McDonald, MD; Medeiros, LR; Morando, MB, 2009
)
2.52
"The fluoxetine treatment induced active somatic membrane properties resembling immature granule cells and markedly reduced synaptic facilitation that characterizes the mature dentate-to-CA3 signal transmission."( Reversal of hippocampal neuronal maturation by serotonergic antidepressants.
Haneda, E; Ikeda, Y; Kobayashi, K; Miyakawa, T; Sakai, A; Suzuki, H; Yamasaki, N, 2010
)
0.84
"Fluoxetine treatment decreased immobility in the TST and latency to eat in the NIH test, but only the highest dose of fluoxetine significantly altered behavior in both tests."( Fluoxetine treatment induces dose dependent alterations in depression associated behavior and neural plasticity in female mice.
Hill-Smith, TE; Hodes, GE; Lucki, I, 2010
)
2.52
"Fluoxetine treatment was found to enhance the expression of glial marker genes following neural differentiation, as observed by immunocytochemical analysis or quantitative RT-PCR."( Fluoxetine promotes gliogenesis during neural differentiation in mouse embryonic stem cells.
Kusakawa, S; Miyamoto, Y; Nakamura, K; Sanbe, A; Tanoue, A; Torii, T; Yamauchi, J, 2010
)
2.52
"Fluoxetine treatment resulted in an increase in circulating levels of 5-HT, regardless of social status."( Higher levels of aggression are observed in socially dominant toadfish treated with the selective serotonin reuptake inhibitor, fluoxetine.
Gonzalez, A; McDonald, MD; Sloman, KA, 2011
)
1.3
"Fluoxetine treatment significantly reduced the immunoreactivity in these areas."( Evidence for the participation of cocaine- and amphetamine-regulated transcript peptide (CART) in the fluoxetine-induced anti-hyperalgesia in neuropathic rats.
Dandekar, MP; Kokare, DM; Singru, PS; Subhedar, NK; Upadhya, MA, 2011
)
1.31
"Fluoxetine-treated dams gave birth to litters 15% smaller than usual and to pups of reduced weight (until postnatal day 7)."( Fluoxetine administration to pregnant rats increases anxiety-related behavior in the offspring.
Afrasiab-Middelman, A; Dederen, JP; Homberg, JR; Jonkers, M; Kiliaan, AJ; Korte-Bouws, GA; Martens, GJ; Olivier, JD; Peeters, EJ; Roelofs, JJ; Schubert, D; Vallès, A; van Heesch, F, 2011
)
2.53
"Fluoxetine treatment led to increasing expression of beta1-AR mRNA in the right atria and left ventricles, while the level of beta2-AR mRNA remained unchanged."( Flouxetine treatment acts selectively increasing myocardial beta1-adrenoceptor mRNA expression in stress-induced depression.
Dronjak, S; Gavrilovic, L; Jovanovic, P; Spasojevic, N, 2011
)
1.09
"Fluoxetine treatment for 21 days reduced both the pressor and tachycardiac responses evoked by acute restraint stress."( Chronic fluoxetine treatment alters cardiovascular functions in unanesthetized rats.
Correa, FM; Crestani, CC; Guimarães, FS; Joca, SR; Resstel, LB; Tavares, RF, 2011
)
1.52
"Fluoxetine treated rats were compared to a saline injected control group with respect to spatial navigation in the water maze, object recognition and object-in-place recognition memory."( The effect of subchronic fluoxetine treatment on learning and memory in adolescent rats.
Sass, A; Wörtwein, G, 2012
)
1.4
"Fluoxetine treatment, compared to placebo, resulted in significantly greater improvement in repetitive behaviors, according to both the Yale-Brown compulsion subscale and CGI rating of obsessive-compulsive symptoms, as well as on the CGI overall improvement rating. "( A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders.
Anagnostou, E; Chaplin, W; Ferretti, CJ; Hollander, E; Settipani, C; Soorya, L; Swanson, E; Taylor, BP; Wasserman, S, 2012
)
2.08
"Fluoxetine treatment increased synaptic plasticity, converted the fear memory circuitry to a more immature state, and acted through local brain-derived neurotrophic factor."( Fear erasure in mice requires synergy between antidepressant drugs and extinction training.
Agústsdóttir, A; Akamine, Y; Antila, H; Bahi, A; Castrén, E; Drew, LJ; Hen, R; Karpova, NN; Kulesskaya, N; Lindholm, J; Pickenhagen, A; Popova, D; Sullivan, R; Tiraboschi, E, 2011
)
1.09
"Fluoxetine treatment decreased activations in all three regions, as compared with the repeat scans of healthy comparison subjects."( Brain activity in adolescent major depressive disorder before and after fluoxetine treatment.
Calley, CS; Emslie, GJ; Hart, J; Kennard, BD; Lu, H; Mayes, TL; Nakonezny, PA; Tamminga, CA; Tao, R, 2012
)
1.33
"Oral fluoxetine treatment increased 5-HT levels in wild mice and increased the 4-day fecal output compared with oral saline."( Effect of progesterone on colonic motility and fecal output in mice with diarrhea.
Behar, J; Biancani, P; Li, CP; Ling, C, 2012
)
0.83
"Fluoxetine pretreatment significantly promoted remission in EAE. "( Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats.
Liu, S; Liu, XJ; Lu, T; Qiu, G; Wang, X; Wu, Y; Yuan, XQ, 2012
)
3.26
"Fluoxetine treatment significantly inhibited messenger RNA expression of matrix metalloprotease 2, 9 and 12 after spinal cord injury."( Fluoxetine inhibits matrix metalloprotease activation and prevents disruption of blood-spinal cord barrier after spinal cord injury.
Choi, HY; Kim, HS; Lee, JY; Oh, TH; Yune, TY, 2012
)
2.54
"Fluoxetine treatment increased 5-HT(4) receptor expression (0.322 ± 0.020 vs 0.308 ± 0.017, P < 0.01) but not SERT expression (0.219 ± 0.039 vs 0.298 ± 0.038, P = 0.654)."( Effect of the 5-HT4 receptor and serotonin transporter on visceral hypersensitivity in rats.
Hua-Hong, W; Jun-Xia, L; Xin-Guang, L; Yan, C; Yi-Xuan, L, 2012
)
1.1
"Fluoxetine treatment inhibited TREK-1 and TREK-2, members of the two-pore domain K(+) channel family expressed in mouse embryos, activities, indicating that fluoxetine-induced membrane depolarization in late 2-cells might have resulted from TREK inhibition."( Dual effects of fluoxetine on mouse early embryonic development.
Cho, YW; Choe, C; Han, J; Han, S; Kang, D; Kim, CW; Kim, EJ; Lee, JI; Tak, HM; Yoon, SY, 2012
)
1.45
"Fluoxetine treatment generated a further increase in muscularisation and did not significantly modify the hyperoxia-induced reductions in alveolar density and increases in the endocrine cells."( Fluoxetine may worsen hyperoxia-induced lung damage in neonatal rats.
Baraldi, M; Chiandetti, L; De Caro, R; Fornaro, E; Grisafi, D; Macchi, V; Masola, V; Onisto, M; Porzionato, A; Salmaso, R; Tassone, E; Zaramella, P, 2012
)
2.54
"fluoxetine in the treatment of patients with depression and anxiety."( Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety.
De Bleeker, E; De Nayer, A; Evrard, JL; Fossion, P; Geerts, S; Leyman, S; Linkowski, P; Mignon, A; Ruelens, L; Schittecatte, M; Van Eeckhoutte, I, 2002
)
1.34
"Fluoxetine treatment completely blocked the oxytocin, ACTH and corticosterone responses to 8-OH-DPAT, but did not inhibit the effect of DOI on any hormone, thus confirming that fluoxetine treatment did not produce a deficit in the functioning of corticotropin releasing hormone or oxytocin containing neurons."( Treatment of cycling female rats with fluoxetine induces desensitization of hypothalamic 5-HT(1A) receptors with no change in 5-HT(2A) receptors.
Battaglia, G; DonCarlos, LL; Garcia, F; Muma, NA; Raap, DK; Van de Kar, LD, 2002
)
1.31
"Fluoxetine treatment had a more rapid effect and greater impact upon anxiety symptoms, while CBT was associated with increased use of cognitive and behavioural coping strategies and a shift from a biomedical to a biopsychosocial causal attribution of premenstrual symptoms."( Medical (fluoxetine) and psychological (cognitive-behavioural therapy) treatment for premenstrual dysphoric disorder: a study of treatment processes.
Browne, S; Cariss, M; Hunter, MS; Jelley, R; Katz, M; Ussher, JM, 2002
)
1.45
"Fluoxetine treatment increased GR mRNA in the hippocampus of young rats (24 and 46% increase in DG and CA3, respectively, P<0.01) but had no effect on hippocampal MR mRNA expression."( The effect of chronic fluoxetine treatment on brain corticosteroid receptor mRNA expression and spatial memory in young and aged rats.
Hibberd, C; Noble, J; Seckl, JR; Yau, JL, 2002
)
1.35
"For fluoxetine-treated patients, the odds ratio for completing therapy relative to tricyclic antidepressant-treated patients dropped from 3.916 to 1.706 in the open-access period."( A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder.
Croghan, TW; McCombs, JS; Shi, L; Stimmel, GL, 2002
)
0.8
"Fluoxetine treatment was well tolerated and safe."( Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
Baumhackl, U; Fruehwald, S; Gatterbauer, E; Rehak, P, 2003
)
1.52
"In fluoxetine-treated animals, blockade of terminal reuptake by local perfusion of fluoxetine increased 5-HT to the same level as it did in controls, suggesting normal terminal 5-HT release after chronic fluoxetine."( Altered glucocorticoid rhythm attenuates the ability of a chronic SSRI to elevate forebrain 5-HT: implications for the treatment of depression.
Gartside, SE; Leitch, MM; Young, AH, 2003
)
0.83
"Fluoxetine treatment also reversed the deficit in escape latency observed in animals exposed to IS."( Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment.
Duman, RS; Malberg, JE, 2003
)
1.26
"Fluoxetine treatment of old mice further increased hippocampal S100B, suggesting that aging does not interfere with fluoxetine's action on hippocampal S100B."( Both aging and chronic fluoxetine increase S100B content in the mouse hippocampus.
Akhisaroglu, E; Akhisaroglu, M; Manev, H; Manev, R; Uz, T, 2003
)
1.35
"Fluoxetine treatment reversed MDMA-induced anxiety in the emergence test and depressive-like effects in the forced swim test, yet exhibited no effects on the social interaction test."( Chronic fluoxetine treatment partly attenuates the long-term anxiety and depressive symptoms induced by MDMA ('Ecstasy') in rats.
Clemens, KJ; Cornish, JL; Gurtman, CG; Hunt, GE; Li, KM; McGregor, IS; Thompson, MR, 2004
)
1.48
"Fluoxetine-treated rats had higher brain levels of cocaine than rats treated with cocaine alone."( Fluoxetine, but not sertraline or citalopram, potentiates the locomotor stimulant effect of cocaine: possible pharmacokinetic effects.
Baker, GB; Fletcher, PJ; Salsali, M; Sinyard, J, 2004
)
2.49
"Fluoxetine-treated osteoclast precursors had reduced NF-kappa B activation and elevated inhibitory protein kappa B alpha (I kappa B alpha) levels compared with untreated cells."( Serotonin regulates osteoclast differentiation through its transporter.
Battaglino, R; Ersoy, U; Fu, J; Joe, M; Sedaghat, L; Späte, U; Stashenko, P, 2004
)
1.04
"Fluoxetine pretreatment did not alter pentylenetetrazol brain concentration indicating that this phenomenon was not related to the pharmacokinetic interaction."( The effect of fluoxetine in a model of chemically induced seizures--behavioral and immunocytochemical study.
Lehner, M; Maciejak, P; Płaźnik, A; Skórzewska, A; Taracha, E; Wisłowska, A; Zienowicz, M, 2005
)
1.41
"Fluoxetine is used in treatment of depression caused by a variety of different factors and from year to year new indications are being added, especially in conditions followed with strong bouts of pain. "( Testing of analgesic effect of fluoxetine.
Becić, F; Begović, A; Zulić, I, 2004
)
2.05
"Fluoxetine-treated patients gained statistically significantly less height (fluoxetine: 1.0 cm +/- 2.4; placebo: 2.1 cm +/- 2.6; p = 0.004) and weight (fluoxetine: 1.2 kg +/- 2.7; placebo: 2.3 kg +/- 2.6; p = 0.008) than placebo-treated patients during the 19 weeks of treatment."( Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents.
Brown, EB; Heiligenstein, JH; Joliat, MJ; Miner, CM; Nilsson, M, 2004
)
1.32
"Fluoxetine treatment alone increased the number of BrdU-positive cells, but did not increase the number of DCX-positive cells."( Decreased proliferation in the adult rat hippocampus after exposure to the Morris water maze and its reversal by fluoxetine.
Námestková, K; Simonová, Z; Syková, E, 2005
)
1.26
"Fluoxetine treatment was associated with greater reduction in depressive symptoms (p<0.05)."( Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder.
Bellace, D; Carino, J; Devlin, MJ; Dobrow, I; Goldfein, JA; Jiang, H; Kamenetz, C; Mayer, L; Petkova, E; Raizman, PS; Walsh, BT; Wolk, S, 2005
)
1.33
"fluoxetine and cocaine), treatment schedule (i.e."( Effect of fluoxetine and cocaine on the expression of clock genes in the mouse hippocampus and striatum.
Ahmed, R; Akhisaroglu, M; Dirim Arslan, A; Imbesi, M; Kurtuncu, M; Manev, H; Uz, T, 2005
)
1.45
"Fluoxetine treatment led to a significant long-lasting increase of serotonin (not noradrenaline) transporter density (Bmax = 1231 +/- 34) in the frontal cortex (compared with saline-treated controls (Bmax = 1112 +/- 58))."( Very early treatment with fluoxetine and reboxetine causing long-lasting change of the serotonin but not the noradrenaline transporter in the frontal cortex of rats.
Banaschewski, T; Bock, N; Hüther, G; Moll, GH; Quentin, DJ; Rothenberger, A, 2005
)
1.35
"Fluoxetine treatment did not produce any deteriorating effect on the conditioning."( Are the effects of the antidepressants amitriptyline, maprotiline, and fluoxetine on inhibitory avoidance state-dependent?
Arenas, MC; Everss, E; Ferrer-Añó, A; Martos, AJ; Monleón, S; Parra, A; Vinader-Caerols, C, 2006
)
1.29
"Fluoxetine treatment appeared to have an anxiolytic effect, reducing immobility, and even seemed to protect subjects from the immune impairment and endocrine alteration caused by social stressors."( Time-dependent behavioral, neurochemical, and immune consequences of repeated experiences of social defeat stress in male mice and the ameliorative effects of fluoxetine.
Arregi, A; Azpiroz, A; Beitia, G; Brain, PF; Garmendia, L; Vegas, O, 2005
)
1.25
"Fluoxetine treatment, but not fenfluramine treatment, significantly increased prepulse inhibition (PPI), a measure of sensorimotor gating, in C57BL/6J mice."( The effect of low estrogen state on serotonin transporter function in mouse hippocampus: a behavioral and electrochemical study.
Bertrand, PP; Chavez, C; Gogos, A; Jones, M; Paranavitane, UT; van den Buuse, M, 2005
)
1.05
"Fluoxetine treatment prevented the stress-induced numerical decrease of astrocytes, but had no counteracting effect on somal volume shrinkage."( Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment.
Czéh, B; Fuchs, E; Hiemke, C; Schmelting, B; Simon, M, 2006
)
1.27
"Fluoxetine treatment reduced body weight within the first 24 h of treatment."( Fluoxetine disrupts food intake and estrous cyclicity in Fischer female rats.
Grossie, B; Hensler, JG; Sarkar, J; Uphouse, L, 2006
)
2.5
"Fluoxetine treatment increased ERK2 and NP25 and decreased vacuolar ATP synthase."( Proteomic analysis of rat hippocampus and frontal cortex after chronic treatment with fluoxetine or putative novel antidepressants: CRF1 and NK1 receptor antagonists.
Carboni, L; Castelletti, L; Domenici, E; Milli, A; Piubelli, C; Vighini, M, 2006
)
1.28
"Fluoxetine treatment, although having no effect in controls, corrected this parameter in diabetic mice."( Reduced hippocampal neurogenesis and number of hilar neurones in streptozotocin-induced diabetic mice: reversion by antidepressant treatment.
Beauquis, J; De Nicola, A; Homo-Delarche, F; Roig, P; Saravia, F, 2006
)
1.06
"Fluoxetine treatment did not affect the 5-HT effect on food intake amount but significantly reduced the 5-HT effect on feeding latency."( Chronic fluoxetine administration desensitizes the hyperglycemia but not the anorexia induced by serotonin in rats receiving fructose-enriched chow.
Cheng, JT; Chung, HH; Hsiao, SH; Tong, YC, 2006
)
1.49
"Fluoxetine treatment also resulted in increased volume in vertebral trabecular bone."( Fluoxetine treatment increases trabecular bone formation in mice.
Battaglino, R; Graves, D; Kohler, T; Müller, R; Schulze-Späte, U; Sharma, A; Stashenko, P; Vokes, M; Yoganathan, S, 2007
)
2.5
"Fluoxetine treatment attenuated most of the positive-like subjective effects including the Affect and Soma scales of the Hallucinogen Rating Scale."( The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.
Johanson, CE; Tancer, M, 2007
)
1.41
"Fluoxetine treatment effects were determined by evaluating respiratory mechanics (elastance/resistance) and exhaled nitric oxide, as well as mononuclear and polymorphonuclear cell recruitment into the lungs, in an experimental guinea pig model. "( Morphological and functional determinants of fluoxetine (Prozac)-induced pulmonary disease in an experimental model.
Capelozzi, MA; Capelozzi, VL; Leick-Maldonado, EA; Martins, MA; Parra, ER; Tibério, IF, 2007
)
2.04
"Fluoxetine treatment before both the conditioning and preference tests abolished METH CPP."( Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: studies in mice.
Hagino, Y; Ikeda, K; Markou, A; Ogai, Y; Takamatsu, Y; Yamamoto, H, 2006
)
2.5
"Fluoxetine treatment counteracted the inhibitory effect of stress."( Chronic social stress inhibits cell proliferation in the adult medial prefrontal cortex: hemispheric asymmetry and reversal by fluoxetine treatment.
Abumaria, N; Czéh, B; Domenici, E; Fuchs, E; Hiemke, C; Müller-Keuker, JI; Rygula, R, 2007
)
1.27
"Fluoxetine treatment significantly reduced mean wound length and healing period (P<.01). "( Fluoxetine enhances cutaneous wound healing in chronically stressed Wistar rats.
Farahani, RM; Mesgari, M; Rad, JS; Sadr, K, 2007
)
3.23
"Fluoxetine pretreatment to provide protection from MDMA induced long term neurotoxicity decreases elimination of MDMA and MDA and may lead to enhanced risk of MDMA acute toxic effects."( Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat.
Eddington, ND; Upreti, VV, 2008
)
2.51
"Fluoxetine treatment for 4 and 8 weeks significantly increased basal TPH2 mRNA levels in the midbrain, an effect that was correlated with the appearance of antidepressant-like effects in the forced swim test."( Up-regulation of tryptophan hydroxylase-2 mRNA in the rat brain by chronic fluoxetine treatment correlates with its antidepressant effect.
Dygalo, NN; Kalinina, TS; Shishkina, GT, 2007
)
1.29
"Fluoxetine treatment did not result in greater worsening but was associated with greater improvement and faster resolution of ideation (P < or = 0.05 vs placebo)."( Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials.
Acharya, N; Ball, SG; Beasley, CM; Nilsson, ME; Plewes, J; Polzer, J; Tauscher-Wisniewski, S, 2007
)
2.5
"Fluoxetine-treated fish seemed less active in their home tanks than controls or blocker-treated fish."( Fish on Prozac: effect of serotonin reuptake inhibitors on cognition in goldfish.
Beulig, A; Fowler, J, 2008
)
1.07
"Fluoxetine pretreatment, likewise, reduced responding in non-lesioned rats and had no observable effect in lesioned animals."( The effects of putative 5-hydroxytryptamine receptor active agents on D-amphetamine self-administration in controls and rats with 5,7-dihydroxytryptamine median forebrain bundle lesions.
Leccese, AP; Lyness, WH, 1984
)
0.99
"Fluoxetine treatment significantly increased serotonin (5-HT) levels in the VMN but did not change 5-HT levels in any other area examined."( Short-term fluoxetine treatment alters monoamine levels and turnover in discrete brain nuclei.
Frankfurt, M; Luine, VN; McKittrick, CR, 1994
)
1.4
"Fluoxetine-treated patients reported an increased frequency of weight gain and anger or aggression."( Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine.
Bryant, SG; Fisher, S; Kent, TA, 1995
)
1.23
"Fluoxetine treatment did not influence positive schizophrenic symptoms, while it induced a slight, but statistically significant, decrease (p < 0.05) in depressive symptoms, as measured by the Hamilton Rating Scale for Depression."( Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients.
Ancione, M; Caputi, AP; De Domenico, P; Di Rosa, AE; Gitto, C; Longobardo, N; Ruello, C; Spina, E, 1994
)
1.4
"Fluoxetine-treated patients demonstrated a significantly greater reduction in the Hamilton Rating Scale for Depression total score and a significantly greater response rate than placebo-treated patients in both the SREML and the combined strata."( Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in nonpsychotic depressed outpatients.
Andersen, JS; Dunner, D; Faries, DE; Gillin, JC; Heiligenstein, JH; James, SP; Lahmeyer, H; Pande, AC; Roffwarg, HP; Rush, AJ, 1994
)
1.24
"For fluoxetine-treated patients with depression included on their computerized medical problem list, the mean daily dose was 21 +/- 6 mg for the first prescription and 26 +/- 12 mg for the ninth."( Selective serotonin reuptake inhibitor dose titration in the naturalistic setting.
Coons, SJ; Gregor, KJ; McDonald, RC; Overhage, JM,
)
0.61
"Fluoxetine treatment resulted in a nonsignificant increase in nociceptive response at 30 min posttreatment which returned to the baseline by 1 h."( Serotonin modulation of pain responsiveness in the aged rat.
Akunne, HC; Soliman, KF, 1994
)
1.01
"Fluoxetine treatment also resulted in upregulation of 5-HT2 receptors in layers of frontoparietal cortex (31-38%) and in CA2-3 fields of hippocampus (by 39%)."( Chronic fluoxetine treatment upregulates 5-HT uptake sites and 5-HT2 receptors in rat brain: an autoradiographic study.
Hrdina, PD; Vu, TB, 1993
)
1.44
"Fluoxetine-treated and placebo-treated patients did not differ statistically significantly in the incidence of suicidality either during or after discontinuation of therapy."( Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction.
Beasley, CM; Goldstein, DJ; Masica, DN; Potvin, JH; Rampey, AH, 1993
)
1.01
"fluoxetine in the treatment of major depression (DSM-III-R)."( Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression.
Aguglia, E; Bolino, F; Casacchia, M; Cassano, GB; Faravelli, C; Ferrari, G; Giordano, P; Pancheri, P; Ravizza, L; Trabucchi, M, 1993
)
1.24
"Fluoxetine-treated patients showed statistically significantly higher rates of response and remission than placebo-treated patients within all three severity subgroups."( Severity of depression and response to fluoxetine.
Pande, AC; Sayler, ME, 1993
)
1.28
"Fluoxetine treatment resulted in weight loss, whereas imipramine treatment resulted in a slight but significant weight increase."( A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder.
Arup, P; Behnke, K; Christiansen, PE; Geisler, A; Ipsen, E; Maach-Møller, B; Nielsen, BM; Ohrberg, SC, 1993
)
1.35
"Fluoxetine treatment produced a significant weight loss of 1.97 kg over the two weeks of treatment compared to a weight loss of only 0.04 kg on placebo."( Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects.
Blundell, JE; Hill, AJ; Lawton, CL; Wales, JK, 1995
)
1.24
"Fluoxetine-treated subjects who remained sober at 12 weeks reported a significant decrease in mean subjective alcohol craving scores from 2.9 to 0.7 on a 10-point scale (t = 2.828, p = 0.02)."( A placebo-controlled, double-blind study of fluoxetine in severe alcohol dependence: adjunctive pharmacotherapy during and after inpatient treatment.
Kabel, DI; Petty, F, 1996
)
1.28
"Fluoxetine treatment terminated stereotypic pacing behavior, facial tic, and huffing/coughing activity."( Use of fluoxetine for the treatment of stereotypical pacing behavior in a captive polar bear.
Honeyman, V; Poulsen, EM; Teskey, GC; Valentine, PA, 1996
)
1.47
"Fluoxetine treatment produced significant improvements in self-visual analogue scale scores for sexual desire, anxiety for rapid ejaculation, and partner's satisfaction with ejaculation and overall sexual function."( An open clinical trial of fluoxetine in the treatment of premature ejaculation.
Choi, HK; Kim, CH; Lee, HS; Song, DH, 1996
)
1.32
"Fluoxetine pretreatment did not prevent fenfluramine-induced increases in prolactin."( Prolactin response to fenfluramine is independent of serotonin release.
Hatzidimitriou, G; McCann, UD; Ricaurte, GA, 1996
)
1.02
"Fluoxetine treatment increased the potency of 5-HT for the 5-HT1A receptor-mediated hyperpolarization in area CA1, but not area CA3, and decreased the potency of baclofen for the GABA(B) receptor-mediated hyperpolarization in area CA1, but not area CA3."( Fluoxetine selectively alters 5-hydroxytryptamine1A and gamma-aminobutyric acidB receptor-mediated hyperpolarization in area CA1, but not area CA3, hippocampal pyramidal cells.
Beck, SG; Birnstiel, S; Choi, KC; Pouliot, WA, 1997
)
2.46
"Fluoxetine pretreatment prevented the AET-induced disruption of PPI and reduced the AET-induced disruption of startle habituation."( Characterization of the disruptions of prepulse inhibition and habituation of startle induced by alpha-ethyltryptamine.
Geyer, MA; Martinez, DL, 1997
)
1.02
"Fluoxetine pretreatment prevented the methamphetamine-induced decrease in tryptophan hydroxylase activity: this effect cannot be attributed to altered body temperatures or brain concentrations of methamphetamine which suggests that neither, per se, is sufficient to impair 5-hydroxytryptaminergic neuronal function."( Methamphetamine-induced decrease in tryptophan hydroxylase activity: role of 5-hydroxytryptaminergic transporters.
Beyeler, ML; Fleckenstein, AE; Gibb, JW; Hanson, GR; Jackson, JC; Wilkins, DG, 1997
)
1.02
"Fluoxetine-treated patients did show a slight reduction in agitation and in the need for routine."( A controlled trial of fluoxetine in nondepressed patients with Huntington's disease.
Como, PG; Henderson, R; Hickey, C; Lawler, K; McDermott, M; McDermott, MP; O'Brien, CF; Rubin, AE; Rubin, AJ; Shoulson, I; Steinberg, K, 1997
)
1.33
"Fluoxetine-treated patients demonstrated numerically superior improvement rates compared with TCA-treated patients; however, this difference was not significant."( Course of psychomotor agitation during pharmacotherapy of depression: analysis from double-blind controlled trials with fluoxetine.
Sayler, ME; Tollefson, GD,
)
1.06
"Fluoxetine treatment had no appreciable effect on the density of 5-HT immunoreactivity in the cortex."( Contributions of raphe-cortical and thalamocortical axons to the transient somatotopic pattern of serotonin immunoreactivity in rat cortex.
Bennett-Clarke, CA; Chiaia, NL; Rhoades, RW, 1997
)
1.02
"Fluoxetine treatment has an antiaggressive effect on impulsive aggressive individuals with DSM-III-R personality disorder."( Fluoxetine and impulsive aggressive behavior in personality-disordered subjects.
Coccaro, EF; Kavoussi, RJ, 1997
)
3.18
"Fluoxetine treatment attenuated the locomotor activating effect of acute morphine treatments and blocked the sensitized response to the morphine challenge."( Fluoxetine attenuates morphine-induced locomotion and blocks morphine-sensitization.
Fletcher, PJ; Sills, TL, 1997
)
2.46
"Fluoxetine-treated animals displayed a longer latency to exhibit parental responsiveness than did saline-treated controls (p < 0.02), but they did not differ in other aspects of parental care."( Effects of the selective serotonin reuptake inhibitor fluoxetine on social behaviors in male and female prairie voles (Microtus ochrogaster).
Boyle, PA; Caliguri, EJ; De Vries, GJ; Villalba, C, 1997
)
1.27
"Fluoxetine pre-treatment (20 mg kg(-1) for 5 days) resulted in an increase in serum imipramine levels in both groups of mice and the extent of the increase was greater in transgenic mice than in control mice (4.5-fold increase compared with 3.1-fold)."( Kinetic interaction between fluoxetine and imipramine as a function of elevated serum alpha-1-acid glycoprotein levels.
Dewey, MJ; Holladay, JW; Yoo, SD, 1998
)
1.32
"Fluoxetine-treated patients also experienced less reemergence of depressive symptoms than sertraline-treated or paroxetine-treated patients (p < .001)."( Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.
Ascroft, RC; Fava, M; Hoog, SL; Krebs, WB; Rosenbaum, JF, 1998
)
1.02
"Fluoxetine-treated rats gained significantly less weight than placebo-treated rats (p = 0.01), in keeping with fluoxetine's anorexigenic properties."( Vasopressin, oxytocin, corticotrophin-releasing factor, and sodium responses during fluoxetine administration in the rat.
Amico, JA; Marar, IE, 1998
)
1.25
"Fluoxetine treatment alone was associated with statistically significant improvements in MPAC Mood scale scores."( A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer.
Heiligenstein, JH; Holland, JC; Romano, SJ; Tepner, RG; Wilson, MG,
)
1.17
"Fluoxetine treatment for panic disorder was well tolerated, with a safety profile consistent with that observed for fluoxetine in other disorders."( Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group.
Demitrack, MA; Hoog, SL; Lydiard, RB; Michelson, D; Pollack, MH; Tamura, RN; Tepner, R; Tollefson, GD, 1998
)
1.23
"Fluoxetine treatment resulted in decreased symptoms of depression and increased serum concentrations of fluoxetine and norfluoxetine."( Antidepressants augment natural killer cell activity: in vivo and in vitro.
Burke, WJ; Frank, MG; Hendricks, SE; Johnson, DR; Wieseler, JL, 1999
)
1.02
"Fluoxetine (alone) treatment of rats for 1 or 15 days had no effect on open-arm activity and cortical CRE-DNA-binding activity."( Potential role of the gene transcription factor cyclic AMP-responsive element binding protein in ethanol withdrawal-related anxiety.
Mittal, N; Nayyar, D; Pandey, SC; Zhang, D, 1999
)
1.02
"Fluoxetine 60 mg treatment statistically significantly reduced (p < .05) the median number of binge eating and vomiting episodes. "( Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression.
al-Banna, M; Ascroft, RC; Goldstein, DJ; Wilson, MG, 1999
)
2.09
"Fluoxetine treatment yielded an enhanced [3H]5-HT release in the three brain areas, but a desensitization of the 5-HT autoreceptor only in the hypothalamus and orbitofrontal cortex. "( Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder.
Bergqvist, PB; Blier, P; Bouchard, C, 1999
)
1.75
"Fluoxetine treatment also resulted in a higher concentration of amphetamine in the CNS."( Acute fluoxetine treatment potentiates amphetamine hyperactivity and amphetamine-induced nucleus accumbens dopamine release: possible pharmacokinetic interaction.
Baker, GB; Fletcher, PJ; Greenshaw, AJ; Sills, TL, 1999
)
1.51
"Fluoxetine-treated animals on the other hand, showed a great amplification of plasticity with a conspicuous sprouting of the uncrossed retinal axons into denervated areas."( Fluoxetine-induced plasticity in the rodent visual system.
Amaral, AR; Bastos, EF; Marcelino, JL; Serfaty, CA, 1999
)
2.47
"Fluoxetine treatment did not modify the binding parameters of [3H]-prazosin to vas deferens."( Long-term treatment with fluoxetine associates with peripheral effects on rat vas deferens contractility.
Borda, E; Busch, L; Wald, M, 1999
)
1.33
"Fluoxetine treatment elevated NPY-LI in the arcuate and anterior cingulate cortex and increased Y1 binding sites in the medial amygdala and occipital cortex in both strains."( Alterations in neuropeptide Y levels and Y1 binding sites in the Flinders Sensitive Line rats, a genetic animal model of depression.
Caberlotto, L; Fuxe, K; Hurd, YL; Jimenez, P; Mathé, AA; Overstreet, DH, 1999
)
1.02
"Fluoxetine pretreatment diminished social defeat-induced hypophagia, body weight loss and anxiety without affecting these variables in control animals."( Behavioral, neuroendocrine and serotonergic consequences of single social defeat and repeated fluoxetine pretreatment in the Lewis rat strain.
Aguerre, S; Berton, O; Chaouloff, F; Durand, M; Mormède, P, 1999
)
1.24
"Fluoxetine treatment caused lower levels of ACTH, but not of corticosterone secretion, in response to immobilization stress."( An investigation of serotonergic involvement in the regulation of ACTH and corticosterone in the olfactory bulbectomized rat.
Anglade, G; Faudon, M; Hery, F; Marcilhac, A; Siaud, P, 1999
)
1.02
"In fluoxetine-treated rats, but not in desipramine-treated ones, this inhibitory effect was markedly attenuated in cortex (26%) and hippocampus ("( Activation and desensitization by cyclic antidepressant drugs of alpha2-autoreceptors, alpha2-heteroreceptors and 5-HT1A-autoreceptors regulating monamine synthesis in the rat brain in vivo.
Esteban, S; García-Sevilla, JA; Lladó, J; Sastre-Coll, A, 1999
)
0.82
"Fluoxetine treatment was started in the CTH group, with follow-up over a 1-year period."( Cluster of MMPI personality profiles in chronic tension-type headache and predictable response to Fluoxetine.
Aguirre, J; Gallardo, R; Pareja, JA; Pérez-Miranda, M, 2000
)
1.25
"Fluoxetine pretreatment decreased [(3)H]citalopram binding at midbrain serotonin (5-HT) transporters, whereas tricyclic and/or fluoxetine decreased [(3)H]ketanserin binding at cortical 5-HT(2A) receptors, [(3)H]CGP-12177 binding at cortical ss-adrenoceptors, and [(3)H]nisoxetine binding at midbrain noradrenaline (NA) transporters in both strains."( Strain-dependent neurochemical and neuroendocrine effects of desipramine, but not fluoxetine or imipramine, in spontaneously hypertensive and Wistar-Kyoto rats.
Aguerre, S; Chaouloff, F; Combourieu, I; Durand, M; Edno, L; Fernandez, F; Mormède, P, 2000
)
1.25
"In fluoxetine-treated animals killed on days 42 or 62 (1 or 21 days post-treatment, respectively), dendritic spine density remained at levels present in CA1 at 21 days."( Chronic fluoxetine administration to juvenile rats prevents age-associated dendritic spine proliferation in hippocampus.
Norrholm, SD; Ouimet, CC, 2000
)
1.26
"Fluoxetine-treated subjects (n = 6) had significantly lower Impulsivity Index scores than controls (n = 12)."( Social impulsivity inversely associated with CSF 5-HIAA and fluoxetine exposure in vervet monkeys.
Fairbanks, LA; Jorgensen, MJ; Kaplan, JR; McGuire, MT; Melega, WP, 2001
)
1.27
"Fluoxetine treatment was statistically superior to placebo, with no significant differences between the two fluoxetine dosages in their effects on physical symptoms."( The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder.
Babcock, S; Berger, C; Carter, D; Dillon, J; Judge, R; Reid, R; Romano, SJ; Shuler, C; Steinberg, S; Steiner, M; Stewart, D, 2001
)
2.1
"Fluoxetine treatment for depression in AD did not differ significantly from treatment with placebo. "( A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease.
Chemerinski, E; Petracca, GM; Starkstein, SE, 2001
)
2.01
"Fluoxetine-treated patients exhibited a longer time to relapse than placebo-treated patients."( A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment.
Halmi, KA; Koke, SC; Lee, JS; Romano, SJ; Sarkar, NP, 2002
)
1.32
"The fluoxetine pre-treatment also potentiated the DA increases induced by 10 mg/kg of bupropion in the Pfc (260% for bupropion alone vs 357% for the combination) and in the Acb (224% vs 645%)."( Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats.
Li, SX; Perry, KW; Wong, DT, 2002
)
1.16
"Fluoxetine treatment reverted the alterations induced by CMS."( Altered expression of autonomic neurotransmitter receptors and proliferative responses in lymphocytes from a chronic mild stress model of depression: effects of fluoxetine.
Cremaschi, GA; Edgar, VA; Genaro, AM; Sterin-Borda, L, 2002
)
1.23
"Fluoxetine treated subjects who completed the trial (n = 16) lost more weight than placebo treated subjects (n = 20) (9.3 +/- 2.4 vs."( Fluoxetine treatment of the obese diabetic.
Bray, GA; Devine, W; Fujioka, K; Gray, DS, 1992
)
2.45
"In fluoxetine-treated subjects, weight gain/loss was strongly correlated with initial body mass index, with higher BMI being associated with greater decreases in weight."( Effects of fluoxetine on weight gain and food intake in smokers who reduce nicotine intake.
Lowenbergh, JM; Morrell, EM; Pomerleau, CS; Pomerleau, OF, 1991
)
1.19
"The fluoxetine and placebo treatment phases consisted of 6-week trials of each agent separated by a 5-week washout period."( A placebo-controlled, double-blind crossover study of fluoxetine in trichotillomania.
Callies, AL; Christenson, GA; Mackenzie, TB; Mitchell, JE, 1991
)
1.01
"or fluoxetine p.m. treatment groups, such that 30 patients were in each group at each of two sites."( Efficacy and safety of morning versus evening fluoxetine administration.
Beasley, CM; Bosomworth, JC; Usher, RW, 1991
)
1.05
"Fluoxetine treatment of mice restricted to 3.2 g of laboratory diet per day caused small but persistent depressions of body weight in both phenotypes."( Ineffectiveness of parenteral fluoxetine or RU-486 to alter long-term food intake, body weight or body composition of genetically obese mice.
Dubuc, PU; Peterson, CM, 1990
)
1.29
"Fluoxetine treatment may be effective in treating major depression in HIV-seropositive asymptomatic patients."( A report of eight HIV-seropositive patients with major depression responding to fluoxetine.
Anderson, D; Baron, D; Bystritsky, A; Levine, S, 1990
)
1.23
"The fluoxetine treatment is not instead of, but in addition to the traditional behavioral treatment with strict limits regarding food and meals."( Drugs in the treatment of bulimia nervosa.
Trygstad, O, 1990
)
0.76
"When fluoxetine treatment was terminated, ethanol self-administration quickly returned to the prefluoxetine levels, while water intake began to decrease."( Effects of fluoxetine on the intragastric self-administration of ethanol in the alcohol preferring P line of rats.
Gatto, GJ; Li, TK; Lumeng, L; McBride, WJ; Murphy, JM; Waller, MB,
)
0.98
"Treatment with fluoxetine for 26 weeks did not change the prevalence of these thoughts compared with placebo."( Wishing to die or self-harm after stroke: A planned secondary analysis of the AFFINITY Randomised Controlled Trial.
Almeida, OP; Etherton-Beer, C; Flicker, L; Ford, A; Hackett, M; Hankey, GJ, 2022
)
1.06
"Treatment with fluoxetine 10 mg/kg significantly improved GJIC and anhedonia of rats until six days."( Gap junction is essential for the antidepressant effects of fluoxetine.
Chen, NH; Chu, SF; Jiang, H; Li, FF; Lou, YX; Ren, Q; Shao, QH; Wan, JF; Wang, ZZ; Xia, CY; Yan, X; Yang, PF; Zhang, NN; Zhang, XL; Zhang, Y; Zhang, YN; Zhu, HY, 2023
)
1.49
"Treatment with fluoxetine or 5-hydroxytryptophan significantly increased intracellular serotonin concentrations and subsequently increased PTHrP gene expression, which was reduced with transglutaminase inhibition."( Serotonin stimulated parathyroid hormone related protein induction in the mammary epithelia by transglutaminase-dependent serotonylation.
Hernandez, LL; Sheftel, CM, 2020
)
0.9
"Treatment with fluoxetine resulted in remarkable improvement and regain of muscle power and independence from assisted ventilation."( A rare mutation in the COLQ gene causing congenital myasthenic syndrome with remarkable improvement to fluoxetine: A case report.
Beeson, D; Chang, T; Cossins, J; Fernando, A; Gooneratne, IK; Gunaratne, K; Maxwell, S; Nandasiri, S; Vidanagamage, A, 2021
)
1.18
"Treatment with fluoxetine, desipramine (10 mg/kg) or saline was performed twice daily (12-12 h interval), for 7 consecutive days."( Both serotonergic and noradrenergic systems modulate the development of tolerance to chronic stress in rats with lesions of the serotonergic neurons of the median raphe nucleus.
Carvalho, MC; Padovan, CM; Pereira, AC, 2019
)
0.85
"The treatment with fluoxetine increase taurine transport and the incubation with the agonist of 5-HT"( Role of 5-HT
Colmenares-Aguilar, M; Lima, L,
)
0.45
"Treatment with fluoxetine for 7 days, but not 24 hours, also reinstated social interaction behavior in mice that were susceptible to chronic social defeat."( Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine.
Berton, O; Browne, CA; Falcon, E; Lucki, I; Robinson, SA, 2018
)
0.82
"Rats treated with fluoxetine demonstrated lower IL-1β in plasma and brain after 90 and 120-day treatment respectively (p<0.05)."( Chronic administration of fluoxetine and pro-inflammatory cytokine change in a rat model of depression.
Chua, AN; Ho, CS; Ho, RC; Liu, X; Lu, Y; McIntyre, RS; Wang, W, 2017
)
1.08
"Treatment with fluoxetine for 90 days after acute ischemic stroke significantly reduces the three-year recurrence rate of ischemic stroke."( Effect of fluoxetine on three-year recurrence in acute ischemic stroke: A randomized controlled clinical study.
Cai, Z; Chang, X; Chen, S; Guo, Y; He, Y; Liang, Y; Tang, B; Zeng, S, 2018
)
1.24
"Treatment with fluoxetine, or its major metabolite, norfluoxetine, adversely affected EB morphogenesis at concentrations of 6 µM and above."( Fluoxetine Inhibits Canonical Wnt Signaling to Impair Embryoid Body Morphogenesis: Potential Teratogenic Mechanisms of a Commonly Used Antidepressant.
Marikawa, Y; Warkus, ELL, 2018
)
2.26
"Treatment with fluoxetine over 8 weeks led to reductions in cognitive distortions, with decreased negative and increased positive affect in adolescents with MDD. "( Changes in cognitive distortions and affectivity levels in adolescent depression after acute phase fluoxetine treatment.
Stevanovic, D; Zalsman, G, 2019
)
1.08
"Treatment with fluoxetine 60 mg/day for 12 weeks reduced obsessive symptoms by 60%, improving her quality of life."( The Stuck Song Syndrome: A Case of Musical Obsessions.
Lizarazo Rodríguez, IL; Orjuela Rojas, JM, 2018
)
0.82
"Treatment with fluoxetine did not affect the motor coordination caused by haloperidol."( The effect of acute and repeated administration of buspirone, 8-OHDPAT and fluoxetine on haloperidol-induced extrapyramidal symptoms.
Ahmadi, SA; Haddadi, R; Sabahi, M, 2019
)
1.08
"Co-treatment with fluoxetine or mirtazapine and risperidone did not reduce the stress-induced increase in plasma corticosterone concentration in animals subjected to the FST."( Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test.
Gądek-Michalska, A; Kabziński, M; Rachwalska, P; Rogóż, Z; Sadaj, W, 2012
)
1
"Mice treated with fluoxetine in an enriched condition improved their depression-like phenotype compared to controls, displaying higher saccharin preference, higher brain BDNF levels and reduced corticosterone levels."( Antidepressant treatment outcome depends on the quality of the living environment: a pre-clinical investigation in mice.
Alleva, E; Branchi, I; Capoccia, S; Cirulli, F; D'Andrea, I; Poggini, S; Santarelli, S, 2013
)
0.71
"Treatment with fluoxetine/olanzapine demonstrated similar biomarkers of response to monotherapeutic strategies. "( Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation.
Downar, J; Giacobbe, P; Kennedy, SH; Konarski, JZ; McIntyre, RS; Rizvi, SJ; Salomons, TV, 2013
)
0.74
"Treatment with fluoxetine increased the number of proliferating NSPCs in the granule cell layer and dentate hilus, and that of endothelial cells in the granule cell layer."( Antidepressant-induced vascular dynamics in the hippocampus of adult mouse brain.
Fukushima, S; Furube, E; Mannari, T; Miyata, S; Nakashimna, T; Nishikawa, K; Sawa, H, 2014
)
0.74
"Pretreatment with fluoxetine blocked the anxiogenic effects of CAS on the light/dark test as well as all physiological parameters and the increase in extracellular brain 5-HT, but not the reduction in nocifensive behavior."( Fluoxetine and WAY 100,635 dissociate increases in scototaxis and analgesia induced by conspecific alarm substance in zebrafish (Danio rerio Hamilton 1822).
Costa, CC; Guedes, IM; Herculano, AM; Lima, MG; Maximino, C, 2014
)
2.17
"Treatment with fluoxetine had no effect on tumor growth, muscle wasting, fatigue behavior, or cytokine expression in the brain."( Fluoxetine prevents the development of depressive-like behavior in a mouse model of cancer related fatigue.
Bicer, S; Devine, R; Godbout, JP; Jing, R; McCarthy, DO; Norden, DM; Reiser, PJ; Wold, LE, 2015
)
2.2
"Pretreatment with fluoxetine significantly suppressed these increases."( Morphine-Induced Constipation Develops With Increased Aquaporin-3 Expression in the Colon via Increased Serotonin Secretion.
Fueki, A; Haga, Y; Hayakawa, A; Ikarashi, N; Kon, R; Kusunoki, Y; Machida, Y; Ochiai, W; Sugiyama, K; Tajima, M, 2015
)
0.74
"Treatment with fluoxetine was an independent factor affecting the NIHSS and BI scores on day 180 after treatment."( Effects of Fluoxetine on Neural Functional Prognosis after Ischemic Stroke: A Randomized Controlled Study in China.
Cai, ZL; Guo, Y; He, YT; Jiang, X; Tang, BS; Zeng, SL, 2016
)
1.16
"Treatment with fluoxetine for 90 days after ischemic stroke can improve the long-term neural functional outcomes."( Effects of Fluoxetine on Neural Functional Prognosis after Ischemic Stroke: A Randomized Controlled Study in China.
Cai, ZL; Guo, Y; He, YT; Jiang, X; Tang, BS; Zeng, SL, 2016
)
1.18
"Pretreatment with fluoxetine to raise brain allopregnanolone concentration during late diestrus prevents the withdrawal effect."( Short term, low dose fluoxetine blocks estrous cycle-linked changes in responsiveness to diazepam in female rats.
André, E; de Sousa Pinto, ÍA; Gavioli, EC; Lovick, T; Santos, RO; Soares-Rachetti, Vde P, 2016
)
1.08
"Treatment with fluoxetine attenuated the expression of Htr2B mRNA, stimulated post-stroke neurogenesis in the subventricular zone and was associated with an improved anhedonic behavior and an increased activity in the forced swim test in aged animals."( Up-regulation of serotonin receptor 2B mRNA and protein in the peri-infarcted area of aged rats and stroke patients.
Bădescu, GM; Bogdan, C; Buga, AM; Ciobanu, O; Di Napoli, M; Popa-Wagner, A; Slevin, M; Weston, R, 2016
)
0.77
"Co-treatment with fluoxetine and vitamin C significantly attenuated BSCB permeability at 1 d after SCI."( Fluoxetine and vitamin C synergistically inhibits blood-spinal cord barrier disruption and improves functional recovery after spinal cord injury.
Choi, HY; Lee, JY; Yune, TY, 2016
)
2.2
"Treatment with fluoxetine between postnatal days P4 and P21 resulted in a significant loss of body weight and long-lasting behavioural inhibition in adult mice in response to stressful events such as the light-dark or open field tests."( Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice.
Castrén, E; Karpova, NN; Lindholm, J; Pruunsild, P; Timmusk, T, 2009
)
0.92
"Treatment with fluoxetine increased CB(1) receptor density in the prefrontal cortex, but had no effect on endocannabinoid contents in any brain region examined."( Differential effects of the antidepressants tranylcypromine and fluoxetine on limbic cannabinoid receptor binding and endocannabinoid contents.
Gorzalka, BB; Hill, MN; Hillard, CJ; Ho, WS, 2008
)
0.92
"Treatment with fluoxetine modified immune parameters in plasma and lymphocytes of rats, which might be relevant for its systemic therapeutic action as an antidepressant."( Fluoxetine treatment to rats modifies serotonin transporter and cAMP in lymphocytes, CD4+ and CD8+ subpopulations and interleukins 2 and 4.
Cedeño, N; Fazzino, F; Lima, L; Urbina, M, 2009
)
2.14
"Treatment of fluoxetine could reverse CUMS-induced impairment."( Cytoskeletal alterations in rat hippocampus following chronic unpredictable mild stress and re-exposure to acute and chronic unpredictable mild stress.
Liu, Z; Wang, G; Wang, H; Wang, X; Yang, C, 2009
)
0.71
"Treatment with fluoxetine during CRS reversed the decrease in DG H3K9me3, but had no effect on the other marks."( Regulation of hippocampal H3 histone methylation by acute and chronic stress.
Hunter, RG; McCarthy, KJ; McEwen, BS; Milne, TA; Pfaff, DW, 2009
)
0.69
"Treatment with fluoxetine significantly reversed these adverse effects of stress."( Effects of psychological stress and fluoxetine on development of oral candidiasis in rats.
Balboa, J; Freire-Garabal, M; Novío, S; Núñez, MJ; Suárez, JA, 2010
)
0.98
"Pretreatment with fluoxetine attenuated the increased IκB kinase (IKK) and IκBα phosphorylation induced by TNF-α."( Fluoxetine inhibits NF-κB signaling in intestinal epithelial cells and ameliorates experimental colitis and colitis-associated colon cancer in mice.
Jung, HC; Kim, IK; Kim, JM; Kim, JS; Kim, N; Koh, SJ; Song, IS, 2011
)
2.14
"Treatment with fluoxetine partially reverses the adverse effects of stress."( Effects of fluoxetine on the oxidative status of peripheral blood leucocytes of restraint-stressed mice.
Amigo, G; Freire-Garabal, M; Novío, S; Núñez, MJ, 2011
)
1.1
"Treatments (fluoxetine 10 mg/kg; NaCl 0.9%) started at the third week until the end of the seventh week of each procedure."( Fluoxetine effect on aortic nitric oxide-dependent vasorelaxation in the unpredictable chronic mild stress model of depression in mice.
Belzung, C; Camus, V; Freslon, JL; Isingrini, E; Machet, MC, 2012
)
2.18
"Mice treated with fluoxetine and mice who exercised daily showed, not only similar antidepressant behavior, but also similar changes in gene expression and hippocampal neurons."( Neurogenomic evidence for a shared mechanism of the antidepressant effects of exercise and chronic fluoxetine in mice.
Ben-David, E; Edwards, A; Flint, J; Huang, GJ; Shifman, S; Tort Piella, A, 2012
)
0.92
"Treatment with fluoxetine fully restored all these defects."( Early pharmacotherapy with fluoxetine rescues dendritic pathology in the Ts65Dn mouse model of down syndrome.
Bartesaghi, R; Bianchi, P; Calzà, L; Ciani, E; Grossi, G; Guidi, S; Mangano, C; Ragazzi, E; Stagni, F; Trazzi, S, 2013
)
1.03
"Treatment with fluoxetine (10 mg · kg(-1) · day(-1), days 36-42), tegaserod (1 mg · kg(-1) · day(-1), day 43), or the combination of both, reduced visceral hypersensitivity and plasma 5-HT levels."( Effect of the 5-HT4 receptor and serotonin transporter on visceral hypersensitivity in rats.
Hua-Hong, W; Jun-Xia, L; Xin-Guang, L; Yan, C; Yi-Xuan, L, 2012
)
0.72
"Treatment with fluoxetine reduced the PSA-NCAM level only in isolated animals."( Effects of fluoxetine on plasticity and apoptosis evoked by chronic stress in rat prefrontal cortex.
Adzic, M; Djordjevic, A; Djordjevic, J; Elaković, I; Matić, G; Radojcic, MB, 2012
)
1.11
"Treatment with fluoxetine reversed the changes in CRF and CRF1 expressions, but not in ERK1/2 activation."( Effects of fluoxetine on CRF and CRF1 expression in rats exposed to the learned helplessness paradigm.
Cassanelli, PM; Cladouchos, ML; Fernández Macedo, GV; Sifonios, L; Wikinski, S, 2013
)
1.12
"Pretreatment with fluoxetine for 5 min inhibited [Ca(2+)](i) increases induced by glutamate, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, and N-methyl-d-aspartate."( Fluoxetine suppresses synaptically induced [Ca²⁺]i spikes and excitotoxicity in cultured rat hippocampal neurons.
Choi, SJ; Hahn, SJ; Hong, YJ; Kim, HJ; Kim, TH; Rhie, DJ; Sung, KW; Yang, JS; Yoon, SH, 2013
)
2.16
"Treatment with fluoxetine for 3 weeks abolished the neurobehavioral effects of LPS."( A new animal model of (chronic) depression induced by repeated and intermittent lipopolysaccharide administration for 4 months.
Basta-Kaim, A; Budziszewska, B; Curzytek, K; Duda, W; Holan, V; Kubera, M; Lason, W; Leskiewicz, M; Maes, M; Roman, A; Szczesny, E; Zajicova, A, 2013
)
0.73
"Treatment with fluoxetine was associated with a reversal of high Neuroticism scores and low Extraversion scores in the whole sample and in a subgroup of responders but not in non-responders."( Does fluoxetine influence major depression by modifying five-factor personality traits?
Bakish, D; Du, L; Hrdina, PD; Ravindran, AV, 2002
)
1.17
"Rats treated with fluoxetine showed a loss in body weight."( Treatment of cycling female rats with fluoxetine induces desensitization of hypothalamic 5-HT(1A) receptors with no change in 5-HT(2A) receptors.
Battaglia, G; DonCarlos, LL; Garcia, F; Muma, NA; Raap, DK; Van de Kar, LD, 2002
)
0.91
"Treatment with fluoxetine (10 mg/kg) significantly decreased the duration of feeding behavior and increased the active behavior duration at 0-10 and 30-40 min as compared with the control group."( Involvement of normal physiological mechanisms in mediation of satiety by polyherbal antiobesity preparation, OB-200G, in female mice.
Kaur, G; Kulkarni, SK,
)
0.47
"Treatment with fluoxetine for 21 or 42 days produced diminished adrenocorticotropic hormone (ACTH) and oxytocin (but not corticosterone) responses to DOI injections (2.5 mg/kg i.p.; 15 min postinjection)."( Chronic fluoxetine differentially affects 5-hydroxytryptamine (2A) receptor signaling in frontal cortex, oxytocin- and corticotropin-releasing factor-containing neurons in rat paraventricular nucleus.
Battaglia, G; D'Souza, DN; Damjanoska, KJ; Garcia, F; Kindel, GH; Muma, NA; Van de Kar, LD; Zhang, Y, 2003
)
1.09
"Treatment with fluoxetine increased this enzyme activity and reversed the effect of stress."( Reduction of hippocampal Na+, K+-ATPase activity in rats subjected to an experimental model of depression.
Dalmaz, C; Gamaro, GD; Matté, C; Prediger, ME; Streck, EL; Wyse, AT, 2003
)
0.66
"Treatment with fluoxetine or nortriptyline for 12 weeks during the first 6 months poststroke significantly increased the survival of both depressed and nondepressed patients. "( Mortality and poststroke depression: a placebo-controlled trial of antidepressants.
Arndt, S; Jorge, RE; Robinson, RG; Starkstein, S, 2003
)
0.67
"Treatment with fluoxetine reversed these changes, as in SC rats."( Alterations in voiding frequency and cystometry in the clomipramine induced model of endogenous depression and reversal with fluoxetine.
Dean-McKinney, T; Klausner, AP; Lee, KS; Na, YG; Steers, WD; Tuttle, JB, 2003
)
0.86
"Treatment with fluoxetine for 6 months resulted in significant symptom relief and an increasing density of serotonin transporter sites when compared to the beginning of treatment."( Fluoxetine in Alzheimer's disease with severe obsessive compulsive symptoms and a low density of serotonin transporter sites.
Bodner, T; Donnemiller, E; Gurka, P; Marksteiner, J; Walch, T, 2003
)
2.1
"Treatment with fluoxetine inhibited the gain in weight in rats maintained on the control diet."( Fluoxetine-induced changes in body weight and 5-HT1A receptor-mediated hormone secretion in rats on a tryptophan-deficient diet.
Battaglia, G; D'Souza, DN; Garcia, F; Van de Kar, LD; Zhang, Y, 2004
)
2.11
"Treatment with fluoxetine and citalopram reversed these biochemical parameters."( Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors.
Dakhale, GN; Khanzode, SD; Khanzode, SS; Palasodkar, R; Saoji, A, 2003
)
0.66
"Treatment with Fluoxetine reduced aggressive response in well-nourished but not in malnourished rats."( Malnutrition during brain growth spurt alters the effect of fluoxetine on aggressive behavior in adult rats.
Barreto-Medeiros, JM; Cabral-Filho, JE; De-Castro, CM; Feitoza, EG; Magalhaes, K; Manhaes-De-Castro, FM; Manhaes-De-Castro, R, 2004
)
0.91
"Treatment with fluoxetine did not alter the male response to stress."( Males and females respond differently to controllability and antidepressant treatment.
Leuner, B; Mendolia-Loffredo, S; Shors, TJ, 2004
)
0.66
"Treatment with fluoxetine progressively decreased (35-55%) 5-HTT gene expression in dorsal raphe nucleus at 8, 16 and 31 days."( Time course of opioid and cannabinoid gene transcription alterations induced by repeated administration with fluoxetine in the rat brain.
Manzanares, J; Oliva, JM; Pérez-Rial, S; Urigüen, L, 2005
)
0.88
"Treatment with fluoxetine (100 nM to 30 microM) for 5 min inhibited the ATP-induced [Ca(2+)](i) increases in a concentration-dependent manner (IC(50) = 1.85 microM)."( Fluoxetine inhibits ATP-induced [Ca(2+)](i) increase in PC12 cells by inhibiting both extracellular Ca(2+) influx and Ca(2+) release from intracellular stores.
Choi, JS; Hahn, SJ; Hong, SH; Jo, YH; Kim, HJ; Kim, MJ; Kim, MS; Lee, YM; Min, DS; Rhie, DJ; Shim, EY; Yoon, SH, 2005
)
2.11
"Pretreatment with fluoxetine (10 mg/kg, ip) significantly potentiated the behavioural syndrome induced by dextromethorphan and 5-hydroxytryptophan but significantly antagonised dexfenfluramine induced behavioural syndrome."( Involvement of central serotonergic systems in dextromethorphan-induced behavioural syndrome in rats.
Balsara, JJ; Gaikwad, RV; Gaonkar, RK; Jadhav, JH; Jadhav, SA; Thorat, VM, 2005
)
0.65
"Pretreatment with fluoxetine or norfluoxetine (20mg/kg s.c.), as well as phenytoin (30 mg/kg s.c.) and clonazepam (0.1mg/kg s.c.) significantly increased both the rate and duration of survival, demonstrating a significant protective effect against pentylenetetrazol-induced epilepsy."( Norfluoxetine and fluoxetine have similar anticonvulsant and Ca2+ channel blocking potencies.
Harasztosi, C; Kecskeméti, V; Nánási, PP; Pál, B; Riba, P; Rusznák, Z; Szûcs, G; Wagner, R, 2005
)
1.27
"Treatment with fluoxetine (10 mg/kg, intraperitoneal) suppressed long-term potentiation induction in the chronic mild stress group."( Fluoxetine reverses stress-induced fimbria-prefrontal long-term potentiation facilitation.
Chessel, A; Deschaux, O; Garcia, R; Kessal, K; Moreau, JL; Xu, L, 2006
)
2.12
"Treatment with fluoxetine is less likely to lead to remission of MDD in patients with stable PDs."( Problem-solving ability and comorbid personality disorders in depressed outpatients.
Farabaugh, A; Fava, M; Harley, R; Papakostas, GI; Petersen, T; Scalia, M, 2006
)
0.67
"Treatment with fluoxetine can ameliorate pathological changes in the duodenum of depressed rats, which suggests that antidepressants are an effective therapeutic agent for some duodenal diseases caused by chronic stress."( Effect of fluoxetine on depression-induced changes in the expression of vasoactive intestinal polypeptide and corticotrophin releasing factor in rat duodenum.
Chen, ZH; Huang, YL; Wang, GH; Wang, Q; Xiao, L; Yu, JP, 2007
)
1.08
"Pretreatment with fluoxetine failed to antagonize the fenfluramine-induced suppression of slow-wave sleep and rapid-eye-movement sleep."( Sleep suppressant action of fenfluramine in rats. II. Evidence against the involvement of presynaptic serotonergic mechanism.
Fornal, C; Radulovacki, M, 1983
)
0.59
"Pretreatment with fluoxetine (20 mg/kg), which presumably blocks the uptake of PCA into 5-HT nerve terminals, completely blocked the PCA-induced decreases in both 5-HT and corticosteroid receptor concentrations."( Short-term and long-term effects of p-chloroamphetamine on hippocampal serotonin and corticosteroid receptor levels.
Lowy, MT; Novotney, S, 1995
)
0.61
"Treatment with fluoxetine at a dose of 20 mg per day reduces the potential for side effects while maximizing therapeutic efficacy."( Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group.
Berger, C; Carter, D; Grover, D; Reid, R; Steinberg, S; Steiner, M; Stewart, D; Streiner, D, 1995
)
2.07
"The treatment of fluoxetine at 9:30 AM did not affect any sleep patterns."( Changes in sleep patterns by intralaminar thalamic microinjection of fluoxetine in rats.
Tsai, LL; Tsai, YF, 1993
)
0.85
"Treatment with fluoxetine was followed by an overall increase in the prolactin response to TRH among the depressed patients with anger attacks."( Anger attacks in unipolar depression, Part 2: Neuroendocrine correlates and changes following fluoxetine treatment.
Bouffides, E; Fava, M; McCarthy, MK; Pava, JA; Rosenbaum, JF; Steingard, RJ, 1993
)
0.84
"Pretreatment with fluoxetine significantly increased (38%) the Bmax for the 5-HT1C/2 agonist sites ([125I]DOI) in the hypothalamus.(ABSTRACT TRUNCATED AT 250 WORDS)"( Long-term treatment with the antidepressants fluoxetine and desipramine potentiates endocrine responses to the serotonin agonists 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212) and (+-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI).
Battaglia, G; Brownfield, MS; Cabrera, TM; Levy, AD; Li, Q; Rittenhouse, PA; van de Kar, LD, 1993
)
0.87
"Pretreatment with fluoxetine inhibited AVP-facilitated offensive aggression."( Serotonin blocks vasopressin-facilitated offensive aggression: interactions within the ventrolateral hypothalamus of golden hamsters.
Delville, Y; Ferris, CF; Mansour, KM,
)
0.45
"Rats treated with fluoxetine lost significantly less weight, ran significantly less, and increased food intake more rapidly during restriction of food availability than saline-treated rats."( Effects of serotonergic agents on food-restriction-induced hyperactivity.
Altemus, M; Galliven, E; Glowa, JR; Leong, YM; Murphy, DL, 1996
)
0.62
"Treatment with fluoxetine resulted in a dose-dependent decrease in saccharin intake to, but not below, the normal level of their DFI."( Fluoxetine reduces saccharin-induced elevation of fluid intake in alcohol-preferring Fawn-Hooded rats.
Kampov-Polevoy, AB; Rezvani, AH, 1997
)
2.08
"Treatment with fluoxetine was introduced to alleviate the compulsive aspects of those disorders."( Divergent responses to fluoxetine from two compulsive, food-related conditions: bulimia nervosa and compulsive water drinking.
Dan, B; Fontaine, E; Kornreich, C; Pelc, I; Verbanck, P, 1998
)
0.95
"Treatment with fluoxetine (5 mg/kg) partially reversed those adverse effects of surgery, but the difference was clearer when it was administered before surgery was performed."( Effects of fluoxetine on the development of lung metastases induced by operative stress in rats.
Fernández-Rial, JC; Freire-Garabal, M; García-Iglesias, E; Losada, C; Mayán, JM; Núñez, MJ; Pereiro, D; Prizmic, J; Rey-Méndez, M; Riveiro, P, 1998
)
1.03
"Pretreatment with fluoxetine increases extracellular 5-HT due to reuptake inhibition."( Modulation of delta9-tetrahydrocannabinol-induced hypothermia by fluoxetine in the rat.
Malone, DT; Taylor, DA, 1998
)
0.86
"Pretreatment with fluoxetine (10 mg kg-1 i.p.) abolished the Delta9-THC-induced DA release."( Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats.
Malone, DT; Taylor, DA, 1999
)
0.99
"The treatment of fluoxetine significantly correlated with body mass index (T1: p < 0.023, T2: p < 0.03, T3: p < 0.004)."( [The combined effect of psychotherapy and fluoxetine on obesity].
Haász, P; Jákó, P; Resch, M; Sidó, Z, 1999
)
0.9
"Treatment with fluoxetine either 1 h prior to or 4 h following the administration of MDMA reduced the MDMA-induced formation of 2,3-DHBA and also attenuated the MDMA-induced depletion of 5-HT in the striatum."( Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine.
Gudelsky, GA; Shankaran, M; Yamamoto, BK, 1999
)
0.64
"Pretreatment with fluoxetine (20 mg/kg IP) 1 hour before MK801 prevented the induction of HSP70 by MK801 in the cingulate and retrosplenial cortices. "( Fluoxetine prevents PCP- and MK801-induced HSP70 expression in injured limbic cortical neurons of rats.
Rajdev, S; Sharp, FR; Tomitaka, M; Tomitaka, S, 2000
)
2.08
"Pretreatment with fluoxetine (10 mg/kg, i.p.), a 5-HT reuptake inhibitor, and 8-hydroxy-2-(di-n-propylamino)tetralin, a 5-HT(1A) receptor agonist, also suppressed the HTR induced by BZ-RAs."( Central serotonergic mechanisms on head twitch response induced by benzodiazepine receptor agonists.
Arai, Y; Hishinuma, T; Hozumi, M; Kinemuchi, H; Kisara, K; Mizugaki, M; Nakagawasai, O; Niijima, F; Oka, R; Satoh, N; Tadano, T; Tan-no, K; Yasuhara, H, 2001
)
0.63
"Treatment with fluoxetine (10 mg/kg, i.p.) induced a 41% reduction in the cumulative amount of extracellular DA during 300 min following L-DOPA administration (50 mg/kg, i.p.; p < 0.01)."( Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum.
Kannari, K; Matsunaga, M; Shen, H; Suda, T; Yamato, H, 2001
)
2.09
"Pretreatment with fluoxetine (10 mg kg(-1), x2) failed to alter cerebral MDMA accumulation compared to saline pretreated controls."( The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain.
Camarero, J; Colado, MI; Esteban, B; Green, AR; Peter, MJ; Sanchez, V, 2001
)
0.87
"We treated with fluoxetine 235 outpatients meeting DSM-IV criteria for major depression. "( T3 blood levels and treatment outcome in depression.
Alpert, JE; Fava, M; Howarth, S; Iosifescu, DV; Nierenberg, AA; Worthington, JJ, 2001
)
0.66
"Pretreatment with fluoxetine enhanced rather than blocked these effects."( Synergistic action of p-chloroamphetamine and fluoxetine on food and water consumption patterns in the rat.
Adler-Stein, RL; Kantak, KM; Stein, JM; Wayner, MJ, 1978
)
0.84
"Treatment with fluoxetine, a specific inhibitor of serotonin uptake, did not result in a loss of the cortical pattern of serotonin immunoreactivity, indicating that immunoreactive fibers were not labeled solely as a result of serotonin uptake."( The source of the transient serotoninergic input to the developing visual and somatosensory cortices in rat.
Bennett-Clarke, CA; Chiaia, NL; Crissman, RS; Rhoades, RW, 1991
)
0.62
"Pretreatment with fluoxetine (10 mg/kg, i.p.), a 5-HT uptake blocker, 30 min before the infusion of MDMA produced a slight but significant inhibition of MDMA-induced increase in DA concentration."( Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors.
Brodkin, J; Nash, JF, 1991
)
0.6
"Treatment with fluoxetine hydrochloride was compared with treatment with clomipramine hydrochloride in two groups of patients with obsessive-compulsive disorder using two different experimental designs. "( Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.
Bernstein, SE; Grover, GN; Hill, JL; Murphy, DL; Pato, MT; Pigott, TA; Tolliver, TJ, 1990
)
0.89
"Pretreatment with fluoxetine, an inhibitor of uptake into 5-HT neurons, antagonized the decrease in 5-HT and the increase in 5-HIAA and in the ratio 5-HIAA/5-HT but did not antagonize the changes in dopamine or its metabolites."( Effect of fluoxetine pretreatment on the neurochemical changes induced by amfonelic acid combined with spiperone in rats.
Fuller, RW; Snoddy, HD, 1986
)
1
"Pretreatment with fluoxetine (2.5, 5, and 10 mg/kg), an inhibitor of serotonin reuptake, significantly decreased rates of responding maintained by amphetamine, but had no effect on responding maintained by cocaine at any of the doses tested."( Differential effects of the pharmacological manipulation of serotonin systems on cocaine and amphetamine self-administration in rats.
Goldberg, SR; Goodman, NL; Kuhar, MJ; Porrino, LJ; Ritz, MC; Sharpe, LG, 1989
)
0.6
"Pretreatment with fluoxetine (10 mg/kg i.p.) 16 hr before MDMA administration significantly blunted the effect of MDMA on corticosterone but not PRL secretion."( Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine.
Gudelsky, GA; Meltzer, HY; Nash, JF, 1988
)
0.6

Toxicity

Fluoxetine was found to be safe and well tolerated in this study of children and adolescents with MDD. The frequency of adverse events in response to fluoxetin was lower than under clomipramine treatment.

ExcerptReferenceRelevance
" Generally, newer drugs including fluoxetine have a more favourable adverse effect profile."( Toxicity of antidepressants: comparisons with fluoxetine.
Henry, JA, 1992
)
0.82
" Although fluoxetine has been promoted as a safe antidepressant, a recent literature search revealed a number of case reports of adverse effects and drug interactions attributed to its use."( Adverse effects and drug interactions associated with fluoxetine therapy.
Fuller, DK; Levinson, ML; Lipsy, RJ, 1991
)
0.93
" Evaluation of adverse events and vital signs indicated no clinically significant differences between the two treatment groups."( Efficacy and safety of morning versus evening fluoxetine administration.
Beasley, CM; Bosomworth, JC; Usher, RW, 1991
)
0.54
" The frequency of adverse events in response to fluoxetine was lower than under clomipramine treatment."( [Efficacy and safety of fluoxetine versus clomipramine in ambulatory patients with a depressive syndrome in a clinical trial with private practitioners].
Dossenbach, M; Pakesch, G, 1991
)
0.84
" As indicated by the significant decrease in the Hamilton Depression scale and the Montgomery Asberg Depression scale, fluoxetine showed similar antidepressant effects to amitriptyline with significantly fewer adverse effects."( Fluoxetine in major depression: efficacy, safety and effects on sleep polygraphic variables.
Czarka, M; de Maertelaer, V; Kerkhofs, M; Linkowski, P; Mendlewicz, J; Rielaert, C, 1990
)
1.93
" Different side effect profiles may have a bearing on patient selection."( Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy.
Baer, L; Greist, JH; Jenike, MA, 1990
)
0.6
" Data pooled from these two studies suggest a dose relationship for adverse events during fluoxetine therapy."( Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression.
Beasley, CM; Bosomworth, JC; Wernicke, JF, 1990
)
1.94
" Frequently encountered adverse effects are emphasized, but some of the more serious rare ones are also considered."( Antidepressant drug side effects.
Bodkin, JA; Cole, JO, 1990
)
0.28
" Safety was monitored weekly by recording body weight, blood pressure, pulse rate, temperature, physical conditions, laboratory tests, adverse experiences and concomitant medication."( Double-blind controlled study on the clinical efficacy and safety of fluoxetine vs clomipramine in the treatment of major depressive disorders.
Agnoli, A; Manna, V; Martucci, N, 1989
)
0.51
"The side effect profile and safety of fluoxetine are reviewed."( The side effect profile and safety of fluoxetine.
Wernicke, JF, 1985
)
0.81
" The adverse event profile in obese patients, though differing slightly from that seen in depressed patients, was similar in that events observed were generally mild and well tolerated."( Safety of fluoxetine in the treatment of obesity.
Zerbe, RL, 1987
)
0.68
" The findings indicate that MPTP (or MPP+) is a substrate for the specific DA reuptake system and may explain, in part, its selective toxic effects on DA neurons."( Dopamine but not norepinephrine or serotonin uptake inhibitors protect mice against neurotoxicity of MPTP.
Cohen, O; Globus, M; Melamed, E; Rosenthal, J; Uzzan, A, 1985
)
0.27
"They assessed the notifications of extrapyramidal manifestations in patients given fluoxetine in the New Zealand Intensive Medicines Monitoring Programme, a national system that monitored adverse reactions associated with fluoxetine over a 4-year period, and determined whether these adverse reactions were causally related to fluoxetine."( Fluoxetine and extrapyramidal side effects.
Coulter, DM; Pillans, PI, 1995
)
1.96
"In reports of adverse reactions in 5,555 patients given fluoxetine throughout New Zealand, there were 15 notifications of extrapyramidal events probably or possibly caused by fluoxetine."( Fluoxetine and extrapyramidal side effects.
Coulter, DM; Pillans, PI, 1995
)
1.98
"This study tested the hypothesis that some patients treated with an antidepressant who develop adverse events (e."( Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression.
Beasley, CM; Enas, GG; Potvin, JH; Rampey, AH; Tollefson, GD, 1994
)
0.29
" The adverse reactions include the "serotonin syndrome", cardiovascular complications, extrapyramidal side effects such as akathisia, dyskinesias, and parkinsonian-like syndromes and an apparently increased risk of suicidality."( Fluoxetine: adverse effects and drug-drug interactions.
Messiha, FS, 1993
)
1.73
" The incidence of adverse events was similar for both treatments; 40."( Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression.
Aguglia, E; Bolino, F; Casacchia, M; Cassano, GB; Faravelli, C; Ferrari, G; Giordano, P; Pancheri, P; Ravizza, L; Trabucchi, M, 1993
)
0.52
"A re-analysis of the profile of adverse events observed in controlled clinical trials in summarized."( Adverse events and treatment discontinuations in fluoxetine clinical trials.
Pande, AC; Sayler, ME, 1993
)
0.54
" The fates of SSRI-associated sexual adverse effects and clinical managements of restoring these side effects were described."( Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients.
Hsu, JH; Shen, WW, 1995
)
0.29
"With some limitations in interpreting the data, the findings of this study suggest that SSRI-associated female sexual dysfunction occurs at a higher rate than we previously thought, equal potentials in implicating female sexual side effects among three SSRIs, and the absence or the low incidence of female sexual adverse effects from bupropion, and that these side effects can be managed by waiting for a spontaneous remission, dosage reduction of SSRIs, substitution with bupropion and other antidepressants, or the use of an antidote."( Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients.
Hsu, JH; Shen, WW, 1995
)
0.29
"Comprehensive review of safety data from approximately 3500 patients who received nefazodone in premarketing clinical trials demonstrates the drug to be very well tolerated, with a favorable side effect profile compared with other antidepressant drugs."( The safety profile of nefazodone.
Kaplita, SB; Marcus, RN; Roberts, DL; Robinson, DS; Seminara, JA; Smith, JM; Stringfellow, JC, 1996
)
0.29
"Data from an intensive observational drug utilization study were analyzed to determine whether patients who received the combination of fluoxetine and lithium had more and different adverse events as compared with those receiving fluoxetine alone."( Adverse events and tolerability of the combination of fluoxetine/lithium compared with fluoxetine.
Bauer, M; Linden, M; Schaaf, B; Weber, HJ, 1996
)
0.75
" There were 188 adverse events: insomnia, dizziness, headache, nausea, dry mouth and myoclonic jerks were the most common."( Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients.
Hawley, CJ; McPhee, S; Pattinson, HA; Quick, SJ; Ratnam, S, 1996
)
0.29
"To study the adverse drug reaction (ADR) profile of selective serotonin re-uptake inhibitors (SSRI) in Belgium and the Netherlands."( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands].
Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996
)
0.29
"All adverse reactions of fluoxetine, fluvoxamine, paroxetine and sertraline, reported between the moment of registration of these drugs and January 1st 1995, were assessed for causality."( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands].
Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996
)
0.6
"At the national monitoring centres of Belgium and of the Netherlands adverse reactions were reported 78 and 537 times, respectively."( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands].
Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996
)
0.29
" More adverse reactions were reported in the Netherlands than in Belgium."( [Reports of suspected side effects of selective serotonin reuptake inhibitors in Belgium and The Netherlands].
Kurz, X; Ottervanger, JP; Roisin, T; Stricker, BH; Van Ermen, AM, 1996
)
0.29
" We have addressed the question of whether there is a 'serotonin withdrawal syndrome' by analysis of spontaneous reports of suspected adverse drug reactions (ADRs) associated with four SSRIs."( A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal.
MacKay, AV; Price, JS; Waller, PC; Wood, SM, 1996
)
0.29
" Hyponatraemia has previously been described as an adverse effect to fluoxetine and paroxetine, but not to citalopram."( [Adverse effects of selective serotonin uptake inhibitors. Hyponatremia caused by Schwartz-Bartter syndrome].
Almdal, TP; Christensen, O; Sørensen, HA, 1996
)
0.53
" Overall, 27% of the SSRI-treated patients had no adverse sexual side effects; in contrast, 86% of patients treated with bupropion had no adverse sexual effects, and 77% of bupropion-treated patients reported at least one aspect of heightened sexual functioning."( Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline.
DePalma, RL; Katholi, CR; Modell, JD; Modell, JG, 1997
)
0.56
"SSRI-induced adverse sexual effects appear to be the rule rather than the exception and may be substantially underreported unless patients are specifically asked about the effects of these medications on various aspects of sexual function."( Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline.
DePalma, RL; Katholi, CR; Modell, JD; Modell, JG, 1997
)
0.56
"Selective serotonin reuptake inhibitors may be associated with new adverse events after abrupt discontinuation."( Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study.
Amsterdam, J; Beasley, C; Fawcett, J; Michelson, D; Quitkin, F; Reimherr, F; Rosenbaum, J; Zajecka, J, 1998
)
0.58
" Side-effect profiles were not significantly different between groups except for a significantly greater frequency of dose-related increase in heart rate > or = 100 bpm in milnacipran recipients and a significantly greater weight loss in fluoxetine recipients."( A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients.
Ansseau, M; Corruble, E; Guelfi, JD; Plétan, Y; Samuelian, JC; Tonelli, I; Tournoux, A, 1998
)
0.71
"English-language articles identified through MEDLINE (1985 through 1997), and case reports from the American Association of Poison Control Centers (AAPCC) (1987 through 1996) and United States Food and Drug Administration (FDA) adverse event database (through 1997) that describe findings of fatal and nonfatal overdoses involving SSRIs alone or in combination with other ingestants were reviewed."( SSRI safety in overdose.
Barbey, JT; Roose, SP, 1998
)
0.3
" At very high doses (> 75 times the common daily dose), more serious adverse events, including seizures, electrocardiogram (ECG) changes, and decreased consciousness may occur."( SSRI safety in overdose.
Barbey, JT; Roose, SP, 1998
)
0.3
" Discontinuation for lack of efficacy was lower in BP II (5%) than in UP (12%) patients (p = not significant [NS]), whereas dropouts for adverse events were similar in BP II (11%) and UP (9%) patients."( Efficacy and safety of fluoxetine in treating bipolar II major depressive episode.
Amsterdam, JD; Beasley, C; Fawcett, J; Garcia-España, F; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Schweizer, E, 1998
)
0.61
"Although a period of 6 to 12 months of antidepressant therapy is recommended for most patients with depression, systematic examinations of the course of adverse events over time, the resolution of early-onset events, and the possible emergence of later-onset events are limited."( Changes in adverse events reported by patients during 6 months of fluoxetine therapy.
Amsterdam, JD; Beasley, CM; Michelson, D; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Sundell, KL; Tamura, RN; Zajecka, J, 1999
)
0.54
" No previously uncommon adverse events became common during long-term treatment."( Changes in adverse events reported by patients during 6 months of fluoxetine therapy.
Amsterdam, JD; Beasley, CM; Michelson, D; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Sundell, KL; Tamura, RN; Zajecka, J, 1999
)
0.54
"Common adverse events associated with initiating fluoxetine treatment in depressed patients, including nausea, insomnia, nervousness, and somnolence, resolve in the majority of patients and become significantly less frequent with continued treatment over a 6-month period."( Changes in adverse events reported by patients during 6 months of fluoxetine therapy.
Amsterdam, JD; Beasley, CM; Michelson, D; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Sundell, KL; Tamura, RN; Zajecka, J, 1999
)
0.79
"Differences between the side effect profiles of clomipramine (CMI) and the selective serotonin reuptake inhibitors may be important factors in both treatment outcome and patient selection in obsessive-compulsive disorder (OCD)."( Side effects as predictors of drug response in obsessive-compulsive disorder.
Ackerman, DL; Bystritsky, A; Greenland, S, 1999
)
0.3
" The rate of discontinuation due to adverse effects with reboxetine was not significantly different from that observed with placebo in short-term studies."( Reboxetine: tolerability and safety profile in patients with major depression.
Tanum, L, 2000
)
0.31
" Data collection--at the start and the end of the observation period (< or =6 weeks)--included patient characteristics, diagnoses, medication, co-medication, efficacy, and adverse events (AEs)."( Efficacy and safety findings from naturalistic fluoxetine drug treatment in adolescent and young adult patients.
Czekalla, J; Dittmann, RW; Hundemer, HP; Linden, M, 2000
)
0.56
" We hypothesized that in patients taking 20 mg/day, efficacy would be maintained but the incidence of adverse events would be lower."( Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose.
Beasley, CM; Gonzales, JS; Koke, SC; Nilsson, ME, 2000
)
0.55
" Safety assessments included treatment-emergent adverse events, reasons for discontinuation, and adverse events leading to discontinuation."( Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose.
Beasley, CM; Gonzales, JS; Koke, SC; Nilsson, ME, 2000
)
0.55
" The incidence of specific adverse events leading to discontinuation and the frequency of study discontinuations due to adverse events were similar among fluoxetine-treated and placebo-treated patients (6."( Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose.
Beasley, CM; Gonzales, JS; Koke, SC; Nilsson, ME, 2000
)
0.75
" Safety measures included comparison of treatment-emergent adverse events, both spontaneous and solicited (using the Association for Methodology of Documentation in Psychiatry-Module 5), vital signs, and laboratory measures."( The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.
Fava, M; Judge, R; Robinson, JM; Schmidt, ME, 2000
)
0.55
" Spontaneously reported treatment-emergent adverse events, reasons for discontinuation, and events leading to discontinuation were compared between groups."( Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis.
Beasley, CM; Gonzales, JS; Koke, SC; Nilsson, ME, 2000
)
0.54
" At a dose of 20 mg/d, fluoxetine-treated patients had a discontinuation rate due to adverse events that was not statistically significantly different from that in placebo recipients."( Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis.
Beasley, CM; Gonzales, JS; Koke, SC; Nilsson, ME, 2000
)
0.85
" Patients without serious adverse effects who wished to continue participating in the study were given fluoxetine or placebo for an additional 16 weeks."( Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial.
Cheriex, EC; Honig, A; Kuijpers, PM; Lousberg, AH; Lousberg, R; Strik, JJ; Tuynman-Qua, HG; Van Praag, HM; Wellens, HJ,
)
0.66
" Even though the newer generation of selective serotonin reuptake inhibitor antidepressants exhibits a more favorable short-term, side-effect profile, effects of chronic use of such drugs remain unknown."( Side effects of long-term treatment with fluoxetine.
Baruch, Y; Buchman, N; Strous, RD,
)
0.4
" The severity and incidence of extrapyramidal symptoms and adverse events did not significantly increase when fluoxetine was added."( The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients.
Baumann, P; Bertschy, G; Bondolfi, G; Eap, CB; Vermeulen, A; Zullino, D, 2002
)
0.89
" Differences in treatment-emergent adverse events, unplanned pregnancies, and 17-item Hamilton Depression Scale (HAMD-17) scores were analyzed."( Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy.
Brown, EB; Koke, SC; Miner, CM, 2002
)
0.63
"The only treatment-emergent adverse events that showed a statistically significantly different odds ratio for oral contraceptive use versus no oral contraceptive use were headache, asthenia, and pain."( Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy.
Brown, EB; Koke, SC; Miner, CM, 2002
)
0.63
"In men with premature ejaculation 90 mg fluoxetine weekly may be regarded as an effective and safe treatment."( Comparison of the efficacy and safety of 90 mg versus 20 mg fluoxetine in the treatment of premature ejaculation.
Alcover Garcia, J; Gutierrez del Pozo, R; Manasia, P; Pomerol, J; Ribè, N, 2003
)
0.83
" Safety was evaluated by recording spontaneously reported adverse events."( Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
Fava, M; McGrath, PJ; Sheu, WP, 2003
)
0.53
" Treatment-emergent adverse effects were assessed at each study visit."( Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment.
Fava, M; Lamon-Fava, S; Lin, KM; Mischoulon, D; Perlis, RH; Rosenbaum, JF; Smoller, JW; Wan, YJ, 2003
)
0.56
" Safety was assessed via adverse events, vital signs, laboratory analytes, electrocardiography, and extrapyramidal symptom measures."( Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study.
Andersen, SW; Corya, SA; Detke, HC; Dubé, S; Kelly, LS; Sanger, TM; Van Campen, LE; Williamson, DJ, 2003
)
0.56
" The most frequently reported adverse events were somnolence, weight gain, dry mouth, increased appetite, and headache."( Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study.
Andersen, SW; Corya, SA; Detke, HC; Dubé, S; Kelly, LS; Sanger, TM; Van Campen, LE; Williamson, DJ, 2003
)
0.56
"Treatment-related adverse events (TRAEs), particularly those that occur early on, may increase the likelihood for premature discontinuation of antidepressants."( Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder.
Alpert, JE; Denninger, JW; Fava, M; Montoya, HD; Nierenberg, AA; Papakostas, GI; Petersen, T,
)
0.37
" These children will have no adverse effects or only minimal effects and require no emergency treatment or gastric decontamination."( Fluoxetine exposures: are they safe for children?
Baker, SD; Morgan, DL, 2004
)
1.77
"The purpose of this study was to examine the relationship between the degree of anxiety or somatic symptoms present before treatment with the subsequent diagnosis of treatment-related adverse events (TRAEs) in patients with major depressive disorder (MDD) enrolled in an 8-week open trial of fluoxetine (20 mg)."( Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder.
Alpert, JE; Fava, M; Hughes, ME; Nierenberg, AA; Papakostas, GI; Petersen, T, 2004
)
0.5
" Fluoxetine is generally safe and well-tolerated."( Safety and side effect profile of fluoxetine.
Wernicke, JF, 2004
)
1.51
" Clinical Global Impression of Severity (CGI-S) at the onset and end of the period evaluated, presence of adverse events, drop-out index and impression of patient's satisfaction with the treatment and use pattern were used."( [Once weekly fluoxetine, tolerability and safety according to use patterns in the psychiatric clinical practice].
de la Gándara, J; Majadas Fernández, S; Montejo González, AL; Varona, A; Vega Fernández, FM,
)
0.5
" The most frequent adverse effects were: anxiety (10."( [Once weekly fluoxetine, tolerability and safety according to use patterns in the psychiatric clinical practice].
de la Gándara, J; Majadas Fernández, S; Montejo González, AL; Varona, A; Vega Fernández, FM,
)
0.5
"Change to once weekly fluoxetine generally improves satisfaction of treatment efficacy and its use pattern, although some patients return to the initial regime after adverse effects appear."( [Once weekly fluoxetine, tolerability and safety according to use patterns in the psychiatric clinical practice].
de la Gándara, J; Majadas Fernández, S; Montejo González, AL; Varona, A; Vega Fernández, FM,
)
0.82
" Safety was evaluated through the reporting of concomitant medications, vital signs, routine laboratory testing, electrocardiograms (ECGs), and adverse event data."( Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents.
Brown, EB; Heiligenstein, JH; Joliat, MJ; Miner, CM; Nilsson, M, 2004
)
0.6
"Fluoxetine was found to be safe and well tolerated in this study of children and adolescents with MDD."( Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents.
Brown, EB; Heiligenstein, JH; Joliat, MJ; Miner, CM; Nilsson, M, 2004
)
2.04
"Although adverse events are a key factor in compliance, their evolution during treatment with antidepressants is poorly documented."( What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?
Albert, A; De Bruyckere, K; Demyttenaere, K; Dewé, W; Mesters, P; Sangeleer, M, 2005
)
0.33
" At each visit, the presence and severity of treatment-emergent adverse events were assessed systematically using the UKU Side Effect Rating Scale (UKU)."( What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?
Albert, A; De Bruyckere, K; Demyttenaere, K; Dewé, W; Mesters, P; Sangeleer, M, 2005
)
0.33
"Overall, the number of at least moderately severe adverse events decreased with time."( What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?
Albert, A; De Bruyckere, K; Demyttenaere, K; Dewé, W; Mesters, P; Sangeleer, M, 2005
)
0.33
"The time course of adverse events varies with the severity of depression, sex, completer or dropout status, and recurrent versus first-episode depression."( What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?
Albert, A; De Bruyckere, K; Demyttenaere, K; Dewé, W; Mesters, P; Sangeleer, M, 2005
)
0.33
" All adverse events which developed during the study period were recorded."( Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression.
Chee, IS; Choe, BM; Ham, BJ; Jung, HY; Kee, BS; Kim, JB; Lee, C; Lee, MS; Oh, BH; Oh, KS; Paik, IH; Yeon, BK, 2005
)
0.58
" In the milnacipran group, 13 patients reported 28 adverse reactions, and in the fluoxetine group 11 patients reported 18 adverse reactions."( Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression.
Chee, IS; Choe, BM; Ham, BJ; Jung, HY; Kee, BS; Kim, JB; Lee, C; Lee, MS; Oh, BH; Oh, KS; Paik, IH; Yeon, BK, 2005
)
0.8
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Finally, the dopamine transporter inhibitor GBR 12909 completely prevented dopamine neurotoxicity caused by the malonate/MDMA combination and reversed the exacerbating toxic effects of malonate on MDMA-induced 5-HT depletion without significantly altering the hyperthermic response."( Studies on striatal neurotoxicity caused by the 3,4-methylenedioxymethamphetamine/ malonate combination: implications for serotonin/dopamine interactions.
Aguirre, N; Goñi-Allo, B; Herv'as, I; Lasheras, B; Ramos, M, 2006
)
0.33
"Safety assessments included adverse events (AEs) collected by spontaneous report, as well as systematic measures for specific physical and psychiatric symptoms."( Treatment for Adolescents with Depression Study (TADS): safety results.
Casat, C; Emslie, G; Kratochvil, C; March, J; Mayes, T; McNulty, S; Pathak, S; Posner, K; Rohde, P; Silva, S; Vitiello, B; Walkup, J; Waslick, B; Weller, E, 2006
)
0.33
" Adverse effects and other clinical features associated with the emergence of suicidality, defined using item 3 of the Hamilton Depression Rating Scale, were examined using Cox regression models."( Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes.
Amsterdam, J; Beasley, CM; Cusin, C; Fava, M; Perlis, RH; Quitkin, F; Rosenbaum, JF; Shear, D; Strong, RE; Tamura, RN; Wines, JD, 2007
)
0.56
" Whether prophylaxis against or aggressive treatment of adverse events can decrease emergence of SI merits further study."( Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes.
Amsterdam, J; Beasley, CM; Cusin, C; Fava, M; Perlis, RH; Quitkin, F; Rosenbaum, JF; Shear, D; Strong, RE; Tamura, RN; Wines, JD, 2007
)
0.56
"In this sample of children and adolescents with epilepsy and depressive disorders, we observed that SSRIs are a good therapeutic option, considering their efficacy in remission of depressive symptoms, their few adverse effects, and their maintenance of satisfactory seizure control."( Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression.
Kuczynski, E; Thomé-Souza, MS; Valente, KD, 2007
)
0.69
"The association between treatment-emergent suicidality as an adverse event and fluoxetine treatment was examined using a fluoxetine double-blind placebo-controlled database of clinical trials for indications other than major depressive disorder."( Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder.
Ball, S; Beasley, CM; Disch, D; Plewes, J; Tauscher-Wisniewski, S, 2007
)
0.81
" Within each study, patient adverse event reports and narratives were searched extensively for treatment-emergent thoughts and behaviors associated with suicide."( Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder.
Ball, S; Beasley, CM; Disch, D; Plewes, J; Tauscher-Wisniewski, S, 2007
)
0.58
"We examined the hyperthermic and lethal toxic effects of methamphetamine in dopamine transporter (DAT) and/or serotonin transporter (SERT) knockout (KO) mice."( Methamphetamine-induced hyperthermia and lethal toxicity: role of the dopamine and serotonin transporters.
Fukushima, S; Hall, FS; Hata, H; Kobayashi, H; Lesch, KP; Murphy, DL; Numachi, Y; Ohara, A; Sora, I; Uhl, GR; Watanabe, H; Yamashita, M, 2007
)
0.34
" Adverse events occurring in 10% of patients or more with adjunctive placebo or aripiprazole were akathisia (4."( The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH, 2008
)
0.35
" In contrast, fluoxetine revealed a toxic effect and exhibited an additive effect against the toxicity of MPP(+)."( Antidepressants reveal differential effect against 1-methyl-4-phenylpyridinium toxicity in differentiated PC12 cells.
Han, YS; Lee, CS, 2009
)
0.71
"The authors sought to identify predictors of self-harm adverse events in treatment-resistant, depressed adolescents during the first 12 weeks of treatment."( Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009
)
0.35
", suicidal and non-suicidal self-injury adverse events were assessed by spontaneous report for the first 181 participants, and by systematic weekly assessment for the last 153 participants."( Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009
)
0.35
"2%), but not serious adverse events (8."( Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009
)
0.35
"Since predictors of suicidal adverse events also predict poor response to treatment, and many of these events occurred early in treatment, improving the speed of response to depression, by targeting of family conflict, suicidal ideation, and drug use may help to reduce their incidence."( Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009
)
0.35
" Treatment-emergent adverse events with OFC (SP1 and SP2) included increased appetite, increased weight, somnolence, anxiety, insomnia, and depressed mood."( Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico.
Diaz, B; Fumero, I; Jamal, HH; Mattei, MA; Sutton, VK; Tamayo, JM; Tohen, M; Vieta, E; Zarate, CA, 2009
)
0.61
"3, 4-Methylenedioxymethamphetamine (MDMA, "ecstasy") has toxic effects on serotonergic neurons in the brain."( Study on the neuroprotective effect of fluoxetine against MDMA-induced neurotoxicity on the serotonin transporter in rat brain using micro-PET.
Chyueh, SC; Hu, SH; Huang, WS; Huang, YY; Li, IH; Liao, MH; Liu, JC; Liu, RS; Ma, KH; Shen, LH; Shiue, CY, 2010
)
0.63
" Agomelatine is probably hepatotoxic; (8) In summary, agomelatine has unproven efficacy and poorly documented adverse effects."( Agomelatine: new drug. Adverse effects and no proven efficacy.
, 2009
)
0.35
" Abeta is aggregated to form oligomers which are toxic to neurons and are critical to the onset and progression of AD."( Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans.
Aboukhatwa, M; Keowkase, R; Luo, Y,
)
1.57
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Therefore, we hypothesized that the high toxicity of aliphatic amines in algae is a toxicokinetic effect caused by speciation and not a toxicodynamic effect caused by a specific mode of toxic action."( The pH-dependent toxicity of basic pharmaceuticals in the green algae Scenedesmus vacuolatus can be explained with a toxicokinetic ion-trapping model.
Escher, BI; Neuwoehner, J, 2011
)
0.37
" Embryo toxic responses showed a clear dose-related tendency whereas no clear dose-dependent effect was observed in micronucleus induction."( Linking embryo toxicity with genotoxic responses in the freshwater snail Physa acuta: single exposure to benzo(a)pyrene, fluoxetine, bisphenol A, vinclozolin and exposure to binary mixtures with benzo(a)pyrene.
Aparicio, N; Fernández, C; Sánchez-Argüello, P, 2012
)
0.59
" This study provides first clinical evidence that curcumin may be used as an effective and safe modality for treatment in patients with MDD without concurrent suicidal ideation or other psychotic disorders."( Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial.
Goel, A; Panchal, B; Patel, T; Sanmukhani, J; Satodia, V; Tiwari, D; Tripathi, CB; Trivedi, J, 2014
)
0.4
" Participants were evaluated by Hamilton depression rating scale (HDRS) at weeks 3 and 6 and the adverse events were systemically recorded."( A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients.
Abbasi, SH; Akhondzadeh, S; Arjmandi-Beglar, A; Farokhnia, M; Forghani, S; Gougol, A; Kassaian, SE; Mahmoodian, M; Noorbala Tafti, AA; Saroukhani, S; Shahmansouri, N; Yekehtaz, H, 2014
)
0.62
" There was no significant difference between two groups in the frequency of adverse events during this trial."( A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients.
Abbasi, SH; Akhondzadeh, S; Arjmandi-Beglar, A; Farokhnia, M; Forghani, S; Gougol, A; Kassaian, SE; Mahmoodian, M; Noorbala Tafti, AA; Saroukhani, S; Shahmansouri, N; Yekehtaz, H, 2014
)
0.62
" Tolerability and safety evaluations were based on emergent adverse events."( Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.
Crutel, VS; Fones Soon Leng, C; Huang, YS; Kim, YS; Shu, L; Sulaiman, AH, 2014
)
0.63
" There were no significant differences between patients treated with OFC and fluoxetine in extrapyramidal symptoms or serious adverse events."( Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.
Brunner, E; Landry, J; Osuntokun, O; Thase, ME; Tohen, M, 2014
)
0.91
" Measures included: Children's Depression Rating Scale-Revised (CDRS-R), treatment-emergent adverse events (TEAEs), and Columbia-Suicide Severity Rating Scale (C-SSRS)."( A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
Atkinson, SD; Bangs, ME; Emslie, GJ; March, JS; Pangallo, BA; Prakash, A; Zhang, Q, 2014
)
0.4
" Measures included: Children's Depression Rating Scale-Revised (CDRS-R), treatment-emergent adverse events (TEAEs), and Columbia-Suicide Severity Rating Scale (C-SSRS)."( A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
Bangs, ME; Emslie, GJ; March, JS; Pangallo, BA; Prakash, A; Zhang, Q, 2014
)
0.4
" Safety measures included treatment-emergent adverse events (TEAEs), the Columbia-Suicide Severity Rating Scale, vital signs, electrocardiograms, laboratory samples, and growth (height and weight) assessments."( Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
Bangs, ME; Emslie, GJ; March, JS; Pangallo, BA; Prakash, A; Wells, TG; Zhang, Q, 2015
)
0.42
"Significantly more patients discontinued because of adverse events during duloxetine (8."( Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
Bangs, ME; Emslie, GJ; March, JS; Pangallo, BA; Prakash, A; Wells, TG; Zhang, Q, 2015
)
0.42
" Both the antidepressants were found to be safe and well tolerated."( Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine.
Bhatia, MS; Ghosh, R; Gupta, LK; Gupta, R; Tripathi, AK, 2015
)
0.62
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" We performed a random-effects meta-analysis of depression ratings, response, remission, and adverse effects calculating standardized mean difference (SMD) and risk ratio (RR) ±95% confidence intervals (CIs)."( Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016
)
0.43
" Adverse effects and all-cause/specific-cause discontinuation were similar across all comparisons."( Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016
)
0.43
"Lamotrigine was superior to placebo in improving unipolar and bipolar depressive symptoms, without causing more frequent adverse effects/discontinuations."( Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016
)
0.43
" Nevertheless, there is a dearth of information regarding their potential adverse effects on non-target organisms."( Multi-biomarker investigation to assess toxicity induced by two antidepressants on Dreissena polymorpha.
Binelli, A; Catani, M; Cavazzini, A; de Oliveira, LF; Della Torre, C; Guzzinati, R; Magni, S; Parolini, M, 2017
)
0.46
" The MAO inhibitors clorgyline and deprenyl, and the SERT inhibitor fluoxetine, per se or in combination, were not able to mimic the toxic effects of MDMA in the P19-derived neurons or block the MDMA-induced cell toxicity."( Non-Serotonergic Neurotoxicity by MDMA (Ecstasy) in Neurons Derived from Mouse P19 Embryonal Carcinoma Cells.
Forsblad, A; Hashemian, S; Jacobsson, SO; Popova, D, 2016
)
0.67
" The aim of the present work was to evaluate the toxic response of the crustacean Daphnia magna exposed to individual and combined pharmaceuticals."( Assessing the environmental hazard of individual and combined pharmaceuticals: acute and chronic toxicity of fluoxetine and propranolol in the crustacean Daphnia magna.
Fabbri, E; Pasteris, A; Varano, V, 2017
)
0.67
" There were no published papers on adverse drug reactions (ADRs) of fluoxetine analyzing spontaneous adverse events reports."( Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database.
Choi, HJ; Kim, MS; Kim, S; Park, BJ; Park, K; Yang, BR, 2017
)
0.93
"Fluoxetine for BN and lisdexamfetamine for BED are relatively safe and well-tolerated."( Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder.
Bello, NT; Yeomans, BL, 2018
)
1.92
"While it is well known that fluoxetine is more toxic to aquatic organisms at high pH, the metabolic dysregulations related to observed pH-dependent effects are still poorly understood."( Assessing pH-dependent toxicity of fluoxetine in embryonic zebrafish using mass spectrometry-based metabolomics.
Gong, Z; Kelly, BC; Mishra, P, 2019
)
1.08
"A multicenter cohort study of US patients with AFM in 2015-2016 compared serious adverse events (SAEs), adverse effects, and outcomes between fluoxetine-treated patients and untreated controls."( Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis.
Abzug, MJ; Bains, HK; Benson, LA; DeBiasi, RL; Desai, J; Dominguez, SR; Glanternik, JR; Gorman, MP; Hopkins, SE; Hurst, AL; Kruer, MC; Makhani, N; Martin, JA; Messacar, K; Otten, C; Santoro, JD; Schreiner, T; Sillau, S; Torres, A; Treister, A; Tremoulet, AH; Tyler, KL; Van Haren, K; Wilson-Murphy, M; Wong, B; Zabrocki, L, 2019
)
0.99
"Investigating adverse events associated with antidepressant treatments in adolescents is important given the concerns about increased risk of suicidal ideation and behavior in this age group."( Adverse events reported by anxious school refusing adolescents receiving cognitive behavioral therapy with and without fluoxetine.
Dudley, AL; Finnin, L; Gordon, MS; Klimkeit, EI; Melvin, GA; Taffe, J; Tonge, B, 2019
)
0.72
"A side-effect symptom checklist was completed by participants prior to commencing treatment and during treatment (weekly/fortnightly)."( Adverse events reported by anxious school refusing adolescents receiving cognitive behavioral therapy with and without fluoxetine.
Dudley, AL; Finnin, L; Gordon, MS; Klimkeit, EI; Melvin, GA; Taffe, J; Tonge, B, 2019
)
0.72
"CBT-plus-fluoxetine was well tolerated and not associated with higher levels of adverse events than the other treatments."( Adverse events reported by anxious school refusing adolescents receiving cognitive behavioral therapy with and without fluoxetine.
Dudley, AL; Finnin, L; Gordon, MS; Klimkeit, EI; Melvin, GA; Taffe, J; Tonge, B, 2019
)
1.14
" In addition, we will carefully observe the patient's adverse reactions during the medication."( Effectiveness and safety of fluoxetine for premature ejaculation: Protocol for a systematic review.
Dai, H; Li, J; Li, X; Wang, J, 2019
)
0.81
"This study will provide a high-quality synthesis of current evidence of fluoxetine for PE from several aspects, including IELT, PEDT, AIPE, IPE, and adverse events."( Effectiveness and safety of fluoxetine for premature ejaculation: Protocol for a systematic review.
Dai, H; Li, J; Li, X; Wang, J, 2019
)
1.04
" FLX in aquatic ecosystems has been detected in a range varying from pg/L to ng/L, while adverse effects have been reported in several organisms inhabiting freshwater and marine environments."( Marine contamination and cytogenotoxic effects of fluoxetine in the tropical brown mussel Perna perna.
Abessa, DMS; Cesar, A; Cortez, FS; Fontes, MK; Guimarães, LL; Maranho, LA; Moreno, BB; Nobre, CR; Pereira, CDS; Pusceddu, FH; Souza, LDS, 2019
)
0.77
" Adverse drug reactions in older patients are particularly important because of reduced drug metabolism, polypharmacy, drug-drug interactions, and drug-disease interactions."( Fluoxetine and Risk of Bleeding in Patients Aged 60 Years and Older Using the Korea Adverse Event Reporting System Database: A Case/Noncase Study.
Kim, MS; Kim, S; Ko, YJ; Park, BJ; Park, K; Yang, BR,
)
1.57
"We detected signals of bleeding risk associated with fluoxetine in an elderly population using the Korea Adverse Event Reporting System database."( Fluoxetine and Risk of Bleeding in Patients Aged 60 Years and Older Using the Korea Adverse Event Reporting System Database: A Case/Noncase Study.
Kim, MS; Kim, S; Ko, YJ; Park, BJ; Park, K; Yang, BR,
)
1.82
"A total of 16,517 adverse events related to antidepressants were reported."( Fluoxetine and Risk of Bleeding in Patients Aged 60 Years and Older Using the Korea Adverse Event Reporting System Database: A Case/Noncase Study.
Kim, MS; Kim, S; Ko, YJ; Park, BJ; Park, K; Yang, BR,
)
1.57
" However, investigation of their toxic effects on aquatic animals, single or in mixture with other occurring psychoactive drugs, has been neglected."( Norfluoxetine and venlafaxine in zebrafish larvae: Single and combined toxicity of two pharmaceutical products relevant for risk assessment.
Cunha, V; Ferreira, M; Guimarães, L; Oliva-Teles, L; Rodrigues, P, 2020
)
1.18
" Adverse events were also assessed."( The safety and efficacy of transcranial direct current stimulation as add-on therapy to fluoxetine in obsessive-compulsive disorder: a randomized, double-blind, sham-controlled, clinical trial.
Amanat, M; Behzadmanesh, J; Mousavi, SV; Safary, V; Salehi, B; Salehi, M; Yoonesi, A; Yoosefee, S, 2020
)
0.78
"Fluoxetine is frequently detected in aquatic environment, and chronic FLX exposure exhibits adverse effects on aquatic communities."( New insights into cardiotoxicity induced by chiral fluoxetine at environmental-level: Enantioselective arrhythmia in developmental zebrafish (Danio rerio).
Chai, T; Cui, F; Di, S; Wang, X; Wu, S; Zhang, Y, 2021
)
2.32
"Although attention-deficit/hyperactivity disorder (ADHD) is widely studied, problems regarding the adverse effect risks and non-responder problems still need to be addressed."( Synergistic efficacy and diminished adverse effect profile of composite treatment of several ADHD medications.
Adil, KJ; Cheong, JH; Han, SH; Jeon, SJ; Kim, HJ; Kim, HY; Kim, R; Kwon, KJ; Mabunga, DFN; Park, D; Ryu, O; Shin, CY; Valencia, S, 2021
)
0.62
" Overall, this study provides new concepts to remove and assess the toxicity of emerging contaminants in aquatic environments and highlights the need to consider the formation and persistence of toxic transformation products."( Degradation and toxicity of the antidepressant fluoxetine in an aqueous system by UV irradiation.
Jiang, L; Pan, C; Wu, M; Yang, M; Zhao, X; Zhu, F, 2022
)
0.98
" In conclusion, the combined RE and FLX treatment can ameliorate the toxic effect of MSG on rat hippocampus probably through its antioxidant and anti-inflammatory effects."( Protective effects of Rosemary extract and/or Fluoxetine on Monosodium Glutamate-induced hippocampal neurotoxicity in rat.
Abdel Fattah, IO; Abdel-Rahman, GM; Atef, RM; Mahmoud, OM; Salem, NA,
)
0.39
"Current ecotoxicity testing programs are impeded as they predominantly rely on slow and expensive animal tests measuring adverse outcomes."( Characterizing toxicity pathways of fluoxetine to predict adverse outcomes in adult fathead minnows (Pimephales promelas).
Alcaraz, AJ; Basu, N; Colville, C; Crump, D; Green, D; Hecker, M; Hogan, N; Hruṧka, P; Park, B; Potěšil, D; Soufan, O; Xia, J; Zdráhal, Z, 2022
)
1
" Nonetheless, at high concentrations of this drug, adverse effects occur in the brain of exposed organisms."( Fluoxetine-induced neurotoxicity at environmentally relevant concentrations in adult zebrafish Danio rerio.
Cardoso-Vera, JD; Elizalde-Velázquez, GA; Galar-Martínez, M; García-Medina, S; Gómez-Oliván, LM; Heredia-García, G; Islas-Flores, H; Orozco-Hernández, JM; Rosales-Pérez, KE, 2022
)
2.16
" The results revealed the transformation pathways of these drugs under the UV disinfection process in wastewater treatment plants, especially the formation of toxic by-products during the disinfection process."( Ultraviolet oxidative degradation of typical antidepressants: Pathway, product toxicity, and DFT theoretical calculation.
Ji, Y; Lin, W; Ping, S; Ren, Y; Zhang, X; Zhao, B, 2022
)
0.72
" Treatment-related adverse effects and nighttime arousal were secondary outcomes."( The Safety and Efficacy of Fluoxetine for the Treatment of Refractory Primary Monosymptomatic Nocturnal Enuresis in Children: A Randomized Placebo-Controlled Trial.
Abdelhalim, A; El-Kenawy, MR; Hashem, A; Helmy, TE; Hussiny, M; Soltan, MA, 2022
)
1.02
"Fluoxetine is safe treatment for refractory primary monosymptomatic nocturnal enuresis in children with good initial response that declines at 12 weeks."( The Safety and Efficacy of Fluoxetine for the Treatment of Refractory Primary Monosymptomatic Nocturnal Enuresis in Children: A Randomized Placebo-Controlled Trial.
Abdelhalim, A; El-Kenawy, MR; Hashem, A; Helmy, TE; Hussiny, M; Soltan, MA, 2022
)
2.46
"Clinical trials are an important source of adverse effects data, including analyses in systematic reviews and recommendations in therapy guidelines."( Biases in reporting of adverse effects in clinical trials, and potential impact on safety assessments in systematic reviews and therapy guidelines.
Klemp, M; Narum, S; Westergren, T, 2022
)
0.72
"The objectives of this work are to analyse risk of gastrointestinal bleeding in systemic corticosteroid trials and to assess adverse effects reporting in a fluoxetine trial in depression (Treatment for Adolescents With Depression Study [TADS]) and descriptions of adverse effects in adolescent depression therapy guidelines."( Biases in reporting of adverse effects in clinical trials, and potential impact on safety assessments in systematic reviews and therapy guidelines.
Klemp, M; Narum, S; Westergren, T, 2022
)
0.92
" We identified several biases concerning TADS safety reporting, including severity thresholds and nonpublication of most adverse effects data beyond the initial 12 weeks."( Biases in reporting of adverse effects in clinical trials, and potential impact on safety assessments in systematic reviews and therapy guidelines.
Klemp, M; Narum, S; Westergren, T, 2022
)
0.72
"We identified several pitfalls in adverse effects reporting in clinical trials."( Biases in reporting of adverse effects in clinical trials, and potential impact on safety assessments in systematic reviews and therapy guidelines.
Klemp, M; Narum, S; Westergren, T, 2022
)
0.72
"All nine drugs can relieve the pain of CPSP patients to different degrees; among them pregabalin and gabapentin have the most significant effect, and gabapentin and pregabalin also have the most adverse reactions."( Efficacy and safety of different antidepressants and anticonvulsants in central poststroke pain: A network meta-analysis and systematic review.
Chen, KY; Li, RY, 2022
)
0.72
"Outcomes were mortality, hospitalization, composite of hospitalization/emergency room visits, hypoxemia, requirement for supplemental oxygen, ventilator support, and serious adverse events."( Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.
Abbas, U; Deng, J; Garcia, C; Heybati, K; Huang, E; Moskalyk, M; Park, YJ; Ramaraju, HB; Rayner, D; Zhou, F, 2023
)
0.91
" Fluvoxamine was not associated with increased serious adverse events."( Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.
Abbas, U; Deng, J; Garcia, C; Heybati, K; Huang, E; Moskalyk, M; Park, YJ; Ramaraju, HB; Rayner, D; Zhou, F, 2023
)
0.91
"The concomitant use of MPHs and SSRIs showed generally safe profiles in adolescent ADHD patients with depression."( Safety outcomes of selective serotonin reuptake inhibitors in adolescent attention-deficit/hyperactivity disorder with comorbid depression:
Alhambra, DP; Kim, C; Kim, SJ; Lee, DY; Lee, J; Lee, S; Lee, YH; Park, J; Park, RW; Shin, Y; Tan, EH; Yang, SJ, 2023
)
0.91
" There were no significant differences between the groups regarding gastrointestinal adverse reactions (P > 0."( The efficacy and safety of fluoxetine versus placebo for stroke recovery: a meta-analysis of randomized controlled trials.
Qin, G; Wu, J, 2023
)
1.21
" We aimed to characterise the prevalence and seriousness of adverse drug events (ADEs) related to anti-obesity medications and to identify predictors associated with increased risk of serious adverse events (SAE), thereby conveying evidence on drug safety."( A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication.
Choi, CY; Choi, YJ; Kim, CU; Shin, S, 2023
)
0.91
"We conducted a cross-sectional analysis on ADE cases spontaneously reported to the Korea Adverse Event Reporting System Database (KIDS-KD)."( A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication.
Choi, CY; Choi, YJ; Kim, CU; Shin, S, 2023
)
0.91

Pharmacokinetics

The objective of this study was to examine the pharmacokinetic and pharmacodynamic consequences of concomitant administration of fluoxetine and carvedilol in heart failure patients. The study was extended to evaluate the pharmacokeretic interaction between DCV and a co-prescribed antidepressant drug.

ExcerptReferenceRelevance
" When the sequence of trials was placebo first and fluoxetine second, fluoxetine coadministration significantly prolonged alprazolam half-life (20 versus 17 hours) and reduced clearance (48 versus 61 ml/min)."( Fluoxetine impairs clearance of alprazolam but not of clonazepam.
Cotreau, MM; Greenblatt, DJ; Harmatz, JS; Horst, WD; Preskorn, SH, 1992
)
1.98
"The pharmacokinetic properties of the newer specific serotonin (5-HT) reuptake inhibitors are reviewed."( Pharmacokinetics of the selective serotonin reuptake inhibitors.
DeVane, CL, 1992
)
0.28
" These results indicate that no pharmacokinetic interaction exists between triazolam and fluoxetine or norfluoxetine."( A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine.
Lasher-Sisson, TA; Steenwyk, RC; Swanson, CN; Wright, CE, 1992
)
0.73
"The pharmacokinetic and pharmacodynamic effects of concomitant administration of alprazolam and fluoxetine were studied in this double-blind parallel study in 80 healthy, male volunteers."( Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine.
Antal, EJ; Fleishaker, JC; Lasher, TA; Steenwyk, RC, 1991
)
0.72
"To determine the effect of fluoxetine on diazepam's pharmacokinetic and psychomotor responses, single oral doses of 10 mg diazepam were administered to six normal subjects on three occasions, either alone or in combination with 60 mg fluoxetine."( The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.
Bergstrom, RF; Bosomworth, JC; Lemberger, L; Rowe, H; Tenbarge, JB, 1988
)
0.93
" The hysteresis between peak blood levels and maximal pharmacodynamic effects suggests formation of an active metabolite."( Classification and determination of cerebral bioavailability of fluoxetine: pharmacokinetic, pharmaco-EEG, and psychometric analyses.
Grünberger, J; Saletu, B, 1985
)
0.51
" From a clinical point of view, it is of relevance that potency to inhibit the cytochrome P450 isozyme CYP2D6 gradually decreases from paroxetine, fluoxetine, norfluoxetine, desmethylcitalopram, fluvoxamine, and sertraline down to citalopram, explaining to a great extent differences in pharmacokinetic interactions between the SSRIs and tricyclic antidepressants, which are metabolized by this enzyme."( Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror.
Baumann, P; Rochat, B, 1995
)
0.49
"The time course of change in plasma levels of cocaine and its major metabolite benzoylecgonine following 3 mg/kg IV cocaine and the pharmacokinetic interaction between cocaine and several monoamine uptake inhibitors were investigated in conscious rats implanted with arterial and venous cannulae."( Monoamine uptake inhibitors alter cocaine pharmacokinetics.
Goldberg, SR; Tella, SR, 1993
)
0.29
" The elimination half-life of fluoxetine is about 1 to 4 days, while that of its metabolite norfluoxetine ranges from 7 to 15 days."( Clinical pharmacokinetics of fluoxetine.
Altamura, AC; Moro, AR; Percudani, M, 1994
)
0.87
"The pharmacokinetic interactions of sertraline and fluoxetine with the tricyclic antidepressant desipramine were studied in 18 healthy male volunteers phenotyped as extensive metabolizers of dextromethorphan."( Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.
Alderman, J; Chung, M; Harris, S; Harrison, W; Messig, M; Preskorn, SH, 1994
)
0.78
" This study attempted to evaluate the pharmacokinetic and pharmacodynamic interactions between zolpidem 10 mg, a short-acting hypnotic, and fluoxetine 20 mg, an SSRI."( The effect of co-administration of zolpidem with fluoxetine: pharmacokinetics and pharmacodynamics.
Allard, S; Johnson, M; Piergies, AA; Roth-Schechter, BF; Sweet, J, 1996
)
0.75
"The extent and clinical significance of the pharmacokinetic interaction between fluoxetine and haloperidol was studied in 13 schizophrenic patients with prominent negative symptoms."( Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.
Avenoso, A; Campo, G; Caputi, AP; Facciolă, G; Ferlito, M; Perucca, E; Spinà, E; Zuccaro, P, 1997
)
0.85
" Noncompartmental pharmacokinetic data for terfenadine and terfenadine acid metabolite were compared between treatments."( Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine.
Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Hatcher, BL, 1997
)
0.53
" The area under the concentration-time curve for terfenadine was lower after fluoxetine administration, a statistically significant difference, but the peak concentration of terfenadine was not significantly different."( Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine.
Bergstrom, RF; Cerimele, BJ; Goldberg, MJ; Hatcher, BL, 1997
)
0.76
" Further, the pharmacokinetic disposition and pharmacological activity of several highly bound drugs have been reported to be significantly altered as a result of elevated serum AAG."( Pharmacokinetics and antidepressant activity of fluoxetine in transgenic mice with elevated serum alpha-1-acid glycoprotein levels.
Dewey, MJ; Holladay, JW; Yoo, SD, 1998
)
0.56
"To document a case of serotonin syndrome associated with venlafaxine and fluoxetine that did not involve a monoamine oxidase inhibitor, and to examine the multiple factors, including pharmacodynamic and pharmacokinetic interactions, that likely caused this adverse drug reaction (ADR)."( Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.
Bhatara, VS; Magnus, RD; Paul, KL; Preskorn, SH, 1998
)
0.79
", an idiosyncratic reaction to venlafaxine), a pharmacokinetic interaction, a pharmacodynamic interaction, a combined pharmacokinetic-pharmacodynamic interaction, and the patient' s panic disorder."( Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.
Bhatara, VS; Magnus, RD; Paul, KL; Preskorn, SH, 1998
)
0.56
" Adverse events and vital signs were recorded and pharmacokinetic parameters of fluoxetine and moclobemide were determined."( Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome".
Amrein, R; Dingemanse, J; Gieschke, R; Guentert, T; Wallnöfer, A, 1998
)
0.77
" 3,4-Dihydroxyphenylglycol, 5-hydroxyindoleacetic acid, and 3,4-dihydroxyphenylacetic acid plasma levels and serotonin uptake did not reveal a pharmacodynamic interaction."( Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome".
Amrein, R; Dingemanse, J; Gieschke, R; Guentert, T; Wallnöfer, A, 1998
)
0.55
"A sensitive, robust gas chromatographic-mass spectrometric assay suitable for use in pharmacokinetic or bioequivalence studies is presented for the selective serotonin reuptake inhibitor, fluoxetine, and its major metabolite, norfluoxetine (N-desmethylfluoxetine)."( Sensitive, high-throughput gas chromatographic-mass spectrometric assay for fluoxetine and norfluoxetine in human plasma and its application to pharmacokinetic studies.
Addison, RS; Franklin, ME; Hooper, WD, 1998
)
0.72
" They differ, however, in their pharmacokinetic properties."( Pharmacokinetics of selective serotonin reuptake inhibitors.
Härtter, S; Hiemke, C, 2000
)
0.31
" Fluvoxamine brain elimination half-life (79 +/- 24 hours; n = 4) was significantly shorter than that of CF-norfluoxetine (382 +/- 48 hours; n = 2)."( Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy.
Bolo, NR; Hodé, Y; Lainé, E; Macher, JP; Nédélec, JF; Wagner, G, 2000
)
0.75
" Treatment effects on pharmacokinetic parameters were assessed by analysis of variance."( Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers.
Azie, NE; Carel, BJ; Fleishaker, JC; Ryan, KK, 2001
)
0.54
"The objective of this study was to examine the pharmacokinetic and pharmacodynamic consequences of concomitant administration of fluoxetine and carvedilol in heart failure patients."( Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.
Adams, KF; Carson, SW; Cascio, WE; Graff, DW; Patterson, JH; Pieper, JA; Williamson, KM, 2001
)
0.92
" Fluoxetine AUC0-24, C0, and Cmax did not differ in young and elderly subjects."( Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers.
Harvey, AT; Preskorn, SH, 2001
)
2.66
" The results showed small delays in peak concentration but no clinically significant effect of alosetron on the pharmacokinetics of S- and R-fluoxetine or S- and R-norfluoxetine."( Effect of alosetron on the pharmacokinetics of fluoxetine.
D'Souza, DL; Dimmitt, DC; Koch, KM; Nezamis, J; Robbins, DK; Simms, L, 2001
)
0.77
" Key assessments included pharmacokinetic analysis of quetiapine, the Udvalg for kliniske undersøgelser (UKU) Side Effect Rating Scale, and safety evaluations (e."( Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine.
Alva, G; Arvanitis, LA; Carreon, D; Kalali, A; Potkin, SG; Thyrum, PT; Yeh, C, 2002
)
0.72
" A full pharmacokinetic time profile of lithium was obtained."( Bayesian pharmacokinetics of lithium after an acute self-intoxication and subsequent haemodialysis: a case report.
Beijnen, JH; Kerbusch, T; Mathôt, RA; Meesters, EW; Otten, HM; Schellens, JH; van Kan, HJ, 2002
)
0.31
" The purpose of this study was to assess the potential for pharmacokinetic interaction between olanzapine and fluoxetine, a popular antidepressant that is a selective serotonin reuptake inhibitor."( Influence of fluoxetine on olanzapine pharmacokinetics.
de Suray, JM; Gangji, D; Gossen, D; Onkelinx, C; Vandenhende, F, 2002
)
0.9
" DOM brain levels were measured using a GC-MS method both in the presence and absence of citalopram and fluoxetine in order to evaluate the pharmacokinetic contribution to the observed behavioral effect."( Potentiation of DOM-induced stimulus control by fluoxetine and citalopram: role of pharmacokinetics.
Doat, MM; Eckler, JR; Rabin, RA; Winter, JC, 2002
)
0.78
"The objective of this study was to evaluate the pharmacokinetic profile of fluoxetine (FLX) and its major metabolite, norfluoxetine (NORFLX), in children and adolescent patients undergoing psychiatric treatment."( Fluoxetine pharmacokinetics in pediatric patients.
Abrams, A; Biederman, J; Cohen, L; Faird, N; Neft, D; Sinha, V; Wilens, TE, 2002
)
1.99
" Treatments were compared for the pharmacokinetic parameters AUC0-infinity, Cmax, tmax, and t 1/2 of highly lipophilic drugs and active metabolites."( Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers.
Kanitra, L; Moore, R; Mulligan, TE; Zhi, J, 2003
)
0.53
" Building on the existing in vitro and in vivo evidence that suggest a minimal effect of citalopram on cytochrome P450 3A4, we hypothesized that therapeutic doses of citalopram (20 mg/d), as compared with fluoxetine (20 mg/d), would cause less impairment in the metabolism of the probe drug alprazolam (1 mg) through inhibition of the cytochrome P450 3A4 isozyme as measured by pharmacokinetic and pharmacodynamic parameters in vivo."( Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine.
Hall, J; Herrmann, N; Naranjo, CA; Sproule, BA, 2003
)
0.72
"The objective of this study was to investigate pharmacokinetic and pharmacodynamic interactions between midazolam and fluoxetine, fluvoxamine, nefazodone, and ketoconazole."( Pharmacokinetic and pharmacodynamic interactions of oral midazolam with ketoconazole, fluoxetine, fluvoxamine, and nefazodone.
Alfaro, CL; Ereshefsky, L; Lam, YW; Miller, M, 2003
)
0.75
" On the other hand, age and sex had a significant influence on the pharmacokinetic pattern of trazodone, causing higher concentrations in females and in older patients."( Therapeutic drug monitoring of trazodone: are there pharmacokinetic interactions involving citalopram and fluoxetine?
Conca, A; König, P; Moll, W; Prapotnik, M; Waschgler, R, 2004
)
0.54
" Coadministration of desloratadine with a potent inhibitor of CYP2D6 did not result in clinically relevant changes in its pharmacokinetic parameters."( Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers.
Banfield, C; Flannery, B; Gupta, S; Herron, J; Kantesaria, B, 2004
)
0.57
" Given the common practice of polypharmacy in this population, additional pharmacokinetic information in elderly men and women is needed so that physicians can better assess potential drug-drug interactions."( Pharmacokinetics of fluoxetine in elderly men and women.
Ferguson, JM; Hill, H, 2006
)
0.66
" The present study investigated potential modifications to the pharmacokinetic profile of milnacipran at steady-state when it is substituted for fluoxetine without any washout period."( Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran.
Chassard, D; Hermann, P; Puozzo, C, 2006
)
0.78
"The pharmacokinetic interaction of fluoxetine with metoclopramide in healthy volunteers was evaluated."( Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers.
Farcau, D; Leucuta, A; Nanulescu, M; Vlase, L, 2006
)
0.89
" This study investigated the pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole on the basis of 155 drug monitoring samples from psychiatric patients treated with therapeutic doses of aripiprazole (10-30 mg/day)."( Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients.
Lunde, H; Lunder, N; Molden, E; Refsum, H, 2006
)
0.33
"The evaluation of drug disposition properties of chemical entities in drug discovery research typically involves the conduct of pharmacokinetic studies in rodents that requires blood sampling over several time points, preferably without disrupting the physiological status of the animals."( Pharmacokinetic comparisons of tail-bleeding with cannula- or retro-orbital bleeding techniques in rats using six marketed drugs.
Bina, H; Chiang, A; Ebbert, L; Huang, NH; Hui, YH; Kern, T; Maples, C; Patel, N; Pritt, M,
)
0.13
" The purpose of this investigation is to evaluate the pharmacokinetic drug interaction between MDMA and fluoxetine and also to determine the role of P-glycoprotein (P-gp) on mediating drug-drug interactions with MDMA."( Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat.
Eddington, ND; Upreti, VV, 2008
)
2
" Blood samples were collected for pharmacokinetic analysis of ADTs."( The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Balch, AH; Berman, RM; Boulton, DW; Mallikaarjun, S; Patel, CG; Reeves, RA; Royzman, K, 2010
)
0.36
" Because of its sensitivity, this HPLC/MS/MS method is suitable both for routine therapeutic drug monitoring and for pharmacokinetic studies, due to its low limits of quantification."( A simple method to monitor serum concentrations of fluoxetine and its major metabolite for pharmacokinetic studies.
Faggiani, A; Franceschi, L; Furlanut, M, 2009
)
0.6
" The aim of this study was to characterize extracellular level of serotonin (5-hydroxytryptamine, 5-HT)-time profile of norfluoxetine after acute administration over 18 h post dose and to establish the relationship between this pharmacodynamic (PD) profile and its pharmacokinetic (PK) properties."( Pharmacokinetics and pharmacodynamics of norfluoxetine in rats: Increasing extracellular serotonin level in the frontal cortex.
Aluisio, L; Boggs, J; Hoey, K; Lord, B; Lovenberg, T; Mazur, C; Qu, Y, 2009
)
0.82
"The aim of the work was to retrospectively evaluate the pharmacokinetic data of fluoxetine and norfluoxetine from several bioavailability/bioequivalence (BA/BE) studies to identify the poor metabolizer (PM) phenotypes from the unsuspected healthy subjects across varied protocol designs, dose sizes and differing formulations."( Unsuspected poor metabolizer phenotypes of fluoxetine in bioavailability/bioequivalence studies from an indian population perspective. Retrospective pharmacokinetic data evaluation.
Kamath, N; Kandasamy, M; Kristjansson, F; Pai, B; Ravi, S; Srinivas, NR; Thangam, S; Tripathy, K, 2010
)
0.85
"The pharmacokinetic data of fluoxetine and norfluoxetine were gathered from several BA/BE studies conducted at clinical facilities located at Bangalore and Chennai, India."( Unsuspected poor metabolizer phenotypes of fluoxetine in bioavailability/bioequivalence studies from an indian population perspective. Retrospective pharmacokinetic data evaluation.
Kamath, N; Kandasamy, M; Kristjansson, F; Pai, B; Ravi, S; Srinivas, NR; Thangam, S; Tripathy, K, 2010
)
0.92
"Retrospective evaluation of fluoxetine and norfluoxetine pharmacokinetic data demonstrated existence of both PM and EM phenotypes in the Indian population."( Unsuspected poor metabolizer phenotypes of fluoxetine in bioavailability/bioequivalence studies from an indian population perspective. Retrospective pharmacokinetic data evaluation.
Kamath, N; Kandasamy, M; Kristjansson, F; Pai, B; Ravi, S; Srinivas, NR; Thangam, S; Tripathy, K, 2010
)
0.92
"The aim of this study was to evaluate the pharmacokinetic interaction between fluoxetine and lansoprazole in healthy subjects."( Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects.
Leucuta, SE; Muntean, D; Neag, M; Popa, A; Vlase, L, 2011
)
1
" The pharmacokinetic parameters of lansoprazole were calculated using non-compartmental analysis."( Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects.
Leucuta, SE; Muntean, D; Neag, M; Popa, A; Vlase, L, 2011
)
0.77
"The data demonstrate a pharmacokinetic interaction between fluoxetine and lansoprazole and suggest that the observed interaction may be clinically significant, although its clinical relevance has yet to be confirmed."( Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects.
Leucuta, SE; Muntean, D; Neag, M; Popa, A; Vlase, L, 2011
)
1.01
" This validated method was used successfully for analysis of plasma samples from a pharmacokinetic study."( Validated LC-MS/MS method for quantification of agomelatine in human plasma and its application in a pharmacokinetic study.
Kalamkar, AM; Mangaonkar, KV; Nerurkar, KK; Patil, SR; Pingale, SG; Pukale, V, 2012
)
0.38
" The method was successfully applied to a pharmacokinetic study of fixed dose combination of Olanzapine/Fluoxetine in healthy male volunteers."( Simultaneous determination of Olanzapine and Fluoxetine in human plasma by LC-MS/MS: its pharmacokinetic application.
Bhadane, RP; Bonde, SL; Gaikwad, A; Gavali, SR; Katale, DU; Narendiran, AS, 2014
)
0.88
" Using nonlinear modeling, standard pharmacokinetic parameters were derived."( Fluoxetine: juvenile pharmacokinetics in a nonhuman primate model.
Golub, MS; Hogrefe, CE, 2014
)
1.85
" In the present study, we aimed to evaluate putative pharmacokinetic and brain omega-3 fatty acid-related aspects for fluoxetine potentiation of omega-3 fatty acid antidepressant effect in rats."( Fluoxetine potentiation of omega-3 fatty acid antidepressant effect: evaluating pharmacokinetic and brain fatty acid-related aspects in rodents.
Garcia, P; Höcht, C; Laino, CH; Podestá, MF; Reinés, A; Slobodianik, N, 2014
)
2.05
" Accordingly, pharmacokinetic analysis of a series of fluoxetine and norfluoxetine administrations to pregnant baboons was performed."( Pharmacokinetics of fluoxetine in pregnant baboons (Papio spp.).
Garland, M; Shoulson, RL; Stark, RL, 2014
)
0.97
" The AUC (6 hours ng mL(-1)) and CMAX (6 ng mL(-1)) of methadone significantly increased to 541 hours ng mL(-1) and 47."( Chloramphenicol significantly affects the pharmacokinetics of oral methadone in Greyhound dogs.
KuKanich, B; KuKanich, K, 2015
)
0.42
"Volume of distribution is one of the most important pharmacokinetic properties of a drug candidate."( Volume of Distribution in Drug Design.
Beaumont, K; Di, L; Maurer, TS; Smith, DA, 2015
)
0.42
"Serial sampling methods have been used for rat pharmacokinetic (PK) studies for over 20 years."( Utility of capillary microsampling for rat pharmacokinetic studies: Comparison of tail-vein bleed to jugular vein cannula sampling.
Guo, Y; Ho, S; Korfmacher, W; Luo, Y; O'Shea, T; Shen, L; Snow, G; Sun, W; Wang, J; Wu, Z,
)
0.13
" In this article, we report the evidence that contributed to the implementation of pharmacokinetic pharmacogenetic guidelines for antidepressants primarily metabolized by CYP2D6 and CYP2C19."( Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine.
Black, JL; Elliott, MA; Frye, MA; Nassan, M; Nicholson, WT; Rohrer Vitek, CR, 2016
)
0.43
"This study examined the presence of increased pharmacodynamic tolerance with reduced effectiveness following repeated antidepressant trials over the course of the affective illness in subjects with treatment-responsive bipolar II depression."( Increase in pharmacodynamic tolerance after repeated antidepressant trials in treatment-responsive bipolar I depressed subjects: An exploratory study.
Amsterdam, JD; Lorenzo-Luaces, L, 2018
)
0.48
" This was an exploratory study of post hoc, analyses, and the trial was not specifically powered to test the development of increased pharmacodynamic tolerance."( Increase in pharmacodynamic tolerance after repeated antidepressant trials in treatment-responsive bipolar I depressed subjects: An exploratory study.
Amsterdam, JD; Lorenzo-Luaces, L, 2018
)
0.48
" In addition, the study was extended to evaluate the pharmacokinetic interaction between DCV and a co-prescribed antidepressant drug, fluoxetine (FLX) in real blood samples, collected from volunteering patients who were diagnosed with HCV and treated with DCV alone or combined with FLX."( A clinical study for the evaluation of pharmacokinetic interaction between daclatasvir and fluoxetine.
Abdul-Rahman, E; Ali, R; Elsutohy, MM; Khorshed, A; Oraby, M, 2019
)
0.94
" Similar trends of fluoxetine and amitriptyline pharmacokinetic parameters were revealed in volunteers and animals."( Experimental and Clinical Pharmacokinetics of Fluoxetine and Amitriptyline: Comparative Analysis and Possible Methods of Extrapolation.
Gneushev, ET; Kondratenko, SN; Kukes, VG; Savelyeva, MI; Shikh, EV, 2019
)
1.1
" Also a generally very high correlation between the clinical pharmacokinetic effects of inherited deficiency and inhibition by drug-drug interactions could be demonstrated."( How precise is quantitative prediction of pharmacokinetic effects due to drug-drug interactions and genotype from in vitro data? A comprehensive analysis on the example CYP2D6 and CYP2C19 substrates.
Brockmöller, J; Dücker, C, 2021
)
0.62
" A physiologically based pharmacokinetic model for fluoxetine and norfluoxetine metabolism was developed to predict and investigate changes in concentration-time profiles according to fluoxetine dosage in the Korean population."( Prediction of Fluoxetine and Norfluoxetine Pharmacokinetic Profiles Using Physiologically Based Pharmacokinetic Modeling.
Chae, YJ; Jeong, HC; Kang, W; Lee, S; Shin, KH; Yun, HY, 2021
)
1.23
" Pharmacokinetic parameters were estimated using a noncompartmental model."( Pharmacokinetics of fluoxetine in horses following oral administration.
Lozoya, M; Norris, JW; Pearman, K; Veltri, CA; Waitt Wolker, LH, 2022
)
1.04
"A high-performance liquid chromatography-tandem mass spectrometry(LC-MS/MS) was developed for simultaneously determining the components(magnoflorine, jatrorrhizine, berberrubine, coptisine, berberine) of Jiaotai Pills and Fluoxetine in plasma of rats with chronic unpredictable mild stress(CUMS)-induced depression to investigate the pharmacokinetic herb-drug interaction of Jiaotai Pills and Fluoxetine in the rats."( [Pharmacokinetic interaction of Jiaotai Pills and Fluoxetine in rats with CUMS-induced depression].
Cao, Y; Chen, SS; Dai, GL; Ju, WZ; Li, FR; Li, Y; Liu, MC; Wang, YQ; Yang, XY, 2022
)
1.16
" Physiologically based Pharmacokinetic Model (PBPK) approaches can be utilized to predict the drug exposure in the milk of breastfeeding women and can act as a supporting tool in the risk assessment of feeding infants."( Prediction of basic drug exposure in milk using a lactation model algorithm integrated within a physiologically based pharmacokinetic model.
Abduljalil, K; Faisal, M; Jamei, M; Pansari, A, 2022
)
0.72
" From a knowledge of pharmacokinetics, it can be shown that stopping a drug for just 1 half-life and then resuming it at half the dose results in the immediate achievement of steady state; that is, there is no need to wait for 4 additional half-lives as with the usual strategy of dose reduction without dosing interruption."( Practical Psychopharmacology: Using a Knowledge of Pharmacokinetics to More Rapidly Stabilize Patients at Lower Drug Doses.
Andrade, C, 2022
)
0.72

Compound-Compound Interactions

Study looked at effects of enriched environment (EE) combined with fluoxetine in a chronic unpredictable stress (CUS) rat model. Four weeks after CMS, Sini San alone was less effective in reducing depression-like behavior than fluoxettine alone or in combination with SiniSan. But combined use was more effective than fluxetine alone.

ExcerptReferenceRelevance
" We should be mindful that any unique therapeutic benefits may be accompanied by a unique adverse effects profile and a special propensity for drug-drug interactions."( Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.
Ciraulo, DA; Shader, RI, 1990
)
1.72
"The drug-drug interactions with fluoxetine, a pure serotonergic reuptake blocker with a unique profile of side effects, have not been studied adequately."( Drug-drug interactions of fluoxetine with tricyclics.
von Ammon Cavanaugh, S, 1990
)
0.86
" The present study was conducted to investigate the effects of amfonelic acid, an indirect dopamine agonist, and nisoxetine, a highly selective norepinephrine uptake blocker, alone and in combination with morphine, on the reward threshold for rewarding electrical intracranial stimulation."( The effect of amfonelic acid or nisoxetine in combination with morphine on brain-stimulation reward.
Izenwasser, S; Kornetsky, C, 1989
)
0.28
"A series of agents were tested for their ability to interact with the analgetic actions of either d-amphetamine (d-AMP) or l-amphetamine (l-AMP), or morphine in rats using the hot plate procedure."( Differential analgetic actions of amphetamine enantiomers in the mouse: a drug-drug interaction study.
Maickel, RP; Spratto, GR; Tocco, DR, 1985
)
0.27
" Ninety healthy adult men participated in a study of the effects on performance of 60 mg fluoxetine, 50 mg amitriptyline or placebo, alone and in combination with 5 mg diazepam or placebo."( The effects on performance of two antidepressants, alone and in combination with diazepam.
Burns, M; Moskowitz, H, 1988
)
0.5
" We present our clinical experience with the use of fluoxetine combined with an HCA in a group of 25 treatment-resistant depressed subjects."( The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis.
Fawcett, J; Jeffries, H; Zajecka, JM, 1995
)
0.89
" To minimize the potential for an adverse event, the practitioner must remember the drug-drug interactions, and possible consequences when one of these antidepressants is being prescribed."( Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs.
Richelson, E, 1997
)
0.3
"To understand the mechanism of the clinical efficacy of olanzapine and fluoxetine combination therapy for treatment-resistant depression (TRD), we studied the effects of olanzapine and other antipsychotics in combination with the selective serotonin uptake inhibitors fluoxetine or sertraline on neurotransmitter release in rat prefrontal cortex (PFC) using microdialysis."( Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex.
Bao, J; Bymaster, FP; Perry, KW; Potts, BD; Tollefson, GD; Wong, DT; Zhang, W, 2000
)
0.76
"Free feeding rats given supplementary 1 h access per day to a palatable dessert test meal were tested for the anorectic effect of dehydroepiandrosterone alone or in combination with either the serotonin releasing agent dexfenfluramine or the norepinephrine uptake inhibitor thionisoxetine (LY 368975)."( Anorectic effect of dehydroepiandrosterone combined with dexfenfluramine or thionisoxetine.
Marshall, M; Robertson, K; Rowland, NE, 2001
)
0.31
" By contrast, the same drug combination treatment did not reduce the somatic signs of nicotine withdrawal indicating symptom-specific neurobiological abnormalities."( Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats.
Harrison, AA; Liem, YT; Markou, A, 2001
)
1.75
" The implications of this on the prediction of drug-drug interactions from in vitro data are discussed."( Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions.
Margolis, JM; Obach, RS, 2003
)
0.32
" In order to accelerate and maximise the clinical response in depressive patients, clinician should prefer to optimize the fluoxetine dose instead of in combination with buspirone."( Faster response in depressive patients treated with fluoxetine alone than in combination with buspirone.
Onder, E; Tural, U, 2003
)
0.78
"Patients with major depressive disorder (MDD) treated with olanzapine in combination with fluoxetine (OFC) demonstrate robust improvement in their depressive symptoms."( Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.
Andersen, SW; Clemow, DB; Corya, SA, 2005
)
0.77
"Patients taking antidepressants are more likely to also be taking multiple medications, increasing the risk of adverse drug-drug interactions (DDIs)."( The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline.
Choi, J; Golbeck, AL; Neff, M; Preskorn, SH; Shah, R, 2007
)
0.55
"The aim of this study was to compare the efficacy of fluoxetine alone and combined with sildenafil in patients complaining of premature ejaculation."( Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation.
Hosseini, MM; Yarmohammadi, H, 2007
)
0.99
"Fluoxetine combined with sildenafil seems to provide significantly better ejaculatory latency time and intercourse satisfaction as compared with fluoxetine alone in patients with premature ejaculation."( Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation.
Hosseini, MM; Yarmohammadi, H, 2007
)
2.18
"A three-phase, liquid-phase microextraction using a hollow fibre (HF-LPME) combined with high performance liquid chromatography-fluorescence detection (HPLC-FL) was developed for the analysis of fluoxetine (FLX) and its active metabolite, norfluoxetine (NFLX), in human plasma."( Three-phase, liquid-phase microextraction combined with high performance liquid chromatography-fluorescence detection for the simultaneous determination of fluoxetine and norfluoxetine in human plasma.
de Freitas, DF; de Siqueira, ME; Porto, CE; Vieira, EP, 2010
)
0.75
"This study is to investigate the clinical therapeutic effects and safety of treating mild or moderate depression with somatic symptoms with electroacupuncture combined with Fluoxetine."( Efficacy evaluation for depression with somatic symptoms treated by electroacupuncture combined with Fluoxetine.
Chen, LP; Duan, DM; Tu, Y; Wu, ZJ, 2009
)
0.76
"Electroacupuncture combined with Fluoxetine takes effect faster for relieving the somatic symptoms with fewer adverse reactions."( Efficacy evaluation for depression with somatic symptoms treated by electroacupuncture combined with Fluoxetine.
Chen, LP; Duan, DM; Tu, Y; Wu, ZJ, 2009
)
0.85
" Drug-drug interactions were investigated when nebivolol was coadministered to subjects classified as poor CYP2D6 metabolizers and extensive CYP2D6 metabolizers who were receiving other drugs commonly administered to patients with hypertension or compounds metabolized by cytochrome P450 (CYP) 2D6."( Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies.
Gorski, JC; Lindamood, C; Ortiz, S; Rackley, R; Shaw, A, 2011
)
0.37
"Folic acid or 17-β estradiol produces antidepressant effects, either alone or combined with several antidepressants."( The folic acid combined with 17-β estradiol produces antidepressant-like actions in ovariectomized rats forced to swim.
Jaramillo, MT; Molina-Hernández, M; Olivera-López, JI; Téllez-Alcántara, NP, 2011
)
0.37
"To probe the relevance between depressive symptoms and hippocampal volume and its metabolites detected by magnetic resonance imaging (MRI) in depressed patients who were given electro-acupuncture (EA) combined with Fluoxetine before and after treatment."( The relevance between symptoms and magnetic resonance imaging analysis of the hippocampus of depressed patients given electro-acupuncture combined with Fluoxetine intervention - A randomized, controlled trial.
Duan, DM; Jiao, S; Qin, W; Tu, Y, 2011
)
0.75
" A total of 75 cases of mild or moderate depression were randomly assigned to two groups: the EA group which received EA combined with Fluoxetine; the Fluoxetine group which received Fluoxetine only as the control."( The relevance between symptoms and magnetic resonance imaging analysis of the hippocampus of depressed patients given electro-acupuncture combined with Fluoxetine intervention - A randomized, controlled trial.
Duan, DM; Jiao, S; Qin, W; Tu, Y, 2011
)
0.77
"There was a significant improvement in the hippocampal metabolites in depressed patients who treated by EA combined with Fluoxetine."( The relevance between symptoms and magnetic resonance imaging analysis of the hippocampus of depressed patients given electro-acupuncture combined with Fluoxetine intervention - A randomized, controlled trial.
Duan, DM; Jiao, S; Qin, W; Tu, Y, 2011
)
0.78
"We report a case of a potential drug-drug interaction in a woman treated by a first injection of high-dose methotrexate for a T-lymphoblastic lymphoma."( Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: a case report - should the practice be changed?
Bouafia, F; Franchon, E; Gouraud, A; Pham, BN; Ranchon, F; Rioufol, C; Salles, G; Schwiertz, V; Vantard, N; Vial, T; You, B, 2011
)
0.37
"To evaluate the outcome of dissecting the styloid process via an extraoral approach combined with antidepressants for treating Eagle's syndrome."( Eagle's syndrome treated with dissection of the styloid process via an extraoral approach combined with antidepressants.
Chen, WL; Pan, JY; Peng, GG; Wu, JW, 2011
)
0.37
"Dissection of the styloid process via an extraoral approach is simple and reliable; dissection of the styloid process combined with antidepressants (fluoxetine) is preferred for treating Eagle's syndrome."( Eagle's syndrome treated with dissection of the styloid process via an extraoral approach combined with antidepressants.
Chen, WL; Pan, JY; Peng, GG; Wu, JW, 2011
)
0.57
" In the present study, the antidepressant like activity of curcumin and its combination with fluoxetine and imipramine was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats."( Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: an acute and chronic study.
Anovadiya, A; Sanmukhani, J; Tripathi, CB,
)
0.58
"Folic acid is antidepressant, either alone or combined with several antidepressant drugs."( Fluoxetine, 17-β estradiol or folic acid combined with intra-lateral septal infusions of neuropeptide Y produced antidepressant-like actions in ovariectomized rats forced to swim.
Molina-Hernández, M; Téllez-Alcántara, NP, 2011
)
1.81
"To quantify the importance of drug-drug interactions (DDIs) in the occurrence of adverse drug reactions (ADRs) reported with serotoninergic reuptake inhibitors in a pharmacovigilance database."( The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France.
Bagheri, H; Bondon-Guitton, E; Bui, E; Durrieu, G; Lapeyre-Mestre, M; Montastruc, F; Montastruc, JL; Schmitt, L; Sommet, A, 2012
)
0.38
"Predictions of drug-drug interactions (DDIs) are commonly performed for single inhibitors, but interactions involving multiple inhibitors also frequently occur."( In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors.
Isoherranen, N; Lutz, JD, 2012
)
0.38
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
" This was combined with two different doses of fluoxetine (10 and 20 mg/kg)."( Evaluation of antidepressant activity of ropinirole coadministered with fluoxetine in acute and chronic behavioral models of depression in rats.
Ghorpade, S; Manjrekar, N; Sonawane, D; Tripathi, R, 2011
)
0.86
"To study the effect of early intervention of liver-soothing and Blood-activating decoction combined with acupuncture in improving neurological functions, depressive symptom and life quality of patients with post-stroke depression, and compare with fluoxetine hydrochloride."( [Effect of early intervention of liver-smoothing and blood-activating decoction combined with acupuncture on patients with post-stroke depression].
Bi, XL; Chen, CJ; Fan, ZJ; Hu, JF; Liu, TF; Liu, Y; Yang, PQ; Yu, ZH, 2013
)
0.57
"The effectiveness of clorazepate dipotassium combined with fluoxetine and a behaviour modification programme for the treatment of anxiety disorders in dogs was investigated."( Fluoxetine combined with clorazepate dipotassium and behaviour modification for treatment of anxiety-related disorders in dogs.
Anzola, B; Ibáñez, M; Olivares, A; Pineda, S, 2014
)
2.09
" This observed discrepancy between in vitro risk assessment and in vivo drug-drug interaction (DDI) profile was rationalized by time-varying dynamic pharmacokinetic models that incorporated circulating concentrations of fluoxetine and norfluoxetine enantiomers, mutual inhibitor-inhibitor interactions, and CYP3A4 induction."( Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4.
Davis, C; Foti, RS; Isoherranen, N; Kunze, KL; Lutz, JD; Sager, JE, 2014
)
2.03
" Four weeks after CMS, Sini San alone was less effective in reducing depression-like behavior than fluoxetine alone or in combination with Sini San, but combined use was more effective than fluoxetine alone."( Effects of Sini San used alone and in combination with fluoxetine on central and peripheral 5-HT levels in a rat model of depression.
Chen, J; Guo, S; Li, Y; Ma, X; Ouyang, Y; Sun, Y; Wang, W; Wu, Z; Xue, X; Zhang, W, 2013
)
0.85
"The purpose of this work was to determine the antimicrobial activity of fluoxetine, alone and combined with fluconazole, against 29 Candida strains isolated from patients with vulvovaginal candidiasis."( Anti-Candida activity of fluoxetine alone and combined with fluconazole: a synergistic action against fluconazole-resistant strains.
Gaspar, CA; Martinez-de-Oliveira, J; Oliveira, AS; Palmeira-de-Oliveira, A; Palmeira-de-Oliveira, R, 2014
)
0.94
"Much recent research aims to identify evidence for Drug-Drug Interactions (DDI) and Adverse Drug reactions (ADR) from the biomedical scientific literature."( MONITORING POTENTIAL DRUG INTERACTIONS AND REACTIONS VIA NETWORK ANALYSIS OF INSTAGRAM USER TIMELINES.
Correia, RB; Li, L; Rocha, LM, 2016
)
0.43
" This leads to CYP2D6-mediated drug-drug interactions (DDI)."( The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly.
Bahar, MA; Borgsteede, SD; Bos, JHJ; Hak, E; Wilffert, B, 2017
)
0.66
"Effects of enriched environment (EE) combined with fluoxetine in a chronic unpredictable stress (CUS) rat model were examined in our study."( Enriched environment combined with fluoxetine ameliorates depression-like behaviors and hippocampal SYP expression in a rat CUS model.
Feng, YY; Gu, JY; Han, JH; Li, Y; Liu, C; Lv, TT; Shao, QJ; Wang, CH; Yan, FL; Zhang, XY; Zhao, LQ, 2017
)
0.98
"Metoprolol (a CYP2D6 substrate) is often co-prescribed with paroxetine/fluoxetine (a CYP2D6 inhibitor) because the clinical relevance of this drug-drug interaction (DDI) is still unclear."( The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine.
Bahar, MA; Borgsteede, SD; Hak, E; Kamp, J; Wilffert, B, 2018
)
0.92
" This will be the first clinical attempt of the intravenous administration of ATP and PCr combined with orally administered fluoxetine in MDD."( Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study.
Cao, X; Chen, Y; Gao, T; Ou, CQ; Shen, X; Tan, S; Zang, W; Zhao, L, 2019
)
0.94
" Patients will receive an intravenous administration of ATP or PCr or saline twice daily combined with orally administered fluoxetine (20 mg/day) for the first 2 weeks and fluoxetine monotherapy for the following 4 weeks."( Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study.
Cao, X; Chen, Y; Gao, T; Ou, CQ; Shen, X; Tan, S; Zang, W; Zhao, L, 2019
)
0.94
" Also a generally very high correlation between the clinical pharmacokinetic effects of inherited deficiency and inhibition by drug-drug interactions could be demonstrated."( How precise is quantitative prediction of pharmacokinetic effects due to drug-drug interactions and genotype from in vitro data? A comprehensive analysis on the example CYP2D6 and CYP2C19 substrates.
Brockmöller, J; Dücker, C, 2021
)
0.62
" As a combination therapy, simple acupuncture combined with fluoxetine has achieved good clinical effect, but there is a lack of evidence-based medicine."( Simple acupuncture combined with fluoxetine in the treatment of poststroke depression: A protocol for systematic review and meta-analysis.
Bi, J; Gao, L; Gong, P; Ma, X, 2021
)
1.14
" A randomized controlled trial of simple acupuncture combined with fluoxetine in the treatment of poststroke depression will be selected."( Simple acupuncture combined with fluoxetine in the treatment of poststroke depression: A protocol for systematic review and meta-analysis.
Bi, J; Gao, L; Gong, P; Ma, X, 2021
)
1.14
"In this study, the efficacy and safety of acupuncture combined with fluoxetine in the treatment of post-stroke depression are evaluated by Hamilton Depression scale (HAMD) and its reduction rate, Treatment Emergency Symptom Scale, Self-rating Depression Scale, and Activities of Daily living scale."( Simple acupuncture combined with fluoxetine in the treatment of poststroke depression: A protocol for systematic review and meta-analysis.
Bi, J; Gao, L; Gong, P; Ma, X, 2021
)
1.14
"This study will provide reliable evidence-based evidence for the clinical application of acupuncture combined with fluoxetine in the treatment of post-stroke depression."( Simple acupuncture combined with fluoxetine in the treatment of poststroke depression: A protocol for systematic review and meta-analysis.
Bi, J; Gao, L; Gong, P; Ma, X, 2021
)
1.11
"This single-center, randomized, single-blind, parallel-controlled study aimed to analyze the changes in resting-state functional connectivity (RSFC) in young patients with a suicide attempt caused by depression before and after cognitive-behavioral therapy (CBT) combined with fluoxetine or fluoxetine alone by functional magnetic resonance imaging (fMRI)."( Changes of functional connectivity of the subgenual anterior cingulate cortex and precuneus after cognitive behavioral therapy combined with fluoxetine in young depressed patients with suicide attempt.
Bi, B; Kuang, L; Liu, J; Shu, Y; Wu, G; Xiong, J, 2022
)
1.1

Bioavailability

Fluoxetine is well absorbed after oral intake, is highly protein bound, and has a large volume of distribution. The pharmacokinetics and relative bioavailability of fluoxetne capsules (reference) and tablets were compared in 24 healthy subjects of both sexes.

ExcerptReferenceRelevance
" They are well absorbed orally but exhibit an extensive first-pass extraction in the liver."( Pharmacokinetics of the selective serotonin reuptake inhibitors.
DeVane, CL, 1992
)
0.28
" Paroxetine is well absorbed from the gastrointestinal tract and undergoes first-pass metabolism that is partially saturable."( The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.
Johnson, AM; Tulloch, IF, 1992
)
0.28
" No significant changes were determined for fraction of absorbed dose, volume of distribution, absorption rate constant, and elimination rate constant."( Increased carbamazepine plasma concentrations after fluoxetine coadministration.
Carter, JG; D'Mello, AP; D'Souza, MJ; Grimsley, SR; Jann, MW, 1991
)
0.53
" At the lowest dose tested (5 mg/kg) the drug was efficiently extracted by the liver (extraction ratio about 60%), resulting in bioavailability of only about 38%."( Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat.
Caccia, S; Cappi, M; Fracasso, C; Garattini, S, 1990
)
0.52
" It is well absorbed after oral administration, with absolute bioavailability in dogs of approximately 72 +/- 27."( Fluoxetine: a serotonin-specific, second-generation antidepressant.
Bowden, CL; Crismon, ML; Sommi, RW,
)
1.57
" Fluoxetine is well absorbed after oral administration in both the fed and fasted states and demonstrates dose proportionality."( Fluoxetine: clinical pharmacology and physiologic disposition.
Aronoff, GR; Bergstrom, RF; Enas, GG; Farid, NA; Lemberger, L; Wolen, RL, 1985
)
2.62
"Fluoxetine is well absorbed after oral intake, is highly protein bound, and has a large volume of distribution."( Clinical pharmacokinetics of fluoxetine.
Altamura, AC; Moro, AR; Percudani, M, 1994
)
2.02
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" The three experiments taken together suggest that the complexation of fluoxetine HCl into gamma-cyclodextrin increases its pharmacological efficacy in animals, this effect being related to an enhancement of its oral bioavailability as demonstrated in human healthy subjects."( The inclusion of fluoxetine into gamma-cyclodextrin increases its bioavailability: behavioral, electrophysiological and pharmacokinetic studies.
Bruhwyler, J; Decamp, E; Dresse, A; Géczy, J; Lejeune, C; Liégeois, JF; Masset, H; Scuvée-Moreau, J; Seutin, V; Szejtli, J; Szente, L; Van Heugen, JC, 2000
)
0.88
"P-glycoprotein (P-gp) is an efflux transporter involved in limiting the oral bioavailability and tissue penetration of a variety of structurally divergent molecules."( Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.
Dantzig, AH; Ekins, S; Kim, RB; Lan, LB; Leake, BF; Schuetz, EG; Schuetz, JD; Shepard, RL; Wikel, JH; Winter, MA; Wrighton, SA; Yasuda, K, 2002
)
0.31
" Observations of brain fluoxetine bioavailability and elimination half-life also were similar between age groups."( Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders.
Cowan, C; Dager, SR; Dawson, G; Strauss, WL; Unis, AS, 2002
)
0.85
" Relative bioavailability of each dose administered via the TD route was 10% of the value for oral administration of the drug."( Comparative bioavailability of fluoxetine after transdermal and oral administration to healthy cats.
Ciribassi, J; Kaloostian-Whittymore, L; Luescher, A; Pasloske, KS; Robertson-Plouch, C; Zimmerman, A, 2003
)
0.6
" However, the relative bioavailability for TD administration is approximately only 10% of that for the oral route of administration."( Comparative bioavailability of fluoxetine after transdermal and oral administration to healthy cats.
Ciribassi, J; Kaloostian-Whittymore, L; Luescher, A; Pasloske, KS; Robertson-Plouch, C; Zimmerman, A, 2003
)
0.6
" In contrast, activation of somatodendritc 5-HT(1A) receptors in the raphe nuclei reduces forebrain 5-HT bioavailability and agonists of these receptors, including 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT), reliably stimulate eating behavior."( Sex differences in the reversal of fluoxetine-induced anorexia following raphe injections of 8-OH-DPAT.
Braver, M; Currie, PJ; Mirza, A; Sricharoon, K, 2004
)
0.6
" Due to hepatic first-pass metabolism, the oral bioavailability is < 90%."( [Fluoxetine: an update of its use in major depressive disorder in adults].
Gourion, D; Perrin, E; Quintin, P,
)
1.04
"This study was conducted to determine the relative rectal bioavailability of fluoxetine capsules as well as the acceptability of the rectal route of fluoxetine capsule administration."( Relative rectal bioavailability of fluoxetine in normal volunteers.
Cameron, OG; Guthrie, SK; Phan, KL; Teter, CJ, 2005
)
0.83
"The pharmacokinetics and relative bioavailability of fluoxetine capsules (reference) and tablets (test) were compared in 24 healthy subjects of both sexes after a single 20 mg oral dose of fluoxetine (as a hydrochloride salt)."( Bioequivalence testing of a new tablet formulation of generic fluoxetine.
Dordević, S; Jovanović, D; Jovanović, M; Jovic-Stosić, J; Kilibarda, V; Knezević, T; Srdić, D,
)
0.62
" Logarithmic transformation of the AUC and Cmax was used for the statistical analyses and to assess the bioavailability of the two formulations, using analyses of variance (ANOVA) and Satherwait t-tests for unequal variances."( Bioequivalence study of two fluoxetine capsule formulations in healthy Middle Eastern volunteers.
Bowirrat, A; Kort, JJ; Oscar-Berman, M; Zaid, AN, 2006
)
0.63
"The two formulations had equivalent pharmacokinetic parameters, were well-tolerated, and their relative bioavailability was 98."( Bioequivalence study of two fluoxetine capsule formulations in healthy Middle Eastern volunteers.
Bowirrat, A; Kort, JJ; Oscar-Berman, M; Zaid, AN, 2006
)
0.63
" Cannula-bleeding, especially coupled with automated blood-collection techniques, has become the most efficient way for pharmaceutical industry to perform rat bioavailability studies."( Pharmacokinetic comparisons of tail-bleeding with cannula- or retro-orbital bleeding techniques in rats using six marketed drugs.
Bina, H; Chiang, A; Ebbert, L; Huang, NH; Hui, YH; Kern, T; Maples, C; Patel, N; Pritt, M,
)
0.13
" SAR studies, driven primarily by in vitro liver microsomal stability assessment, identified compound 10b, which displayed improved oral bioavailability and lower intrinsic clearance."( The synthesis and biological evaluation of quinolyl-piperazinyl piperidines as potent serotonin 5-HT1A antagonists.
Abou-Gharbia, MA; Adedoyin, A; Andree, TH; Aschmies, SH; Asselin, M; Bach, AC; Beyer, C; Bicksler, JJ; Childers, WE; Chong, DC; Comery, TA; Day, M; Grauer, SM; Grosu, GT; Harrison, BL; Havran, LM; Hirst, WD; Hughes, ZA; Huselton, C; Kagan, N; Kleintop, T; Magolda, R; Marathias, V; Platt, B; Pulicicchio, C; Robichaud, AJ; Rosenzweig-Lipson, S; Sabb, AL; Shen, Z; Smith, DE; Sukoff-Rizzo, SJ; Sullivan, KM; Zhang, MY, 2010
)
0.36
"The aim of this study was to compare the bioavailability and tolerability of the proposed generic formulation with the established reference formulation of fluoxetine hydrochloride 20 mg in a fasting, healthy Chinese male population."( Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study.
Li, Z; Liu, Y; Shi, S; Wu, J; Zeng, F; Zhao, Y; Zhong, D, 2010
)
0.79
" Until now, treatments for depression have focused on the inhibition of monoaminergic reuptake sites, which augment the bioavailability of monoamines in the CNS."( Fluoxetine: a case history of its discovery and preclinical development.
Berrocoso, E; Bravo, L; Mico, JA; Perez-Caballero, L; Torres-Sanchez, S, 2014
)
1.85
" In contrast MAOi antidepressants, that also increase extracellular serotonin bioavailability have little or no effects on this condition."( Differential modulation of Nav1.7 and Nav1.8 channels by antidepressant drugs.
Beaulieu, JM; Chahine, M; Poulin, H; Thériault, O, 2015
)
0.42
"8% oral bioavailability and good penetration to the brain."( Novel N-acyl-carbazole derivatives as 5-HT7R antagonists.
Choo, H; Kim, Y; Rhim, H; Tae, J; Yeom, M, 2016
)
0.43
" cancer, but bioavailability was low."( Toxicokinetics, disposition and metabolism of fluoxetine in crabs.
Hucher, N; Knigge, T; Monsinjon, T; Robert, A; Schultz, IR, 2017
)
0.71
"Studies on the bioavailability of organic contaminants adsorbed to nanomaterials are increasing."( Accumulation, metabolite and active defence system responses of fluoxetine in zebrafish embryos: Influence of multiwalled carbon nanotubes with different functional groups.
Dong, H; Ji, Y; Jiang, R; Liu, J; Lu, G; Sun, H; Yan, Z; Yang, H, 2018
)
0.72
"Few studies have focused on the influence of environmental conditions on the bioavailability of pollutants interacted with nanomaterials in organisms."( Comparison of the accumulation and metabolite of fluoxetine in zebrafish larva under different environmental conditions with or without carbon nanotubes.
Bao, X; Ji, Y; Jiang, R; Liu, J; Lu, G; Sun, H; Yan, Z, 2019
)
0.77
" Herein, we tested the safety and effectiveness of increasing serotonin bioavailability in preweaned dairy calves by oral supplementation of a serotonin precursor (5-hydroxytryptophan, 5-HTP) or a serotonin reuptake inhibitor (fluoxetine, FLX)."( Increasing serotonin bioavailability in preweaned dairy calves impacts hematology, growth, and behavior.
da Silva, DR; Dado-Senn, B; Field, SL; Laporta, J; Marrero, MG; Skibiel, AL, 2019
)
0.7
" The bioavailability parameters of the test drugs in dogs and volunteers did not differ."( Experimental and Clinical Pharmacokinetics of Fluoxetine and Amitriptyline: Comparative Analysis and Possible Methods of Extrapolation.
Gneushev, ET; Kondratenko, SN; Kukes, VG; Savelyeva, MI; Shikh, EV, 2019
)
0.77
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" We hypothesized that increased serotonin bioavailability promotes serotonergic signaling and modulates the expression of immune related genes in peripheral leukocytes and immune-related tissues of dairy calves."( Increasing serotonin bioavailability alters gene expression in peripheral leukocytes and lymphoid tissues of dairy calves.
Dado-Senn, B; Driver, JP; Field, SL; Laporta, J; Marrero, MG; Skibiel, AL, 2020
)
0.56
" Improving serotonin bioavailability could serve as a potent regulator of endocrine and metabolic processes in dairy calves."( Peripheral serotonin regulates glucose and insulin metabolism in Holstein dairy calves.
Dado-Senn, B; Field, SL; Laporta, J; Marrero, MG; Ramos, PM; Scheffler, TL; Skibiel, AL, 2021
)
0.62
" Pharmacological manipulation of systemic 5-HT bioavailability alters the electrical activity of mPFC neurons."( Information capacity and robustness of encoding in the medial prefrontal cortex are modulated by the bioavailability of serotonin and the time elapsed from the cue during a reward-driven task.
Mininni, CJ; Pereyra, AE; Zanutto, BS, 2021
)
0.62
" Alterations caused by RYGB could modify drug bioavailability and cause potential subtherapeutic plasma concentrations, increasing the risk of depressive relapse."( The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants.
Eap, CB; Favre, L; Frantz, J; Garin, P; Vandenberghe, F; Vionnet, N, 2023
)
0.91
"The results showed that CYP2C19 inhibitors could significantly improve the bioavailability of mavacamten in rats, which indicated that we should pay more attention to the patient's condition to prevent the occurrence of side effects when used mavacamten in combination with CYP2C19 inhibitors."( Effects of CYP2C19 inhibitors on mavacamten pharmacokinetics in rats based on UPLC-MS/MS.
Chen, C; Li, Q; Liu, YN; Xie, S; Xu, RA; Zhan, R, 2023
)
0.91

Dosage Studied

A dosage of 2 mg/kg day given over a 14-week period led to steady-state serum concentrations of active agent. Fluoxetine dosing inhibited CYP2C19 activity in both age groups, increasing the (S)- to (R)-mephenytoin ratio 3- to 4-fold.

ExcerptRelevanceReference
" The mean HAM-D-17 and CGIS scores of these 15 patients decreased significantly at the end of 4 weeks on a higher dosage of fluoxetine (60 or 80 mg/day) with respect to the beginning of the four-week study."( High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine.
Clancy, K; Cohen, L; Fava, M; McCarthy, M; Reiter, S; Rosenbaum, JF; Steingard, R, 1992
)
0.89
"Eighty-six patients aged between 60 and 80 years and affected with major depression according to the diagnostic criteria of the DSM III-R were treated with fluoxetine per os at the single dosage of 20 mg/die."( [Fluoxetine and depression in the elderly. Clinical experience].
Ambrosio, LA; Barrese, E; Bertini, M; Buccomino, D; Casini, A; Filippo, A; Filippo, P; Marchese, G; Paoletti, C,
)
1.24
" When imipramine or desipramine are to be coadministered with fluoxetine, a lower dosage may be needed to maintain steady-state concentrations and to avoid undesirable side effects caused by excessive tricyclic concentrations."( Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction.
Bergstrom, RF; Lemberger, L; Peyton, AL, 1992
)
0.8
" Fluoxetine at 20 mg/d produced an effect between that of the 60-mg/d dosage and that of placebo."( Fluoxetine in the treatment of bulimia nervosa. A multicenter, placebo-controlled, double-blind trial. Fluoxetine Bulimia Nervosa Collaborative Study Group.
, 1992
)
2.64
" Further study is needed to determine the optimal dosage and to identify risk factors that increase individual vulnerability to fluoxetine induced mania in adolescents."( Mania associated with fluoxetine treatment in adolescents.
King, CA; Naylor, MW; Venkataraman, S, 1992
)
0.8
" These results suggest that, at comparable dosage levels relative to their ED50s, fluoxetine and D-fenfluramine cause comparable reversible effects on brain serotonin release."( Effects of fluoxetine or D-fenfluramine on serotonin release from, and levels in, rat frontal cortex.
Gleason, R; Morse, AN; Sarkissian, CF; Wurtman, RJ, 1990
)
0.89
" A subchronic study in severe seizure GEPRs demonstrated that the ED50 after 28 days of dosing (8."( Effects of fluoxetine on convulsions and on brain serotonin as detected by microdialysis in genetically epilepsy-prone rats.
Burger, RL; Dailey, JW; Jobe, PC; Mishra, PK; Yan, QS, 1992
)
0.67
" Other antidepressants are so affected, and toxicity may result if proper dosage adjustments are not made."( Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.
Ciraulo, DA; Shader, RI, 1990
)
1.72
" Desipramine plasma levels drawn 24 hours after an initial standardized dose were used to rapidly adjust desipramine dosage and compensate for the interactive effects of fluoxetine on desipramine levels in the blood."( A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression.
Bowers, MB; Jatlow, PI; Mazure, CM; Nelson, JC, 1991
)
0.73
" The study was designed as a randomised double-blind parallel study involving 139 patients, comparing the effects of a daily dosage of 20 mg fluoxetine, 40 mg fluoxetine and 50 mg clomipramine."( [Efficacy and safety of fluoxetine versus clomipramine in ambulatory patients with a depressive syndrome in a clinical trial with private practitioners].
Dossenbach, M; Pakesch, G, 1991
)
0.79
" In reducing the tricyclic dosage after fluoxetine, blood level decreases were behind dosage decreases; and blood level and dosage decreases were not well correlated with each other."( Fluoxetine-induced tricyclic toxicity: extent and duration.
Westermeyer, J, 1991
)
1.99
" The primary adverse events associated with serotonin reuptake inhibitors involve the gastrointestinal system, although side effects may be less frequent at lower dosage levels."( Clinical overview of serotonin reuptake inhibitors.
Rickels, K; Schweizer, E, 1990
)
0.28
" In general, fluoxetine, which was administered from 4 to 20 weeks at a dosage of 10 or 40 mg per day, was well tolerated."( Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience.
Hardin, MT; King, R; Riddle, MA; Scahill, L; Woolston, JL, 1990
)
2.09
" Treatment of reserpinized rats with pargyline, a non-selective inhibitor of monoamine oxidase, in order to increase cerebral 5-HT levels, shifts the PCA dose-response curve for inducing the 5-HT behavioural syndrome to the left."( 5-Hydroxytryptamine release in vivo from a cytoplasmic pool: studies on the 5-HT behavioural syndrome in reserpinized rats.
Kuhn, DM; Wolf, WA; Youdim, MB, 1985
)
0.27
" The authors hypothesize that fluoxetine 20 mg/day may be an ineffective dosage of the drug or that fluoxetine has a slower onset of antidepressant action than does trazodone."( A comparative trial of fluoxetine versus trazodone in outpatients with major depression.
Cook, BL; Dunner, FJ; Garvey, MJ; Kelly, MW; Perry, PJ; Winokur, G, 1989
)
0.88
" Imipramine and fluoxetine have already been compared in other studies, but never at such a low dosage (20 mg) for fluoxetine."( A double-blind study of fluoxetine and imipramine in major depression.
Bressa, GM; Brugnoli, R; Pancheri, P, 1989
)
0.93
" Further increases in the fluoxetine dosage resulted in improvement of her depression and increased pain relief."( Relief of diabetic neuropathy with fluoxetine.
Marsh, WR; Theesen, KA,
)
0.71
" Treatment was generally very well tolerated, but careful dosage titration was important in some patients, especially to manage agitation."( Fluoxetine in borderline personality disorder.
Norden, MJ, 1989
)
1.72
" Dosage modification of either fluoxetine or diazepam is unlikely to be necessary."( The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.
Bergstrom, RF; Bosomworth, JC; Lemberger, L; Rowe, H; Tenbarge, JB, 1988
)
0.92
" The dose-pressor responses, determined from the incremental elevation of systolic blood pressure, were unchanged in each of the three dosing intervals."( Pressor responses to tyramine and norepinephrine after subchronic administration of fluoxetine to man.
Bowsher, DJ; Farid, NA; Lemberger, L; Rowe, H; Tenbarge, JB, 1988
)
0.5
" Thus, at steady state both fluoxetine and norfluoxetine concentrations will be higher in patients with cirrhosis, unless the dosage is reduced."( Fluoxetine disposition and elimination in cirrhosis.
Bergstrom, RF; Lemberger, L; Schenker, S; Wolen, RL, 1988
)
2.01
" Although doses as high as 80 mg/day have been used, the optimal dosage range appears to be 20-40 mg once daily."( Fluoxetine: a serotonin-specific, second-generation antidepressant.
Bowden, CL; Crismon, ML; Sommi, RW,
)
1.57
" A non-anorectic dosage of L110-140 (3."( The role of norepinephrine in feeding behavior.
Davies, RF; Panksepp, J; Rossi, J; Zolovick, AJ, 1982
)
0.26
" Naloxone clearly antagonizes the release of prolactin induced by 5-hydroxytryptophan administered alone at a dosage of 50 mg/Kg/b."( Effects of naloxone on the secretion of prolactin and corticosterone induced by 5-hydroxytryptophan and a serotonergic agonist, mCPP.
Cerrito, F; Preziosi, P; Vacca, M, 1983
)
0.27
" Blood samples for the measurement of fluoxetine and its active metabolite norfluoxetine were drawn 13 times in the first 48 hr after dosing and thrice weekly thereafter for 4 wk."( Fluoxetine kinetics and protein binding in normal and impaired renal function.
Aronoff, GR; Bergstrom, RF; Lemberger, L; Pottratz, ST; Sloan, RS; Wolen, RL, 1984
)
1.98
" In the present study we determined the time-course and dose-response effects of 6-MeO-THbetaC for blockade of AGS."( Effects of 6-methoxy-1,2,3,4-tetrahydro-beta-carboline (6-MeO-THbetaC) on audiogenic seizures in DBA/2J mice.
Buckholtz, NS; Sparks, DL, 1980
)
0.26
" The dose-response curve for this discrimination was orderly with an ED50 of about one-half of the training dose (0."( A neuropharmacological analysis of the discriminative stimulus properties of fenfluramine.
Appel, JB; White, FJ, 1981
)
0.26
" Doubling the low dosage in non-responders after 3 weeks resulted in a statistically significant improvement of CGI in the moclobemide group by comparison with the fluoxetine group at study end, suggesting that 600 mg moclobemide/day can still improve the patient's condition, while 40 mg fluoxetine/day does not."( Moclobemide versus fluoxetine for a major depressive episode.
Haazen, L; Janne, P; Mirel, J; Parent, M; Reynaert, C, 1995
)
0.82
" Outpatients at a Veterans Affairs mental health clinic who were being treated with fluoxetine were randomly assigned to receive either 50 or 75 mg of sertraline hydrochloride for every 20 mg of fluoxetine (as the hydrochloride salt) or to continue to receive their current dosage of fluoxetine."( Clinical effect of converting antidepressant therapy from fluoxetine to sertraline.
Christenson, JL; Cushing, AG; Haider, A; Miller, DR; Station, RD, 1995
)
0.76
"6-mg/kg doses of GBR 12909 produced downward shifts in the dose-response curves for cocaine (0."( Effects of monoamine reuptake inhibitors on cocaine self-administration in rats.
Tella, SR, 1995
)
0.29
" However, assessment of the results of previous studies is confounded by the relative lack of standards in diagnostic criteria, outcome measures, dosage and duration of treatment."( Studies of reversible and selective inhibitors of monoamine oxidase A in dysthymia.
Pétursson, H, 1995
)
0.29
" First, a dose-response study revealed that all doses of AET tested (5, 10, 20 mg/kg) significantly increased locomotor activity."( Behavioral characterization of alpha-ethyltryptamine, a tryptamine derivative with MDMA-like properties in rats.
Geyer, MA; Krebs, KM, 1993
)
0.29
" These levels remained below the therapeutic window even when the tricyclic antidepressant dosage was increased."( [A case of metabolic interaction: amitriptyline, fluoxetine, antitubercular agents].
Bertschy, G; Perault, MC; Vandel, S,
)
0.39
" A daily dosage of 300 mg of moclobemide and 20 mg of fluoxetine would thus appear to be comparable both in antidepressant efficacy and tolerability."( Moclobemide versus fluoxetine for major depressive episodes.
Bruynooghe, F; De Cuyper, H; Demeulemeester, F; Geerts, S; Haazen, L, 1994
)
0.87
" At t1/2 of 24 h makes once-daily dosing feasible and allows for new steady-state concentrations and wash-out within a reasonable time after dose adjustment."( Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline.
Preskorn, S, 1994
)
0.51
" There was a significant shift to the right in the dose-response curve for RU24969 in the SCN in fluoxetine treated animals but a shift to the left for the dose-response curve for 8-OH-DPAT in the DRN."( Effects of 21 days treatment with fluoxetine on stimulated endogenous 5-hydroxytryptamine overflow in the rat dorsal raphe and suprachiasmatic nucleus studied using fast cyclic voltammetry in vitro.
Kruk, ZL; O'Connor, JJ, 1994
)
0.79
" With a few exceptions, the cumulative dosage of FLU and the AUC of FLU and NFLU were better predictors of the changes in awake and movement time in the PSG than single-sample concentrations of FLU and NFLU taken at the time of PSG assessment."( The effects of fluoxetine on the polysomnogram of depressed outpatients: a pilot study.
Armitage, R; Battaglia, J; Cain, JW; Debus, JR; Grannemann, BD; Hendrickse, WA; Orsulak, PJ; Roffwarg, HP; Rush, AJ, 1994
)
0.64
" The Regenstrief Medical Record System was used to analyze the dosing of SSRIs in the outpatient population of an urban teaching hospital."( Selective serotonin reuptake inhibitor dose titration in the naturalistic setting.
Coons, SJ; Gregor, KJ; McDonald, RC; Overhage, JM,
)
0.13
" In the present report, we confirm and extend our original results to include dose-response data and the effect of selective uptake inhibition on the levels of monoamine neurotransmitters in various regions of the mouse brain following treatment with 2'-NH2-MPTP."( Fluoxetine and desipramine selectively attenuate 2'-NH2-MPTP-induced depletions in serotonin and norepinephrine.
Andrews, AM; Murphy, DL, 1993
)
1.73
" Concentrations in plasma were determined after 7 days of desipramine (50 mg/day) dosing alone, during the 21 days of desipramine and selective serotonin reuptake inhibitor (SSRI) coadministration (fluoxetine, 20 mg/day; sertraline, 50 mg/day), and for 21 days of continued desipramine administration after SSRI discontinuation."( Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine.
Alderman, J; Chung, M; Harris, S; Harrison, W; Messig, M; Preskorn, SH, 1994
)
0.71
" A week of daily dosing with CLZ led to no accumulation of drug in brain; a week of fluoxetine pretreatment increased analyte concentrations (serum, 86%; brain, 61%), but valproate had little effect."( Tissue concentrations of clozapine and its metabolites in the rat.
Baldessarini, RJ; Centorrino, F; Cohen, BM; Flood, JG; Huston-Lyons, D; Volpicelli, SA, 1993
)
0.51
" Bruxism remitted in all patients after a decrease in antidepressant dosage (N = 1) or addition of buspirone (N = 3)."( SSRI-associated nocturnal bruxism in four patients.
Ellison, JM; Stanziani, P, 1993
)
0.29
" In addition, they suggest that a decrease in SSRI dosage or the addition of buspirone may relieve SSRI-associated nocturnal bruxism."( SSRI-associated nocturnal bruxism in four patients.
Ellison, JM; Stanziani, P, 1993
)
0.29
" This dosing strategy may be of particular benefit for patients with panic disorder."( Use of low-dose fluoxetine in major depression and panic disorder.
Lannon, RA; Lewis, TB; Louie, AK, 1993
)
0.63
" In contrast to older agents fluoxetine requires no titration and can be dosed once daily."( Fluoxetine: a five-year review.
Stokes, PE,
)
1.87
"With some limitations in interpreting the data, the findings of this study suggest that SSRI-associated female sexual dysfunction occurs at a higher rate than we previously thought, equal potentials in implicating female sexual side effects among three SSRIs, and the absence or the low incidence of female sexual adverse effects from bupropion, and that these side effects can be managed by waiting for a spontaneous remission, dosage reduction of SSRIs, substitution with bupropion and other antidepressants, or the use of an antidote."( Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients.
Hsu, JH; Shen, WW, 1995
)
0.29
" Therefore, a dose-response curve of posttraining injection (intraperitoneal) of fluoxetine was carried out in an associative learning task (auto-shaping)."( Effect of fluoxetine on learning and memory involves multiple 5-HT systems.
Hong, E; Meneses, A, 1995
)
0.92
" Blood level:dose ratios and dose-response relationships for cyclosporine were virtually identical in all three groups before and during treatment."( Fluoxetine and cyclosporine in organ transplantation. Failure to detect significant drug interactions or adverse clinical events in depressed organ recipients.
Fairbanks, LA; Fawzy, FI; Skotzko, CE; Strouse, TB,
)
1.57
" In the frontal cortex, fluoxetine showed a marked dose-response effect whereas in the ventral hippocampus and raphe nuclei the fluoxetine-induced effect was maximum at 10 mg/kg."( Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study.
Gardier, AM; Jacquot, C; Malagié, I; Trillat, AC, 1995
)
0.94
" If the response was inadequate after two weeks of treatment, the dosage of venlafaxine could be increased to 75 mg twice daily."( A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients.
Dierick, M; Martin, A; Ravizza, L; Realini, R, 1996
)
0.55
" Indeed, planned pharmacokinetic drug interactions at the level of P450s have been proposed to reduce cyclosporine dosage requirements, to reduce variability of TCA levels, and to manipulate the contribution of alternative metabolic pathways to minimize toxic effects."( Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II.
Harvey, AT; Preskorn, SH, 1996
)
0.29
"This study explored serum concentrations of fluoxetine and norfluoxetine in subjects treated under different dosing regimens."( Fluoxetine and norfluoxetine serum concentrations and clinical response in weekly versus daily dosing.
Burke, WJ; Hendricks, SE; Jacques, D; McArthur-Campbell, D; Stull, T, 1996
)
2
" Daily injections of fluoxetine (10 mg/kg/day) for 0, 3, 7, 14 or 22 days gradually produced a shift to the right in the dose-response curve effects of 8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT) on plasma adrenal corticotropic hormone, corticosterone and oxytocin."( Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(o) proteins and in neuroendocrine responses to a 5-HT1A agonist.
Li, Q; Muma, NA; van de Kar, LD, 1996
)
1.05
" Each patient manually collected 3 to 6 milk samples throughout a dosing interval."( Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk.
Ito, S; Koren, G; Taddio, A, 1996
)
0.66
" It was concluded that fluoxetine was clearly the drug of choice in treating chronic depression in this patient sample, and that the PDDs used in the patient population studied were in agreement with local and internationally acceptable dosage ranges."( An investigation into the prescribing patterns of selective serotonin re-uptake inhibitors in South Africa.
Kotze, TJ; Truter, I, 1996
)
0.6
"1 for protocols 1 and 2, respectively) in stimulating the 5-HTP-induced HTR and produced a bell-shaped dose-response curve."( The stimulatory and inhibitory components of cocaine's actions on the 5-HTP-induced 5-HT2A receptor response.
Darmani, NA; Reeves, SL, 1996
)
0.29
" The tolerability of therapeutic doses of fluoxetine in the daily range 20 to 40 mg is comparable while the dosage augmentation to 60 mg per day causes increase in the percentage of patients demonstrating side effects."( [A test for using meta-analysis to evaluate antidepressive effects of fluoxetine].
Jarema, M,
)
0.63
" The aim of the present study was to examine whether pindolol may increase the efficacy of a subtherapeutical dosage of trazodone in the treatment of major depression and TRD, defined according to the Thase and Rush criteria (1995)."( Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression.
Desnyder, R; Maes, M; Vandoolaeghe, E, 1996
)
0.53
" Only a regular daily dosing schedule of amantadine has been used for the treatment of sexual dysfunction so far."( Intermittent amantadine for fluoxetine-induced anorgasmia.
Balon, R, 1996
)
0.59
" The dose-response curve was biphasic for citalopram with a maximum of 64% inhibition."( Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
Meier, E; Sánchez, C, 1997
)
0.3
"With conservative dosing and close monitoring, combinations of SRIs with bupropion in this uncontrolled clinical series appeared to be safe and often more effective than monotherapy."( Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.
Baldessarini, RJ; Bodkin, JA; Gardner, DM; Lasser, RA; Wines, JD, 1997
)
0.3
" No gender difference in HPA axis activation was observed in a dose-response study of cocaine-induced HPA activation in 10 day old rats."( Gender difference in cocaine-induced HPA axis activation.
Francis, R; Kuhn, C, 1997
)
0.3
" Dosage increases (to 500 mg/day for nefazodone and 40 mg/day for fluoxetine) were available after day 29, depending on clinician judgement."( A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients.
Armitage, R; Cole, D; Rush, AJ; Yonkers, K, 1997
)
0.77
" 1737 patients received fluoxetine at a dosage of 20 mg per day over a period of 6 months."( [Maintenance therapy with 20 mg fluoxetine. Results of an administration study of 1,737 depressed patients].
Hesselmann, B; Kasper, S; Wein, W, 1997
)
0.89
"5 mg/kg) produced a leftward shift in the cocaine dose-response curve (0."( Modulation of the discriminative stimulus properties of cocaine: comparison of the effects of fluoxetine with 5-HT1A and 5-HT1B receptor agonists.
Callahan, PM; Cunningham, KA, 1997
)
0.52
" In these rats, the power values were less than three times those before the dosing of PTZ or beta-CCM."( [A study of the effects of antidepressants on the GABAA receptor and its complex based on the drug actions on the power-spectral changes of rat hippocampal EEG induced by GABA antagonists and inverse agonists].
Hatsuda, S; Matsubara, M; Miura, K; Murakami, H; Nakazawa, K; Ohara, M; Sugita, S; Suzuki, S; Terashima, M, 1997
)
0.3
" Mild symptoms can often be treated by simply reassuring the patient that they are usually transient, but for more severe symptoms, it may be necessary to reinstitute the dosage of the original antidepressant and slow the rate of taper."( Clinical management of antidepressant discontinuation.
Rosenbaum, JF; Zajecka, J, 1997
)
0.3
") was also active in each session, but presented a biphasic dose-response curve."( S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of
Audinot, V; Brocco, M; Cistarelli, L; Gobert, A; Lacroix, P; Millan, MJ; Newman-Tancredi, A; Rivet, JM, 1997
)
0.3
" The finding that 50% of the non-responders at 3 months were improved at 6 months, after fluoxetine dosage was increased to 40 mg daily, argues in favour of treating dysthymic patients for at least 6 months, and with a higher dosage if the initial doses are ineffective."( Controlled efficacy study of fluoxetine in dysthymia.
Attar-Levy, D; Blin, P; Bouhassira, M; Olié, JP; Poirier, MF; Vanelle, JM, 1997
)
0.81
" Though our findings confirm that fluoxetine impairs haloperidol clearance, this interaction is unlikely to have adverse clinical consequences, at least in patients chronically stabilized on a low dosage of haloperidol."( Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications.
Avenoso, A; Campo, G; Caputi, AP; Facciolă, G; Ferlito, M; Perucca, E; Spinà, E; Zuccaro, P, 1997
)
0.9
" No subject required dosage reduction or discontinuation of medication because of side effects."( Fluoxetine in drug-dependent delinquents with major depression: an open trial.
Coffman, LM; Crowley, TJ; Mikulich, SK; Riggs, PD, 1997
)
1.74
" Fluoxetine has been widely prescribed by physicians knowledgeable in pharmacology and in the treatment of depression because of its proven efficacy (ie, equal to that of tricyclic antidepressants [TCAs]), its ease of administration (with full therapeutic dosing usually starting from day 1), its generally benign side-effect profile, its remarkable safety in over-dose, and its proven effectiveness in the most common depressed patient population--anxious, agitated, depressed patients--as well as in patients with various subtypes and severities of depression."( Fluoxetine tenth anniversary update: the progress continues.
Holtz, A; Stokes, PE,
)
2.48
" No significant time or dosage effect or time by treatment effect was observed for YMRS."( Lamotrigine in rapid-cycling bipolar disorder.
Calabrese, JR; Fatemi, SH; Rapport, DJ; Thuras, P, 1997
)
0.3
"7%) in the continuous dosing group and 18 women (75."( Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria.
Korzekwa, M; Lamont, J; Steiner, M; Wilkins, A, 1997
)
0.67
"Twenty-one adults with chronic pathologic skin picking agreed to participate and received 10 weeks of placebo or fluoxetine with a flexible dosing schedule up to 80 mg/day."( A double-blind trial of fluoxetine in pathologic skin picking.
Gross, S; Hollander, E; Islam, N; Schmeidler, J; Simeon, D; Stein, DJ, 1997
)
0.81
" However, multiple dosing of moclobemide did not lead the excessive accumulation."( Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome".
Amrein, R; Dingemanse, J; Gieschke, R; Guentert, T; Wallnöfer, A, 1998
)
0.55
" A 60-mg dosage was associated with a greater drop in Yale-Brown Obsessive-Compulsive Scale total score and a greater drop in Compulsion items than a 20-mg dosage."( Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder.
Ackerman, DL; Bystritsky, A; Greenland, S, 1998
)
0.57
"" These behaviors emerged despite gradual dose elevation (2-5 mg/wk), conservative dosing (maximum 40 mg daily), and careful weekly outpatient monitoring of each patient."( Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder.
Birmaher, B; Go, FS; Malley, EE; Rosenberg, DR, 1998
)
0.58
"The objective was to evaluate possible pharmacokinetic and pharmacodynamic interactions for repeated nightly zolpidem dosing with fluoxetine."( Minimal interaction between fluoxetine and multiple-dose zolpidem in healthy women.
Allard, S; MacIntyre, J; Roth-Schechter, B; Sainati, S, 1998
)
0.8
" On day 15, if clinically indicated to improve patient response, the dosage could be increased at the investigator's discretion to venlafaxine 75 mg twice daily or fluoxetine 40 mg once daily."( A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients.
Basquedano, G; Benassinni, O; Diaz-Martinez, A; Gonzalez, S; Martinez, RA; Ontiveros, A; Salin, R,
)
0.57
" Since psychostimulant treatment often requires frequent dosing and may be associated with unacceptable side effects and risks, other classes of medication have been studied as possible treatment alternatives."( Psychopharmacology of ADHD: children and adolescents.
Dogin, JW; Findling, RL, 1998
)
0.3
" The purpose of this study was to assess whether there was a difference in expenditures during the first 90 days of SSRI therapy with paroxetine or sertraline versus fluoxetine in patients who were also receiving a stable dosage of a nonpsychiatric drug also metabolized by the CYP-450 2D6 or 3A4 isoenzyme systems."( Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system.
Croghan, TW; Crown, WH; Hylan, TR; Melfi, CA; Meneades, LM; Ozminkowski, RJ; Robinson, RL,
)
0.33
" In patients with partial response, the dosage should be increased to the maximum by 5-9 weeks."( Pharmacotherapy of primary obsessive-compulsive disorder: review of the literature.
Ellingrod, VL,
)
0.13
" At 1 and 2 weeks after the 4 d dosing regimen, acute FEN (1."( Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats.
Ayestas, MA; Baumann, MH; Rothman, RB, 1998
)
0.3
"The present studies examined the dose-response relationship of fluoxetine-induced desensitization of hypothalamic postsynaptic 5-HT1A receptors, as measured from the reduced neuroendocrine responses to a 5-HT1A agonist."( Daily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins.
Battaglia, G; Evans, S; Garcia, F; Li, Q; Muma, NA; Raap, DK; Van De Kar, LD; Wolf, WA, 1999
)
0.87
" Divalproex sodium was increased as tolerated using a flexible dosing schedule."( Divalproex sodium for impulsive aggressive behavior in patients with personality disorder.
Coccaro, EF; Kavoussi, RJ, 1998
)
0.3
" Cost, number of prescriptions, and dosage strength data is also presented."( Trends in the use of selective serotonin reuptake inhibitors in nine Department of Veterans Affairs outpatient facilities.
Voris, JC, 1999
)
0.3
" An antidepressant drug utilization review study performed in two different HMO models revealed important variations among available SSRI therapies in terms of dosage escalation and discontinuation, as well as concomitant medication costs associated with treating side effects."( Antidepressant utilization in managed care: an evaluation of SSRI use in two HMO settings.
Navarro, R; Spangler, M; Valler, WE, 1995
)
0.29
" In particular, patients beginning therapy with fluoxetine are more likely to receive treatment regimens that meet minimum recommended guidelines for dosage and duration and are less likely to require treatment switching/augmentation than those receiving tricyclic antidepressants or other SSRIs as initial therapy."( Fluoxetine. A pharmacoeconomic review of its use in depression.
Benfield, P; Wilde, MI, 1998
)
2
" Once panic free, these patients were switched to once-weekly dosing of fluoxetine, and dosage was titrated as needed."( Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder.
Ballenger, JC; Brawman-Mintzer, O; Emmanuel, NP; Lydiard, RB; Ware, MR, 1999
)
0.85
" After a brief treatment for 4 weeks with benzodiazepines and daily fluoxetine, the patient was once again maintained on once-weekly dosing when rechallenged."( Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder.
Ballenger, JC; Brawman-Mintzer, O; Emmanuel, NP; Lydiard, RB; Ware, MR, 1999
)
0.85
" Preliminary findings suggest that intermittent luteal-phase fluoxetine dosing may also be a suitable treatment strategy for selected patients with PMDD."( The role of fluoxetine in the treatment of premenstrual dysphoric disorder.
Dillon, J; Judge, R; Romano, S; Shuler, C; Sundell, K, 1999
)
0.92
" From week 7-12, dosing could be adjusted biweekly, as required (paroxetine 20-50 mg/day, and fluoxetine 20-80 mg/day)."( A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder.
Bakish, D; Beauclair, L; Bélanger, MC; Chouinard, G; Manchanda, R; Morris, P; O'Neill, MC; Ravindran, A; Reesal, R; Remick, R; Saxena, B; Vasavan Nair, NP, 1999
)
0.76
" The dosage of FLX was fixed at either 20, 40, or 60 mg per day."( Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder.
Dossenbach, M; Hornik, K; Meszaros, K; Twaroch, T; Zapotoczky, HG; Zitterl, W; Zitterl-Eglseer, K, 1999
)
0.68
" In the case of the hypericum extracts the dose-response relationship was inverted U-shaped with a MED value of 20 mg/kg and a maximal effect of 41% and 32% immobility reduction, for Ze 117 and LI 160, respectively."( Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism.
de Beun, R; De Vry, J; Jentzsch, KR; Maurel, S; Schreiber, R, 1999
)
0.55
" The proposed methods were applied successfully to the determination of the cited drugs either in pure or dosage forms with good accuracy and precision."( Spectrophotometric determination of fluoxetine and sertraline using chloranil, 2, 3 dichloro-5, 6 dicyano benzoquinone and iodine.
Bebawy, LI; El-Kousy, N; Shokry, M; Suddik, JK, 1999
)
0.58
"Our study's limitations include a possible selection bias, lack of controls and fixed dosing of fluoxetine."( Tridimensional personality questionnaire and treatment response in major depressive disorder: a negative study.
Borus, JS; Ewing, SE; Fava, M; McColl, RD; Newman, JR; Nierenberg, AA; Pava, J,
)
0.35
" However, there is no data on the dosage of selective serotonin uptake inhibitors (SSRIs) required to maintain symptom resolution in women treated for major depression during pregnancy."( Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications.
Hostetter, A; Llewellyn, A; McLaughlin, E; Stowe, ZN; Strader, JR, 2000
)
0.31
" Its major metabolite, norfluoxetine (NFLX), possesses FLX's antidepressant efficacy and a half-life of 7 to 15 days, suggesting the possibility of nonstandard dosing strategies."( Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial.
Bessette, D; Burke, WJ; Hendricks, SE; Jacques, D; McArthur-Miller, D; McKillup, T; Stull, T; Wilson, J, 2000
)
0.95
" Prospective studies utilizing flexible dosing of modern antidepressants and, if necessary, sequential trials of dissimilar medications are needed to confirm these findings."( Treatment of men with major depression: a comparison of sequential cohorts treated with either cognitive-behavioral therapy or newer generation antidepressants.
Berman, SR; Fasiczka, AL; Frank, E; Friedman, ES; Nofzinger, EA; Reynolds, CF; Thase, ME, 2000
)
0.31
" To test this relationship directly, microdialysis and electrophysiology studies were performed to assess the magnitude of increase in extracellular serotonin and changes in cellular activity produced by the serotonin reuptake inhibitor fluoxetine and the 5-HT(1A) receptor antagonist WAY-100635 under various dosing regimens."( Differential effects of coadministration of fluoxetine and WAY-100635 on serotonergic neurotransmission in vivo: sensitivity to sequence of injections.
Gribkoff, VK; Kinney, GG; Pieschl, RL; Taber, MT; Yocca, FD, 2000
)
0.75
" Fluoxetine at the dosage studied does not predictably effect the hypoprothrombinemic response of warfarin."( Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin.
Anderson, ML; Ford, MA; Jaskar, DW; Rindone, JP, 1997
)
1.54
") using the same dosing regimen as described above."( Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine.
Cheetham, SC; Heal, DJ; Slater, NA; Viggers, JA, 2000
)
0.53
" A significant, non-parallel shift in the dose-response curve of serotonergic neurons to the serotonin-1A (5-HT1A) agonist 8-OH-DPAT occurred over the 21 days of treatment with fluoxetine, indicating a desensitization of the 5-HT1A receptor during this period."( Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat.
Czachura, JF; Rasmussen, K, 2000
)
0.76
" No cases of serotonin syndrome occurred, and the combination was well tolerated, although the 4 g per day dosage of tryptophan produced daytime drowsiness."( Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
Driver, HS; Jindal, R; Kennedy, SH; Levitan, RD; Shapiro, CM; Shen, JH, 2000
)
0.53
" It is also suggested that positron emission tomography may be used to define therapeutic dosing early on in the process of clinical evaluation of new treatment strategies."( Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies.
Broft, A; Laruelle, M; Martinez, D, 2000
)
0.31
"A simple, once-weekly dosing regimen could be a convenient alternative for many patients during long-term treatment of depression."( The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.
Fava, M; Judge, R; Robinson, JM; Schmidt, ME, 2000
)
0.55
" Monitoring during long-term treatment for evidence of sustained remission is important regardless of dosing regimen."( The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.
Fava, M; Judge, R; Robinson, JM; Schmidt, ME, 2000
)
0.55
"Data from this large series of clinical trials confirm that fluoxetine is well tolerated in the acute treatment of MDD in adults, especially at a dosage of 20 mg/d, and is better tolerated than the recommended doses of TCAs."( Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis.
Beasley, CM; Gonzales, JS; Koke, SC; Nilsson, ME, 2000
)
0.78
" Reduction of the fluoxetine dosage to 10 mg twice weekly was associated with the attainment of euthymia in 18 days."( Treatment of bipolar depression with twice-weekly fluoxetine: management of antidepressant-induced mania.
Devitt, PJ; Megna, JL, 2001
)
0.9
" Plasma was collected over the 12-hour carvedilol dosing interval, and the concentrations of the R(+) and S(-) enantiomers of carvedilol were measured."( Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.
Adams, KF; Carson, SW; Cascio, WE; Graff, DW; Patterson, JH; Pieper, JA; Williamson, KM, 2001
)
0.71
" Dosing order was determined randomly and counterbalanced."( Subjective and discriminative stimulus effects of two de-nicotinized cigarettes with different tar yields.
Downey, KK; Schuh, KJ; Schuh, LM; Stamat, HM, 2001
)
0.31
" Fluoxetine dosing inhibited CYP2C19 activity in both age groups, increasing the (S)- to (R)-mephenytoin ratio 3- to 4-fold (p < ."( Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers.
Harvey, AT; Preskorn, SH, 2001
)
2.66
"4]) who received fluoxetine at a dosage of 20 mg per day; group B included 20 patients (14 women; mean age, 38."( Fluoxetine for migraine prophylaxis: a double-blind trial.
Alfano, V; d'Amato, CC; Giordano, E; Marmolo, T; Nasta, A; Pizza, V,
)
1.91
" Dosing was initiated at 10 mg daily for 2 weeks, then increased to 20 mg daily."( Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.
Geller, DA; Heiligenstein, JH; Hoog, SL; Jacobson, JG; Kluszynski, S; Ricardi, RK; Tamura, R, 2001
)
1.75
"80 SD, were treated with clomipramine at a mean dosage of 57."( A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics.
Cavagnini, F; Clemente, A; Ferrari, VM; Laini, V; Lugo, F; Mantero, M; Mauri, MC; Redaelli, G; Ruggiero, GM; Zappulli, D, 2001
)
0.57
" Seventeen patients with RBD according to DSM-IV and ICD-10 diagnostic criteria, who had no history of major depression were treated with a dosage of 20-40 mg fluoxetine daily."( Fluoxetine treatment in patients with recurrent brief depression.
Aschauer, HN; Blasbichier, T; Brandstätter, N; Kasper, S; Pezawas, L; Riederer, F; Stamenkovic, M, 2001
)
1.95
"2% 2-6 h after ip dosing in a fasting-induced feeding model in rats."( Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
Crooke, JJ; Kordik, CP; Lovenberg, TW; Luo, C; Reitz, AB; Rosenthal, DI; Vaidya, AH; Wilson, SJ; Zanoni, BC, 2001
)
0.31
" Because fluoxetine and its primary metabolite norfluoxetine have long half-lives and flat dose-response curves, we examined the tolerability of a weekly dose and its equivalence to daily dosing during the continuation phase of treatment for major depressive disorder (MDD)."( Exploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder.
Burke, WJ; McArthur-Miller, DA, 2001
)
0.98
" Study phase I was a baseline assessment of 20 mg of fluoxetine daily dosing for 4 weeks (N = 117)."( Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder.
de Klerk, E, 2001
)
0.82
" Compliance decreased over time when patients remained on daily dosing; however, when patients switched from daily dosing to weekly dosing, compliance did not decrease."( Patient compliance with enteric-coated weekly fluoxetine during continuation treatment of major depressive disorder.
de Klerk, E, 2001
)
0.57
"A new formulation of fluoxetine has been developed that is intended to allow for weekly dosing during the long-term treatment of depression."( Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder.
Dinan, TG, 2001
)
0.87
" We investigated patient perceptions of antidepressant dosing to determine whether weekly dosing could provide an additional tool to help more patients remain compliant with antidepressant treatment."( Patient perspectives on once-weekly fluoxetine.
Judge, R, 2001
)
0.59
" Patients in the telephone survey agreed most strongly with statements indicating that they considered once-weekly dosing more convenient than daily dosing, that they believed taking 1 pill a week would make them feel less dependent on pills, and that they perceived more advantages than disadvantages in taking 1 pill a week."( Patient perspectives on once-weekly fluoxetine.
Judge, R, 2001
)
0.59
" Positive patient perceptions of weekly dosing suggest that some patients may remain on continuation or maintenance therapy longer when they have the option of weekly dosing."( Patient perspectives on once-weekly fluoxetine.
Judge, R, 2001
)
0.59
" Peak breast milk concentrations occurred approximately 8 hours after maternal dosing and predicted norfluoxetine concentrations in infant serum."( Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk.
Altshuler, LL; Fukuchi, A; Hendrick, V; Hostetter, A; Hwang, S; Leight, K; Mintz, J; Stowe, ZN; Suri, R, 2001
)
1.97
" Our hypothesis was that subchronic intake should cause changes qualitatively different from the single dose and that such changes could be sufficiently long-lived to suggest the possibility of a dosing in intervals of several days."( Fluoxetine and sleep EEG: effects of a single dose, subchronic treatment, and discontinuation in healthy subjects.
Berger, M; Dittmann, R; Feige, B; Hohagen, F; Riemann, D; Voderholzer, U, 2002
)
1.76
" However, the time course for maximum inhibition to occur or for inhibition to dissipate when dosing is discontinued, requires clarification."( Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers.
Boulton, DW; DeVane, CL; Goldman, J; Liston, HL; Markowitz, JS; Risch, SC, 2002
)
0.55
" Fluoxetine increased the quetiapine area under the plasma concentration time curve during a 12-hour interval (+12%), maximum plasma concentration during the dosing interval (C(ss)(max); +26%), and minimum plasma concentration at the end of the dosing interval (+8%), although it decreased oral clearance (-11%)."( Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine.
Alva, G; Arvanitis, LA; Carreon, D; Kalali, A; Potkin, SG; Thyrum, PT; Yeh, C, 2002
)
1.63
" Given the long half-life of fluoxetine and the short duration of PMDD symptoms per cycle, larger, well-designed clinical trials evaluating intermittent dosing for only 1 week or a few doses need to be performed."( Fluoxetine in the treatment of premenstrual dysphoric disorder.
Carr, RR; Ensom, MH, 2002
)
2.05
" This raises the important question of whether once-weekly enteric-coated fluoxetine, 90 mg, is effective for maintenance of response in patients whose depressive symptoms have responded to daily dosing with selective serotonin reuptake inhibitors (SSRIs) such as citalopram, paroxetine, or sertraline."( Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
Brown, EB; Gonzales, JS; Miner, CM; Munir, R, 2002
)
0.77
"Because the symptoms of premenstrual dysphoric disorder (PMDD) are limited to the luteal phase of the menstrual cycle, the potential benefit of luteal-phase dosing has been hypothesized."( Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.
Brown, E; Gonzales, J; McCray, S; Miner, C; Wohlreich, M, 2002
)
0.57
"This is the first study to examine the antidepressant dose-response relationship to 5-HTT kinetics and genetics."( Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome.
Fei, YJ; Ganapathy, V; Hobby, HM; Johnson, ME; Leibach, FH; Li, JQ; Rausch, JL; Shendarkar, N, 2002
)
0.31
" Little is known about the age-related brain pharmacokinetics of SSRIs; there is a lack of data regarding optimal dosing of medications for children."( Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders.
Cowan, C; Dager, SR; Dawson, G; Strauss, WL; Unis, AS, 2002
)
0.54
" Fluoxetine 20 mg has been reported to be effective for emotional and physical premenstrual symptoms with continuous daily dosing (every day of the menstrual cycle) and with luteal phase daily dosing (from ovulation to menses)."( Review of fluoxetine and its clinical applications in premenstrual dysphoric disorder.
Pearlstein, T; Yonkers, KA, 2002
)
1.63
" We prospectively evaluated the likelihood of response to increasing the fluoxetine doses in patients relapsing during a long-term efficacy study of two fluoxetine dosing regimens."( Treatment approaches to major depressive disorder relapse. Part 1: dose increase.
Fava, M; Gonzales, J; Judge, R; Raute, NJ; Schmidt, ME; Zhang, S,
)
0.36
" We evaluated the likelihood of response to reinitiation of fluoxetine treatment in patients relapsing after switching to placebo during a long-term efficacy study of two different dosing regimens of fluoxetine."( Treatment approaches to major depressive disorder relapse. Part 2: reinitiation of antidepressant treatment.
Fava, M; Gonzales, J; Judge, R; Raute, NJ; Schmidt, ME; Zhang, S,
)
0.37
" Amitriptyline was dosed as follows: 8 mg/day for 6 days, 8 mg twice a day for 6 days, 20 mg/day for 6 days, and 20 mg twice a day for 45 days."( Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study.
Alves, LA; Barbosa, JS; Krymchantowski, AV; Silva, MT, 2002
)
0.57
"For paroxetine and fluoxetine, plasma concentrations and dosage strongly influence the magnitude of enzyme inhibition."( CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.
Alfaro, CL; Ereshefsky, L; Gaedigk, A; Lam, YW; Simpson, J, 2002
)
0.64
" In behavioral studies, EMD 68843 produced antidepressant-like effects in the forced swimming test in both rats and mice but only within a narrow dosage range."( Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist.
Cryan, JF; Dalvi, A; Lucki, I; Manning, DR; Page, ME; Saucy, B; Sullivan, A, 2002
)
0.31
"To evaluate premenstrual daily dosing with fluoxetine for treatment of premenstrual dysphoric disorder."( Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries.
Brown, EW; Cohen, LS; Freeman, E; Halbreich, U; McCray, S; Miner, C; Sundell, K, 2002
)
0.91
"Premenstrual daily dosing with fluoxetine effectively treats mood, physical, and social functioning symptoms associated with premenstrual dysphoric disorder."( Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries.
Brown, EW; Cohen, LS; Freeman, E; Halbreich, U; McCray, S; Miner, C; Sundell, K, 2002
)
0.93
"A simple, accurate and sensitive high pressure liquid chromatographic technique is described for the determination of fluoxetine in the capsule dosage form, human plasma and in biological fluid."( Liquid chromatographic determination of fluoxetine.
El-Barbary, FA; El-dawy, MA; Mabrouk, MM, 2002
)
0.79
" In the second experiment, in order to assess the effects of chronic dosing or handling on baseline UEEPM behaviour, subjects received either 21 days vehicle injection (p."( Further evidence for the predictive validity of the unstable elevated exposed plus-maze, a behavioural model of extreme anxiety in rats: differential effects of fluoxetine and chlordiazepoxide.
Duxon, MS; Jones, N; King, SM, 2002
)
0.51
" Dosing was fixed for the first 6 weeks (up to 60 mg/day) and then could be increased to 80 mg/day."( Fluoxetine in children and adolescents with OCD: a placebo-controlled trial.
Beidel, DC; Clarvit, SR; Davies, SO; Graae, F; Jaffer, M; Liebowitz, MR; Lin, SH; Piacentini, J; Sallee, FR; Schmidt, AB; Simpson, HB; Turner, SM, 2002
)
1.76
" A comparison of citalopram and fluoxetine pharmacokinetics in the same animal and at the same dosage (1 mg/kg) showed that citalopram SERT occupancy and plasma half-lives were 9 times and 14 times shorter, respectively, than those of fluoxetine and norfluoxetine."( [11C]-DASB, a tool for in vivo measurement of SSRI-induced occupancy of the serotonin transporter: PET characterization and evaluation in cats.
Ginovart, N; Houle, S; Hussey, D; Meyer, JH; Wilson, AA, 2003
)
0.6
"At an average dosage of 35."( [A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson's disease].
Serrano-Dueñas, M,
)
0.13
" The presented patient had a second episode of OCD which was resistant to more than 10 weeks of high dosage clomipramine even though he responded very well during the first episode 4 years earlier and had been off clomipramine for 3 years."( Clomipramine-resistant, fluoxetine-responsive obsessive compulsive disorder: a case report.
Paholpak, S, 2002
)
0.62
" Experiment 2 was a dose-response study using three doses of 8-OH-DPAT (0."( Effects of acute treatment with 8-OH-DPAT and fluoxetine on aggressive behaviour in male song sparrows (Melospiza melodia morphna).
Sperry, TS; Thompson, CK; Wingfield, JC, 2003
)
0.58
" Therefore, a careful dosing strategy starting with a low dose might be effective for avoiding emesis associated with the clinical use of fluvoxamine."( Possible involvement of peripheral serotonin 5-HT3 receptors in fluvoxamine-induced emesis in Suncus murinus.
Baba, J; Fujiwara-Sawada, M; Imanishi, T; Yoshida, A, 2003
)
0.32
"33 kg/m(2), were treated with nutritional management and FLX at a mean dosage of 30."( Nutritional management of anorexic patients with and without fluoxetine: 1-year follow-up.
Cavagnini, F; Dipasquale, S; Malvini, L; Mauri, MC; Omboni, AC; Pasqualinotto, L; Redaelli, G; Ruggiero, GM; Volonteri, LS, 2003
)
0.56
" Patients were treated with fluoxetine or placebo for three cycles, with the use of several different dosing regimens, followed by single blind placebo treatment for one cycle."( Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment.
Brown, EB; Joliat, MJ; Miner, CM; Pearlstein, T, 2003
)
0.83
" The heterocyclic agent trazodone significantly inhibited paw oedema by 46 and 41% at 1 and 2h after dosing at the highest dose (40 mg kg(-1)) examined."( Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat.
Abdel-Salam, OM; El-Shenawy, SM; Nofal, SM, 2003
)
0.32
"A self-control and follow-up study on subclinical dosage of antidepressants therapy (fluoxetine 10 mg/d, paroxetine 10 mg/d or doxepin 45 mg/d) for 9-12 wks in 46 patients with refractory IBS symptoms according to Rome II criteria was performed, the clinical outcomes were evaluated by scales changes of symptom-related-anxiety, severity index of symptom, and quality of life specific of IBS, as well as general psychiatric health by SCL-90 during treatment and follow-up periods."( [Treatment of refractory irritable bowel syndrome with subclinical dosage of antidepressants].
Pan, GZ; Qian, JM; Wang, WA, 2003
)
0.54
"Treatment of refractory IBS with subclinical dosage antidepressant is rational and effective, However a further study on its mechanisms is suggested."( [Treatment of refractory irritable bowel syndrome with subclinical dosage of antidepressants].
Pan, GZ; Qian, JM; Wang, WA, 2003
)
0.32
" Fluoxetine in a formulation of pluronic lecithin organogel (PLO gel) was applied to the hairless portion of the pinnae of cats at 2 dosages (5 or 10 mg/kg), or it was administered orally in capsules at a dosage of 1 mg/kg."( Comparative bioavailability of fluoxetine after transdermal and oral administration to healthy cats.
Ciribassi, J; Kaloostian-Whittymore, L; Luescher, A; Pasloske, KS; Robertson-Plouch, C; Zimmerman, A, 2003
)
1.52
"It is proposed that either every third day or daily dosing with the same dose of fluoxetine could treat the patients with major depressive disorder during the acute and continuation period of treatment."( Fluoxetine once every third day in the treatment of major depressive disorder.
Onder, E; Tural, U, 2003
)
1.99
" The patient developed severe restlessness and de novo suicidal ideation approximately 1 week after the dosage of fluoxetine was doubled, 1 year on from when the drug was first introduced."( Fluoxetine dose-increment related akathisia in depression: implications for clinical care, recognition and management of selective serotonin reuptake inhibitor-induced akathisia.
Hansen, L, 2003
)
1.97
" At a sub-effective dose, pargyline could cause a leftward shift in the dose-response curve of 5-HTP-induced antinociception."( L-type calcium channel blockers enhance 5-HTP-induced antinociception in mice.
Chen, B; Han, R; Li, JX; Liang, JH; Lu, Y; Wang, XH; Ye, XF; Zhang, P, 2004
)
0.32
"Intention-to-treat analysis revealed that fluoxetine (mean dosage 48 mg/day) was not superior to placebo except for a clinically minimal but statistically significantly greater improvement in CGI-I score in the fluoxetine group prior to covarying for anxiety and depression (2."( Fluoxetine therapy in depersonalisation disorder: randomised controlled trial.
Guralnik, O; Knutelska, M; Schmeidler, J; Simeon, D, 2004
)
2.03
" Experiment 2 was a dose-response study of the influence of fluoxetine (0."( Chronic fluoxetine suppresses circulating estrogen and the enhanced spatial learning of estrogen-treated ovariectomized rats.
Farr, S; Klinga, K; Taylor, GT; Weiss, J, 2004
)
1
" Multiple SSRI dosing ranges were evaluated in autistic patients of different ages with various functional impairments."( Treating functional impairment of autism with selective serotonin-reuptake inhibitors.
Eichner, SF; Jones, JR; Moore, ML, 2004
)
0.32
"We have previously reported that repeated dosing with the selective serotonin reuptake inhibitor (SSRI) citalopram decreases striatal [11C]raclopride binding in healthy volunteers."( Effects of fluoxetine on dopamine D2 receptors in the human brain: a positron emission tomography study with [11C]raclopride.
Aalto, S; Hietala, J; Hirvonen, J; Ilonen, T; Kajander, J; Någren, K; Penttilä, J; Syvälahti, E, 2004
)
0.71
"Initial experiments measured the half-life of fluoxetine and dosing required to achieve human therapeutic blood levels in the guinea pig."( Long-term effects of fluoxetine or vehicle administration during pregnancy on behavioral outcomes in guinea pig offspring.
Baker, GB; Boksa, P; Malik, S; Vartazarmian, R, 2005
)
0.91
" Dose-response curves for the inhibitory effect of clonidine showed subsensitivity of alpha2-adrenergic autoreceptors in protein-deprived rats, a phenomenon reversed by fluoxetine treatment."( Locus coeruleus activity in perinatally protein-deprived rats: effects of fluoxetine administration.
Cuadra, GR; Orsingher, OA; Ramírez, OA; Sodero, AO; Valdomero, A, 2004
)
0.75
"5 mg/kg dosing paradigm suggesting differences in tolerability rates as a function of olanzapine dose."( Weight loss dynamics during combined fluoxetine and olanzapine treatment.
Chabla, JM; Hallas, BH; Horowitz, JM; Perrone, JA; Torres, G, 2004
)
0.6
" Fluoxetine applied in 5 mg/kg dosage causes increased pain reaction 60 and 90 minutes (p=0."( Testing of analgesic effect of fluoxetine.
Becić, F; Begović, A; Zulić, I, 2004
)
1.52
" This study examined international dosage differences in antidepressant clinical trials, using a database formed and maintained as a component of a Cochrane review of comparative clinical trials of fluoxetine."( International dosage differences in fluoxetine clinical trials.
Barbui, C; Brambilla, P; Cipriani, A; Nosè, M; Patten, S, 2005
)
0.79
" To evaluate the dosages of comparison medications, a defined daily dosage (DDD) ratio was calculated as the trial mean dosage divided by the DDD for that drug."( International dosage differences in fluoxetine clinical trials.
Barbui, C; Brambilla, P; Cipriani, A; Nosè, M; Patten, S, 2005
)
0.6
"Both the maximum and mean dosages for fluoxetine and comparison medications were higher in trials conducted in the US (fluoxetine weighted mean dosage 49."( International dosage differences in fluoxetine clinical trials.
Barbui, C; Brambilla, P; Cipriani, A; Nosè, M; Patten, S, 2005
)
0.87
"Three simple and sensitive spectrophotometric methods were developed and validated for determination of the hydrochloride salts of fluoxetine, sertraline, and paroxetine in their pharmaceutical dosage forms."( Development and validation of spectrophotometric methods for determination of fluoxetine, sertraline, and paroxetine in pharmaceutical dosage forms.
Darwish, IA,
)
0.56
" In all, 13 healthy volunteers received study drug for 5 weeks using a dosing schedule designed to achieve steady state for 20 mg/day racemic fluoxetine, 80 mg/day R-fluoxetine, or 120 mg/day R-fluoxetine."( A comparison of brain and serum pharmacokinetics of R-fluoxetine and racemic fluoxetine: A 19-F MRS study.
Butman, ML; Cohen, B; Hennen, J; Henry, ME; Kerner, LT; Renshaw, PF; Schmidt, ME; Tran, P; Villafuerte, RA, 2005
)
0.78
" Blood phenytoin levels were taken after 1 week, 3 weeks, and 6 weeks, and dosage was adjusted to achieve blood levels of 10 to 20 microg/mL, to a maximum dose of 4 capsules per day or a minimum dose of 2 capsules per day."( Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder.
Belmaker, RH; Bersudsky, Y; Nemets, B, 2005
)
0.59
" Interestingly, the same dosage regimen significantly increased the social interaction time in rats, suggesting an additional potential anxiolytic activity."( Preclinical pharmacology of F-98214-TA, a novel potent serotonin and norepinephrine uptake inhibitor with antidepressant and anxiolytic properties.
Artaiz, I; Castro, E; Del Olmo, E; Díaz, A; Innerárity, A; Labeaga, L; Orjales, A; Pazos, A; Pena, R; Ruiz-Ortega, JA; Zazpe, A, 2005
)
0.33
" Following recovery, the animals were orally dosed at light onset with either desipramine (20 mg/kg), fluoxetine (10 mg/kg), citalopram (10 or 40 mg/kg) or vehicle in a cross-over design."( Antidepressants and REM sleep in Wistar-Kyoto and Sprague-Dawley rats.
Hutson, PH; Ivarsson, M; Paterson, LM, 2005
)
0.54
" Although the dosage of Fluoxetine used in these trials was lower than earlier published, it should be noted that these positive results were achieved without any relevant side effects."( Hot-flashes in breast cancer survivors: effectiveness of low-dosage fluoxetine. A pilot study.
Atlante, M; Barbati, A; Galati, M; Giannarelli, D; Mariani, L; Quattrini, M, 2005
)
0.87
" Binary mixtures of a drug, acetylsalicylic acid, or fluoxetine hydrochloride, and of excipients commonly used in solid dosage forms were prepared at a ratio of approximately 1:100 in 96-well microtiter plates."( Drug-excipient compatibility testing using a high-throughput approach and statistical design.
Alsenz, J; Birringer, C; Kuentz, M; Wyttenbach, N, 2005
)
0.58
" Antidepressant medication costs, however, are significantly higher when fluoxetine is the initial SSRI rather than sertraline or paroxetine, reflecting the larger proportion of fluoxetine patients prescribed a daily dosage of two or more capsules."( Comparing SSRI treatment costs for depression using retrospective claims data: the role of nonrandom selection and skewed data.
Berndt, ER; Colucci, SV; Grudzinski, AN; Miceli, R; Russell, JM; Xu, Y,
)
0.36
"The aim of this study was to compare fluoxetine dosage titration to 40-60 mg/day with fixed fluoxetine 20-mg/day treatment for an additional 10 weeks in pediatric outpatients with major depressive disorder (MDD) who had not met protocol-defined response criteria after 9-week acute fluoxetine treatment."( Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study.
Brown, EB; Busner, J; Findling, RL; Galil, N; Heiligenstein, JH; Hoog, SL; Jacobson, JG; Kaplan, S; Nilsson, ME; Wagner, KD,
)
1.85
"More than two thirds of patients whose dosage was increased responded within 10 weeks, suggesting dose escalation may benefit some patients."( Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study.
Brown, EB; Busner, J; Findling, RL; Galil, N; Heiligenstein, JH; Hoog, SL; Jacobson, JG; Kaplan, S; Nilsson, ME; Wagner, KD,
)
1.57
"3% at a dosage of 100 mg/kg administrated orally once daily for 5 days, respectively."( Saponins from Polygala japonica and their effects on a forced swimming test in mice.
Chen, HS; Li, TZ; Liu, WY; Shen, YH; Yang, GJ; Zhang, WD, 2006
)
0.33
" Serum samples, obtained before dosing and at various appropriate time points up to 192 hours, were analyzed for fluoxetine and norfluoxetine content by a simple, accurate and precise HPLC method."( Bioequivalence testing of a new tablet formulation of generic fluoxetine.
Dordević, S; Jovanović, D; Jovanović, M; Jovic-Stosić, J; Kilibarda, V; Knezević, T; Srdić, D,
)
0.58
" Section headings with the least conformity with study references were those related to dosage (57 +/- 28%) and side effects (54 +/- 30%)."( Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia.
Al Haidari, K; Gebran, N,
)
0.13
" Compound 6a was found to give a dose-response similar to the SSRI fluoxetine in microdialysis studies in rats."( Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors.
Beno, BR; Cipollina, JA; Deskus, JA; Dextraze, P; Epperson, JR; Gao, Q; Krause, RG; Lodge, NJ; Ma, B; Mattson, GK; Mattson, RJ; Molski, TF; Qian-Cutrone, J; Sloan, CP; Taber, MT, 2007
)
0.58
" Depending on the intended indication and dosing regimen, PPL can delay or stop development of a compound in the drug discovery process."( Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential.
Gehlhaar, D; Greene, N; Johnson, TO; Pelletier, DJ; Tilloy-Ellul, A,
)
0.13
" A secondary analysis of dose-response relationships indicated that this advantage was not attributable to the studies using higher doses of duloxetine."( Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
Detke, MJ; Ossanna, MJ; Pritchett, YL; Swindle, RW; Thase, ME; Xu, J, 2007
)
0.34
" Overall, the dose-response and time-of-recovery relationships for altered NET expression matched those for production of antidepressant-like effects on behavior."( Norepinephrine transporter regulation mediates the long-term behavioral effects of the antidepressant desipramine.
Baros, AM; Bondi, CO; Lapiz, MD; Morilak, DA; O'Donnell, JM; Zhang, HT; Zhao, Z, 2008
)
0.35
"Selective serotonin reuptake inhibitors were found to be effective in treating premenstrual symptoms, with continuous dosing regimens favored for effectiveness."( Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis.
Aperi, J; Borenstein, J; Jones, JB; Karne, A; Shah, NR; Shemtov, R, 2008
)
0.35
" In contrast to the chronic treatment, an acute application of fluoxetine in slices induces a leftward shift in the dose-response curve of the 5-HT-induced potentiation."( Chronic fluoxetine bidirectionally modulates potentiating effects of serotonin on the hippocampal mossy fiber synaptic transmission.
Haneda, E; Ikeda, Y; Kobayashi, K; Suzuki, H, 2008
)
1.02
" The selectivity, efficacy, side effects and simplicity of dosage contributed to fluoxetine's clinical acceptance."( Neurofunctional effects in rats prenatally exposed to fluoxetine.
Ambrosi, G; Auteri, P; Benagiano, V; Bera, I; Cagiano, R; Cioca, G; Flace, P; Maries, L; Marzullo, A; Sabatini, R; Stefanelli, R; Vermesan, D,
)
0.61
" Quetiapine was flexibly dosed starting at 25 mg to a maximum of 100 mg daily."( A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
Fava, M; Garakani, A; Hirschowitz, J; Marcus, S; Martinez, JM; Rickels, K; Weaver, J, 2008
)
0.57
" dosing with either fluoxetine or imipramine."( Differential sensitivity to SSRI and tricyclic antidepressants in juvenile and adult mice of three strains.
Baker, KB; Davis, KW; Gerhardt, B; Lanthorn, TH; Malbari, MM; Mason, SS; Pogorelov, VM; Ritter, R; Savelieva, KV; Wray, SP, 2009
)
0.68
"The present study compared multiple BrdU dosing and loading protocols to determine a dosing strategy that produced the best signal to noise ratio."( Flow cytometric analysis of BrdU incorporation as a high-throughput method for measuring adult neurogenesis in the mouse.
Balu, DT; Bender, CN; Dwyer, JM; Hill, TE; Ho, N; Hodes, GE; Hughes, ZA; Lucki, I; Rahman, Z; Ring, RH; Rosenzweig-Lipson, S; Schechter, LE,
)
0.13
"0 mg/kg) was coadministered with saline or different cocaine doses, we observed similar upward shifts in dose-response in both phenotypes."( Reduced sensitivity to the locomotor-stimulant effects of cocaine is associated with increased sensitivity to its discriminative stimulus properties.
Gulley, JM; Klein, DA, 2009
)
0.35
" The products formed in marketed tablet dosage forms are similar to those formed in standard drug solutions under similar stress conditions."( Development of a stability-indicating HPLC method for simultaneous determination of olanzapine and fluoxetine in combined dosage forms.
Pathak, A; Rajput, SJ, 2009
)
0.57
"0 mg/kg) attenuated the priming effects of cocaine, shifting the cocaine dose-response function rightward and downward."( Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys: kappa opioid and serotonergic mechanisms.
Platt, DM; Rowlett, JK; Rüedi-Bettschen, D; Spealman, RD, 2010
)
0.36
" However, the aqueous-ethanolic fraction induced a biphasic dose-response profile since it produced a graded effect up to 200 mg/kg but the highest dose (250 mg/kg) was inactive in the FST."( Terpenoid content of Valeriana wallichii extracts and antidepressant-like response profiles.
Gilani, AH; Karim, N; Sewell, RD; Subhan, F, 2010
)
0.36
" If the patient is currently taking other mood stabilizers, their dosage should be optimized, and the clinician should consider adding or switching to lithium, quetiapine, or lamotrigine."( The psychopharmacology algorithm project at the Harvard South Shore Program: an update on bipolar depression.
Ansari, A; Osser, DN,
)
0.13
"It is important that variations in drug metabolism during pregnancy be considered as these changes may necessitate a dosage adjustment to ensure that therapeutic failure does not occur during pregnancy."( Changes in antidepressant metabolism in pregnancy evidenced by metabolic ratios in hair: a novel approach.
Baumer, C; Koren, G; O'Brien, L; Sachs, H; Thieme, D, 2010
)
0.36
" Therefore, rat urine taken after dosing with fluoxetine was screened in the same way."( Gas chromatography-mass spectrometry detection of a norfluoxetine artifact in hydrolyzed urine samples may falsely indicate tranylcypromine ingestion.
Maurer, HH; Meyer, MR; Schwaninger, AE,
)
0.64
" Blood samples were collected for at least 672 h after fluoxetine dosing and the plasma was analyzed using validated tandem liquid chromatography mass spectrometric assay to determine fluoxetine and norfluoxetine levels."( Unsuspected poor metabolizer phenotypes of fluoxetine in bioavailability/bioequivalence studies from an indian population perspective. Retrospective pharmacokinetic data evaluation.
Kamath, N; Kandasamy, M; Kristjansson, F; Pai, B; Ravi, S; Srinivas, NR; Thangam, S; Tripathy, K, 2010
)
0.87
" WAY100635 attenuated the effect of fluoxetine; prior treatment with fluoxetine decreased 8-OH-DPAT's potency in reducing lordosis behavior; and progesterone shifted fluoxetine's dose-response curve to the right."( Role of 5-HT(1A) receptors in fluoxetine-induced lordosis inhibition.
Guptarak, J; Hiegel, C; Sarkar, J; Uphouse, L, 2010
)
0.92
" In autoshaping task a dose-response curve for METH was determined."( Autoradiographic study of serotonin transporter during memory formation.
Castillo, C; Meneses, A; Rocha, L; Tellez, R, 2010
)
0.36
" Five hundred and ten major depressive disorder patients received 12 weeks of fluoxetine with flexible dosing [target dosages: 10 mg/day (week 1), 20 mg/day (weeks 2-4), 40 mg/day (weeks 4-8), and 60 mg/day (weeks 5-12)]."( Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome.
Alpert, J; Baer, L; Bitran, S; Chuzi, S; Clain, AJ; Dording, C; Farabaugh, AH; Fava, M; McGrath, PJ; Mischoulon, D; Papakostas, GI; Witte, J, 2010
)
0.59
" These data may inform treatment decisions related to dosing in patients who receive fluoxetine during pregnancy."( Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing.
Helsel, JC; Luther, JF; Perel, JM; Sit, D; Wisner, KL; Wisniewski, SR, 2010
)
0.86
" The mother was under treatment with Fluoxetine 20 mg/day prior to conception and maintained the same dosage throughout her pregnancy."( Goldenhar syndrome associated with prenatal maternal Fluoxetine ingestion: Cause or coincidence?
Awwad, J; Farra, C; Majdalani, M; Mikati, M; Yazbeck, N; Yunis, K, 2010
)
0.88
" Acute amphetamine treatment in wild-type mice produced a biphasic dose-response modulation of LTP, with a low dose enhancing LTP and a high dose impairing it."( Amphetamine modulation of long-term potentiation in the prefrontal cortex: dose dependency, monoaminergic contributions, and paradoxical rescue in hyperdopaminergic mutant.
Ma, Q; Spealman, RD; Xu, TX; Yao, WD, 2010
)
0.36
" Dosing of fluoxetine/placebo was double blind."( A randomized controlled trial of fluoxetine in the treatment of cocaine dependence among methadone-maintained patients.
Bigelow, GE; Johnson, RE; Silverman, K; Strain, EC; Winstanley, EL, 2011
)
1.04
" Patients of the group 1 received naltrexone (N) in dosage 50 mg/day and fluoxetine (F) in dosage 20 mg/day during 6 months."( [Naltrexone and fluoxetine for maintenance of remission in patients with heroin addiction: a double-blind randomized placebo-controlled trial].
Bespalov, AIu; Burakov, AM; Didenko, TIu; Egorova, VIu; Grineneko, AIa; Ivanova, EB; Krupitskiĭ, EM; Masalov, DV; Neznanov, NG; O'Brien, C; Romanova, TN; Tsoĭ-Podosenin, MV; Verbitskaia, EV; Woody, D; Zvartau, EE, 2010
)
0.94
" Patients on higher dosage of antidepressant have higher risk of having FSD."( Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine.
Asmidar, D; Guan, NC; Hod, R; Sidi, H, 2012
)
0.59
"05-10 μg/mouse) produced antidepressant-like effect dose-dependently, whereas influenced the MBB in a biphasic manner (produced a U-shaped dose-response curve)."( Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice.
Jain, NS; Manna, SS; Umathe, SN, 2011
)
0.6
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" Dam dosing was adjusted to reflect the 50th and 85th percentiles of serum concentrations observed in pregnant women."( Serotonin transporter occupancy in rats exposed to serotonin reuptake inhibitors in utero or via breast milk.
Bourke, CH; Capello, CF; Nemeroff, A; Newport, DJ; Owens, MJ; Ritchie, JC; Stowe, ZN, 2011
)
0.37
"Although selective serotonin reuptake inhibitors (SSRI) are generally effective in reducing impulsive aggression in individuals with intermittent explosive disorder, a large proportion of intermittent explosive disorder patients fail to achieve full remission despite adequate dosage and duration of treatment."( Personality predictors of antiaggressive response to fluoxetine: inverse association with neuroticism and harm avoidance.
Coccaro, EF; Lee, R; Phan, KL, 2011
)
0.62
" 10b was additionally bioavailable following oral dosing and demonstrated efficacy in rat models of acute, inflammatory, and neuropathic pain."( Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152).
Adedoyin, A; Bray, JA; Deecher, DC; Fensome, A; Goldberg, JA; Harrison, J; Leventhal, L; Mann, C; Mark, L; Nogle, L; O'Neill, DJ; Spangler, TB; Sullivan, NR; Terefenko, EA; Trybulski, EJ; Uveges, AJ; Vu, A; Whiteside, GT; Zhang, P, 2011
)
0.37
" High inter-individual variability in serum concentrations of the active moiety of FLX at each dosage level was observed and no relationship between serum concentration and clinical outcome was found."( Therapeutic drug monitoring of children and adolescents treated with fluoxetine.
Burger, R; Egberts, K; Fegert, JM; Gerlach, M; Kliegl, K; Koelch, M; Ludolph, AG; Mehler-Wex, C; Pfalzer, AK; Rothenhöfer, S; Stingl, J; Taurines, R, 2012
)
0.61
" Moderate to high antidepressant dosage is another significant predictor of HSD in depressed women treated with SSRIs."( Hypoactive sexual desire among depressed female patients treated with selective serotonin reuptake inhibitors: a comparison between escitalopram and fluoxetine.
Asmidar, D; Guan, NC; Hod, R; Jaafar, NR; Sidi, H, 2012
)
0.58
" After rats were injected subcutaneously with nisoxetine, dose-response curves were constructed."( Nisoxetine produces local but not systemic analgesia against cutaneous nociceptive stimuli in the rat.
Chen, YC; Chen, YW; Chu, CC; Hung, CH; Shao, DZ; Wang, JJ, 2012
)
0.38
" Dosage followed a fixed schedule, starting at 10 mg/day and increasing as tolerated up to 80 mg/day."( A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders.
Anagnostou, E; Chaplin, W; Ferretti, CJ; Hollander, E; Settipani, C; Soorya, L; Swanson, E; Taylor, BP; Wasserman, S, 2012
)
0.64
"0 mg/kg) or saline according to a sub-acute dosing schedule."( Sex-specific antidepressant effects of dietary creatine with and without sub-acute fluoxetine in rats.
Allen, PJ; D'Anci, KE; Kanarek, RB; Renshaw, PF, 2012
)
0.6
" Rhesus macaques self-administering cocaine underwent a 6-week dosing regimen with fluoxetine designed to approximate serum concentrations observed in humans."( Neurobiological changes mediating the effects of chronic fluoxetine on cocaine use.
Goodman, MM; Howell, LL; Kimmel, HL; Mun, J; Nye, JA; Rice, KC; Sawyer, EK; Stehouwer, JS; Voll, RJ, 2012
)
0.85
" This dosage also decreased pERK1/2 levels and inhibited proliferation of pulmonary arterial smooth muscle cells in MCT-treated rats."( Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor.
Han, DD; Liu, JR; Wang, HL; Wang, Y; Zhang, XH, 2012
)
1.82
" The purpose of this study was to investigate whether Flx presents neuroprotective effect against 3-nitropropionic acid (3-NP)-induced hypoxic brain injury, and what is the most suitable dosage of Flx."( Optimal dosages of fluoxetine in the treatment of hypoxic brain injury induced by 3-nitropropionic acid: implications for the adjunctive treatment of patients after acute ischemic stroke.
Sun, Y; Sun, ZQ; Yang, G; Zhou, CH; Zhu, BG; Zhu, RS, 2012
)
0.71
"Five children with SM (one boy and four girls aged 6-11 years) participated in the 14-week 'Meeky Mouse' programme, in addition to being prescribed with an unchanged dosage of fluoxetine 10-20 mg daily."( Application of a web-based cognitive-behavioural therapy programme for the treatment of selective mutism in Singapore: a case series study.
Fung, DS; Koh, JB; Ooi, YP; Raja, M; Sung, SC, 2012
)
0.57
" The drugs were spinally administered alone as well as in combination, and their potencies were compared via dose-response curves and isobolographic analysis."( Isobolographic analysis of interaction between nisoxetine- and mepivacaine-induced spinal blockades in rats.
Chen, YW; Chu, CC; Hung, CH; Kuo, CS; Leung, YM; Wang, JJ, 2014
)
0.4
"CD-1 mice were dosed with Bacille Calmette-Guérin (BCG) and measures of body weight, locomotor activity, and immobility in the tail suspension test (TST) were made."( A depressive phenotype induced by Bacille Calmette Guérin in 'susceptible' animals: sensitivity to antidepressants.
Clark, JA; Klee, N; Nizami, M; Platt, B; Schulenberg, J, 2013
)
0.39
"OFC trades simplicity of administration for loss of flexibility of dosing and lack of a generic preparation, both of which are available for olanzapine and fluoxetine separately."( Pharmacokinetic evaluation of olanzapine + fluoxetine for the treatment of bipolar depression.
Dubovsky, SL, 2013
)
0.85
" We undertook parallel studies in endothelial cells derived from brain microvessels to determine the dose-response and time-course of effects."( Effects of sertraline and fluoxetine on p-glycoprotein at barrier sites: in vivo and in vitro approaches.
Gibb, W; Ho, HL; Iqbal, M; Kapoor, A; Matthews, SG; Petropoulos, S, 2013
)
0.69
"Though encouraging evidence exists for the use of folic acid as an augmenting agent to antidepressants, evidence regarding its optimal dosage is lacking."( A randomized double-blind comparison of fluoxetine augmentation by high and low dosage folic acid in patients with depressive episodes.
Kumar, CN; Pandey, RS; Venkatasubramanian, R, 2013
)
0.66
"Vanillin at the dosage of 100 mg/kg has demonstrated antidepressant activity in mice, which is comparable with fluoxetine."( Evaluation of antidepressant activity of vanillin in mice.
Chowta, M; Pallempati, G; Rai, A; Shoeb, A; Singh, A,
)
0.34
" Acute and repeated dosing of vortioxetine produced more pronounced anxiolytic- and antidepressant-like activities than fluoxetine."( Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice.
David, DJ; Ebert, B; Gardier, AM; Guiard, BP; Guilloux, JP; Hen, R; Mendez-David, I; Miller, S; Orvoën, S; Pehrson, A; Repérant, C; Sanchez, C, 2013
)
0.6
" In in vivo studies, after rats were intrathecally injected with nisoxetine and mepivacaine, the dose-response curves were constructed."( Nisoxetine blocks sodium currents and elicits spinal anesthesia in rats.
Chen, YW; Chu, CC; Kuo, CS; Leung, YM; Wang, JJ, 2013
)
0.39
" Participants were assigned to receive 3 weeks of oral dosing with placebo or fluoxetine, 40 mg per day."( Central 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: a [11C]SB207145 PET study.
Baaré, WF; Fisher, PM; Frokjaer, VG; Haahr, ME; Jensen, CG; Knudsen, GM; Lehel, S; Madsen, K; Mahon, BM; Norremolle, A; Rabiner, EA, 2014
)
0.63
"5-year-old rhesus monkeys, n = 6) received single administration of doses of 1, 2, and 4 mg/kg day fluoxetine on a background of chronic dosing at an intermediate level to provide steady-state conditions to model therapeutic administration."( Fluoxetine: juvenile pharmacokinetics in a nonhuman primate model.
Golub, MS; Hogrefe, CE, 2014
)
2.06
" A dosage of 2 mg/kg day given over a 14-week period led to steady-state serum concentrations of active agent (fluoxetine + norfluoxetine) similar to those recorded from drug monitoring studies in children."( Fluoxetine: juvenile pharmacokinetics in a nonhuman primate model.
Golub, MS; Hogrefe, CE, 2014
)
2.06
" Dose-response curves of racemic fluoxetine (IC50 = 39 μM) and its optical isomers had a similar IC50 [40 and 47 μM for the (+) and (-) isomers, respectively]."( Fluoxetine blocks Nav1.5 channels via a mechanism similar to that of class 1 antiarrhythmics.
Beaulieu, JM; Bruhova, I; Chahine, M; Frassati, D; Poulin, H; Theriault, O; Timour, Q, 2014
)
2.13
" The novel 5-HT7R antagonist 1-8 exhibited an antidepressant effect at a dose of 25mg/kg in the forced swimming test in mice and showed a U-shaped dose-response curve which typically appears in 5-HT7R antagonists such as SB-269970 and lurasidone."( Novel N-biphenyl-2-ylmethyl 2-methoxyphenylpiperazinylalkanamides as 5-HT7R antagonists for the treatment of depression.
Cho, H; Choo, H; Choo, IH; Keum, G; Kim, Y; Lee, K; Park, WK; Rhim, H; Tae, J, 2014
)
0.4
" This is a novel site of action for fluoxetine, with implications for the development of new agents and/or dosing regimens to raise brain allopregnanolone."( Fluoxetine elevates allopregnanolone in female rat brain but inhibits a steroid microsomal dehydrogenase rather than activating an aldo-keto reductase.
Cockcroft, S; Devall, AJ; Fry, JP; Honour, JW; Li, KY; Lovick, TA, 2014
)
2.12
"Withdrawal from long-term dosing with exogenous progesterone precipitates increased anxiety-linked changes in behavior in animal models due to the abrupt decrease in brain concentration of allopregnanolone (ALLO), a neuroactive metabolite of progesterone."( Elevation of brain allopregnanolone rather than 5-HT release by short term, low dose fluoxetine treatment prevents the estrous cycle-linked increase in stress sensitivity in female rats.
Brandão, ML; Devall, AJ; Fry, JP; Honour, JW; Lovick, TA; Santos, JM, 2015
)
0.64
"A single injected dose of the antidepressant fluoxetine had no significant effect on animals' activity in the open-arm test, neither in a small dosage (5 mg/kgbw) nor in a higher one (10 mg/kgbw), whereas a single high dose of buspirone significantly impeded the open-arm activity of the rats."( Dose dependent effects of serotonergic agents on anxiety.
Dogaru, MT; Gáll, Z; Kolcsar, M, 2014
)
0.66
" Our results also are applicable to determining appropriate dosing of nonhuman primates in clinical settings."( Pharmacokinetics of fluoxetine in pregnant baboons (Papio spp.).
Garland, M; Shoulson, RL; Stark, RL, 2014
)
0.73
" It is a major determinant of half-life and dosing frequency of a drug."( Volume of Distribution in Drug Design.
Beaumont, K; Di, L; Maurer, TS; Smith, DA, 2015
)
0.42
" We calculated the ratio of the mean doses for each study and weighted it by the total sample size to find the weighted mean ratio for each drug, which was then used to define the drug׳s dosage equivalent to fluoxetine 40mg/d."( Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015
)
0.6
" In the primary analysis, fluoxetine 40mg/day was equivalent to paroxetine dosage of 34."( Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015
)
0.72
" On the basis of these data, novel dosing strategies were developed for five antidepressants to mimic the pharmacological profile of the antidepressant with the longest half-life, fluoxetine."( The role of 5-HT1A receptors in mediating acute negative effects of antidepressants: implications in pediatric depression.
Cao, YJ; Hendrix, CW; Kaplin, AI; Rahn, KA, 2015
)
0.61
" Moreover, 20 mg/kg fluoxetine, administered subchronically, may lead to atypical effects of those commonly observed in the FST, highlighting the importance and impact of both environmental condition and dosing regimen in common animal models of depression."( Differential Rearing Alters Forced Swim Test Behavior, Fluoxetine Efficacy, and Post-Test Weight Gain in Male Rats.
Arndt, DL; Cain, ME; Peterson, CJ, 2015
)
0.99
"In this report, five compounds were dosed orally into rats."( Utility of capillary microsampling for rat pharmacokinetic studies: Comparison of tail-vein bleed to jugular vein cannula sampling.
Guo, Y; Ho, S; Korfmacher, W; Luo, Y; O'Shea, T; Shen, L; Snow, G; Sun, W; Wang, J; Wu, Z,
)
0.13
" DMI and fluoxetine produced an antidepressant-like effect in YA and MA animals, although in the latter group, a shift to the right in the dose-response curve was found for DMI."( Age-related changes in the antidepressant-like effect of desipramine and fluoxetine in the rat forced-swim test.
Fernández-Guasti, A; Martínez-Mota, L; Olivares-Nazario, M, 2016
)
1.08
" In conclusion, the results show that fluoxetine exposure alters behavior beyond the level of overall response and highlights the importance of studying the behavioral effects of inadvertent pharmaceutical exposure in multiple contexts and with different dosing regimes."( Fluoxetine exposure impacts boldness in female Siamese fighting fish, Betta splendens.
Campbell, BA; Dzieweczynski, TL; Kane, JL; Lavin, LE, 2016
)
2.15
" The present study was designed to clarify the relationship between dosage and treatment response in major depressive disorder."( Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.
Bloch, MH; Freemantle, N; Jakubovski, E; Taylor, MJ; Varigonda, AL, 2016
)
0.43
" Endpoint and tolerability analyses were analyzed using meta-regression and stratified subgroup analysis by predefined SSRI dose categories in order to assess the effect of SSRI dosing on the efficacy and tolerability of SSRIs for major depressive disorder."( Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.
Bloch, MH; Freemantle, N; Jakubovski, E; Taylor, MJ; Varigonda, AL, 2016
)
0.43
" Food and Drug Administration (FDA) on the risk of suicidality among children associated with use of antidepressants, but the warning's effect on dosing of antidepressants has not been evaluated."( Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning.
Azrael, D; Bushnell, GA; Miller, M; Pate, V; Stürmer, T; Swanson, SA; White, A, 2016
)
0.43
"The proportion of commercially insured children initiating an SSRI with a low dose was higher after the 2004 FDA warning on the risk of suicidality among children, suggesting improved prescribing practices surrounding SSRI dosing among children."( Dosing of Selective Serotonin Reuptake Inhibitors Among Children and Adults Before and After the FDA Black-Box Warning.
Azrael, D; Bushnell, GA; Miller, M; Pate, V; Stürmer, T; Swanson, SA; White, A, 2016
)
0.43
" Rats were dosed for 1 and 4 weeks with vortioxetine and fluoxetine at doses relevant for antidepressant activity."( Vortioxetine promotes early changes in dendritic morphology compared to fluoxetine in rat hippocampus.
Chen, F; du Jardin, KG; Nyengaard, JR; Sanchez, C; Waller, JA; Wegener, G, 2016
)
0.91
" They were observed for social interactions with their familiar cagemate over a 2-year dosing period."( Peer social interaction is facilitated in juvenile rhesus monkeys treated with fluoxetine.
Bulleri, AM; Golub, MS; Hogrefe, CE, 2016
)
0.66
" This study stresses the potential fitness consequences of fluoxetine exposure and suggests that examining behavioral effects of PPCPs under different dosing regimens and in multiple contexts is important to gain an increased understanding of how exposure affects behavior."( Dose-dependent fluoxetine effects on boldness in male Siamese fighting fish.
Campbell, BA; Dzieweczynski, TL; Kane, JL, 2016
)
1.03
"Psychoactive pharmaceuticals have been found as teratogens at clinical dosage during pregnancy."( Maternal exposure to carbamazepine at environmental concentrations can cross intestinal and placental barriers.
Aho, K; Bearden, S; Finney, B; Huber, DP; Kaushik, G; Thomas, MA; Zarbalis, KS, 2016
)
0.43
" Furthermore, behavioural shifts were sex-dependent, with evidence of a non-monotonic dose-response among the fluoxetine-exposed fish."( Impacts of the antidepressant fluoxetine on the anti-predator behaviours of wild guppies (Poecilia reticulata).
Clarke, BO; Johnstone, CP; McLennan, A; Saaristo, M; Wong, BBM, 2017
)
0.96
" We found that fluoxetine exposure at the lower dosage resulted in increased activity levels irrespective of the presence or absence of a predatory dragonfly nymph (Hemianax papuensis)."( The psychoactive pollutant fluoxetine compromises antipredator behaviour in fish.
Bertram, MG; Clarke, BO; Coggan, TL; Lewis, PJ; Martin, JM; Saaristo, M; Wong, BBM, 2017
)
1.11
" In this study, male juvenile rhesus monkeys (three-four years of age) were dosed with fluoxetine or vehicle (N=16/group) for two years."( Cognitive performance of juvenile monkeys after chronic fluoxetine treatment.
Elsworth, JD; Golub, MS; Hackett, EP; Hogrefe, CE; Leranth, C; Roth, RH, 2017
)
0.92
" An understanding of CYP450 metabolism and drug interaction as well as metabolism phenotypes should inform prescribing and dosing psychotropic medications."( Case report: Cytochrome P450 implications for comorbid ADHD and OCD pharmacotherapy.
Hogan, MK; Rao, NP, 2017
)
0.46
" At the end of dosing schedule, neurobehavioral tests were conducted; followed by mechanistic evaluation through biochemical analysis, RTPCR and western blot in serum and hippocampus."( Antidepressant activity of vorinostat is associated with amelioration of oxidative stress and inflammation in a corticosterone-induced chronic stress model in mice.
Js, IC; Kv, A; Lahkar, M; Madhana, RM; Naidu, VGM; Sinha, S, 2018
)
0.48
" We report the case of a 6-year-old girl who was successfully treated with once-nightly dosing of buspirone for fluoxetine-induced sleep bruxism, which was confirmed with clear on-off-on treatment sequence."( Fluoxetine-Induced Sleep Bruxism Rapidly Treated With Once-Nightly Dosing of Buspirone in a 6-Year-Old Girl.
Akbaş, B; Bilgiç, A,
)
1.79
" Results showed that TUDCA pretreatment (once daily for 7 consecutive days) at the dosage of 200 and 400 mg/kg, but not 100 mg/kg, markedly attenuated LPS (0."( Tauroursodeoxycholic Acid Ameliorates Lipopolysaccharide-Induced Depression Like Behavior in Mice via the Inhibition of Neuroinflammation and Oxido-Nitrosative Stress.
Chen, Z; Cheng, L; Huang, C, 2019
)
0.51
" We also investigated the effects of dosing time on the pharmacological activity of several antidepressants acting on serotonergic, noradrenergic, and/or dopaminergic neurons."( Antidepressants with different mechanisms of action show different chronopharmacological profiles in the tail suspension test in mice.
Ishibashi, T; Iwadate, R; Kawai, H; Kawashima, Y; Kudo, N; Mitsumoto, A, 2019
)
0.51
"The pharmacokinetics of two fluoxetine capsulated dosage forms and two amitriptyline tablet forms after a single oral intake was studied in dogs and healthy volunteers."( Experimental and Clinical Pharmacokinetics of Fluoxetine and Amitriptyline: Comparative Analysis and Possible Methods of Extrapolation.
Gneushev, ET; Kondratenko, SN; Kukes, VG; Savelyeva, MI; Shikh, EV, 2019
)
1.07
" Median effective dose was interpolated from the triplicated experiments and the dose-response curves were generated for each drug-virus combination."( A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses.
Honkimaa, A; Hyöty, H; Sioofy-Khojine, AB, 2020
)
0.56
" Selective serotonin reuptake inhibitors, while instructive with regard to mechanism, require impractical dosing and may carry additional risk in the form of greater challenges for resuscitation."( An oxygen-rich atmosphere or systemic fluoxetine extend the time to respiratory arrest in a rat model of obstructive apnea.
Banerjee, A; Gurevich, R; Kollmar, R; Mooney, S; Silverman, JB; Stewart, M; Sundaram, K; Tromblee, J, 2020
)
0.83
"The antidepressant medication fluoxetine at 90 mg dosed weekly is as effective and safe as standard formulation fluoxetine 20 mg dosed daily in patients with major depressive disorder."( Higher dose weekly fluoxetine in hemodialysis patients: A case series report.
Dolata, J; Figueroa, M; Gunzler, D; Huml, A; Kauffman, KM; Pencak, J; Sajatovic, M; Sehgal, AR, 2021
)
1.24
" Dosage titration was made at the discretion of the prescribing clinician."( Higher dose weekly fluoxetine in hemodialysis patients: A case series report.
Dolata, J; Figueroa, M; Gunzler, D; Huml, A; Kauffman, KM; Pencak, J; Sajatovic, M; Sehgal, AR, 2021
)
0.95
" Similarly, fluoxetine exposure at the higher dosage was associated with a significant (26%) reduction in individual-level variation in oxygen uptake relative to unexposed fish."( Chronic exposure to a pervasive pharmaceutical pollutant erodes among-individual phenotypic variation in a fish.
Bertram, MG; Bywater, CL; Martin, JM; Palacios, MM; Polverino, G; Tan, H; White, CR; Wiles, SC; Wong, BBM, 2020
)
0.94
" To evaluate the effects of GPR139 pharmacological activation on sleep, rats were orally dosed with the selective GPR139 agonist JNJ-63533054 (3-30 mg/kg)."( Putative role of GPR139 on sleep modulation using pharmacological and genetic rodent models.
Bonaventure, P; Dugovic, C; Dvorak, C; Liu, C; Lord, B; Lovenberg, T; Wang, L; White, A; Yun, S, 2020
)
0.56
" This method involves manipulating pharmaceutical active ingredients to a suitable dosage and formulation for administration to humans or animals."( Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4.
Espana, B; Jaquet, C; Joseph-Tornabène, F; Perrot, S; Prouillac, C,
)
0.39
" Behavioral tests such as Morris water maze test, novel object recognition test, and object in place test were performed at the end of the dosing schedule to assess cognition."( Cognitive Improvement by Vorinostat through Modulation of Endoplasmic Reticulum Stress in a Corticosterone-Induced Chronic Stress Model in Mice.
Bais, AK; K V, A; Kumar, P; Lahkar, M; Madhana, RM; Malik, A; Samudrala, PK; Singh, VB; Sinha, S, 2020
)
0.56
" This difference could be related to data artifacts, or, more likely, evidencing a hormetic dose-response curve, with different ranges of exposure concentrations considered in studies on fish and crustaceans."( Effects of antidepressants in the reproduction of aquatic organisms: a meta-analysis.
Antunes, M; Duarte, IA; Fonseca, VF; Lopes, DG, 2020
)
0.56
"Recent meta-analyses on dose-response relationships of SSRIs are largely based on indirect evidence."( In search of a dose-response relationship in SSRIs-a systematic review, meta-analysis, and network meta-analysis.
Adams, A; Baethge, C; Braun, C; Bschor, T; Kuhr, K; Rink, L, 2020
)
0.56
" Comparisons of dosage groups (low, medium, and high) resulted in only small and clinically non-significant differences for SSRIs as a group, the strongest relating to medium vs low doses (SMD: -0."( In search of a dose-response relationship in SSRIs-a systematic review, meta-analysis, and network meta-analysis.
Adams, A; Baethge, C; Braun, C; Bschor, T; Kuhr, K; Rink, L, 2020
)
0.56
"There is no conclusive level I or level II evidence of a clinically meaningful dose-response relationship of SSRIs as a group or of single substances."( In search of a dose-response relationship in SSRIs-a systematic review, meta-analysis, and network meta-analysis.
Adams, A; Baethge, C; Braun, C; Bschor, T; Kuhr, K; Rink, L, 2020
)
0.56
" Serotonin dosage shows that fluoxetine at 10 nM blocks serotonin reuptake in 1C11ND but slows down its release when cells are differentiated through a decrease of 5HT1b receptors density."( First Evidence of Kv3.1b Potassium Channel Subtype Expression during Neuronal Serotonergic 1C11 Cell Line Development.
Ayeb, ME; Bendahhou, S; Benkhalifa, R; Cheikh, A; Maatoug, S; Tabka, H, 2020
)
0.85
" However, in the long-term exposure test, high dosage of FLX inhibited EBPR."( Effect of fluoxetine on enhanced biological phosphorus removal using a sequencing batch reactor.
Bian, R; Sun, Y; Yuan, Q; Zhang, D; Zhang, J; Zhao, J, 2021
)
1.02
" We suggest that the complex nature of the serotonergic system with multilateral effects at the genomic, biochemical and physiological levels interacting with environmental stimuli result in non-linear dose-response behavioural patterns."( Time-, dose- and transgenerational effects of fluoxetine on the behavioural responses of zebrafish to a conspecific alarm substance.
Al Shuraiqi, A; Al-Habsi, A; Barry, MJ, 2021
)
0.88
"Since several recent meta-analyses report a dose-response relationship for the antidepressant effect of the selective serotonin reuptake inhibitors (SSRIs), we investigated how these drugs are dosed in clinical practice."( Low SSRI dosing in clinical practice-a register-based longitudinal study.
Eriksson, E; Hieronymus, F; Lisinski, A; Wallerstedt, SM, 2021
)
0.62
" The lack of consensus regarding effective dosing of SSRIs may have contributed to this state of affairs."( Low SSRI dosing in clinical practice-a register-based longitudinal study.
Eriksson, E; Hieronymus, F; Lisinski, A; Wallerstedt, SM, 2021
)
0.62
" A physiologically based pharmacokinetic model for fluoxetine and norfluoxetine metabolism was developed to predict and investigate changes in concentration-time profiles according to fluoxetine dosage in the Korean population."( Prediction of Fluoxetine and Norfluoxetine Pharmacokinetic Profiles Using Physiologically Based Pharmacokinetic Modeling.
Chae, YJ; Jeong, HC; Kang, W; Lee, S; Shin, KH; Yun, HY, 2021
)
1.23
" Concentrations causing 50% cytotoxicity (LC50) were derived, the whole transcriptome was sequenced, and gene tPOD and pathway benchmark dose (BMD) values were derived from transcriptomic dose-response analysis."( Transcriptomic Points of Departure Calculated from Rainbow Trout Gill, Liver, and Gut Cell Lines Exposed to Methylmercury and Fluoxetine.
Basu, N; Ewald, J; Mittal, K, 2022
)
0.93
" Small and mostly insignificant differences in average daily metoprolol dosage were found between patients treated with the various antidepressants."( Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway.
Gedde-Dahl, A; Molden, E; Spigset, O, 2022
)
0.72
"Three drug dosing strategies can be employed to address dose-dependent drug adverse effects."( Practical Psychopharmacology: Using a Knowledge of Pharmacokinetics to More Rapidly Stabilize Patients at Lower Drug Doses.
Andrade, C, 2022
)
0.72
" Another interesting aspect of antidepressants is that they have shown to induce non-monotonic dose-response (NMDR) curves."( Contrasting dose response relationships of neuroactive antidepressants on the behavior of C. elegans.
Estruch, IM; van den Brink, NW; van der Most, MA, 2023
)
0.91
" Different dosing regimens may have contributed to the contradictory findings."( Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.
Abbas, U; Deng, J; Garcia, C; Heybati, K; Huang, E; Moskalyk, M; Park, YJ; Ramaraju, HB; Rayner, D; Zhou, F, 2023
)
0.91
"To evaluate the efficacy and safety of SSRIs and the effect of different dosing regimens on the treatment of acute COVID-19."( Efficacy and safety of selective serotonin reuptake inhibitors in COVID-19 management: a systematic review and meta-analysis.
Abbas, U; Deng, J; Garcia, C; Heybati, K; Huang, E; Moskalyk, M; Park, YJ; Ramaraju, HB; Rayner, D; Zhou, F, 2023
)
0.91
" Health workers should be mindful of dosing to minimise side effects and considerate of the additional pill burden."( The acceptability of antidepressant treatment in people living with HIV in Malawi: A patient perspective.
Gaynes, BN; Hosseinipour, MC; Kulisewa, K; Minnick, CE; Mphonda, S; Pence, BW; Sansbury, G; Stockton, MA; Udedi, MM, 2023
)
0.91
" Mianserin and mirtazapine (separately) induced dose-dependent antinociception, each one yielding a biphasic dose-response curve, and they were antagonized by naloxone."( Treatment-Resistant Depression (TRD): Is the Opioid System Involved?
Keidan, L; Pick, CG; Schreiber, S, 2023
)
0.91
" We found that these effects were differential between female mice dosed lactationally or peripartally, and there were also impacts on maternal mammary gland at weaning in both of these groups."( In utero, lactational, or peripartal fluoxetine administration has differential implications on the murine maternal skeleton.
Brettingen, LJ; Charles, JF; Fricke, HP; Hernandez, LL; Krajco, CJ; Perry, MJ; Reisner, MA; Wake, LA, 2023
)
1.18
"Annual average treatment costs of amitriptyline, escitalopram, and fluoxetine in patients with depression at baseline with equivalent dosing as mono-drug therapy were 2765."( Cost-minimization analysis of escitalopram, fluoxetine, and amitriptyline in the treatment of depression.
Divakar, A; Raghav, MV; Rawat, VS; Salian, HH,
)
0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
antidepressantAntidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions.
serotonin uptake inhibitorA compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amineAn aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
(trifluoromethyl)benzenesAn organofluorine compound that is (trifluoromethyl)benzene and derivatives arising from substitution of one or more of the phenyl hydrogens.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Fluoxetine Action Pathway3618
Fluoxetine Metabolism Pathway69

Protein Targets (169)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.44670.100020.879379.4328AID588453
15-lipoxygenase, partialHomo sapiens (human)Potency12.58930.012610.691788.5700AID887
NFKB1 protein, partialHomo sapiens (human)Potency5.01190.02827.055915.8489AID895; AID928
TDP1 proteinHomo sapiens (human)Potency7.95690.000811.382244.6684AID686978; AID686979
ThrombopoietinHomo sapiens (human)Potency14.18060.02517.304831.6228AID917; AID918
thyroid stimulating hormone receptorHomo sapiens (human)Potency19.96830.001318.074339.8107AID926
regulator of G-protein signaling 4Homo sapiens (human)Potency4.22440.531815.435837.6858AID504845
glucocerebrosidaseHomo sapiens (human)Potency8.91250.01268.156944.6684AID2101
arylsulfatase AHomo sapiens (human)Potency2.68551.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency31.62280.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency3.92170.00207.533739.8107AID891
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency58.04790.01262.451825.0177AID485313
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency16.91310.316212.443531.6228AID902; AID924
cytochrome P450 2C19 precursorHomo sapiens (human)Potency8.29290.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency25.11890.00636.904339.8107AID883
chromobox protein homolog 1Homo sapiens (human)Potency31.62280.006026.168889.1251AID488953
mitogen-activated protein kinase 1Homo sapiens (human)Potency25.11890.039816.784239.8107AID995
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency26.12160.00669.809418.4927AID1347050
ras-related protein Rab-9AHomo sapiens (human)Potency58.04790.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency24.70120.00378.618923.2809AID2667; AID2668
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency3.54810.00798.23321,122.0200AID2551
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency11.95650.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency8.91250.251215.843239.8107AID504327
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency11.28150.00106.000935.4813AID943; AID944
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency11.95651.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency13.87250.316212.765731.6228AID881
Integrin beta-3Homo sapiens (human)Potency22.96520.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency22.96520.316211.415731.6228AID924
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency11.95651.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency11.95651.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency11.95651.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency11.95651.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency11.95651.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency11.95651.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency11.95651.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency11.95651.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency11.95651.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency11.95651.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency16.93970.00638.235039.8107AID881; AID883
D(1A) dopamine receptorSus scrofa (pig)Potency26.12160.00378.108123.2809AID2667
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency11.95651.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency11.95651.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency11.95651.000012.224831.6228AID885
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency12.58931.000010.475628.1838AID1457
GABA theta subunitRattus norvegicus (Norway rat)Potency11.95651.000012.224831.6228AID885
Ataxin-2Homo sapiens (human)Potency14.12540.011912.222168.7989AID588378
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency11.95651.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency9.52830.060110.745337.9330AID485368
thioredoxin reductaseRattus norvegicus (Norway rat)Potency1.12200.100020.879379.4328AID588453
RAR-related orphan receptor gammaMus musculus (house mouse)Potency24.34140.006038.004119,952.5996AID1159521; AID1159523
TDP1 proteinHomo sapiens (human)Potency17.80030.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency19.64420.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency25.37300.000221.22318,912.5098AID1259243; AID1259247; AID743042; AID743054
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency18.83360.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency31.06340.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency31.67040.000417.946075.1148AID1346784; AID1346795
regulator of G-protein signaling 4Homo sapiens (human)Potency10.62130.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency7.76190.01237.983543.2770AID1645841
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency23.81500.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency16.30470.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency34.51310.001530.607315,848.9004AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency33.49150.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency32.27740.000229.305416,493.5996AID1259244; AID1259248; AID743079
GVesicular stomatitis virusPotency38.90180.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency1.23020.00108.379861.1304AID1645840
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency33.48890.001024.504861.6448AID743212
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency6.68190.001019.414170.9645AID743191
caspase-3Homo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.70790.035520.977089.1251AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency33.49150.001723.839378.1014AID743083
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency10.682219.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency12.49130.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency61.93150.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency33.49150.006723.496068.5896AID1346980
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency58.04790.01262.451825.0177AID485313
D(1A) dopamine receptorHomo sapiens (human)Potency12.67280.02245.944922.3872AID488981; AID488983
chromobox protein homolog 1Homo sapiens (human)Potency25.11890.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency5.01190.01789.637444.6684AID588834
caspase-3Cricetulus griseus (Chinese hamster)Potency33.49150.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency11.23710.000323.4451159.6830AID743065; AID743067
huntingtin isoform 2Homo sapiens (human)Potency35.48130.000618.41981,122.0200AID1688
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency16.48160.00669.809418.4927AID1347050
ras-related protein Rab-9AHomo sapiens (human)Potency58.04790.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency22.63170.00378.618923.2809AID2660; AID2667; AID2668
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency37.57510.000627.21521,122.0200AID743202
gemininHomo sapiens (human)Potency16.78890.004611.374133.4983AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency14.38180.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency1.41250.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency33.49150.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency38.90180.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency33.49150.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency33.49150.001551.739315,848.9004AID1259244
D(1A) dopamine receptorSus scrofa (pig)Potency23.28090.00378.108123.2809AID2667
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
Ataxin-2Homo sapiens (human)Potency14.12540.011912.222168.7989AID588378
cytochrome P450 2C9, partialHomo sapiens (human)Potency38.90180.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piHomo sapiens (human)IC50 (µMol)5.20000.00011.02016.0000AID269938
Gamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)IC50 (µMol)5.20000.00011.02016.0000AID269938
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Sodium-dependent noradrenaline transporterMus musculus (house mouse)Ki0.08500.01200.09050.2900AID134216
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)0.10950.00011.00768.7800AID61413; AID625218
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki0.06200.00000.887110.0000AID625218
Potassium channel subfamily K member 2Homo sapiens (human)IC50 (µMol)16.50000.40003.92279.0000AID1307725; AID1307726
Bile salt export pumpHomo sapiens (human)IC50 (µMol)137.26670.11007.190310.0000AID1443980; AID1449628; AID1473738
Sodium channel protein type 1 subunit alphaRattus norvegicus (Norway rat)IC50 (µMol)13.10000.01001.14052.9390AID726266
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)1.30300.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki1.29200.00322.28879.3160AID625207
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)115.50000.00022.318510.0000AID681144
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)10.00000.00011.753610.0000AID1651172
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)IC50 (µMol)0.10000.00040.629810.0000AID5064
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki1.00000.00020.667710.0000AID5241
Muscarinic acetylcholine receptor M5Homo sapiens (human)IC50 (µMol)1.35800.00010.99178.0000AID625155
Muscarinic acetylcholine receptor M5Homo sapiens (human)Ki0.97600.00000.72926.9183AID625155
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.00630.00010.807410.0000AID36350
Cytochrome P450 2C8Homo sapiens (human)Ki294.00000.00180.38733.3000AID589253
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)0.70000.00002.015110.0000AID625249
Muscarinic acetylcholine receptor M1Homo sapiens (human)IC50 (µMol)3.20300.00001.403910.0000AID625151
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki0.77100.00000.59729.1201AID625151
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)50.00000.00002.800510.0000AID1210069
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)IC50 (µMol)12.28640.00001.612910.0000AID625171
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)Ki10.06600.00042.03378.6606AID625171
Dipeptidyl peptidase 4Rattus norvegicus (Norway rat)Ki7.30007.30007.30007.3000AID306610
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.10000.00040.908610.0000AID5064
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki1.00000.00010.601710.0000AID5241
Gamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)IC50 (µMol)5.20000.00011.14948.0000AID269938
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.10000.00021.874210.0000AID219623
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki3.28200.00010.949010.0000AID218673; AID36017; AID37309
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)1.52800.00001.23808.1590AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki0.69800.00020.725710.0000AID625202
Gamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)IC50 (µMol)5.20000.00011.03936.0000AID269938
Gamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)IC50 (µMol)5.20000.00011.29158.0000AID269938
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Ki4.49650.00000.929610.0000AID35630; AID36017
Muscarinic acetylcholine receptor M3Homo sapiens (human)IC50 (µMol)3.59500.00011.01049.9280AID625153
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki0.76200.00000.54057.7600AID625153
AcetylcholinesteraseMus musculus (house mouse)IC50 (µMol)10.00000.00071.11818.4000AID1525514
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Ki4.49650.00000.970810.0000AID35630; AID36017
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)5.06500.00000.933210.0000AID314091; AID482894
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Ki4.49650.00000.937510.0000AID35630; AID36017
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)6.00000.00021.557410.0000AID362027
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.10000.00021.270410.0000AID219623
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Ki3.28200.00000.575110.0000AID218673; AID36017; AID37309
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)2.83320.00081.541620.0000AID1164248; AID1181447; AID268715; AID269938; AID343580; AID352215; AID362025; AID387487; AID395504; AID412743; AID625207; AID752492
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki1.40090.00031.465610.0000AID1799063; AID254282; AID254338; AID395501; AID412740; AID625207; AID752492
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)IC50 (µMol)6.00000.00070.97749.7000AID411213
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)Ki1.09200.00030.37088.1600AID1061168
Potassium voltage-gated channel subfamily C member 1Rattus norvegicus (Norway rat)IC50 (µMol)13.10000.80000.80000.8000AID726266
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)Ki1.56000.00041.43528.7600AID1799063
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)0.45200.00010.88018.8500AID1651167; AID625192
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.05500.00000.385510.0000AID625192
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)0.13950.00011.03029.0000AID1651169; AID625218
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.06200.00010.954910.0000AID625218
Gamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)IC50 (µMol)5.20000.00011.30188.0000AID269938
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)0.10000.00040.615610.0000AID5064
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki1.00000.00020.590910.0000AID5241
Gamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)IC50 (µMol)5.20000.00010.98006.0000AID269938
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)0.03420.00010.86458.7096AID1164247; AID1181446; AID1651170; AID1718178; AID204069; AID268271; AID268714; AID269937; AID314096; AID339394; AID343579; AID352217; AID362026; AID387488; AID388703; AID395503; AID410151; AID412742; AID431883; AID441347; AID446937; AID459375; AID459948; AID481498; AID483448; AID504077; AID550776; AID578419; AID611191; AID619832; AID625222; AID751639; AID752491; AID773434
Sodium-dependent serotonin transporterHomo sapiens (human)Ki0.45770.00000.70488.1930AID1783169; AID1799064; AID204093; AID254277; AID254322; AID292944; AID300626; AID305407; AID306609; AID395334; AID412739; AID625222; AID751639; AID752491
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)IC50 (µMol)0.05380.00030.81978.4900AID1525515; AID200770; AID550776
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)Ki0.00660.00000.705610.0000AID196234; AID204533; AID204695; AID268270; AID292943; AID295325; AID300625; AID305406; AID306608; AID339528; AID388702; AID422846
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)0.05250.00002.398310.0000AID1254876; AID1651173
Gamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)IC50 (µMol)5.20000.00011.19936.0000AID269938
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.10000.00001.819410.0000AID219623
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki3.28200.00000.965010.0000AID218673; AID36017; AID37309
Gamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)IC50 (µMol)5.20000.00011.02016.0000AID269938
Gamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)IC50 (µMol)5.20000.00010.93746.0000AID269938
Gamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)IC50 (µMol)5.20000.00011.01936.0000AID269938
5-hydroxytryptamine receptor 6Homo sapiens (human)IC50 (µMol)1.66100.00170.83815.4200AID625221
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki0.77100.00020.522910.0000AID625221
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)50.00000.01202.53129.4700AID1210069
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.10000.00010.54948.4000AID61413
Gamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)IC50 (µMol)5.20000.00011.02016.0000AID269938
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)11.74670.00071.841946.0000AID1164249; AID1181448; AID268716; AID269939; AID343578; AID362027; AID395502; AID412741; AID752493
Sodium-dependent dopamine transporter Homo sapiens (human)Ki4.52500.00021.11158.0280AID1799064; AID254272; AID254319; AID395333; AID412738; AID752493
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)Ki1.56000.00041.16418.7600AID1799063
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)Ki1.56000.00041.52938.7600AID1799063
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)3.79930.00091.901410.0000AID1054122; AID161281; AID1651171; AID243151; AID408340; AID497189; AID576612; AID625171
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)Ki10.06600.00211.840710.0000AID625171
Gamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)IC50 (µMol)5.20000.00011.02016.0000AID269938
Cytochrome P450 1B1Homo sapiens (human)IC50 (µMol)475.00000.00130.86969.9000AID1453029
Sigma intracellular receptor 2Rattus norvegicus (Norway rat)Ki16.10000.00241.10509.3000AID1718151
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)Ki0.00220.00000.338510.0000AID306609
Sodium-dependent serotonin transporterMus musculus (house mouse)Ki0.01080.00040.59574.1000AID134217
Sodium-dependent dopamine transporterMus musculus (house mouse)Ki2.00000.40400.68731.0350AID134215
TransporterRattus norvegicus (Norway rat)Ki2.00000.00010.76295.5000AID411214
Nuclear receptor subfamily 3 group C member 3 Bos taurus (cattle)IC50 (µMol)12.28640.10482.83988.3173AID625171
Nuclear receptor subfamily 3 group C member 3 Bos taurus (cattle)Ki10.06600.08582.95428.6606AID625171
Beta-2 adrenergic receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.00940.00040.16800.9772AID481498
Gamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)IC50 (µMol)5.20000.00011.02016.0000AID269938
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)0.67510.00030.70285.3660AID203852; AID625223
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.21000.00000.490110.0000AID625223
Gamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)IC50 (µMol)5.20000.00011.02016.0000AID269938
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)Ki0.24000.00030.26715.0700AID1718165
Gamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)IC50 (µMol)5.20000.00011.02016.0000AID269938
TransporterRattus norvegicus (Norway rat)Ki0.79430.00010.866710.0000AID196233
Histamine H3 receptorHomo sapiens (human)Ki7.30000.00010.33998.5110AID292945; AID300627; AID305408; AID306610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium channel subfamily K member 2Homo sapiens (human)EC50 (µMol)19.00000.18702.72248.1800AID1802150
AlbuminRattus norvegicus (Norway rat)Kd36.10001.47006.53179.3100AID1215123
Sodium-dependent noradrenaline transporter Homo sapiens (human)Kd0.24000.00080.25331.0600AID145563
Sodium-dependent serotonin transporterHomo sapiens (human)EC50 (µMol)0.00270.00112.38838.7000AID652440
Sodium-dependent serotonin transporterHomo sapiens (human)Kd0.00080.00010.03170.2000AID204080
Sodium-dependent dopamine transporter Homo sapiens (human)Kd3.60000.02502.14439.3000AID64372
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (637)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cardiac ventricle developmentPotassium channel subfamily K member 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayPotassium channel subfamily K member 2Homo sapiens (human)
memoryPotassium channel subfamily K member 2Homo sapiens (human)
response to mechanical stimulusPotassium channel subfamily K member 2Homo sapiens (human)
response to axon injuryPotassium channel subfamily K member 2Homo sapiens (human)
negative regulation of cardiac muscle cell proliferationPotassium channel subfamily K member 2Homo sapiens (human)
cellular response to hypoxiaPotassium channel subfamily K member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium channel subfamily K member 2Homo sapiens (human)
cochlea developmentPotassium channel subfamily K member 2Homo sapiens (human)
positive regulation of cellular response to hypoxiaPotassium channel subfamily K member 2Homo sapiens (human)
negative regulation of DNA biosynthetic processPotassium channel subfamily K member 2Homo sapiens (human)
stabilization of membrane potentialPotassium channel subfamily K member 2Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cardiac ventricle developmentPotassium channel subfamily K member 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayPotassium channel subfamily K member 2Homo sapiens (human)
memoryPotassium channel subfamily K member 2Homo sapiens (human)
response to mechanical stimulusPotassium channel subfamily K member 2Homo sapiens (human)
response to axon injuryPotassium channel subfamily K member 2Homo sapiens (human)
negative regulation of cardiac muscle cell proliferationPotassium channel subfamily K member 2Homo sapiens (human)
cellular response to hypoxiaPotassium channel subfamily K member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium channel subfamily K member 2Homo sapiens (human)
cochlea developmentPotassium channel subfamily K member 2Homo sapiens (human)
positive regulation of cellular response to hypoxiaPotassium channel subfamily K member 2Homo sapiens (human)
negative regulation of DNA biosynthetic processPotassium channel subfamily K member 2Homo sapiens (human)
stabilization of membrane potentialPotassium channel subfamily K member 2Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
lipid hydroxylationCytochrome P450 2C8Homo sapiens (human)
organic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C8Homo sapiens (human)
steroid metabolic processCytochrome P450 2C8Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C8Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C8Homo sapiens (human)
retinol metabolic processCytochrome P450 2C8Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
oxidative demethylationCytochrome P450 2C8Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
monoatomic ion transportGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
response to toxic substanceGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
central nervous system neuron developmentGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
response to progesteroneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ovulation cycleGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
post-embryonic developmentGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
adult behaviorGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
signal transductioncAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
sensory perception of smellcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
regulation of protein kinase A signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cellular response to xenobiotic stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
roof of mouth developmentGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
behavioral fear responseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
associative learningGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inner ear receptor cell developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
innervationGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cellular response to histamineGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cochlea developmentGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
negative regulation of chloride transportGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationGastrin/cholecystokinin type B receptor Bos taurus (cattle)
positive regulation of cell population proliferationGastrin/cholecystokinin type B receptor Bos taurus (cattle)
cholecystokinin signaling pathwayGastrin/cholecystokinin type B receptor Bos taurus (cattle)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
neutrophil homeostasiscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
neutrophil chemotaxiscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
leukocyte migrationcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to lipopolysaccharidecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to xenobiotic stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to epinephrine stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-5 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of peptidyl-serine phosphorylationcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of heart contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
establishment of endothelial barriercAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conductioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
cellular response to organic cyclic compoundCytochrome P450 1B1Homo sapiens (human)
angiogenesisCytochrome P450 1B1Homo sapiens (human)
trabecular meshwork developmentCytochrome P450 1B1Homo sapiens (human)
DNA modificationCytochrome P450 1B1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1B1Homo sapiens (human)
nitric oxide biosynthetic processCytochrome P450 1B1Homo sapiens (human)
cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to nutrientCytochrome P450 1B1Homo sapiens (human)
steroid metabolic processCytochrome P450 1B1Homo sapiens (human)
estrogen metabolic processCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell population proliferationCytochrome P450 1B1Homo sapiens (human)
male gonad developmentCytochrome P450 1B1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to oxidative stressCytochrome P450 1B1Homo sapiens (human)
toxin metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionCytochrome P450 1B1Homo sapiens (human)
positive regulation of smooth muscle cell migrationCytochrome P450 1B1Homo sapiens (human)
sterol metabolic processCytochrome P450 1B1Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 1B1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
collagen fibril organizationCytochrome P450 1B1Homo sapiens (human)
adrenal gland developmentCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell migrationCytochrome P450 1B1Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityCytochrome P450 1B1Homo sapiens (human)
response to follicle-stimulating hormoneCytochrome P450 1B1Homo sapiens (human)
response to estradiolCytochrome P450 1B1Homo sapiens (human)
negative regulation of cell adhesion mediated by integrinCytochrome P450 1B1Homo sapiens (human)
benzene-containing compound metabolic processCytochrome P450 1B1Homo sapiens (human)
retinol metabolic processCytochrome P450 1B1Homo sapiens (human)
retinal metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of apoptotic processCytochrome P450 1B1Homo sapiens (human)
blood vessel endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
endothelial cell migrationCytochrome P450 1B1Homo sapiens (human)
estrous cycleCytochrome P450 1B1Homo sapiens (human)
positive regulation of translationCytochrome P450 1B1Homo sapiens (human)
positive regulation of angiogenesisCytochrome P450 1B1Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATCytochrome P450 1B1Homo sapiens (human)
membrane lipid catabolic processCytochrome P450 1B1Homo sapiens (human)
response to arsenic-containing substanceCytochrome P450 1B1Homo sapiens (human)
blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
retinal blood vessel morphogenesisCytochrome P450 1B1Homo sapiens (human)
ganglion developmentCytochrome P450 1B1Homo sapiens (human)
cellular response to hydrogen peroxideCytochrome P450 1B1Homo sapiens (human)
cellular response to cAMPCytochrome P450 1B1Homo sapiens (human)
cellular response to tumor necrosis factorCytochrome P450 1B1Homo sapiens (human)
cellular response to luteinizing hormone stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to cortisol stimulusCytochrome P450 1B1Homo sapiens (human)
cellular response to progesterone stimulusCytochrome P450 1B1Homo sapiens (human)
response to dexamethasoneCytochrome P450 1B1Homo sapiens (human)
endothelial cell-cell adhesionCytochrome P450 1B1Homo sapiens (human)
response to indole-3-methanolCytochrome P450 1B1Homo sapiens (human)
cellular response to toxic substanceCytochrome P450 1B1Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1B1Homo sapiens (human)
response to 3-methylcholanthreneCytochrome P450 1B1Homo sapiens (human)
regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCytochrome P450 1B1Homo sapiens (human)
positive regulation of DNA biosynthetic processCytochrome P450 1B1Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
response to xenobiotic stimulusGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
synaptic transmission, GABAergicGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
inhibitory synapse assemblyGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
neurotransmitter transportGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
signal transductionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neurotransmitter secretionHistamine H3 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H3 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H3 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H3 receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (222)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
outward rectifier potassium channel activityPotassium channel subfamily K member 2Homo sapiens (human)
potassium ion leak channel activityPotassium channel subfamily K member 2Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
outward rectifier potassium channel activityPotassium channel subfamily K member 2Homo sapiens (human)
potassium ion leak channel activityPotassium channel subfamily K member 2Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
monooxygenase activityCytochrome P450 2C8Homo sapiens (human)
iron ion bindingCytochrome P450 2C8Homo sapiens (human)
protein bindingCytochrome P450 2C8Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C8Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C8Homo sapiens (human)
aromatase activityCytochrome P450 2C8Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
heme bindingCytochrome P450 2C8Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C8Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ligand-gated monoatomic ion channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
identical protein bindingGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
signaling receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
gastrin receptor activityGastrin/cholecystokinin type B receptor Bos taurus (cattle)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
gamma-tubulin bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
enzyme bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
signaling receptor regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
beta-2 adrenergic receptor bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
ATPase bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
scaffold protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
heterocyclic compound bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
monooxygenase activityCytochrome P450 1B1Homo sapiens (human)
iron ion bindingCytochrome P450 1B1Homo sapiens (human)
protein bindingCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
heme bindingCytochrome P450 1B1Homo sapiens (human)
aromatase activityCytochrome P450 1B1Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1B1Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1B1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 1B1Homo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA receptor bindingGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
benzodiazepine receptor activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmembrane signaling receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-A receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neurotransmitter transmembrane transporter activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
protein bindingGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
histamine receptor activityHistamine H3 receptorHomo sapiens (human)
G protein-coupled acetylcholine receptor activityHistamine H3 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (137)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endoplasmic reticulum membranePotassium channel subfamily K member 2Homo sapiens (human)
plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
cell surfacePotassium channel subfamily K member 2Homo sapiens (human)
apical plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
neuronal cell bodyPotassium channel subfamily K member 2Homo sapiens (human)
calyx of HeldPotassium channel subfamily K member 2Homo sapiens (human)
astrocyte projectionPotassium channel subfamily K member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium channel subfamily K member 2Homo sapiens (human)
plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
apical plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit piHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
axonGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
dendriteGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit deltaHomo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
endoplasmic reticulum membranePotassium channel subfamily K member 2Homo sapiens (human)
plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
cell surfacePotassium channel subfamily K member 2Homo sapiens (human)
apical plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
neuronal cell bodyPotassium channel subfamily K member 2Homo sapiens (human)
calyx of HeldPotassium channel subfamily K member 2Homo sapiens (human)
astrocyte projectionPotassium channel subfamily K member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium channel subfamily K member 2Homo sapiens (human)
plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C8Homo sapiens (human)
plasma membraneCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
cytoplasmCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
GABA receptor complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-1Homo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
nuclear envelopeGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
dendriteGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
presynaptic active zone membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
Schaffer collateral - CA1 synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-2Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
nucleoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
ruffle membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-3Homo sapiens (human)
nucleoplasmGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
cytosolGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuronal cell body membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
presynaptic membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-5Homo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
axonGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synaptic vesicle membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuronal cell bodyGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
inhibitory synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
cytoplasmic vesicle membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
extracellular exosomeGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit beta-2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-4Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
postsynaptic membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit epsilonHomo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
synaptic vesiclecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
postsynaptic densitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
Z disccAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
dendritic spinecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
excitatory synapsecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
gamma-tubulin complexcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
apical plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
cerebellar Golgi cell to granule cell synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynaptic specialization membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit alpha-6Homo sapiens (human)
mitochondrionCytochrome P450 1B1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1B1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1B1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-1Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
nucleolusGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
microtubule cytoskeletonGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
dendrite membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
postsynapseGamma-aminobutyric acid receptor subunit gamma-3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
receptor complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit thetaHomo sapiens (human)
plasma membraneHistamine H3 receptorHomo sapiens (human)
presynapseHistamine H3 receptorHomo sapiens (human)
plasma membraneHistamine H3 receptorHomo sapiens (human)
synapseHistamine H3 receptorHomo sapiens (human)
dendriteHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (689)

Assay IDTitleYearJournalArticle
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID113260Antagonistic activity against acetic acid induced abdominal constriction (writhing) in mice, when administered in combination with 0.2 mg/kg of morphine1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor.
AID116526Inhibition of serotonin uptake carrier in mice1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor.
AID113259Antagonistic activity against acetic acid induced abdominal constriction (writhing) in mice1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor.
AID177554Ability to antagonize saccharin-induced drinking (palatability-induced ingestion) in rats1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor.
AID110195Ability to antagonize p-chloroamphetamine-induced depletion of brain serotonin in mouse1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Absolute configurations and pharmacological activities of the optical isomers of fluoxetine, a selective serotonin-uptake inhibitor.
AID499952Displacement of [3H]leucine from Leucine transporter2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile) analogues at monoamine transporters.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1802150TREK1 Assay from Article 10.1111/cbdd.12810: \\Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.\\2016Chemical biology & drug design, Dec, Volume: 88, Issue:6
Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.
AID1854622Antidepressant activity in ICR (CD-1) mouse assessed as decrease in immobility time at 160 mg/kg, po and measured after 1 hr by forced swim test2022RSC medicinal chemistry, Jul-20, Volume: 13, Issue:7
Biphenyl scaffold for the design of NMDA-receptor negative modulators: molecular modeling, synthesis, and biological activity.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID134217Tested in vitro for serotonin(5-HT) neuronal uptake inhibition1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID773437Inhibition of human SERT-mediated serotonin uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.
AID1857248Antidepressant activity in reserpine-induced mouse assessed as increase in 5-HT1AR expression at 20 mg/kg pretreated with reserpine for 3 days followed by compound addition on day 4 to 10 by Western blot analysis2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Development of MAO-A and 5-HT
AID411213Displacement of [125I]RTI55 from DAT in Sprague-dawley rat striatum by liquid scintillation spectrophotometry2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
1-Naphthyl and 4-indolyl arylalkylamines as selective monoamine reuptake inhibitors.
AID1405817Antidepressant activity in Kunming mouse assessed as decrease in immobility time at 20 mg/kg, po by tail suspension test2018European journal of medicinal chemistry, Aug-05, Volume: 156Synthesis and biological evaluation of magnolol derivatives as melatonergic receptor agonists with potential use in depression.
AID170352Effect on food consumption was determined in 24 rats at 2-6h after ip administration at the dose of 10 mg/kg; expressed as change in percent weight of the jar containing food2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
AID601155Antidepressant activity in albino mouse assessed as reduction of immobility time at 20 mg/kg, ip qd for 15 days by forced swimming test2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Novel benzo[b]thiophene derivatives as new potential antidepressants with rapid onset of action.
AID309941Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 3.24 mM/kg, ip after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID309949Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in intraperitoneally dosed mouse after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1783169Displacement of [3H]citalopram from human SERT in HEK293 cells by Topcount scintillation analysis2021European journal of medicinal chemistry, Aug-05, Volume: 220Tuning the activity of known drugs via the introduction of halogen atoms, a case study of SERT ligands - Fluoxetine and fluvoxamine.
AID298031Lipophilicity, log D at pH7.42007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID589253Mechanism based inhibition of human cytochrome P450 2C8 measured by paclitaxel hydroxylation using a recombinant system2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID412742Inhibition of [3H]5HT from human recombinant SERT expressed in HEK293 cells2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID309942Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 4.86 mM/kg, ip after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1315363Neuroprotective activity against corticosterone-induced cell injury in rat PC12 cells assessed as cell viability at 3 uM after 48 hrs by MTT assay (Rvb = 55.6 +/- 0.87%)2016Journal of natural products, 05-27, Volume: 79, Issue:5
Polycyclic Polyprenylated Derivatives from Hypericum uralum: Neuroprotective Effects and Antidepressant-like Activity of Uralodin A.
AID218673Binding affinity towards alpha-1 adrenergic receptor1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1061167Displacement of [3H]5-HT from rat cerebral cortex SERT after 10 mins2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.
AID179990Tested in vivo for serotonin syndrome antagonizing activity in rat1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1124852Octanol-water partition coefficient, log P of the compound2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and evaluation of amide side-chain modified Agomelatine analogues as potential antidepressant-like agents.
AID349962Anxiolytic activity in BALB/c mouse assessed as velocity at 5 mg/kg, po after 90 mins by open-field test (RVb= 7.07+/-0.51 cm/s)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID339528Displacement of [3H]paroxetine from rat cortical 5HTT reuptake site2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Studies toward the discovery of the next generation of antidepressants. Part 6: Dual 5-HT1A receptor and serotonin transporter affinity within a class of arylpiperazinyl-cyclohexyl indole derivatives.
AID65486Inhibition of [3H]DA uptake at Dopamine transporter into rat nerve endings (synaptosomes)2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
A convenient procedure for the synthesis of nonsymmetrical bivalent selective serotonin reuptake inhibitors using polymer-supported reagents.
AID344479Anticonvulsant activity in ip dosed CF1 albino mouse assessed as minimum effective dose after 4 hrs by MES screen test2008European journal of medicinal chemistry, May, Volume: 43, Issue:5
N-{[(6-substituted-1,3-benzothiazole-2-yl)amino]carbonothioyl}-2/4-substituted benzamides: synthesis and pharmacological evaluation.
AID269939Inhibition of DA transporter expressed in HEK293 cells2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.
AID1181459Inhibition of norepinephrine reuptake at human NET expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID752491Inhibition of [3H]5-HT uptake at human SERT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.
AID254277Inhibition constant against serotonin transporter2005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Designed multiple ligands. An emerging drug discovery paradigm.
AID263919Reduction of serotonergic neuron level in dorsal raphe nucleus of anesthetized rat after 3 days of sub-chronic administration at 10 mg/kg/day2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 5.
AID1470711Anti-depressant like activity in Swiss albino mouse assessed as reduction in immobility time at 20 mg/kg, po administered 60 mins prior to test measured for 5 mins by forced swim test relative to control2017European journal of medicinal chemistry, May-26, Volume: 132Novel aryl piperazines for alleviation of 'andropause' associated prostatic disorders and depression.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1187939Antidepressant activity in ICR (CD1) mouse assessed as immobility during last 5 mins of 6-mins testing period at 10 mg/kg, ip dosed 30 mins before testing by forced swimming test2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Novel N-biphenyl-2-ylmethyl 2-methoxyphenylpiperazinylalkanamides as 5-HT7R antagonists for the treatment of depression.
AID229635Selectivity ratio measured as the ratio of IC50 of NE/IC50 of 5-HT1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Molecular structure of fluoxetine hydrochloride, a highly selective serotonin-uptake inhibitor.
AID64372Equilibrium dissociation constant (KD) for Competitive binding between [3H]WIN-35428 and the compound at human transporter-hDAT1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID387487Inhibition of norepinephrine uptake at human NET expressed in MDCK cells2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.
AID309944Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 9.71 mM/kg, ip after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1718178Inhibition of SERT (unknown origin)2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID187183Inhibition of dopamine uptake into rat synaptosomes2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake.
AID1675873Inhibition of human TREK1 R207A mutant at intermediate transition state expressed in CHO cells by whole-cell patch-clamp electrophysiological method2020Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19
Discovery of an Inhibitor for the TREK-1 Channel Targeting an Intermediate Transition State of Channel Gating.
AID1217710Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID204695Displacement of [3H]citalopram from rat cortical serotonin transporter (SERT)2002Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5
Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 2: 4-substituted 6-nitroquipazines.
AID352218Selectivity ratio of IC50 for human SERT to IC50 for human NET2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.
AID292945Binding affinity to human histamine H3 receptor2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Dual serotonin transporter/histamine H3 ligands: Optimization of the H3 pharmacophore.
AID386925Antifungal activity against Aspergillus fumigatus after 48 hrs by broth microdilution technique2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Carbodithioic acid esters of fluoxetine, a novel class of dual-function spermicides.
AID306610Displacement of N-[3H]alpha-methylhistamine from human histamine H3 receptor expressed in SK-N-MC cells2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Novel naphthyridines are histamine H3 antagonists and serotonin reuptake transporter inhibitors.
AID1074427Antidepressant activity in KunMing mouse at 50 mg/kg, ip by tail suspension test2014European journal of medicinal chemistry, Feb-12, Volume: 73Design, synthesis and evaluation of the antidepressant and anticonvulsant activities of triazole-containing quinolinones.
AID289402Displacement of [3H]leucine from Aquifex aeolicus His-LeuT expressed in Escherichia coli by scintillation proximity assay2007Science (New York, N.Y.), Sep-07, Volume: 317, Issue:5843
LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake.
AID196234In vitro binding affinity was determined against serotonin reuptake site of rat in presence of [3H]paroxetine radioligand2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties.
AID1181444Inhibition of norepinephrine reuptake at human NET expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
AID1221960Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID388904Antidepressant activity against dark-induced depression in Albino Swiss mouse assessed as increase in brain serotonin level at 20 mg/kg, ip once daily for 4 days and 30 mins before test on day 52008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
PASS-assisted exploration of antidepressant activity of 1,3,4-trisubstituted-beta-lactam derivatives.
AID218789Inhibition of [3H]DA uptake by dopamine transporter of rat striata synaptosomes2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Further SAR studies of piperidine-based analogues of cocaine. 2. Potent dopamine and serotonin reuptake inhibitors.
AID539464Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
AID1870231Antidepressant activity in restraint-stressed C57BL/6J mouse model assessed as reduction in immobility time at 20 mg/kg, ip measured at 14 mins relative to control (Rvb= 569.6 +/- 27.6 sec)
AID1217706Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1181463Inhibition of norepinephrine reuptake at human NET expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
AID132117Tested in vivo for head twitches antagonizing activity in mice1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID170492Effect on food consumption was determined in 8 rats at 6 hr after ip administration at the dose of 10 mg/kg; expressed as change in weight of the jar containing food2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
AID1315578Antidepressant- like activity in mouse assessed as duration of immobility time at 10 mg/kg, ip by tail suspension test (Rvb = 130.5 +/- 9.6 secs)2016European journal of medicinal chemistry, Oct-04, Volume: 121Antidepressant-like effects and mechanisms of flavonoids and related analogues.
AID504089Anxiolytic activity in mouse assessed as inhibition of marble buried at 10 mg/kg, ip by marble burying test2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.
AID1315367Antidepressant-like activity in LPS-induced ICR mouse assessed as decrease in immobility time at 25 mg/kg, ig qd for 5 days followed by LPS stimulation on 5th day injected 30 mins post last dose measured 24 hrs after stimulation monitored for last 4 mins 2016Journal of natural products, 05-27, Volume: 79, Issue:5
Polycyclic Polyprenylated Derivatives from Hypericum uralum: Neuroprotective Effects and Antidepressant-like Activity of Uralodin A.
AID245919Cytotoxicity to reduce chronic myeloid leukemia K 562 cells2004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
Imidazole analogues of fluoxetine, a novel class of anti-Candida agents.
AID1211298Dissociation constant, pKa of the compound2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID1175702Antidepressant-like activity in Swiss albino mouse assessed as decrease in immobility time at 0.5 mg/kg, ip measured for 5 mins by tail suspension test relative to control2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Design and synthesis of new series of coumarin-aminopyran derivatives possessing potential anti-depressant-like activity.
AID1074428Antidepressant activity in KunMing mouse assessed as immobility time at 50 mg/kg, ip by forced swimming test2014European journal of medicinal chemistry, Feb-12, Volume: 73Design, synthesis and evaluation of the antidepressant and anticonvulsant activities of triazole-containing quinolinones.
AID395327Dissociation constant, pKa by capillary electrophoresis2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1165007Oral bioavailability in rat2014Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20
Synthesis and evaluation of new 3-phenylcoumarin derivatives as potential antidepressant agents.
AID208588Binding affinity against human Tachykinin receptor 1 expressed in CHO cells using [3H]-substance P as the radioligand; less than 50% inhibition at 10e-5 M2002Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21
Dual NK(1) antagonists--serotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1217727Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1215348Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone at 0.01 to 100 uM preincubated for 60 mins followed by testosterone treatment measured after 10 mins by LC-MS/MS analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors.
AID1221965Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID170489Effect on food consumption was determined in 8 rats at 4 hr after ip administration at the dose of 10 mg/kg; expressed as change in percent weight of the jar containing food2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
AID1207650Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID408340Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Support vector machines classification of hERG liabilities based on atom types.
AID679767TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: ? uM, Fluoxetine: 100 uM) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID744699Displacement of [3H]-8-OH-DPAT from 5HT1A receptor in rat hippocampal membranes after 20 mins2013European journal of medicinal chemistry, May, Volume: 63Synthesis and biological evaluation of novel pyrrolidine-2,5-dione derivatives as potential antidepressant agents. Part 1.
AID311933Inhibition of ASM in rat PC12 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1164247Inhibition of human SERT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
AID1155487Cytotoxicity against human HEK293 cells as inhibition of cell viability at 80 uM after 24 hrs by MTT assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Synthesis and biological evaluation of novel naphthalene compounds as potential antidepressant agents.
AID249259Minimum inhibitory concentration to inhibit 50% of the isolates2004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
Imidazole analogues of fluoxetine, a novel class of anti-Candida agents.
AID65171Ability to inhibit high affinity reuptake of [3H]DA from dopamine transporter into nerve endings synaptosomes2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Further studies on conformationally constrained tricyclic tropane analogues and their uptake inhibition at monoamine transporter sites: synthesis of (Z)-9-(substituted arylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes as a novel class of serotonin transpo
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID309943Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 6.47 mM/kg, ip after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID179747In vitro inhibition of serotonin (5-HT) uptake in crude rat brain synaptosomes1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Molecular structure of fluoxetine hydrochloride, a highly selective serotonin-uptake inhibitor.
AID244787Antifungal activity to inhibit Candida parapsilosis ATCC 220192004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
Imidazole analogues of fluoxetine, a novel class of anti-Candida agents.
AID1164251Selectivity index, ratio of IC50 for human DAT to IC50 for human SERT2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
AID349973Anxiolytic activity in BALB/c mouse assessed as immobility at 5 mg/kg, po after 90 mins by open-field test (RVb= 458.4+/-41 s)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1217723Time dependent inhibition of CYP2D6 (unknown origin) at 10 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID309940Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 1.62 mM/kg, ip after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID249257Antifungal activity to cause 99% reduction of surviving cells in 50% isolates2004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
Imidazole analogues of fluoxetine, a novel class of anti-Candida agents.
AID1232310Volume of distribution at steady state in human2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Volume of Distribution in Drug Design.
AID144700Noncompetitive inhibition of N-methyl-D-aspartate (NMDA) Receptor, by the displacement of [3H]MK-801 in rat brain membranes; nd means not determined1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID387488Inhibition of serotonin uptake at human SERT expressed in JAR cells2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.
AID387489Selectivity for human NET over human SERT2008Bioorganic & medicinal chemistry letters, Sep-15, Volume: 18, Issue:18
Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors.
AID1211297Drug recovery in plasma (unknown origin)2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID386922Antifungal activity against Cryptococcus neoformans after 48 hrs by broth microdilution technique2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Carbodithioic acid esters of fluoxetine, a novel class of dual-function spermicides.
AID393267Antidepressant activity in BALB/c mouse assessed as change in duration of immobility at 20 mg/kg, ip pretreated 30 mins before test by forced swimming test2009Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5
2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.
AID386924Antifungal activity against Trichophyton mentagrophytes after 48 hrs by broth microdilution technique2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Carbodithioic acid esters of fluoxetine, a novel class of dual-function spermicides.
AID567860Antifungal activity against Penicillium citrinum NCIM 768 after 72 hrs2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis, antidepressant and antifungal evaluation of novel 2-chloro-8-methylquinoline amine derivatives.
AID1636480Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 70.1 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID343579Inhibition of serotonin uptake at human SERT in human HEK293 cells2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).
AID1599372Antiviral activity against DENV2 infected in human Huh7 cells by qRT-PCR analysis2019European journal of medicinal chemistry, Aug-15, Volume: 176Recent update on anti-dengue drug discovery.
AID509967Neurotoxicity in Swiss albino mouse assessed as effect on motor coordination at 100 mg/kg, ip by rotarod test2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
New pyrazoline derivatives and their antidepressant activity.
AID145881Inhibition of norepinephrine transporter by inhibition of [3H]NE uptake into rat nerve endings (synaptosomes)2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
A convenient procedure for the synthesis of nonsymmetrical bivalent selective serotonin reuptake inhibitors using polymer-supported reagents.
AID596123Inhibition of SERT in rat cerebral cortex assessed as [3H]serotonin accumulation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.
AID377490Antidepressant activity in CF1 mouse assessed as decrease in duration of immobility at 20 mg/kg during final 4 mins of the 6 mins session by forced swimming test2005Journal of natural products, Mar, Volume: 68, Issue:3
Psychopharmacological profile of the alkaloid psychollatine as a 5HT2A/C serotonin modulator.
AID1776492Antidepressant activity in icv dosed C57BL/6N mouse assessed as decrease in immobility time measured after 36 mins2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Discovery of Novel and Potent
AID504078Inhibition of norepinephrine reuptake at human NET expressed in MDCK cells2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.
AID170491Effect on food consumption was determined in 8 rats at 6 hr after ip administration at the dose of 10 mg/kg; expressed as change in percent weight of the jar containing food2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID283756Antidepressant activity in ICR mouse assessed as reduction of immobility time at 10 mg/kg, po after 5 days by tail suspension test2007Journal of natural products, Apr, Volume: 70, Issue:4
Triterpene saponins from Bacopa monnieri and their antidepressant effects in two mice models.
AID3804Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines.
AID187185Inhibition of serotonin uptake into rat synaptosomes2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake.
AID1315586Antidepressant- like activity in Balb/c mouse assessed as immobility time at 10 mg/kg, ip administered 30 mins prior to testing by tail suspension test (Rvb = 130.5 +/- 9.6 secs)2016European journal of medicinal chemistry, Oct-04, Volume: 121Antidepressant-like effects and mechanisms of flavonoids and related analogues.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID683020Antidepressant activity in CD1 mouse assessed as decrease in immobility time at 20 mg/kg, ip after 15 mins by forced swim test relative to vehicle-treated control2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
Low Doses of Allyphenyline and Cyclomethyline, Effective against Morphine Dependence, Elicit an Antidepressant-like Effect.
AID406959Antifungal activity against dermatophytes at 28 degC after 7 days by broth microdilution test2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
1-[(3-Aryloxy-3-aryl)propyl]-1H-imidazoles, new imidazoles with potent activity against Candida albicans and dermatophytes. Synthesis, structure-activity relationship, and molecular modeling studies.
AID775111Antidepressant activity in ICR mouse assessed as immobility time at 20 mg/kg, ip by tail suspension test2013Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21
2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID309938Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 12.94 mM/kg, ip after 20 mins2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID415383Inhibition of human recombinant CYP2D6 at 5 uM assessed as blockade of O-demethylation of dextromethorphan in to dextrophan by nanoscale automated in-capillary assay2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
Development of an in-capillary approach to nanoscale automated in vitro cytochromes p450 assays.
AID772368Antidepressant-like activity in mouse assessed as reduction in immobility time at 20 mg/kg, ip by forced swimming test2013ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9
Exploring multitarget interactions to reduce opiate withdrawal syndrome and psychiatric comorbidity.
AID1155480Neurorestorative activity against H2O2-induced oxidant injury in rat PC12 cells assessed as restorative rate at 10 uM measured after 48 hrs pretreated with 200 uM H2O2 for 1 hr by MTT assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Synthesis and biological evaluation of novel naphthalene compounds as potential antidepressant agents.
AID1124855Cytotoxicity against human HEK293 cells assessed as inhibitory rate at 80 uM after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and evaluation of amide side-chain modified Agomelatine analogues as potential antidepressant-like agents.
AID178457Antidepressant activity was measured by the potentiation of head twitching induced by 5-hydroxy-tryptophan in pargyline-pretreated rats after ip administration1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Novel tetracyclic spiropiperidines. 1. 3-Aryl-1,3-dihydrospiro[benzo[c]thiophene-1,4'-piperidines] as potential antidepressants.
AID170358Effect on food consumption was determined in 24 rats at 6 hr after ip administration at the dose of 10 mg/kg; expressed as change in percent weight of the jar containing food2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
AID386926Antifungal activity against Candida parapsilosis ATCC 22019 after 48 hrs by broth microdilution technique2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Carbodithioic acid esters of fluoxetine, a novel class of dual-function spermicides.
AID1221964Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1571160Antitrypanosomal activity against Trypanosoma brucei brucei by pathogen box screening based assay2018MedChemComm, Dec-01, Volume: 9, Issue:12
Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery.
AID204533Binding affinity against serotonin transporter in rat cortical tissues using radioligand [3H]paroxetine2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines.
AID196233In vitro binding affinity was determined against NA (noradrenaline) reuptake site of rat in presence of [3H]nisoxetine radioligand2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties.
AID3544Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines.
AID1217728Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID129284Antidepressant activity was measured by the inhibition of tetrabenazine ptosis in mice after po administration.1981Journal of medicinal chemistry, Jan, Volume: 24, Issue:1
Novel tetracyclic spiropiperidines. 1. 3-Aryl-1,3-dihydrospiro[benzo[c]thiophene-1,4'-piperidines] as potential antidepressants.
AID1858351Antidepressant activity in Kunming mouse assessed as decrease in immobility time at 20 mg/kg, po administered two times at 1 hrs and 24 hrs and measured at last 4 mins of 6 mins test by forced swim test relative to control2022RSC medicinal chemistry, Oct-19, Volume: 13, Issue:10
Synthesis and biological evaluation of paeoveitol D derivatives as new melatonin receptor agonists with antidepressant activities.
AID230532Ratio of selective inhibition of dopamine(DA) to serotonin(5-HT) was evaluated2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
A convenient procedure for the synthesis of nonsymmetrical bivalent selective serotonin reuptake inhibitors using polymer-supported reagents.
AID50343Maximal activatory effect against human carbonic anhydrase I (hCA I) at a concentration of 1 uM2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram are strong activators of isozymes I and II.
AID1217705Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1636421Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 80.4 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of N2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1155489Toxicity in C57 mouse assessed as increase in spontaneous locomotor activity at 32 mg/kg, ip for 14 days by open field test2014European journal of medicinal chemistry, Jul-23, Volume: 82Synthesis and biological evaluation of novel naphthalene compounds as potential antidepressant agents.
AID1659913Antidepressant activity in mouse assessed as immobility time at 3 mg/kg, ip by forced swimming test (Rvb = 172.3 +/- 9.67 sec)
AID643383Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
AID1315577Antidepressant- like activity in mouse assessed as duration of immobility time at 10 mg/kg, ip by forced swimming test (Rvb = 141.5 +/- 10.9 secs)2016European journal of medicinal chemistry, Oct-04, Volume: 121Antidepressant-like effects and mechanisms of flavonoids and related analogues.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID309947Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 25.89 mM/kg, ip after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1659923Antidepressant activity in mouse assessed as increase in serotonin level at 3 mg/kg, ip
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID5064Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
New indole derivatives as potent and selective serotonin uptake inhibitors.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1659925Antidepressant activity in mouse assessed as change in dopamine level at 3 mg/kg, ip
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID652440Inhibition of human SERT-mediated serotonin reuptake in HEK293 cells2011ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9
NO-SSRIs: Nitric Oxide Chimera Drugs Incorporating a Selective Serotonin Reuptake Inhibitor.
AID550776Inhibition of [3H]serotonin reuptake at human SERT expressed in HEK293 cells by scintillation counting2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.
AID245227Minimum inhibitory concentration to inhibit Candida albicans strain range is equal to 32-1282004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
Imidazole analogues of fluoxetine, a novel class of anti-Candida agents.
AID1221961Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID309950Selectivity ratio of ED50 for 5-HT reuptake in mouse to ED50 for norepinephrine reuptake in mouse2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1221958Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1651170Displacement of [3H]imipramine from SERT receptor (unknown origin) by cell based radioligand competitive binding analysis2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Evaluation of anti-depressant effects of phthalazinone-based triple-acting small molecules against 5-HT
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID624696Mechanism based inhibition of rat cytochrome P450 CYP2C11 measured by 2-alpha and 16-alpha hydroxylation of testosterone2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1181464Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
AID1434735Modulation of human SERT expressed in HEK293 cells at 2 uM using APP+ as substrate by fluorescence assay relative to control2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Nardonaphthalenones A and B from the roots and rhizomes of Nardostachys chinensis Batal.
AID589127Mechanism based inhibition of human cytochrome P450 3A4 measured by midazolam hydroxylase activity2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1164245Inhibition of human NET expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
AID362026Inhibition of serotonin uptake at human SERT expressed in HEK cells2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.
AID234449Uptake ratio Ki of norepinephrine relative to dopamine at monoamine transporter2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Further studies on conformationally constrained tricyclic tropane analogues and their uptake inhibition at monoamine transporter sites: synthesis of (Z)-9-(substituted arylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes as a novel class of serotonin transpo
AID459745Inhibition of [3H]5HT uptake at SERT in rat brain hippocampal synaptosomes by liquid scintillation spectrophotometry2010Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
Lobeline esters as novel ligands for neuronal nicotinic acetylcholine receptors and neurotransmitter transporters.
AID314091Inhibition of human AchE2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Multi-target-directed ligands to combat neurodegenerative diseases.
AID179745In vitro inhibition of norepinephrine (NE) uptake in crude rat brain synaptosomes (% inhibition at maximum concentration)1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
Molecular structure of fluoxetine hydrochloride, a highly selective serotonin-uptake inhibitor.
AID1307724Inhibition of of human TREK1 expressed in tsA201 cells assessed as reduction in channel currents at 100 uM2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
AID1215124Binding affinity to Wistar rat brain lipid assessed as percentage unbound by TRANSIL assay2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1164250Selectivity index, ratio of IC50 for human NET to IC50 for human SERT2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
AID1623644Anxiolytic-like activity in C57Bl/6J mouse assessed as increase in total time spent in the light side of the chamber at 15 mg/kg, ip measured during 10-min testing period2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Discovery of an Orally Bioavailable and Central Nervous System (CNS) Penetrant mGlu
AID567858Antifungal activity against Aspergillus flavus MTCC 277 after 72 hrs2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis, antidepressant and antifungal evaluation of novel 2-chloro-8-methylquinoline amine derivatives.
AID395507Antidepressant activity in ICR mouse assessed as decrease in immobility duration at 40 mg/kg, ip by forced swimming test2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
AID186086Compound was tested in schedule induced polydipsia in rats expressed as %maximum suppression at minimum effective dose of 30 mg/kg intraperitoneally1997Journal of medicinal chemistry, Aug-15, Volume: 40, Issue:17
Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder.
AID1857247Antidepressant activity in reserpine-induced mouse assessed as downregulation of 5-HT2AR expression at 20 mg/kg pretreated with reserpine for 3 days followed by compound addition on day 4 to 10 by Western blot analysis2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Development of MAO-A and 5-HT
AID459375Displacement of [I125]RTI-55 from human SERT transfected in human HEK293 cells2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis and hSERT activity of homotryptamine analogs. Part 6: [3+2] dipolar cycloaddition of 3-vinylindoles.
AID1164248Inhibition of human NET expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
AID326622Antidepressant activity in mouse assessed as immobility time during final 5 mins of the 6 mins session at 100 mg/kg, po administered 60 mins before the test in forced-swimming test2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Novel quinazolinone derivatives as 5-HT7 receptor ligands.
AID412740Displacement of [125I]RTI55 from human recombinant NET expressed in HEK293 cells2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.
AID652516Antiamnesic activity in scopolamine-induced C57BL/6 mouse assessed as aversive memory measuring increase in latency to enter dark area at 1.54 mg/kg, ip administered 20 mins prior training measured after 48 hrs by step-through passive avoidance task analy2011ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9
NO-SSRIs: Nitric Oxide Chimera Drugs Incorporating a Selective Serotonin Reuptake Inhibitor.
AID752492Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.
AID292943Binding affinity to rat SERT2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Dual serotonin transporter/histamine H3 ligands: Optimization of the H3 pharmacophore.
AID504085Potentiation of 5-hydroxytryptamine-induced serotonin syndrome like behavior in po dosed mouse2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.
AID1636365Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 68 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NAD2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID300627Binding affinity to human histamine H3 receptor2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Benzylamine histamine H(3) antagonists and serotonin reuptake inhibitors.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1155483Neuroprotective activity against rat PC12 cells assessed as protection against corticosterone- induced lesion at 1.25 uM after 1 day by MTT assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Synthesis and biological evaluation of novel naphthalene compounds as potential antidepressant agents.
AID305407Binding affinity at human SERT2007Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors.
AID1232311Unbound volume of distribution at steady state in human2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Volume of Distribution in Drug Design.
AID752493Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID5241Binding affinity towards 5-hydroxytryptamine 2 receptor1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID170361Effect on food consumption was determined in 8 rats at 2-6h after ip administration at the dose of 10 mg/kg; expressed as change in weight of the jar containing food2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
AID1215121Fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID145392Ability to inhibit high affinity reuptake of [3H]-NE (Norepinephrine transporter) into nerve ending synaptosomes prepared from brain regions2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Further studies on conformationally constrained tricyclic tropane analogues and their uptake inhibition at monoamine transporter sites: synthesis of (Z)-9-(substituted arylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes as a novel class of serotonin transpo
AID611039Antidepressant activity in Swiss mouse assessed as immobility duration at 20 mg/kg, ip administered 30 mins prior test measured during last 4 mins of 6 mins observation period by forced-swimming test (Rvb = 166 +/- 12.23 to 218.54 +/- 8.11 Secs)2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Synthesis and antidepressant-like activity evaluation of sulphonamides and sulphonyl-hydrazones.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1718151Displacement of [3H]DTG from sigma 2 receptor in Sprague-Dawley rat brain membranes in presence of (+)-pentazocine by scintillation counting method2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID1172784Antidepressant activity in C57BL/6 mouse assessed as decrease in immobility duration at 10 mg/kg, ig by forced swim test2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Synthesis and structure-activity relationship of novel cinnamamide derivatives as antidepressant agents.
AID395502Displacement of [3H]dopamine from human recombinant DAT expressed in HEK293 cells by scintillation counting2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
AID219623Binding affinity at alpha-1-adrenoceptor by the inhibition of binding to [3H]prazosin in rat cortical membranes1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
New indole derivatives as potent and selective serotonin uptake inhibitors.
AID1217729Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID1221982Fraction absorbed in human2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID170356Effect on food consumption was determined in 24 rats at 4 hr after ip administration at the dose of 10 mg/kg; expressed as change in percent weight of the jar containing food2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
AID547621Cytotoxicity against BESM cells after 88 hrs by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID254338Binding inhibition towards human norepinephrine transporter2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.
AID309939Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 25.89 mM/kg, ip after 20 mins2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1700182Antidepressant activity in mouse assessed as decrease in immobility time at 10 mg/kg, ip by forced swimming test (Rvb = 147.8 +/- 10.2 sec)2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Novel piperazine-2,5-dione analogs bearing 1H-indole: Synthesis and biological effects.
AID170490Effect on food consumption was determined in 8 rats at 4 hr after ip administration at the dose of 10 mg/kg; expressed as change in weight of the jar containing food2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
AID386923Antifungal activity against Sporothrix schenckii after 48 hrs by broth microdilution technique2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Carbodithioic acid esters of fluoxetine, a novel class of dual-function spermicides.
AID567859Antifungal activity against Monascus purpureus MTCC 369 after 72 hrs2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis, antidepressant and antifungal evaluation of novel 2-chloro-8-methylquinoline amine derivatives.
AID388905Antidepressant activity against dark-induced depression in Albino Swiss mouse assessed as decrease in immobility period at 20 mg/kg, ip once daily for 4 days and 30 mins before test on day 5 by forced swimming test2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
PASS-assisted exploration of antidepressant activity of 1,3,4-trisubstituted-beta-lactam derivatives.
AID388703Inhibition of 5-HT transporter-mediated [3H]5HT uptake in human Jar cells2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Advances toward new antidepressants with dual serotonin transporter and 5-HT1A receptor affinity within a class of 3-aminochroman derivatives. Part 2.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1651166Displacement of [3H]ketanserin from 5HT2A receptor (unknown origin) at 10 uM by cell based radioligand competitive binding analysis relative to control2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Evaluation of anti-depressant effects of phthalazinone-based triple-acting small molecules against 5-HT
AID130138Compound was evaluated for potentiating 5-HTP-induced Head twitches in mice for 6 hour before 5-HTP administration (peroral)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
New indole derivatives as potent and selective serotonin uptake inhibitors.
AID493410Antidepressant activity in Swiss albino mouse assessed as reduction of immobility duration at 30 mg/kg, ip administered 3 times for 24 hrs measured after 1 hr last post dose by tail suspension test2010Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15
Synthesis, antidepressant evaluation and QSAR studies of novel 2-(5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)-N-(substituted phenyl)acetamides.
AID1181445Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
AID1372773Antidepressant activity in Balb/c mouse assessed as decrease in immobility time administered ip 30 mins prior to test measured for 6 mins by tail suspension test2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
5-HT
AID130137Compound was evaluated for potentiating 5-HTP-induced Head twitches in mice for 6 hour before 5-HTP administration (Subcutaneous)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
New indole derivatives as potent and selective serotonin uptake inhibitors.
AID611191Inhibition of serotonin reuptake at SERT expressed in HEK293 cells2011Journal of medicinal chemistry, Aug-11, Volume: 54, Issue:15
Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.
AID547804Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID482894Inhibition of AChE2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Prediction of acetylcholinesterase inhibitors and characterization of correlative molecular descriptors by machine learning methods.
AID567855Antidepressant activity in Albino rat assessed as immobility time at 20 mg/kg, ip by forced swimming test (Rvb = 112.4 +/- 2.88 sec)2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis, antidepressant and antifungal evaluation of novel 2-chloro-8-methylquinoline amine derivatives.
AID1589639Cytotoxicity against human RD cells after 3 days by neutral red dye-based photometric method2019Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8
Discovery of Quinoline Analogues as Potent Antivirals against Enterovirus D68 (EV-D68).
AID1589640Selectivity index, ratio of CC50 for human RD cells to EC50 for Enterovirus D68 US/KY/14-18953 infected in human RD cells2019Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8
Discovery of Quinoline Analogues as Potent Antivirals against Enterovirus D68 (EV-D68).
AID1172778Antidepressant activity in C57BL/6 mouse assessed as decrease in immobility duration at 10 mg/kg, ig by tail suspension test2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Synthesis and structure-activity relationship of novel cinnamamide derivatives as antidepressant agents.
AID611035Antidepressant activity in Swiss mouse assessed as reduction of immobility duration at 20 mg/kg, ip administered 30 mins prior test measured during last 4 mins of 6 mins observation period by forced-swimming test (Rvb = 0 %)2011Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14
Synthesis and antidepressant-like activity evaluation of sulphonamides and sulphonyl-hydrazones.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1210013Inhibition of recombinant CYP2J2 (unknown origin)-mediated terfenadine hydroxylation assessed as remaining activity at 30 uM after 5 mins by LC-MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID36350Binding affinity for human alpha-2 adrenergic receptor expressed in CHO cell2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties.
AID35630In vitro binding affinity against alpha-2 adrenergic receptor of rat in presence of [3H]-RX 821002 radioligand2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties.
AID305408Binding affinity at human histamine H3 receptor2007Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors.
AID234450Uptake ratio Ki of norepinephrine relative to serotonin (5-HT) at monoamine transporter2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Further studies on conformationally constrained tricyclic tropane analogues and their uptake inhibition at monoamine transporter sites: synthesis of (Z)-9-(substituted arylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes as a novel class of serotonin transpo
AID36017In vitro binding affinity against alpha-1 adrenergic receptor of rat in presence of [3H]-prazosin radioligand2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties.
AID1597737Half life in human at 20 mg2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Sleep modulating agents.
AID1232306Dissociation constant of the compound2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Volume of Distribution in Drug Design.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID338208Inhibition of serotonin reuptake site of serotonin transporter at 1 nM1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID234448Uptake ratio Ki of dopamine relative to serotonin (5-HT) at monoamine transporter2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Further studies on conformationally constrained tricyclic tropane analogues and their uptake inhibition at monoamine transporter sites: synthesis of (Z)-9-(substituted arylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes as a novel class of serotonin transpo
AID338210Inhibition of histamine H1 receptor at 100 nM1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID726266Inhibition of rat voltage-gated K channel 3.1 expressed in CHO cells by patch clamp assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Ion channels as therapeutic targets: a drug discovery perspective.
AID349967Anxiolytic activity in BALB/c mouse assessed as velocity at 10 mg/kg, po after 90 mins by open-field test (RVb= 7.07+/-0.51 cm/s)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID186979Inhibition of [3H]- DA reuptake into rat striatal synaptosomes1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID254272Inhibition constant against dopamine transporter2005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Designed multiple ligands. An emerging drug discovery paradigm.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1175707Antidepressant-like activity in Swiss albino mouse assessed as decrease in immobility time at 20 mg/kg, ip measured for 5 mins by forced swimming test relative to control2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Design and synthesis of new series of coumarin-aminopyran derivatives possessing potential anti-depressant-like activity.
AID422846Displacement of [3H]paroxetine from 5HT transporter in rat cortical membrane2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonists.
AID1211294Unbound fraction in plasma (unknown origin) at pH 7.4 after 6 hrs by equilibrium dialysis method in presence of 5% CO22011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1405819Antidepressant activity in Kunming mouse assessed as decrease in immobility duration at 20 mg/kg, po by forced swim test2018European journal of medicinal chemistry, Aug-05, Volume: 156Synthesis and biological evaluation of magnolol derivatives as melatonergic receptor agonists with potential use in depression.
AID292944Binding affinity to human SERT2007Bioorganic & medicinal chemistry letters, Feb-01, Volume: 17, Issue:3
Dual serotonin transporter/histamine H3 ligands: Optimization of the H3 pharmacophore.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1164988Antidepressant activity in Swiss mouse assessed as reduction of immobility time at 20 mg/kg, ip after 30 mins by forced swimming test relative to vehicle-treated control2014Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20
Synthesis and evaluation of new 3-phenylcoumarin derivatives as potential antidepressant agents.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID330660Effect on life span of Caenorhabditis elegans at 100 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID1700183Antidepressant activity in mouse assessed as decrease in immobility time at 10 mg/kg, ip by forced swimming test relative to control2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Novel piperazine-2,5-dione analogs bearing 1H-indole: Synthesis and biological effects.
AID269937Inhibition of [3H]5-HT uptake at 5HT transporter expressed in HEK293 cells2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.
AID412743Inhibition of [3H]NE from human recombinant NET expressed in HEK293 cells2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.
AID1210014Inhibition of recombinant CYP2J2 (unknown origin)-mediated astemizole O-demethylation assessed as remaining activity at 30 uM after 5 mins by LC-MS/MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1651167Displacement of [3H]ketanserin from 5HT2A receptor (unknown origin) by cell based radioligand competitive binding analysis2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Evaluation of anti-depressant effects of phthalazinone-based triple-acting small molecules against 5-HT
AID751704Displacement of [3H]Paroxetine from human recombinant SERT expressed in HEK293 cells at 10 uM after 60 mins relative to control2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID306609Binding affinity to human SERT2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Novel naphthyridines are histamine H3 antagonists and serotonin reuptake transporter inhibitors.
AID386921Antifungal activity against Candida albicans after 48 hrs by broth microdilution technique2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Carbodithioic acid esters of fluoxetine, a novel class of dual-function spermicides.
AID406960Antifungal activity against dermatophytes at 35 degC after 48 to 96 hrs by broth microdilution test2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
1-[(3-Aryloxy-3-aryl)propyl]-1H-imidazoles, new imidazoles with potent activity against Candida albicans and dermatophytes. Synthesis, structure-activity relationship, and molecular modeling studies.
AID145563Equilibrium dissociation constant (KD) for Competitive binding between [3H]- nisoxatine and the compound at human Norepinephrine transporter1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID411215Displacement of [3H]citalopram from SERT in Sprague-dawley rat frontal cortex by liquid scintillation spectrophotometry2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
1-Naphthyl and 4-indolyl arylalkylamines as selective monoamine reuptake inhibitors.
AID1211293Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.22 after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID547622Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID395509Antidepressant activity in BALB/c mouse assessed as decrease in immobility duration at 20 mg/kg, ip administered 30 mins prior to test by forced swimming test2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
AID1254876Inhibition of CYP2C19 (unknown origin) using luciferin tagged substrate preincubated for 10 mins before substrate addition2015European journal of medicinal chemistry, Oct-20, Volume: 103Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM).
AID145396Inhibition of [3H]NE uptake by Norepinephrine transporter of rat occipital cortex synaptosomes2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Further SAR studies of piperidine-based analogues of cocaine. 2. Potent dopamine and serotonin reuptake inhibitors.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1215120Binding affinity to Wistar rat brain lipid by TRANSIL assay2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID408252Inhibition of [3H]dopamine reuptake at human NET expressed in african green monkey COS7 cells at 100 nM2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies.
AID504070Antidepressant activity in po dosed mouse assessed as reduction of mobility time by forced swimming test2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.
AID688847Octanol-phosphate buffered saline partition coefficient, log K of the compound2011Bioorganic & medicinal chemistry letters, Dec-15, Volume: 21, Issue:24
Fluorescent reporters of monoamine transporter distribution and function.
AID187184Inhibition of norepinephrine uptake into rat synaptosomes2003Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24
Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake.
AID1164244Inhibition of human SERT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
AID1215123Binding affinity to Wistar rat serum albumin2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1155482Neurorestorative activity against H2O2-induced oxidant injury in rat PC12 cells assessed as restorative rate at 40 uM measured after 48 hrs pretreated with 200 uM H2O2 for 1 hr by MTT assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Synthesis and biological evaluation of novel naphthalene compounds as potential antidepressant agents.
AID1278665Antidepressant activity in ICR mouse assessed as immobility time at 50 mg/kg, iv administered 30 mins before testing by forced swim test (Rvb = 159.1 sec)2016European journal of medicinal chemistry, Mar-03, Volume: 110Novel N-acyl-carbazole derivatives as 5-HT7R antagonists.
AID343578Inhibition of dopamine uptake at human DAT in human HEK293 cells2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).
AID1221966Ratio of plasma AUC in po dosed mdr1 knock out mouse to plasma AUC in po dosed wild type mouse2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID268716Inhibition of [3H]DA reuptake at DA transporter in HEK293 cells2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.
AID1217711Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID170357Effect on food consumption was determined in 24 rats at 4 hr after ip administration at the dose of 10 mg/kg; expressed as change in weight of the jar containing food2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1217722Time dependent inhibition of CYP2C19 in human liver microsomes at 30 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID459948Inhibition of serotonin uptake at human SERT expressed in human JAR cells2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
1-(Indolin-1-yl)-1-phenyl-3-propan-2-olamines as potent and selective norepinephrine reuptake inhibitors.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID314096Inhibition of SERT2008Journal of medicinal chemistry, Feb-14, Volume: 51, Issue:3
Multi-target-directed ligands to combat neurodegenerative diseases.
AID244797Antifungal activity to cause 99% reduction of surviving cells range is equal to 64-1282004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
Imidazole analogues of fluoxetine, a novel class of anti-Candida agents.
AID204871Binding affinity against Serotonin transporter in rat cerebral cortex using [3H]paroxetine binding assay.2002Bioorganic & medicinal chemistry letters, Nov-04, Volume: 12, Issue:21
Dual NK(1) antagonists--serotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives.
AID408251Inhibition of [3H]5-hydroxytryptamine reuptake at human SERT expressed in african green monkey COS7 cells at 100 nM2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
From the selective serotonin transporter inhibitor citalopram to the selective norepinephrine transporter inhibitor talopram: synthesis and structure-activity relationship studies.
AID1124854Cytotoxicity against human L02 cells assessed as inhibitory rate at 80 uM after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and evaluation of amide side-chain modified Agomelatine analogues as potential antidepressant-like agents.
AID410151Inhibition of serotonin uptake at human SERT expressed in JAR cells2008Bioorganic & medicinal chemistry letters, Dec-01, Volume: 18, Issue:23
Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.
AID375984Antidepressant activity in ICR mouse assessed as reduction in immobility time of forced swimming at 10 mg/kg, po administered once daily for 5 days by forced swimming test relative to control2006Journal of natural products, Apr, Volume: 69, Issue:4
Saponins from Polygala japonica and their effects on a forced swimming test in mice.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID344488Hepatotoxicity in Sprague-Dawley rat assessed as presence of normal hepatic parenchyma with portal triad and central vein by histopathological study2008European journal of medicinal chemistry, May, Volume: 43, Issue:5
N-{[(6-substituted-1,3-benzothiazole-2-yl)amino]carbonothioyl}-2/4-substituted benzamides: synthesis and pharmacological evaluation.
AID170362Effect on food consumption was determined in 8 rats at 2 hr after ip administration at the dose of 10 mg/kg; expressed as change in percent weight of the jar containing food2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
AID393266Antidepressant activity in BALB/c mouse assessed as decrease in duration of immobility at 10 mg/kg, ip pretreated 30 mins before test by forced swimming test2009Bioorganic & medicinal chemistry, Mar-01, Volume: 17, Issue:5
2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors.
AID349999Anxiolytic activity in BALB/c mouse assessed as distance moved at 5 mg/kg, po after 90 mins by open-field test (RVb= 8485+/-610 cm)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID395512Antidepressant activity in BALB/c mouse assessed as decrease in immobility duration at 32.3 umol/kg, ip administered 23 hrs, 5 hrs and 1 hr prior to test measured after 4 weeks by forced swimming test2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
AID1124853Inhibition of corticosterone-induced rat PC12 cells lesions assessed as protection rate at 1.25 uM after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Apr-01, Volume: 24, Issue:7
Synthesis and evaluation of amide side-chain modified Agomelatine analogues as potential antidepressant-like agents.
AID601167Toxicity in albino mouse assessed as increase in locomotor activity at 10 to 20 mg/kg, ip2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Novel benzo[b]thiophene derivatives as new potential antidepressants with rapid onset of action.
AID204703Inhibition of [3H]citalopram binding to Serotonin transporter of rat cerebral cortex2000Bioorganic & medicinal chemistry letters, Jul-17, Volume: 10, Issue:14
Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 1.
AID1247105Inhibition of human SERT expressed in HEK293 cells using 4-[4-(Dimethylamino)phenyl]-1-methyl pyridinium as substrate assessed as fluorescent intensity at 2 uM after 3 hrs relative to control2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
A novel sesquiterpene and three new phenolic compounds from the rhizomes of Acorus tatarinowii Schott.
AID349978Anxiolytic activity in BALB/c mouse assessed as immobility at 10 mg/kg, po after 90 mins by open-field test (RVb= 458.4+/-41 s)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID446937Inhibition of serotonin uptake at human SERT expressed in JAR cells2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.
AID339531Displacement of [3H]8-OH-DPAT from human 5HT1A receptor expressed in CHO cells2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Studies toward the discovery of the next generation of antidepressants. Part 6: Dual 5-HT1A receptor and serotonin transporter affinity within a class of arylpiperazinyl-cyclohexyl indole derivatives.
AID540237Phospholipidosis-positive literature compound observed in rat
AID309946Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 19.42 mM/kg, ip after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID170363Effect on food consumption was determined in 8 rats at 2 hr after ip administration at the dose of 10 mg/kg; expressed as change in weight of the jar containing food2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
AID309948Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced intraperitoneally dosed mouse head twitch after 20 mins2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1718165Displacement of [3H]-(+)-pentazocine from sigma 1 receptor in Sprague-Dawley rat brain membranes by scintillation counting method2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Small Molecules Selectively Targeting Sigma-1 Receptor for the Treatment of Neurological Diseases.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1651169Displacement of [3H]mesulergine from 5-HT2C receptor (unknown origin) by cell based radioligand competitive binding analysis2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Evaluation of anti-depressant effects of phthalazinone-based triple-acting small molecules against 5-HT
AID1571161Antitrypanosomal activity against Trypanosoma brucei brucei 427 bloodstream forms assessed as parasite viability at 10 uM after 24 hrs by resazurin dye based fluorescence assay relative to control2018MedChemComm, Dec-01, Volume: 9, Issue:12
Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery.
AID1181446Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
AID1525515Inhibition of rat synaptosome SERT2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms.
AID1164246Inhibition of human DAT expressed in HEK293 cells at 0.1 uM incubated for 15 mins by neurotransmitter reuptake assay2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID343580Inhibition of norepinephrine uptake at human NET in human HEK293 cells2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI).
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID509960Antidepressant-like activity in Swiss albino mouse assessed as effect on climbing time at 10 mg/kg, ip after 24 hrs measured for 5 mins by modified forced swimming test (Rvb = 56.8 +/- 2.6 sec)2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
New pyrazoline derivatives and their antidepressant activity.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID338211Inhibition of 5HT2 receptor at 100 nM1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID619832Inhibition of human SERT expressed in JAR cells assessed as serotonin uptake2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152).
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1181462Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
AID1314090Antidepressant activity in Swiss albino mouse assessed as duration of immobility at 10 mg/kg, po dosed 1 hr before test measured after 6 mins by tail suspension test (Rvb = 183 sec)2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Synthesis of benzimidazole based thiadiazole and carbohydrazide conjugates as glycogen synthase kinase-3β inhibitors with anti-depressant activity.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID330661Effect on life span of Caenorhabditis elegans at 200 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID1315365Neuroprotective activity against corticosterone-induced cell injury in rat PC12 cells assessed as cell viability at 0.3 uM after 48 hrs by MTT assay (Rvb = 55.6 +/- 0.87%)2016Journal of natural products, 05-27, Volume: 79, Issue:5
Polycyclic Polyprenylated Derivatives from Hypericum uralum: Neuroprotective Effects and Antidepressant-like Activity of Uralodin A.
AID1210069Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID596122Inhibition of NET in rat cerebral cortex assessed as [3H]norepinephrine accumulation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.
AID309936Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 4.86 mM/kg, ip after 20 mins2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID504079Displacement of [3H]paroxetine from SERT in rat cerebral cortex2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.
AID1232307Lipophilicity, log P of the compound2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Volume of Distribution in Drug Design.
AID1155481Neurorestorative activity against H2O2-induced oxidant injury in rat PC12 cells assessed as restorative rate at 20 uM measured after 48 hrs pretreated with 200 uM H2O2 for 1 hr by MTT assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Synthesis and biological evaluation of novel naphthalene compounds as potential antidepressant agents.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID200773Inhibition of high affinity re-uptake of [3H]5-HT (serotonin) into nerve ending synaptosomes2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Further studies on conformationally constrained tricyclic tropane analogues and their uptake inhibition at monoamine transporter sites: synthesis of (Z)-9-(substituted arylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes as a novel class of serotonin transpo
AID349956Anxiolytic activity in BALB/c mouse assessed as distance moved at 10 mg/kg, po after 90 mins by open-field test (RVb= 8485+/-610 cm)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID170353Effect on food consumption was determined in 24 rats at 2-6h after ip administration at the dose of 10 mg/kg; expressed as change in weight of the jar containing food2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
AID1221963Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID134216Tested in vitro for norepinephrine (NE) neuronal uptake inhibition1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID186981Inhibition of [3H]5-HT reuptake into rat frontal cortex synaptosomes1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID652441Inhibition of human SERT-mediated serotonin reuptake in HEK293 cells at 100 nM2011ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9
NO-SSRIs: Nitric Oxide Chimera Drugs Incorporating a Selective Serotonin Reuptake Inhibitor.
AID305406Binding affinity at rat SERT2007Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors.
AID1155488Antidepressant-like activity in C57 mouse assessed as reduction in immobility time at 32 mg/kg, ip administered from day 2 to 15 measured on 2nd and 15th day 30 mins after drug challenge by forced swim test2014European journal of medicinal chemistry, Jul-23, Volume: 82Synthesis and biological evaluation of novel naphthalene compounds as potential antidepressant agents.
AID170355Effect on food consumption was determined in 24 rats at 2 hr after ip administration at the dose of 10 mg/kg; expressed as change in weight of the jar containing food2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
AID1307725Inhibition of of human TREK1 expressed in tsA201 cells assessed as reduction in channel currents2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
AID509959Antidepressant-like activity in Swiss albino mouse assessed as reduction of immobility time at 10 mg/kg, ip measured last 4 mins for 6 mins test by tail suspension test (Rvb = 116.4 +/- 4.6 sec)2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
New pyrazoline derivatives and their antidepressant activity.
AID1211296Unbound fraction in plasma (unknown origin) under normal atmospheric condition at pH 7.72 after 6 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID1181443Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells at 0.1 uM after 15 mins by fluorescence neurotransmitter transporter assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1651174Antidepressant activity in mouse assessed as reduction in immobility time at 50 mg/kg, ip administered 30 mins prior to testing and measured for last 5 mins of 6 mins test period by forced swim test2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Evaluation of anti-depressant effects of phthalazinone-based triple-acting small molecules against 5-HT
AID395334Displacement of [125I]RTI-55 from human recombinant SERT expressed in HEK293 cells by scintillation counting2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
AID344478Anticonvulsant activity in ip dosed CF1 albino mouse assessed as minimum effective dose after 0.5 hrs by MES screen test2008European journal of medicinal chemistry, May, Volume: 43, Issue:5
N-{[(6-substituted-1,3-benzothiazole-2-yl)amino]carbonothioyl}-2/4-substituted benzamides: synthesis and pharmacological evaluation.
AID386927Antitrichomonas activity against Trichomonas vaginalis after 48 hrs by trypan blue staining2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Carbodithioic acid esters of fluoxetine, a novel class of dual-function spermicides.
AID269938Inhibition of [3H]NA uptake at NA transporter expressed in HEK293 cells2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID395504Displacement of [3H]norepinephrine from human recombinant NET expressed in HEK293 cells by scintillation counting2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
AID200770Inhibition of [3H]peroxitine binding to rat cortical membranes as measure of inhibitory activity towards 5-HT uptake1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
New indole derivatives as potent and selective serotonin uptake inhibitors.
AID1571162Antitrypanosomal activity against Trypanosoma brucei brucei 427 bloodstream forms after 24 hrs by resazurin dye based fluorescence assay2018MedChemComm, Dec-01, Volume: 9, Issue:12
Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery.
AID268714Inhibition of [3H]5-HT reuptake at 5HT transporter in HEK293 cells2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.
AID504076Inhibition of dopamine reuptake at human dopamine transporter expressed in CHO cells2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.
AID1181447Inhibition of norepinephrine reuptake at human NET expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
AID268270Displacement of [3H]paroxetine from 5-HT transporter in Sprague-Dawley rat cortical membranes2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Synthesis and biological evaluation of novel compounds within a class of 3-aminochroman derivatives with dual 5-HT1A receptor and serotonin transporter affinity.
AID36349Antagonistic activity as [35S]GTP gamma-S binding at alpha-2a adrenergic receptor expressed in CHO cells2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Potential antidepressants displayed combined alpha(2)-adrenoceptor antagonist and monoamine uptake inhibitor properties.
AID412741Inhibition of [3H]DA from human recombinant DAT expressed in HEK293 cells2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.
AID420787Antagonist activity at human 5HT3A receptor expressed in HEK293 cells assessed as inhibition of serotonin-induced inward Na+ current at >= 10 uM2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors.
AID388702Displacement of [3H]paroxetine from serotonin transporter in Sprague-Dawley rat frontal cortical membrane2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Advances toward new antidepressants with dual serotonin transporter and 5-HT1A receptor affinity within a class of 3-aminochroman derivatives. Part 2.
AID349930Antinociceptive activity in BALB/c mouse assessed as decrease in paw withdrawal latency at 10 mg/kg, po after 240 mins by hot plate method2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1215347Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone at 0.01 to 100 uM preincubated for 60 mins followed by testosterone treatment measured after 10 mins by LC-MS/MS analysis in 2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID349979Anxiolytic activity in BALB/c mouse assessed as immobility at 20 mg/kg, po after 90 mins by open-field test (RVb= 458.4+/-41 s)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID203916Binding affinity towards serotonin S1 receptor at 1.0 uM1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID1215349Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone at 0.01 to 100 uM preincubated for 60 mins followed by testosterone treatment measured after 10 mins by refined CYP450 IC50 s2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1215122Percentage unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID170360Effect on food consumption was determined in 8 rats at 2-6h after ip administration at the dose of 10 mg/kg; expressed as change in percent weight of the jar containing food2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
AID681116TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1571163Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 48 hrs by resazurin dye based fluorescence assay2018MedChemComm, Dec-01, Volume: 9, Issue:12
Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID204698Inhibition of [3H]5-HT uptake by Serotonin transporter of rat midbrain or parietal synaptosomes2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Further SAR studies of piperidine-based analogues of cocaine. 2. Potent dopamine and serotonin reuptake inhibitors.
AID1221962Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID186980Inhibition of [3H]- NE reuptake into rat hippocampal synaptosomes1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1211295Unbound fraction in plasma (unknown origin) at pH 7.63 after 6 hrs by equilibrium dialysis method in presence of 5% CO22011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1315366Neuroprotective activity against corticosterone-induced cell injury in rat PC12 cells assessed as cell viability at 0.1 uM after 48 hrs by MTT assay (Rvb = 55.6 +/- 0.87%)2016Journal of natural products, 05-27, Volume: 79, Issue:5
Polycyclic Polyprenylated Derivatives from Hypericum uralum: Neuroprotective Effects and Antidepressant-like Activity of Uralodin A.
AID395503Displacement of [3H]serotonin from human recombinant SERT expressed in HEK293 cells by scintillation counting2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
AID509963Antidepressant-like activity in Swiss albino mouse assessed as effect on swimming time at 10 mg/kg, ip after 24 hrs measured for 5 mins by modified forced swimming test (Rvb = 95 +/- 9.7 sec)2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
New pyrazoline derivatives and their antidepressant activity.
AID441347Inhibition of human SERT expressed in JAR cells2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
Structure-activity relationships of the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ol series of monoamine reuptake inhibitors.
AID497189Displacement of [3H] astemizole from human recombinant ERG channel expressed in HEK293 cells2010Bioorganic & medicinal chemistry, Aug-15, Volume: 18, Issue:16
Further optimization of novel pyrrole 3-carboxamides for targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.
AID567857Antifungal activity against Aspergillus niger MTCC 281 after 72 hrs2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis, antidepressant and antifungal evaluation of novel 2-chloro-8-methylquinoline amine derivatives.
AID1307733Inhibition of of human TASK3 expressed in HEK293 cells assessed as reduction in channel currents at 10 uM2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID204846Inhibition of [3H]5-HT uptake into rat synaptosomes by Serotonin transporter2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
A convenient procedure for the synthesis of nonsymmetrical bivalent selective serotonin reuptake inhibitors using polymer-supported reagents.
AID298032Acid dissociation constant, pKa of the compound2007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
AID1659915Antidepressant activity in mouse assessed as reduction in duration of immobility at 3 mg/kg, ip relative to control
AID230533Ratio of selective inhibition of norepinephrine (NE) to serotonin(5-HT) was evaluated2000Bioorganic & medicinal chemistry letters, Dec-18, Volume: 10, Issue:24
A convenient procedure for the synthesis of nonsymmetrical bivalent selective serotonin reuptake inhibitors using polymer-supported reagents.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1181460Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells at 1 uM after 15 mins by fluorescence neurotransmitter transporter assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
AID616837Anti-depressant activity in mouse assessed as immobility effect at 10 mg/kg, po after 60 mins by forced swimming test2011Journal of medicinal chemistry, Sep-22, Volume: 54, Issue:18
Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.
AID395501Displacement of [125I]RTI-55 from human recombinant NET expressed in HEK293 cells by scintillation counting2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
AID1054122Inhibition of human ERG2013Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22
Polypharmacology - foe or friend?
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID601163Displacement of [3H]5-HT from of SERT in rat midbrain homogenates after 5 mins by scintillation counting2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Novel benzo[b]thiophene derivatives as new potential antidepressants with rapid onset of action.
AID3541Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID245920Cytotoxicity to reduce human histolytic lymphoma U937 cells2004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
Imidazole analogues of fluoxetine, a novel class of anti-Candida agents.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID349968Anxiolytic activity in BALB/c mouse assessed as velocity at 20 mg/kg, po after 90 mins by open-field test (RVb= 7.07+/-0.51 cm/s)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID268271Inhibition of [3H]5-HT uptake at human 5-HT transporter expressed in Jar cells2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Synthesis and biological evaluation of novel compounds within a class of 3-aminochroman derivatives with dual 5-HT1A receptor and serotonin transporter affinity.
AID1140142Displacement of [3H]mesulergine from 5-HT2C receptor in Sprague-Dawley rat choroid plexus membranes after 30 mins by liquid scintillation spectrophotometric analysis2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Design of novel multiple-acting ligands towards SERT and 5-HT2C receptors.
AID739002Antidepressant activity in gerbil assessed as decrease in immobility time at 10 mg/kg, po administered for 30 mins prior to testing measured for 6 mins by forced swimming test2013Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8
Discovery of disubstituted piperidines and homopiperidines as potent dual NK1 receptor antagonists-serotonin reuptake transporter inhibitors for the treatment of depression.
AID181689Compound was evaluated for its ability to antagonizing serotonin high affinity uptake was determined using [3H]5-HT on synaptosomes prepared from rat midbrain or parietal cortices.2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Further SAR studies of piperidine-based analogues of cocaine. 2. Potent dopamine and serotonin reuptake inhibitors.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID596120Inhibition of DAT in rat striatum assessed as [3H]dopamine accumulation2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.
AID362027Inhibition of dopamine uptake at human DAT expressed in HEK cells2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.
AID362025Inhibition of norepinephrine uptake at human NET expressed in HEK cells2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint.
AID481498Inhibition of human SERT expressed in human JAR cells2010Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9
Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.
AID309945Inhibition of NET-mediated norepinephrine-reuptake assessed as yohimbine induced mortality in mouse at 12.94 mM/kg, ip after 24 hrs2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID773435Inhibition of human DAT-mediated dopamine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.
AID295325Displacement of [3H]citalopram from Sprague-Dawley rat SERT2007Bioorganic & medicinal chemistry, May-15, Volume: 15, Issue:10
Syntheses and binding affinities of 6-nitroquipazine analogues for serotonin transporter. Part 5: 2'-Substituted 6-nitroquipazines.
AID170354Effect on food consumption was determined in 24 rats at 2 hr after ip administration at the dose of 10 mg/kg; expressed as change in percent weight of the jar containing food2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
AID50342Maximal activatory effect against human carbonic anhydrase I (hCA I) at a concentration of 1 mM2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertraline and citalopram are strong activators of isozymes I and II.
AID227291Effect on helpless behavior in rats and the number of escape failures was determined in shuttle-box session-3 (SB-3) at 30 mg/kg dose2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
AID352215Inhibition of norepinephrine uptake at human NET expressed in MDCK-Net6 cells2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.
AID1061168Displacement of [3H]-dopamine from rat striatum DAT after 5 mins2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID227284Effect on helpless behavior in rats and the number of escape failures was determined in shuttle-box session-1 (SB-1) at 30 mg/kg dose2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
AID1525514Inhibition of mouse brain AChE2019Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms.
AID352217Inhibition of serotonin uptake at human SERT expressed in human JAR cells2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.
AID1164249Inhibition of human DAT expressed in HEK293 cells at incubated for 15 mins by neurotransmitter reuptake assay2014ACS medicinal chemistry letters, Sep-11, Volume: 5, Issue:9
Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.
AID1181461Inhibition of DA reuptake at human DAT expressed in HEK293 cells at 10 uM after 15 mins by fluorescence neurotransmitter transporter assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
AID254319Binding inhibition towards human dopamine transporter2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.
AID1061166Displacement of [3H]-dopamine from rat cerebral cortex NET after 7 mins2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.
AID751639Displacement of [3H]Paroxetine from human recombinant SERT expressed in HEK293 cells after 60 mins2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID1315361Antidepressant-like activity in LPS-induced ICR mouse assessed as decrease in immobility time at 25 mg/kg, ig qd for 5 days followed by LPS stimulation on 5th day injected 30 mins post last dose measured 24 hrs after stimulation monitored for last 4 mins 2016Journal of natural products, 05-27, Volume: 79, Issue:5
Polycyclic Polyprenylated Derivatives from Hypericum uralum: Neuroprotective Effects and Antidepressant-like Activity of Uralodin A.
AID338212Inhibition of low conductance potassium channel at 100 nM1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID254322Binding inhibition towards human serotonin transporter2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Conformationally restricted homotryptamines. 2. Indole cyclopropylmethylamines as selective serotonin reuptake inhibitors.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID3511Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines.
AID309935Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 3.24 mM/kg, ip after 20 mins2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1651168Displacement of [3H]mesulergine from 5-HT2C receptor (unknown origin) at 10 uM by cell based radioligand competitive binding analysis relative to control2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Evaluation of anti-depressant effects of phthalazinone-based triple-acting small molecules against 5-HT
AID567861Neurotoxicity in rat assessed as impair in motor coordination at after 30 mins by rotarod test (Rvb = 116.50 +/- 1.18 sec)2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Synthesis, antidepressant and antifungal evaluation of novel 2-chloro-8-methylquinoline amine derivatives.
AID1215126Ratio of fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method to fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID263913Increase in 5HT level in Sprague-Dawley rat hypothalamus by microdialysis at 10 mg/kg, ip (basal value set at 100%)2006Bioorganic & medicinal chemistry letters, May-01, Volume: 16, Issue:9
Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 5.
AID61413Binding affinity at dopamine receptor D2 by the inhibition of binding to [3H]spiperone in rat striatal membranes1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
New indole derivatives as potent and selective serotonin uptake inhibitors.
AID338213Inhibition of norepinephrine reuptake site of norepinephrine transporter at 100 nM1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID395324Lipophilicity, log D at pH 7.4 by liquid chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID338209Inhibition of sigma opioid receptor at 100 nM1993Journal of natural products, Apr, Volume: 56, Issue:4
The role of receptor binding in drug discovery.
AID1654609Photodegradation of compound in deionized H20 at 10 uM by HPLC analysis2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Metabolic and Pharmaceutical Aspects of Fluorinated Compounds.
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1307726Inhibition of of human TREK1 expressed in HEK293 cells assessed as reduction in channel currents2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
AID1217712Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID431883Inhibition of [3H]hydroxytryptamine creatinine sulfate uptake at human SERT expressed in human JAR cells2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID412739Displacement of [125I]RTI55 from human recombinant SERT expressed in HEK293 cells2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.
AID1315587Antidepressant activity in albino mouse assessed as immobility time at 10 mg/kg, ip administered 30 mins prior to testing by forced swimming test (Rvb = 141 +/- 14.2 secs)2016European journal of medicinal chemistry, Oct-04, Volume: 121Antidepressant-like effects and mechanisms of flavonoids and related analogues.
AID1328322Neuroprotective activity in rat PC12 cells assessed as reduction in corticosterone-induced lesions by measuring cell viability at 12.5 uM pretreated for 24 hrs followed by corticosterone-challenge after 48 hrs by MTT assay2016Journal of natural products, 08-26, Volume: 79, Issue:8
Polyprenylated Tetraoxygenated Xanthones from the Roots of Hypericum monogynum and Their Neuroprotective Activities.
AID1651173Inhibition of CYP2C19 (unknown origin)2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Evaluation of anti-depressant effects of phthalazinone-based triple-acting small molecules against 5-HT
AID249258Antifungal activity to cause 99% reduction of surviving cells in 90% isolates2004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
Imidazole analogues of fluoxetine, a novel class of anti-Candida agents.
AID590298Antidepressant activity in Swiss albino mouse assessed as decrease in immobility duration at 20 mg/kg, ip administered 30 mins prior to test measured after 30 mins by tail suspension test (Rvb = 79.9%)2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Discovery and synthesis of novel 3-phenylcoumarin derivatives as antidepressant agents.
AID1074429Antidepressant activity in KunMing mouse assessed as decrease in immobility time at 50 mg/kg, ip by forced swimming test relative to control2014European journal of medicinal chemistry, Feb-12, Volume: 73Design, synthesis and evaluation of the antidepressant and anticonvulsant activities of triazole-containing quinolinones.
AID412738Displacement of [125I]RTI55 from human recombinant DAT expressed in HEK293 cells2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.
AID681144TP_TRANSPORTER: cell accumulation of calcein in L-MDR1 cells2003The Journal of pharmacology and experimental therapeutics, Apr, Volume: 305, Issue:1
Inhibition of P-glycoprotein by newer antidepressants.
AID1365300Antidepressant-like activity in Swiss albino mouse assessed as reduction in immobility time at 15 mg/kg, ip dosed 1 hr before test by forced swimming test2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
New 5-HT
AID306608Binding affinity to rat SERT2007Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9
Novel naphthyridines are histamine H3 antagonists and serotonin reuptake transporter inhibitors.
AID395333Displacement of [125I]RTI-55 from human recombinant DAT expressed in HEK293 cells by scintillation counting2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
AID483448Inhibition of SERT-mediated serotonin uptake in human JAR cells2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).
AID395517Antidepressant activity in ICR mouse assessed as decrease in immobility duration at 65 umol/kg, ip administered 30 mins prior to test by forced swimming test2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1212341Cytotoxicity against human Fa2N-4 cells by lactate dehydrogenase assay2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID1315362Neuroprotective activity against corticosterone-induced cell injury in rat PC12 cells assessed as cell viability at 10 uM after 48 hrs by MTT assay (Rvb = 55.6 +/- 0.87%)2016Journal of natural products, 05-27, Volume: 79, Issue:5
Polycyclic Polyprenylated Derivatives from Hypericum uralum: Neuroprotective Effects and Antidepressant-like Activity of Uralodin A.
AID283755Antidepressant activity in ICR mouse assessed as reduction of immobility time at 10 mg/kg, po after 5 days by forced swimming test2007Journal of natural products, Apr, Volume: 70, Issue:4
Triterpene saponins from Bacopa monnieri and their antidepressant effects in two mice models.
AID1217709Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID244975Minimum inhibitory concentration to inhibit Candida parapsilosis ATCC 220192004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
Imidazole analogues of fluoxetine, a novel class of anti-Candida agents.
AID195551Inhibition of neuronal uptake of 5 - Hydroxytryptamine in rat brain homogenate1997Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22
Novel tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors.
AID204093Compound was evaluated for its binding affinity towards human serotonin transporter2000Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5
2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors.
AID249325Minimum inhibitory concentration to inhibit 90% of the isolates2004Journal of medicinal chemistry, Jul-29, Volume: 47, Issue:16
Imidazole analogues of fluoxetine, a novel class of anti-Candida agents.
AID204069Inhibition concentration against [3H]5-HT uptake by human serotonin transporter in JAR cells2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines.
AID349957Anxiolytic activity in BALB/c mouse assessed as distance moved at 20 mg/kg, po after 90 mins by open-field test (RVb= 8485+/-610 cm)2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Gamma-aminobutyric acid amides of nortriptyline and fluoxetine display improved pain suppressing activity.
AID1571159Antitrypanosomal activity against Trypanosoma brucei brucei 427 bloodstream forms after 48 hrs by resazurin dye based fluorescence assay2018MedChemComm, Dec-01, Volume: 9, Issue:12
Screening of the Pathogen Box reveals new starting points for anti-trypanosomal drug discovery.
AID1659924Antidepressant activity in mouse assessed as change in norepinephrine level at 3 mg/kg, ip
AID300625Binding affinity to rat SERT2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Benzylamine histamine H(3) antagonists and serotonin reuptake inhibitors.
AID735860Antidepressant activity in gerbil assessed as decrease in immobility time at 10 mg/kg, po by forced swimming test relative to vehicle-treated control2013Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2
Design, optimization, and in vivo evaluation of a series of pyridine derivatives with dual NK1 antagonism and SERT inhibition for the treatment of depression.
AID386920Spermicidal activity in liquefied human semen assessed as drug level required to kill 100% sperm in 20 seconds2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
Carbodithioic acid esters of fluoxetine, a novel class of dual-function spermicides.
AID339394Inhibition of 5HT uptake at human SERT expressed in human JAR cells2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.
AID134215Tested in vitro for dopamine(DA) neuronal uptake inhibition1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.
AID773436Inhibition of human NET-mediated norepinephrine uptake expressed in HEK293 cells at 10 uM after 15 mins by fluorescence plate reader analysis2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.
AID1215350Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone at 0.01 to 100 uM preincubated for 60 mins followed by testosterone treatment measured after 10 mins by refined CYP450 IC50 s2011Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 39, Issue:6
A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors.
AID1589638Antiviral activity against Enterovirus D68 US/KY/14-18953 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 mins under shaking condition and measured after 3 days by neutral red dye-based photometric meth2019Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8
Discovery of Quinoline Analogues as Potent Antivirals against Enterovirus D68 (EV-D68).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1140140Displacement of [3H]citalopram from SERT in Sprague-Dawley rat whole brain membranes after 1 hr by liquid scintillation spectrophotometric analysis2014Bioorganic & medicinal chemistry letters, May-01, Volume: 24, Issue:9
Design of novel multiple-acting ligands towards SERT and 5-HT2C receptors.
AID1232309Unbound fraction in human plasma2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Volume of Distribution in Drug Design.
AID268715Inhibition of [3H]NA reuptake at NA transporter in HEK293 cells2006Bioorganic & medicinal chemistry letters, Aug-15, Volume: 16, Issue:16
Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors.
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1164992Antidepressant activity in Swiss mouse assessed as reduction of immobility time at 20 mg/kg, ip by tail suspension test relative to vehicle-treated control2014Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20
Synthesis and evaluation of new 3-phenylcoumarin derivatives as potential antidepressant agents.
AID1651171Displacement of [3H]astemizole from human ERG2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Evaluation of anti-depressant effects of phthalazinone-based triple-acting small molecules against 5-HT
AID181687Compound was evaluated for its ability to antagonizing norepinephrine (NE) high affinity uptake was determined using [3H]NE on synaptosomes prepared from rat occipital cortices.2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Further SAR studies of piperidine-based analogues of cocaine. 2. Potent dopamine and serotonin reuptake inhibitors.
AID227287Effect on helpless behavior in rats and the number of escape failures was determined in shuttle-box session-2 (SB-2) at 30 mg/kg dose2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID311935Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1453029Inhibition of CYP1B1 (unknown origin) expressed in Escherichia coli DH5alpha coexpressing human NADPH-P450 reductase using 7-Ethoxyresorufin as substrate up to 6 mins in presence of NADP+ by spectrofluorometric analysis2017European journal of medicinal chemistry, Jul-28, Volume: 135Inhibitors of cytochrome P450 (CYP) 1B1.
AID1221957Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1365301Antidepressant-like activity in Swiss albino mouse assessed as reduction in immobility time at 20 mg/kg, ip dosed 1 hr before test by forced swimming test2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
New 5-HT
AID309934Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 1.62 mM/kg, ip after 20 mins2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1155486Cytotoxicity against human L02 cells as inhibition of cell viability at 80 uM after 24 hrs by MTT assay2014European journal of medicinal chemistry, Jul-23, Volume: 82Synthesis and biological evaluation of novel naphthalene compounds as potential antidepressant agents.
AID411214Displacement of [3H]nisoxetine from Sprague-dawley rat NET by liquid scintillation spectrophotometry2009Bioorganic & medicinal chemistry letters, Jan-01, Volume: 19, Issue:1
1-Naphthyl and 4-indolyl arylalkylamines as selective monoamine reuptake inhibitors.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID309937Inhibition of SERT-mediated serotonin-reuptake assessed as 5-hydroxytryptophan induced mouse head twitch at 6.47 mM/kg, ip after 20 mins2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Synthesis of some tropane derivatives of anticipated activity on the reuptake of norepinephrine and/or serotonin.
AID1315583Antidepressant- like activity in Balb/c mouse assessed as immobility time at 10 mg/kg, ip administered 30 mins prior to testing by forced swimming test (Rvb = 123.3 +/- 10.7 secs)2016European journal of medicinal chemistry, Oct-04, Volume: 121Antidepressant-like effects and mechanisms of flavonoids and related analogues.
AID1221956Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID504077Inhibition of serotonin reuptake at human SERT expressed in HEK293 cells2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.
AID37309Binding affinity against rat cortical alpha-1 adrenergic receptor labeled with [3H]prazosin radioligand2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines.
AID1232308Distribution coefficient, log D of the compound2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Volume of Distribution in Drug Design.
AID330659Effect on life span of Caenorhabditis elegans at 50 uM2007Nature, Nov-22, Volume: 450, Issue:7169
An antidepressant that extends lifespan in adult Caenorhabditis elegans.
AID578419Inhibition of [3H]serotonin reuptake at human recombinant SERT expressed in LLC-PK1 cells by liquid scintillation counting2011Bioorganic & medicinal chemistry letters, Mar-01, Volume: 21, Issue:5
Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a novel triple serotonin, norepinephrine and dopamine reuptake inhibitor.
AID744698Displacement of [3H]-citalopram from SERT in rat cerebral cortex after 1 hr by liquid scintillation counting analysis2013European journal of medicinal chemistry, May, Volume: 63Synthesis and biological evaluation of novel pyrrolidine-2,5-dione derivatives as potential antidepressant agents. Part 1.
AID504095Antidepressant activity in mouse assessed as reduction of mobility time by forced swimming test at 50 mg/kg, po2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.
AID601157Antidepressant activity in albino mouse assessed as reduction of immobility time at 10 to 20 mg/kg, ip measured up to 4 mins by forced swimming test2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Novel benzo[b]thiophene derivatives as new potential antidepressants with rapid onset of action.
AID1181448Inhibition of DA reuptake at human DAT expressed in HEK293 cells after 15 mins by fluorescence neurotransmitter transporter assay2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors.
AID3514Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells2004Journal of medicinal chemistry, Jul-15, Volume: 47, Issue:15
Studies toward the discovery of the next generation of antidepressants. 3. Dual 5-HT1A and serotonin transporter affinity within a class of N-aryloxyethylindolylalkylamines.
AID204080Equilibrium dissociation constant (KD) for Competitive binding between [3H]- imipramine and the compound at human transporter-hSERT1998Bioorganic & medicinal chemistry letters, Mar-03, Volume: 8, Issue:5
Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID685416Antidepressant activity in Kunming mouse assessed as decrease in immobility time at 100 mg/kg, ip measured for last 4 mins of 6 mins test after 30 mins post dose by forced swimming test relative to control2012European journal of medicinal chemistry, Oct, Volume: 56Synthesis and evaluation of anticonvulsant and antidepressant activities of 5-alkoxytetrazolo[1,5-c]thieno[2,3-e]pyrimidine derivatives.
AID254282Inhibition constant against norepinephrine transporter2005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Designed multiple ligands. An emerging drug discovery paradigm.
AID181697Compound was evaluated for its ability to inhibit the uptake of dopamine(DA) into nerve ending using [3H]DA on synaptosomes obtained from dissected rat striata.2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
Further SAR studies of piperidine-based analogues of cocaine. 2. Potent dopamine and serotonin reuptake inhibitors.
AID1212314Drug uptake in lysosomes of human Fa2N-4 cells assessed as inhibition of LysoTracker Red fluorescence after 30 mins2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
AID509965Antidepressant-like activity in Swiss albino mouse assessed as effect on immobility time at 10 mg/kg, ip after 24 hrs measured for 5 mins by modified forced swimming test (Rvb = 102.2 +/- 7.5 sec)2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
New pyrazoline derivatives and their antidepressant activity.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1651172Inhibition of CYP3A4 (unknown origin)2020Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4
Evaluation of anti-depressant effects of phthalazinone-based triple-acting small molecules against 5-HT
AID243151Inhibitory concentration against potassium channel HERG2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID504082Potentiation of 5-hydroxytryptamine-induced serotonin syndrome like behavior in mouse at 3 mg/kg, po2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.
AID300626Binding affinity to human SERT2007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Benzylamine histamine H(3) antagonists and serotonin reuptake inhibitors.
AID64630Binding affinity towards dopamine receptor D2 at 1.0 uM concentration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
AID1217704Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system2011Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
AID203852The compound was tested for affinity towards sigma-3 receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Conformational analysis, pharmacophore identification, and comparative molecular field analysis of ligands for the neuromodulatory sigma 3 receptor.
AID773434Displacement of [3H]imipramin from human recombinant SERT over-expressed in HEK293 cells2013Bioorganic & medicinal chemistry letters, Oct-15, Volume: 23, Issue:20
Synthesis and biological evaluation of novel 3,4-diaryl lactam derivatives as triple reuptake inhibitors.
AID130135Compound was evaluated for potentiating 5-HTP-induced Head twitches in mice for 1 hour 30 min before 5-HTP administration (peroral)1993Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9
New indole derivatives as potent and selective serotonin uptake inhibitors.
AID1172777Toxic CNS activity in C57BL/6 mouse assessed as locomotor activity by measuring exploratory activity counts at 10 mg/kg, ig by open-field test (Rvb = 94.50 +/- 6.18 counts)2014Bioorganic & medicinal chemistry letters, Nov-15, Volume: 24, Issue:22
Synthesis and structure-activity relationship of novel cinnamamide derivatives as antidepressant agents.
AID1674935Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth2020Bioorganic & medicinal chemistry letters, 09-01, Volume: 30, Issue:17
Evaluation of the effect of synthetic compounds derived from azidothymidine on MDA-MB-231 type breast cancer cells.
AID1315364Neuroprotective activity against corticosterone-induced cell injury in rat PC12 cells assessed as cell viability at 1 uM after 48 hrs by MTT assay (Rvb = 55.6 +/- 0.87%)2016Journal of natural products, 05-27, Volume: 79, Issue:5
Polycyclic Polyprenylated Derivatives from Hypericum uralum: Neuroprotective Effects and Antidepressant-like Activity of Uralodin A.
AID161281Inhibition of human Potassium channel HERG expressed in mammalian cells2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID170359Effect on food consumption was determined in 24 rats at 6 hr after ip administration at the dose of 10 mg/kg; expressed as change in weight of the jar containing food2001Bioorganic & medicinal chemistry letters, Sep-03, Volume: 11, Issue:17
Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID624218Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2B2000Circulation, Dec-05, Volume: 102, Issue:23
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
AID1345154Rat 5-HT6 receptor (5-Hydroxytryptamine receptors)1993Molecular pharmacology, Mar, Volume: 43, Issue:3
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.
AID1346943Human SERT (Monoamine transporter subfamily)1997European journal of pharmacology, Dec-11, Volume: 340, Issue:2-3
Pharmacological profile of antidepressants and related compounds at human monoamine transporters.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)2000Circulation, Dec-05, Volume: 102, Issue:23
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
AID624222Antagonists at Rat 5-Hydroxytryptamine receptor 5-HT2A2000Circulation, Dec-05, Volume: 102, Issue:23
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
AID1346662Rat Kv3.1 (Voltage-gated potassium channels)2001Neuropharmacology, Sep, Volume: 41, Issue:4
Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1.
AID1345181Human Plasma membrane monoamine transporter (SLC29 family)2005Molecular pharmacology, Nov, Volume: 68, Issue:5
Interaction of organic cations with a newly identified plasma membrane monoamine transporter.
AID1346868Rat 5-HT2C receptor (5-Hydroxytryptamine receptors)2000Circulation, Dec-05, Volume: 102, Issue:23
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
AID1345181Human Plasma membrane monoamine transporter (SLC29 family)2016Clinical pharmacology and therapeutics, Nov, Volume: 100, Issue:5
The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition.
AID1346501Mouse Kir3.2 (Inwardly rectifying potassium channels)2003British journal of pharmacology, Mar, Volume: 138, Issue:6
Inhibition of G protein-activated inwardly rectifying K+ channels by fluoxetine (Prozac).
AID1346919Rat 5-HT2A receptor (5-Hydroxytryptamine receptors)2000Circulation, Dec-05, Volume: 102, Issue:23
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.
AID1799064Radioligand Binding Assay (Ki) and Inhibition of Substrate Uptake (EC50/IC50) from Article 10.1021/jm8010993: \\Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.\\2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
AID1799063PDE4 Enzyme Assay from Article 10.1021/jm8010993: \\Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.\\2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.
AID493017Wombat Data for BeliefDocking2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
AID493017Wombat Data for BeliefDocking2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Further studies on conformationally constrained tricyclic tropane analogues and their uptake inhibition at monoamine transporter sites: synthesis of (Z)-9-(substituted arylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes as a novel class of serotonin transpo
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9,524)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990523 (5.49)18.7374
1990's2643 (27.75)18.2507
2000's2768 (29.06)29.6817
2010's2780 (29.19)24.3611
2020's810 (8.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 134.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index134.15 (24.57)
Research Supply Index9.37 (2.92)
Research Growth Index5.11 (4.65)
Search Engine Demand Index257.10 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (134.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials1,663 (16.47%)5.53%
Reviews0 (0.00%)6.00%
Reviews726 (7.19%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies1,264 (12.51%)4.05%
Observational0 (0.00%)0.25%
Observational9 (0.09%)0.25%
Other14 (100.00%)84.16%
Other6,438 (63.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (250)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Assessment of Fluoxetine's Effect in Patients With Multiple System Atrophy : a Double Blind Placebo-controlled Randomized Trial [NCT01146548]Phase 287 participants (Actual)Interventional2008-05-31Completed
Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial [NCT01269788]Phase 2/Phase 3144 participants (Actual)Interventional2010-08-31Completed
A Randomized, Assessor-blind, Controlled Trial of Electroacupuncture Combined With Antidepressants in Treating Patients With Post-stroke Depression [NCT01174394]43 participants (Actual)Interventional2010-05-31Completed
Extended Management & Measurement of Autism (Emma): An Open-Label, Follow-On Study to Investigate the Safety and Impact on Developmental Trajectory of 18 Months Treatment With Fluoxetine Orally Dissolving Tablet (Odt) In Childhood and Adolescent Autistic [NCT00787111]Phase 3128 participants (Anticipated)Interventional2008-11-30Terminated
Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients [NCT01352572]300 participants (Anticipated)Interventional2002-01-31Active, not recruiting
Pharmacological Intervention Project (Fluoxetine) [NCT00027378]Phase 250 participants (Actual)Interventional2001-07-31Completed
Model for Early Prediction of Clinical Response in Patients With Major Depression Receiving Fluoxetine [NCT01075529]Phase 4140 participants (Actual)Interventional2007-03-31Completed
A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's and Prozac®Weekly 90 mg DR Capsules of Eli Lilly and Company, USA in H [NCT01166100]Phase 154 participants (Actual)Interventional2006-02-28Completed
[NCT01204086]Phase 4200 participants (Anticipated)Interventional2007-03-31Recruiting
Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection: A Multi-Arm Multi-Stage Randomized Trial (MAMS) to Evaluate the Effectiveness of Several Specific Treatments in Reducing the Risk of Clinical Worsening or Death in Sub-Saharan [NCT04920838]Phase 2/Phase 3600 participants (Anticipated)Interventional2021-04-12Recruiting
Fluoxetine to Reduce Intubation and Death After COVID19 Infection [NCT04377308]Phase 416 participants (Actual)Interventional2020-05-01Completed
Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF - a Multicenter Study [NCT02359513]Phase 451 participants (Actual)Interventional2015-11-09Completed
Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients [NCT01237275]300 participants (Anticipated)Interventional1999-10-31Active, not recruiting
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FLUOXETINE-REFERENCED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF DESVENLAFAXINE SUCCINATE SUSTAINED RELEASE (DVS SR) IN THE TREATMENT OF CHILDREN AND ADOLESCENT O [NCT01372150]Phase 3340 participants (Actual)Interventional2011-11-17Completed
Prediction of Antidepressant Response Using Pharmacogenetics of Bioamine Transporter and Peripheral Lymphocytic Phenotype [NCT01352559]1,000 participants (Anticipated)Interventional2001-11-30Active, not recruiting
Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome: A Randomized Double Blind Placebo Controlled Trial [NCT02427334]Phase 3210 participants (Anticipated)Interventional2015-04-30Recruiting
MAMBO: Measuring Ambulation, Motor, and Behavioral Outcomes With Post-Stroke Fluoxetine in Tanzania [NCT03728153]Phase 234 participants (Actual)Interventional2019-11-26Completed
Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression in Papua New Guinea: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial [NCT05283954]Phase 2/Phase 30 participants (Actual)Interventional2022-05-01Withdrawn(stopped due to Lack of funding)
Bariatric Surgery and Pharmacokinetics Fluoxetine: BAR-MEDS Fluoxetine [NCT03476525]12 participants (Anticipated)Observational2016-11-02Recruiting
Fluoxetine's Effects on Attention and Emotional Memory in Anxious and Depressed Youth and Adults [NCT03283930]Phase 22,290 participants (Actual)Interventional2001-10-02Completed
Fluoxetine/Dextromethorphan in Obsessive-Compulsive and Related Disorders: an Open-Label Crossover Pilot Study [NCT04899687]Phase 260 participants (Anticipated)Interventional2022-01-20Recruiting
A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members and Veterans With PT [NCT05948553]Phase 2200 participants (Anticipated)Interventional2023-11-02Recruiting
Pediatric MDD: Sequential Treatment With Fluoxetine and Relapse Prevention [NCT00612313]144 participants (Actual)Interventional2008-02-29Completed
The Synergistic Use of Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in the Management of Severe Premenstrual Syndrome: A Randomized Double Blind Placebo Controlled Trial [NCT02488538]Phase 3300 participants (Anticipated)Interventional2015-07-31Recruiting
Deep Brain Stimulation of Nucleus Accumbens as a New Treatment to Treat Severe Anorexia Nervosa [NCT02593695]10 participants (Anticipated)Interventional2015-10-31Active, not recruiting
Initial Severity and Antidepressant Efficacy for Anxiety Disorders: an Individual Patient Data Meta-analysis [NCT02476136]8,800 participants (Anticipated)Observational2015-05-31Active, not recruiting
Brain Network Changes Accompanying and Predicting Responses to Pharmacotherapy in OCD [NCT04131829]Phase 1/Phase 2100 participants (Anticipated)Interventional2019-10-14Recruiting
Multi-dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics [NCT03219008]Phase 4800 participants (Anticipated)Interventional2017-08-01Recruiting
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD) [NCT02709746]Phase 3784 participants (Actual)Interventional2016-05-31Completed
Investigating the Effects of the Antidepressant Fluoxetine on the Emotional Processing of Young People With Depression - a Double Blind, Placebo-controlled Design fMRI Study [NCT03436173]32 participants (Actual)Interventional2012-05-23Completed
A Proof-of-Concept, Multicenter, Randomized, Double-Blind, Parallel Study of Naltrexone Sustained-Release (SR) and/or Fluoxetine Therapy in the Treatment of Subjects With Obsessive-Compulsive Disorder (OCD) [NCT00758966]Phase 28 participants (Actual)Interventional2008-09-30Terminated(stopped due to Sponsor Decision- Financial Considerations)
Fluoxetine : Clinical and Anatomy-functional Therapeutic Effects in Children With Autism [NCT00873834]Phase 20 participants (Actual)Interventional2009-09-30Withdrawn(stopped due to Withdrawn for problem of logistics with the associated laboratories)
"Adaptive Treatment Strategies for Children and Adolescents With Psychiatric Disorders in the Context of Public Health: Medicine in Practice" [NCT01148316]144 participants (Actual)Interventional2010-08-31Completed
Preventative Treatment of Depression in Survivors of Aneurysmal Subarachnoid Hemorrhage [NCT03826875]Phase 2224 participants (Anticipated)Interventional2019-03-01Recruiting
Development of an Integrated Microfinance and Depression Care Program for Women [NCT02069301]166 participants (Actual)Interventional2014-02-28Completed
The Effects of the Selective Serotonin Reuptake Inhibitor, Fluoxetine and/or DHEA, on Neuroendocrine, Autonomic Nervous System and Metabolic Counterregulatory Responses During Repeated Hypoglycemia in T1DM Individuals [NCT03228732]Early Phase 160 participants (Anticipated)Interventional2017-12-19Recruiting
Fluoxetine Versus Fluoxetine Plus DU125530 in Latency of Antidepressant Response Shortening in Major Depressive Disorder [NCT01119430]Phase 250 participants (Actual)Interventional2004-05-31Terminated(stopped due to interim analysis suggested no differences with whole sample)
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder [NCT00849693]Phase 3463 participants (Actual)Interventional2009-03-31Completed
Clinical Study of Cang Ai Volatile Oil (CAVO) on Mild to Moderate Depression in Children and Adolescents [NCT05789186]Early Phase 1108 participants (Anticipated)Interventional2023-05-01Recruiting
Neurophysiologic Monitoring of Antidepressant Treatment [NCT01360190]Phase 424 participants (Actual)Interventional1994-08-31Completed
Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury [NCT02320240]3,255,526 participants (Actual)Observational2013-06-30Completed
Fluoxetine for Visual Recovery After Ischemic Stroke [NCT02737930]Phase 217 participants (Actual)Interventional2016-05-31Terminated(stopped due to Slow recruitment and lack of funding to expand to other sites.)
Morphological and Functional Investigation of the Serotoninergic System in Multiple System Atrophy: a 18F-MPPF PET Study [NCT01136213]53 participants (Actual)Observational2010-04-30Completed
A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's and Prozac®Weekly 90 mg Delayed Release Capsules of Eli Lilly and Comp [NCT01166087]Phase 154 participants (Actual)Interventional2006-02-28Completed
Biomarkers of Antidepressant Treatment in Adolescents With Major Depression [NCT01185977]Phase 426 participants (Actual)Interventional2010-04-30Completed
Continuation Electroconvulsive Therapy Associated With Pharmacotherapy Versus Pharmacotherapy Alone for Relapse Prevention in Major Depression. A Clinical, Controlled, Prospective and Randomized Trial [NCT01305707]Phase 4104 participants (Actual)Interventional2009-07-31Terminated(stopped due to Difficulties in recruiting)
Stepped Care vs Best Available Care for Bulimia Nervosa [NCT00733525]293 participants (Actual)Interventional2000-09-30Completed
A Study to Assess the Long-Term Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Fluoxetine Only in the Relapse Prevention of Stabilized Patients With Treatment-Resistant Depression [NCT00958568]Phase 3892 participants (Actual)Interventional2009-08-31Completed
TRY FIRST: A 12-Week, Randomized, Open-Label Trial of Duloxetine Versus Generic SSRIs in the Treatment of a Severe Depressive Episode [NCT00666757]Phase 4750 participants (Actual)Interventional2008-05-31Completed
Imaging Antidepressant vs. Cognitive Behavior Therapy Effects on Unipolar Depression [NCT00787501]Phase 198 participants (Actual)Interventional2008-06-30Completed
Study to Assess the Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Placebo in Patients Ages 10-17 in the Treatment of Major Depressive Episodes Associated With Bipolar I Disorder [NCT00844857]Phase 4291 participants (Actual)Interventional2009-04-30Completed
Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients [NCT00817375]1,000 participants (Anticipated)Interventional2003-02-28Recruiting
Prevention of Relapse & Recurrence of Bipolar Depression [NCT00961961]Phase 4177 participants (Actual)Interventional2009-07-01Completed
A Phase 2, Multi-center, Multi-arm, Randomized, Placebo-controlled, Double-blind, Adaptive Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Potential Pharmacotherapeutic Interventions in Active-Duty Service Members and Veterans With PT [NCT05422612]Phase 2600 participants (Anticipated)Interventional2023-11-02Recruiting
Predict Antidepressant Responsiveness Using Pharmacogenomics [NCT01228357]1,000 participants (Anticipated)Interventional2003-02-28Recruiting
"Evaluation by Transcranial Magnetic Stimulation of the Benefit of Fluoxetine on Motor Recovery After Stroke" [NCT02063425]6 participants (Actual)Interventional2014-02-28Terminated(stopped due to Not enough recruitment)
Can Fluoxetine Mitigate the Mental Health Decline Seen in Patients With Musculoskeletal Trauma? [NCT04850222]Early Phase 1150 participants (Anticipated)Interventional2021-09-01Recruiting
A Multicenter, Prospective, Adaptive, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Interferon Lambda 1A, Fluvoxamina + Budesonida, Fluoxetina + Budesonida in Mild COVID-19 and High Risk of Complications [NCT04727424]Phase 36,246 participants (Anticipated)Interventional2021-01-19Recruiting
A Randomized, Single Oral Dose, Two-way Crossover, Open-label, Laboratory Blind, Bioequivalence Study Comparing Fluoxetine From Two Different Drug Products After Oral Administration to Healthy Adult Subjects Under Fasting Conditions [NCT05532332]Phase 134 participants (Actual)Interventional2021-01-18Completed
Comparison of the Effects of Acupuncture and Fluoxetine on Quality of Life in Menopausal Women [NCT02188225]140 participants (Anticipated)Interventional2014-07-31Enrolling by invitation
Fluoxetine vs. Brief Psychotherapy in the Treatment of Major Depression - a Randomized Comparative Study [NCT00714779]85 participants (Actual)Interventional2000-01-31Completed
A Comparative Bioavailability Study of Fluoxetine Hydrochloride Capsules, 40 mg [NCT00947076]Phase 130 participants (Actual)Interventional2001-02-28Completed
A Randomized, Active Controlled, Open Label, Parallel Group Study to Compare the Efficacy of Extract of Curcuma Longa (Turmeric) With Fluoxetine and to Study Its Effect as an Add on Therapy to Fluoxetine in Patients of Depression [NCT01022632]60 participants (Actual)Interventional2009-03-31Completed
Assessment of PACAP-BDNF Signaling System Involvement in Etiology and Treatment of Major Depression [NCT00944996]100 participants (Actual)Interventional2009-06-30Completed
Does Adding Combined Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome? A Double Blind Placebo Controlled Study. [NCT02562053]Phase 3300 participants (Anticipated)Interventional2015-10-31Recruiting
Integrating a Stepped Care Model of Screening and Treatment for Depression Into Malawi's National HIV Care Delivery Platform [NCT04777006]Phase 4487 participants (Actual)Interventional2021-09-01Active, not recruiting
Hypoglycemia Associated Autonomic Failure in Type 1 DM, SSRI and Exercise [NCT01672255]Early Phase 164 participants (Anticipated)Interventional2012-10-31Recruiting
Evaluating the Results of Physician and Parent Decisions to Treat Selective Mutism With Fluoxetine [NCT05378711]Phase 26 participants (Actual)Interventional2014-01-01Completed
Staged Treatment in Early Psychosis (STEP): A Sequential Multistage Randomized Clinical Trial (SMART) of Interventions for Ultra High Risk (UHR) of Psychosis Patients. [NCT02751632]Phase 3340 participants (Anticipated)Interventional2016-04-30Active, not recruiting
Resting State MRI Connectivity in Acute Ischemic Stroke: Serotonin Selective Reuptake Inhibitor (SSRI) in Enhancing Motor Recovery: a Placebo Controlled Study [NCT02767999]Phase 425 participants (Actual)Interventional2017-02-27Completed
Effect of Serotonin Reuptake Inhibitors on Gonadal Steroid Hormones [NCT00611975]Phase 483 participants (Actual)Interventional2005-10-31Completed
Measurement-based Care for Depression in Resource-Poor Settings [NCT02916238]Phase 4140 participants (Actual)Interventional2014-02-28Completed
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Health Adult Males Under Fasting Conditions Following Administration of a 40 mg Dose [NCT00913718]Phase 146 participants (Actual)Interventional1996-06-30Completed
Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change [NCT00834834]Phase 484 participants (Actual)Interventional2009-03-31Completed
A Sequential, Multiple Assignment Randomized Trial (SMART) for Non-specialist Treatment of Common Mental Disorders in Kenya: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research (DAPPER) Project [NCT03466346]2,710 participants (Anticipated)Interventional2020-08-31Active, not recruiting
Joining Forces: Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana [NCT02593734]Phase 4139 participants (Actual)Interventional2013-07-31Completed
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder [NCT00797966]Phase 2850 participants (Actual)Interventional2009-05-31Completed
The Objective of This Randomized, Single-dose, Two-way Evaluation is to Compare the Bioequivalence of a Test Fluoxetine HCL Formulation (Ranbaxy Laboratories Limited, Lot No. 6320101) to an Equivalent Oral Dose of the Commercially Available Fluoxetine HCL [NCT00778024]36 participants (Actual)Interventional2003-08-31Completed
Establishing the Effect(s) and Safety of Fluoxetine Initiated in the Acute Phase of Stroke [NCT02683213]Phase 31,500 participants (Actual)Interventional2014-10-20Completed
Deep Brain Stimulation of Nucleus Accumbens/Anterior Limb of Internal Capsule to Prevent Treatment-Refractory Obsessive Compulsive Disorder [NCT02601677]10 participants (Anticipated)Interventional2015-11-30Not yet recruiting
Investigation of Drug-drug Interaction Between Clopidogrel and Fluoxetine [NCT00732290]Phase 110 participants (Actual)Interventional2009-02-28Completed
Improving Outcomes in Depression in Primary Care in a Low Resource Setting [NCT05944926]Phase 31,500 participants (Anticipated)Interventional2024-03-01Not yet recruiting
Effects of 3 Months Daily Treatment With Selective Serotonin Reuptake Inhibitor (SSRI, Fluoxetine) on Motor Rehabilitation After Ischemic Stroke. FLAME Trial [NCT00657163]Phase 2100 participants (Anticipated)Interventional2005-03-31Completed
Phase 4 Study of Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness [NCT00817011]1,000 participants (Anticipated)Interventional2006-04-30Recruiting
Light and Ion Treatment to Enhance Medication Efficacy in Depression [NCT00958204]Phase 3134 participants (Actual)Interventional2009-10-31Completed
[NCT00265291]Phase 2700 participants (Actual)Interventional1999-11-30Completed
Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension [NCT00942708]Phase 26 participants (Actual)Interventional2009-09-30Completed
A Pilot Treatment Study of Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder [NCT00592852]Phase 413 participants (Actual)Interventional2005-12-31Terminated(stopped due to Slow subject recruitment.)
Study Of Fluoxetine In Autism: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group 14-Week Study To Investigate The Effect Of Fluoxetine Orally Dissolving Tablet (ODT) On Repetitive Behaviors In Childhood And Adolescent Autistic Disorder. [NCT00515320]Phase 3158 participants (Actual)Interventional2007-08-31Completed
Dichotic Listening as a Predictor of Placebo and Medication Response in Depression [NCT00296725]Phase 1/Phase 225 participants (Actual)Interventional1994-04-30Completed
Fluoxetine in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC): A Phase II Pilot Study to Improve Quality of Life During Chemotherapy [NCT00005850]Phase 221 participants (Actual)Interventional2001-08-31Completed
Combined Pharmacotherapy in Depressed Alcoholics [NCT00006204]Phase 4106 participants Interventional2000-03-31Completed
[NCT00000381]Phase 30 participants Interventional1997-06-30Completed
[NCT00009178]0 participants Interventional1998-03-31Completed
The Use of Quantitative EEG (QEEG) as a Predictor of Treatment Outcome in Major Depressive Disorder [NCT00157547]Phase 495 participants (Actual)Interventional2003-04-30Completed
Efficacy of Hierarchical Treatment For Suspected Coronary Heart Disease Based on Somatization Symptom Checklist and Coronary Angiography [NCT02723903]Phase 1/Phase 2200 participants (Anticipated)Interventional2015-12-31Recruiting
An Open-Label Clinical Trial of Fluoxetine Treatment of Juvenile Primary Fibromyalgia Syndrome [NCT00115804]Phase 36 participants (Actual)Interventional2005-06-30Completed
A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis. [NCT01910259]Phase 2445 participants (Actual)Interventional2014-12-18Completed
Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage (FMRICH): a Randomised Placebo-controlled Trial [NCT01737541]Phase 332 participants (Actual)Interventional2012-11-30Terminated(stopped due to Study recruitment was suspended due to lack of funding)
RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke [NCT01963832]Phase 20 participants (Actual)Interventional2016-11-30Withdrawn(stopped due to not funded)
A Single-Center, Open-Label, One-Sequence, 2-Period, Within-Subject Study in 2 Cohorts to Investigate the Effect of Multiple Doses of Itraconazole (Cohort 1) and Fluoxetine (Cohort 2) on the Pharmacokinetics of a Single Dose of RO5285119 in Healthy Subjec [NCT01967979]Phase 128 participants (Actual)Interventional2013-10-31Completed
A 12-Week Open-Label Trial of Once-Weekly Fluoxetine for the Treatment of Depression in Patients With End-Stage Renal Disease [NCT00573547]Phase 40 participants (Actual)Interventional2007-02-28Withdrawn(stopped due to Principal Investigator decided not to initiate the study.)
Does Fluoxetine Reverse the Effects of Early Life Stress on the CNS Corticotropin-Releasing Factor System and Improve Psychological and Neuroendocrine Function?: A Therapy Outcome Study in Women With Childhood Abuse Experiences [NCT00208897]80 participants (Anticipated)Interventional1997-12-31Completed
Treatment for Adolescents With Depression Study (TADS) [NCT00006286]Phase 3432 participants Interventional1998-09-30Completed
Selective Serotonin Reuptake Inhibitors, Fluoxetine Versus the Standard Oral Desmopressin for Management of Mono-symptomatic Nocturnal Enuresis. A Randomised Controlled Trial [NCT06185361]60 participants (Actual)Interventional2022-12-01Active, not recruiting
Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19) [NCT04570449]Early Phase 10 participants (Actual)Interventional2020-11-30Withdrawn(stopped due to Study timeline is not feasible)
Study on the Optimal Strategy of Chinese Patients With Bulimia Nervosa After Fluoxetine Treatment [NCT04154813]550 participants (Anticipated)Interventional2020-02-01Recruiting
Can Immediate Post-injury Fluoxetine Improve the Recovery Trajectories of Victims in Bodily Trauma? [NCT06046859]Early Phase 1200 participants (Anticipated)Interventional2023-11-01Not yet recruiting
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies [NCT02893371]1,037,352 participants (Actual)Observational2016-09-30Completed
Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 6 [NCT00592670]48 participants (Actual)Interventional2005-03-31Completed
Fluoxetine Treatment of Depression in Adults With Down Syndrome [NCT05458479]Phase 425 participants (Anticipated)Interventional2022-12-05Recruiting
Efficacy of Fluoxetine Against Seizure-induced Central Apneas : a Randomized Placebo-controled Double-blind Trial. [NCT02569970]Phase 370 participants (Actual)Interventional2010-11-30Completed
Efficacy of Antidepressants in Chronic Back Pain [NCT00018200]Phase 2130 participants (Actual)Interventional1999-04-30Completed
Single-Dose Fasting Bioequivalence Study of Fluoxetine Capsules (40 mg; Mylan) and Prozac Pulvules (40 mg; Dista) in Healthy Adult Volunteers [NCT00649636]Phase 132 participants (Actual)Interventional2006-02-28Completed
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder [NCT00849901]Phase 3337 participants (Actual)Interventional2009-03-31Completed
A Double-blind, Parallel Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS) [NCT00965562]49 participants (Actual)Interventional2000-09-30Completed
Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Randomized Open Trial for Any Patient. [NCT00680602]Phase 4158 participants (Actual)Interventional2006-01-31Completed
Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure [NCT00633685]Phase 4300 participants (Anticipated)Interventional2010-03-31Recruiting
Open-labeled Randomized Comparative Study of the Efficacy and Tolerability of Two Times Daily 250mg Hypericum Versus Once Daily 20 - 40 mg Fluoxetine in Adolescent Patients With Mild to Moderate Depression [NCT00557427]Phase 430 participants (Anticipated)Interventional2009-01-31Terminated(stopped due to Lack of enrollment)
Finding Treatments for COVID-19: A Phase 2 Multi-centre Adaptive Platform Trial to Assess Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV) [NCT05041907]Phase 23,000 participants (Anticipated)Interventional2021-09-30Recruiting
An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE Study of Fluoxetine Tablets 20 mg [Torrent,India] Versus Sarafem 20 mg Tablet [ Warner Chilcott LLC, USA] in Healthy Subjects-Fasted Condition. [NCT02965261]Phase 126 participants (Actual)Interventional2013-11-30Completed
Comparative, Randomized, Single-Dose, 3-way Crossover Bioavailability Study of Geneva and Dista (Prozac) 20 mg Fluoxetine Hydrochloride Capsules (Pulvules) In Health Adult Males Under Fed and Fasted Conditions Following Administration of a 40 mg Dose [NCT00913588]Phase 124 participants (Actual)Interventional1996-05-31Completed
Continuation Phase CBT for Youth With MDD [NCT00158301]72 participants (Actual)Interventional2004-09-30Completed
Depression Treatment to Improve Antiretroviral Adherence [NCT00338767]Phase 2150 participants (Actual)Interventional2001-01-31Completed
Neural Correlates of Emotional Processing in Depressed and Remitted Bipolar and Unipolar Depressed Subjects: An fMRI Investigation [NCT00188942]Phase 442 participants (Actual)Interventional2005-02-28Completed
A Sequential Multiple Assignment Randomized Trial (SMART) Assessing Medication and CBT Sequencing Strategies in the Treatment of Predominantly Ethnic Minority, Underserved Youth With Anxiety Disorders [NCT04760275]Phase 3404 participants (Anticipated)Interventional2021-02-10Recruiting
Bipolar Depression Assessment Study on Tx Response [NCT00191399]Phase 4150 participants Interventional2004-05-31Completed
The Safety and Efficacy of Selective Serotonin Reuptake Inhibitors, Fluoxetine, for Refractory Primary Mono-symptomatic Nocturnal Enuresis in Children: A Randomized Controlled Trial [NCT04676139]Phase 3100 participants (Anticipated)Interventional2020-07-01Recruiting
Comparison of Aripiprazole Augmentation vs Switching to Different Class of Antidepressants for Patients With MDD Who Are Partially/Minimally Responsive to Current Antidepressants:Randomized, Rater-blinded, Prospective Study [NCT01488266]90 participants (Anticipated)Interventional2011-11-30Active, not recruiting
Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy [NCT00986310]2 participants (Actual)Interventional2009-08-31Completed
The Impact of GABA-Enhancing Agents on Cortical GABA Concentrations Across the Menstrual Cycle in Women [NCT00676026]8 participants (Actual)Interventional2005-05-31Completed
The Identification of Central Neural Network for Antidepressant Effects of Dense Cranial Electroacupuncture Stimulation - a Positron Emission Topographic (PET) Study [NCT01479920]36 participants (Actual)Interventional2012-06-30Completed
Fluoxetine Combined With ATP Rapidly Improves Moderate to Severe Depression: a Pilot Study [NCT05431413]Phase 2195 participants (Anticipated)Interventional2020-01-07Recruiting
Exploratory Study to Investigate the Efficacy and Safety of Recombinant Growth Hormone as Add-on Treatment in Patients With Severe Fibromialgia [NCT00497562]Phase 20 participants Interventional2004-05-31Completed
[NCT02934035]10,000 participants (Anticipated)Observational2016-09-30Active, not recruiting
A Multi-Centre, Double-Blind, Randomised, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SRTM) in Combination With an Antidepressant in the Treatment of Patients With Major [NCT00351910]Phase 3494 participants (Actual)Interventional2006-05-31Completed
A Long-term, Phase 3, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder, the Orion Trial [NCT01360866]Phase 32,944 participants (Actual)Interventional2011-10-31Completed
Randomized Clinical Trial Comparing Mindfulness, Pharmacological Treatment, and Control Group in Generalized Anxiety Disorder (GAD) [NCT03072264]200 participants (Actual)Interventional2016-10-31Completed
[NCT00004446]80 participants Interventional1998-04-30Completed
A 8-week, Rater-blind, Active-controlled, Randomized Study to Compare the Effectiveness of Venlafaxine With Fluoxetine in the Treatment of Postmenopausal Women With Major Depressive Disorder [NCT01824433]Phase 4189 participants (Actual)Interventional2013-03-07Completed
Lamotrigine Use in Treatment Refractory Depression in Adolescents [NCT00284791]50 participants Interventional2006-01-31Terminated
Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder - Results From a Long-term Nation-wide Population-based Study Emulating a Randomized Trial [NCT05952713]73,336 participants (Actual)Observational2022-10-01Completed
An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Fluoxetine Tablets 20 mg [Torrent,India] Versus Sarafem 20 mg Tablet [ Warner Chilcott LLC, USA] in Healthy Subjects-Fed Condition. [NCT02965274]Phase 126 participants (Actual)Interventional2013-11-30Completed
Serotonin Treatment of Cocaine Dependence [NCT00142779]220 participants Interventional2001-04-30Completed
Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study [NCT00466609]Phase 454 participants (Actual)Interventional2007-05-31Completed
Identifying and Treating Depression in the Orthopaedic Trauma Population [NCT05976347]Phase 4100 participants (Anticipated)Interventional2024-02-29Not yet recruiting
Fluoxetine's Effects on Attention and Emotional Memory in Anxious and Depressed Youth and Adults [NCT00018057]Phase 22,530 participants (Anticipated)Interventional2001-10-02Recruiting
PET Imaging of Dopaminergic Transmission and Serotonin Markers in Anorexia Nervosa [NCT00603018]23 participants (Actual)Interventional2007-06-30Completed
Measurement of GABA and Neurosteroid Levels in Women With Menopausal Major Depression Before and After Treatment With Estrogen Alone, Fluoxetine Alone, or Estrogen and Fluoxetine and Normal Controls Before and After Treatment With Estrogen [NCT00626340]Phase 418 participants (Actual)Interventional1999-07-31Completed
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY110140 in Healthy Japanese Male Subjects [NCT01569126]Phase 156 participants (Actual)Interventional2012-04-30Completed
A Double-blind, Randomized, Placebo- and Active-Controlled Study of F2695 SR in Adult Patients With Fatigue Associated With Major Depressive Disorder [NCT01254305]Phase 2262 participants (Actual)Interventional2011-04-30Completed
Phase I Dose-Finding Pilot Study of the Safety and Tolerability of Olanzapine in Patients With Advanced Cancer and Weight Loss [NCT00489593]Phase 157 participants (Actual)Interventional2006-10-31Completed
Olanzapine/Fluoxetine Combination Versus Lamotrigine in the Treatment of Bipolar I Depression [NCT00485771]Phase 4403 participants (Actual)Interventional2003-11-30Completed
Efectividad de la Farmacoterapia Monitorizada en Pacientes Deprimidas de la atención Primaria de Salud y su repercusión Sobre la Salud Mental de Sus Hijos [NCT00519051]345 participants (Actual)Interventional2004-03-31Completed
Study of Subcutaneous Olanzapine for Hyperactive or Mixed Delirium [NCT00512291]25 participants (Actual)Interventional2005-06-30Completed
Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Efficacy of Two Fixed Dose Combination of Metformin/Fluoxetin 1000/40 mg vs. 1700/40 mg in the Management of Overweight and Obesity [NCT03051451]Phase 2150 participants (Anticipated)InterventionalSuspended(stopped due to Business decision)
Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause [NCT05346445]91 participants (Actual)Interventional2021-01-20Completed
SERT Affinity Determinants in Antidepressant Outcomes [NCT00108316]0 participants (Actual)Interventional2004-01-31Withdrawn(stopped due to Study PI resigned)
[NCT00113737]0 participants Interventional1998-02-28Completed
A Relative Bioavailability Study of 90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions [NCT01247272]Phase 126 participants (Actual)Interventional2001-05-31Completed
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI [NCT02929667]Phase 230 participants (Actual)Interventional2017-02-16Completed
Treatment of Childhood Social Phobia [NCT00043537]Phase 3139 participants (Actual)Interventional2001-04-30Completed
Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers [NCT00018174]Phase 3247 participants (Actual)Interventional1998-02-28Completed
[NCT00080158]Phase 2/Phase 3120 participants Interventional2004-03-31Completed
Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder [NCT00533117]Phase 491 participants (Actual)Interventional2001-03-31Completed
The Effect of Fluoxetine on Measures of Domestic Violence [NCT00011765]Phase 2104 participants (Actual)Interventional2001-02-22Completed
Using Latent Variables and Directly Observed Treatment to Improve the Diagnosis and Management of Depression Among Hemodialysis Patients [NCT03390933]Phase 416 participants (Actual)Interventional2018-03-01Completed
Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) [NCT00018902]Phase 2/Phase 3334 participants (Actual)Interventional2001-01-31Completed
Fluoxetine vs Placebo in Adult Autistic Disorder [NCT00027404]48 participants Interventional2001-09-30Completed
Substance Dependent Teens - Impact of Treating Depression Study 1 [NCT00061113]Phase 4126 participants (Actual)Interventional2001-02-28Completed
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features [NCT00035321]Phase 3600 participants Interventional2002-04-30Completed
Relapse Prevention of Bipolar Type-II Disorder [NCT00044616]Phase 4180 participants Interventional2001-02-28Completed
Treatment of Hypochondriasis With CBT and/or SSRI [NCT00339079]Phase 1/Phase 2195 participants (Actual)Interventional2006-06-30Completed
The Role of Antidepressants or Antipsychotics in Preventing Psychosis: Fluoxetine vs Aripiprazole Comparative Trial (FACT) [NCT02357849]Phase 49 participants (Actual)Interventional2014-07-31Terminated
FLOW Trial: Fluoxetine to Open the Critical Period Time Window to Improve Motor Recovery After Stroke [NCT03448159]Phase 252 participants (Actual)Interventional2019-01-01Completed
Sequential Use of Fluoxetine for Smokers With Elevated Depressive Symptoms [NCT00578669]Phase 3206 participants (Actual)Interventional2008-04-30Completed
The Effect of Dialectical Behavioral Group Therapy on the Patients With Bulimia Nervosa : A Multicenter Randomized Controlled Study [NCT03455088]101 participants (Actual)Interventional2018-06-13Completed
Randomized Trial of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Major Depression [NCT01740726]3 participants (Actual)Interventional2013-01-31Terminated(stopped due to Lack of success with recruitment)
[NCT02655354]635 participants (Actual)Interventional2015-10-31Completed
Maintenance Psychotherapies in Recurrent Depression: Study II [NCT00227981]93 participants Interventional1995-03-31Completed
A 21-week, Multicenter, Open Label Study to Evaluate the Safety and Tolerability Profile of the Combination of a SSRI or SNRI Antidepressive Therapy With Oral Fingolimod in the Treatment of RRMS Patients With Mild to Moderate Depression [NCT01436643]Phase 454 participants (Actual)Interventional2011-11-30Terminated(stopped due to Due to slow enrollment the study was terminated early)
Childhood Depression: Remission and Relapse [NCT00332787]200 participants Interventional2000-06-30Completed
[NCT00004486]45 participants Interventional1998-09-30Completed
Bupropion for Depression in ESRD Patients on Hemodialysis [NCT02238977]Phase 41 participants (Actual)Interventional2016-03-31Terminated(stopped due to Study stopped due to difficulty recruiting)
Early Detection and Intervention for the Prevention of Psychosis Project [NCT00531518]292 participants (Actual)Interventional2007-10-31Completed
A Double-blind, Placebo- and Active-controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Pediatric Patients 7-17 Years With Major Depressive Disorder [NCT03569475]Phase 3501 participants (Actual)Interventional2018-07-06Completed
Fluoxetine for the Treatment of Major Depression in Youth With Bipolar Disorder _ [NCT00005015]Phase 30 participants InterventionalTerminated
Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder [NCT01699490]Phase 4200 participants (Anticipated)Interventional2012-08-31Recruiting
A Personalized Approach to Achieving a Sustained Response to Treatment for Adolescent Depression [NCT02017535]Phase 1/Phase 215 participants (Actual)Interventional2012-06-30Completed
Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging [NCT02473250]Phase 440 participants (Actual)Interventional2015-01-31Completed
Algorithm Guided Treatment Strategies for Major Depressive Disorder [NCT01764867]Phase 41,080 participants (Anticipated)Interventional2012-06-30Recruiting
Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child [NCT01796132]Phase 4500 participants (Anticipated)Interventional2012-08-31Recruiting
A Randomized, Placebo-controlled Trial of Fluoxetine in Preschool Children [NCT00183339]Phase 218 participants (Actual)Interventional2005-07-31Completed
A Double-blind, Placebo- and Active-Controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder [NCT02431806]Phase 3552 participants (Actual)Interventional2015-06-23Completed
IV Cocaine Abuse: A Laboratory Model [NCT00000213]Phase 20 participants Interventional1990-04-30Completed
A Multicenter Clinical Study to Evaluate the Efficacy and Safety of Shuganjieyu Capsule Combined With Fluoxetine in the Treatment of Depression [NCT05361330]160 participants (Anticipated)Interventional2022-05-30Not yet recruiting
Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder [NCT01460212]Phase 480 participants (Anticipated)Interventional2011-12-31Recruiting
A Phase 2, Open-label, Clinical Trial of Fluoxetine, a Selective Serotonin Reuptake Inhibitor, in the Treatment of Pulmonary Arterial Hypertension [NCT03638908]Phase 28 participants (Actual)Interventional2013-11-30Completed
The Activation on Prefrontal Cortex With Acupuncture and Moxibustion for Major Depressive Disorder: A Study of Functional Near Infrared Spectroscopy (ACUfNIRS) [NCT04272476]Phase 220 participants (Actual)Interventional2014-01-31Completed
The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder [NCT00678574]Phase 445 participants (Actual)Interventional1998-03-31Completed
A Pilot Study Examining the Gut Microbiota in Patients With Obsessive-Compulsive Disorder vs. Healthy Controls and Following 12-weeks of Open-label Selective Serotonin Reuptake Inhibitors Treatment [NCT02285699]43 participants (Anticipated)Interventional2014-11-01Completed
LY2216684 and Fluoxetine Pharmacokinetic Interaction Study in Healthy Subjects [NCT01243957]Phase 120 participants (Actual)Interventional2010-10-31Completed
The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity [NCT01361217]10 participants (Actual)Interventional2011-09-30Completed
An Adaptive Treatment Strategy for Adolescent Depression [NCT01802437]Phase 1/Phase 240 participants (Actual)Interventional2010-11-30Completed
Efficacy of Exposure and Response Prevention(ERP) and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder [NCT02022709]Phase 478 participants (Actual)Interventional2014-01-31Completed
Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression [NCT01896349]74 participants (Anticipated)Interventional2013-04-30Recruiting
Treatment of Pediatric OCD for SRI Partial Responders [NCT00074815]Phase 3124 participants (Actual)Interventional2003-09-30Completed
Fluoxetine in Pediatric Body Dysmorphic Disorder [NCT00245635]Phase 443 participants (Actual)Interventional2004-11-30Completed
Assessing Tolerability and Efficacy of Vortioxetine Versus SSRIs in Elderly Patients With Depression: a Pragmatic, Multicenter, Open-label, Parallel-group, Superiority, Randomized Trial [NCT03779789]Phase 4362 participants (Actual)Interventional2019-02-01Completed
A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder [NCT02372799]Phase 3473 participants (Actual)Interventional2015-02-28Completed
Non-Invasive Brain Imaging Techniques That Predict Antidepressant Responsiveness and Provide Insights Into the Mechanism of Action of Venlafaxine ER vs. Fluoxetine [NCT00909155]50 participants (Actual)Interventional2002-07-31Completed
Research and Application of Key Technologies for Early Identification, Risk Warning and Comprehensive Intervention of Adolescent Depression [NCT05945342]400 participants (Anticipated)Interventional2023-01-01Recruiting
Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression [NCT01545843]Phase 268 participants (Actual)Interventional2009-03-31Completed
Prevention of Cognitive Decline After Chemotherapy, With Fluoxetine Treatment [NCT01615055]Early Phase 10 participants (Actual)Interventional2018-06-30Withdrawn(stopped due to Study withdrawn. No participants enrolled.)
Assessment of Efficacy and Safety of Anodal Transcranial Direct Current Stimulation (TDCS) in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemics [NCT04780152]Phase 2/Phase 3172 participants (Anticipated)Interventional2021-10-31Recruiting
Prophylactic Cognitive Therapy for Depression. [NCT00118404]Phase 3523 participants (Actual)Interventional2000-03-31Completed
Prozac Treatment of Major Depression: Discontinuation Study [NCT00427128]Phase 4627 participants (Actual)Interventional1995-11-30Completed
Neurobiology/Treatment of Obsessive-Compulsive Disorder [NCT00000373]Phase 474 participants (Actual)Interventional1992-09-30Completed
Treatment of Outcomes of Fluoxetine vs EMDR in PTSD [NCT00000379]Phase 30 participants Interventional1999-01-31Completed
Comparison of Antidepressants in the Real-World: Retrospective Cohort Study Using Big Data [NCT04446039]405,349 participants (Actual)Observational2022-07-04Completed
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol [NCT05814640]Phase 1/Phase 2520 participants (Anticipated)Interventional2023-02-20Recruiting
A Randomized Surgical Window of Opportunity Study With Dose Escalation to Evaluate Whether Oral Fluoxetine Can Induce Cytotoxic Lysosomal Stress and Enhance Temozolomide Efficacy in Clinical Glioma [NCT05634707]Early Phase 130 participants (Anticipated)Interventional2023-08-05Recruiting
Research on Standardized Electronic Cognitive Training Technique in Early Stage of Senile Depression With Cognitive Impairment [NCT05588102]128 participants (Anticipated)Interventional2021-05-18Recruiting
16-week Open Randomized Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression: Pharmacogenomic and Biomarker Predictors of Response [NCT02389712]Phase 42 participants (Actual)Interventional2015-03-31Terminated(stopped due to Difficulties with recruitment)
Fluoxetine for Major Depressive Disorder/Cannabis Disorder in Young People [NCT00149643]Phase 270 participants (Actual)Interventional2004-09-30Completed
A Randomized Controlled Study Comparing Fluoxetine With Bupropion for Impulsivity and Suicidality in Patients With Major Depressive Disorder and Comorbid Alcoholism (Abuse or Dependence) [NCT00449007]Phase 45 participants (Actual)Interventional2006-02-28Terminated(stopped due to recruitment of this population was not feasible)
A Study to Assess the Short-Term Efficacy and Safety of Olanzapine and Fluoxetine Compared to Placebo and Fluoxetine for Nonpsychotic Treatment-Resistant Depression [NCT01687478]Phase 3176 participants (Actual)Interventional2012-09-30Terminated(stopped due to Interim assessment: Lack of efficacy)
Comparative Efficacy and Safety of Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in the Treatment of Post Schizophrenic Depression: A Randomized Controlled Trial [NCT04876521]Phase 460 participants (Anticipated)Interventional2021-05-04Recruiting
Efficacy and Safety of Light Therapy in the Treatment of Non-seasonal Depressive [NCT05499117]80 participants (Anticipated)Interventional2022-02-01Recruiting
Interventional, Randomized, Double-blind, Placebo-controlled, Active-reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years, With Major Depressive Disorder (MDD) [NCT02709655]Phase 3683 participants (Actual)Interventional2016-05-18Completed
Efficacy of Hydroxyzine Versus Treatment as Usual for Panic Disorder: An Eight-Week, Open Label, Pilot, Randomized Controlled Trial. [NCT05737511]Phase 480 participants (Anticipated)Interventional2023-12-30Not yet recruiting
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]Phase 3407 participants (Actual)Interventional2015-01-31Terminated
Pharmaco(Epi)Genetic Study of Obsessive-Compulsive Disorder [NCT02431845]200 participants (Anticipated)Interventional2013-01-31Recruiting
The Role of Antidepressants or Antipsychotics in Preventing Psychosis [NCT01724372]0 participants (Actual)Interventional2012-10-31Withdrawn
Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders [NCT05792540]Phase 275 participants (Anticipated)Interventional2023-06-06Recruiting
Pilot RCT of Fluoxetine vs Placebo to Treat Motor, Language and Unilateral Neglect After Ischemic Stroke [NCT01674868]0 participants (Actual)Interventional2013-04-30Withdrawn(stopped due to unable to find patients meeting inclusion/exclusion criteria)
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Parallel-Design Study to Evaluate the Short-Term, Fixed Dose Efficacy and Safety of LY110140 Once Daily Dosing in Japanese Patients With Major Depressive Disorder [NCT01808612]Phase 3513 participants (Actual)Interventional2013-03-31Completed
Fluoxetine and Divalproex: Treatment Correlates in IED [NCT00078754]Phase 290 participants (Actual)Interventional2003-05-31Completed
Hypnotics in the Treatment of Psychiatric Disorders [NCT00247624]Phase 460 participants (Actual)Interventional2005-10-31Completed
Fluoxetine After Weight Restoration in Anorexia Nervosa [NCT00288574]Phase 493 participants (Actual)Interventional2000-01-31Completed
Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation [NCT01714310]Phase 234 participants (Actual)Interventional2013-01-31Completed
Effects of Contralesional Repetitive Magnetic Stimulation Combined With Fluoxetine on Motor Recovery in Acute Stroke Patients [NCT02208466]Phase 244 participants (Actual)Interventional2014-09-30Completed
Effects of Treatment on Decision-making in Major Depression [NCT01916824]Phase 453 participants (Actual)Interventional2013-08-31Completed
A Phase 3, Open-label, Long-Term Study to Evaluate the Safety of LY110140 Once Daily Dosing for 52-week in Japanese Patients With Major Depressive Disorder [NCT01808651]Phase 3200 participants (Actual)Interventional2013-05-31Completed
A Relative Bioavailability Study of 90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions [NCT01247285]Phase 126 participants (Actual)Interventional2001-05-31Completed
Improving Metabolic Parameters of Antipsychotic Child Treatment (IMPACT) [NCT00806234]Phase 4127 participants (Actual)Interventional2009-01-31Completed
Safety and Efficacy of Dental Pulp Mesenchymal Cells in the Treatment of Depression: [NCT05127369]48 participants (Anticipated)Interventional2022-01-01Not yet recruiting
NMDA Antagonists in Bipolar Depression [NCT01833897]Phase 48 participants (Actual)Interventional2013-03-31Completed
Comparison of Acupuncture and Fluoxetine for of Ischemic Post-stroke Depression:A Multicentre Randomized Controlled Trial [NCT02472613]208 participants (Anticipated)Interventional2016-05-31Completed
Efficacy of Individualized Homeopathic Treatment for Moderate to Severe Depression in Peri- and Postmenopausal Women: a Randomized Placebo-controlled, Double-blind, Double-dummy, Study Protocol [NCT01635218]Phase 2133 participants (Actual)Interventional2012-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00027378 (2) [back to overview]Alcohol Use Behaviors
NCT00027378 (2) [back to overview]Depressive Symptoms
NCT00074815 (1) [back to overview]Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
NCT00078754 (2) [back to overview]Overt Aggression Scale-Modified for Outpatient Use (OAS-M)
NCT00078754 (2) [back to overview]OAS-M
NCT00115804 (8) [back to overview]The Functional Disability Inventory-child Version
NCT00115804 (8) [back to overview]The Clinical Global Impression of Severity
NCT00115804 (8) [back to overview]Multidimensional Anxiety Scale for Children
NCT00115804 (8) [back to overview]Fibromyalgia Impact Questionnaire Modified for Children
NCT00115804 (8) [back to overview]Children's Depression Inventory
NCT00115804 (8) [back to overview]Average Pain Severity Score
NCT00115804 (8) [back to overview]The Patient Global Impression of Improvement
NCT00115804 (8) [back to overview]The Functional Disability Inventory-parent Version
NCT00118404 (3) [back to overview]Depressive Relapse/Recurrence or MDD
NCT00118404 (3) [back to overview]Depressive Relapse or MDD
NCT00118404 (3) [back to overview]Depressive Relapse/Recurrence or MDD
NCT00149643 (3) [back to overview]Number of Cannabis Use Disorder Criterion Met at a Particular Time Point.
NCT00149643 (3) [back to overview]Days Per Week of Cannabis Use.
NCT00149643 (3) [back to overview]Depression Symptoms at Week 12
NCT00183339 (4) [back to overview]Change From Baseline to 12 Months in Total Score on Caregiver Strain Questionnaire
NCT00183339 (4) [back to overview]Rate of Attrition
NCT00183339 (4) [back to overview]Change From Baseline to Month 12 in Aberrant Behavior Checklist Irritability Subscale Score (ABC-I)
NCT00183339 (4) [back to overview]Rate of Recruitment
NCT00245635 (1) [back to overview]Change in Total Score on the BDD-Y-BOCS Scale
NCT00247624 (4) [back to overview]Daily Living and Role Functioning (DLRF) Basis-32 Subscale Ratings
NCT00247624 (4) [back to overview]Relation to Self/Others (RSO) Basis-32 Subscale Ratings
NCT00247624 (4) [back to overview]Quality of Life Ratings, as Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)
NCT00247624 (4) [back to overview]Insomnia Severity Index (ISI)
NCT00288574 (11) [back to overview]Change Per Month in Psychological Symptoms During Treatment, Assessed With the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).
NCT00288574 (11) [back to overview]Change Per Month in Psychological Symptoms During Treatment, Assessed With the Yale Brown Cornell Obsessive Compulsive Scale for Eating Disorders (YBC-EDS)
NCT00288574 (11) [back to overview]Change Per Month in Psychological Symptoms During Treatment, Assessed With the Eating Disorders Inventory (EDI), Perfectionism Subscale.
NCT00288574 (11) [back to overview]Change in Weight Per Month During Treatment
NCT00288574 (11) [back to overview]Change Per Month in Psychological Symptoms During Treatment, Assessed With Beck Anxiety Inventory (BAI)
NCT00288574 (11) [back to overview]Change Per Month in Psychological Symptoms During Treatment, Assessed With Beck Depression Inventory (BDI)
NCT00288574 (11) [back to overview]Change Per Month in Psychological Symptoms During Treatment, Assessed With the Eating Disorders Inventory (EDI), Drive for Thinness Subscale.
NCT00288574 (11) [back to overview]Change Per Month in Psychological Symptoms During Treatment, Assessed With the Rosenberg Self-Esteem Scale (RSES).
NCT00288574 (11) [back to overview]Change Per Month in Psychological Symptoms During Treatment, Assessed With the Eating Disorders Inventory (EDI), Bulimia Subscale.
NCT00288574 (11) [back to overview]Change Per Month in Psychological Symptoms During Treatment, Assessed With the Eating Disorders Inventory (EDI), Body Dissatisfaction Subscale.
NCT00288574 (11) [back to overview]Proportion of Patients Remaining in Study at 1 Year
NCT00296725 (2) [back to overview]Hamilton Depression Scale (HAM-D)
NCT00296725 (2) [back to overview]Number of Participants With Positive Response as Assessed by the Clinical Global Impression -Global Improvement Scale (CGI-I)
NCT00339079 (1) [back to overview]25% Improvement on Both Whiteley Index and H-YBOCS-M
NCT00449007 (2) [back to overview]Suicidal Ideation at 6 Months
NCT00449007 (2) [back to overview]Occurrence of Suicide Events Either a Suicide Death, a Suicide Attempt, or Suicidal Ideation Severe Enough to Warrant a Medical Intervention
NCT00531518 (1) [back to overview]Psychotic Symptoms
NCT00533117 (1) [back to overview]Suicide Attempts
NCT00578669 (2) [back to overview]Number of Participants Achieving Smoking Abstinence
NCT00578669 (2) [back to overview]Self-reported Depressive Symptoms
NCT00592852 (2) [back to overview]Young Mania Rating Scale (YMRS)
NCT00592852 (2) [back to overview]Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
NCT00603018 (1) [back to overview]Serotonin Receptor 1A Binding Potential In Regions of Interest (ROI) Accounting for Binding Potential in a Region Without Serotonin 1A Receptors
NCT00611975 (8) [back to overview]Change in Free Testosterone
NCT00611975 (8) [back to overview]Change in Progesterone
NCT00611975 (8) [back to overview]Change in Prolactin
NCT00611975 (8) [back to overview]Change in Arizona Sexual Experiences Scale (ASEX)
NCT00611975 (8) [back to overview]Change in Androstenedione
NCT00611975 (8) [back to overview]Change in 17-OH Pregnenolone
NCT00611975 (8) [back to overview]Change in Estradiol
NCT00611975 (8) [back to overview]Change in Dehydroepiandrosterone Sulfate (DHEA-S)
NCT00612313 (6) [back to overview]Relapse
NCT00612313 (6) [back to overview]Remission
NCT00612313 (6) [back to overview]Remission
NCT00612313 (6) [back to overview]K-Life (Time Well)
NCT00612313 (6) [back to overview]Relapse
NCT00612313 (6) [back to overview]Time to Remission
NCT00626340 (1) [back to overview]Comparison of Cortical GABA Levels in 4 Groups of Subjects Using Estrogen Alone, Fluoxetine Alone, Estrogen and Fluoxetine Combined in Pre and Post 4.0T Magnetic Resonance Spectroscopy Sessions.
NCT00666757 (25) [back to overview]Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Absenteeism at 12-Week Endpoint
NCT00666757 (25) [back to overview]Change From Baseline in Pulse Rate at Week-12 Endpoint
NCT00666757 (25) [back to overview]Change From Baseline in HAMD-17 Total Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]Change From Baseline in HAMD-17 Sleep Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]Change From Baseline in HAMD-17 Retardation Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]Change From Baseline in SDS Work/School Item Score at 12-Week Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]Change From Baseline in HAMD-17 Maier Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]Change From Baseline in HAMD-17 Bech Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]Change From Baseline in Weight at Week-12 Endpoint
NCT00666757 (25) [back to overview]Change From Baseline in Diastolic Blood Pressure at Week-12 Endpoint
NCT00666757 (25) [back to overview]Change From Baseline in Brief Pain Inventory (BPI) Average 24-hour Pain Score, in Particpants With a Baseline BPI Average 24-hour Pain Score of 3 or Greater, at 12-Week Endpoint (Pain Measure)
NCT00666757 (25) [back to overview]Probability of Response [QIDS-SR Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]
NCT00666757 (25) [back to overview]Probability of Response [HAMD-17 Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]
NCT00666757 (25) [back to overview]Probability of Remission [17-item Hamilton Depression Rating Scale (HAMD-17) (Mood Measure) Less Than or Equal to 7 at 12-Week Endpoint]
NCT00666757 (25) [back to overview]Probability of Remission [16-item Quick Inventory of Depressive Symptomatology (QIDS-SR) Score Less Than or Equal to 5 at 12-Week Endpoint]
NCT00666757 (25) [back to overview]Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Presenteeism Score, at Week-12 Endpoint
NCT00666757 (25) [back to overview]Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Dollars of Income Lost Due to Work Presenteeism (WP)Score, at Week-12 Endpoint
NCT00666757 (25) [back to overview]Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Dollars of Income Lost Due to Work Absenteeism Score at Week-12 Endpoint
NCT00666757 (25) [back to overview]Change From Baseline in BPI Average 24 Hour Pain Score at 12-Week Endpoint (Pain Measure)
NCT00666757 (25) [back to overview]Change From Baseline in Systolic Blood Pressure at Week-12 Endpoint
NCT00666757 (25) [back to overview]Change From Baseline in Sheehan Disability Scale (SDS) Global Functional Impairment Score at 12-Week Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]Change From Baseline in Sheehan Disability Scale (SDS) Family/Home Item Score at Week-12 Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]Change From Baseline in HAMD-17 Anxiety/Somatization Subscale Score at 12-Week Endpoint (Mood Measure)
NCT00666757 (25) [back to overview]Change From Baseline in SDS Social Item Score at 12-Week Endpoint (Functional Outcome Measure)
NCT00666757 (25) [back to overview]Change From Baseline in QIDS-SR Total Score at 12-Week Endpoint (Mood Measure)
NCT00797966 (14) [back to overview]Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 15 Score (Satisfaction With Medication).
NCT00797966 (14) [back to overview]Percentage of Participants With CGI-I Response From End of Phase A (Week 8 Visit).
NCT00797966 (14) [back to overview]Percentage of Participants With MADRS Remission From End of Phase A (Week 8 Visit).
NCT00797966 (14) [back to overview]Percentage of Participants With MADRS Response From End of Phase A (Week 8 Visit).
NCT00797966 (14) [back to overview]Change From End of Phase A (Week 8 Visit) in Mean CGI-S Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.
NCT00797966 (14) [back to overview]Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Clinical Global Impression - Severity of Illness Scale (CGI-S) Score.
NCT00797966 (14) [back to overview]Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Depression Rating Scale (HAM-D17) Score.
NCT00797966 (14) [back to overview]Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 16 Score (Overall Life Satisfaction).
NCT00797966 (14) [back to overview]Clinical Global Impression-Improvement Scale (CGI-I) Score at Each Study Week Visit in Phase B.
NCT00797966 (14) [back to overview]Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Score (the Mean of 3 Individual Item Scores).
NCT00797966 (14) [back to overview]Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score.
NCT00797966 (14) [back to overview]Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score.
NCT00797966 (14) [back to overview]Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.
NCT00797966 (14) [back to overview]Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Quality of Life, Enjoyment, and Satisfaction Questionnaire - Short Form (QLES-Q-SF) Subscale Score - the Overall General Subscore (Sum of First 14 Items).
NCT00806234 (4) [back to overview]Change in Low Density Lipoprotein (LDL) Cholesterol Level
NCT00806234 (4) [back to overview]Change in Whole Body Insulin Sensitivity Index
NCT00806234 (4) [back to overview]Triglyceride Levels
NCT00806234 (4) [back to overview]Body Mass Index (BMI) Z-score Change
NCT00834834 (2) [back to overview]Suicide Events
NCT00834834 (2) [back to overview]Number of Participants With Suicide Events
NCT00844857 (20) [back to overview]Change From Baseline in the YMRS Total Score at Week 8
NCT00844857 (20) [back to overview]Change From Baseline in Weight Up to Week 8
NCT00844857 (20) [back to overview]Percentage of Participants With at Least One Incident of Worsening of Mania Up to Week 8
NCT00844857 (20) [back to overview]Percentage of Participants With at Least One Treatment-Emergent Incident of Akathisia Up to Week 8
NCT00844857 (20) [back to overview]Percentage of Participants With at Least One Treatment-Emergent Incident of Dyskinesia Up to Week 8
NCT00844857 (20) [back to overview]Percentage of Participants With at Least One Treatment-Emergent Incident of Parkinsonism Up to Week 8
NCT00844857 (20) [back to overview]Percentage of Participants With Remission Up to Week 8
NCT00844857 (20) [back to overview]Percentage of Participants With Response Up to Week 8
NCT00844857 (20) [back to overview]Percentage of Participants in Each Improvement Category Up to Week 8
NCT00844857 (20) [back to overview]Percentage of Participants With Treatment Emergent Suicidal Ideation or Behavior Up to Week 8
NCT00844857 (20) [back to overview]Change From Baseline in Fasting Metabolic Parameters Up to Week 8
NCT00844857 (20) [back to overview]Change From Baseline in Alanine Aminotransferase/Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) Up to Week 8
NCT00844857 (20) [back to overview]Change From Baseline in Electrocardiogram (ECG) QTcF Interval Up to Week 8
NCT00844857 (20) [back to overview]Change From Baseline in Prolactin Up to Week 8
NCT00844857 (20) [back to overview]Change From Baseline in Symptoms of Attention-Deficit/Hyperactivity Disorder Up to Week 8
NCT00844857 (20) [back to overview]Change From Baseline in the CDRS-R Total Score Up to Week 8
NCT00844857 (20) [back to overview]Change From Baseline in the Children's Depression Rating Scale Revised (CDRS-R) Total Score at Week 8
NCT00844857 (20) [back to overview]Change From Baseline in the Clinical Global Impression Scale - Bipolar Version (CGI-BP) Score at Week 8
NCT00844857 (20) [back to overview]Change From Baseline in the Quality of Life Questionnaire for Children and Adolescents (KINDL) Kid and Kiddo Combined Scale Up to Week 8
NCT00844857 (20) [back to overview]Change From Baseline in the Quality of Life Questionnaire for Children and Adolescents (KINDL) Parent Scale Up to Week 8
NCT00849693 (12) [back to overview]Change From Baseline in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 10 Endpoint
NCT00849693 (12) [back to overview]Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 36 Endpoint
NCT00849693 (12) [back to overview]Change From Week 10 in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 36 Endpoint
NCT00849693 (12) [back to overview]Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Week 10 Through Week 36
NCT00849693 (12) [back to overview]Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 10 Endpoint
NCT00849693 (12) [back to overview]Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 36 Endpoint
NCT00849693 (12) [back to overview]Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Baseline Through Week 10
NCT00849693 (12) [back to overview]Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Week 10 Through Week 36
NCT00849693 (12) [back to overview]Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Baseline Through Week 10
NCT00849693 (12) [back to overview]Number of Participants With Suicidal Ideation or Suicidal Behavior Week 10 Through Week 36
NCT00849693 (12) [back to overview]Number of Participants With Suicidal Ideation or Suicidal Behavior Baseline Through Week 10
NCT00849693 (12) [back to overview]Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint
NCT00849901 (12) [back to overview]Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 36 Endpoint
NCT00849901 (12) [back to overview]Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 10 Endpoint
NCT00849901 (12) [back to overview]Change From Week 10 in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 36 Endpoint
NCT00849901 (12) [back to overview]Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 36 Endpoint
NCT00849901 (12) [back to overview]Change From Baseline in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 10 Endpoint
NCT00849901 (12) [back to overview]Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint
NCT00849901 (12) [back to overview]Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Baseline Through Week 10
NCT00849901 (12) [back to overview]Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Week 10 Through Week 36
NCT00849901 (12) [back to overview]Number of Participants With Suicidal Ideation or Suicidal Behavior Baseline Through Week 10
NCT00849901 (12) [back to overview]Number of Participants With Suicidal Ideation or Suicidal Behavior Week 10 Through Week 36
NCT00849901 (12) [back to overview]Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Baseline Through Week 10
NCT00849901 (12) [back to overview]Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Week 10 Through Week 36
NCT00909155 (2) [back to overview]Hamilton Depression (HAM-D) and Anxiety (HAM-A) Rating Scales
NCT00909155 (2) [back to overview]Functional Magnetic Resonance Imaging (fMRI) Response to an Emotional Regulation Task.
NCT00942708 (3) [back to overview]Change in Pulmonary Vascular Resistance (PVR) at Three Months
NCT00942708 (3) [back to overview]Change Between Baseline and Three Month in the QIDS-SR Depression Scale
NCT00942708 (3) [back to overview]Change in Six Minute Walk Distance at 3 Months
NCT00958568 (39) [back to overview]Mean Change From Week 20 to Week 47 in Weight
NCT00958568 (39) [back to overview]Mean Change From Week 20 to Week 47 in Montgomery-Asberg Depression Rating Scale (MADRS) Using Mixed-Effects Model Repeated Measures (MMRM) Analysis
NCT00958568 (39) [back to overview]Mean Change From Week 20 to Week 47 in Montgomery-Asberg Depression Rating Scale (MADRS) Using Last Observation Carried Forward (LOCF) Analysis
NCT00958568 (39) [back to overview]Kaplan-Meier Estimate of Percentage of Subjects Not Relapsing at Week 27 (Day 189)
NCT00958568 (39) [back to overview]Percent of Participants With Suicide-Related Thoughts and Behaviors
NCT00958568 (39) [back to overview]Percent of Participants With Treatment-Emergent High Fasting Glucose
NCT00958568 (39) [back to overview]Percent of Participants With Treatment-Emergent High Fasting Low-Density Lipoprotein (LDL) Cholesterol
NCT00958568 (39) [back to overview]Percent of Participants With Treatment-Emergent High Fasting Total Cholesterol
NCT00958568 (39) [back to overview]Resource Utilization (Number of Psychiatric Visits, Number of Emergency Room or Equivalent Facility Visits for Psychiatric Illness)
NCT00958568 (39) [back to overview]Time to Relapse Based on the Montgomery-Åsberg Depression Rating Scale (MADRS) Score With Concomitant Clinical Global Impressions-Severity (CGI-S) of Depression Score
NCT00958568 (39) [back to overview]Time to Relapse as Measured by Hospitalization for Depression or Suicidality
NCT00958568 (39) [back to overview]Mean Change From Week 20 to Week 47 in Clinical Global Impressions - Severity (CGI-S) of Depression Using Mixed-Effects Model Repeated Measures (MMRM) Analysis
NCT00958568 (39) [back to overview]Mean Change From Week 20 to Week 47 in Fasting Glucose
NCT00958568 (39) [back to overview]Mean Change From Week 20 to Week 47 in Fasting Low-Density Lipoprotein (LDL) Cholesterol
NCT00958568 (39) [back to overview]Mean Change From Week 20 to Week 47 in Fasting High-Density Lipoprotein (HDL) Cholesterol
NCT00958568 (39) [back to overview]Change From Week 20 to Week 47 Endpoint in the Sheehan Disability Scale (SDS)
NCT00958568 (39) [back to overview]Mean Change From Week 20 to Week 47 in Fasting Triglycerides
NCT00958568 (39) [back to overview]Percentage of Participants Achieving Remission at Any Point During Stabilization Treatment Phase
NCT00958568 (39) [back to overview]Percentage of Participants Maintaining Remission
NCT00958568 (39) [back to overview]Mean Change From Week 20 to Week 47 in Fasting Total Cholesterol
NCT00958568 (39) [back to overview]Percentage of Participants Maintaining Response at Any Point During Stabilization Treatment Phase
NCT00958568 (39) [back to overview]Percentage of Participants Responding to Treatment During Open-Label Acute Treatment Phase
NCT00958568 (39) [back to overview]Percentage of Participants Who Relapse as Measured by Discontinuation Due to Lack of Efficacy/Worsening of Depression/Suicidality
NCT00958568 (39) [back to overview]Percent of Participants With Week 20-to-Week 47 Endpoint Increase in Weight of at Least 7%
NCT00958568 (39) [back to overview]Percent of Participants With Treatment-Emergent Parkinsonism
NCT00958568 (39) [back to overview]Percent of Participants With Treatment-Emergent Low Fasting High-Density Lipoprotein (HDL) Cholesterol
NCT00958568 (39) [back to overview]Percent of Participants With Treatment-Emergent Hepatic Events
NCT00958568 (39) [back to overview]Percent of Participants With Treatment-Emergent Dyskinesia
NCT00958568 (39) [back to overview]Time to Relapse by Any Criteria
NCT00958568 (39) [back to overview]Percent of Participants With Treatment-Emergent Corrected (for Rate) Cardiac QT Interval Using Fridericia's Formula (QTcF) on Electrocardiogram ≥500 Milliseconds (Msec)
NCT00958568 (39) [back to overview]Percent of Participants With Treatment-Emergent High Fasting Triglycerides
NCT00958568 (39) [back to overview]Percent of Participants With a 60 Milliseconds (Msec) Increase in Fridericia-Corrected (for Rate) Cardiac QT Interval (QTcF) on Electrocardiogram
NCT00958568 (39) [back to overview]Mean Change in Corrected (for Rate) Cardiac QT Interval Using Fridericia's Formula (QTcF) on Electrocardiogram
NCT00958568 (39) [back to overview]Percentage of Participants Who Relapse as Measured by Hospitalization for Depression or Suicidality
NCT00958568 (39) [back to overview]Percentage of Participants Who Relapse Based on Montgomery-Åsberg Depression Rating Scale (MADRS) Score With Concomitant Clinical Global Impressions-Severity (CGI-S) of Depression Score
NCT00958568 (39) [back to overview]Percentage of Participants Who Relapse by Any Criteria
NCT00958568 (39) [back to overview]Resource Utilization - Average Number of Hours Worked for Pay Per Week at Week 47
NCT00958568 (39) [back to overview]Time to Relapse as Measured by Discontinuation Due to Lack of Efficacy/Worsening of Depression/Suicidality
NCT00958568 (39) [back to overview]Percent of Participants With Treatment-Emergent Akathisia
NCT00961961 (3) [back to overview]Number of Participants With an Onset of a Hypomanic Episode Within 1 Year
NCT00961961 (3) [back to overview]Number of Participants With an Onset of a Manic Episode Within 1 Year
NCT00961961 (3) [back to overview]Number of Participants With Relapse of Major Depressive Episode Within 1 Year
NCT00965562 (11) [back to overview]Proportion of Patients With PMTS Visit-wise Response to Treatment (50% Improvement)
NCT00965562 (11) [back to overview]Comparison of the Change in CGI Improvement Scores Among Groups
NCT00965562 (11) [back to overview]Comparison of the Change in CGI-S Symptom Scores Among Groups
NCT00965562 (11) [back to overview]Comparison of the Change in DRSP Symptom Scores Among Groups
NCT00965562 (11) [back to overview]Comparison of the Change in IDS Symptom Scores Among Groups
NCT00965562 (11) [back to overview]Comparison of the Change in PMTS Symptom Scores Among Groups
NCT00965562 (11) [back to overview]Proportion of Participants With DRSP LOCF Response to Treatment (50% Improvement)
NCT00965562 (11) [back to overview]Proportion of Participants With DRSP Visit-wise Response to Treatment (50% Improvement)
NCT00965562 (11) [back to overview]Proportion of Participants With IDS LOCF Response to Treatment (50% Improvement)
NCT00965562 (11) [back to overview]Proportion of Participants With PMTS LOCF Response to Treatment (50% Improvement)
NCT00965562 (11) [back to overview]Proportion of Patients With IDS Visit-wise Response to Treatment (50% Improvement)
NCT01243957 (6) [back to overview]Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of LY2216684
NCT01243957 (6) [back to overview]Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of Fluoxetine and Norfluoxetine
NCT01243957 (6) [back to overview]Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-Time Curve Over a 24-Hour Dosing Interval (AUCτ) of LY2216684
NCT01243957 (6) [back to overview]Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration Time-Curve Over a 24-Hour Dosing Interval (AUCτ) of Fluoxetine and Norfluoxetine
NCT01243957 (6) [back to overview]Pharmacokinetic (PK) Parameter: Time to Maximum Plasma Concentration (Tmax) of LY2216684
NCT01243957 (6) [back to overview]Pharmacokinetic (PK) Parameter: Time to Maximum Plasma Concentration (Tmax) of Fluoxetine and Norfluoxetine
NCT01247272 (6) [back to overview]AUC0-t of Fluoxetine.
NCT01247272 (6) [back to overview]AUC0-inf of Fluoxetine.
NCT01247272 (6) [back to overview]AUC0-inf of Norfluoxetine.
NCT01247272 (6) [back to overview]AUC0-t of Norfluoxetine.
NCT01247272 (6) [back to overview]Cmax of Fluoxetine.
NCT01247272 (6) [back to overview]Cmax of Norfluoxetine.
NCT01247285 (6) [back to overview]AUC0-inf of Fluoxetine.
NCT01247285 (6) [back to overview]AUC0-inf of Norfluoxetine.
NCT01247285 (6) [back to overview]AUC0-t of Fluoxetine.
NCT01247285 (6) [back to overview]AUC0-t of Norfluoxetine.
NCT01247285 (6) [back to overview]Cmax of Fluoxetine.
NCT01247285 (6) [back to overview]Cmax of Norfluoxetine.
NCT01254305 (3) [back to overview]Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score
NCT01254305 (3) [back to overview]Change in Cognitive and Physical Functioning Questionnaire (CPFQ), Last Observation Carried Forward
NCT01254305 (3) [back to overview]Change in Patient Global Impressions of Severity (PGI-S) for Fatigue Score
NCT01360866 (5) [back to overview]Change From Baseline in Mean Clinical Global Impression - Improvement (CGI-I) Score
NCT01360866 (5) [back to overview]Change From Baseline in the Inventory of Depressive Symptomatology - Self Report (IDS-SR) Total Score
NCT01360866 (5) [back to overview]Summary of Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Score
NCT01360866 (5) [back to overview]Adverse Events (AEs) - All Participants
NCT01360866 (5) [back to overview]Mean Change From Baseline in Clinical Global Impression - Severity (CGI-S) of Illness Score
NCT01361217 (2) [back to overview]AUC of Dextromethorphan, Midazolam and Omeprazole in the Presence of Fluoxetine
NCT01361217 (2) [back to overview]Lovastatin AUC in the Presence of Fluoxetine
NCT01372150 (4) [back to overview]Change From Baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score
NCT01372150 (4) [back to overview]Change From Baseline to Week 8 in the Clinical Global Impression of Severity (CGI-S) Score
NCT01372150 (4) [back to overview]Percentage of Participants by Clinical Global Impression Improvement (CGI-I) Score at Weeks 1, 2, 3, 4, 6, and 8
NCT01372150 (4) [back to overview]Percentage of Participants With a CGI-I Response Defined as a Score of 'Very Much Improved' or 'Much Improved'
NCT01436643 (1) [back to overview]Number of Participants Who Experienced Adverse Events, Serious Adverse Events and Death
NCT01545843 (8) [back to overview]Hamilton Rating Scale for Depression-17 Item Minus Sleep Items
NCT01545843 (8) [back to overview]Quick Inventory of Depressive Symptoms (QIDS)
NCT01545843 (8) [back to overview]Change in EEG Sleep Measures I: Total Sleep Time
NCT01545843 (8) [back to overview]Change in EEG Sleep Measures II (Sleep Efficiency)
NCT01545843 (8) [back to overview]Change in Neurologic Functioning: Reaction Time
NCT01545843 (8) [back to overview]Change in Neuropsychological Functioning: Memory
NCT01545843 (8) [back to overview]Neurological Function (Emotional Perception)
NCT01545843 (8) [back to overview]Pittsburgh Sleep Quality Index
NCT01569126 (9) [back to overview]Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Single Dose (SD) of LY110140
NCT01569126 (9) [back to overview]Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Multiple Doses (MD) of LY110140
NCT01569126 (9) [back to overview]Pharmacokinetics: Area Under the Concentration-Time Curve From Zero to Last Time Point [AUC(0-tlast)] of Single Dose (SD) of LY110140
NCT01569126 (9) [back to overview]Pharmacokinetics: Area Under the Concentration-Time Curve From Zero to Infinity [AUC(0-infinity)] of Single Dose (SD) of LY110140
NCT01569126 (9) [back to overview]Pharmacokinetics: Area Under the Concentration-Time Curve From Zero to 24 Hours [AUC(0-24)] of Multiple Doses (MD) of LY110140
NCT01569126 (9) [back to overview]Pharmacokinetics: Area Under the Concentration-Time Curve for Dosing Interval (Tau) at Steady State [AUC(Tau,Steady State)] of Multiple Doses (MD) of LY110140
NCT01569126 (9) [back to overview]Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious AEs During the Single-Dose (SD) Period
NCT01569126 (9) [back to overview]Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious AEs During the Multiple-Dose (MD) Period
NCT01569126 (9) [back to overview]Change From Baseline in Bazett's and Fridericia's Corrected QT (QTcB and QTcF) Intervals
NCT01635218 (5) [back to overview]Responder Rates at 6 Weeks.
NCT01635218 (5) [back to overview]Change From Baseline in Beck Depression Inventory at 6 Weeks.
NCT01635218 (5) [back to overview]Change From Baseline in 17-item Hamilton Rating Scale for Depression at 6 Weeks.
NCT01635218 (5) [back to overview]Remission Rates at 6 Weeks
NCT01635218 (5) [back to overview]Change From Baseline in Greene´s Scale at 6 Weeks.
NCT01687478 (9) [back to overview]Mean Change From Baseline to 8 Week Endpoint in the Barnes Akathisia Scale (BAS)
NCT01687478 (9) [back to overview]Mean Change From Baseline to 8 Week Endpoint in the Abnormal Involuntary Movement Scale (AIMS)
NCT01687478 (9) [back to overview]Mean Change From Baseline to 8 Week Endpoint in Montgomery-Äsberg Depression Rating Scale (MADRS)
NCT01687478 (9) [back to overview]Percentage of Participants Who Achieve a Response Based on a ≥50% Reduction From Baseline in MADRS Total Score
NCT01687478 (9) [back to overview]Mean Change From Baseline to 8 Week Endpoint in the Simpson-Angus Scale (SAS)
NCT01687478 (9) [back to overview]Mean Change From Baseline to 8 Week Endpoint in Clinical Global Impressions-Severity of Depression (CGI-S) Scale
NCT01687478 (9) [back to overview]Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36)
NCT01687478 (9) [back to overview]Mean Change From Baseline to 8 Week Endpoint in the Sheehan Disability Scale (SDS)
NCT01687478 (9) [back to overview]Percentage of Participants Who Achieve Remission Based on MADRS Total Score ≤10 at 8 Weeks
NCT01714310 (23) [back to overview]ADHD-IV Rating Scale
NCT01714310 (23) [back to overview]ADHD-IV Rating Scale
NCT01714310 (23) [back to overview]Affective Reactivity Index - Parent Report
NCT01714310 (23) [back to overview]Affective Reactivity Index - Parent Report
NCT01714310 (23) [back to overview]Clinical Global Impression-Severity-Severe Mood Dysregulation
NCT01714310 (23) [back to overview]Clinical Global Impression-Severity-Severe Mood Dysregulation
NCT01714310 (23) [back to overview]Conners Global Index Emotional Lability Subscale - Parent Report
NCT01714310 (23) [back to overview]Conners Global Index Restless-Impulsive Subscale Parent Report
NCT01714310 (23) [back to overview]Conners Parent Global Index
NCT01714310 (23) [back to overview]Conners Teacher Global Index
NCT01714310 (23) [back to overview]Diastolic Blood Pressure
NCT01714310 (23) [back to overview]Diastolic Blood Pressure
NCT01714310 (23) [back to overview]Height
NCT01714310 (23) [back to overview]Height
NCT01714310 (23) [back to overview]Pulse
NCT01714310 (23) [back to overview]Pulse
NCT01714310 (23) [back to overview]Revised Modified Overt Aggression Scale - Total Score
NCT01714310 (23) [back to overview]Revised Modified Overt Aggression Scale - Total Score
NCT01714310 (23) [back to overview]Systolic Blood Pressure
NCT01714310 (23) [back to overview]Systolic Blood Pressure
NCT01714310 (23) [back to overview]Weight
NCT01714310 (23) [back to overview]Weight
NCT01714310 (23) [back to overview]Clinical Global Impression - Improvement
NCT01740726 (1) [back to overview]Change in Depressive Symptoms From Baseline Based on Beck Depression Inventory, 2nd Edition (BDI-II)
NCT01802437 (3) [back to overview]SAS-SR Score
NCT01802437 (3) [back to overview]CGAS Score
NCT01802437 (3) [back to overview]CDRS-R Score
NCT01808612 (7) [back to overview]Percentage of Participants Achieving a Remission at 6-Week Endpoint
NCT01808612 (7) [back to overview]Mean Change From Baseline to 6-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale
NCT01808612 (7) [back to overview]Mean Change From Baseline to 6-Week Endpoint on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score
NCT01808612 (7) [back to overview]Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia - Suicide Severity Rating Scale (C-SSRS)
NCT01808612 (7) [back to overview]Mean Change From Baseline to 6-Week Endpoint on the HAMD21 Subscale Scores
NCT01808612 (7) [back to overview]Mean Change From Baseline to 6-Week Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscale Scores
NCT01808612 (7) [back to overview]Percentage of Participants Achieving a Response at 6-Week Endpoint
NCT01808651 (8) [back to overview]Percentage of Participants Achieving a Remission at Week 52
NCT01808651 (8) [back to overview]Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia - Suicide Severity Rating Scale (C-SSRS)
NCT01808651 (8) [back to overview]Mean Change From Baseline to Week 52 on the Clinical Global Impression of Severity (CGI-S) Scale
NCT01808651 (8) [back to overview]Mean Change From Baseline to Week 52 on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score
NCT01808651 (8) [back to overview]Percentage of Participants Achieving a Response at Week 52
NCT01808651 (8) [back to overview]Change From Baseline to Week 52 in Sheehan Disability Scale (SDS) Total Score and Subscale Scores
NCT01808651 (8) [back to overview]Mean Change From Baseline to Week 52 on the HAMD21 Subscale Scores
NCT01808651 (8) [back to overview]Number of Participants With Adverse Events (AEs) or Serious AEs (SAEs)
NCT01833897 (5) [back to overview]Loss of Motivated Behavior HAM-D Factor
NCT01833897 (5) [back to overview]Beck's Depression Inventory
NCT01833897 (5) [back to overview]HAM-D Suicide Item
NCT01833897 (5) [back to overview]Hamilton Anxiety Scale
NCT01833897 (5) [back to overview]Hamilton Depression Rating Scale (HAM-D)
NCT01916824 (1) [back to overview]Money Earned
NCT02017535 (4) [back to overview]Children's Depression Rating Scale-Revised (CDRS-R)
NCT02017535 (4) [back to overview]Beck Depression Inventory-II (BDI-II)
NCT02017535 (4) [back to overview]Social Adjustment Scale - Self Report (SAS-SR)
NCT02017535 (4) [back to overview]Children's Global Assessment Scale (CGAS)
NCT02208466 (3) [back to overview]Changes in Motor Function (Jebsen-Taylor Task)
NCT02208466 (3) [back to overview]Changes in Cortical Excitability Measures
NCT02208466 (3) [back to overview]Changes in Fugl-Meyer Assessment (FMA) Scale
NCT02238977 (1) [back to overview]Depression Severity
NCT02372799 (2) [back to overview]Change in Clinical Global Impressions-Severity (CGI-S) Score
NCT02372799 (2) [back to overview]Change in Children's Depression Rating Scale-Revised (CDRS-R) Total Score
NCT02431806 (2) [back to overview]Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score
NCT02431806 (2) [back to overview]Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale
NCT02473250 (4) [back to overview]Hamilton Anxiety Rating Scale
NCT02473250 (4) [back to overview]Clinical Global Impression-1
NCT02473250 (4) [back to overview]Young Mania Rating Scale
NCT02473250 (4) [back to overview]Montgomery-Asberg Depression Rating Scale
NCT02655354 (13) [back to overview]Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]Cognitive Impairment Scale
NCT02655354 (13) [back to overview]Number of Participants Endorsing a Single Item That Assesses Marijuana Use
NCT02655354 (13) [back to overview]Number of Participants Endorsing a Single Item That Assesses Opioid Use
NCT02655354 (13) [back to overview]Number of Participants Endorsing a Single Item That Assesses Stimulant Use
NCT02655354 (13) [back to overview]Number of Participants With Suicidal Ideation
NCT02655354 (13) [back to overview]SF-36 Quality of Life
NCT02655354 (13) [back to overview]TSOS Patient Satisfaction: Mental Health Care
NCT02655354 (13) [back to overview]TSOS Patient Satisfaction: Overall Health Care
NCT02655354 (13) [back to overview]Brief Pain Inventory
NCT02655354 (13) [back to overview]Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury
NCT02655354 (13) [back to overview]Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury
NCT02709655 (21) [back to overview]Change From Baseline in PedsQL VAS Total Average Score at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]Change From Baseline in PedsQL VAS: Angry Score at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]Change From Baseline in PedsQL VAS: Pain or Hurt Score at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B
NCT02709655 (21) [back to overview]Change From Baseline in CDRS-R Subscores (Mood, Somatic, Subjective, and Behaviour) at Weeks 2, 4, 6, and 8 of Phase B
NCT02709655 (21) [back to overview]Change From Baseline in CDRS-R Total Score at Weeks 2, 4, and 6 of Phase B
NCT02709655 (21) [back to overview]Change From Baseline in PedsQL Emotional Distress Summary Average Score at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]Change From Baseline in Children's Global Assessment Scale (CGAS) Score at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Weeks 1, 2, 3, 4, 6, and 8 of Phase B
NCT02709655 (21) [back to overview]Change From Baseline in General Behaviour Inventory (GBI) Depression Subscale Score, Using the 10-Item Depression Subscale Assessed by Parent (PGBI-10D) and Child (CGBI-10D) at Weeks 2, 4, 6, and 8 of Phase B
NCT02709655 (21) [back to overview]Change From Baseline in PedsQL VAS: Tired (Fatigue) Score at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]Parent Global Assessment (PGA) Score
NCT02709655 (21) [back to overview]Change From Baseline in PedsQL VAS: Worry Score at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]Change From Baseline in PQ-LES-Q Overall Evaluation Score (Item 15) at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]Clinical Global Impression - Global Improvement (CGI-I) Score
NCT02709655 (21) [back to overview]Change From Baseline in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Score (Items 1 to 14) at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]Percentage of Participants With CDRS-R Remission
NCT02709655 (21) [back to overview]Percentage of Participants With CDRS-R Response
NCT02709655 (21) [back to overview]Percentage of Participants With CGI-S Remission
NCT02709655 (21) [back to overview]Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score at Weeks 4 and 8 of Phase B
NCT02709655 (21) [back to overview]Change From Baseline in PedsQL VAS: Sad or Blue (Sadness) Score at Weeks 4 and 8 of Phase B
NCT02709746 (28) [back to overview]Change in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score
NCT02709746 (28) [back to overview]Change in PedsQL Emotional Distress Summary Average Score
NCT02709746 (28) [back to overview]Change in PedsQL VAS Total Average Score
NCT02709746 (28) [back to overview]Change in PedsQL VAS: Angry Score
NCT02709746 (28) [back to overview]Change in PedsQL VAS: Pain or Hurt Score
NCT02709746 (28) [back to overview]Change in PedsQL VAS: Sad or Blue (Sadness) Score
NCT02709746 (28) [back to overview]Parent Global Assessment-Global Improvement (PGA) Score
NCT02709746 (28) [back to overview]Clinical Global Impression - Global Improvement (CGI-I) Score
NCT02709746 (28) [back to overview]Change in Symbol Digit Modalities Test (SDMT)
NCT02709746 (28) [back to overview]Change in Children's Global Assessment Scale (CGAS) Score
NCT02709746 (28) [back to overview]Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment
NCT02709746 (28) [back to overview]Change in CDRS-R Total Score During Treatment (at Week 6)
NCT02709746 (28) [back to overview]Change in CDRS-R Total Score During Treatment (at Week 4)
NCT02709746 (28) [back to overview]Change in CDRS-R Total Score During Treatment (at Week 2)
NCT02709746 (28) [back to overview]Change in CDRS-R Subjective Score
NCT02709746 (28) [back to overview]Change in PedsQL VAS: Tired (Fatigue) Score
NCT02709746 (28) [back to overview]Change in PedsQL VAS: Worry Score
NCT02709746 (28) [back to overview]Change in CDRS-R Somatic Score
NCT02709746 (28) [back to overview]Change in CDRS-R Mood Score
NCT02709746 (28) [back to overview]Change in CDRS-R Behaviour Score
NCT02709746 (28) [back to overview]Change General Behaviour Inventory (GBI) Depression Subscale Score Assessed by the Child
NCT02709746 (28) [back to overview]CGI-S Remission
NCT02709746 (28) [back to overview]CDRS-R Response
NCT02709746 (28) [back to overview]CDRS-R Remission
NCT02709746 (28) [back to overview]Change in Clinical Global Impression Severity of Illness (CGI-S) Score
NCT02709746 (28) [back to overview]Change in General Behaviour Inventory (GBI) Depression Sub Scale Score Assessed by the Parents
NCT02709746 (28) [back to overview]Change in PQ-LES-Q Overall Score
NCT02709746 (28) [back to overview]Change in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Scores
NCT02737930 (7) [back to overview]Mean Percent Change in Field Points Tested
NCT02737930 (7) [back to overview]Mean Percent Change in Post-stroke Retinal Nerve Fiber Layer Thickness
NCT02737930 (7) [back to overview]Median Change in Patient Health Questionnaire-9 Score
NCT02737930 (7) [back to overview]Median Modified Rankin Scale Score
NCT02737930 (7) [back to overview]Number of Participants With >95% Recovery
NCT02737930 (7) [back to overview]Percent Change in Mean Visual Function Questionnaire-25 Score
NCT02737930 (7) [back to overview]Percent Change in the Bionocularly Averaged Perimetric Mean Deviation
NCT02929667 (5) [back to overview]Study Retention Rate
NCT02929667 (5) [back to overview]Study Recruitment Rate
NCT02929667 (5) [back to overview]Change in Slope of HCVR
NCT02929667 (5) [back to overview]Change in PHQ-9 Score.
NCT02929667 (5) [back to overview]Change in Minute Ventilation During Hypercapnic Ventilatory Response (HCVR) Testing
NCT03569475 (2) [back to overview]Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale
NCT03569475 (2) [back to overview]Change From Baseline in Children's Depression Rating Scale- Revised (CDRS-R)
NCT03638908 (4) [back to overview]Quick Inventory of Depressive Symptomatology
NCT03638908 (4) [back to overview]Pulmonary Vascular Resistance (PVR)
NCT03638908 (4) [back to overview]Exercise Capacity
NCT03638908 (4) [back to overview]5-HIAA (HYDROXYINDOLE ACETIC ACID) Level
NCT03728153 (6) [back to overview]Montgomery-Asberg Depression Rating Scale
NCT03728153 (6) [back to overview]Modified Rankin Scale
NCT03728153 (6) [back to overview]The Patient Health Questionnaire-9 (PHQ-9) Scale for Measuring Depression
NCT03728153 (6) [back to overview]Serum Sodium Concentration
NCT03728153 (6) [back to overview]Serum Alanine Aminotransferase (ALT)
NCT03728153 (6) [back to overview]Fugl-Meyer Motor Scale Score for Assessment of Motor Function After Stroke
NCT04377308 (5) [back to overview]Number of Subjects Undergoing Intubation
NCT04377308 (5) [back to overview]Number of Patients Who Died Within 2 Months of Entry Into the Study
NCT04377308 (5) [back to overview]Number of Outpatient Subject Hospitalizations
NCT04377308 (5) [back to overview]Participants With Patient Health Questionnaire (PHQ) -9 Score Below 10 After Baseline Assessment
NCT04377308 (5) [back to overview]Participants With Generalized Anxiety Disorder (GAD) -7 Scale Score Below 10 After Baseline Assessment

Alcohol Use Behaviors

Alcohol use behaviors measured by drinks per week. (NCT00027378)
Timeframe: Average number of drinks as recorded on the Timeline Follow-Back (subject-reported) measure daily over the 12-week acute phase.

Interventionstandard drink (14 gr. alcohol) (Mean)
Fluoxetine Plus Treatment As Usual (TAU)1.56
Placebo Plus Treatment as Usual (TAU)1.73

[back to top]

Depressive Symptoms

Beck Depression Inventory (BDI) Scores measured at Weeks 1-4, 6, 8, 10, 12. The BDI is a subject reported measure that has a minimum score of 0 and a maximum score of 63. A better outcome would consist of values near the minimum end of the scale (0) and a worse outcome would consist of values near the maximum end of the scale (63). (NCT00027378)
Timeframe: Average score as measured by participant's report on the Beck Depression Inventory (BDI).

Interventionunits on a scale (Mean)
Fluoxetine Plus Treatment As Usual (TAU)6.79
Placebo Plus Treatment as Usual (TAU)10.46

[back to top]

Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)

"OCD symptom severity was measured using the CY-BOCS, an interviewer-rated instrument that assess obsessions and compulsions separately on time consumed, distress, interference, degree of resistance, and control; it yields separate severity scores for obsessions and for compulsions (0 - 20), and a composite symptom severity score (0 to 40).~Consistent with signal detection analyses examining the optimal criterion for treatment response, a CY-BOCS reduction of 30% or more from baseline to week 12 was used as the criterion for RESPONSE and was the primary dichotomous outcome measure." (NCT00074815)
Timeframe: Measured at baseline and Week 12.

InterventionProportion of Participants with RESPONSE (Number)
MM + CBT0.69
MM + ICBT0.34
MM Only0.30

[back to top]

Overt Aggression Scale-Modified for Outpatient Use (OAS-M)

OAS-M is a validated instrument that measures aggression. Anti-aggressive effect of the drug/placebo was measured by the aggression score from OAS-M. Possible scores for aggression range from 0 (no aggression) to infinity (because the score is calculated by the number of times an aggressive behavior occurred, which theoretically has no possible maximum). Therefore the bigger number, the worse anti-aggression effect, thus the worse outcome. In each weekly visit, OAS-M score was calculated for the past week. (NCT00078754)
Timeframe: Measured at Week 12

Interventionunits on a scale (Mean)
Group A - Fluoxetine Drug7.86
Group B - Divalproex Drug15.73
Group C - Placebo8.88

[back to top]

OAS-M

Overt Aggression Scale Modified for Outpatient Use. Minimum value = 0 Maximum value = Infinity. Higher scores means worse outcome. (NCT00078754)
Timeframe: Measured at Week 12

,,
Interventionscore on a scale (Mean)
High Aggression GroupMedium Aggression Group
Divalproex13.729.6
Fluoxetine13.225.1
Placebo19.526.9

[back to top]

The Functional Disability Inventory-child Version

A self-report inventory that assesses patients' ability to perform a variety of daily physical, social, and recreational activities. The scale ranges from 0 (no disability) to 60 (severe disability). (NCT00115804)
Timeframe: "Over the last few days."

Interventionunits on a scale (Mean)
Fluoxetine24.2

[back to top]

The Clinical Global Impression of Severity

Measures severity of illness at the time of the assessment on a scale of 1 (normal, not at all ill) to 7 (among the most extremely ill). (NCT00115804)
Timeframe: at the time of the assessment

Interventionunits on a scale (Mean)
Fluoxetine5

[back to top]

Multidimensional Anxiety Scale for Children

A 39-item self-report inventory that assesses four areas of anxiety symptoms (emotional, cognitive, physical, and behavioral). Score ranges from 0 (no anxiety symptoms) to 117 (severe anxiety symptoms). (NCT00115804)
Timeframe: Over the past week.

Interventionunits on a scale (Mean)
Fluoxetine52

[back to top]

Fibromyalgia Impact Questionnaire Modified for Children

A 19 item self-report instrument that measures overall impact of fibromyalgia including assessments of function, pain, fatigue, sleep quality, stiffness, anxiety and depression. Score range from 0 (no impact) to 100 (severe impact). (NCT00115804)
Timeframe: Over the past week.

Interventionunits on a scale (Mean)
Fluoxetine55.1

[back to top]

Children's Depression Inventory

A 27-item, self-report measure of depressive symptoms with a score range of 0 (no depressive symptoms) to 54 (severe depressive symptoms. (NCT00115804)
Timeframe: Over the past 2 weeks.

Interventionunits on a scale (Mean)
Fluoxetine14.2

[back to top]

Average Pain Severity Score

"The primary outcome measure was average pain severity on the Pediatric Pain Questionnaire's 100-mm visual analog scale.~(0=no pain and 100 = severe pain )" (NCT00115804)
Timeframe: Daily on average in the past week.

Interventionmm (Mean)
Fluoxetine62

[back to top]

The Patient Global Impression of Improvement

Measures the patient's impression of improvement since baseline on a scale of 1 (very much better) to 7 (very much worse). (NCT00115804)
Timeframe: since baseline, at the time of the assessment

Interventionunits on a scale (Mean)
Fluoxetine1.5

[back to top]

The Functional Disability Inventory-parent Version

Consists of the same 15 items as the child version but allows the parent to provide their perception of the child's difficulty in performing daily physical, social, and recreational activities. The score ranges from 0 (no disability) to 60 (severe disability). (NCT00115804)
Timeframe: "Over the last few days."

Interventionunits on a scale (Mean)
Fluoxetine19.2

[back to top]

Depressive Relapse/Recurrence or MDD

"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring MDD) for 2 consecutive weeks according to evaluator blinded to randomized assignment~LIFE-PSR Scale:~= No residual symptoms, no current evidence of the disorder.~= Mild symptoms~= Considerably less psychopathology than full criteria with no more than moderate impairment~= Does not meet full criteria but has major symptoms of impairment~= Meets criteria without extreme impairment in functioning~= Meets criteria with extreme impairment in functioning~Relapse/recurrence rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481)" (NCT00118404)
Timeframe: Measured at month 20

Intervention% patients who relapsed/recurred (Number)
Continuation Phase Fluoxetine35.1
Continuation Phase Cognitive Therapy35.0
Continuation Phase Pill Placebo42.7

[back to top]

Depressive Relapse or MDD

"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring major depressive disorder) for 2 consecutive weeks according to evaluator blinded to randomized assignment~LIFE-PSR Scale:~= No residual symptoms, no current evidence of the disorder.~= Mild symptoms~= Considerably less psychopathology than full criteria with no more than moderate impairment~= Does not meet full criteria but has major symptoms of impairment~= Meets criteria without extreme impairment in functioning~= Meets criteria with extreme impairment in functioning~The relapse rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481)" (NCT00118404)
Timeframe: Measured at month 8

Intervention% patients who relapsed (Number)
Continuation Phase Fluoxetine18
Continuation Phase Cognitive Therapy18.3
Continuation Phase Pill Placebo32.7

[back to top]

Depressive Relapse/Recurrence or MDD

"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring MDD) for 2 consecutive weeks according to evaluator blinded to randomized assignment~LIFE-PSR Scale:~= No residual symptoms, no current evidence of the disorder.~= Mild symptoms~= Considerably less psychopathology than full criteria with no more than moderate impairment~= Does not meet full criteria but has major symptoms of impairment~= Meets criteria without extreme impairment in functioning~= Meets criteria with extreme impairment in functioning~Relapse/recurrence rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481)." (NCT00118404)
Timeframe: Measured at month 32

Intervention% patients who relapsed/recurred (Number)
Continuation Phase Fluoxetine41.1
Continuation Phase Cognitive Therapy45.2
Continuation Phase Pill Placebo56.3

[back to top]

Number of Cannabis Use Disorder Criterion Met at a Particular Time Point.

Criterion used in this study was the number of DSM-IV cannabis use disorder symptoms (criteria) that were met. (NCT00149643)
Timeframe: 12 Weeks

InterventionNumber of DSM-IV criterion (Mean)
Fluoxetine0.59
Placebo0.47

[back to top]

Days Per Week of Cannabis Use.

The number days out of the last seven days that cannabis was used. (NCT00149643)
Timeframe: 12 Weeks

InterventionDays of cannabis use per week (Mean)
Fluoxetine3.88
Placebo3.1

[back to top]

Depression Symptoms at Week 12

Average of Beck Depression Inventory (BDI) Scores measured at Weeks 1-4, 6, 8, 10 and 12. The BDI is a subject reported measure that has a minimim score of 0 and a maximum score of 63. A better outcome would consist of values near the minimum end of the scale (0) and a worse outcome would consist of values near the maximum end of the scare (63). Each DSM-IV criteron asses a different depressive symptom. (NCT00149643)
Timeframe: 12 Weeks

InterventionBDI Total (Mean)
Fluoxetine7.79
Placebo7.31

[back to top]

Change From Baseline to 12 Months in Total Score on Caregiver Strain Questionnaire

This is a caregiver completed measure that assesses the extent to which the caregiver feels care of the participant influences the caregiver's and other family members' emotional states and/or activities. There are a total of 22 items rated from 1 - not at all to 5 - very much (with one item reverse scored). Total score is the sum of all the items (with one item reverse scored). There are three subscales objective strain -12 items, internalized subjective strain 6 items, externalized subjective 4 items. The total score can range from a minimum of 0 - no strain at all, to 110 all items rated as very much. (NCT00183339)
Timeframe: 12 months

Interventionunits on a scale (Mean)
Placebo0.8
Fluoxetine-1.86

[back to top]

Rate of Attrition

The percentage of participants who discontinued treatment prior to completion of the 12 month study (NCT00183339)
Timeframe: Measured at Month 12

Interventionpercent of group that discontinued early (Number)
Placebo60
Fluoxetine50

[back to top]

Change From Baseline to Month 12 in Aberrant Behavior Checklist Irritability Subscale Score (ABC-I)

The Aberrant Behavior Checklist (ABC) is a caregiver completed rating scale that assesses problem behaviors frequently seen in individuals with developmental disabilities. There are a total of 58 items on 5 subscales that are rated from 0 - not at all a problem to 3 - problem is severe in degree. The ABC-I consists of 15 items that reflect mood swings, self-injury and aggression. The subscale score is the sum of the score on each of the 15 items. The minimum score on the ABC-I is 0 and the maximum score is 45. Higher scores reflect more severe behavioral problems. A score > or = to 18 is generally considered clinically significant. (NCT00183339)
Timeframe: 12 months

Interventionunits on a scale (Mean)
Placebo-0.70
Fluoxetine-8.50

[back to top]

Rate of Recruitment

In order for a larger trial with similar design to be feasible a number of factors needed to be examined. The first was whether families would enroll very young children with ASD into a year long blinded medication study. To determine this we examined the average number of months to randomize 1 participant per site. We calculated this (as total # months required for recruitment* 2sites ) /[ # participants randomized ] and compared it to the typical # of months required to recruit an older child with ASD for a double-blind 12 week placebo controlled medication study, which is typically about 1.2 months at each of the sites involved in the study. (NCT00183339)
Timeframe: 19 months

Interventionmonths/participant at 1 site (Number)
Placebo2.1
Fluoxetine2.1

[back to top]

Change in Total Score on the BDD-Y-BOCS Scale

To assess the change in total score on the Body Dysmorphic Disorder-Yale-Brown Obsessive Compulsive Scale (BDD-Y-BOCS) from baseline (visit 0) to endpoint (week 12). This is a 12-item scale that assesses obsessions and compulsions related to the patient's BDD. Each item's score ranges from 0 to 4, with a total possible score of 48 on the full assessment. Scores of 0 indicate no impairment, while scores of 4 indicate maximum impairment. Thus higher scores are considered to be a worse outcome. (NCT00245635)
Timeframe: Baseline compared to the study endpoint (week 12) [two time points]

Interventionunits on a scale (Mean)
Fluoxetine-12.27
Placebo-9.53

[back to top]

Daily Living and Role Functioning (DLRF) Basis-32 Subscale Ratings

"The BASIS 32 psychometric includes several subscales, including daily living and role functioning (DLRF). These subscales are rated from 0-4, with higher scores indicating a greater deal of difficulty in this dimension and lower scores denoting better outcomes. Measured weekly for 9 weeks. Reported as mean of 9 weeks." (NCT00247624)
Timeframe: 9 weeks

Interventionunits on a scale (Mean)
Fluoxetine (FLX) Plus Eszopiclone (ESZ)0.81
FLX Plus Placebo1.2

[back to top]

Relation to Self/Others (RSO) Basis-32 Subscale Ratings

"The BASIS 32 psychometric includes several subscales, including relation to self and others (RSO). These subscales are rated from 0-4, with higher scores indicating a greater deal of difficulty in this dimension. Measured weekly for 9 weeks. Reported as mean of 9 weeks." (NCT00247624)
Timeframe: 9 weeks

Interventionunits on a scale (Mean)
Fluoxetine (FLX) Plus Eszopiclone (ESZ)0.74
FLX Plus Placebo1.04

[back to top]

Quality of Life Ratings, as Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)

The Q-LES-Q is scored from 0-100, with higher scores better than lower. Measured weekly for 9 weeks. Reported as mean of 9 weeks. (NCT00247624)
Timeframe: 9 weeks

Interventionunits on a scale (Mean)
Fluoxetine (FLX) Plus Eszopiclone (ESZ)50.2
FLX Plus Placebo46.9

[back to top]

Insomnia Severity Index (ISI)

The Insomnia Severity Index has seven questions. The seven answers are added up to get a total score, range 0-28. Lower scores represent better outcomes. Total score categories: 0-7 = No clinically significant insomnia, 8-14 = Subthreshold insomnia, 15-21 = Clinical insomnia (moderate severity), 22-28 = Clinical insomnia (severe). (NCT00247624)
Timeframe: 9 weeks

Interventionunits on a scale (Mean)
Fluoxetine (FLX) Plus Eszopiclone (ESZ)21.1
FLX Plus Placebo20.2

[back to top]

Change Per Month in Psychological Symptoms During Treatment, Assessed With the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).

The Q-LES-Q is a 93 item self-report measure of enjoyment and satisfaction experienced by individuals in various areas of daily functioning. Each of the 93 items is scored on a five-point scale, and the total score is converted to a percentage of the maximum score possible. The range is therefore from 0 to 100, with a higher score indicating greater enjoyment or satisfaction. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Interventionpercentage of maximum possible score (Mean)
Fluoxetine0.23
Placebo0.31

[back to top]

Change Per Month in Psychological Symptoms During Treatment, Assessed With the Yale Brown Cornell Obsessive Compulsive Scale for Eating Disorders (YBC-EDS)

The YBC-EDS is an eight item, clinician-rated instrument assessing eating related preoccupations and/or rituals. Possible scores range from 0 to 32, with higher scores indicating greater preoccupations. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Interventionunits on a scale (Mean)
Fluoxetine-0.18
Placebo0.028

[back to top]

Change Per Month in Psychological Symptoms During Treatment, Assessed With the Eating Disorders Inventory (EDI), Perfectionism Subscale.

The EDI is a 64 item self-report measure of psychological and behavioral characteristics of eating disorders. The Perfectionism subscale is comprised of six items Indicating excessive personal expectations for superior achievement. Possible scores range from 0 to 18, with higher scores indicating greater expectations. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Interventionunits on a scale (Mean)
Fluoxetine-0.037
Placebo0.05

[back to top]

Change in Weight Per Month During Treatment

(NCT00288574)
Timeframe: 12 months

Interventionkg per month (Mean)
Fluoxetine-1.94
Placebo-2.14

[back to top]

Change Per Month in Psychological Symptoms During Treatment, Assessed With Beck Anxiety Inventory (BAI)

The Beck Anxiety Inventory is a 21 question self-report measure of anxiety symptoms during the past week. Possible scores range from 0 - 63, with higher scores indicating more severe symptoms. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Interventionunits on a scale (Mean)
Fluoxetine-0.70
Placebo-0.22

[back to top]

Change Per Month in Psychological Symptoms During Treatment, Assessed With Beck Depression Inventory (BDI)

The Beck Depression Inventory-II is a 21 question self-report measure of depressive symptoms. Possible scores range from 0 - 63, with higher scores indicating more severe symptoms.Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Interventionunits on a scale (Mean)
Fluoxetine0.12
Placebo0.20

[back to top]

Change Per Month in Psychological Symptoms During Treatment, Assessed With the Eating Disorders Inventory (EDI), Drive for Thinness Subscale.

The EDI is a 64 item self-report measure of psychological and behavioral characteristics of eating disorders. The Drive for Thinness subscale is comprised of seven items indicating excessive concern with dieting, preoccupation with weight and entrenchment in an extreme pursuit of thinness. Possible scores range from 0 to 21, with higher scores indicating greater Drive for Thinness. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Interventionunits on a scale (Mean)
Fluoxetine-0.24
Placebo-0.81

[back to top]

Change Per Month in Psychological Symptoms During Treatment, Assessed With the Rosenberg Self-Esteem Scale (RSES).

The RSES is a 10 item self-report measure of self-esteem. Possible scores range from 0 - 30, with lower scores indicating more severe symptoms. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Interventionunits on a scale (Mean)
Fluoxetine0.12
Placebo0.07

[back to top]

Change Per Month in Psychological Symptoms During Treatment, Assessed With the Eating Disorders Inventory (EDI), Bulimia Subscale.

The EDI is a 64 item self-report measure of psychological and behavioral characteristics of eating disorders. The Bulimia subscale is comprised of seven items indicating the tendency towards episodes of uncontrollable overeating (binge eating). Possible scores range from 0 to 21, with higher scores indicating greater tendency. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Interventionunits on a scale (Mean)
Fluoxetine-0.11
Placebo0.035

[back to top]

Change Per Month in Psychological Symptoms During Treatment, Assessed With the Eating Disorders Inventory (EDI), Body Dissatisfaction Subscale.

The EDI is a 64 item self-report measure of psychological and behavioral characteristics of eating disorders. The Body Dissatisfaction subscale is comprised of nine items indicating the belief that parts of the body are too large. Possible scores range from 0 to 27, with higher scores indicating greater dissatisfaction. Random effects regression models were used to compare fluoxetine vs placebo groups over time, using data from all patients. (NCT00288574)
Timeframe: 12 months

Interventionunits on a scale (Mean)
Fluoxetine-0.24
Placebo-0.26

[back to top]

Proportion of Patients Remaining in Study at 1 Year

The primary outcome measure was the proportion of patients with AN successfully completing 1 year of treatment and maintaining > 85% Ideal Body Weight. (NCT00288574)
Timeframe: 12 months

Interventionproportion of participants (Number)
Fluoxetine0.265
Placebo0.315

[back to top]

Hamilton Depression Scale (HAM-D)

"The HAM-D is a commonly used measure of the severity of depression. While several versions exist consisting of different numbers of items, virtually all include the original 17. Each item is scored from on a 3 or 5 point scale (so, from 0-2 or 0-4), with 0 indicating the item is not present and the highest item score indicating it is present nearly all the time to the severest extent. Item scores are added to obtain a total HAM-D score. Minimum possible score is 0 (indicating none of the 17 items is present), maximal possible score is 52. By convention, scores of <=7 are accepted as indicating remission and scores that have decreased >= 50% from pre-treatment indicate positive response. Higher scores indicate worse depression, while lower scores indicate milder depression or lack of depressive symptoms." (NCT00296725)
Timeframe: 6 weeks

Interventionscore on a scale (Mean)
Fluoxetine10
Imipramine9

[back to top]

Number of Participants With Positive Response as Assessed by the Clinical Global Impression -Global Improvement Scale (CGI-I)

"The CGI consists of two ratings: 1) Global Severity (CGI-S) and 2) Global Improvement (CGI-I), both having seven possible ratings, each from 1-7. Ratings on the CGI-S are: 1=No psychopathology 2=Minimal psychopathology 3=Mild psychopathology 4=Moderate psychopathology 5=Moderately severe psychopathology 6=Severe psychopathology 7 Extreme psychopathology. CGI-I ratings are rated for how the past week's psychopathology compares to the week immediately prior to start of treatment and includes: 1=Very much improved 2=much improved 3=minimally improved 4=Unchanged 5=minimally worse 6=much worse 7=very much worse. Scores on both thus range from 1-7 with lower scores indicating less psychopathology/greater improvement, respectively, and higher scores indicating more psychopathology/less improvement, respectively. We define response as a CGI-I of 1 or 2; nonresponse is all other ratings (i.e., CGI-I = 3 or higher." (NCT00296725)
Timeframe: 6 weeks.

InterventionParticipants (Count of Participants)
Fluoxetine7
Imipramine4

[back to top]

25% Improvement on Both Whiteley Index and H-YBOCS-M

Whitley index is a self-report measure of hypochondriasis H-YBOCS-M is an independent evaluator structured assessment of hypochondriasis (NCT00339079)
Timeframe: Measured at Week 24

InterventionParticipants (Count of Participants)
Cognitive Behavioral Therapy (CBT)21
Placebo13
Fluoxetine20
Combined CBT and Fluoxetine25

[back to top]

Suicidal Ideation at 6 Months

"Participant Score on the Scale for Suicidal Ideation will be the outcome variable.~The SSI range is from 0-38 and higher score is worse and may predict suicide risk" (NCT00449007)
Timeframe: 6 month

Interventionunits on a scale (Mean)
Fluoxetine 6 Months of Antidepressant0.5
Bupropion 6 Months of Antidepressant8.5

[back to top]

Occurrence of Suicide Events Either a Suicide Death, a Suicide Attempt, or Suicidal Ideation Severe Enough to Warrant a Medical Intervention

"patients have either a suicide death, a suicide attempt, or suicidal ideation severe enough to warrant a medical intervention. this is assessed using the Columbia Suicide History Form and a consensus conference rules on whether the event meets criteria or not. Medical interventions can include hospitalization, a change in medication (adding adjunctive meds) or an increase in frequency of visits or other methods to monitor the patient.~The range is 0 and up and denotes the number of suicide events (not the number of participants and not the number of suicide attempts). Higher score is worse and predicts future suicidal behavior" (NCT00449007)
Timeframe: 6 months

Interventionsuicide events (Number)
Fluoxetine for 6 Months2
Bupropion for 6 Months3

[back to top]

Psychotic Symptoms

Psychotic symptoms were assessed and scored using the Structured Interview for the Prodromal Syndrome (SIPS) and the Scale of Prodromal Symptoms (SOPS). The SOPS provides a measure of four domains of symptoms, including positive, negative, disorganized and general symptoms. The Positive Symptom sub-scale score reported is the sum of all five symptom items in the Positive Symptom sub-scale. The Positive Symptom sub-scale assesses psychotic symptoms, each item on a scale of 0-6. The sum scale score is 0-30, with 30 indicating severe psychotic symptoms, while 0 indicates no psychotic symptoms. (NCT00531518)
Timeframe: two years

Interventionunits on a scale (Mean)
Control9.2
Family-aided Assertive Community Treatment6.7

[back to top]

Suicide Attempts

Suicide attempt count total over the course of the 12 month treatment period (sum of 6 bimonthly assessments during the treatment phase) (NCT00533117)
Timeframe: Assessed bimonthly

Interventionsuicide attempt (Number)
Dialectical Behavior Therapy With Fluoxetine2
Dialectical Behavior Therapy With Placebo1
Supportive Therapy With Fluoxetine4
Supportive Therapy With Placebo1

[back to top]

Number of Participants Achieving Smoking Abstinence

7-day point prevalence abstinence (NCT00578669)
Timeframe: One year

InterventionParticipants (Count of Participants)
Sequential Fluoxetine24
Sequential Placebo18

[back to top]

Self-reported Depressive Symptoms

Self-reported depressive symptoms based on the Center for Epidemiologic Studies-Depression (CES-D) scale. CES-D consists of 20 items, with total scores on the scale ranging from 0 - 60. Higher scores are indicative of greater levels of depressive symptoms. (NCT00578669)
Timeframe: One year

Interventionscore on a scale (Mean)
Sequential Fluoxetine9.9
Sequential Placebo9.64

[back to top]

Young Mania Rating Scale (YMRS)

This scale measures mania symptoms in children and adolescents using 11 items rated from 0 (least severe) to 4 (most severe), although 4 items are rated from 0-8. The minimum (least severe) possible score is 0, and the maximum (most severe) possible score is 60. (NCT00592852)
Timeframe: weekly

InterventionUnits on a scale (Mean)
Fluoxetine13

[back to top]

Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)

This sale measures impairment on 5 items relating to Obsessions from 0 (none) to 4 (extreme) and 5 item relating to Compulsions from 0 (none) to 4 (extreme). These scores are totaled for a range of 0 (least impaired) to 40 (most impaired). (NCT00592852)
Timeframe: weekly

InterventionUnits on a scale (Mean)
Fluoxetine14.18

[back to top]

Serotonin Receptor 1A Binding Potential In Regions of Interest (ROI) Accounting for Binding Potential in a Region Without Serotonin 1A Receptors

We used PET and [11C]WAY to assess 5-HT1A binding potential (BP) = [11C]WAY 100635 BP = Distribution Volume (DV)ROI-DVcerebellum in striatal regions; subcortical regions including insula, medial temporal lobe, amygdala, hippocampus, midbrain, parahippocampal gyrus; and the neocortical regions (i.e., anterior cingulate cortex). Analysis of the PET data was performed using the Logan graphical method (Logan et al. 2001) with the cerebellum as a reference region for non-displaceable uptake. 23 REC AN were studied. The Binding Potential (BP) was calculated as followed: BPP = fP Bavail/KD = VT-VND;(Abbrev.: BPP = In vivo binding potential; fP = free fraction in plasma; Bavail = Density of receptors available to bind radioligand in vivo; KD = Dissociation Constant; V = Volumes of Distribution expressed relative to total plasma ligand concentration; T = Total radioligand in tissue; ND = Nondisplaceable tissue uptake; see Innis et al. 2007); Units: mL cm -3 (NCT00603018)
Timeframe: Baseline and 8 weeks

,
InterventionmL/cm^3 (Mean)
insulamedial temporal lobeamygdalahippocampusmidbrainanterior cingulate cortexparahippocampal gyrus
1/Recovered Anorexia After 8 Weeks of Treatment5.896.916.299.92.584.126.05
1/Recovered Anorexia Before 8 Weeks of Treatment5.976.665.919.080.373.836.08

[back to top]

Change in Free Testosterone

Free testosterone was calculated from total testosterone ng/ml divided by sex hormone binding globulin (SHBG) nmol/l multiplied by 100. Hormone levels at early follicular, ovulation, and luteal phase of 3 menstrual cycles which included baseline month, month 1 of daily antidepressant treatment and month 2 of daily antidepressant treatment. Differential effects of the two antidepressant treatments and menstrual cycle on hormone levels were examined. (NCT00611975)
Timeframe: Measured in baseline menstrual cycle and during antidepressant treatment for two menstrual cycles

,
Interventioncalculated ratio (Mean)
Baseline month follicularBaseline month ovulationBaseline month lutealTreatment month 1 follicularTreatment month 1 ovulationTreatment month 1 lutealTreatment month 2 follicularTreatment month 2 ovulationTreatment month 2 luteal
Bupropion.44.69.47.51.65.48.40.81.44
Fluoxetine.41.52.47.39.41.49.36.50.50

[back to top]

Change in Progesterone

Hormone levels at early follicular, ovulation, and luteal phase of the cycle were averaged for the baseline pre-treatment month and compared to average values during the 1st and 2nd months of antidepressant treatment. (NCT00611975)
Timeframe: Measured in baseline menstrual cycle and during antidepressant treatment for two menstrual cycles

,
Interventionng/ml (Mean)
Baseline month follicularBaseline month ovulationBaseline month lutealTreatment month 1 follicularTreatment month 1 ovulationTreatment month 1 lutealTreatment month 2 follicularTreatment month 2 ovulationTreatment month 2 luteal
Bupropion0.52.89.60.73.97.40.63.28.1
Fluoxetine0.662.49.50.72.48.40.62.98.6

[back to top]

Change in Prolactin

Hormone levels at early follicular, ovulation, and luteal phase of 3 menstrual cycles which included baseline month, month 1 of daily antidepressant treatment and month 2 of daily antidepressant treatment. Differential effects of the two antidepressant treatments and menstrual cycle on hormone levels were examined. (NCT00611975)
Timeframe: Measured in baseline menstrual cycle and during antidepressant treatment for two menstrual cycles

,
Interventionng/ml (Mean)
Baseline month follicularBaseline month ovulationBaseline month lutealTreatment month 1 follicularTreatment month 1 ovulationTreatment month 1 lutealTreatment month 2 follicularTreatment month 2 ovulationTreatment month 2 luteal
Bupropion11.014.115.411.716.016.610.818.312.1
Fluoxetine11.215.916.412.112.914.012.817.113.7

[back to top]

Change in Arizona Sexual Experiences Scale (ASEX)

"A five-item scale with each item scored from 1 to 6. Score range is 5 to 30. Higher scores indicate more sexual dysfunction.~Scores at early follicular, ovulation, and luteal phase of 3 menstrual cycles which included baseline month, month 1 of daily antidepressant treatment and month 2 of daily antidepressant treatment. Differential effects of the two antidepressant treatments and menstrual cycle on ASEX scores were examined." (NCT00611975)
Timeframe: Measured in baseline menstrual cycle and during antidepressant treatment for two menstrual cycles

,
Interventionscore on a scale (Mean)
Baseline month follicularBaseline month ovulationBaseline month lutealTreatment month 1 follicularTreatment month 1 ovulationTreatment month 1 lutealTreatment month 2 follicularTreatment month 2 ovulationTreatment month 2 luteal
Bupropion12.912.112.413.612.613.814.315.214.4
Fluoxetine13.111.314.015.115.014.814.413.615.1

[back to top]

Change in Androstenedione

Hormone levels at early follicular, ovulation, and luteal phase of 3 menstrual cycles which included baseline month, month 1 of daily antidepressant treatment and month 2 of daily antidepressant treatment. Differential effects of the two antidepressant treatments and menstrual cycle on hormone levels were examined. (NCT00611975)
Timeframe: Measured in baseline menstrual cycle and during antidepressant treatment for two menstrual cycles

,
Interventionng/ml (Mean)
Baseline month follicularBaseline month ovulationBaseline month lutealTreatment month 1 follicularTreatment month 1 ovulationTreatment month 1 lutealTreatment month 2 follicularTreatment month 2 ovulationTreatment month 2 luteal
Bupropion0.891.281.140.840.961.13.851.001.12
Fluoxetine0.841.131.310.891.131.040.791.071.13

[back to top]

Change in 17-OH Pregnenolone

Hormone levels at early follicular, ovulation, and luteal phase of 3 menstrual cycles which included baseline, month 1 of daily antidepressant treatment and month 2 of daily antidepressant treatment. Effects of the two antidepressant treatments and menstrual cycle on hormone level were examined. (NCT00611975)
Timeframe: Measured in baseline menstrual cycle and during antidepressant treatment for two menstrual cycles

,
Interventionng/dl (Mean)
Baseline month follicularBaseline month ovulationBaseline month lutealTreatment month 1 follicularTreatment month 1 ovulationTreatment month 1 lutealTreatment month 2 follicularTreatment month 2 ovulationTreatment month 2 luteal
Bupropion158170189184142163138176161
Fluoxetine120171141151122109101174167

[back to top]

Change in Estradiol

Hormone levels at early follicular, ovulation, and luteal phase of 3 menstrual cycles which included baseline, month 1 of daily antidepressant treatment and month 2 of daily antidepressant treatment. Effects of the two antidepressant treatments and menstrual cycle on hormone levels were examined. (NCT00611975)
Timeframe: Measured in baseline menstrual cycle and during antidepressant treatment for two menstrual cycles

,
Interventionpg/ml (Mean)
Baseline month follicularBaseline month ovulationBaseline Month LutealTreatment month 1 follicularTreatment month 1 ovulationTreatment month 1 lutealTreatment month 2 follicularTreatment month 2 ovulationTreatment month 2 luteal
Bupropion381341094212110835113101
Fluoxetine42131107419112640122112

[back to top]

Change in Dehydroepiandrosterone Sulfate (DHEA-S)

Hormone levels at early follicular, ovulation, and luteal phase of 3 menstrual cycles which included baseline month, month 1 of daily antidepressant treatment and month 2 of daily antidepressant treatment. Differential effects of the two antidepressant treatments and menstrual cycle on hormone levels were examined. (NCT00611975)
Timeframe: Measured in baseline menstrual cycle and during antidepressant treatment for two menstrual cycles

,
Interventionug/ml (Mean)
Baseline month follicularBaseline month ovulationBaseline month lutealTreatment month 1 follicularTreatment month 1 ovulationTreatment month 1 lutealTreatment month 2 follicularTreatment month 2 ovulationTreatment month 2 luteal
Bupropion1.82.01.91.91.91.91.81.81.9
Fluoxetine1.61.81.61.61.71.71.61.91.9

[back to top]

Relapse

"Up through week 30, relapse was defined as:~1) CDRS-R score >=40 with a history of 2 weeks of clinical deterioration or 2) CDRS-R<40, but with a 2 week history of significant clinical deterioration.~From week 31-78, relapse was assessed using the K-Life. Relapse was defined as at least 2 weeks of a K-Life rating of 5 or 6; participants may also be identified as relapsing with a K-Life rating of 4 if the rating was for several weeks and not strictly related to stressful life events." (NCT00612313)
Timeframe: Weeks 52 and 78

,
InterventionProbability of Relapse (%) (Number)
Week 52Week 78
Continued Medication Alone4962
Continued Medication Plus CBT2736

[back to top]

Remission

Remission is defined as CDRS-R <=28 (up through week 30) or at least 8 consecutive weeks of a K-Life rating of 1 or 2. Timing of remission is based on clinical assessment using the CDRS-R and K-Life to identify the week at which point the patient remitted. (NCT00612313)
Timeframe: Weeks 52 and 78

,
InterventionProbability of remission (%) (Number)
Week 52Week 78
Continued Medication Alone8992
Continued Medication Plus CBT9496

[back to top]

Remission

Remission is defined as CDRS-R <=28. (NCT00612313)
Timeframe: Measured at Weeks 12, 18, 24, and 30

,
Interventionprobability of remitting (%) (Number)
Week 12Week 18Week 24Week 30
Continued Medication Alone59718084
Continued Medication Plus CBT68798690

[back to top]

K-Life (Time Well)

"K-Life interview was conducted at Weeks 6, 12, 18, 24, and 30, with ratings for depressive illness for each week throughout the study.~Ratings definitions: 1=Normal, no residual symptoms; 2=Presence of 1 or more symptosm in no more than mild degree; 3=Considerably less psychopathology than full criteria, but still obvious evidence of disorder with no more than moderate impairment; 4=Does not meet full criteria, but has major symptoms or impairment from the disorder; 5=Meets full criteria, but no extreme impairment; 6=Meets full criteria, and either has prominent psychotic symptoms or extreme impairment.~Time well is defined as each week the depression rating was a 1 or 2. Percent time well was defined as each week the depression rating was a 1 or 2 divided by the total number of weeks in the study.~Statistic: anova" (NCT00612313)
Timeframe: 30 weeks

InterventionWeeks spent well (Mean)
Continued Medication Alone12.8
Continued Medication Plus CBT16.0

[back to top]

Relapse

"Relapse was defined as:~1) CDRS-R score >=40 with a history of 2 weeks of clinical deterioration or 2) CDRS-R<40, but with a 2 week history of significant clinical deterioration." (NCT00612313)
Timeframe: Measured at Weeks 12, 18, 24, and 30

,
Interventionprobability of relapse (%) (Number)
Week 12Week 18Week 24Week 30
Continued Medication Alone31020.526.5
Continued Medication Plus CBT13.579

[back to top]

Time to Remission

Remission is defined as CDRS-R <=28. Timing of remission is based on clinical assessment using the CDRS-R and K-Life to identify the week at which point the patient remitted. (NCT00612313)
Timeframe: 30 weeks

Interventionweeks (Mean)
Continued Medication Alone13.67
Continued Medication Plus CBT11.33

[back to top]

Comparison of Cortical GABA Levels in 4 Groups of Subjects Using Estrogen Alone, Fluoxetine Alone, Estrogen and Fluoxetine Combined in Pre and Post 4.0T Magnetic Resonance Spectroscopy Sessions.

"This study was conducted at Yale University almost two decades ago. Our group at the University of Pennsylvania only has very basic information about this study. This includes the number of participants, which was 18, and the fact that no adverse events occurred. Staff members at the University of Pennsylvania do not have access to any additional study data. The contact person who initially entered this study protocol information is no longer at the University of Pennsylvania and we are unable to contact for additional information.~We only know that 18 participants completed, but as far as we know data was never analyzed for these 18 participants." (NCT00626340)
Timeframe: Healthy controls will undergo scans pre and post 3 weeks of estrogen treatment. Women with depression will undergo scans pre and post 6 weeks of treatment with estrogen alone, estrogen and fluoxetine, or fluoxetine alone

Intervention ()
All Participants0

[back to top]

Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Absenteeism at 12-Week Endpoint

Self-administered assessment used to determine a subject's work performance in terms of employment status, absenteeism if employed, productivity while at work, usual occupation, and annual income. Tool assesses the potential impact of change in depressive symptoms on work productivity and its associated employer costs. Defined on a 0-100 scale for the percentage of work days the respondent missed in the past 30 days. Absolute absenteeism: actual hours worked minus expected hours equals number of missed work days. Mean change baseline to endpoint is reported. (NCT00666757)
Timeframe: Baseline, 12 Weeks

Interventionhours lost per week (Least Squares Mean)
Duloxetine-9.56
Selective Serotonin Reuptake Inhibitor (SSRI)0.41

[back to top]

Change From Baseline in Pulse Rate at Week-12 Endpoint

Mean change from baseline to endpoint in pulse rate (NCT00666757)
Timeframe: Baseline, 12 Weeks

Interventionbeats per minute (bpm) (Least Squares Mean)
Duloxetine2.74
Selective Serotonin Reuptake Inhibitor (SSRI)0.47

[back to top]

Change From Baseline in HAMD-17 Total Score at 12-Week Endpoint (Mood Measure)

The HAMD-17 is a rater-administered assessment of depression severity and improvement, with total score ranges from 0 (not at all depressed) to 52 (most severely depressed). (NCT00666757)
Timeframe: Baseline, 12 Weeks

Interventionunits on a scale (Least Squares Mean)
Duloxetine-17.03
Selective Serotonin Reuptake Inhibitor (SSRI)-15.3

[back to top]

Change From Baseline in HAMD-17 Sleep Subscale Score at 12-Week Endpoint (Mood Measure)

The HAMD-17 Sleep Subscale consists of Items 4, 5, 6 and evaluates initial, middle, and late insomnia. Total subscale scores range from 0 (no difficulty) to 6 (difficulty). (NCT00666757)
Timeframe: Baseline, 12 Weeks

Interventionunits on a scale (Least Squares Mean)
Duloxetine-2.77
Selective Serotonin Reuptake Inhibitor (SSRI)-2.58

[back to top]

Change From Baseline in HAMD-17 Retardation Subscale Score at 12-Week Endpoint (Mood Measure)

The HAMD-17 Retardation subscale consists of Items 1, 7, 8, 14 and evaluates dysfunction in mood, work, and sexual activity, as well as overall motor retardation. Total subscale scores range from 0 (normal) to 14 (severe). (NCT00666757)
Timeframe: Baseline, 12 Weeks

Interventionunits on a scale (Least Squares Mean)
Duloxetine-5.99
Selective Serotonin Reuptake Inhibitor (SSRI)-5.49

[back to top]

Change From Baseline in SDS Work/School Item Score at 12-Week Endpoint (Functional Outcome Measure)

The SDS is completed by the participant and Item 1 is used to assess the effect of the participant's symptoms on their work/school schedule. Scores range from 0 to 10 with higher values indicating greater disruption in the participant's work/school life. (NCT00666757)
Timeframe: Baseline, 12 Weeks

Interventionunits on a scale (Least Squares Mean)
Duloxetine-4.52
Selective Serotonin Reuptake Inhibitor (SSRI)-3.85

[back to top]

Change From Baseline in HAMD-17 Maier Subscale Score at 12-Week Endpoint (Mood Measure)

"HAMD-17 Maier Subscale consists of Items 1, 2, 7, 8, 9, 10 and represents the core symptoms of depression. Total subscale scores range from 0 (normal) to 24 (severe)." (NCT00666757)
Timeframe: Baseline, 12 weeks

Interventionunits on a scale (Least Squares Mean)
Duloxetine-9.01
Selective Serotonin Reuptake Inhibitor (SSRI)-8.16

[back to top]

Change From Baseline in HAMD-17 Bech Subscale Score at 12-Week Endpoint (Mood Measure)

HAMD-17 Bech subscale consists of items 1, 2, 7, 8, 10, and 13 used to evaluate core symptoms of Major Depressive Disorder (MDD). Total subscale scores range from 0 (normal) to 22 (severe). (NCT00666757)
Timeframe: Baseline, 12 Weeks

Interventionunits on a scale (Least Squares Mean)
Duloxetine-9.21
Selective Serotonin Reuptake Inhibitor (SSRI)-8.40

[back to top]

Change From Baseline in Weight at Week-12 Endpoint

Mean change from baseline to endpoint in weight (NCT00666757)
Timeframe: Baseline, 12 Weeks

Interventionkilograms (kg) (Least Squares Mean)
Duloxetine-0.32
Selective Serotonin Reuptake Inhibitor (SSRI)-0.17

[back to top]

Change From Baseline in Diastolic Blood Pressure at Week-12 Endpoint

Mean change from baseline to endpoint in diastolic blood pressure (NCT00666757)
Timeframe: Baseline, 12 Weeks

InterventionmmHg (Least Squares Mean)
Duloxetine-0.14
Selective Serotonin Reuptake Inhibitor (SSRI)0.45

[back to top]

Change From Baseline in Brief Pain Inventory (BPI) Average 24-hour Pain Score, in Particpants With a Baseline BPI Average 24-hour Pain Score of 3 or Greater, at 12-Week Endpoint (Pain Measure)

The BPI is a self-reported scale measuring pain severity and pain-specific interference on function on a scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). The BPI average 24-hour pain measure was used to derive the overall mean change from baseline to endpoint, in those participants who had a BPI average 24-hour pain score of 3 or greater at baseline. (NCT00666757)
Timeframe: Baseline, 12 Weeks

Interventionunits on a scale (Least Squares Mean)
Duloxetine-2.95
Selective Serotonin Reuptake Inhibitor (SSRI)-2.39

[back to top]

Probability of Response [QIDS-SR Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]

Visitwise percentages of participants meeting response criteria (50% reduction from baseline QIDS-SR total score at 12-week endpoint) were estimated using a categorical, pseudolikelihood-based repeated measures approach, & included fixed, categorical effects of treatment group, visit, treatment group-by-visit interaction, & continuous, fixed covariate of baseline QIDS-SR. The primary analysis will be the contrast of response rates at week 12 endpoint between treatment groups, and represents estimated response rates for each treatment group had all participants completed 12 weeks of therapy. (NCT00666757)
Timeframe: Baseline, 12-Weeks

InterventionProbability of response (Least Squares Mean)
Duloxetine0.71
Selective Serotonin Reuptake Inhibitor (SSRI)0.64

[back to top]

Probability of Response [HAMD-17 Total Score (Mood Measure) Greater Than Or Equal To 50 Percent Reduction From Baseline To 12 Week Endpoint]

Visitwise percentages of participants meeting response criteria 50% reduction from baseline in HAMD-17 total score at 12-Week endpoint) were estimated using a categorical, pseudolike-lihood-based repeated measures approach, & included fixed, categorical effects of treatment group, visit, treatment group-by-visit interaction, & continuous, fixed covariate of baseline HAMD-17 TS. Primary analysis will be the contrast of response rates at week 12 endpoint between treatment groups, & represents estimated response rates for each treatment group had all participants completed 12 weeks of therapy. (NCT00666757)
Timeframe: Baseline, 12-Weeks

InterventionProbability of response (Least Squares Mean)
Duloxetine0.73
Selective Serotonin Reuptake Inhibitor (SSRI)0.61

[back to top]

Probability of Remission [17-item Hamilton Depression Rating Scale (HAMD-17) (Mood Measure) Less Than or Equal to 7 at 12-Week Endpoint]

Visitwise percentages of participants meeting remission criteria HAMD-17 total score [TS] NCT00666757)
Timeframe: 12 weeks

InterventionProbability of remission (Least Squares Mean)
Duloxetine0.53
Selective Serotonin Reuptake Inhibitor (SSRI)0.44

[back to top]

Probability of Remission [16-item Quick Inventory of Depressive Symptomatology (QIDS-SR) Score Less Than or Equal to 5 at 12-Week Endpoint]

Visitwise probability of participants per treatment meeting remission criteria (QIDS-SR total score [TS]NCT00666757)
Timeframe: 12 weeks

InterventionProbability of remission (Least Squares Mean)
Duloxetine0.36
Selective Serotonin Reuptake Inhibitor (SSRI)0.32

[back to top]

Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Presenteeism Score, at Week-12 Endpoint

"Self-administered assessment used to determine a participant's work performance (employment status, absenteeism if employed, productivity while at work, usual occupation, & annual income). Tool assesses the potential impact of change in depressive symptoms on work productivity & its associated employer costs using a 0-100 scale in which 0 meant doing no work at all on days spent at work and 100 meant performing at the level of a top worker. Absolute presenteeism: difference between score for self and score for average worker in same job. Mean change baseline to endpoint is reported." (NCT00666757)
Timeframe: Baseline, 12 Weeks

Interventionunits on a scale (Least Squares Mean)
Duloxetine24.56
Selective Serotonin Reuptake Inhibitor (SSRI)20.73

[back to top]

Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Dollars of Income Lost Due to Work Presenteeism (WP)Score, at Week-12 Endpoint

WP score was calculated by taking midpoint of annual before-tax income reported on HPQ. A multiplier of 1.25 produced estimated direct & indirect (i.e. benefits) income. Annual hours expected to work were calculated from expected daily work hours, multiplied by 236 days. Hourly, indirect income was total direct + indirect income, divided by # of expected annual work hours. Indirect hours lost annually for WP=hours expected to be worked annually times WP percent, times hourly rate=dollars earned, and then subtracted from total direct + indirect income=dollars lost annually due to WP. (NCT00666757)
Timeframe: Baseline, 12 Weeks

Interventiondollars (Least Squares Mean)
Duloxetine7250.93
Selective Serotonin Reuptake Inhibitor (SSRI)5074.09

[back to top]

Change From Baseline in World Health Organization Health and Work Performance Questionnaire, Clinical Trials 7-Day Version (HPQ), Dollars of Income Lost Due to Work Absenteeism Score at Week-12 Endpoint

Self-administered assessment used to determine a participant's work performance in terms of employment status, absenteeism if employed, productivity while at work, usual occupation, and annual income. Tool assesses the potential impact of change in depressive symptoms on work productivity and its associated employer costs. Scale ranges from 0 to 100% of work days in past 30 days. Absenteeism and presenteeism were combined into a measure of total lost work performance by adding absenteeism to the value ([100-absenteeism] × [100-presenteeism]). Mean change baseline to endpoint. (NCT00666757)
Timeframe: Baseline, 12 weeks

Interventiondollars (Least Squares Mean)
Duloxetine-3978.98
Selective Serotonin Reuptake Inhibitor (SSRI)-1932.46

[back to top]

Change From Baseline in BPI Average 24 Hour Pain Score at 12-Week Endpoint (Pain Measure)

The BPI is a self-reported scale measuring pain severity and pain-specific interference on function, with scores ranging from 0 (does not interfere) to 10 (completely interferes). The BPI average 24-hour pain measure was used to derive the overall mean change from baseline to endpoint. (NCT00666757)
Timeframe: Baseline, 12 weeks

Interventionunits on a scale (Least Squares Mean)
Duloxetine-1.83
Selective Serotonin Reuptake Inhibitor (SSRI)-1.43

[back to top]

Change From Baseline in Systolic Blood Pressure at Week-12 Endpoint

Mean change from baseline to endpoint in systolic blood pressure (NCT00666757)
Timeframe: Baseline, 12 Weeks

Interventionmillimeters of mmercury (mmHg) (Least Squares Mean)
Duloxetine0.58
Selective Serotonin Reuptake Inhibitor (SSRI)0.55

[back to top]

Change From Baseline in Sheehan Disability Scale (SDS) Global Functional Impairment Score at 12-Week Endpoint (Functional Outcome Measure)

The SDS is a participant-rated anchored visual analog scale to assess disability across the three domains of work/school, social life, and family life, with each item scored from 0 (not at all) to 10 (very severely), with a summarization of the 3 items to evaluate global functioning. The Global Functional Impairment Score is a total score score that ranges from 0 (unimpaired) to 30 (highly impaired), and was used to derived the mean change from baseline to endpoint. (NCT00666757)
Timeframe: Baseline, 12 weeks

Interventionunits on a scale (Least Squares Mean)
Duloxetine-13.56
Selective Serotonin Reuptake Inhibitor (SSRI)-11.53

[back to top]

Change From Baseline in Sheehan Disability Scale (SDS) Family/Home Item Score at Week-12 Endpoint (Functional Outcome Measure)

The SDS is completed by the participant and Item 3 is used to assess the effect of the participant's symptoms on their family life/home responsibilities. Scores range from 0 to 10 with higher values indicating greater disruption in the participant's family life/home responsibilities. (NCT00666757)
Timeframe: Baseline, 12 Weeks

Interventionunits on a scale (Least Squares Mean)
Duloxetine-4.51
Selective Serotonin Reuptake Inhibitor (SSRI)-3.94

[back to top]

Change From Baseline in HAMD-17 Anxiety/Somatization Subscale Score at 12-Week Endpoint (Mood Measure)

HAMD-17 subscale consists of items 10, 11, 12, 13, 15, and 17 evaluates agitation, and severity of psychic and somatic manifestations of anxiety. Total subscale scores range from 0 (normal) to 18 (severe). Mean change from baseline to endpoint. (NCT00666757)
Timeframe: Baseline, 12 Weeks

Interventionunits on a scale (Least Squares Mean)
Duloxetine-4.89
Selective Serotonin Reuptake Inhibitor (SSRI)-4.24

[back to top]

Change From Baseline in SDS Social Item Score at 12-Week Endpoint (Functional Outcome Measure)

The SDS is completed by the participant and is used to assess the effect of the participant's symptoms on their work/social/family life. Total scores range from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. (NCT00666757)
Timeframe: Baseline, 12 Weeks

Interventionunits on a scale (Least Squares Mean)
Duloxetine-4.69
Selective Serotonin Reuptake Inhibitor (SSRI)-4.04

[back to top]

Change From Baseline in QIDS-SR Total Score at 12-Week Endpoint (Mood Measure)

The QIDS-SR is a 16-item, participant-rated short form of the Inventory of Depressive Symptomatology that assesses 9 domains: sad mood, concentration, self-outlook, suicidal ideation, involvement, energy/fatigability, sleep disturbance, appetite/weight increase/decrease and psychomotor agitation/retardation. Scores range from 0 (none) to 27 (very severe). The QIDS-SR total score was used to derive the mean change from baseline to endpoint depression. (NCT00666757)
Timeframe: Baseline, 12 weeks

Interventionunits on a scale (Least Squares Mean)
Duloxetine-13.4
Selective Serotonin Reuptake Inhibitor (SSRI)-12.6

[back to top]

Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 15 Score (Satisfaction With Medication).

The Q-LES-Q (Short Form) is a self-report measure designed to enable physicians to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. According to the scoring system suggested for this questionnaire, item 15 (Satisfaction with Medication) will yield a separate subscore. (NCT00797966)
Timeframe: Week 8 to Week 14

InterventionUnits on a scale (Mean)
OPC-34712 0.15 mg Fixed Dose0.02
OPC-34712 0.5 ± 0.25 mg Low Dose0.01
OPC-34712 1.5 ± 0.5 mg High Dose0.02
Placebo0.00

[back to top]

Percentage of Participants With CGI-I Response From End of Phase A (Week 8 Visit).

CGI-I response is defined as CGI-I of 1 [very much improved] or 2 [much improved]. (NCT00797966)
Timeframe: Week 9, 10, 11, 12, 13 and 14.

,,,
Interventionpercentage of participants (Number)
Week 9 (N=62, 117, 116, 121)Week 10 (N=62, 119, 118, 126)Week 11 (N=62, 119, 118, 126)Week 12 (N=62, 119, 118, 126)Week 13 (N=62, 119, 118, 126)Week 14 (N=62, 119, 118, 126)
OPC-34712 0.15 mg Fixed Dose16.125.832.335.537.138.7
OPC-34712 0.5 ± 0.25 mg Low Dose11.117.629.433.637.037.0
OPC-34712 1.5 ± 0.5 mg High Dose14.724.635.642.449.252.5
Placebo14.927.029.431.733.341.3

[back to top]

Percentage of Participants With MADRS Remission From End of Phase A (Week 8 Visit).

A MADRS remission was defined as MADRS Total Score /= 50% reduction in MADRS Total Score from end of Phase A (Week 8 visit). (NCT00797966)
Timeframe: Week 8 to each of Week 9, 10, 11, 12, 13 and 14.

,,,
InterventionPercentage of participants (Number)
Week 9 (N=61, 117, 116, 121)Week 10 (N=62, 119, 118, 126)Week 11 (N=62, 119, 118, 126)Week 12 (N=62, 119, 118, 126)Week 13 (N=62, 119, 118, 126)Week 14 (N=62, 119, 118, 126)
OPC-34712 0.15 mg Fixed Dose3.288.0612.921.019.422.6
OPC-34712 0.5 ± 0.25 mg Low Dose1.715.0410.110.116.815.1
OPC-34712 1.5 ± 0.5 mg High Dose1.7210.214.419.515.323.7
Placebo4.138.7311.110.315.113.5

[back to top]

Percentage of Participants With MADRS Response From End of Phase A (Week 8 Visit).

A MADRS response was defined as >/= 50% reduction in MADRS Total Score from end of Phase A (Week 8 visit). (NCT00797966)
Timeframe: Week 8 to each of Week 9, 10, 11, 12, 13 and 14.

,,,
InterventionPercentage of participants (Number)
Week 9 (N=61, 117, 116, 121)Week 10 (N=62, 119, 118, 126)Week 11 (N=62, 119, 118, 126)Week 12 (N=62, 119, 118, 126)Week 13 (N=62, 119, 118, 126)Week 14 (N=62, 119, 118, 126)
OPC-34712 0.15 mg Fixed Dose4.928.0619.430.624.227.4
OPC-34712 0.5 ± 0.25 mg Low Dose6.848.4015.115.122.720.2
OPC-34712 1.5 ± 0.5 mg High Dose2.5911.018.625.425.434.7
Placebo8.269.5213.511.918.319.8

[back to top]

Change From End of Phase A (Week 8 Visit) in Mean CGI-S Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.

CGI-S items are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients. The score 0 (= not assessed) was set to missing. The CGI-S was therefore a 7-point scale from 1 through 7. CGI-S was assessed at screening, baseline and each subsequent visit from Week 1 through Week 14. (NCT00797966)
Timeframe: Week 8 to each of Week 9, 10, 11, 12 and 13.

,,,
InterventionUnits on a scale (Mean)
Week 9 (N=62,117,116,121)Week 10 (N=62,119,118,126)Week 11 (N=62,119,118,126)Week 12 (N=62,119,118,126)Week 13 (N=62,119,118,126)
OPC-34712 0.15 mg Fixed Dose-0.21-0.42-0.53-0.76-0.74
OPC-34712 0.5 ± 0.25 mg Low Dose-0.26-0.39-0.53-0.66-0.78
OPC-34712 1.5 ± 0.5 mg High Dose-0.33-0.61-0.69-0.86-0.88
Placebo-0.21-0.40-0.47-0.52-0.59

[back to top]

Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Clinical Global Impression - Severity of Illness Scale (CGI-S) Score.

CGI-S items are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients. The score 0 (= not assessed) was set to missing. The CGI-S was therefore a 7-point scale from 1 through 7. CGI-S was assessed at screening, baseline and each subsequent visit from Week 1 through Week 14. (NCT00797966)
Timeframe: Week 8 to Week 14

InterventionUnits on a scale (Least Squares Mean)
OPC-34712 0.15 mg Fixed Dose-0.83
OPC-34712 0.5 ± 0.25 mg Low Dose-0.81
OPC-34712 1.5 ± 0.5 mg High Dose-1.06
Placebo-0.71

[back to top]

Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Depression Rating Scale (HAM-D17) Score.

"The HAM-D17 is utilized as a secondary assessment of a participant's level of depression. The HAM-D (17-Item) consists of 17 items. Eight items are rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) are rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 is the best rating and the highest score (2 or 4) is the worst rating. The possible total scores are from 0 to 52." (NCT00797966)
Timeframe: Week 8 to Week 14

InterventionUnits on a scale (Least Squares Mean)
OPC-34712 0.15 mg Fixed Dose-5.77
OPC-34712 0.5 ± 0.25 mg Low Dose-5.28
OPC-34712 1.5 ± 0.5 mg High Dose-6.59
Placebo-5.23

[back to top]

Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 16 Score (Overall Life Satisfaction).

The Q-LES-Q (Short Form) is a self-report measure designed to enable physicians to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. According to the scoring system suggested for this questionnaire, item 16 (Overall Life Satisfaction) will yield a separate subscore. (NCT00797966)
Timeframe: Week 8 to Week 14

InterventionUnits on a scale (Mean)
OPC-34712 0.15 mg Fixed Dose0.30
OPC-34712 0.5 ± 0.25 mg Low Dose0.30
OPC-34712 1.5 ± 0.5 mg High Dose0.35
Placebo0.28

[back to top]

Clinical Global Impression-Improvement Scale (CGI-I) Score at Each Study Week Visit in Phase B.

CGI-I items are: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse. The score of 0 (= not assessed) will be set to missing. The CGI-I is therefore a 7-point scale from 1 through 7. CGI-I was assessed at each visit in Phase B, and improvement is judged with respect to the participant's condition at baseline. CGI-I was also assessed at each visit in Phase B, but in that phase improvement is judged with respect to the partcipant's condition at the end of Phase A. (NCT00797966)
Timeframe: Week 8 to each of Week 9, 10, 11, 12, 13 and 14.

,,,
InterventionUnits on a scale (Mean)
Week 9 (N=62, 117, 116, 121)Week 10 (N=62, 119, 118, 126)Week 11 (N=62, 119, 118, 126)Week 12 (N=62, 119, 118, 126)Week 13 (N=62, 119, 118, 126)Week 14 (N=62, 119, 118, 126)
OPC-34712 0.15 mg Fixed Dose3.393.162.942.872.852.74
OPC-34712 0.5 ± 0.25 mg Low Dose3.303.193.022.902.762.78
OPC-34712 1.5 ± 0.5 mg High Dose3.202.952.802.702.642.52
Placebo3.313.112.942.952.902.83

[back to top]

Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Score (the Mean of 3 Individual Item Scores).

The Sheehan Disability Scale (SDS) is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable. (NCT00797966)
Timeframe: Week 8 to Week 14

InterventionUnits on a scale (Least Squares Mean)
OPC-34712 0.15 mg Fixed Dose-0.84
OPC-34712 0.5 ± 0.25 mg Low Dose-0.80
OPC-34712 1.5 ± 0.5 mg High Dose-1.27
Placebo-0.61

[back to top]

Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score.

"The MADRS is utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the best rating and 6 being the worst rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60. The MADRS Total Score was unevaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items were recorded, the MADRS Total Score was the mean of the recorded items multiplied by 10 and then rounded to the first decimal place." (NCT00797966)
Timeframe: Week 8 to Week 14

InterventionUnits on a scale (Least Squares Mean)
OPC-34712 0.15 mg Fixed Dose-6.62
OPC-34712 0.5 ± 0.25 mg Low Dose-6.46
OPC-34712 1.5 ± 0.5 mg High Dose-8.23
Placebo-6.09

[back to top]

Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score.

"The IDS-SR is a 30-item self-report measure used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorders. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the best rating and 3 being the worst rating. The IDS-SR Total Score is the sum of ratings of 28 item scores. The possible IDS-SR Total Score ranges from 0 to 84. The IDS-SR Total Score was un-evaluable if less than 23 of the 28 items are recorded. If the number of items was at least 23 and at most 27, the IDS-SR Total Score will be the mean of the recorded items multiplied by 28 and then rounded to the first decimal place." (NCT00797966)
Timeframe: Week 8 to each of Week 9, 10, 11, 12, 13 and 14

,,,
InterventionUnits on a scale (Mean)
Week 9 (N=61, 117,116,121)Week 10 (N=62, 119, 118, 126)Week 11 (N=62, 119, 118, 126)Week 12 (N=62, 119, 118, 126)Week 13 (N=62, 119, 118, 126)Week 14 (N=62, 119, 118, 126)
OPC-34712 0.15 mg Fixed Dose-0.98-2.13-3.58-5.11-5.34-5.55
OPC-34712 0.5 ± 0.25 mg Low Dose-1.88-2.58-3.41-3.77-5.22-4.96
OPC-34712 1.5 ± 0.5 mg High Dose-2.04-4.08-4.82-5.77-5.65-6.74
Placebo-0.98-1.62-2.09-2.07-2.37-3.08

[back to top]

Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.

"The MADRS is utilized as the primary efficacy assessment of a patient's level of depression. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the best rating and 6 being the worst rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60. The MADRS Total Score was unevaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items were recorded, the MADRS Total Score was the mean of the recorded items multiplied by 10 and then rounded to the first decimal place." (NCT00797966)
Timeframe: Week 8 to each of Week 9, 10, 11, 12 and 13.

,,,
InterventionUnits on a scale (Mean)
Week 9 (N=61,117,116,121)Week 10 (N=62,119,118,126)Week 11 (N=62,119,118,126)Week 12 (N=62,119,118,126)Week 13 (N=62,119,118,126)
OPC-34712 0.15 mg Fixed Dose-2.13-3.69-5.53-6.97-6.90
OPC-34712 0.5 ± 0.25 mg Low Dose-3.00-3.78-5.71-6.31-6.76
OPC-34712 1.5 ± 0.5 mg High Dose-2.75-4.97-5.88-7.01-7.18
Placebo-2.48-3.64-4.40-4.41-5.47

[back to top]

Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Quality of Life, Enjoyment, and Satisfaction Questionnaire - Short Form (QLES-Q-SF) Subscale Score - the Overall General Subscore (Sum of First 14 Items).

The Q-LES-Q is a self-report measure to enable physicians to obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. The Overall-General Subscore will be defined by summing the scores on all 14 items and expressing it as the percent of the maximum possible score. When expressing the total score as a percentage, if items are left blank the range will be modified to reflect the number of items scored. Raw score is sum of non-missing ratings from items 1 to 14. Minimum score is number of non-missing items. Maximum score is 5*(minimum score). Range is maximum score minus minimum score. Total score is 100*(Raw score minus minimum score)/ Range, rounded to nearest integer. (NCT00797966)
Timeframe: Week 8 to Week 14

InterventionPercentage of maximum possible score (Least Squares Mean)
OPC-34712 0.15 mg Fixed Dose7.60
OPC-34712 0.5 ± 0.25 mg Low Dose6.53
OPC-34712 1.5 ± 0.5 mg High Dose7.46
Placebo5.92

[back to top]

Change in Low Density Lipoprotein (LDL) Cholesterol Level

(NCT00806234)
Timeframe: From Baseline to Week 24

Interventionmg/dL (Least Squares Mean)
Healthy Lifestyle Information3.6
Switch Treatment + Healthy Lifestyle Instruction-8.1
Metformin Treatment + Healthy Lifestyle Instruction-4.1

[back to top]

Change in Whole Body Insulin Sensitivity Index

(NCT00806234)
Timeframe: Change from baseline to 24 weeks

InterventionmU/L (Least Squares Mean)
Healthy Lifestyle Information0.74
Switch Treatment + Healthy Lifestyle Instruction0.42
Metformin Treatment + Healthy Lifestyle Instruction-0.34

[back to top]

Triglyceride Levels

(NCT00806234)
Timeframe: Change from baseline to 24 weeks

Interventionmg/dL (Least Squares Mean)
Healthy Lifestyle Information0.2
Switch Treatment + Healthy Lifestyle Instruction16.6
Metformin Treatment + Healthy Lifestyle Instruction14.7

[back to top]

Body Mass Index (BMI) Z-score Change

(NCT00806234)
Timeframe: Change from baseline to 24 weeks

InterventionZ Score (Least Squares Mean)
Healthy Lifestyle Information0.040
Switch Treatment + Healthy Lifestyle Instruction-0.112
Metformin Treatment + Healthy Lifestyle Instruction-0.088

[back to top]

Suicide Events

Data on suicidal behavior was collected with the Columbia Suicide History Interview (CSHI), a semi-structured interview developed by our group. It is used to elicit history of the individual's actual suicide attempts , as well as specific questions concerning the circumstances surrounding any suicidal behavior and its degree of medical lethality. In addition to obtaining measurements of actual suicide attempts, the CSHI also captures suicide-related behaviors such as aborted and interrupted suicide attempts. An actual suicide attempt is operationally defined by the CSHI as a self-injurious act performed with at least some intent to die. (NCT00834834)
Timeframe: Measured after 6 months of treatment

Interventionsuicide events (Number)
Fluoxetine12
Dialectical Behavior Therapy4

[back to top]

Number of Participants With Suicide Events

Data on suicidal behavior was collected with the Columbia Suicide History Interview (CSHI), a semi-structured interview developed by our group. It is used to elicit history of the individual's actual suicide attempts , as well as specific questions concerning the circumstances surrounding any suicidal behavior and its degree of medical lethality. In addition to obtaining measurements of actual suicide attempts, the CSHI also captures suicide-related behaviors such as aborted and interrupted suicide attempts. An actual suicide attempt is operationally defined by the CSHI as a self-injurious act performed with at least some intent to die. (NCT00834834)
Timeframe: measured after 6 months of treatment

Interventionparticipants (Number)
Fluoxetine6
Dialectical Behavior Therapy4

[back to top]

Change From Baseline in the YMRS Total Score at Week 8

The YMRS is an 11-item scale measuring the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total scores ranges: 0 to 60. LS mean was adjusted for baseline, country, treatment, visit, and treatment * visit interaction. (NCT00844857)
Timeframe: Baseline, Week 8

Interventionunits on a scale (Least Squares Mean)
Olanzapine/Fluoxetine Combination-2.02
Placebo-1.57

[back to top]

Change From Baseline in Weight Up to Week 8

Weight LS mean was adjusted for baseline and treatment. (NCT00844857)
Timeframe: Baseline, Week 8

Interventionkilogram (kg) (Least Squares Mean)
Olanzapine/Fluoxetine Combination4.37
Placebo0.50

[back to top]

Percentage of Participants With at Least One Incident of Worsening of Mania Up to Week 8

Worsening of mania was defined as YMRS score of ≥20 and a CGI severity of mania score of ≥ 5 at the same visit. The YMRS is an 11-item scale measuring severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe) with remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. CGI measures severity of the participant's overall severity of bipolar symptoms and scores range from 1 (normal) to 7 (among the most extremely ill participants). (NCT00844857)
Timeframe: Baseline up to Week 8

Interventionpercentage of participants (Number)
Olanzapine/Fluoxetine Combination1.2
Placebo0.0

[back to top]

Percentage of Participants With at Least One Treatment-Emergent Incident of Akathisia Up to Week 8

Akathisia was measured using the Barnes Akathisia Rating Scale where the global scores range from 0 (absent) to 5 (severe) and a score ≥ 2 is considered abnormal. (NCT00844857)
Timeframe: Baseline up to Week 8

Interventionpercentage of participants (Number)
Olanzapine/Fluoxetine Combination1.3
Placebo0.0

[back to top]

Percentage of Participants With at Least One Treatment-Emergent Incident of Dyskinesia Up to Week 8

Dyskinesia was measured using the Abnormal Involuntary Movement Scale (AIMS) a 12-item scale designed to record the occurrence of dyskinetic movements. Items 1 through 10 are rated on a 5-point scale: 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Items 11 and 12 are yes/no questions regarding the dental condition of a patient. Total score (0-40) is obtained by adding the scores of the first 10 items. An abnormal result is defined as having a score ≥3 for at least 1 of the first 7 items or a score ≥2 for at least two of the first 7 items. (NCT00844857)
Timeframe: Baseline, Week 8

Interventionpercentage of participants (Number)
Olanzapine/Fluoxetine Combination0.6
Placebo0.0

[back to top]

Percentage of Participants With at Least One Treatment-Emergent Incident of Parkinsonism Up to Week 8

Parkinsonism was measured using the Simpson-Angus Scale with a total scores range from 0 to 40. A score > 3 was considered abnormal. Simpson-Angus Scale consists of 10 items, each rated on a 5-point scale, 0 (complete absence of the condition) to 4 (presence of the condition in extreme form). (NCT00844857)
Timeframe: Baseline, Week 8

Interventionpercentage of participants (Number)
Olanzapine/Fluoxetine Combination0.6
Placebo1.3

[back to top]

Percentage of Participants With Remission Up to Week 8

Remission is defined as a CDRS-R total score less than or equal to (≤)28, and Young Mania Rating Scale (YMRS) total score ≤ 8 and Clinical Global Impressions-Bipolar Version (CGI-BP) total score ≤3. CDRS-R is a 17-item scale measuring presence/severity of depression in children and is scored on a 1-to-5- or 1-to-7-point scale. Rating of 1 indicates normal function. Scores range: 17 to 113. Scores <20 indicate an absence of depression, scores 20 to 30 indicate borderline depression, scores 40 to 60 indicate moderate depression. The YMRS is an 11-item scale measuring severity of manic episodes; 4 items are rated on a scale from 0 (symptoms not present) to 8 (symptom extremely severe) with remaining items rated on a scale from 0 (symptoms not present) to 4 (symptom extremely severe). YMRS score ranges from 0 to 60. CGI-BP measures participant's overall severity of bipolar symptoms. Scores range: 1 (normal, not at all ill ) to 7 (among the most extremely ill participants). (NCT00844857)
Timeframe: Baseline up to Week 8

Interventionpercentage of participants (Number)
Olanzapine/Fluoxetine Combination59.0
Placebo43.4

[back to top]

Percentage of Participants With Response Up to Week 8

Response is defined as a CDRS-R total score greater than or equal to (≥)50% reduction from baseline and YMRS elevated mood score ≤2. CDRS-R Total score measure the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. Rating of 1 indicates normal function. Scores range: 17 to 113. In general, <20 indicate an absence of depression, scores 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptoms not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptoms not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. (NCT00844857)
Timeframe: Baseline up to Week 8

Interventionpercentage of participants (Number)
Olanzapine/Fluoxetine Combination78.2
Placebo59.2

[back to top]

Percentage of Participants in Each Improvement Category Up to Week 8

CDRS-R scores: No/low improvement is < 25 percent (%) of maximum reduction from baseline. Mild improvement: maximum reduction from baseline on CDRS-R score ≥ 25% up to <50% and YMRS elevated mood score ≤ 2. Moderate improvement: maximum reduction from baseline on CDRS-R score ≥50% and <75% and YMRS elevated mood score ≤ 2. Major improvement: maximum reduction from baseline on CDRS-R score ≥75% and YMRS elevated mood score ≤ 2. CDRS-R measures presence/severity of depression in children. Scale is 17 items scored 1-to-5- or 1-to-7. Rating of 1 indicates normal function. Scores range: 17 to 113. Scores < 20 absence of depression, scores 20 to 30 borderline depression, scores 40 to 60 indicate moderate depression. YMRS is an 11-item scale that measures severity of manic episodes. Four items rated 0 (symptoms not present) to 8 (symptom extremely severe). Remaining items rated 0 (symptoms not present) to 4 (symptom extremely severe). Score range: 0 to 60. (NCT00844857)
Timeframe: Baseline up to Week 8

,
Interventionpercentage of participants (Number)
No or Low ImprovementMild ImprovementModerate ImprovementMajor Improvement
Olanzapine Plus Fluoxetine Combination12.89.021.856.4
Placebo22.418.418.440.8

[back to top]

Percentage of Participants With Treatment Emergent Suicidal Ideation or Behavior Up to Week 8

"Columbia-Suicide Severity Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Percentage of participants with suicidal ideation, behavior, and acts are provided. Suicidal ideation: a yes answer to any 1 of 5 suicidal ideation questions, which includes wish to be dead, and 4 different categories of active suicidal ideation. Suicidal behavior: a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal act: a yes answer to actual attempt or completed suicide." (NCT00844857)
Timeframe: Baseline up to Week 8

,
Interventionpercentage of participants (Number)
Total Suicidal Ideation (1 - 5)Total Suicidal Behavior (6 - 10)Total Suicidal Ideation or Behavior (1 - 10)
Olanzapine/Fluoxetine Combination10.61.810.6
Placebo15.52.415.5

[back to top]

Change From Baseline in Fasting Metabolic Parameters Up to Week 8

Fasting glucose, fasting cholesterol and fasting triglycerides. LS means were adjusted for baseline and treatment. (NCT00844857)
Timeframe: Baseline, Week 8

,
Interventionmillimoles/liter (mmol/L) (Least Squares Mean)
Fasting Glucose (157, 79)Fasting Cholesterol (158, 81)Fasting Triglycerides (158, 81)
Olanzapine/Fluoxetine Combination0.030.420.40
Placebo0.03-0.11-0.04

[back to top]

Change From Baseline in Alanine Aminotransferase/Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) Up to Week 8

ALT/SGPT LS mean was adjusted for baseline and treatment. (NCT00844857)
Timeframe: Baseline, Week 8

Interventionunits/Liter (U/L) (Least Squares Mean)
Olanzapine/Fluoxetine Combination7.63
Placebo0.46

[back to top]

Change From Baseline in Electrocardiogram (ECG) QTcF Interval Up to Week 8

QTcF is defined as ECG QT interval corrected for heart rate using the Fridericia correction factor. (NCT00844857)
Timeframe: Baseline, Week 8

Interventionmillisecond (msec) (Least Squares Mean)
Olanzapine/Fluoxetine Combination8.19
Placebo-1.07

[back to top]

Change From Baseline in Prolactin Up to Week 8

Prolactin LS mean was adjusted for baseline and treatment. (NCT00844857)
Timeframe: Baseline, Week 8

Interventionmicrogram/Liter (μg/L) (Least Squares Mean)
Olanzapine/Fluoxetine Combination8.66
Placebo0.70

[back to top]

Change From Baseline in Symptoms of Attention-Deficit/Hyperactivity Disorder Up to Week 8

Attention Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version (ADHDRS-IV-PI): Investigator Administered and Scored measures the 18 symptoms contained in the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of Attention-Deficit/Hyperactivity Disorder. Individual item scores range from 0 (none/never or rarely) to 3 (severe/very often). Scores range: 0 to 54. The LS mean was adjusted for baseline and treatment. (NCT00844857)
Timeframe: Baseline up to Week 8

Interventionunits on a scale (Least Squares Mean)
Olanzapine/Fluoxetine Combination-4.31
Placebo-3.57

[back to top]

Change From Baseline in the CDRS-R Total Score Up to Week 8

CDRS-R Total score measure the presence and severity of depression in children and consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. Rating of 1 indicates normal function. Total scores range from 17 to 113. In general, scores < 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. LS mean was adjusted for baseline, country, and treatment. (NCT00844857)
Timeframe: Baseline, Week 8

Interventionunits on a scale (Least Squares Mean)
Olanzapine/Fluoxetine Combination-28.57
Placebo-23.38

[back to top]

Change From Baseline in the Children's Depression Rating Scale Revised (CDRS-R) Total Score at Week 8

CDRS-R Total score measures the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning. Total scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. Least Square (LS) mean was adjusted for baseline, country, treatment, visit, and treatment times (*) visit interaction. (NCT00844857)
Timeframe: Baseline, Week 8

Interventionunits on a scale (Least Squares Mean)
Olanzapine/Fluoxetine Combination-28.43
Placebo-23.40

[back to top]

Change From Baseline in the Clinical Global Impression Scale - Bipolar Version (CGI-BP) Score at Week 8

CGI-BP measures severity of illness for bipolar illness. Scores range: 1 (normal, not ill at all) to 7 (among the most extremely ill patients). LS mean was adjusted for baseline, country, treatment, visit, and treatment * visit interaction. (NCT00844857)
Timeframe: Baseline, Week 8

Interventionunits on a scale (Least Squares Mean)
Olanzapine/Fluoxetine Combination-2.21
Placebo-1.83

[back to top]

Change From Baseline in the Quality of Life Questionnaire for Children and Adolescents (KINDL) Kid and Kiddo Combined Scale Up to Week 8

The KINDL consists of 24 Likert-scale items. Kid-KINDL was administered to ages 8-11 and Kiddo-KINDL to ages 12-16. Total scores were standardized to a 0 (lowest quality of life) to 100 (highest quality of life). LS mean was adjusted for baseline, country, and treatment. (NCT00844857)
Timeframe: Baseline, Week 8

Interventionunits on a scale (Least Squares Mean)
Olanzapine/Fluoxetine Combination12.83
Placebo7.91

[back to top]

Change From Baseline in the Quality of Life Questionnaire for Children and Adolescents (KINDL) Parent Scale Up to Week 8

The KINDL consists of 24 Likert-scale items. Total scores were standardized to a 0 (lowest quality of life) to 100 (highest quality of life). LS mean was adjusted for baseline, country, and treatment. (NCT00844857)
Timeframe: Baseline, Week 8

Interventionunits on a scale (Least Squares Mean)
Olanzapine/Fluoxetine Combination15.98
Placebo10.88

[back to top]

Change From Baseline in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 10 Endpoint

CGI-Severity evaluates the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). LS means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Baseline, Week 10

Interventionunits on a scale (Least Squares Mean)
Duloxetine 60mg-1.5
Duloxetine 30mg-1.5
Fluoxetine 20mg-1.4
Placebo-1.4

[back to top]

Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 36 Endpoint

CDRS-R Total score measure the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning. Total scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Week 10, Week 36

Interventionunits on a scale (Least Squares Mean)
Duloxetine 60 mg / Duloxetine 60-120 mg-7.8
Duloxetine 30 mg/Duloxetine 60-120 mg-7.4
Fluoxetine 20 mg/Fluoxetine 20-40 mg-10.0
Placebo/Duloxetine 60-120 mg-9.0

[back to top]

Change From Week 10 in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 36 Endpoint

CGI-Severity evaluates the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Week 10, Week 36

Interventionunits on a scale (Least Squares Mean)
Duloxetine 60 mg / Duloxetine 60-120 mg-1.1
Duloxetine 30 mg/Duloxetine 60-120 mg-0.9
Fluoxetine 20 mg/Fluoxetine 20-40 mg-1.3
Placebo/Duloxetine 60-120 mg-1.0

[back to top]

Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Week 10 Through Week 36

Total number of participants with any abnormal post-baseline value, based on all values at scheduled and unscheduled visits. Potentially clinically significant hepatic laboratory results at any time are defined as ALT ≥3 x ULN, ALT ≥5 x ULN and ALT ≥10 x ULN, as well as ALT≥3 x ULN and Total Bilirubin ≥2 x ULN. (NCT00849693)
Timeframe: Week 10 through Week 36

,,,
Interventionparticipants (Number)
ALT≥3 x ULNALT≥5 x ULNALT≥10 x ULNALT≥3 x ULN and Total Bilirubin≥2 x ULN
Duloxetine 30 mg/Duloxetine 60-120 mg0000
Duloxetine 60 mg / Duloxetine 60-120 mg0000
Fluoxetine 20 mg/Fluoxetine 20-40 mg0000
Placebo/Duloxetine 60-120 mg0000

[back to top]

Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 10 Endpoint

CDRS-R Subscale scores include Mood (Sum of items 8, 11, 14, 15), Somatic (Sum of items 4-7, 16, 17), Subjective (Sum of items 9, 10, 12, 13) and Behavior (Sum of items 1-3). Mood and Subjective subscale scores range from 4 to 28; Somatic subscale scores range from 6 to 36; Behavior subscale scores range from 3 to 21. Higher score indicates greater severity of disease. LS means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Baseline, Week 10

,,,
Interventionunits on a scale (Least Squares Mean)
MoodSomaticSubjectiveBehavior
Duloxetine 30mg-7.2-7.9-4.0-5.6
Duloxetine 60mg-7.1-7.6-3.6-5.8
Fluoxetine 20mg-6.6-7.1-3.5-5.6
Placebo-6.4-6.4-3.6-5.4

[back to top]

Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 36 Endpoint

CDRS-R Subscale scores include Mood (Sum of items 8, 11, 14, 15), Somatic (Sum of items 4-7, 16, 17), Subjective (Sum of items 9, 10, 12, 13) and Behavior (Sum of items 1-3). Mood and Subjective subscale scores range from 4 to 28; Somatic subscale scores range from 6 to 36; Behavior subscale scores range from 3 to 21. Higher score indicates greater severity of disease. LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Week 10, Week 36

,,,
Interventionunits on a scale (Least Squares Mean)
MoodSomaticSubjectiveBehavior
Duloxetine 30 mg/Duloxetine 60-120 mg-1.9-2.4-1.3-1.8
Duloxetine 60 mg / Duloxetine 60-120 mg-1.9-2.8-1.2-2.1
Fluoxetine 20 mg/Fluoxetine 20-40 mg-2.4-4.0-1.5-2.7
Placebo/Duloxetine 60-120 mg-2.3-3.2-1.0-2.4

[back to top]

Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Baseline Through Week 10

Total number of participants with any abnormal post-baseline value, based on all values at scheduled and unscheduled visits. Potentially clinically significant hepatic laboratory results at any time are defined as alanine transaminase (ALT) ≥3 x upper limit of normal (ULN), ALT ≥5 x ULN and ALT ≥10 x ULN, as well as ALT ≥3 x ULN and Total Bilirubin ≥2 x ULN. (NCT00849693)
Timeframe: Baseline through Week 10

,,,
Interventionparticipants (Number)
ALT≥3 x ULNALT≥5 x ULNALT≥10 x ULNALT≥3 x ULN and Total Bilirubin≥2 x ULN
Duloxetine 30mg0000
Duloxetine 60mg0000
Fluoxetine 20mg0000
Placebo0000

[back to top]

Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Week 10 Through Week 36

PCS increase in systolic and diastolic BP was defined as increase of ≥5 mm Hg from baseline (BL) high value to a value above the 95th percentile at post-BL; PCS increase of pulse was defined as >140 and increase of ≥15 from BL high value for age 7-11 and >120 and increase of ≥15 from BL high value for age 12-17; PCS decrease of pulse was defined as <60 and a decrease of ≥25 from BL low value for age 7-11 and <50 and a decrease of ≥15 from BL low value for age 12-17; PCS decrease of weight was defined as decrease of at least 3.5% from BL low value. (NCT00849693)
Timeframe: Week 10 through Week 36

,,,
Interventionpercentage of participants (Number)
Diastolic BP Increase (N=55, 65, 64, 69)Systolic BP Increase (N=53, 62, 57, 57)Pulse Decrease (N=68, 75, 76, 73)Pulse Increase (N=71, 78, 81, 79)Weight Decrease (N=71, 78, 81, 79)
Duloxetine 30 mg/Duloxetine 60-120 mg4.66.5009.0
Duloxetine 60 mg / Duloxetine 60-120 mg14.59.401.42.8
Fluoxetine 20 mg/Fluoxetine 20-40 mg20.37.0003.7
Placebo/Duloxetine 60-120 mg11.610.501.313.9

[back to top]

Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Baseline Through Week 10

PCS increase in systolic and diastolic BP was defined as increase of ≥5 millimeter mercury (mm Hg) from baseline (BL) high value to a value above the 95th percentile at post-BL; PCS increase of pulse was defined as >140 and increase of ≥15 from BL high value for age 7-11 and >120 and increase of ≥15 from BL high value for age 12-17; PCS decrease of pulse was defined as <60 and a decrease of ≥25 from BL low value for age 7-11 and <50 and a decrease of ≥15 from BL low value for age 12-17; PCS decrease of weight was defined as decrease of at least 3.5% from BL low value. (NCT00849693)
Timeframe: Baseline through Week 10

,,,
Interventionpercentage of participants (Number)
Diastolic BP Increase (N=93, 100, 99, 110)Systolic BP Increase (N=88, 95, 93, 98)Pulse Decrease (N=100, 108, 108, 112)Pulse Increase (N=105, 114, 112, 117)Weight Decrease (N=105, 114, 112, 117)
Duloxetine 30mg7.012.6008.8
Duloxetine 60mg11.89.10013.3
Fluoxetine 20mg10.112.90011.6
Placebo4.510.2005.1

[back to top]

Number of Participants With Suicidal Ideation or Suicidal Behavior Week 10 Through Week 36

"Columbia Suicide Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation: a yes answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Treatment Emergent Suicidal Ideation is worsening or new occurrence of events during treatment compared to lead-in baseline (Week 7-10)." (NCT00849693)
Timeframe: Week 10 through Week 36

,,,
Interventionparticipants (Number)
Suicidal IdeationSuicidal BehaviorTreatment Emergent Suicidal Ideation
Duloxetine 30 mg/Duloxetine 60-120 mg1238
Duloxetine 60 mg / Duloxetine 60-120 mg625
Fluoxetine 20 mg/Fluoxetine 20-40 mg807
Placebo/Duloxetine 60-120 mg816

[back to top]

Number of Participants With Suicidal Ideation or Suicidal Behavior Baseline Through Week 10

"Columbia Suicide Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation: a yes answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Treatment Emergent Suicidal Ideation is worsening or new occurrence of events during treatment compared to lead-in baseline (Week -1 to 0)." (NCT00849693)
Timeframe: Baseline through Week 10

,,,
Interventionparticipants (Number)
Suicidal IdeationSuicidal BehaviorTreatment Emergent Suicidal Ideation
Duloxetine 30mg1106
Duloxetine 60mg1607
Fluoxetine 20mg1319
Placebo15111

[back to top]

Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint

CDRS-R Total score measure the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning. Total scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. Least Square (LS) means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Baseline, Week 10

,
Interventionunits on a scale (Least Squares Mean)
Duloxetine 60mg-23.9
Placebo-21.6
Duloxetine 30mg-24.6
Fluoxetine 20mg-22.6
Placebo-21.6

[back to top]

Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 36 Endpoint

CDRS-R Subscale scores include Mood (Sum of items 8, 11, 14, 15), Somatic (Sum of items 4-7, 16, 17), Subjective (Sum of items 9, 10, 12, 13) and Behavior (Sum of items 1-3). Mood and Subjective subscale scores range from 4 to 28; Somatic subscale scores range from 6 to 36; Behavior subscale scores range from 3 to 21. Higher score indicates greater severity of disease. LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Week 10, Week 36

,,
Interventionunits on a scale (Least Squares Mean)
MoodSomaticSubjectiveBehavior
Duloxetine/Duloxetine-1.9-2.8-0.3-1.9
Fluoxetine/Fluoxetine-2.5-3.6-1.3-2.8
Placebo/Duloxetine-2.9-3.2-1.2-2.1

[back to top]

Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 10 Endpoint

CDRS-R Subscale scores include Mood (Sum of items 8, 11, 14, 15), Somatic (Sum of items 4-7, 16, 17), Subjective (Sum of items 9, 10, 12, 13) and Behavior (Sum of items 1-3). Mood and Subjective subscale scores range from 4 to 28; Somatic subscale scores range from 6 to 36; Behavior subscale scores range from 3 to 21. Higher score indicates greater severity of disease. LS means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Baseline, Week 10

,,
Interventionunits on a scale (Least Squares Mean)
Mood (N=113, 113, 103)Somatic (N=113, 113, 103)Subjective (N=113, 113, 103)Behavior (N=113, 112, 103)
Duloxetine-7.0-7.7-4.0-5.6
Fluoxetine-7.1-7.6-3.6-5.4
Placebo-7.0-7.7-4.0-5.7

[back to top]

Change From Week 10 in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 36 Endpoint

CGI-Severity evaluates the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Week 10, Week 36

Interventionunits on a scale (Least Squares Mean)
Duloxetine/Duloxetine-0.6
Fluoxetine/Fluoxetine-1.0
Placebo/Duloxetine-1.1

[back to top]

Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 36 Endpoint

CDRS-R Total score measure the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning. Total scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Week 10, Week 36

Interventionunits on a scale (Least Squares Mean)
Duloxetine/Duloxetine-7.2
Fluoxetine/Fluoxetine-9.9
Placebo/Duloxetine-9.6

[back to top]

Change From Baseline in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 10 Endpoint

CGI-Severity evaluates the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). LS means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Baseline, Week 10

Interventionunits on a scale (Least Squares Mean)
Duloxetine-1.9
Fluoxetine-1.8
Placebo-1.9

[back to top]

Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint

CDRS-R Total score measure the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning. Total scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. Least Square (LS) means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Baseline, Week 10

Interventionunits on a scale (Least Squares Mean)
Duloxetine-24.3
Fluoxetine-23.7
Placebo-24.3

[back to top]

Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Baseline Through Week 10

Total number of participants with any abnormal post-baseline value, based on all values at scheduled and unscheduled visits. Potentially clinically significant hepatic laboratory results at any time are defined as alanine transaminase (ALT) ≥3 x upper limit of normal (ULN), ALT ≥5 x ULN and ALT ≥10 x ULN, as well as ALT ≥3 x ULN and Total Bilirubin ≥2 x ULN. (NCT00849901)
Timeframe: Baseline through Week 10

,,
Interventionparticipants (Number)
ALT≥3 x ULNALT≥5 x ULNALT≥10 x ULNALT≥3 x ULN and Total Bilirubin≥2 x ULN
Duloxetine0000
Fluoxetine0000
Placebo0000

[back to top]

Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Week 10 Through Week 36

Total number of participants with any abnormal post-baseline value, based on all values at scheduled and unscheduled visits. Potentially clinically significant hepatic laboratory results at any time are defined as alanine transaminase (ALT) ≥3 x upper limit of normal (ULN), ALT ≥5 x ULN and ALT ≥10 x ULN, as well as ALT ≥3 x ULN and Total Bilirubin ≥2 x ULN. (NCT00849901)
Timeframe: Week 10 through Week 36

,,
Interventionparticipants (Number)
ALT≥3 x ULNALT≥5 x ULNALT≥10 x ULNALT≥3 x ULN and Total Bilirubin≥2 x ULN
Duloxetine/Duloxetine0000
Fluoxetine/Fluoxetine1100
Placebo/Duloxetine0000

[back to top]

Number of Participants With Suicidal Ideation or Suicidal Behavior Baseline Through Week 10

"Columbia Suicide Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation: a yes answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Treatment Emergent Suicidal Ideation is worsening or new occurrence of events during treatment compared to lead-in baseline (Week -1 - 0)." (NCT00849901)
Timeframe: Baseline through Week 10

,,
Interventionparticipants (Number)
Suicidal IdeationSuicidal BehaviorTreatment Emergent Suicidal Ideation
Duloxetine1608
Fluoxetine1619
Placebo1507

[back to top]

Number of Participants With Suicidal Ideation or Suicidal Behavior Week 10 Through Week 36

"Columbia Suicide Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation: a yes answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Treatment Emergent Suicidal Ideation is worsening or new occurrence of events during treatment compared to lead-in baseline (Week 7-10)." (NCT00849901)
Timeframe: Week 10 through Week 36

,,
Interventionparticipants (Number)
Suicidal IdeationSuicidal BehaviorTreatment Emergent Suicidal Ideation
Duloxetine/Duloxetine1319
Fluoxetine/Fluoxetine13113
Placebo/Duloxetine808

[back to top]

Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Baseline Through Week 10

PCS increase in systolic and diastolic BP was defined as increase of ≥5 millimeter mercury (mm Hg) from baseline (BL) high value to a value above the 95th percentile at post-BL; PCS increase of pulse was defined as >140 and increase of ≥15 from BL high value for age 7-11 and >120 and increase of ≥15 from BL high value for age 12-17; PCS decrease of pulse was defined as <60 and a decrease of ≥25 from BL low value for age 7-11 and <50 and a decrease of ≥15 from BL low value for age 12-17; PCS decrease of weight was defined as decrease of at least 3.5% from BL low value. (NCT00849901)
Timeframe: Baseline through Week 10

,,
Interventionpercentage of participants (Number)
Diastolic BP Increase (N=102, 106, 93)Systolic BP Increase (N=100, 106, 90)Pulse Decrease (N=111, 112, 102)Pulse Increase (N=113, 114, 103)Weight Decrease (N=113, 114, 103)
Duloxetine8.87.00.9012.4
Fluoxetine7.55.70.9011.4
Placebo17.26.71.01.04.9

[back to top]

Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Week 10 Through Week 36

PCS increase in systolic and diastolic BP was defined as increase of ≥ 5mm Hg from baseline (BL) high value to a value above the 95th percentile at post-BL; PCS increase of pulse was defined as >140 and increase of ≥15 from BL high value for age 7-11 and >120 and increase of ≥15 from BL high value for age 12-17; PCS decrease of pulse was defined as <60 and a decrease of ≥25 from BL low value for age 7-11 and <50 and a decrease of ≥15 from BL low value for age 12-17; PCS decrease of weight was defined as decrease of at least 3.5% from BL low value. (NCT00849901)
Timeframe: Week 10 through Week 36

,,
Interventionpercentage of participants (Number)
Diastolic BP Increase (N=65, 76, 61)Systolic BP Increase (N=64, 80, 69)Pulse Decrease (N=78, 84, 82)Pulse Increase (N=81, 91, 84)Weight Decrease (N=81, 91, 85)
Duloxetine/Duloxetine16.912.5006.2
Fluoxetine/Fluoxetine11.812.5003.3
Placebo/Duloxetine4.910.1009.4

[back to top]

Hamilton Depression (HAM-D) and Anxiety (HAM-A) Rating Scales

"Hamilton Depression rating scale is a clinician assessment tool to measure severity of depression symptoms. Minimum score is 0 (no symptoms); maximum score is 52 (severe symptoms of depression).~Hamilton Anxiety rating scale is a clinician assessment tool to measure severity of anxiety symptoms. Minimum score is 0 (no symptoms); maximum score is 56 (severe symptoms of anxiety)." (NCT00909155)
Timeframe: Study entry, 2 months, and at end of study (6 mos)

,,
Interventionunits on a scale (Mean)
HAMD T0HAMA T0HAMD 2monthsHAMA 2monthsHAMD 6monthsHAMA 6months
Control (Non-psychiatric Subjects)1NA1.25NA1.64NA
Currently Depressed Subjects: Fluoxetine21.3615.5710.158.547.335.89
Currently Depressed Subjects: Venlafaxine20.0714.078.867.554.25

[back to top]

Functional Magnetic Resonance Imaging (fMRI) Response to an Emotional Regulation Task.

"Depressed participants were scanned while viewing a sequence of positive and negative images; they were instructed to enhance or supress their emotional response to the image or to continue to attend. To examine brain function when regulating negative affect, we created contrast maps for each participant at all 3 time points by subtracting the attend condition from the suppress condition in response to negative stimuli. Data from all 3 scan sessions were used to assess treatment-induced change in brain activity when regulating emotion. Analyses examining change using difference scores (end vs. starting points), we subtracted initial HAMD score from final HAMD score. For fMRI analyses, in a voxelwise manner, we subtracted initial negative suppress vs attend from final negative suppress vs attend.~Control subjects were not depressed, repeat scans to assess change were not completed.~Reported results are from BA10, one of our areas of interest." (NCT00909155)
Timeframe: At study entry, 2 months and end of study (6 months)

InterventionfMRI signal change (Mean)
Depressed; Venlafaxine Treatment-0.042666667
Depressed; Fluoxetine Treatment0.0414

[back to top]

Change in Pulmonary Vascular Resistance (PVR) at Three Months

PVR will be measured by right heart catheterization at baseline and 3 months. Change in PVR will be determined by baseline value minus 3 month value. (NCT00942708)
Timeframe: Change in PVR at 3 mos (Baseline - 3 months)

InterventionWood units (Mean)
Fluoxetine-0.49

[back to top]

Change Between Baseline and Three Month in the QIDS-SR Depression Scale

The Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR) depression scale is a questionnaire completed by the patient. Lower scores are better. Scoring can be interpreted as 7 or less: normal, 8-12: mild depression, 13-16 moderate depression, 17-20 moderate to severe depression and >20 severe depression. Results here show the median change between baseline and 3 months, making a positive change in score indicative of improvement. Total minimum score is 0 and the maximum is 27. (NCT00942708)
Timeframe: Baseline - 3 months (median change)

Interventionunits on a scale (Median)
Fluoxetine1

[back to top]

Change in Six Minute Walk Distance at 3 Months

Six minute walk distance will be measured at baseline and after 3 months of fluoxetine. Change in walk distance (mean and SD) will be reported by taking subtracting baseline values from result at 3 months. (NCT00942708)
Timeframe: 3 months

Interventionmeters (Mean)
Fluoxetine10

[back to top]

Mean Change From Week 20 to Week 47 in Weight

Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction. (NCT00958568)
Timeframe: Randomization (Week 20), Week 47

Interventionkilograms (kg) (Least Squares Mean)
OFC (SPIV)1.14
Flu (SPIV)-2.78

[back to top]

Mean Change From Week 20 to Week 47 in Montgomery-Asberg Depression Rating Scale (MADRS) Using Mixed-Effects Model Repeated Measures (MMRM) Analysis

The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction. (NCT00958568)
Timeframe: Randomization (Week 20), Week 47

Interventionunits on a scale (Least Squares Mean)
OFC (SPIV)2.06
Flu (SPIV)4.97

[back to top]

Mean Change From Week 20 to Week 47 in Montgomery-Asberg Depression Rating Scale (MADRS) Using Last Observation Carried Forward (LOCF) Analysis

The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment and country. (NCT00958568)
Timeframe: Randomization (Week 20), up to Week 47

Interventionunits on a scale (Least Squares Mean)
OFC (SPIV)3.03
Flu (SPIV)6.84

[back to top]

Kaplan-Meier Estimate of Percentage of Subjects Not Relapsing at Week 27 (Day 189)

Relapse is defined as meeting any of the following criteria (Relapse-any reason): 50% increase in MADRS score from randomization with concomitant CGI-S of Depression score increase to a score of 4 or more (MADRS score/CGI-S Depression Score); Hospitalization for depression or suicidality; Discontinuation due to lack of efficacy/worsening of depression/suicidality. MADRS is a rating scale for severity of depressive mood symptoms with 10 items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Lack of Efficacy/Worsening of depression was at the discretion of the investigator and based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator. (NCT00958568)
Timeframe: Randomization (Week 20) to Week 27

,
Interventionpercentage of participants (Number)
Relapse-any criteriaRelapse-MADRS score/CGI-S Depression ScoreRelapse-Hospitalization for depression/suicidalityRelapse-Discontinued for lack efficacy/worsening
Flu (SPIV)66.569.698.669.8
OFC (SPIV)83.685.397.787.4

[back to top] [back to top]

Percent of Participants With Treatment-Emergent High Fasting Glucose

Impaired to High fasting glucose: ≥100 milligrams/deciliter (mg/dL) and <126 mg/dL at baseline and ≥126 mg/dL any time post baseline; Normal to High glucose: <100 mg/dL at baseline and ≥126 mg/dL any time post baseline; Normal to Impaired fasting glucose is <100 mg/dL at baseline, ≥100 mg/dL and <126 mg/dL any time post baseline; Normal/Impaired to High fasting glucose: <126 mg/dL at baseline and ≥126 mg/dL any time post baseline. (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

,
Interventionpercentage of participants (Number)
Impaired to High (n=98, 97)Normal to High (n=90, 96)Normal to Impaired (n=90, 96)Normal/Impaired to High (n= 188, 193)
Flu (SPIV)7.25.228.16.2
OFC (SPIV)18.44.435.611.7

[back to top]

Percent of Participants With Treatment-Emergent High Fasting Low-Density Lipoprotein (LDL) Cholesterol

Borderline to High fasting LDL cholesterol: ≥100 milligrams/deciliter (mg/dL) and <160 mg/dL at baseline and ≥160 mg/dL any time post baseline; Normal to Borderline fasting LDL cholesterol: <100 mg/dL at baseline, ≥100 mg/dL and <160 mg/dL any time post baseline; Normal to High fasting LDL cholesterol: <100 mg/dL at baseline and ≥160 mg/dL any time post baseline. (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

,
Interventionpercent of participants (Number)
Borderline to High (n= 115, 134)Normal to Borderline (n=22, 26)Normal to High (n=22, 26)
Flu (SPIV)10.430.80.0
OFC (SPIV)17.422.74.5

[back to top]

Percent of Participants With Treatment-Emergent High Fasting Total Cholesterol

Borderline to High fasting total cholesterol: ≥200 milligrams/deciliter (mg/dL) and <240 mg/dL at baseline and ≥240 mg/dL any time post baseline; Normal to Borderline fasting total cholesterol: <200 mg/dL at baseline, ≥200 mg/dL and <240 mg/dL any time post baseline; Normal to High fasting total cholesterol: <200 mg/dL at baseline and ≥240 mg/dL any time post baseline. (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

,
Interventionpercentage of participants (Number)
Borderline to High (n= 75, 83)Normal to Borderline (n=47, 59)Normal to High (n=47, 59)
Flu (SPIV)20.516.93.4
OFC (SPIV)28.017.02.1

[back to top]

Resource Utilization (Number of Psychiatric Visits, Number of Emergency Room or Equivalent Facility Visits for Psychiatric Illness)

Resource utilization is defined as the average number of psychiatric visits and number of emergency room or equivalent facility visits for psychiatric illness. (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

,
Interventionvisits per participant (Mean)
Psychiatric visits (n=136, 113)Emergency room or equivalent facility visits
Flu (SPIV)0.810.00
OFC (SPIV)0.650.00

[back to top]

Time to Relapse Based on the Montgomery-Åsberg Depression Rating Scale (MADRS) Score With Concomitant Clinical Global Impressions-Severity (CGI-S) of Depression Score

"Relapse is defined as a 50% increase in the Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with concomitant Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Those who did not relapse were censored at their last observation." (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

Interventiondays (Median)
OFC (SPIV)NA
Flu (SPIV)NA

[back to top]

Time to Relapse as Measured by Hospitalization for Depression or Suicidality

"Those who did not relapse were censored at their last observation." (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

Interventiondays (Median)
OFC (SPIV)NA
Flu (SPIV)NA

[back to top]

Mean Change From Week 20 to Week 47 in Clinical Global Impressions - Severity (CGI-S) of Depression Using Mixed-Effects Model Repeated Measures (MMRM) Analysis

CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction. (NCT00958568)
Timeframe: Randomization (Week 20), Week 47

Interventionunits on a scale (Least Squares Mean)
OFC (SPIV)0.20
Flu (SPIV)0.54

[back to top]

Mean Change From Week 20 to Week 47 in Fasting Glucose

Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction. (NCT00958568)
Timeframe: Randomization (Week 20), Week 47

Interventionmilligrams/deciliter (mg/dL) (Least Squares Mean)
OFC (SPIV)3.67
Flu (SPIV)-2.22

[back to top]

Mean Change From Week 20 to Week 47 in Fasting Low-Density Lipoprotein (LDL) Cholesterol

Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction. (NCT00958568)
Timeframe: Randomization (Week 20), Week 47

Interventionmilligrams/deciliter (mg/dL) (Least Squares Mean)
OFC (SPIV)-0.72
Flu (SPIV)0.85

[back to top]

Mean Change From Week 20 to Week 47 in Fasting High-Density Lipoprotein (HDL) Cholesterol

Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction. (NCT00958568)
Timeframe: Randomization (Week 20), Week 47

Interventionmilligrams/deciliter (mg/dL) (Least Squares Mean)
OFC (SPIV)-1.71
Flu (SPIV)2.02

[back to top]

Change From Week 20 to Week 47 Endpoint in the Sheehan Disability Scale (SDS)

The SDS is completed by the participant and is used to assess the effect of the participant's symptoms on their work or school (Item 1), social (Item 2), and family life and home responsibilities (Item 3). Each item is measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. Total scores is the sum of the 3 items and range from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. Least Squares (LS) Mean values were controlled for baseline (Week 20), treatment and country. (NCT00958568)
Timeframe: Randomization (Week 20), up to Week 47

Interventionunits on a scale (Least Squares Mean)
OFC (SPIV)1.30
Flu (SPIV)3.24

[back to top]

Mean Change From Week 20 to Week 47 in Fasting Triglycerides

Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction. (NCT00958568)
Timeframe: Randomization (Week 20), Week 47

Interventionmilligrams/deciliter (mg/dL) (Least Squares Mean)
OFC (SPIV)-8.24
Flu (SPIV)-21.51

[back to top]

Percentage of Participants Achieving Remission at Any Point During Stabilization Treatment Phase

Remission is defined as the Montgomery-Asberg Depression Rating Scale (MADRS) score ≤8. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). (NCT00958568)
Timeframe: Week 8 to Week 20

Interventionpercentage of participants (Number)
OFC (SPIII)77.9

[back to top]

Percentage of Participants Maintaining Remission

Remission is defined as the Montgomery-Asberg Depression Rating Scale (MADRS) score ≤8. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

Interventionpercentage of participants (Number)
OFC (SPIV)86.4
Flu (SPIV)78.9

[back to top]

Mean Change From Week 20 to Week 47 in Fasting Total Cholesterol

Mixed-effects model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) Mean and standard error (SE). LS Mean values were controlled for baseline (Week 20), treatment, country, visit, and treatment by visit interaction. (NCT00958568)
Timeframe: Randomization (Week 20), Week 47

Interventionmilligrams/deciliter (mg/dL) (Least Squares Mean)
OFC (SPIV)-2.65
Flu (SPIV)-1.74

[back to top]

Percentage of Participants Maintaining Response at Any Point During Stabilization Treatment Phase

A 50% or greater improvement from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) and a Clinical Global Impressions-Severity (CGI-S) of Depression score ≤3 will be considered as response criteria met. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). (NCT00958568)
Timeframe: Week 8 to Week 20

Interventionpercentage of participants (Number)
OFC (SPIII)68.2

[back to top]

Percentage of Participants Responding to Treatment During Open-Label Acute Treatment Phase

A 50% or greater improvement from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) and a Clinical Global Impressions-Severity (CGI-S) of Depression score ≤3 will be considered as response criteria met. The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). (NCT00958568)
Timeframe: Week 0 to Week 8

Interventionpercentage of participants (Number)
OFC (SPII-Wk 0-8, Acute Open-label)78.0

[back to top]

Percentage of Participants Who Relapse as Measured by Discontinuation Due to Lack of Efficacy/Worsening of Depression/Suicidality

Lack of Efficacy/Worsening of depression was at the discretion of the investigator and was based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator. (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

Interventionpercentage of participants (Number)
OFC (SPIV)10.9
Flu (SPIV)28.3

[back to top]

Percent of Participants With Week 20-to-Week 47 Endpoint Increase in Weight of at Least 7%

(NCT00958568)
Timeframe: Week 20 to Week 47

Interventionpercentage of participants (Number)
OFC (SPIV)11.8
Flu (SPIV)2.3

[back to top]

Percent of Participants With Treatment-Emergent Parkinsonism

Simpson-Angus Scale is used to measure Parkinsonian-type symptoms in participants exposed to neuroleptics. The scale consists of 10 items, each rated on a 5-point scale, with 0 meaning complete absence of the condition and 4 meaning the presence of the condition in extreme form. The total score is obtained by adding the items and ranges from 0-40 with higher scores indicating worse conditions. Treatment emergent parkinsonism is defined as total score ≤3 of items 1 through 10 of the Simpson-Angus scale at baseline (Week 20) and a total score >3 of items 1 through 10 post-baseline (Weeks 21-47). (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

Interventionpercentage of participants (Number)
OFC (SPIV)1.4
Flu (SPIV)0.0

[back to top]

Percent of Participants With Treatment-Emergent Low Fasting High-Density Lipoprotein (HDL) Cholesterol

Normal to Low fasting HDL cholesterol is ≥40 milligrams/deciliter (mg/dL) at baseline and <40 mg/dL anytime post baseline. (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

Interventionpercentage of participants (Number)
OFC (SPIV)39.2
Flu (SPIV)25.5

[back to top]

Percent of Participants With Treatment-Emergent Hepatic Events

Participants with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=3 times the upper limit of normal (ULN) at baseline, with ALT or AST >=3 times the ULN post-baseline and total bilirubin >=2 times ULN at the same time are considered having treatment-emergent hepatic events. (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

Interventionpercentage of participants (Number)
OFC (SPIV)0.0
Flu (SPIV)0.0

[back to top]

Percent of Participants With Treatment-Emergent Dyskinesia

Abnormal Involuntary Movement Scale (AIMS) is a 12-item scale designed to record the occurrence of dyskinetic movements. Items 1 through 10 are rated on a 5-point scale, with 0 being no dyskinetic movements and 4 being severe dyskinetic movements. Items 11 and 12 are yes/no questions regarding the dental condition of the participants. Treatment emergent dyskinesia is defined as a score ≥3 on any one of the AIMS items 1-7 post-baseline (Weeks 21-47) or scores ≥2 on any two of the AIMS items 1-7 post-baseline (Weeks 21-47) among participants without either criteria at baseline (Week 20). (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

Interventionpercentage of participants (Number)
OFC (SPIV)0.5
Flu (SPIV)0.0

[back to top]

Time to Relapse by Any Criteria

"Relapse defined as meeting any of these criteria: 50% increase in Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with a Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more; Hospitalized for depression or suicidality; Discontinued due to lack of efficacy/worsening of depression/suicidality. MADRS is a 10-item rating scale for depressive mood symptoms severity, items rated on 0-6 scale, with total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Lack of Efficacy/Worsening of depression was at discretion of investigator based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator. Those who did not relapse were censored at their last observation." (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

Interventiondays (Median)
OFC (SPIV)NA
Flu (SPIV)NA

[back to top]

Percent of Participants With Treatment-Emergent Corrected (for Rate) Cardiac QT Interval Using Fridericia's Formula (QTcF) on Electrocardiogram ≥500 Milliseconds (Msec)

Data presented are the percent of participants whose baseline corrected (for rate) cardiac QT interval <500 msec with post-baseline corrected (for rate) cardiac QT interval ≥500 msec. (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

Interventionpercentage of participants (Number)
OFC (SPIV)0
Flu (SPIV)0

[back to top]

Percent of Participants With Treatment-Emergent High Fasting Triglycerides

Borderline to High fasting triglycerides: ≥150 milligrams/deciliter (mg/dL) and <200 mg/dL at baseline and ≥200 mg/dL any time post baseline; Normal to Borderline fasting triglycerides: <150 mg/dL at baseline, ≥150 mg/dL and <200 mg/dL any time post baseline; Normal to High fasting triglycerides: <150 mg/dL at baseline and ≥200 mg/dL any time post baseline. (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

,
Interventionpercentage of participants (Number)
Borderline to High (n=47, 41)Normal to Borderline (n= 68, 74)Normal to High (n=68, 74)
Flu (SPIV)26.86.85.4
OFC (SPIV)51.122.116.2

[back to top]

Percent of Participants With a 60 Milliseconds (Msec) Increase in Fridericia-Corrected (for Rate) Cardiac QT Interval (QTcF) on Electrocardiogram

(NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

Interventionpercentage of participants (Number)
OFC (SPIV)0
Flu (SPIV)0

[back to top]

Mean Change in Corrected (for Rate) Cardiac QT Interval Using Fridericia's Formula (QTcF) on Electrocardiogram

Least Squares (LS) Mean values were obtained from a mixed model repeated measures (MMRM) analysis. Model includes baseline (Week 20), treatment, country, visit, and treatment by visit interaction. (NCT00958568)
Timeframe: Randomization (Week 20), Week 47

Interventionmilliseconds (msec) (Least Squares Mean)
OFC (SPIV)-3.12
Flu (SPIV)-1.55

[back to top]

Percentage of Participants Who Relapse as Measured by Hospitalization for Depression or Suicidality

(NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

Interventionpercentage of participants (Number)
OFC (SPIV)1.8
Flu (SPIV)1.3

[back to top]

Percentage of Participants Who Relapse Based on Montgomery-Åsberg Depression Rating Scale (MADRS) Score With Concomitant Clinical Global Impressions-Severity (CGI-S) of Depression Score

Relapse is defined as a 50% increase in the Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with concomitant Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more. The MADRS has a 10-item checklist with items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

Interventionpercentage of participants (Number)
OFC (SPIV)14.0
Flu (SPIV)28.3

[back to top]

Percentage of Participants Who Relapse by Any Criteria

Relapse is defined as meeting any of the following criteria: 50% increase in Montgomery-Asberg Depression Rating Scale (MADRS) score from randomization with concomitant Clinical Global Impressions-Severity (CGI-S) of Depression score increase to a score of 4 or more; Hospitalization for depression or suicidality; Discontinuation due to lack of efficacy/worsening of depression/suicidality. MADRS is a rating scale for severity of depressive mood symptoms with 10 items rated on a scale of 0-6, for a total score range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). CGI-S measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (the most extremely ill). Lack of Efficacy/Worsening of depression was at the discretion of the investigator and based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator. (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

Interventionpercentage of participants (Number)
OFC (SPIV)15.8
Flu (SPIV)31.8

[back to top]

Resource Utilization - Average Number of Hours Worked for Pay Per Week at Week 47

(NCT00958568)
Timeframe: Week 47

Interventionhours (Mean)
OFC (SPIV)37.49
Flu (SPIV)37.76

[back to top]

Time to Relapse as Measured by Discontinuation Due to Lack of Efficacy/Worsening of Depression/Suicidality

"Lack of Efficacy/Worsening of depression was at the discretion of the investigator and was based on clinical observation. Suicidality is thoughts or actions of self-harm as determined by the investigator. Those who did not relapse were censored at their last observation." (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

Interventiondays (Median)
OFC (SPIV)NA
Flu (SPIV)NA

[back to top]

Percent of Participants With Treatment-Emergent Akathisia

Barnes Akathisia Scale (BAS) rates observable, restless movements of drug-induced akathisia as well as the subjective awareness of restlessness and any distress associated with the akathisia. It consists of 4 items. 3 items (objective akathisia, subjective awareness of restlessness and subjective distress related to restlessness) rated on a 4-point scale, with 0 being no akathisia and 3 being severe akathisia. Item 4 (global clinical assessment of Akathisia) is derived from the responses on Items 1-3 rated on a 6-point scale, with 0 being absence and 5 being extreme Akathisia. Treatment emergent akathisia is defined as a global clinical assessment score on BAS <2 at baseline (Week 20) and a global clinical assessment score on BAS ≥2 post-baseline (Weeks 21-47). (NCT00958568)
Timeframe: Randomization (Week 20) to Week 47

Interventionpercentage of participants (Number)
OFC (SPIV)0.9
Flu (SPIV)0.9

[back to top]

Number of Participants With an Onset of a Hypomanic Episode Within 1 Year

Onsets of a hypomanic episodes were ascertained with the clinician-rated Hypomania Interview Guide and associated scoring rules. (NCT00961961)
Timeframe: 1 Year

InterventionParticipants (Count of Participants)
Lithium Plus Fluoxetine Phase I0
Lithium Plus Placebo Phase I0
Lithium Plus Fluoxetine Phase II0
Lithium Plus Placebo Phase II0

[back to top]

Number of Participants With an Onset of a Manic Episode Within 1 Year

Onsets of a manic episodes were ascertained with the clinician-rated Young Mania Rating Scale (YMRS). The YMRS covers 11 symptom groups over the previous 48 hours. Four of the items are rated on a scale from 0 to 4; the other 4 are rated on a scale of 0 to 8. A score of 12 or above indicates a manic episode. (NCT00961961)
Timeframe: 1 Year

InterventionParticipants (Count of Participants)
Lithium Plus Fluoxetine Phase I0
Lithium Plus Placebo Phase I0
Lithium Plus Fluoxetine Phase II0
Lithium Plus Placebo Phase II0

[back to top]

Number of Participants With Relapse of Major Depressive Episode Within 1 Year

Patients who were randomized to one of the Phase II conditions were interviewed once each month. If they met criteria for a relapse of a Major Depressive Episode, this was considered the study outcome. If they participated for the full year of Phase II without a documented relapse, they were considered a completer. (NCT00961961)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Lithium Plus Fluoxetine Phase II4
Lithium Plus Placebo Phase II5

[back to top]

Proportion of Patients With PMTS Visit-wise Response to Treatment (50% Improvement)

Visit-wise response considers participants who remained in the study until Visit 5 and provided data for the visit. PMTS = Premenstrual Tension Syndrome (Observer Rating) Scale: a clinician-administered retrospective scale developed for the study of PMS, a sum of responses to 10 items each with 4 points (0=no symptoms, 40=most severe). (NCT00965562)
Timeframe: over duration of treatment from baseline to visit 5, including 4 menstrual cycles averaging 4 months after baseline visit

Interventionproportion of participants (Number)
I: Fluoxetine0.75
II: Calcium0.36
III: Placebo0.17

[back to top]

Comparison of the Change in CGI Improvement Scores Among Groups

CGI-I = Clinical Global Impression Improvement: the improvement subscale of CGI measuring change at each visit as compared to visit 1 (1=very much improved, 7=very much worse). This outcome is a measure of effect size between the two trial groups and the placebo group, with the placebo effect size value used as a reference. (NCT00965562)
Timeframe: over duration of treatment, 4 menstrual cycles averaging 4 months after baseline visit

,,
Interventionunits on CGI Improvement scale (Mean)
Visit 1Visit 2Visit 3Visit 4Visit 5
I: FluoxetineNA2.231.671.751.88
II: CalciumNA3.462.302.362.45
III: PlaceboNA3.003.082.772.83

[back to top]

Comparison of the Change in CGI-S Symptom Scores Among Groups

CGI-S = Clinical Global Impression-Severity: a severity scale widely used in psychopharmacology research (1=normal not at all ill, 7=among most extremely ill). This outcome is a measure of effect size between the two trial groups and the placebo group, with the placebo effect size value used as a reference. (NCT00965562)
Timeframe: over duration of treatment, 4 menstrual cycles averaging 4 months after baseline visit

,,
Interventionunits on CGI-S scale (Mean)
Visit 1Visit 2Visit 3Visit 4Visit 5
I: Fluoxetine4.922.542.332.562.50
II: Calcium4.464.233.002.732.91
III: Placebo4.153.383.382.923.17

[back to top]

Comparison of the Change in DRSP Symptom Scores Among Groups

DRSP = Daily Record of Severity of Problems, which combines responses to 21 items each with scale: 1=no symptoms, 6=extreme. This outcome is a measure of effect size between the two trial groups and the placebo group, with the placebo effect size value used as a reference. (NCT00965562)
Timeframe: over duration of treatment, 4 menstrual cycles averaging 4 months after baseline visit

,,
Interventionunits on DRSP scale (Mean)
Visit 1Visit 2Visit 3Visit 4Visit 5
I: Fluoxetine2.160.970.270.720.44
II: Calcium1.120.760.610.510.75
III: Placebo1.290.931.190.590.74

[back to top]

Comparison of the Change in IDS Symptom Scores Among Groups

IDS = Inventory of Depressive Symptomatology: measures depressive symptoms during the previous premenstrual phase with high internal consistency: sum of responses to 28 of 30 possible items each scored 0 to 3 points with total scoring (0=no symptoms, 84=most severe). This outcome is a measure of effect size between the two trial groups and the placebo group, with the placebo effect size value used as a reference. (NCT00965562)
Timeframe: over duration of treatment, 4 menstrual cycles averaging 4 months after baseline visit

,,
Interventionunits on IDS scale (Mean)
Visit 1Visit 2Visit 3Visit 4Visit 5
I: Fluoxetine31.8514.0811.4411.7810.00
II: Calcium30.9225.7718.5518.5019.55
III: Placebo28.8520.6920.1516.4618.08

[back to top]

Comparison of the Change in PMTS Symptom Scores Among Groups

PMTS = Premenstrual Tension Syndrome (Observer Rating) Scale: a clinician-administered retrospective scale developed for the study of PMS, a sum of responses to 10 items each with 4 points (0=no symptoms, 40=most severe). This outcome is a measure of effect size between the two trial groups and the placebo group, with the placebo effect size value used as a reference. (NCT00965562)
Timeframe: over duration of treatment, 4 menstrual cycles averaging 4 months after baseline visit

,,
Interventionunits on PMTS scale (Mean)
Visit 1Visit 2Visit 3Visit 4Visit 5
I: Fluoxetine24.1511.1510.3312.1110.13
II: Calcium21.5818.5413.3612.8311.91
III: Placebo20.8516.0016.3812.7714.58

[back to top]

Proportion of Participants With DRSP LOCF Response to Treatment (50% Improvement)

DRSP: Daily Record of Severity of Problems, which combines responses to 21 items each with scale: 1=no symptoms, 6=extreme. LOCF: the last observation carried forward. (NCT00965562)
Timeframe: over duration of treatment, 4 menstrual cycles averaging 4 months after baseline visit

Interventionproportion of participants (Number)
I: Fluoxetine0.80
II: Calcium0.42
III: Placebo0.42

[back to top]

Proportion of Participants With DRSP Visit-wise Response to Treatment (50% Improvement)

Visit-wise response considers participants who remained in the study until Visit 5 and provided data for the visit. DRSP = Daily Record of Severity of Problems, which combines responses to 21 items each with scale: 1=no symptoms, 6=extreme. (NCT00965562)
Timeframe: over duration of treatment from baseline to visit 5, including 4 menstrual cycles averaging 4 months after baseline visit

Interventionproportion of participants (Number)
I: Fluoxetine1.00
II: Calcium0.50
III: Placebo0.33

[back to top]

Proportion of Participants With IDS LOCF Response to Treatment (50% Improvement)

IDS: Inventory of Depressive Symptomatology: measures depressive symptoms during the previous premenstrual phase with high internal consistency: sum of responses to 28 of 30 possible items each scored 0 to 3 points with total scoring (0=least severe, 84=most severe). LOCF: last observation carried forward. (NCT00965562)
Timeframe: over duration of treatment, 4 menstrual cycles averaging 4 months after baseline visit

Interventionproportion of participants (Number)
I: Fluoxetine0.77
II: Calcium0.31
III: Placebo0.31

[back to top]

Proportion of Participants With PMTS LOCF Response to Treatment (50% Improvement)

PMTS: Premenstrual Tension Syndrome (Observer Rating) Scale: a clinician-administered retrospective scale developed for the study of PMS, a sum of responses to 10 items each with 4 points (0=no symptoms, 40=most severe). LOCF: last observation carried forward. (NCT00965562)
Timeframe: over duration of treatment, 4 menstrual cycles averaging 4 months after baseline visit

Interventionproportion of participants (Number)
I: Fluoxetine0.62
II: Calcium0.33
III: Placebo0.16

[back to top]

Proportion of Patients With IDS Visit-wise Response to Treatment (50% Improvement)

"Visit-wise response considers participants who remained in the study until Visit 5 and provided data for the visit.~IDS = Inventory of Depressive Symptomatology: measures depressive symptoms during the previous premenstrual phase with high internal consistency, sum of responses to 28 of 30 possible items each scored 0 to 3 points with total scoring (0=no symptoms, 84=most severe)." (NCT00965562)
Timeframe: over duration of treatment from baseline to visit 5, including 4 menstrual cycles averaging 4 months after baseline visit

Interventionproportion of participants (Number)
I: Fluoxetine1.00
II: Calcium0.36
III: Placebo0.33

[back to top]

Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of LY2216684

The Least Squares (LS) geometric mean Cmax of LY2216684 was determined when LY2216684 was administered alone (Day 3) and when LY2216684 was coadministered with fluoxetine (Day 27). The Day 27-to-Day 3 ratio of the LY2216684 LS geometric mean of Cmax and the associated 90% confidence interval (CI) of the ratio were calculated. (NCT01243957)
Timeframe: Predose and 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose on Days 3 and 27

Interventionnanogram per milliliter (ng/mL) (Least Squares Mean)
LY2216684 aloneLY2216684 + fluoxetine
LY2216684 + Fluoxetine55.590.6

[back to top]

Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of Fluoxetine and Norfluoxetine

The Least Squares (LS) geometric means Cmax of fluoxetine and norfluoxetine were determined when fluoxetine was administered alone (Day 24) and when fluoxetine was coadministered with LY2216684 (Day 27). The Day 27-to-Day 24 ratios of fluoxetine and norfluoxetine LS geometric means of Cmax and the associated 90% confidence interval (CI) of the ratios were calculated. (NCT01243957)
Timeframe: Predose and 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose on Days 24 and 27

Interventionnanogram per milliliter (ng/mL) (Least Squares Mean)
fluoxetine alonefluoxetine + LY2216684norfluoxetine alonenorfluoxetine + LY2216684
LY2216684 + Fluoxetine160160144148

[back to top]

Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-Time Curve Over a 24-Hour Dosing Interval (AUCτ) of LY2216684

The Least Squares (LS) geometric mean AUCτ of LY2216684 was calculated based on the LY2216684 plasma concentration time curve from time 0 hour (hr) to time 24 hr (tau [τ]) when LY2216684 was administered alone (Day 3) and when LY2216684 was coadministered with fluoxetine (Day 27). The Day 27-to-Day 3 ratio of the LY2216684 LS geometric mean of AUCτ and the associated 90% confidence interval (CI) of the ratio were calculated. (NCT01243957)
Timeframe: Predose and 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose on Days 3 and 27

Interventionhour*nanogram per milliliter (h*ng/mL) (Least Squares Mean)
LY2216684 aloneLY2216684 + fluoxetine
LY2216684 + Fluoxetine6771210

[back to top]

Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration Time-Curve Over a 24-Hour Dosing Interval (AUCτ) of Fluoxetine and Norfluoxetine

The Least Squares (LS) geometric means AUCτ of fluoxetine and norfluoxetine were calculated based on the fluoxetine and norfluoxetine plasma concentration time curves from time 0 hour (hr) to time 24 hr (tau [τ]) when fluoxetine was administered alone (Day 24) and when fluoxetine was coadministered with LY22166684 (Day 27). The Day 27-to-Day 24 ratios of fluoxetine and norfluoxetine LS geometric means of AUCτ and the associated 90% confidence interval (CI) of the ratios were calculated. (NCT01243957)
Timeframe: Predose and 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose on Days 24 and 27

Interventionhour*nanogram per milliliter (h*ng/mL) (Least Squares Mean)
fluoxetine alonefluoxetine + LY2216684norfluoxetine alonenorfluoxetine + LY2216684
LY2216684 + Fluoxetine3450350031703280

[back to top]

Pharmacokinetic (PK) Parameter: Time to Maximum Plasma Concentration (Tmax) of LY2216684

Tmax of LY2216684 was determined using the median of paired differences between the 2 treatment groups when LY2216684 was administered alone (Day 3) and when LY2216684 was coadministered with fluoxetine (Day 27). The 90% confidence interval (CI) for the median of differences was calculated. (NCT01243957)
Timeframe: Predose and 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose on Days 3 and 27

Interventionhours (Median)
LY2216684 aloneLY2216684 + fluoxetine
LY2216684 + Fluoxetine3.003.00

[back to top]

Pharmacokinetic (PK) Parameter: Time to Maximum Plasma Concentration (Tmax) of Fluoxetine and Norfluoxetine

Tmax of fluoxetine and norfluoxetine was determined using the median of paired differences between the 2 treatment groups when fluoxetine was administered alone (Day 24) and when fluoxetine was coadministered with LY2216684 (Day 27). The 90% confidence interval (CI) for the median of differences was calculated. (NCT01243957)
Timeframe: Predose and 1, 2, 3, 4, 6, 8, 12, and 24 hours post-dose on Days 24 and 27

Interventionhours (Median)
fluoxetine alonefluoxetine + LY2216684norfluoxetine alonenorfluoxetine + LY2216684
LY2216684 + Fluoxetine6.006.0012.004.00

[back to top]

AUC0-t of Fluoxetine.

Bioequivalence based on Fluoxetine AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration). (NCT01247272)
Timeframe: Blood samples collected over a 25 day period.

Interventionng*h/mL (Mean)
Fluoxetine Hydrochloride (Test) First3625.61
Prozac® Weekly (Reference) First3363.94

[back to top]

AUC0-inf of Fluoxetine.

Bioequivalence based on Fluoxetine AUC0-inf (area under the concentration-time curve from time zero to infinity). (NCT01247272)
Timeframe: Blood samples collected over a 25 day period.

Interventionng*h/mL (Mean)
Fluoxetine Hydrochloride (Test) First3900.75
Prozac® Weekly (Reference) First3645.90

[back to top]

AUC0-inf of Norfluoxetine.

Bioequivalence based on Norfluoxetine AUC0-inf (area under the concentration-time curve from time zero to infinity). (NCT01247272)
Timeframe: Blood samples collected over a 25 day period.

Interventionng*h/mL (Mean)
Fluoxetine Hydrochloride (Test) First12685.67
Prozac® Weekly (Reference) First11986.28

[back to top]

AUC0-t of Norfluoxetine.

Informational comparison of AUC0-t values for the metabolite Norfluoxetine. (NCT01247272)
Timeframe: Blood samples collected over a 25 day period.

Interventionng*h/mL (Mean)
Fluoxetine Hydrochloride (Test) First10996.87
Prozac® Weekly (Reference) First10393.71

[back to top]

Cmax of Fluoxetine.

Bioequivalence based on Fluoxetine Cmax (maximum observed concentration of drug substance in plasma). (NCT01247272)
Timeframe: Blood samples collected over a 25 day period.

Interventionng/mL (Mean)
Fluoxetine Hydrochloride (Test) First64.17
Prozac® Weekly (Reference) First56.61

[back to top]

Cmax of Norfluoxetine.

Informational comparison of Cmax values for the metabolite Norfluoxetine. (NCT01247272)
Timeframe: Blood samples collected over a 25 day period.

Interventionng/mL (Mean)
Fluoxetine Hydrochloride (Test) First34.18
Prozac® Weekly (Reference) First33.00

[back to top]

AUC0-inf of Fluoxetine.

Bioequivalence based on Fluoxetine AUC0-inf (area under the concentration-time curve from time zero to infinity). (NCT01247285)
Timeframe: Blood samples collected over a 25 day period.

Interventionng*h/mL (Mean)
Fluoxetine Hydrochloride (Test)4432.21
Prozac® Weekly (Reference)4398.46

[back to top]

AUC0-inf of Norfluoxetine.

Informational comparison of AUC0-inf values for the metabolite Norfluoxetine. (NCT01247285)
Timeframe: Blood samples collected over a 25 day period.

Interventionng*h/mL (Mean)
Fluoxetine Hydrochloride (Test)13505.84
Prozac® Weekly (Reference)13365.13

[back to top]

AUC0-t of Fluoxetine.

Bioequivalence based on Fluoxetine AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration). (NCT01247285)
Timeframe: Blood samples collected over a 25 day period.

Interventionng*h/mL (Mean)
Fluoxetine Hydrochloride (Test)4148.71
Prozac® Weekly (Reference)4120.11

[back to top]

AUC0-t of Norfluoxetine.

Informational comparison of AUC0-t values for the metabolite Norfluoxetine. (NCT01247285)
Timeframe: Blood samples collected over a 25 day period.

Interventionng*h/mL (Mean)
Fluoxetine Hydrochloride (Test)114575.21
Prozac® Weekly (Reference)10849.08

[back to top]

Cmax of Fluoxetine.

Bioequivalence based on Fluoxetine Cmax (maximum observed concentration of drug substance in plasma). (NCT01247285)
Timeframe: Blood samples collected over a 25 day period.

Interventionng/mL (Mean)
Fluoxetine Hydrochloride (Test)75.32
Prozac® Weekly (Reference)69.86

[back to top]

Cmax of Norfluoxetine.

Informational comparison of Cmax values for the metabolite Norfluoxetine. (NCT01247285)
Timeframe: Blood samples collected over a 25 day period.

Interventionng/mL (Mean)
Fluoxetine Hydrochloride (Test)35.11
Prozac® Weekly (Reference)33.47

[back to top]

Change in Clinical Global Impression of Severity (CGI-S) for Fatigue Score

The CGI-S is a clinician-rated scale that rates the severity of the patient's current state of fatigue based on the Investigator's clinical opinion with regard to the patient population with Major Depressive Disorder (MDD). Patient were rated on a scale from 1 to 7, with 1 indicating a normal state and 7 indicating that the patient was among the most extremely fatigued (NCT01254305)
Timeframe: From Baseline to Week 8

Interventionunits on a scale (Mean)
Placebo-1.5
Levomilnacipran ER-1.8
SSRI-1.9

[back to top]

Change in Cognitive and Physical Functioning Questionnaire (CPFQ), Last Observation Carried Forward

The Cognitive and Physical Functioning Questionnaire is a patient-rated, 7-item scale used to measure cognitive and executive dysfunction in mood and anxiety disorders. The CPFQ is sensitive to change with treatment and displays convergent validity by significant correlations with other measures of sleepiness, fatigue, apathy, and neuropsychological functioning. Patients are rated on a scale from 1 to 6 for seven common complaints of depressed patients reporting fatigue or cognitive/executive problems-with 1 indicating greater than normal functioning, 2 indicating normal functioning, and 3 to 6 indicating degrees of impaired functioning. The CPFQ ranges from the best possible score of 7 (greater than normal functioning) to the worst possible score of 42 (totally absent). (NCT01254305)
Timeframe: From Baseline to Week 8

Interventionunits on a scale (Mean)
Placebo-5.9
Levomilnacipran ER-7.0
SSRI-6.4

[back to top]

Change in Patient Global Impressions of Severity (PGI-S) for Fatigue Score

The PGI-S is a clinician-rated scale that rates was used to rate the severity of the patient's current state of overall fatigue. Patients were rated on a scale from 1 to 7, with 1 indicating no symptoms of fatigue and 7 indicating extreme fatigue. (NCT01254305)
Timeframe: From Baseline to Week 8

Interventionunits on a scale (Mean)
Placebo-1.4
Levomilnacipran ER-1.7
SSRI-1.7

[back to top]

Change From Baseline in Mean Clinical Global Impression - Improvement (CGI-I) Score

The efficacy of trial treatment was rated for each participant using the CGI-I. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. All responses were compared to the participant's condition at screening. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse and 7 = very much worse. (NCT01360866)
Timeframe: From screening to week 52/early termination

Interventionunits on a scale (Mean)
Prior Placebo2.60
Prior Brexpiprazole2.63
Prior ADT2.63
Prior Seroquel2.40

[back to top]

Change From Baseline in the Inventory of Depressive Symptomatology - Self Report (IDS-SR) Total Score

"The IDS-SR was a 30-item self-report measure used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of MDD. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the best rating and 3 being the worst rating. The IDS-SR Total Score is the sum of ratings of 28 item scores. The possible IDS-SR Total Score ranges from 0 (best) to 84 (worst).~Under item 9, two sub-items 9A and 9B exist, with possible scores of 1, 2 or 3 for item 9A, and 0 or 1 for item 9B. The scores for these two sub-items are not included in the calculation of the total score. Item 11 or item 12 should be completed but not both, and similarly, item 13 or item 14 should be completed but not both. If the number of items recorded is at least 23 and at most 27, the IDS-SR Total Score will be the mean of the recorded items multiplied by 28 and then rounded to the first decimal place." (NCT01360866)
Timeframe: From screening to week 52/early termination

Interventionunits on a scale (Mean)
Prior Placebo-5.25
Prior Brexpiprazole-4.76
Prior ADT-3.94
Prior Seroquel-7.44

[back to top]

Summary of Mean Change From Baseline in Sheehan Disability Scale (SDS) Mean Score

"The SDS was a self-rated instrument used to measure the effect of the participant's symptoms on regular life responsibilities. The SDS was a visual analogue scale that used spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the 3 domains with scores from 0 = not at all, to 10 = extremely.~Scores of 5 and above were associated with significant functional impairment." (NCT01360866)
Timeframe: From screening to week 52/early termination

Interventionunits on a scale (Mean)
Prior Placebo-0.80
Prior Brexpiprazole-0.70
Prior ADT-0.40
Prior Seroquel-1.00

[back to top]

Adverse Events (AEs) - All Participants

To assess the frequency and severity of AEs as the variables of safety and tolerability of brexpiprazole. (NCT01360866)
Timeframe: From screening to week 52/early termination

,,,
InterventionParticipants (Count of Participants)
Participants with adverse eventsParticipants with treatment emergent AE (TEAE)Participants with serious TEAEParticipants with severe TEAEPartcipants discontinued due to AEs
Prior ADT116511633399134
Prior Brexpiprazole511510236458
Prior Placebo400399144855
Prior Seroquel5151146

[back to top]

Mean Change From Baseline in Clinical Global Impression - Severity (CGI-S) of Illness Score

"The severity of illness for each participant was rated using the CGI-S . On the basis of the investigator answer to the question: Considering your total clinical experience with this particular population, how mentally ill was the participant at that time? Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants." (NCT01360866)
Timeframe: From screening to week 52/early termination

Interventionunits on a scale (Mean)
Prior Placebo-0.77
Prior Brexpiprazole-0.63
Prior ADT-0.48
Prior Seroquel-0.93

[back to top]

AUC of Dextromethorphan, Midazolam and Omeprazole in the Presence of Fluoxetine

Our secondary outcome measure will be the interaction between fluoxetine and each CYP evaluated in the cocktail. A 50% increase in the AUC of caffeine (CYP1A2), dextromethorphan (CYP2D6), omeprazole (CYP2C19) or midazolam (CYP3A4) between treatment and control days is considered clinically significant. The interaction of fluoxetine with caffeine (CYP1A2) will be considered as a negative control for the study. These AUCs will be measured on study day 1 (control day) and study day 18 (NCT01361217)
Timeframe: The secondary outcome will be assessed within 2 months after the last subject is enrolled or at 2 years from the start of study enrollment, which ever is sooner.

Interventionnmol*hr/L (Mean)
caffeine control AUCCaffeine treatment AUCdextromethophan control AUCDextromethorphan treatment AUCOmeprazole control AUComeprazole treatment AUCmidazolam control AUCmidazolam treatment AUC
Midazolam, Caffeine, Omeprazole, Caffeine AUC After Fluoxetine4300043000681850120085003024

[back to top]

Lovastatin AUC in the Presence of Fluoxetine

Our primary outcome measure will be the interaction of fluoxetine with CYP3A4. A 50% increase in the AUC for lovastatin plus hydroxy-lovastatin acid (the active form of lovastatin) between treatment day 14 (study day 20) and control days (study day 2) is considered clinically significant. (NCT01361217)
Timeframe: The primary outcome will be assessed within 2 months after the last subject is enrolled or at 2 years from the start of study enrollment, which ever is sooner.

Interventionnmol*hr/L (Mean)
Lovastatin AUC After Fluoxetine Dosing170
Lovastatin Before Fluoxetine180

[back to top]

Change From Baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score

Clinician-rated interview-based scale (with both child and parent or guardian) to assess 17 distinct symptom areas to derive an index of depression severity. Discrepancies between informants' responses were resolved by using most impaired rating given by valid informant. Rated on a 7-point scale; range from 1 (no impairment) to 7 (indicates greater impairment). Total score calculated as sum of the 17 items (range 1 to 119); higher score indicates greater impairment. Adjusted mean presented. (NCT01372150)
Timeframe: Baseline and Week 8

InterventionScore on a Scale (Mean)
Placebo-23.07
Fluoxetine-24.79
DVS SR-22.61

[back to top]

Change From Baseline to Week 8 in the Clinical Global Impression of Severity (CGI-S) Score

A 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal - not ill at all) to 7 (among the most extremely ill patients). Higher score = more affected. Change: score at observation minus score at baseline. Adjusted mean presented. (NCT01372150)
Timeframe: Baseline and Week 8

InterventionScore on a Scale (Mean)
Placebo-1.71
Fluoxetine-1.88
DVS SR-1.70

[back to top]

Percentage of Participants by Clinical Global Impression Improvement (CGI-I) Score at Weeks 1, 2, 3, 4, 6, and 8

A 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. (NCT01372150)
Timeframe: Baseline and Weeks 1, 2, 3, 4, 6, and 8

,,
InterventionPercentage of Participants (Number)
Week 1, Very Much Improved (n=102, 101, 111)Week 1, Much Improved (n=102, 101, 111)Week 1, Minimally Improved (n=102, 101, 111)Week 1, No Change (n=102, 101, 111)Week 1, Minimally Worse (n=102, 101, 111)Week 1, Much Worse (n=102, 101, 111)Week 1, Very Much Worse (n=102, 101, 111)Week 2, Very Much Improved (n=103, 105, 110)Week 2, Much Improved (n=103, 105, 110)Week 2, Minimally Improved (n=103, 105, 110)Week 2, No Change (n=103, 105, 110)Week 2, Minimally Worse (n=103, 105, 110)Week 2, Much Worse (n=103, 105, 110)Week 2, Very Much Worse (n=103, 105, 110)Week 3, Very Much Improved (n=105, 102, 107)Week 3, Much Improved (n=105, 102, 107)Week 3, Minimally Improved (n=105, 102, 107)Week 3, No Change (n=105, 102, 107)Week 3, Minimally Worse (n=105, 102, 107)Week 3, Much Worse (n=105, 102, 107)Week 3, Very Much Worse (n=105, 102, 107)Week 4, Very Much Improved (n=101, 101, 100)Week 4, Much Improved (n=101, 101, 100)Week 4, Minimally Improved (n=101, 101, 100)Week 4, No Change (n=101, 101, 100)Week 4, Minimally Worse (n=101, 101, 100)Week 4, Much Worse (n=101, 101, 100)Week 4, Very Much Worse (n=101, 101, 100)Week 6, Very Much Improved (n=100, 100, 102)Week 6, Much Improved (n=100, 100, 102)Week 6, Minimally Improved (n=100, 100, 102)Week 6, No Change (n=100, 100, 102)Week 6, Minimally Worse (n=100, 100, 102)Week 6, Much Worse (n=100, 100, 102)Week 6, Very Much Worse (n=100, 100, 102)Week 8, Very Much Improved (n=99, 101, 99)Week 8, Much Improved (n=99, 101, 99)Week 8, Minimally Improved (n=99, 101, 99)Week 8, No Change (n=99, 101, 99)Week 8, Minimally Worse (n=99, 101, 99)Week 8, Much Worse (n=99, 101, 99)Week 8, Very Much Worse (n=99, 101, 99)
DVS SR2.76.343.245.91.8003.631.844.519.10.9007.542.138.311.20.90020.044.025.010.01.00023.545.120.69.81.00023.245.521.29.11.000
Fluoxetine3.011.935.647.52.0006.726.742.922.91.00014.736.336.311.81.00013.947.527.79.91.00026.045.024.05.000030.747.516.84.01.000
Placebo1.07.846.143.12.0003.925.238.830.11.90013.329.541.015.21.00015.838.629.713.92.00018.041.034.06.001.0027.335.432.34.01.000

[back to top]

Percentage of Participants With a CGI-I Response Defined as a Score of 'Very Much Improved' or 'Much Improved'

A 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. (NCT01372150)
Timeframe: Weeks 1, 2, 3, 4, 6, and 8

,,
InterventionPercentage of Participants (Number)
Week 1 (n=102, 101, 111)Week 2 (n=103, 105, 110)Week 3 (n=105, 102, 107)Week 4 (n=101, 101, 100)Week 6 (n=100, 100, 102)Week 8 (n=99, 101, 99)
DVS SR9.0135.4549.5364.0068.6368.69
Fluoxetine14.8533.3350.9861.3971.0078.22
Placebo8.8229.1342.8654.4659.0062.63

[back to top]

Number of Participants Who Experienced Adverse Events, Serious Adverse Events and Death

"In this analysis patients with all (serious and non-serious) adverse events, and death were reported.~See Safety Section." (NCT01436643)
Timeframe: 21 weeks

,,,
InterventionParticipants (Number)
Any Adverse EventDeathSerious Adverse Event
Citalopram and Fingolimod1201
Fingolimod1501
Fluoxetine and Fingolimod1100
Venlafaxine and Fingolimod1201

[back to top]

Hamilton Rating Scale for Depression-17 Item Minus Sleep Items

Total score on a clinician-rated measure of depressive symptoms, minus 3 sleep items Total score range: 0-46. Higher scores represent more severe depression. (NCT01545843)
Timeframe: Post-treatment (8 weeks)

Interventionunits on a scale (Mean)
No Sleep Deprivation6.1
Late Bedtime Sleep Deprivation8.1
Early Risetime Sleep Deprivation6.3

[back to top]

Quick Inventory of Depressive Symptoms (QIDS)

Patient-reported depression symptom severity at post-treatment, total score. Total scores range from 0 to 27. Higher scores represent more severe depression. (NCT01545843)
Timeframe: Post-treatment (8 weeks)

Interventionunits on a scale (Mean)
No Sleep Deprivation5.3
Late Bedtime Sleep Deprivation6.9
Early Risetime Sleep Deprivation6.7

[back to top]

Change in EEG Sleep Measures I: Total Sleep Time

Measurement of EEG activity during sleep using polysomnography: Total Sleep Time is the length of time from sleep onset to final wake up minus any wakefulness during the night. It reflects the total amount of time asleep during the night. (NCT01545843)
Timeframe: Baseline, 2 weeks, 8 weeks

,,
Interventionminutes (Mean)
BaselineWeek 2Week 8
Early Risetime Sleep Deprivation444.040332.909433.333
Late Bedtime Sleep Deprivation439.208337.75428.264
No Sleep Deprivation430.132435.382439.6

[back to top]

Change in EEG Sleep Measures II (Sleep Efficiency)

Measurement of EEG activity during sleep using polysomnography: Sleep efficiency [(total sleep time/time in bed)*100] (NCT01545843)
Timeframe: Baseline, 2 weeks, 8 weeks

,,
Interventionpercent of sleep time (Mean)
BaselineWeek 2Week 8
Early Risetime Sleep Deprivation92.824892.908290.3838
Late Bedtime Sleep Deprivation91.682993.332288.9224
No Sleep Deprivation89.700590.782491.6153

[back to top]

Change in Neurologic Functioning: Reaction Time

Reaction Time is measured using a modified Go/No-go test of inhibitory control (NCT01545843)
Timeframe: 0, 2, 8 weeks

,,
Interventionmilliseconds (Mean)
Week 0 (Baseline)Week 2Week 8
Early Risetime Sleep Deprivation470.2942472.7244500.1197
Late Bedtime Sleep Deprivation528.3513519.8196557.1635
No Sleep Deprivation499.1545493.2579483.7349

[back to top]

Change in Neuropsychological Functioning: Memory

Change in different aspects of thinking (e.g., memory, attention, executive functioning) (NCT01545843)
Timeframe: Baseline, 2 weeks, 8 weeks

,,
Interventionwords (Mean)
BaselineWeek 2Week 8
Early Risetime Sleep Deprivation76.09577.40081.200
Late Bedtime Sleep Deprivation74.93881.52979.733
No Sleep Deprivation77.11876.64773.923

[back to top]

Neurological Function (Emotional Perception)

Emotional Perception is measured based on the percent of faces whose emotions are correctly identified using the Facial Emotion Perception Test (FEPT) (NCT01545843)
Timeframe: 0 weeks, 2 weeks, 8 weeks

,,
Interventionpercentage of emotions accurately ID'ed (Mean)
0 weeks (Baseline)Week 2Week 8
Early Risetime Sleep Deprivation88.8388.7587.74
Late Bedtime Sleep Deprivation86.2488.1589.15
No Sleep Deprivation83.5483.0885.95

[back to top]

Pittsburgh Sleep Quality Index

Self-report measure of sleep quality. The Pittsburgh Sleep Quality Index is a validated scale which measures self-reported sleep quality based on a wide variety of questions (duration, quality, disturbances, medication, etc.) and converts them to a scale which ranges from 0 to 21 where 6 or higher denotes poor sleep quality. (NCT01545843)
Timeframe: Baseline, 2 weeks and 8 weeks post-treatment

,,
Interventionunits on a scale (Mean)
BaselineWeek 2Week 8
Early Risetime Sleep Deprivation6.855.506.33
Late Bedtime Sleep Deprivation8.676.076.23
No Sleep Deprivation6.005.234.86

[back to top]

Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Single Dose (SD) of LY110140

Study drug was administered as LY110140 (fluoxetine hydrochloride) and its active portion, fluoxetine, was metabolized to norfluoxetine in the body. The Cmax of plasma total fluoxetine and norfluoxetine during the SD period is reported. (NCT01569126)
Timeframe: Predose up to Day 43

,,
Interventionnanograms per milliliter (ng/mL) (Geometric Mean)
FluoxetineNorfluoxetine
20 mg LY110140 (SD)15.513.0
40 mg LY110140 (SD)38.722.8
5 mg LY110140 (SD)NA2.44

[back to top]

Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Multiple Doses (MD) of LY110140

Study drug was administered as LY110140 (fluoxetine hydrochloride) and its active portion, fluoxetine, was metabolized to norfluoxetine in the body. The Cmax of plasma total fluoxetine and norfluoxetine on Day 1 and Day 28 of the MD period is reported. (NCT01569126)
Timeframe: Days 1 and 28

,
Interventionnanograms per milliliter (ng/mL) (Geometric Mean)
Day 1, FluoxetineDay 28, FluoxetineDay 1, NorfluoxetineDay 28, Norfluoxetine
20 mg LY110140 (MD)16.992.910.6136
40 mg LY110140 (MD)39.928418.3222

[back to top]

Pharmacokinetics: Area Under the Concentration-Time Curve From Zero to Last Time Point [AUC(0-tlast)] of Single Dose (SD) of LY110140

Study drug was administered as LY110140 (fluoxetine hydrochloride) and its active portion, fluoxetine, was metabolized to norfluoxetine in the body. The AUC(0-tlast) of plasma total fluoxetine and norfluoxetine during the SD period is reported. (NCT01569126)
Timeframe: Predose up to Day 43

,,
Interventionnanograms*hour per milliliter (ng*hr/mL) (Geometric Mean)
FluoxetineNorfluoxetine
20 mg LY110140 (SD)3713000
40 mg LY110140 (SD)13605850
5 mg LY110140 (SD)NA195

[back to top]

Pharmacokinetics: Area Under the Concentration-Time Curve From Zero to Infinity [AUC(0-infinity)] of Single Dose (SD) of LY110140

Study drug was administered as LY110140 (fluoxetine hydrochloride) and its active portion, fluoxetine, was metabolized to norfluoxetine in the body. The AUC(0-infinity) of plasma total fluoxetine and norfluoxetine during the SD period is reported. (NCT01569126)
Timeframe: Predose up to Day 43

,,
Interventionnanograms*hour per milliliter (ng*hr/mL) (Geometric Mean)
FluoxetineNorfluoxetine
20 mg LY110140 (SD)4243360
40 mg LY110140 (SD)14306360
5 mg LY110140 (SD)NA407

[back to top]

Pharmacokinetics: Area Under the Concentration-Time Curve From Zero to 24 Hours [AUC(0-24)] of Multiple Doses (MD) of LY110140

Study drug was administered as LY110140 (fluoxetine hydrochloride) and its active portion, fluoxetine, was metabolized to norfluoxetine in the body. The AUC(0-24) of plasma total fluoxetine and norfluoxetine on Day 1 of the MD period is reported. (NCT01569126)
Timeframe: Day 1

,
Interventionnanograms*hour per milliliter (ng*hr/mL) (Geometric Mean)
FluoxetineNorfluoxetine
20 mg LY110140 (MD)228199
40 mg LY110140 (MD)574337

[back to top]

Pharmacokinetics: Area Under the Concentration-Time Curve for Dosing Interval (Tau) at Steady State [AUC(Tau,Steady State)] of Multiple Doses (MD) of LY110140

Study drug was administered as LY110140 (fluoxetine hydrochloride) and its active portion, fluoxetine, was metabolized to norfluoxetine in the body. The AUC(tau,steady state) of plasma total fluoxetine and norfluoxetine during the MD period is reported. (NCT01569126)
Timeframe: Predose up to Day 28

,
Interventionnanograms*hour per milliliter (ng*hr/mL) (Geometric Mean)
FluoxetineNorfluoxetine
20 mg LY110140 (MD)18103010
40 mg LY110140 (MD)59104910

[back to top] [back to top] [back to top]

Change From Baseline in Bazett's and Fridericia's Corrected QT (QTcB and QTcF) Intervals

The number of participants with a maximum increase from baseline in 12-lead electrocardiogram (ECG) QTcB and QTcF intervals >30 milliseconds (ms) and >60 ms for the single-dose (SD) and multiple-dose (MD) periods is reported. (NCT01569126)
Timeframe: Baseline, up to Day 43 (SD period) and Baseline, up to Day 70 (MD period)

,,,,,
Interventionparticipants (Number)
QTcB >30 msQTcF >30 msQTcB >60 msQTcF >60 ms
20 mg LY110140 (MD)3100
20 mg LY110140 (SD)2000
40 mg LY110140 (MD)6400
40 mg LY110140 (SD)2000
5 mg LY110140 (SD)1100
Placebo (MD)2000

[back to top]

Responder Rates at 6 Weeks.

17-item Hamilton Rating Scale for Depression is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in 17-item Hamilton Scale for Depression was assessed for this study. It ranges from 0 (no depression) up to 52 (most severe depression). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). Responder rate definition: a decrease of 50% or more from baseline score using 17-item Hamilton Rating Scale for Depression after six weeks treatment. (NCT01635218)
Timeframe: 6 weeks

Interventionparticipants with a decrease >50% in HS (Number)
Individualized Homeopathic Treatment24
Fluoxetine19
Placebo5

[back to top]

Change From Baseline in Beck Depression Inventory at 6 Weeks.

Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory that assess severity of depression. A total score range was assessed at baseline and after six weeks of treatment. A score 0 (without depression) up to 63 (most severe depression). For this study the change was calculated as the later time point (total score in BDI at 6 weeks) minus the earlier time point (total score in BDI at baseline). A score 0 - 8 is considered normal, 9 - 18 (mild to moderate depression), 19 - 28 (moderate to severe depression), > 29 (severe depression). (NCT01635218)
Timeframe: Baseline and 6 weeks

InterventionUnits in Beck Depression Inventory (Mean)
Individualized Homeopathic Treatment12
Fluoxetine14.2
Placebo15.5

[back to top]

Change From Baseline in 17-item Hamilton Rating Scale for Depression at 6 Weeks.

17-item Hamilton Rating Scale for Depression (HRSD) is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in HRSD was assessed at baseline and after six weeks of treatment. For this study the change was calculated as the later time point (total score in 17- HRSD at 6 weeks) minus the earlier time point (total score at baseline). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). (NCT01635218)
Timeframe: Baseline and 6 weeks

InterventionUnits in Hamilton Scale (Mean)
Individualized Homeopathic Treatment9.9
Fluoxetine11.7
Placebo15

[back to top]

Remission Rates at 6 Weeks

17-item Hamilton Rating Scale for Depression is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in 17-item Hamilton Scale for Depression was assessed for this study. It ranges from 0 (no depression) up to 52 (most severe depression). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). Remission rate definition: 17-item Hamilton Rating Scale for Depression score < 7 points after 6 weeks of treatment. (NCT01635218)
Timeframe: 6 weeks

Interventionparticipants with a score of < 7 in HS (Number)
Individualized Homeopathic Treatment7
Fluoxetine7
Placebo2

[back to top]

Change From Baseline in Greene´s Scale at 6 Weeks.

Greene Climacteric Scale (GS) is intended to be a standard measure of core climacteric symptoms. For this study a total range was assessed at baseline and after six weeks of treatment. A total score 0 (without climacteric symptoms) up to 63 (most severe climacteric symptoms). The change was calculated as the later time point (total score in GS at 6 weeks) minus the earlier time point (total score at baseline).The scale measures four separate sub-scales (anxiety, depression, somatic symptoms and sexual function). The score of the four sub-scales was summed. A total score of 0 -10 is considered without symptoms, 11 - 29 (mild symptoms), 30 - 49 (moderate symptoms) and > 50 (severe symptoms). (NCT01635218)
Timeframe: Baseline and 6 weeks

InterventionUnits in Green Scale (Mean)
Individualized Homeopathic Treatment18.1
Fluoxetine23.1
Placebo26.8

[back to top]

Mean Change From Baseline to 8 Week Endpoint in the Barnes Akathisia Scale (BAS)

BAS is used to rate observable, restless movements of drug induced akathisia and the subjective awareness of restlessness and any distress associated with the akathisia. The BAS consists of the following 3 items: an objective assessment of akathisia symptoms; a subjective assessment of the patient's awareness of inner restlessness; and a global clinical assessment of akathisia. The first two items are rated on a 4-point scale ranging from 0 (no abnormal movements or the absence of inner restlessness) to 3 (severe akathisia or the awareness of intense compulsion to move most of the time). The last item, the global clinical assessment of akathisia, is rated on a 5-point scale, ranging from 0 (no evidence of akathisia) to 5 (severe akathisia). Total BAS score ranges from 0 to 14 with a higher score representing worse results. (NCT01687478)
Timeframe: Baseline, 8 Weeks

Interventionunits on a scale (Mean)
Olanzapine + Fluoxetine-0.01
Placebo + Fluoxetine-0.04

[back to top]

Mean Change From Baseline to 8 Week Endpoint in the Abnormal Involuntary Movement Scale (AIMS)

AIMS is a 12-item scale. Items 1 to 8 are rated on a 5-point scale ranging from 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Item 9 assesses the participant's incapacitation due to abnormal movements, and item 10 assesses the participant's awareness of the abnormal movements and associated distress. Items 9 and 10 are rated on 5-point scales ranging from 0 (none or no awareness) to 4 (severe or aware, severe distress). Items 11 and 12 are yes/no questions regarding the dental status of the participant. The total score is the sum of the scores for the 12 items and the possible total score ranges from 0 to 42. A higher total score is indicative of more severe dyskinetic movements. (NCT01687478)
Timeframe: Baseline, 8 Weeks

Interventionunits on a scale (Mean)
Olanzapine + Fluoxetine-0.16
Placebo + Fluoxetine-0.31

[back to top]

Mean Change From Baseline to 8 Week Endpoint in Montgomery-Äsberg Depression Rating Scale (MADRS)

The MADRS total score is the sum of the 10 items; therefore the possible MADRS total score ranges from 0 to 60. A higher MADRS total score indicates a greater severity of depressive symptoms. Least square means (LSM) change from baseline, standard error was derived using mixed model repeated measures (MMRM) methodology with factors for treatment, Pooled Investigator, Visit, (Baseline + Treatment)*Visit. (NCT01687478)
Timeframe: Baseline, 8 Weeks

InterventionUnits on a scale (Least Squares Mean)
Olanzapine + Fluoxetine-15.92
Placebo + Fluoxetine-14.30

[back to top]

Percentage of Participants Who Achieve a Response Based on a ≥50% Reduction From Baseline in MADRS Total Score

The MADRS total score is the sum of the 10 items; therefore the possible MADRS total score ranges from 0 to 60. A higher MADRS total score indicates a greater severity of depressive symptoms. (NCT01687478)
Timeframe: Baseline,8 Weeks

InterventionPercent of participants (Number)
Olanzapine + Fluoxetine65.5
Placebo + Fluoxetine61.2

[back to top]

Mean Change From Baseline to 8 Week Endpoint in the Simpson-Angus Scale (SAS)

SAS scale consists of 10 items including 7 items that address bradykinesia-rigidity and additional single items for tremor, glabellar tap,and salivation. Each item represents a specific physical condition and is rated on a 5-point category rating scale ranging from 0 (complete absence of the condition) to 4 (the condition is present to an extreme degree).The total score is obtained by adding the scores for the 10 individual items making the maximum possible score is 40. Higher scores are indicative of more severe Parkinsonian-type symptoms. (NCT01687478)
Timeframe: Baseline, 8 Weeks

Interventionunits on a scale (Mean)
Olanzapine + Fluoxetine0.03
Placebo + Fluoxetine-0.14

[back to top]

Mean Change From Baseline to 8 Week Endpoint in Clinical Global Impressions-Severity of Depression (CGI-S) Scale

CGI-S scale measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). The LS mean (LSM) change from baseline, standard error was derived using MMRM methodology with factors for treatment , Pooled Investigator , Visit , (Baseline + Treatment)*Visit. (NCT01687478)
Timeframe: Baseline, 8 Weeks

InterventionUnits on a scale (Least Squares Mean)
Olanzapine + Fluoxetine-1.43
Placebo + Fluoxetine-1.63

[back to top]

Mean Change From Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36)

SF-36, version 2 is a generic participant-rated questionnaire and consists of 36 questions covering the following 8 health domains (subscales): general health, role limitations because of physical problems, role limitations due to emotional problems, physical functioning, bodily pain, mental health, social functioning, and vitality. Each subscale is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. Two summary scores, the physical component summary (PCS) and the mental component summary (MCS) were constructed based on the eight SF-36 subscales. Both PCS and MCS range from 0-100 with higher scores indicating better health or functioning. (NCT01687478)
Timeframe: Baseline, 8 Weeks

,
Interventionunits on a scale (Mean)
Physical FunctioningRole-PhysicalBodily PainGeneral HealthVitalitySocial FunctioningRole-EmotionalMental HealthMental Component ScorePhysical Component Score
Olanzapine + Fluoxetine2.203.996.815.827.436.136.618.988.872.87
Placebo + Fluoxetine0.703.930.022.845.044.566.718.438.73-0.65

[back to top]

Mean Change From Baseline to 8 Week Endpoint in the Sheehan Disability Scale (SDS)

SDS consists of 3 items (work/school, social life/leisure activities, and family life/home responsibilities). Total scores range from 0 to 30 with higher values indicating greater disruption. Individual Item scores range from 0 to 10 with higher values indicating greater disruption. (NCT01687478)
Timeframe: Baseline, 8 Weeks

,
InterventionUnits on a scale (Mean)
Work/School (n=68,65)Social Life (n=79,79)Family Life (n=79,78)SDS Total Score (68,64)
Olanzapine + Fluoxetine-1.34-1.70-1.63-4.57
Placebo + Fluoxetine-1.55-1.49-1.53-4.41

[back to top]

Percentage of Participants Who Achieve Remission Based on MADRS Total Score ≤10 at 8 Weeks

The MADRS consists of 10 items with each item rated on a scale ranging from 0 to 6. Fixed descriptors appear along the scale for each item at points 0, 2, 4, and 6, to standardize the gradation of response along the scale. The MADRS total score is the sum of the 10 items; therefore the possible MADRS total score ranges from 0 to 60. A higher MADRS total score indicates a greater severity of depressive symptoms. (NCT01687478)
Timeframe: Baseline, 8 Weeks

InterventionPercent of participants (Number)
Olanzapine + Fluoxetine37.9
Placebo + Fluoxetine38.8

[back to top]

ADHD-IV Rating Scale

A dimensional rating of ADHD symptoms, with scores ranging from 0 - 54, and higher scores indicating greater symptom severity. (NCT01714310)
Timeframe: Baseline through week 12.

Interventionunits on a scale (Least Squares Mean)
BaselineWeek 4
Open Lisdexamfetamine34.2016.59

[back to top]

ADHD-IV Rating Scale

A dimensional rating of ADHD symptoms, with scores ranging from 0 - 54, and higher scores indicating greater symptom severity. (NCT01714310)
Timeframe: Baseline through week 12.

,
Interventionunits on a scale (Least Squares Mean)
BaselineWeek 4Week 12
Fluoxetine34.5014.9216.29
Placebo34.3118.6411.93

[back to top]

Affective Reactivity Index - Parent Report

A parent completed dimensional measure of emotional reactivity, with scores ranging from 0-12, and higher scores indicating greater severity. (NCT01714310)
Timeframe: Baseline through week 12.

Interventionunits on a scale (Least Squares Mean)
BaselineWeek 4
Open Lisdexamfetamine9.296.87

[back to top]

Affective Reactivity Index - Parent Report

A parent completed dimensional measure of emotional reactivity, with scores ranging from 0-12, and higher scores indicating greater severity. (NCT01714310)
Timeframe: Baseline through week 12.

,
Interventionunits on a scale (Least Squares Mean)
BaselineWeek 4Week 5Week 6Week 7Week 8Week 10Week 12
Fluoxetine10.007.586.586.426.696.496.746.39
Placebo8.577.716.215.326.495.624.895.30

[back to top]

Clinical Global Impression-Severity-Severe Mood Dysregulation

A dimensional clinician rating of overall SMD related impairment, modified by the National Institute of Mental Health to assess specific domains pertinent to Severe Mood Dysregulation. Minimum score = 1. Maximum score = 7. Higher scores means greater impairment. (NCT01714310)
Timeframe: Baseline through week 12.

Interventionunits on a scale (Least Squares Mean)
BaselineWeek 4
Open Lisdexamfetamine4.304.31

[back to top]

Clinical Global Impression-Severity-Severe Mood Dysregulation

A dimensional clinician rating of overall SMD related impairment, modified by the National Institute of Mental Health to assess specific domains pertinent to Severe Mood Dysregulation. Minimum score = 1. Maximum score = 7. Higher scores means greater impairment. (NCT01714310)
Timeframe: Baseline through week 12.

,
Interventionunits on a scale (Least Squares Mean)
BaselineWeek 4Week 5Week 6Week 7Week 8Week 10Week 12
Fluoxetine4.914.424.153.673.613.423.453.51
Placebo3.624.573.513.903.593.373.113.30

[back to top]

Conners Global Index Emotional Lability Subscale - Parent Report

A sub scale of the Conners Global Index, with scores ranging from 0 - 12, with higher scores indicating more impairment. (NCT01714310)
Timeframe: Baseline to week 3.

Interventionunits on a scale (Least Squares Mean)
BaselineWeek 1Week 2Week 3
Open Lisdexamfetamine8.815.906.335.45

[back to top]

Conners Global Index Restless-Impulsive Subscale Parent Report

A dimensional parent report measure of restless-impulsive symptoms, with scores ranging from 0 to 21, and higher scores indicating greater impairment. (NCT01714310)
Timeframe: Baseline through week 3.

Interventionunits on a scale (Least Squares Mean)
BaselineWeek 1Week 2Week 3
Open Lisdexamfetamine15.919.5510.608.60

[back to top]

Conners Parent Global Index

Parent completed dimensional measure of ADHD symptoms, with score range from 0 - 30 and higher scores indicating more severe symptoms. (NCT01714310)
Timeframe: Baseline through week 3.

Interventionunits on a scale (Least Squares Mean)
BaselineWeek 1Week 2Week 3
Open Lisdexamfetamine15.919.5410.608.60

[back to top]

Conners Teacher Global Index

Teacher completed dimensional measure of ADHD symptoms, with scores ranging from 0 - 30, and higher scores indicating more severe impairment. (NCT01714310)
Timeframe: Baseline through week 3.

Interventionunits on a scale (Least Squares Mean)
BaselineWeek 1Week 2Week 3
Open Lisdexamfetamine18.1313.2110.188.31

[back to top]

Diastolic Blood Pressure

Diastolic Blood pressure measured in mmHG. (NCT01714310)
Timeframe: Baseline through week 12.

,
Interventionmm Hg. (Least Squares Mean)
BaselineWeek 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 10Week 12
Fluoxetine68.8671.3366.0068.7471.1771.1769.5868.1468.0670.8177.11
Placebo66.4069.5066.7962.8266.2165.1770.6170.6468.4067.0670.05

[back to top]

Diastolic Blood Pressure

Diastolic Blood pressure measured in mmHG. (NCT01714310)
Timeframe: Baseline through week 12.

Interventionmm Hg. (Least Squares Mean)
BaselineWeek 1Week 2Week 3Week 4
Open Lisdexamfetamine67.3969.1566.6367.2169.31

[back to top]

Height

A dimensional measure assessed in cms. (NCT01714310)
Timeframe: Baseline through week 12.

,
Interventioncm. (Least Squares Mean)
BaselineWeek 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 10Week 12
Fluoxetine140.25140.05139.95140.26140.56140.11140.21140.55140.81140.83140.98
Placebo144.63144.76144.81144.88144.54144.82145.44145.14144.98145.30145.60

[back to top]

Height

A dimensional measure assessed in cms. (NCT01714310)
Timeframe: Baseline through week 12.

Interventioncm. (Least Squares Mean)
BaselineWeek 1Week 2Week 3Week 4
Open Lisdexamfetamine142.37142.35142.43142.59142.59

[back to top]

Pulse

Heart rate in beats per minute. (NCT01714310)
Timeframe: Baseline through week 12.

,
Interventionbeats per minute. (Least Squares Mean)
BaselineWeek 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 10Week 12
Fluoxetine82.2895.0888.2596.3293.0894.1687.3391.9487.1795.8392.75
Placebo84.6485.2181.6485.7983.2183.0090.5590.0085.1082.9090.62

[back to top]

Pulse

Heart rate in beats per minute. (NCT01714310)
Timeframe: Baseline through week 12.

Interventionbeats per minute. (Least Squares Mean)
BaselineWeek 1Week 2Week 3Week 4
Open Lisdexamfetamine80.8488.1584.3390.7188.45

[back to top]

Revised Modified Overt Aggression Scale - Total Score

A parent rated retrospective dimensional assessment of oppositional and aggressive behaviors, with scores ranging from 0-40, and higher scores indicating greater severity. (NCT01714310)
Timeframe: Baseline through week 12.

Interventionunits on a scale (Least Squares Mean)
BaselineWeek 4
Open Lisdexamfetamine26.0317.93

[back to top]

Revised Modified Overt Aggression Scale - Total Score

A parent rated retrospective dimensional assessment of oppositional and aggressive behaviors, with scores ranging from 0-40, and higher scores indicating greater severity. (NCT01714310)
Timeframe: Baseline through week 12.

,
Interventionunits on a scale (Least Squares Mean)
BaselineWeek 4Week 5Week 6Week 7Week 8Week 10Week 12
Fluoxetine22.2314.4413.7210.0013.1914.0912.6114.29
Placebo33.6825.3520.6020.5521.8921.3317.6818.34

[back to top]

Systolic Blood Pressure

Systolic Blood Pressure measured in mmHG (NCT01714310)
Timeframe: Baseline through week 12.

,
Interventionmm Hg. (Least Squares Mean)
BaselineWeek 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 10Week 12
Fluoxetine107.8599.42104.83109.20112.00109.57111.58112.04111.20112.25116.15
Placebo106.68111.71110.36109.89110.07104.20108.98112.80110.94105.67113.90

[back to top]

Systolic Blood Pressure

Systolic Blood Pressure measured in mmHG (NCT01714310)
Timeframe: Baseline through week 12.

Interventionmm Hg. (Least Squares Mean)
BaselineWeek 1Week 2Week 3Week 4
Open Lisdexamfetamine107.40106.03107.48110.73111.77

[back to top]

Weight

Weight in kg. (NCT01714310)
Timeframe: Baseline through week 12.

,
Interventionkg. (Least Squares Mean)
BaselineWeek 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 10Week 12
Fluoxetine37.9637.2936.9636.5536.2036.0835.7335.3035.0834.6134.73
Placebo47.2646.3945.5645.0645.2244.8044.3444.7244.0844.1643.05

[back to top]

Weight

Weight in kg. (NCT01714310)
Timeframe: Baseline through week 12.

Interventionkg. (Least Squares Mean)
BaselineWeek 1Week 2Week 3Week 4
Open Lisdexamfetamine42.5941.8341.2940.7340.67

[back to top]

Clinical Global Impression - Improvement

Percentage improved by treatment group (NCT01714310)
Timeframe: Percentage improved at week 4 for Open Lisdexamfetamine group and at week 12 for fluoxetine and placebo groups.

InterventionParticipants (Count of Participants)
Fluoxetine7
Placebo7
Open Lisdexamfetamine8

[back to top]

Change in Depressive Symptoms From Baseline Based on Beck Depression Inventory, 2nd Edition (BDI-II)

Self-report measure, completed by the child, that assesses depressive symptom severity. The BDI-II total score ranges from 0 to 63, with a higher score indicating a higher level of depression. Change is the difference between the 42 week score and the baseline score. (NCT01740726)
Timeframe: Baseline, 42 weeks

Interventionunits on a scale (Number)
Fluoxetine-45

[back to top]

SAS-SR Score

The SAS-SR provides an understanding of an individual's level of satisfaction with his or her social situation, measuring the level of both behavioral and emotional social adjustment across four major areas (school, friends, family, and dating). Participants answer each item on a scale of 1 to 5. The total score also ranges from 1 to 5 and is the average of all item scores. The total score provides an index of social impairment with higher mean score indicating more difficulties with social adjustment. Lower scores post treatment indicate efficacy of the intervention. (NCT01802437)
Timeframe: Baseline and 16-weeks

Interventionscore on a scale (Mean)
Talk Therapy 4-Week Decision Point2.16
Talk Therapy 8-Week Decision Point2.35

[back to top]

CGAS Score

The Children's Global Assessment Scale (CGAS) is a numeric scale used by mental health clinicians to rate the general functioning. Scores range from 1 to 100, with high scores indicating better functioning. A score of 1-10 indicates the need for constant supervision, while a score of 91-100 indicates superior functioning. (NCT01802437)
Timeframe: Baseline and 16-weeks

Interventionscore on a scale (Mean)
Talk Therapy 4-Week Decision Point66.52
Talk Therapy 8-Week Decision Point60.66

[back to top]

CDRS-R Score

The CDRS-R is a clinician-administered semi-structured interview that assesses symptoms of depression experienced during the previous 2-weeks. The first 14 items are rated on the basis of an interview. The remaining 3 items are rated by a clinician on the basis of the child's nonverbal behavior. Items scales are 1 to 5 for sleep, appetite, and speech and 1 to 7 for the remaining 14 items. Total scores are summed and range from 17 to 113, with lower scores indicating normality while higher scores indicate psychopathology. Lower scores post-intervention indicate treatment efficacy. (NCT01802437)
Timeframe: Baseline and 16-weeks

Interventionscore on a scale (Mean)
Talk Therapy 4-Week Decision Point34.94
Talk Therapy 8-Week Decision Point40.65

[back to top]

Percentage of Participants Achieving a Remission at 6-Week Endpoint

The percentage of participants achieving a remission (defined as a HAMD21 total score ≤7) was calculated by dividing the number of participants achieving a remission at last observation by the total number of participants at risk, multiplied by 100. (NCT01808612)
Timeframe: up to 6 weeks

Interventionpercentage of participants (Number)
20 mg Fluoxetine9.5
40 mg Fluoxetine9.6
Placebo15.1

[back to top]

Mean Change From Baseline to 6-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale

CGI-S measures severity of illness at the time of assessment with scores ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). LS means were calculated using MMRM adjusting for the random effect of participant and fixed categorical effects of treatment, pooled investigative site, visit, and treatment-by-visit interaction, as well as the continuous fixed covariate of baseline CGI-S score. (NCT01808612)
Timeframe: Baseline, 6 weeks

Interventionunits on a scale (Least Squares Mean)
20 mg Fluoxetine-0.69
40 mg Fluoxetine-0.67
Placebo-0.81

[back to top]

Mean Change From Baseline to 6-Week Endpoint on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score

HAMD21 is a 21-item assessment used to measure depression severity. Items were rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score ranging from 0 (not at all depressed) to 64 (severely depressed). Least squares (LS) means were calculated using mixed-model repeated measures (MMRM) adjusting for the random effect of participant and fixed categorical effects of treatment, pooled investigative site, visit, and treatment-by-visit interaction, as well as the continuous fixed covariate of baseline HAMD21 total score. (NCT01808612)
Timeframe: Baseline, 6 weeks

Interventionunits on a scale (Least Squares Mean)
20 mg Fluoxetine-6.18
40 mg Fluoxetine-6.25
Placebo-6.91

[back to top]

Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia - Suicide Severity Rating Scale (C-SSRS)

"C-SSRS captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior is defined as a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation is defined as a yes answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation." (NCT01808612)
Timeframe: Baseline through 6 weeks

,,
Interventionparticipants (Number)
Suicidal behaviorSuicidal ideation
20 mg Fluoxetine05
40 mg Fluoxetine06
Placebo18

[back to top]

Mean Change From Baseline to 6-Week Endpoint on the HAMD21 Subscale Scores

HAMD17 total scores and subscale scores from the HAMD21 are presented. HAMD17 is a 17-item assessment of depression severity (total scores range from 0-52). The Maier subscale (Items 1, 2, 7-10) represents the core symptoms of depression (0-24). Anxiety/Somatization subscale (Items 10-13, 15, 17) evaluates severity of psychic and somatic manifestations of anxiety as well as agitation (0-18). Retardation/Somatization subscale (Items 1, 7, 8, 14) evaluates dysfunction in mood, work, and sexual activity, as well as overall motor retardation (0-14). Sleep subscale (Items 4-6) assesses insomnia (0-6). Individual item scores may range from 0-4 or 0-2. Higher scores indicate more severe symptoms. LS means were calculated using MMRM adjusting for the random effect of participant and fixed categorical effects of treatment, pooled investigative site, visit, and treatment-by-visit interaction, as well as the continuous fixed covariate of baseline score. (NCT01808612)
Timeframe: Baseline, 6 weeks

,,
Interventionunits on a scale (Least Squares Mean)
HAMD17 total scoreMaier subscale scoreAnxiety/Somatization subscale scoreRetardation/Somatization subscale scoreSleep subscale score
20 mg Fluoxetine-5.59-3.35-2.04-2.00-0.83
40 mg Fluoxetine-5.61-3.39-1.84-2.21-0.81
Placebo-6.27-3.30-2.06-2.23-1.10

[back to top]

Mean Change From Baseline to 6-Week Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscale Scores

SDS was completed by the participant and was used to assess the effect of the participant's symptoms on their work/school (Item 1), social life/leisure activities (Item 2), and family life/home responsibilities (Item 3). Each item was measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. Total score was the sum of the 3 items and ranged from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. LS means were calculated using analysis of covariance (ANCOVA) adjusting for treatment, pooled investigative site, and baseline SDS score. (NCT01808612)
Timeframe: Baseline, up to 6 weeks

,,
Interventionunits on a scale (Least Squares Mean)
Total score (n=167, 81, 259)Work/School subscale score (n=143, 64, 226)Social/Leisure subscale score (n=167, 81, 259)Family/Home subscale score (n=167, 81, 259)
20 mg Fluoxetine-1.76-0.79-0.66-0.47
40 mg Fluoxetine-1.55-0.34-0.81-0.30
Placebo-1.99-0.88-0.70-0.41

[back to top]

Percentage of Participants Achieving a Response at 6-Week Endpoint

The percentage of participants achieving a response (defined as a ≥50% improvement from baseline on the HAMD21 total score) was calculated by dividing the number of participants achieving a response at last observation by the total number of participants at risk, multiplied by 100. (NCT01808612)
Timeframe: up to 6 weeks

Interventionpercentage of participants (Number)
20 mg Fluoxetine23.8
40 mg Fluoxetine18.1
Placebo27.8

[back to top]

Percentage of Participants Achieving a Remission at Week 52

The percentage of participants achieving a remission (defined as a HAMD21 total score ≤7) was calculated by dividing the number of participants achieving a remission at last observation by the total number of participants at risk, multiplied by 100. (NCT01808651)
Timeframe: up to Week 52

Interventionpercentage of participants (Number)
PLA/FLX64
FLX20/FLX57
FLX40/FLX76

[back to top]

Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia - Suicide Severity Rating Scale (C-SSRS)

"C-SSRS captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior is defined as a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation is defined as a yes answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation." (NCT01808651)
Timeframe: Baseline through Week 52

Interventionparticipants (Number)
PLA/FLX8
FLX20/FLX4
FLX40/FLX0

[back to top]

Mean Change From Baseline to Week 52 on the Clinical Global Impression of Severity (CGI-S) Scale

CGI-S measures severity of illness at the time of assessment with scores ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). LS means were calculated using MMRM adjusting for the random effect of participant and fixed categorical effects of treatment, pooled investigative site, visit, and treatment-by-visit interaction, as well as the continuous fixed covariate of baseline CGI-S score. (NCT01808651)
Timeframe: Baseline, Week 52

Interventionunits on a scale (Least Squares Mean)
PLA/FLX-1.41
FLX20/FLX-1.45
FLX40/FLX-1.64

[back to top]

Mean Change From Baseline to Week 52 on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score

HAMD21 is a 21-item assessment used to measure depression severity. Items were rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score ranging from 0 (not at all depressed) to 64 (severely depressed). Least squares (LS) means were calculated using mixed-model repeated measures (MMRM) adjusting for the random effect of participant and fixed categorical effects of treatment, pooled investigative site, visit, and treatment-by-visit interaction, as well as the continuous fixed covariate of baseline HAMD21 total score. (NCT01808651)
Timeframe: Baseline, Week 52

Interventionunits on a scale (Least Squares Mean)
PLA/FLX-10.04
FLX20/FLX-11.25
FLX40/FLX-11.70

[back to top]

Percentage of Participants Achieving a Response at Week 52

The percentage of participants achieving a response (defined as a ≥50% improvement from baseline on the HAMD21 total score) was calculated by dividing the number of participants achieving a response at last observation by the total number of participants at risk, multiplied by 100. (NCT01808651)
Timeframe: Baseline, up to Week 52

InterventionPercentage of participants (Number)
PLA/FLX68
FLX20/FLX65
FLX40/FLX83

[back to top]

Change From Baseline to Week 52 in Sheehan Disability Scale (SDS) Total Score and Subscale Scores

SDS was completed by the participant and was used to assess the effect of the participant's symptoms on their work/school (Item 1), social life/leisure activities (Item 2), and family life/home responsibilities (Item 3). Each item was measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. Total score was the sum of the 3 items and ranged from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. LS means were calculated using analysis of covariance (ANCOVA) adjusting for treatment, pooled investigative site, and baseline SDS score. (NCT01808651)
Timeframe: Baseline up to 52 weeks

,,
Interventionunits on a scale (Least Squares Mean)
SDS Total ScoreWork/School subscale (N:85, 60, 28)Social/Leisure subscale (N:98, 64, 36)Family/Home subscale (N:98,64,36)
FLX20/FLX-6.17-2.62-2.11-1.55
FLX40/FLX-6.14-2.24-2.06-2.01
PLA/FLX-6.53-2.46-2.11-1.93

[back to top]

Mean Change From Baseline to Week 52 on the HAMD21 Subscale Scores

HAMD17 total scores and subscale scores from the HAMD21 are presented. HAMD17 is a 17-item assessment of depression severity (total scores range from 0-52). The Maier subscale (Items 1, 2, 7-10) represents the core symptoms of depression (0-24). Anxiety/Somatization subscale (Items 10-13, 15, 17) evaluates severity of psychic and somatic manifestations of anxiety as well as agitation (0-18). Retardation/Somatization subscale (Items 1, 7, 8, 14) evaluates dysfunction in mood, work, and sexual activity, as well as overall motor retardation (0-14). Sleep subscale (Items 4-6) assesses insomnia (0-6). Individual item scores may range from 0-4 or 0-2. Higher scores indicate more severe symptoms. LS means were calculated using MMRM adjusting for the random effect of participant and fixed categorical effects of treatment, pooled investigative site, visit, and treatment-by-visit interaction, as well as the continuous fixed covariate of baseline score. (NCT01808651)
Timeframe: Baseline, Week 52

,,
Interventionunits on a scale (Least Squares Mean)
HAMD17 total scaleMaier subscale scoreAnxiety/Somatization subscale scoreRetardation/Somatization subscale scoreSleep subscale score
FLX20/FLX-10.20-5.55-3.16-3.98-1.34
FLX40/FLX-10.51-5.02-3.61-3.55-1.95
PLA/FLX-9.06-4.73-3.08-3.45-1.49

[back to top]

Number of Participants With Adverse Events (AEs) or Serious AEs (SAEs)

(NCT01808651)
Timeframe: Baseline through Week 52.

,,
Interventionparticipants (Number)
Participants with >=1 SAEParticipants with >=1 AEs
FLX20/FLX146
FLX40/FLX029
PLA/FLX275

[back to top]

Loss of Motivated Behavior HAM-D Factor

includes the total of four HAM-D items: (Item 7: Work and activities, Item 12. Somatic symptoms (appetite), Item 14. Genital symptoms (libido), and Item 16. Weight loss). Range 0-11, higher scores indicate worse symptoms (NCT01833897)
Timeframe: 8 weeks

Interventionunits on a scale (final score) (Mean)
Ketamine and DCS Treatment1.6

[back to top]

Beck's Depression Inventory

Range 0-63, with higher scores worse. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. (NCT01833897)
Timeframe: 8 weeks

Interventionunits on a scale (final score) (Mean)
Ketamine and DCS Treatment10.8

[back to top]

HAM-D Suicide Item

Ham-D suicide item: range 0-4, higher scores indicate worse symptoms (NCT01833897)
Timeframe: 8 weeks

Interventionunits on a scale (final) (Mean)
Ketamine and DCS Treatment0.3

[back to top]

Hamilton Anxiety Scale

Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indi- cates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. (NCT01833897)
Timeframe: 8 weeks

Interventionunits on a scale (final score) (Mean)
Ketamine and DCS Treatment6.4

[back to top]

Hamilton Depression Rating Scale (HAM-D)

"Depression rating scale: Range 0-53, higher scores indicate worse depression. 0-7 = Normal 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression~≥ 23 = Very Severe Depression" (NCT01833897)
Timeframe: 8 weeks

Interventionunits on a scale (final score) (Mean)
Ketamine and DCS Treatment9.5

[back to top]

Money Earned

"Change in amount of money earned between baseline and after 6 weeks of antidepressant treatment is determined through a summary score from a variety of decision-making tasks. Participants received between $5 and $40 per visit, depending on the outcomes of the decisions made on the computerized tasks. Variable payment ensured that the decision-making tasks were approached realistically, as opposed to using hypothetical points that do not have meaning in the real world. Greater earnings indicate better financial decision-making.~The specific tasks were:~risk task~balloon analogue risk task~temporal discounting task~ultimatum game~continuous performance task" (NCT01916824)
Timeframe: Baseline, Week 6

,
InterventionUS Dollars (Mean)
Baseline VisitAfter 6 Weeks of Treatment
Healthy Controls25.021.9
Participants With Major Depressive Disorder23.220.5

[back to top]

Children's Depression Rating Scale-Revised (CDRS-R)

The CDRS-R is a clinician-administered semi-structured interview designed to assess present episode and lifetime history of psychiatric diagnoses based on DSM-IV criteria. This survey contains 17 items; 3 items are rated on a scale from 0 to 5, 5 items are rated on a scale from 0 to 6, and the remaining 9 items are rated on a scale from 0 to 7. Total score is a raw sum of the 17 item scores and ranges from 0 to 108. Higher scores indicate greater depression severity. (NCT02017535)
Timeframe: 16 weeks, 32 weeks

,,,
Interventionscore on a scale (Mean)
16 Weeks32 Weeks
10 IPT-A Sessions + Begin Fluoxetine5129
10 IPT-A Sessions + Increase Dose of Fluoxetine4551
6 IPT-A Sessions32.3829
6 IPT-A Sessions + Continue Current Dose of Fluoxetine26.6733.33

[back to top]

Beck Depression Inventory-II (BDI-II)

BDI-II is a 21-item self-report multiple-choice inventory that assesses the severity of depressive symptoms reflective of DSM-IV diagnostic criteria over the prior week. Items are rated on a 4-point scale ranging from 0 to 3. Total scores are a sum of the 21 item scores ranging from 0 to 63. Higher scores indicate more severe depression symptoms. (NCT02017535)
Timeframe: 16 weeks, 32 weeks

,,,
Interventionscore on a scale (Mean)
16 weeks32 weeks
10 IPT-A Sessions + Begin Fluoxetine101.5
10 IPT-A Sessions + Increase Dose of FluoxetineNA41
6 IPT-A Sessions7.635.86
6 IPT-A Sessions + Continue Current Dose of Fluoxetine11.339

[back to top]

Social Adjustment Scale - Self Report (SAS-SR)

The SAS-SR is a 42-item self report measure of role performance in the past 2 weeks. Items are rated on a 5-point scale. Total scores are calculated by summing the 42 item scores and dividing by the total number of items answered. Total scores range from 1 to 5, with higher scores indicating greater impairment of functioning. (NCT02017535)
Timeframe: 16 weeks, 32 weeks

,,,
Interventionscore on a scale (Mean)
16 weeks32 weeks
10 IPT-A Sessions + Begin Fluoxetine2.752.18
10 IPT-A Sessions + Increase Dose of FluoxetineNA3.09
6 IPT-A Sessions2.032.17
6 IPT-A Sessions + Continue Current Dose of Fluoxetine2.071.62

[back to top]

Children's Global Assessment Scale (CGAS)

The CGAS is a numeric scale used by mental health clinicians to rate the general functioning of youths under the age of 18. Scores range from 1 to 100, with higher scores indicating better functioning. (NCT02017535)
Timeframe: 16 weeks, 32 weeks

,,,
Interventionscore on a scale (Mean)
16 weeks32 weeks
10 IPT-A Sessions + Begin Fluoxetine5372
10 IPT-A Sessions + Increase Dose of Fluoxetine5549
6 IPT-A Sessions6572
6 IPT-A Sessions + Continue Current Dose of Fluoxetine7771

[back to top]

Changes in Motor Function (Jebsen-Taylor Task)

"Jebsen Taylor Hand Function Test: measures hand function in real-life activities, by evaluating the time required to perform 7 different tasks. We used the non-constrained hand for the assessments. The sum of the different tasks was used for the analysis.~Calculation details: value at 9 months minus value at baseline, change in seconds (adjusted mean difference)." (NCT02208466)
Timeframe: baseline and 90 days

Interventionseconds (Mean)
Active rTMS/Active Fluoxetine-214.33
Sham rTMS/Active Fluoxetine-50.16
Sham rTMS/Placebo Fluoxetine-117.98

[back to top]

Changes in Cortical Excitability Measures

We will measure cortical excitability using single-pulsed transcranial magnetic stimulation (TMS) before and after stimulation at three different time-points. Changes from baseline to 90 days (value at 90 days minus value at baseline). (NCT02208466)
Timeframe: Baseline and 90 days

Interventionmotor evoked potential (mV) (Mean)
Active rTMS/Active Fluoxetine-0.05
Sham rTMS/Active Fluoxetine-0.12
Sham rTMS/Placebo Fluoxetine0.33

[back to top]

Changes in Fugl-Meyer Assessment (FMA) Scale

The Fugl-Meyer Assessment (FMA) is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, balance, sensation, and joint functioning in patients with post-stroke hemiplegia. We used the upper limb motor function subscale: minimum values= 0 ; maximum values= 66. Higher scores mean a better outcome. Changes from baseline to 90 days (value at 90 days minus value at baseline). (NCT02208466)
Timeframe: baseline and 90 days

Interventionunits on a scale (Mean)
Active rTMS/Active Fluoxetine10.10
Sham rTMS/Active Fluoxetine6.73
Sham rTMS/Placebo Fluoxetine15.55

[back to top]

Depression Severity

"Depression severity as measured by the 25-item Hamilton Depression Rating Scale. The Hamilton Depression Rating Scale has proven useful for determining the level of depression before, during, and after treatment. It is based on the clinician's interview with the patient/participant and probes symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels and weight loss. The rater enters a number for each symptom construct that ranges from 0 (not present) to 4 (extreme symptoms). The higher the total score the more severe the depression. The scale is scored by summing the total of all items. The maximum possible total score is 66 and the minimum is 0. A score > 17 is considered compatible with a diagnosis of major depression. A score < 10 is considered clinical remission.~The interview and scoring takes about 15 minutes." (NCT02238977)
Timeframe: up to 12 weeks

Interventionunits on a scale (Number)
Bupropion18

[back to top]

Change in Clinical Global Impressions-Severity (CGI-S) Score

The Clinical Global Impressions-Severity (CGI-S) is a clinician-rated instrument used to rate the severity of the patient's current state of mental illness compared with the clinician's total experience with patients with major depressive disorder (MDD). The severity of the patient's MDD was rated on a scale from 1 to 7, with 1 indicating a normal state and 7 indicating a patient who is among the most extremely ill patients. (NCT02372799)
Timeframe: From Baseline to Week 8

Interventionunits on a scale (Least Squares Mean)
Placebo-1.52
Vilazodone-1.57
Fluoxetine-1.72

[back to top]

Change in Children's Depression Rating Scale-Revised (CDRS-R) Total Score

The Children's Depression Rating Scale-Revised (CDRS-R) total score ranges from 17 (minimal or no symptoms of depression) to 133 (indicative of depression) is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6 to 17 years of age and their caregivers. The CDRS-R evaluates the presence and severity of symptoms commonly associated with depression in childhood. (NCT02372799)
Timeframe: From Baseline to Week 8

Interventionunits on a scale (Least Squares Mean)
Placebo-20.32
Vilazodone-20.72
Fluoxetine-22.71

[back to top]

Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score

CDRS-R is a 17-item scale measuring presence and severity of symptoms commonly associated with childhood depression and is scored on a 1-to-5- or 1-to-7-point scale. Rating of 1 indicates normal function. The CDRS-R total score ranges from 17 to 113; higher score indicates more severe depression. A negative change from Baseline indicates improvement. Mixed Model for Repeated Measures (MMRM) was used for analysis. (NCT02431806)
Timeframe: Baseline (Week 0) to Week 8

Interventionscore on a scale (Least Squares Mean)
Placebo-22.90
Levomilnacipran 40 mg/Day-23.28
Levomilnacipran 80 mg/Day-22.64
Fluoxetine 20 mg/Day-24.37

[back to top]

Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale

The CGI-S is a clinician-rated scale used to rate the severity of the participants current state of mental illness compared with MDD population. The participant was rated on a scale from 1 to 7, where 1= Very much improved; 2= Much improved; 3= Minimally improved; 4= No change; 5= Minimally worse; 6= Much worse; 7= Very much worse. Higher score indicates worsening of mental illness. A negative change from Baseline indicates improvement. MMRM was used for analysis. (NCT02431806)
Timeframe: Baseline (Week 0) to Week 8

Interventionscore on a scale (Least Squares Mean)
Placebo-1.54
Levomilnacipran 40 mg/Day-1.52
Levomilnacipran 80 mg/Day-1.52
Fluoxetine 20 mg/Day-1.68

[back to top]

Hamilton Anxiety Rating Scale

Anxiety severity. Minimum=0, Maximum=56. The larger the value on the scale, the more intense the anxiety. The percent difference between week 0 and the last observation was calculated. (NCT02473250)
Timeframe: 6 weeks

InterventionPercent change in HAMA score (Mean)
Bipolar Depressed13.95

[back to top]

Clinical Global Impression-1

General impression of symptoms by clinician. Minimum=1, Maximum=7. The higher value on the scale, the more symptomatic the patient is. The percent difference between week 0 and the last observation was calculated. (NCT02473250)
Timeframe: 6 weeks

InterventionPercent change in CGI score (Mean)
Bipolar Depressed27.17

[back to top]

Young Mania Rating Scale

Measure of manic symptoms. Minimum=0, Maximum=60. The higher the value on the scale, the more intense the manic symptoms. The maximum value of YMRS over the six week clinical trial is reported. (NCT02473250)
Timeframe: 6 weeks

InterventionScores on a scale (Mean)
Bipolar Depressed5.75

[back to top]

Montgomery-Asberg Depression Rating Scale

Depression severity. Minimum=0, Maximum=60. Higher numbers correspond to greater depression severity. The percent change between week 0 and the last observation was calculated. (NCT02473250)
Timeframe: 6 weeks

InterventionPercent change in MADRS from baseline (Mean)
Bipolar Depressed39.24

[back to top]

Change From Baseline PTSD Checklist- Civilian (PCL-C) Over the Course of the Year After Injury

The investigators will use the PTSD Checklist - Civilian (PCL-C). The scoring of the scale ranges from a minimum of 17 to a maximum of 85, with higher scores indicating a worse outcome. The measure can also provide a rating of symptoms consistent with a diagnosis of PTSD. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Change from Baseline at 3 MonthsChange from Baseline at 6 MonthsChange from Baseline at 12 Months
Intervention-1.65-4.02-5.51
Usual Care0.08-1.44-4.25

[back to top]

Change From Baseline Short Form (SF)-12/36 Physical Function Over the Course of the Year After Injury

The investigators used the Medical Outcomes Study Short Form healthy survey (MOS SF-12/36) physical components summary to assess physical function. The minimum and maximum scores are 0-100 with higher scores representing a better outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Change from Baseline at 3 MonthsChange from Baseline at 6 MonthsChange from Baseline at 12 Months
Intervention-16.78-14.17-13.23
Usual Care-15.90-13.83-11.68

[back to top]

Cognitive Impairment Scale

The investigators will use the National Study on the Costs and Outcomes of Trauma (NSCOT) Cognitive Screen, a 4 - Item Traumatic Brain Injury / Post-concussive Symptom Screen. The scoring of the scale ranges from a minimum of 4 to a maximum of 20, with lower scores indicating a worse outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention13.513.313.213.8
Usual Care13.413.213.414.2

[back to top]

Number of Participants Endorsing a Single Item That Assesses Marijuana Use

Single items that assess marijuana use. Single item self-report dichotomized as none versus at least monthly use. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
InterventionParticipants (Count of Participants)
Baseline3 Month6 Month12 Month
Intervention125606051
Usual Care177728279

[back to top]

Number of Participants Endorsing a Single Item That Assesses Opioid Use

Single items that assess non-prescribed opioid use. Single item self-report dichotomized as none versus at least monthly use. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
InterventionParticipants (Count of Participants)
Baseline3 Month6 Month12 Month
Intervention18446
Usual Care4415206

[back to top]

Number of Participants Endorsing a Single Item That Assesses Stimulant Use

Single items that assess non-prescribed stimulant use. Single item self-report dichotomized as none versus at least monthly use. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
InterventionParticipants (Count of Participants)
Baseline3 Month6 Month12 Month
Intervention58978
Usual Care77172216

[back to top]

Number of Participants With Suicidal Ideation

Item 9 of the Patient Health Questionnaire 9-item (PHQ-9) scale assesses suicidal ideation. It is scored from 0 to 3, with a score of 1 or greater indicating a patient has suicidal ideation. Participants with a PHQ-9 item 9 score of greater than or equal to 1 are reported for this outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
InterventionParticipants (Count of Participants)
Baseline3 Month6 Month12 Month
Intervention67696351
Usual Care909910692

[back to top]

SF-36 Quality of Life

The SF-36 assess quality of life domains that span emotional health, overall health status, and role function; a score of 100 indicates perfect health and a score of 0 indicates extremely poor health. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention44.338.338.439.2
Usual Care45.139.139.541.4

[back to top]

TSOS Patient Satisfaction: Mental Health Care

Satisfaction with mental health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied. (NCT02655354)
Timeframe: Baseline, 3 Month, 6 Month, 12 Month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention4.13.63.63.7
Usual Care4.03.53.43.5

[back to top]

TSOS Patient Satisfaction: Overall Health Care

Satisfaction with health care was rated on a scale of 1 to 5, with 1 indicating very dissatisfied and 5 indicating very satisfied. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention4.43.94.03.9
Usual Care4.43.83.83.8

[back to top]

Brief Pain Inventory

A brief measure scored on a 0 to 10 scale to assess a patient's pain, with a higher score indicating more severe pain; a score of 0 indicates no pain and a score of 10 indicates very severe pain. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Baseline3 Month6 Month12 Month
Intervention6.84.34.13.9
Usual Care6.74.74.53.8

[back to top]

Change From Baseline Patient Health Questionnaire 9 Item Depression Scale Over the Course of the Year After Injury

The investigators will use the Patient Health Questionnaire 9-item Depression Scale (PHQ-9). The scoring of the scale ranges from a minimum of 0 to a maximum of 27, with higher scores indicating a worse outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Change from Baseline at 3 MonthsChange from Baseline at 6 MonthsChange from Baseline at 12 Months
Intervention-0.79-1.17-1.84
Usual Care-0.50-0.90-2.16

[back to top]

Change From Baseline Alcohol Use Disorders Identification Over the Course of the Year After Injury

The investigators will use the Alcohol Use Disorders Identification Test (AUDIT) as a continuous measure. The 10-item scale score ranges from 0-40, with higher values indicating a worse outcome. (NCT02655354)
Timeframe: Baseline, 3-month, 6-month, 12-month

,
Interventionscore on a scale (Mean)
Change from Baseline at 3 MonthsChange from Baseline at 6 MonthsChange from Baseline at 12 Months
Intervention-2.04-1.69-1.81
Usual Care-1.90-1.63-1.45

[back to top]

Change From Baseline in PedsQL VAS Total Average Score at Weeks 4 and 8 of Phase B

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome. (NCT02709655)
Timeframe: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

,,,
Interventionunits on a scale (Least Squares Mean)
Change at Week 4Change at Week 8
Double-Blind: Fluoxetine 20 mg-1.01-1.54
Double-Blind: Placebo-0.81-1.17
Double-Blind: Vortioxetine 10 mg-1.19-1.55
Double-Blind: Vortioxetine 20 mg-1.17-1.47

[back to top]

Change From Baseline in PedsQL VAS: Angry Score at Weeks 4 and 8 of Phase B

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709655)
Timeframe: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

,,,
Interventionunits on a scale (Least Squares Mean)
Change at Week 4Change at Week 8
Double-Blind: Fluoxetine 20 mg-1.22-1.67
Double-Blind: Placebo-0.98-1.24
Double-Blind: Vortioxetine 10 mg-1.36-1.98
Double-Blind: Vortioxetine 20 mg-1.33-1.36

[back to top]

Change From Baseline in PedsQL VAS: Pain or Hurt Score at Weeks 4 and 8 of Phase B

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709655)
Timeframe: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

,,,
Interventionunits on a scale (Least Squares Mean)
Change at Week 4Change at Week 8
Double-Blind: Fluoxetine 20 mg-0.50-0.69
Double-Blind: Placebo-0.22-0.70
Double-Blind: Vortioxetine 10 mg-0.81-0.79
Double-Blind: Vortioxetine 20 mg-0.45-1.02

[back to top]

Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B

The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Least square (LS) mean was estimated using a restricted maximum likelihood (REML)-based Mixed Model Repeated Measurements (MMRM) approach. (NCT02709655)
Timeframe: Baseline (Week 4 of Phase A), Week 8 of Phase B

Interventionunits on a scale (Least Squares Mean)
Double-Blind: Placebo-17.48
Double-Blind: Vortioxetine 10 mg-19.20
Double-Blind: Vortioxetine 20 mg-19.94
Double-Blind: Fluoxetine 20 mg-20.78
Vortioxetine Average (Avg. VOR)-19.57

[back to top]

Change From Baseline in CDRS-R Subscores (Mood, Somatic, Subjective, and Behaviour) at Weeks 2, 4, 6, and 8 of Phase B

The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). Four subscores were defined based on the CDRS-R: Mood: sum of items 8, 11, 14, 15; score range 4 to 28, Somatic: sum of items 4, 5, 6, 7, 16, 17; score range 6 to 36, Subjective: sum of items 9, 10, 12, 13; score range 4 to 28, and Behaviour: sum of items 1, 2, 3; score range 3 to 21. Higher scores indicated the most severe measure of depression. (NCT02709655)
Timeframe: Baseline (Week 4 of Phase A), Weeks 2, 4, 6, and 8 of Phase B

,,,
Interventionunits on a scale (Least Squares Mean)
Mood Score: Change at Week 2Mood Score: Change at Week 4Mood Score: Change at Week 6Mood Score: Change at Week 8Somatic Score: Change at Week 2Somatic Score: Change at Week 4Somatic Score: Change at Week 6Somatic Score: Change at Week 8Subjective Score: Change at Week 2Subjective Score: Change at Week 4Subjective Score: Change at Week 6Subjective Score: Change at Week 8Behaviour Score: Change at Week 2Behaviour Score: Change at Week 4Behaviour Score: Change at Week 6Behaviour Score: Change at Week 8
Double-Blind: Fluoxetine 20 mg-3.02-3.73-4.97-5.84-3.02-4.26-5.57-6.44-1.56-2.17-2.38-2.65-2.61-3.80-4.80-5.83
Double-Blind: Placebo-2.82-3.69-4.67-5.08-2.81-4.08-4.86-5.38-1.44-2.04-2.43-2.56-2.16-3.39-4.09-4.47
Double-Blind: Vortioxetine 10 mg-3.10-4.39-5.39-5.64-2.61-4.30-5.53-6.15-1.46-2.12-2.42-2.59-2.40-3.77-4.31-4.80
Double-Blind: Vortioxetine 20 mg-3.47-4.77-5.52-5.95-2.88-4.70-5.33-6.08-1.43-2.20-2.65-2.84-2.56-4.00-4.83-5.09

[back to top]

Change From Baseline in CDRS-R Total Score at Weeks 2, 4, and 6 of Phase B

The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). (NCT02709655)
Timeframe: Baseline (Week 4 of Phase A), Weeks 2, 4, and 6 of Phase B

,,,
Interventionunits on a scale (Least Squares Mean)
Change at Week 2Change at Week 4Change at Week 6
Double-Blind: Fluoxetine 20 mg-10.17-13.97-17.75
Double-Blind: Placebo-9.20-13.15-16.00
Double-Blind: Vortioxetine 10 mg-9.54-14.56-17.64
Double-Blind: Vortioxetine 20 mg-10.30-15.62-18.28

[back to top]

Change From Baseline in PedsQL Emotional Distress Summary Average Score at Weeks 4 and 8 of Phase B

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome. (NCT02709655)
Timeframe: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

,,,
Interventionunits on a scale (Least Squares Mean)
Change at Week 4Change at Week 8
Double-Blind: Fluoxetine 20 mg-1.13-1.66
Double-Blind: Placebo-0.84-1.22
Double-Blind: Vortioxetine 10 mg-1.28-1.80
Double-Blind: Vortioxetine 20 mg-1.22-1.51

[back to top]

Change From Baseline in Children's Global Assessment Scale (CGAS) Score at Weeks 4 and 8 of Phase B

The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally-oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The score ranges from 1 (most functionally impaired child) to 100 (the healthiest). A score greater than 70 indicates normal function. (NCT02709655)
Timeframe: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

,,,
Interventionunits on a scale (Least Squares Mean)
Change at Week 4Change at Week 8
Double-Blind: Fluoxetine 20 mg10.5416.35
Double-Blind: Placebo8.9312.71
Double-Blind: Vortioxetine 10 mg9.8412.98
Double-Blind: Vortioxetine 20 mg8.7313.22

[back to top]

Change From Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score at Weeks 1, 2, 3, 4, 6, and 8 of Phase B

The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants). (NCT02709655)
Timeframe: Baseline (Week 4 of Phase A), Weeks 1, 2, 3, 4, 6, and 8 of Phase B

,,,
Interventionunits on a scale (Least Squares Mean)
Change at Week 1Change at Week 2Change at Week 3Change at Week 4Change at Week 6Change at Week 8
Double-Blind: Fluoxetine 20 mg-0.22-0.63-0.77-1.01-1.23-1.57
Double-Blind: Placebo-0.25-0.50-0.67-0.95-1.13-1.31
Double-Blind: Vortioxetine 10 mg-0.27-0.60-0.62-1.00-1.22-1.40
Double-Blind: Vortioxetine 20 mg-0.28-0.65-0.79-1.06-1.27-1.44

[back to top]

Change From Baseline in General Behaviour Inventory (GBI) Depression Subscale Score, Using the 10-Item Depression Subscale Assessed by Parent (PGBI-10D) and Child (CGBI-10D) at Weeks 2, 4, 6, and 8 of Phase B

The GBI 10-item depression scale was developed to screen for depressive symptoms in children and adolescents. Two versions of the GBI 10-item depression scale were used, the child rated version (CGBI) and the parent rated version (PGBI). The 10 depression items were rated on a 4-point scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranged from 0 to 30, with higher scores indicating greater pathology. (NCT02709655)
Timeframe: Baseline (Week 4 of Phase A), Weeks 2, 4, 6, and 8 of Phase B

,,,
Interventionunits on a scale (Least Squares Mean)
PGBI: Change at Week 2PGBI: Change at Week 4PGBI: Change at Week 6PGBI: Change at Week 8CGBI: Change at Week 2CGBI: Change at Week 4CGBI: Change at Week 6CGBI: Change at Week 8
Double-Blind: Fluoxetine 20 mg-3.78-4.45-6.05-6.56-2.94-3.16-5.14-5.46
Double-Blind: Placebo-3.33-4.11-5.32-5.81-2.66-3.65-4.62-5.26
Double-Blind: Vortioxetine 10 mg-3.38-4.72-5.58-6.51-3.32-4.15-5.43-6.12
Double-Blind: Vortioxetine 20 mg-3.78-5.33-5.82-6.46-3.27-4.16-5.17-5.48

[back to top]

Change From Baseline in PedsQL VAS: Tired (Fatigue) Score at Weeks 4 and 8 of Phase B

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709655)
Timeframe: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

,,,
Interventionunits on a scale (Least Squares Mean)
Change at Week 4Change at Week 8
Double-Blind: Fluoxetine 20 mg-0.94-1.73
Double-Blind: Placebo-1.22-1.39
Double-Blind: Vortioxetine 10 mg-1.19-1.32
Double-Blind: Vortioxetine 20 mg-1.63-1.74

[back to top]

Parent Global Assessment (PGA) Score

The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of symptoms using a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT02709655)
Timeframe: Weeks 2, 4, 6, and 8 of Phase B

,,,
Interventionunits on a scale (Least Squares Mean)
Week 2Week 4Week 6Week 8
Double-Blind: Fluoxetine 20 mg3.132.902.802.59
Double-Blind: Placebo3.312.972.732.68
Double-Blind: Vortioxetine 10 mg3.252.902.732.62
Double-Blind: Vortioxetine 20 mg3.182.842.682.61

[back to top]

Change From Baseline in PedsQL VAS: Worry Score at Weeks 4 and 8 of Phase B

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709655)
Timeframe: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

,,,
Interventionunits on a scale (Least Squares Mean)
Change at Week 4Change at Week 8
Double-Blind: Fluoxetine 20 mg-1.27-1.41
Double-Blind: Placebo-0.63-1.08
Double-Blind: Vortioxetine 10 mg-1.48-1.82
Double-Blind: Vortioxetine 20 mg-1.21-1.45

[back to top]

Change From Baseline in PQ-LES-Q Overall Evaluation Score (Item 15) at Weeks 4 and 8 of Phase B

The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire, which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1 to 14 assess the degree of satisfaction experienced by participants in various areas of daily functioning, and item 15 allows subjects to summarize their experience in a global rating. Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good). (NCT02709655)
Timeframe: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

,,,
Interventionunits on a scale (Least Squares Mean)
Change at Week 4Change at Week 8
Double-Blind: Fluoxetine 20 mg0.240.45
Double-Blind: Placebo0.280.41
Double-Blind: Vortioxetine 10 mg0.370.49
Double-Blind: Vortioxetine 20 mg0.430.52

[back to top]

Clinical Global Impression - Global Improvement (CGI-I) Score

The CGI-I provides the clinician's impression of the participant's improvement (or worsening). The clinician assesses the participant's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT02709655)
Timeframe: Weeks 1, 2, 3, 4, 6, and 8 of Phase B

,,,
Interventionunits on a scale (Least Squares Mean)
Week 1Week 2Week 3Week 4Week 6Week 8
Double-Blind: Fluoxetine 20 mg3.723.263.232.972.782.57
Double-Blind: Placebo3.663.323.202.932.702.69
Double-Blind: Vortioxetine 10 mg3.633.303.202.932.642.58
Double-Blind: Vortioxetine 20 mg3.603.193.142.822.652.60

[back to top]

Change From Baseline in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Score (Items 1 to 14) at Weeks 4 and 8 of Phase B

The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire, which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1 to 14 assess the degree of satisfaction experienced by participants in various areas of daily functioning, and item 15 allows subjects to summarise their experience in a global rating. Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1 to 14 is 14 to 70, with higher scores indicating greater satisfaction. (NCT02709655)
Timeframe: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

,,,
Interventionunits on a scale (Least Squares Mean)
Change at Week 4Change at Week 8
Double-Blind: Fluoxetine 20 mg4.366.79
Double-Blind: Placebo3.946.22
Double-Blind: Vortioxetine 10 mg4.907.08
Double-Blind: Vortioxetine 20 mg4.907.14

[back to top]

Percentage of Participants With CDRS-R Remission

CDRS-R remission was defined as a CDRS-R total score ≤28. The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). (NCT02709655)
Timeframe: Weeks 2, 4, 6, and 8 of Phase B

,,,
Interventionpercentage of participants (Number)
Week 2Week 4Week 6Week 8
Double-Blind: Fluoxetine 20 mg3.89.014.126.9
Double-Blind: Placebo2.09.014.714.7
Double-Blind: Vortioxetine 10 mg5.49.515.416.7
Double-Blind: Vortioxetine 20 mg2.710.115.320.1

[back to top]

Percentage of Participants With CDRS-R Response

CDRS-R response was defined as a ≥50% decrease in CDRS-R total score, calculated as: (change from baseline [Randomization])/(baseline value - 17). The CDRS-R is a clinician-rated scale to measure the severity of depression in children and adolescents. The CDRS-R was rated by a clinician following interviews with the child and parent and consisted of 17 items out of which 3 items rated nonverbal observations (listless speech, hypoactivity, and depressed affect). Fourteen items were rated on a 7-point scale from 1 to 7, and 3 items (sleep disturbance, appetite disturbance, and listless speech) were scored on a 5-point scale from 1 to 5. A rating of 1 indicated normal functioning and a higher number indicated a greater degree of depression. The total score ranged from 17 (normal) to 113 (severe depression). (NCT02709655)
Timeframe: Weeks 2, 4, 6, and 8 of Phase B

,,,
Interventionpercentage of participants (Number)
Week 2Week 4Week 6Week 8
Double-Blind: Fluoxetine 20 mg16.326.933.347.4
Double-Blind: Placebo7.820.730.829.4
Double-Blind: Vortioxetine 10 mg10.223.431.636.4
Double-Blind: Vortioxetine 20 mg11.626.637.241.0

[back to top]

Percentage of Participants With CGI-S Remission

CGI-S remission was defined as a CGI-S score of 1 or 2. The CGI-S provides the clinician's impression of the participant's current state of mental illness. The clinician uses his or her clinical experience of this participant population to rate the severity of the participant's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill participants). (NCT02709655)
Timeframe: Weeks 1, 2, 3, 4, 6, and 8 of Phase B

,,,
Interventionpercentage of participants (Number)
Week 1Week 2Week 3Week 4Week 6Week 8
Double-Blind: Fluoxetine 20 mg03.77.412.314.829.6
Double-Blind: Placebo00.73.38.514.422.9
Double-Blind: Vortioxetine 10 mg0.73.44.18.116.222.3
Double-Blind: Vortioxetine 20 mg01.44.712.816.220.9

[back to top]

Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score at Weeks 4 and 8 of Phase B

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709655)
Timeframe: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

,,,
Interventionunits on a scale (Least Squares Mean)
Change at Week 4Change at Week 8
Double-Blind: Fluoxetine 20 mg-0.41-1.08
Double-Blind: Placebo-0.48-0.73
Double-Blind: Vortioxetine 10 mg-0.51-1.07
Double-Blind: Vortioxetine 20 mg-0.48-1.01

[back to top]

Change From Baseline in PedsQL VAS: Sad or Blue (Sadness) Score at Weeks 4 and 8 of Phase B

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The participants are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709655)
Timeframe: Baseline (Week 4 of Phase A), Weeks 4 and 8 of Phase B

,,,
Interventionunits on a scale (Least Squares Mean)
Change at Week 4Change at Week 8
Double-Blind: Fluoxetine 20 mg-1.42-2.31
Double-Blind: Placebo-1.20-1.72
Double-Blind: Vortioxetine 10 mg-1.65-2.23
Double-Blind: Vortioxetine 20 mg-1.78-2.05

[back to top]

Change in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-0.47
Vortioxetine 20 mg/Day-0.76
Fluoxetine 20 mg/Day,-0.78
Placebo-0.71

[back to top]

Change in PedsQL Emotional Distress Summary Average Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-0.93
Vortioxetine 20 mg/Day-1.09
Fluoxetine 20 mg/Day,-1.33
Placebo-1.18

[back to top]

Change in PedsQL VAS Total Average Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-1.00
Vortioxetine 20 mg/Day-1.13
Fluoxetine 20 mg/Day,-1.33
Placebo-1.14

[back to top]

Change in PedsQL VAS: Angry Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-0.51
Vortioxetine 20 mg/Day-0.70
Fluoxetine 20 mg/Day,-1.01
Placebo-0.59

[back to top]

Change in PedsQL VAS: Pain or Hurt Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-1.12
Vortioxetine 20 mg/Day-0.97
Fluoxetine 20 mg/Day,-0.83
Placebo-0.76

[back to top]

Change in PedsQL VAS: Sad or Blue (Sadness) Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-1.90
Vortioxetine 20 mg/Day-1.71
Fluoxetine 20 mg/Day,-2.45
Placebo-2.12

[back to top]

Parent Global Assessment-Global Improvement (PGA) Score

The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of change from Baseline symptoms using a 7 point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day2.80
Vortioxetine 20 mg/Day2.74
Fluoxetine 20 mg/Day,2.49
Placebo2.72

[back to top]

Clinical Global Impression - Global Improvement (CGI-I) Score

The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day2.81
Vortioxetine 20 mg/Day2.69
Fluoxetine 20 mg/Day,2.50
Placebo2.73

[back to top]

Change in Symbol Digit Modalities Test (SDMT)

The Symbol Digit Modalities Test (SDMT) is a cognitive test designed to assess speed of performance requiring visual perception, spatial decision-making and psychomotor skills. The SDMT consists of 110 geometric symbols that the patient has to substitute with a corresponding digit in a 90-second period. Each correct digit is counted, and the total score ranges from 0 (less than normal functioning) to 110 (greater than normal functioning). (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day3.75
Vortioxetine 20 mg/Day2.64
Fluoxetine 20 mg/Day,2.69
Placebo2.41

[back to top]

Change in Children's Global Assessment Scale (CGAS) Score

The Children's Global Assessment Score (CGAS) is a rating scale which measures psychological, social and school functioning for children. The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The items range in value from 1 (most functionally impaired child) to 100 (the healthiest). A total score above 70 indicates normal function. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day12.24
Vortioxetine 20 mg/Day13.89
Fluoxetine 20 mg/Day,16.43
Placebo14.52

[back to top]

Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment

The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression). (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-17.09
Vortioxetine 20 mg/Day-18.94
Fluoxetine 20 mg/Day,-21.95
Placebo-18.22
Vortioxetine Average (Avg. VOR)-18.01

[back to top]

Change in CDRS-R Total Score During Treatment (at Week 6)

The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression). (NCT02709746)
Timeframe: At week 6

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-15.43
Vortioxetine 20 mg/Day-17.78
Fluoxetine 20 mg/Day,-19.20
Placebo-16.71

[back to top]

Change in CDRS-R Total Score During Treatment (at Week 4)

The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression). (NCT02709746)
Timeframe: At week 4

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-14.32
Vortioxetine 20 mg/Day-15.03
Fluoxetine 20 mg/Day,-16.25
Placebo-13.71

[back to top]

Change in CDRS-R Total Score During Treatment (at Week 2)

The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).Children and parents answer separately. Rater judges and selects 'Best'. (NCT02709746)
Timeframe: At week 2

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-9.58
Vortioxetine 20 mg/Day-10.15
Fluoxetine 20 mg/Day,-10.34
Placebo-8.83

[back to top]

Change in CDRS-R Subjective Score

Change in Children Depression Rating Scale - Revised (CDRS-R): Subjective. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Subjective is one of four subscores defined in the CDRS-R: sum of items 9, 10, 12, 13; score ranges from 4 to 28. The highest possible score indicates the most severe measure of depression. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-2.41
Vortioxetine 20 mg/Day-2.63
Fluoxetine 20 mg/Day,-3.23
Placebo-2.66

[back to top]

Change in PedsQL VAS: Tired (Fatigue) Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-1.18
Vortioxetine 20 mg/Day-1.40
Fluoxetine 20 mg/Day,-1.55
Placebo-1.27

[back to top]

Change in PedsQL VAS: Worry Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-0.96
Vortioxetine 20 mg/Day-1.17
Fluoxetine 20 mg/Day,-0.91
Placebo-1.33

[back to top]

Change in CDRS-R Somatic Score

Change in Children Depression Rating Scale - Revised (CDRS-R): Somatic. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Somatic is one of four subscores defined in the CDRS-R: sum of items 4, 5, 6, 7, 16, 17; score ranges from 6 to 36. The highest possible score indicates the most severe measure of depression. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-5.63
Vortioxetine 20 mg/Day-6.03
Fluoxetine 20 mg/Day,-6.79
Placebo-5.78

[back to top]

Change in CDRS-R Mood Score

Change in Children Depression Rating Scale - Revised (CDRS-R) Mood. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Mood is one of four subscores defined in the CDRS-R: sum of items 8, 11, 14, 15; score range 4 to 28. The highest possible score indicates the most severe measure of depression. (NCT02709746)
Timeframe: From randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-5.05
Vortioxetine 20 mg/Day-5.47
Fluoxetine 20 mg/Day,-6.53
Placebo-5.32

[back to top]

Change in CDRS-R Behaviour Score

Change in Children Depression Rating Scale - Revised (CDRS-R): Behaviour. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. behaviour is one of four subscores defined in the CDRS-R:sum of items 1, 2, 3; score ranges from 3 to 21. The highest possible score indicates the most severe measure of depression. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-4.32
Vortioxetine 20 mg/Day-4.90
Fluoxetine 20 mg/Day,-5.52
Placebo-4.73

[back to top]

Change General Behaviour Inventory (GBI) Depression Subscale Score Assessed by the Child

The GBI 10-item mania scale is a parent- and subject-rated scale designed to screen for manic symptoms in children and adolescents. The 10 items are rated on a scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranges from 0 to 30 points, with high scores indicating greater pathology. (NCT02709746)
Timeframe: From randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-5.48
Vortioxetine 20 mg/Day-5.55
Fluoxetine 20 mg/Day,-6.30
Placebo-6.03

[back to top]

CGI-S Remission

Remission defined as CGI-S score of 1 or 2. (NCT02709746)
Timeframe: From Randomization to Week 8

InterventionParticipants (Count of Participants)
Vortioxetine 10 mg/Day26
Vortioxetine 20 mg/Day33
Fluoxetine 20 mg/Day,36
Placebo24

[back to top]

CDRS-R Response

Children Depression Rating Scale - Response: defined as a >= 50% decrease in CDRS-R total score, calculated as (change from baseline [Randomization])/(baseline value - 17). (NCT02709746)
Timeframe: From Randomization to Week 8

InterventionParticipants (Count of Participants)
Vortioxetine 10 mg/Day53
Vortioxetine 20 mg/Day60
Fluoxetine 20 mg/Day,68
Placebo49

[back to top]

CDRS-R Remission

Remission is defined as a CDRS-R total score <= 28. (NCT02709746)
Timeframe: From Randomization to Week 8

InterventionParticipants (Count of Participants)
Vortioxetine 10 mg/Day21
Vortioxetine 20 mg/Day24
Fluoxetine 20 mg/Day,32
Placebo20

[back to top]

Change in Clinical Global Impression Severity of Illness (CGI-S) Score

The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients). (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-1.23
Vortioxetine 20 mg/Day-1.38
Fluoxetine 20 mg/Day,-1.59
Placebo-1.21

[back to top]

Change in General Behaviour Inventory (GBI) Depression Sub Scale Score Assessed by the Parents

Using the 10-item depression subscale, assessed by parent (PGBI-10D). Change from randomization to Week 8 in GBI Total Parent/Guardian Version Depression score. GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale completed by parent/guardian. Symptoms rated on 4-point Likert scale from 0 (never/hardly ever) to 3 (often/almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome. (NCT02709746)
Timeframe: From randomization to week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-6.23
Vortioxetine 20 mg/Day-6.48
Fluoxetine 20 mg/Day,-8.00
Placebo-6.62

[back to top]

Change in PQ-LES-Q Overall Score

PQ-LES-Q overall evaluation score (item 15). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning and item 15 allows subjects to summarize their experience in a global rating (this outcome measurement). Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good). (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day0.54
Vortioxetine 20 mg/Day0.43
Fluoxetine 20 mg/Day,0.67
Placebo0.51

[back to top]

Change in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Scores

PQ-LES-Q total score (items 1 to 14). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ LES Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning (and item 15 allows subjects to summarize their experience in a global rating). Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1-14 (this outcome measurement) is 14 to 70, with higher scores indicating greater satisfaction. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day7.62
Vortioxetine 20 mg/Day7.56
Fluoxetine 20 mg/Day,9.26
Placebo7.06

[back to top]

Mean Percent Change in Field Points Tested

Visual field recovery is defined as an improvement of more than 6 decibels (dB) in the threshold required to elicit a response at each point in the Humphrey visual field. This is based on the unidirectional test-retest variability of less than 3 dB reported in the Humphrey Field Analyzer manual. The endpoint will be an improvement in threshold values at test locations spanning more than 10 degrees horizontally or 15 degrees vertically in the Humphrey visual field in both eyes at 6 months, based on the definition of visual improvement used by Zhang et al. in their natural history study of stroke patients with hemianopia. (NCT02737930)
Timeframe: 6 months

Interventionpercent of visual field points tested (Mean)
Fluoxetine72.4
Placebo32.1

[back to top]

Mean Percent Change in Post-stroke Retinal Nerve Fiber Layer Thickness

This will be measured by spectral domain optical coherence tomography. Optical coherence tomography is a method of using low-coherence interferometry to determine the echo time delay and magnitude of backscattered light reflected off an object of interest. This method can be used to scan through the layers of a structured tissue sample such as the retina with very high axial resolution (3 to 15 μm), providing images demonstrating 3D structure. (NCT02737930)
Timeframe: baseline to 6 months

Interventionpercent change in microns (Mean)
Fluoxetine-0.02
Placebo-1.49

[back to top]

Median Change in Patient Health Questionnaire-9 Score

This is a self-report inventory used as a screening and diagnostic tool for depression (Appendix F). The 9 items are based on the 9 diagnostic criteria for depression included in the Diagnostic and Statistical Manual of Mental Disorders IV. The scales ranges from 0-27 with higher scores indicating worse outcome. (NCT02737930)
Timeframe: baseline to 6 months

Interventionscore on a scale (Median)
Fluoxetine-1
Placebo0

[back to top]

Median Modified Rankin Scale Score

This is a functional outcome measure widely used in stroke clinical trials, with a score of 0 indicating no disability, 6 indicating death, and scores of 2 or less generally accepted to indicate a favorable functional outcome. (NCT02737930)
Timeframe: 90 days

Interventionscore on a scale (Median)
Fluoxetine1
Placebo2

[back to top]

Number of Participants With >95% Recovery

Recovery is an improvement in the blind visual field. Participants were counted if the percentage of visual field that was blind was reduced by 95%. (NCT02737930)
Timeframe: 6 months

Interventionparticipants (Number)
Fluoxetine3
Placebo1

[back to top]

Percent Change in Mean Visual Function Questionnaire-25 Score

The VFQ-25 consists of a base set of 25 vision targeted questions representing 11 vision-related constructs: global vision rating, difficulty with near vision activities, difficulty with distance vision activities, limitations in social functioning due to vision, role limitations due to vision, dependency on others due to vision, mental health symptoms due to vision, driving difficulties, limitations with peripheral and color vision, and ocular pain. The scores range from 0-100 with higher scores indicating better functioning. (NCT02737930)
Timeframe: baseline to 6 months

Interventionpercent change of units on a scale (Mean)
Fluoxetine-11.2
Placebo-14.9

[back to top]

Percent Change in the Bionocularly Averaged Perimetric Mean Deviation

24-2 Humphrey perimetry was completed for each eye (Zeiss HFAIIi, Swedish Interactive Threshold Algorithm (SITA) Standard, size III white target, fixation enforced, corrected for near vision). The cutoff of a sensitivity of 10 dB to define sighted versus blind test locations was chosen. Perimetric mean deviation is a summary statistic calculated by measuring the deviation from the expected threshold value for stimulation at each point in the visual field and taking an average, with possible values ranging from +2 to -32 dB. (NCT02737930)
Timeframe: baseline to 6 months

Interventionpercent change in dB (Mean)
Fluoxetine64.4
Placebo26.0

[back to top]

Study Retention Rate

Number of participants completing the study every 3 months. (NCT02929667)
Timeframe: From date of enrollment until either completion of study or lost to follow up every 3 months up to 2 years and 3 months

Interventionparticipants/3 months (Mean)
Fluoxetine1.2
Placebo1.1

[back to top]

Study Recruitment Rate

Number of participants enrolled every 3 months. (NCT02929667)
Timeframe: From the date of enrollment every 3 months up to 2 years

Interventionparticipants/3 months (Mean)
Recruitment3.8

[back to top]

Change in Slope of HCVR

All the subjects undergo CO2 rebreathing (HCVR) testing at baseline and 4 weeks after receiving an intervention. During CO2 rebreathing (HCVR) testing, CO2 gradually rise in the body that stimulates breathing, which in turn increases minute ventilation (L/min). The rate of this increase in minute ventilation with each mm Hg rise in CO2 is the HCVR slope, which is calculated for baseline testing and 4 weeks after receiving an intervention. HCVR slope at 4 weeks after receiving an intervention compared to the baseline HCVR slope in each group. (NCT02929667)
Timeframe: At baseline and 4 weeks after receiving an intervention

InterventionLiters/minute/mm Hg (L/min/mm Hg) (Mean)
Fluoxetine-0.049
Placebo0.072

[back to top]

Change in PHQ-9 Score.

Patient Health Questionnaire (PHQ-9) was used to evaluate mood. Score on PHQ-9 scale ranges from 0-27. Scores corresponding to severity of depression: 0-4: minimal to none ; 5-9: mild; 10-14: moderate; 15-19 moderately severe; 20-27: severe. All subjects in the study were interviewed using standard questions per PHQ-09 questionnaire at baseline and 4 weeks after randomization to an intervention. (NCT02929667)
Timeframe: At baseline and 4 weeks after randomization to an intervention

Interventionscore on a scale (Mean)
Fluoxetine0.455
Placebo-1.000

[back to top]

Change in Minute Ventilation During Hypercapnic Ventilatory Response (HCVR) Testing

Minute ventilation was evaluated at baseline HCVR testing and HCVR testing at 4 weeks after receiving an intervention. Change from baseline was calculated. (NCT02929667)
Timeframe: At the end of HCVR testing- at baseline and 4 weeks after receiving an intervention

InterventionLiters/minute (L/min) (Mean)
Fluoxetine1.739
Placebo2.758

[back to top]

Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale

The CGI-S is a clinician-rated scale used to rate the severity of the participant's current state of mental illness compared with MDD population. The participant was rated on a scale from 1 to 7, where 1=normal, not at all ill and 7=among the most extremely ill participants. Higher score indicates worsening of mental illness. A negative change from Baseline indicates improvement. MMRM was used for analysis. (NCT03569475)
Timeframe: Baseline (Week 0) to Week 8

Interventionscore on a scale (Least Squares Mean)
Placebo-1.5
Levomilnacipran ER 40-80 mg/Day-1.6
Fluoxetine 20 mg/Day-1.7

[back to top]

Change From Baseline in Children's Depression Rating Scale- Revised (CDRS-R)

The CDRS-R is a semi-structured, clinician-rated instrument designed for use with children and adolescents between the ages of 6-17 years. It contains 17 ordinally-scaled items that evaluate the presence and severity of symptoms commonly associated with childhood depression and is scored on a 1-to-5- or 1-to-7-point scale. Rating of 1 indicates normal function. The CDRS-R total score ranges from 17 to 113; higher score indicates more severe depression. A negative change from Baseline indicates improvement. Mixed Model for Repeated Measures (MMRM) was used for analysis. (NCT03569475)
Timeframe: Baseline (Week 0) to Week 8

Interventionscore on a scale (Least Squares Mean)
Placebo-21.3
Levomilnacipran ER 40-80 mg/Day-23.0
Fluoxetine 20 mg/Day-23.1

[back to top]

Quick Inventory of Depressive Symptomatology

Patient reported outcome will be assessed using the Quick Inventory of Depressive Symptomatology (16-Item) (Self-Report) (QIDS-SR16) completed at baseline, week 12 and Week 24; baseline and week 24 reported. Each question is scored from minimum of 0 to a maximum of 3; total score ranges from 0 to 42. With zero being better outcome and 42 being severe outcome (NCT03638908)
Timeframe: baseline and Week 24.

Interventionscore on a scale (Mean)
Fluoxetine- Baseline4.7
Fluoxetine- Week 244.3

[back to top]

Pulmonary Vascular Resistance (PVR)

Change in PVR between baseline and follow-up will be utilized. PVR is calculated as [(Pulmonary Artery mean - wedge) / Fick Cardiac Output]. Fick CO will be used in computing PVR over thermodilution because Fick appears to have greater precision (but not accuracy). The calculation of PVR above is measured in woods unit. Change is derived by getting the difference between baseline and week 24 PVR (Week 24 minus Baseline). mean is then computed by getting the average of the change (NCT03638908)
Timeframe: Baseline and Week 24

Interventionwoods unit (Mean)
Fluoxetine6.7

[back to top]

Exercise Capacity

Exercise capacity will be measure using the 6-minute walk test. Data collected at baseline and 24 were analyzed. The test will follow the ATS guidelines for 6MWT at all time. (NCT03638908)
Timeframe: baseline and 24

Interventionmeters (Mean)
Fluoxetine- Baseline380
Fluoxetine- Week 24393

[back to top]

5-HIAA (HYDROXYINDOLE ACETIC ACID) Level

"Urine for spot urine 5-HIAA will be collected at baseline and Week 24. Subjects will be on diet restriction 72 hours prior to urine collection. Sample will be the first morning urine on the visit day. Sample will be brought to site and then sent to affiliate outside laboratory for processing. 5HIAA results are expressed as a ratio to creatinine excretion in the unit mg/g creatinine Change 5-HIAA is derived by getting the difference between baseline and week 24 5HIAA results (Week 24 minus Baseline). mean is then computed by getting the average of the change" (NCT03638908)
Timeframe: Baseline and Week 24

Interventionmg/g CRT (Mean)
Fluoxetine0.375

[back to top]

Montgomery-Asberg Depression Rating Scale

10-item questionnaire used to evaluate the severity of a patient's depressive symptoms. Each item is scored on a scale from 0 to 6, the scores are summed, and the total score (0 to 60 points) is reported. The greater the score, the more severe the degree of depression. (NCT03728153)
Timeframe: 90 days following acute, ischemic stroke

Interventionunits on a scale (Mean)
20mg Dose5.6

[back to top]

Modified Rankin Scale

Validated instrument for measuring the degree of disability in stroke patients. The modified Rankin Scale is based on a physicians subjective evaluation. The scale ranges from 0, indicating perfect health, to 6, indicating that the patient is dead. (NCT03728153)
Timeframe: 90 days following acute, ischemic stroke

Interventionscore on a scale (Median)
20mg Dose2

[back to top]

The Patient Health Questionnaire-9 (PHQ-9) Scale for Measuring Depression

The PHQ-9 is a validated 9-point questionnaire for measuring depression symptom severity. Each question is scored from 0-3. Answers are summed and the total score (0 to 27) is reported. The greater the score, the greater the severity of depression. (NCT03728153)
Timeframe: 90 days following acute ischemic stroke

Interventionunits on a scale (Mean)
20mg Dose4.6

[back to top]

Serum Sodium Concentration

Serum Sodium Concentration was measured in mmol/L. Hyponatremia was considered as <125 mmol/L. (NCT03728153)
Timeframe: 90 days following acute, ischemic stroke

Interventionmmol/L (Mean)
20mg Dose138.7

[back to top]

Serum Alanine Aminotransferase (ALT)

Hepatic impairment was measured by elevation of hepatic enzyme (serum alanine aminotransferase; ALT) of >120 U/L (NCT03728153)
Timeframe: 90 days

InterventionU/L (Mean)
20mg Dose28

[back to top]

Fugl-Meyer Motor Scale Score for Assessment of Motor Function After Stroke

The Fugl Meyer motor scale is used to assess post-stroke motor recovery in stroke patients. It is scored on a scale from 0 to 100, with lower scores indicating greater disability. It evaluates both lower and upper extremities for motor performance: 66 points are allocated to the upper extremities, 34 to the lower extremities. The two extremities are summed to achieve the total score. (NCT03728153)
Timeframe: 90 days following acute, ischemic stroke

Interventionscore on a scale (Mean)
20mg Dose62.7

[back to top]

Number of Subjects Undergoing Intubation

whether the subject is intubated for COVID-19 symptoms (NCT04377308)
Timeframe: 2 months

InterventionParticipants (Count of Participants)
Treatment As Usual1
Fluoxetine0

[back to top]

Number of Patients Who Died Within 2 Months of Entry Into the Study

Patients who died from any cause within 2 months of entry into the study. (NCT04377308)
Timeframe: 2 months

InterventionParticipants (Count of Participants)
Treatment As Usual1
Fluoxetine0

[back to top]

Number of Outpatient Subject Hospitalizations

whether the subject is hospitalized for COVID-19 symptoms (NCT04377308)
Timeframe: 2 months

InterventionParticipants (Count of Participants)
Treatment As Usual0
Fluoxetine0

[back to top]

Participants With Patient Health Questionnaire (PHQ) -9 Score Below 10 After Baseline Assessment

depression score rating from 0 to 27 where higher scores indicate worse depression Scores of 10 or more meet criteria for diagnosis as a mild depressive episode (NCT04377308)
Timeframe: 2 months

InterventionParticipants (Count of Participants)
Treatment As Usual4
Fluoxetine10

[back to top]

Participants With Generalized Anxiety Disorder (GAD) -7 Scale Score Below 10 After Baseline Assessment

anxiety scale with scores ranging from 0 to 21 where higher scores indicate more severe anxiety Scores of 10 or more generally indicate anxiety that might meet criteria for diagnosis as an anxiety disorder (NCT04377308)
Timeframe: 2 months

InterventionParticipants (Count of Participants)
Treatment As Usual4
Fluoxetine10

[back to top]